UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF VIRGINIA
NORFOLK DIVISION

IN RE ZETIA (EZETIMIBE) ANTITRUST LITIGATION This document relates to: All Actions	MDL No. 2:18-md-2836

FINAL PRETRIAL ORDER

TABLE OF CONTENTS

Pursuant to Pretrial Order No. 11 ("PTO 11"), the Federal Rules of Civil Procedure, the Local Rules of this Court, and all other relevant Orders of this Court, direct purchaser plaintiffs McKesson Corporation, AmerisourceBergen Corporation, AmerisourceBergen Drug Corporation, H.D. Smith, LLC, Smith Medical Partners, LLC, Valley Wholesale Drug Company, LLC, Cardinal Health, Inc., The Harvard Drug Group, L.L.C., Cardinal Health P.R. 120, Inc., Meijer, Inc., Meijer Distribution, Inc., SUPERVALU, Inc., Wegmans Food Markets, Inc., KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc., and MLI RX, LLC, Burlington Drug Company, Inc., Dakota Drug, Inc., J. M. Smith d/b/a Smith Drug Company, Louisiana Wholesale Drug Co., Inc., North Carolina Mutual Wholesale Drug Company, Prescription Supply, Inc., Rochester Drug Cooperative, Inc., César Castillo, LLC, FWK Holdings, LLC, and Value Drug Company; retailer plaintiffs CVS Pharmacy, Inc., Rite Aid Corporation, Rite Aid HDQTRS. Corp., Walgreen Co., The Kroger Co., Albertsons Companies Inc., HEB Grocery Company L.P., and Giant Eagle, Inc.; and the end-payor class plaintiffs (collectively, "the purchasers"); and defendants Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and MSP Singapore Co. LLC ("Merck") and Glenmark Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Inc., USA ("Glenmark") (collectively, "the defendants") (the purchasers and the defendants together, "the parties"), having stipulated as to various matters identified herein and having identified exhibits, witnesses, factual contentions, and triable issues,

It is hereby ORDERED as follows:

I. STIPULATION OF UNDISPUTED FACTS

A list of undisputed facts is attached as Exhibit 1.

II. DOCUMENTS, SUMMARIES OF EVIDENCE, AND EXHIBITS

The listing of a document on any exhibit list is not an acknowledgment by any party that such document is relevant or admissible when offered by the opposing side. Each party reserves the right to object to the introduction of any evidence offered by the opposing party at the time such evidence should be admitted for a purpose other than previously indicated. Each party also reserves the right to use any PX, MDX, or GDX exhibit identified herein at trial to the same extent as if listed by the party.

The parties acknowledge that rulings on pending or to-be-filed objections, as well as other future rulings, may impact the exhibits the parties may use and/or the witnesses that the parties may call.

A. Exhibits to Which the Parties Agree

A list of exhibits proffered by the purchasers to which the parties agree and to which no objection is specified, as required by Rule 26(a)(3)(A)(iii) of the Federal Rules of Civil Procedure, is attached as Exhibit 2.

A list of exhibits proffered by Merck to which the parties agree and to which no objection is specified, as required by Rule 26(a)(3)(A)(iii) of the Federal Rules of Civil Procedure, is attached as Exhibit 3.

A list of exhibits proffered by Glenmark to which the parties agree and to which no objection is specified, as required by Rule 26(a)(3)(A)(iii) of the Federal Rules of Civil Procedure, is attached as Exhibit 4.

B. Unresolved Objections to Exhibits

A list of exhibits proffered by the purchasers to which the defendants have advanced objections, excluding exhibits to be used solely for impeachment or rebuttal, is attached as Exhibit 5.

A list of exhibits proffered by Merck to which the purchasers have advanced objections, excluding exhibits to be used solely for impeachment or rebuttal is attached as Exhibit 6.

A list of exhibits proffered by Glenmark to which the purchasers have advanced objections, excluding exhibits to be used solely for impeachment or rebuttal is attached as Exhibit 7.

The unresolved objections are set forth on the exhibit lists offered by the parties and are included as part of this submission. A table of abbreviations for objections is attached as Exhibit 8.[1]

III. WITNESSES

The purchasers' amended list of witnesses they expect to or may call live or by deposition is attached as Exhibit 9.

Merck's amended list of witnesses they expect to or may call live or by deposition is attached as Exhibit 10.

Glenmark's amended list of witnesses they expect to or may call live or by deposition is attached as Exhibit 11.

[1] The parties have agreed to a process and schedule for revising their expect to offer exhibit lists and objections pursuant to the Court's rulings and guidance at the final pretrial conference and the parties' ongoing negotiations. The agreed schedule provides for the exchange of updated objections on April 7. The parties will therefore submit to the Court amended versions of Exhibits 5–7 on April 10.

IV. THE PARTIES' FACTUAL CONTENTIONS[2]

A. The Purchasers' Factual Contentions

Violation. The purchasers contend that in May of 2010 Merck and Glenmark, when settling a patent lawsuit, included in that settlement an unexplained large reverse payment. The reverse payment took the form of (i) an agreement on the part of Merck not to launch an authorized generic (AG) of ezetimibe and (ii) a payment of $9 million for Glenmark's fees and expenses. In exchange, Glenmark dropped its patent charge, avoided settling on the basis of a competitively balanced entry date, and settled on a basis where it agreed not to launch its generic ezetimibe until December 2016, over six years later. The purchasers contend the reverse payment was large from any perspective. Forgoing an AG came at a present value cost to Merck of exceeding $40 million (and likely far more), and the present value benefit to Glenmark alone (i.e., excluding its exclusive distributor, Par) from the reverse payment exceeded $70 million more (and likely far more) than what Glenmark would earn even if it won the Zetia patent litigation—a sum more than sufficient to incentivize a generic company to accept a much later entry date.

The purchasers contend the large reverse payment had substantial anticompetitive effects of generic delay. The Court has ruled that Merck had market power, and the anticompetitive effects can be measured in this context and by the additional profits Merck took in from the delay of generic entry as a result of higher prices paid for Zetia. Merck took in at least $110 million more in profits for *each month* of delay. Modelling of the extent of delay (discussed

[2] As the Court is aware, there are innumerable subsidiary issues of fact in this case laid out in many expert reports and a voluminous summary judgment record. This statement of the parties' factual contentions therefore only provides a general overview of the factual contentions.

momentarily) shows a delay of about 20 months, indicating harm to purchasers exceeding $2 billion.

The purchasers contend that there are no justifications for the challenged restraint—that avoiding the risk of a competitively balanced entry date through Merck's large payoff of Glenmark in exchange for Glenmark's agreement to delay generic entry—had no procompetitive benefits and that none have been proposed by Merck and Glenmark. Any purported benefits proffered by Merck and/or Glenmark do not justify why *the reverse payment in exchange for delay* is in the agreement or provide how the challenged restraint works procompetitive benefits.

Causation. The purchasers contend that, absent the reverse payment, law-abiding companies in the positions of Merck and Glenmark would still have reached a settlement of the litigation in May 2010, but without a reverse payment and with a risk-adjusted agreed entry date in the range of November 2014 to July 2015.

The range is based, in part, on evidence showing that in May 2010 there would be a perceived objective likelihood of between 60% and 80% of Glenmark prevailing in the patent litigation. The purchasers contend that Glenmark had a very strong case against Merck based on its claim that there was inequitable conduct in excluding Dr. Adriano Afonso from the inventorship list for the Zetia patent. Merck countered that Dr. Stuart Rosenblum had conceived of and made the two patented compounds at issue, and that Dr. Afonso, who was the only chemist to make the compounds, was not an inventor. But Dr. Rosenblum, Merck's key witness, had credibility problems. What happened after the settlement, while irrelevant to the issues before the Court, is consistent with the fact that Merck had good reason to settle with Glenmark. Thirty days after the settlement, Merck sought reissue of its patent to address challenges raised in the Glenmark litigation that it admitted would render the patent wholly or partially invalid.

Merck asserted the subsequently reissued patent, now stripped of the claims for which Dr. Afonso claimed he was a co-inventor, against Mylan. During the 18 months after the Glenmark settlement and before the Mylan trial, Merck changed its expert lineup, changed its theory as to who conceived of the compounds at issue, and benefitted from a change in the prevailing law on inequitable conduct. The case it tried and won against Mylan was completely different than the case it was facing against Glenmark.[3]

The purchasers further contend that, with an agreement in place in May 2010 for an agreed entry date in the range of November 2014 to July 2015, a reasonable company in the position of Glenmark would have used the intervening four to five years to prepare for, and be ready to launch, generic ezetimibe by the agreed date, relying just as Glenmark did in December 2016, primarily on externally sourced API from MSN Labs. The purchasers contend that had Glenmark been planning to launch by an earlier agreed-to date, the issues it faced with its internally manufactured API, application of its actual risk mitigation and formal launch planning processes, and Glenmark's knowledge of MSN's product specifications, capacity, price, and delivery lead times (resulting from many years of contact between the companies dating back to 2008), would have led Glenmark to reach and implement the same decision it reached in August 2014 when planning its 2016 launch—i.e. to use MSN as a primary source of API for launch—earlier.

Likewise, given the absence of regulatory or manufacturing capacity impediments to doing so and consistent with its actual practices, Glenmark would have made and implemented other launch decisions, such as those concerning when to seek Final Approval and/or file a Prior

[3] This short discussion of certain *Mylan* case facts may be unnecessary depending on this Court's ruling on the *Mylan* motion.

Approval Supplement adding MSN or which finished product manufacturing sites would be qualified and used, in order to meet the earlier agreed-to target launch date.

The purchasers further contend that a reasonable brand company in the position of Merck would have launched an authorized generic at the time of Glenmark's earlier launch. Merck's interest in launching an AG version of Zetia was undiminished by any arguable financial success of its "LOE contracting strategy." In 2016-2017, Merck engaged in an all-out effort to launch an AG. Merck contracted with an AG distribution company, Prasco, and manufactured and shipped launch quantities totaling 19 million unbranded Zetia AG pills for a May 22, 2017 launch, three weeks before the expiration of Glenmark's 180-day exclusivity period. Glenmark's persistent threats to sue for breach of the May 2010 settlement agreement if Merck launched before June 10, 2017 forced Merck to cancel the short-term AG launch. Absent a no-AG commitment, a reasonable company in Merck's position would have launched an authorized generic during Glenmark's 180-day exclusivity period.

The earlier availability of generic ezetimibe and an AG of Zetia would have driven prices for ezetimibe down, resulting in all purchasers paying substantially less.

Damages. Finally, the purchasers contend that the antitrust violation resulted in significant overcharges to all plaintiffs.

The direct purchaser group contends that, in the aggregate, the total overcharges paid ranges from $1.6686 billion to $2.2688 billion,[4] a range that fluctuates depending on the timing of when earlier generic entry would have occurred. The direct purchaser group further contends that, as a matter of law under the Clayton Act, the awarded single damages number must be

[4] The specific overcharges to each of the direct purchaser plaintiffs are set forth in exhibits to the Expert Report of Jeffrey J. Leitzinger, Ph.D. dated October 14, 2022.

trebled (for a total range of about $5 billion to $6.8 billion, before Court-awarded fees and expenses).

The retailer group contends that, in the aggregate, the total overcharges paid ranges from $757 million to $1.59 billion,[5] a range that fluctuates depending on the timing of when earlier generic entry would have occurred. The retailer group further contends that, as a matter of law under the Clayton Act, the awarded single damages number must be trebled (for a total range of about $2.27 billion to $4.77 billion, before Court-awarded fees and expenses).

The end-payor class contends that, in the aggregate, the total overcharges paid ranges from $657.8 million to $773.5 million,[6] a range that fluctuates depending on the timing of when earlier generic entry would have occurred. The end-payor class further contends that, under various states laws applicable to their class, the awarded single damages are subject to doubling or trebling).

B. Defendants' Factual Contentions

Defendants dispute Plaintiffs' factual contentions and make the following factual contentions:

1. In the late 1980s, Merck began a research program that led to the discovery of a new class of compounds with a unique mechanism for lowering cholesterol, culminating in the discovery of ezetimibe.

2. Merck first obtained claims covering one of the processes a Merck scientist invented in U.S. Patent No. 5,631,365 (the "'365 Patent"). Merck then pursued claims to

[5] The specific overcharges to each of the eight members of the retailer group are set forth in exhibits to the Supplemental Report of Keith Leffler, Ph.D.

[6] Trial Reply Decl. of Dr. Russell L. Lamb, ECF No. 885-5. Other overcharge scenarios are set forth in exhibits to that declaration, and the end-payors' unjust enrichment claims amounts are set forth in Table 5.

chemical compounds in a separate patent application, which issued on June 16, 1998 as U.S. Patent No. 5,767,115. The '115 Patent recited claims covering many compounds Merck had invented, including ezetimibe.

3. On June 15, 2000, Merck sought reissue of the '115 Patent to add claims focused on ezetimibe. The PTO granted the reissue application, and the '115 Patent was reissued as U.S. Patent No. RE37,721 (the "'721 Patent") on May 28, 2002.

4. On December 27, 2001, Merck filed a New Drug Application ("NDA") with FDA for approval to market ezetimibe to treat high cholesterol. FDA approved Zetia on October 25, 2002.

5. Merck subsequently developed a combination product, Vytorin, containing ezetimibe and simvastatin. FDA approved Vytorin on July 23, 2004.

6. On October 25, 2006, Glenmark filed its Abbreviated New Drug Application ("ANDA") for generic ezetimibe. As the first ANDA filer for ezetimibe, Glenmark was eligible for 180-day marketing exclusivity if it met certain conditions. If obtained, this exclusivity would have prohibited FDA from approving any other ANDA for generic ezetimibe until 180 days after Glenmark launched its product. Glenmark met those conditions and preserved its eligibility for 180-day exclusivity.

7. On February 8, 2007, Glenmark mailed Merck its Notice of Paragraph IV Certification informing Merck of Glenmark's position that the '721 Patent was either invalid or unenforceable.

8. On March 22, 2007, Merck filed suit against Glenmark in the U.S. District Court for the District of New Jersey alleging that Glenmark's ANDA for generic Zetia infringed the

'721 Patent ("Merck-Glenmark Patent Litigation"). The case was assigned to Judge Jose Linares for a bench trial.

9. On September 5, 2008, Glenmark stipulated to infringing claims 3 and 8–13 of the '721 patent. Glenmark asserted five affirmative defenses: (1) inherent anticipation of claims 1, 2, 4, and 5; (2) inequitable conduct based on Merck's counsel's alleged failure to disclose information relating to the alleged inherent anticipation during the '721 Patent's Patent Term Extension ("PTE") proceedings; (3) inequitable conduct and invalidity due to the alleged failure to properly name former Merck scientist Dr. Adriano Afonso as an inventor of compounds "4E" and "4F," covered by claims 1, 2, 5, and 7 of the '721 Patent; (4) invalidity of claims 1–5 and 7–13 for obviousness-type double patenting ("ODP") over the '365 Patent; and (5) improper reissue of claims 10–13.

10. Trial in the Merck-Glenmark Patent Litigation was scheduled to begin on May 12, 2010. By that point, Glenmark asserted only three affirmative defenses: (1) invalidity and unenforceability based on alleged improper inventorship; (2) unenforceability due to alleged inequitable conduct relating to the alleged inherent anticipation during the PTE proceedings; and (3) ODP.

11. Prior to trial, third-party analysts and commentators predicted that Merck would win the Merck-Glenmark Patent Litigation.

12. The compound claims of the '721 Patent covered a new chemical entity, ezetimibe, approved by FDA. The '721 patent constituted the gold standard for a patent protecting a medicine. Such patents recite the trifecta of claim types that a generic copy of an approved drug necessarily infringe: claims protecting the ezetimibe active ingredient, pharmaceutical compositions of ezetimibe (the active ingredient combined with a pharmaceutical

acceptable carrier), and the approved medicinal use for Zetia. Such patents are almost never invalidated.

13. As of May 2010, no generic company had ever succeeded in invalidating a gold standard patent based on the core requirements for patentability. Glenmark was relying only on secondary defenses of invalidity and unenforceability that had never been successful against any patent (not just the gold standard patents) in any Hatch-Waxman litigations.

14. In 2007, 2008, 2009, and 2010, Glenmark or a reasonable company in Glenmark's position would have believed that Merck was likely to win the Merck-Glenmark Patent Litigation.

15. In 2007, 2008, 2009, and 2010, Merck or a reasonable company in Merck's position would have believed that Merck was likely to win the Merck-Glenmark Patent Litigation.

16. Merck was overwhelmingly likely to win the Merck-Glenmark Patent Litigation.

17. Glenmark repeatedly reached out to Schering and then Merck to discuss settlement. Glenmark's chief negotiator Vijay Soni repeatedly contacted Henry Hadad, Vice President & Associate General Counsel, Intellectual Property at Schering–Plough, and later repeatedly contacted Paul Matukaitis, in-house lawyer for Merck.

18. In all the settlement discussions, Merck informed Glenmark that it would only consider allowing Glenmark a modest early entry (not more than a few months) before the expiration of the '721 Patent. Merck never deviated from that position.

19. The '721 Patent was scheduled to expire on April 25, 2017.

20. In August 2009, Merck informed Soni that it would agree to no more than two months of early entry. Soni believed, and communicated to his superiors at Glenmark, that

Glenmark could ultimately secure three to four months maximum of early entry. These exchanges took place before anyone mentioned the possibility of Merck agreeing not to launch an authorized generic during Glenmark's 180-day exclusivity period.

21. In November 2009, Glenmark demanded six months of early entry. In February 2010, Merck offered one month. The next day, Glenmark demanded five months. In March 2010, Merck offered two months.

22. In February 2010, Glenmark requested that Merck agree to a broad "No AG" provision, which would have precluded Merck from launching an authorized generic product during Glenmark's period of 180-day exclusivity. Merck refused this request and did not agree to any such provision.

23. In April 2010, Glenmark entered a distribution agreement with Par Pharmaceuticals, whereby Par would distribute Glenmark's generic Zetia product and Glenmark and Par would share the revenues.

24. In May 2010, Glenmark and Merck reached a settlement agreement that gave Glenmark a license to enter the market with generic Zetia on December 12, 2016, or earlier under certain circumstances.

25. The settlement agreement was procompetitive because it allowed Glenmark to enter the market four-and-a-half months earlier than Merck's patent expiration date and earlier under certain circumstances. Had Glenmark demanded an earlier license date, the parties would have gone to trial, and Merck would have won. As a result, Glenmark would have been prohibited from launching its generic Zetia product until April 25, 2017. The licensing term to which the parties agreed precluded Merck from launching an unbranded ezetimibe product under the Zetia NDA (known in the industry as an "unbranded authorized generic") during the period

of Glenmark's regulatory exclusivity up until the end of Merck's pediatric exclusivity on April 25, 2017.

26. The licensing term permitted Merck to launch a branded ezetimibe product under the Zetia NDA (known in the industry as a "branded authorized generic") at any time.

27. There is no meaningful distinction between a branded authorized generic and an unbranded authorized generic in terms of their competitive effect in the marketplace.

28. If the final settlement agreement had been revised to allow Merck to launch an unbranded authorized generic, the December 12, 2016, license date would not have changed.

29. The settlement agreement preserved Merck's right to engage in "conventional commercial conduct in competition with the Glenmark Product," including by using rebates or pricing to compete with Glenmark's product on the generic tier.

30. The settlement agreement provided that if another generic company succeeded in securing a final court decision invalidating or rendering unenforceable Merck's '721 patent, Glenmark would be able to launch its generic product immediately.

31. The settlement agreement provided that Merck would reimburse Glenmark for up to $9 million in legal fees if Glenmark provided Merck with written documentation of its legal expenses. By the time of the settlement, Merck had incurred over $21 million in legal expenses and fees.

32. If the final settlement agreement had been revised to eliminate Merck's agreement to reimburse Glenmark's legal fees, the December 12, 2016, license date would not have changed.

33. During the settlement negotiations between Merck and Glenmark, there was no trade-off or quid pro quo between the license date and any request for any type of "no-AG" agreement.

34. During the settlement negotiations between Merck and Glenmark, there was no trade-off or quid pro quo between the license date and any request for reimbursement of Glenmark's legal expenses.

35. If the Merck-Glenmark Patent Litigation had not settled and had proceeded through two trials and an appeal, as Plaintiffs' experts contend, Merck would have incurred more than $9 million in additional legal fees.

36. Had the licensing term to which the parties agreed been different with respect to Glenmark's period of exclusivity, Merck still would not have agreed to a license date earlier than December 12, 2016.

37. Merck never indicated to Glenmark any openness to a license date earlier than December 12, 2016 regardless of the other terms of the settlement agreement.

38. Merck provided a copy of the settlement agreement to the Department of Justice ("DOJ") and to the Federal Trade Commission ("FTC").

39. At the time of the settlement agreement, the FTC was studying the competitive effects of authorized generics, and Congress was considering legislation that would have prohibited branded companies from launching authorized generics during a first-filer's 180 days of regulatory exclusivity.

40. On June 9, 2010, Merck sought reissue of the '721 Patent by the PTO. Merck provided the PTO with portions of the record from the Merck-Glenmark Patent Litigation, including those that set forth every challenge Glenmark was prepared to make at trial. The PTO

examiner considered each of these challenges but did not reject any of Merck's patent claims on any of these, or other, bases. On June 14, 2011, the PTO reissued the '721 Patent as U.S. Patent No. RE42,461 (the "'461 Patent"), maintaining Merck's exclusive rights to ezetimibe through April 25, 2017.

41. Merck ultimately competed with Glenmark's generic ezetimibe product by engaging in an "LOE contracting" strategy by which Merck discounted brand Zetia to price levels competitive with Glenmark's generic Zetia product.

42. Merck's contracting strategy was successful, drove down the price of ezetimibe substantially, and ensured Merck retained market share and profits at Glenmark and Par's expense.

43. Merck's contracting strategy drove prices of Zetia and generic ezetimibe below what the prices would have been had Merck instead launched an authorized generic product.

44. In 2009 and 2010, while Merck and Glenmark were negotiating the settlement agreement, Merck or a reasonable company in Merck's position would have anticipated that Merck could launch a branded authorized generic product during Glenmark's period of regulatory exclusivity, and would have valued the provisions of the settlement agreement accordingly.

45. In 2009 and 2010, while Merck and Glenmark were negotiating the settlement agreement, Merck or a reasonable company in Merck's position would have anticipated that Merck could engage in an LOE contracting strategy to maximize its revenues, market share, and profit during Glenmark's period of generic exclusivity, and would have valued the provisions of the settlement agreement accordingly.

46. In 2009 and 2010, while Merck and Glenmark were negotiating the settlement agreement, Glenmark or a reasonable company in Glenmark's position would have anticipated that Merck could launch a branded authorized generic product during Glenmark's period of generic exclusivity, and would have valued the provisions of the settlement agreement accordingly.

47. In 2009 and 2010, while Merck and Glenmark were negotiating the settlement agreement, Glenmark or a reasonable company in Glenmark's position would have anticipated that Merck could engage in an LOE contracting strategy to maximize its revenues, market share, and profit during Glenmark's period of generic exclusivity, and would have valued the provisions of the settlement agreement accordingly.

48. While the Merck-Glenmark Patent Litigation was pending, generic drug manufacturer Mylan notified Merck that it had submitted an ANDA as to Merck's blockbuster drug Vytorin, which was a combination of simvastatin and ezetimibe. Mylan's Paragraph IV certification asserted that the '721 Patent—the same patent at issue in the Merck-Glenmark Patent Litigation—was invalid, unenforceable, and/or would not be infringed by the manufacture and sale of Mylan's proposed generic simvastatin/ezetimibe product. Mylan understood that it held first-filer status for ezetimibe/simvastatin.

49. On December 16, 2009, Merck filed a patent infringement suit against Mylan in the District of New Jersey, asserting the '721 Patent. The Mylan case, like the Merck-Glenmark Patent Litigation, was assigned to Judge Linares for a bench trial. Mylan raised the same defenses that Glenmark had sought to prove in Merck-Glenmark Patent Litigation: invalidity and inequitable conduct concerning Dr. Afonso's alleged invention of compounds 4E and 4F, inequitable conduct during the PTE proceedings, and ODP. In May 2011, Judge Linares granted

summary judgment to Merck dismissing Mylan's defense on inequitable conduct during the PTE proceedings. After the '721 Patent was reissued as the '461 Patent, Merck asserted it against Mylan, and Mylan withdrew its ODP defense.

50. Judge Linares held a bench trial on inventorship defenses asserted by Mylan, which were materially identical to inventorship defenses Glenmark had asserted. On December 5, 2011, Mylan proceeded to trial on its defenses of invalidity and unenforceability, one of which was the same unenforceability defense Glenmark had asserted for failure to list Dr. Afonso as an inventor due to his alleged contributions to the inventions of compounds 4E and 4F during the prosecution of the '115 or '721 Patents. On April 27, 2012, Judge Linares ruled for Merck and against Mylan, finding that Merck's patent was valid and enforceable. Judge Linares found that Dr. Afonso was not an inventor of compounds 4E or 4F, that no inequitable conduct was committed during prosecution of the '115 or '721 Patents, and that Merck's patent was valid and enforceable.

51. Mylan appealed Judge Linares's decision to the Federal Circuit, which unanimously affirmed only two days after it heard oral argument.

52. Merck incurred legal expenses exceeding $7 million during the trial preparation, trial, post-trial, and appeal phases of the Mylan litigation.

53. If Glenmark had gone to trial against Merck, the outcome would have been the same as the outcome of the Merck v. Mylan litigation.

54. The reason that Glenmark's operative license date for generic Zetia was December 12, 2016, and not earlier, is because Mylan lost the Merck-Mylan Patent Litigation.

55. Even if Glenmark had secured an earlier license date for generic Zetia through an alternative settlement with Merck, Glenmark would not have launched its generic Zetia product

earlier than December 12, 2016, due to challenges relating to the manufacture of generic Zetia, supply chain management, Active Pharmaceutical Ingredient ("API") availability, and the FDA regulatory approval process.

56. Glenmark would not have been able to manufacture enough ezetimibe API on its own to support an earlier commercial launch.

57. Glenmark attempted, without success, to develop enough API on its own to support a launch.

58. The API process filed in Glenmark's ANDA was termed "Process I" and was synthesized at Glenmark's API facility in Ankleshwar, India. This process was problematic for many reasons, primarily because the process was designed to produce "lab scale" batches which were very small and inadequate to support a full scale launch. Process I was also not cost effective, and relied on a certain solvent, dichloroethane, which is a known carcinogen and gave rise to significant regulatory concerns.

59. Glenmark eventually abandoned Process I and pursued a new formulation for API, known internally as "Process II." Glenmark filed its plans for Process II in a submission to the FDA in April 2011. Process II was filed with a batch size of 12 kg, which, while larger than Process I, was still too small to support a commercial launch. Further, the FDA had many concerns about Process II, and it took several years for Glenmark to resolve those concerns.

60. While Glenmark pursued its own API manufacturing development, it also investigated external suppliers of ezetimibe API. Glenmark diligently pursued external API for years, but was unable to secure a viable external option until late 2014.

61. For example, Glenmark negotiated with third-party supplier Teva Pharmaceuticals in 2010 concerning ezetimibe API, but was unable to reach agreement.

Glenmark also pursued a deal with another third-party company called Changzhou between 2010 and 2014, but Changzhou's facilities failed an audit following an in-person inspection by Glenmark's team. Glenmark also considered another third-party supplier, MSN Laboratories ("MSN"), as early as 2007, but MSN was a competitor of Glenmark's, and MSN's quoted prices were prohibitively high, both of which rendered MSN a non-viable option. Finally, in late 2014, MSN developed a new manufacturing process and dramatically cut its prices, and Glenmark and MSN reached an agreement regarding MSN supplying Glenmark with ezetimibe API. Glenmark also reached an agreement to obtain ezetimibe API from Dishman Carbogen Amcis Ltd. ("Dishman").

62. However, based on the timing of these negotiations, supply constraints, and risk-mitigation concerns, Glenmark would not have been able to secure a third-party supply of ezetimibe API in time to support an earlier commercial launch.

63. Glenmark would not have launched generic Zetia without a viable internal process for manufacturing API. Nor would Glenmark have launched generic Zetia in reliance exclusively on securing API from a third-party supplier, including MSN.

64. Glenmark's planned supply chain for generic Zetia included three different manufacturing sites to make API, and four different manufacturing sites to conduct formulation manufacturing (i.e., to turn the API into finished products). It took Glenmark until 2016 to get this supply chain in place.

65. Glenmark's three manufacturing sites to produce API were Glenmark's Ankleshwar site based in India, the MSN site, and a site operated by Dishman. The four formulation manufacturing sites included Glenmark's Goa and Indore sites, both based in India,

a site operated by a third-party called APPCO based in the United States, and Par's site also based in the United States.

66. It took Glenmark several years to qualify backup finished product manufacturing sites at APPCO and Par. Those steps were necessary components of risk mitigation for the ezetimibe supply chain. Glenmark would not have launched generic Zetia without qualifying backup finished product manufacturing sites in the U.S.

67. The chemical structure of ezetimibe API is highly complex—more complex than the APIs that go into most pharmaceutical products.

68. Glenmark would not have abandoned core principles of supply chain risk mitigation to pursue an earlier commercial launch of generic Zetia. Glenmark would not have pursued an earlier commercial launch without putting in place adequate backup API manufacturing facilities, including both in-house and multiple third-party facilities, as well as backup formulation manufacturing facilities, including in-house and third-party backup facilities in the United States.

69. If Glenmark had pursued a commercial launch without following a robust risk mitigation strategy, it would have encountered supply chain failures threatening its ability to supply the market for generic Zetia.

70. Glenmark would not have pursued final FDA approval of its generic Zetia ANDA until Glenmark first put in place a commercially viable launch process.

71. Plaintiffs are not entitled to damages.

V. TRIABLE ISSUES

A. Triable Issues as Contended by the Purchasers

1. Whether Merck Paid Glenmark to Stay off the Market

- Whether Merck made a large and unjustified payment to Glenmark in the form of a (i) no-AG agreement and (ii) $9 million cash payment from Merck to Glenmark.
- Whether the payment was larger than the legal fees and expenses that Merck avoided by settling the patent case.
- Whether Merck made the payment to avoid the risk of competition in the market for Zetia.

2. Whether the Defendants Have Procompetitive Justifications for the No-AG Agreement

- Whether the defendants have any procompetitive justifications for the reverse payment (the no-AG agreement and $9 million cash payment) in exchange for a later agreed entry date, and if they do, whether those justifications outweigh the delay in generic Zetia reaching the market or could have been achieved without the challenged restraint.

3. Whether Merck and Glenmark Would Have Reached an Alternate Settlement

- Whether law-abiding companies in Merck's and Glenmark's positions would have settled the case for a competitively balanced entry date earlier than December 2016 absent the challenged restraint.

4. Whether Merck's and Glenmark's Conduct Caused Damages to the Purchasers

- Whether and by what date a law-abiding company in Glenmark's position would have entered the market.
- Whether and by what date a law-abiding company in Merck's position would have launched an AG during the 180-day exclusivity period.
- Whether and by what dates other generics (Sandoz/Teva) would have entered the market.
- The quantum of overcharge damages to the purchasers.

5. End-Payor Plaintiffs Only

- Whether the conduct was flagrant and/or willful?
- Whether it is inequitable (unjust) for Merck and/or Glenmark to keep the benefits that they obtained though the conduct alleged.

B. Triable Issues as Contended by Defendants

1. Whether Merck made a large and unjustified payment to Glenmark through (1) provisions of the Settlement Agreement that relate to Merck's launch of an authorized generic; and/or (2) provisions of the Settlement Agreement that required Merck to reimburse Glenmark for up to $9 million in documented legal fees;

2. Whether, in exchange for a large and unjustified payment from Merck, Glenmark agreed to delay the launch of its generic Zetia product;

3. Whether, as a result of a large and unjustified payment to Glenmark, Merck avoided the risk of competition;

4. Whether the Settlement Agreement between Merck and Glenmark was unreasonably anticompetitive, i.e., whether any anticompetitive effects of the Settlement Agreement substantially outweighed its procompetitive benefits;

5. (a) [Merck Position] Whether, had it not been for the Settlement Agreement, Merck and Glenmark would have resolved the Merck-Glenmark patent litigation by agreeing to a different settlement that included a patent license date for Glenmark earlier than December 12, 2016 and, if so, what that date would have been;

(b) [Glenmark Position] Whether, had it not been for the Settlement Agreement, Merck and Glenmark would have resolved the Merck-Glenmark patent litigation by agreeing to a different settlement that included a patent license date for Glenmark between January and May 2015 and, if so, what that date would have been;

6. Whether, if Merck and Glenmark had agreed to a different settlement with a patent license date between January and May 2015, Glenmark would have launched generic Zetia before December 12, 2016, taking into account any manufacturing and/or regulatory obstacles Glenmark may have faced, and if so, in which month and year;

7. Whether any of the Plaintiffs suffered injuries that were caused by Merck and Glenmark's conduct, as opposed to other factors, and whether, as a result of those injuries, any of the Plaintiffs suffered damages in the form of overcharges for purchases of Zetia;

8. Whether the Merck-Glenmark Settlement Agreement was a "flagrant" violation of the antitrust laws;

9. Whether the Merck-Glenmark Settlement Agreement was a "willful" violation of the antitrust laws;

10. Whether the Merck-Glenmark Settlement Agreement was a both "willful and wanton" violation of the antitrust laws;

11. Whether any overcharge damages that the Direct Purchaser Plaintiffs ("DPPs") are owed can be calculated without guessing, speculating, or making speculative assumptions or inferences, and if so, what amount of damages the DPPs have proven;

12. Whether any overcharge damages that the Retailer Plaintiffs are owed can be calculated without guessing, speculating, or making speculative assumptions or inferences, and if so, what amount of damages the Retailer Plaintiffs have proven;

13. Whether any overcharge damages that the End-Payor Plaintiffs ("EPPs") are owed can be calculated without guessing, speculating, or making speculative assumptions or inferences, and if so, what amount of damages the EPPs have proven;

14. Whether EPPs passed on any overcharge they paid to another entity, including through higher insurance premiums or passing on costs to Medicare Part D;

15. Whether the various Plaintiffs in this case are seeking duplicative damages.

Date: 4/14/23

/s/
Douglas E. Miller
United States Magistrate Judge

Douglas E. Miller,
United States Magistrate Judge

In Re: Zetia (Ezetimibe) Antitrust Litigation

Civil Action No. 2:18md2836

FINAL PRETRIAL ORDER EXHIBIT INDEX

Tab No.	Description
1	Stipulation of Undisputed Facts
2	Purchasers' Expect to Use Exhibits (a) Without Objections (b) With Objections
3	Merck's Expect to Use Exhibits With and Without Objections
4	Glenmark's Expect to Use Exhibits With and Without Objections
5	Purchasers' May Use Exhibits (a) Without Objections (b) With Objections
6	Merck's May Use Exhibits With and Without Objections
7	Glenmark's May Use Exhibits With and Without Objections
8	Index for Objections to Exhibits & Deposition Designations
9	Purchasers' Witness List
10	Merck's Witness List
11	Glenmark's Witness List

EXHIBIT 1

UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF VIRGINIA

In re Zetia (Ezetimibe) Antitrust Litigation	MDL No. 1836
This Document Relates to: All Actions	Civil Action No. 18-md-2836-RBS-DEM

STIPULATION OF UNDISPUTED FACTS

All parties stipulate and agree that the facts listed below are true and may be incorporated into the trial record without the necessity of supporting testimony or exhibits:

A. The Parties.

1. Defendant Merck & Co., Inc. is a corporation organized and existing under the laws of the state of New Jersey, with its principal place of business located in Kenilworth, New Jersey.
2. Defendant Merck Sharp & Dohme LLC (f/k/a Merck Sharp & Dohme Corporation) is a company organized and existing under the laws of the state of New Jersey with its principal place of business located in Whitehouse Station, New Jersey.
3. Defendant MSP Singapore Company LLC is a company organized and existing under the laws of the state of Delaware, with its principal place of business located in Singapore.
4. Merck Sharp & Dohme LLC and MSP Singapore Company LLC are each, directly or indirectly, wholly-owned subsidiaries of Merck & Co., Inc.

5. Defendant Schering-Plough Corporation was a corporation organized and existing under the laws of the state of New Jersey, with its principal place of business located in Kenilworth, New Jersey.
6. Defendant Schering Corporation was a corporation organized and existing under the laws of the state of New Jersey, with its principal place of business located in Kenilworth, New Jersey.
7. Schering Corporation was a wholly-owned subsidiary of Schering-Plough Corporation.
8. In 2009, Merck & Co., Inc. acquired Schering-Plough Corporation. Schering-Plough Corporation was renamed Merck & Co., Inc., and the company originally known as Merck & Co., Inc. was renamed Merck Sharp & Dohme Corporation.[1]
9. Defendant Glenmark Pharmaceuticals Limited is a company organized and existing under the law of India, with its corporate and registered offices located in the City of Mumbai.
10. Defendant Glenmark Pharmaceuticals Inc., USA is a subsidiary of Glenmark Pharmaceuticals Limited, with its principal place of business in Mahwah, New Jersey. In 2002, Glenmark Pharmaceuticals Inc., USA was incorporated. Since 2002, Glenmark Pharmaceuticals Inc., USA has been referred to as, done business under, and/or formally been known as, both Glenmark Pharmaceuticals Inc., USA and, at points, Glenmark Generics Inc., USA.
11. Plaintiff FWK Holdings, LLC is a limited liability company organized and existing under the laws of the state of Illinois, with its principal place of business located in Glen Ellyn, Illinois.

---

[1] MRKZETIA_NDA00018071.

12. Plaintiff Rochester Drug Cooperative, Inc. is a stock corporation duly formed and existing under the New York Cooperative Corporations Law, with its principal place of business located in Rochester, New York.

13. Plaintiff Cesar Castillo, LLC is a corporation organized and existing under the laws of the Commonwealth of Puerto Rico, with its principal place of business and headquarters located in Rio Piedras, Puerto Rico.

14. Plaintiff Walgreen Co. is a corporation organized and existing under the laws of the state of Illinois with its principal place of business located in Deerfield, Illinois.

15. Plaintiff The Kroger Co. is a corporation organized and existing under the laws of the state of Ohio with its principal place of business located in Cincinnati, Ohio.

16. Plaintiff Albertsons Companies, Inc., formerly known as Albertsons Companies, LLC, is a corporation organized and existing under the laws of the state of Delaware with its principal place of business located in Boise, Idaho.

17. Plaintiff HEB Grocery Company L.P. is a limited partnership organized and existing under the laws of the state of Texas with its principal place of business located in San Antonio, Texas.

18. Plaintiffs Rite Aid Corporation and Rite Aid Hdqtrs. Corp. ("Rite Aid") are corporations organized and existing under the laws of the state of Delaware with their principal place of business located in Philadelphia, Pennsylvania.

19. Plaintiff CVS Pharmacy, Inc. is a corporation organized and existing under the laws of the state of Rhode Island with its principal place of business located in Woonsocket, Rhode Island.

20. Plaintiff, The City of Providence, Rhode Island, is a municipal corporation with its principal office located in Providence, Rhode Island.

21. Plaintiff, International Union of Operating Engineers Local 49 Health & Welfare Fund, is a Taft-Hartley fund authorized pursuant to Section 302(c)(5) of the National Labor Relations Act, with its principal place of business located in Roseville, Minnesota, and an employee welfare benefit plan as defined in Section 3(1) of ERISA.

22. Plaintiff, Painters District Council No. 30 Health and Welfare Fund, is an employee welfare benefit plan, with its principal place of business located in Aurora, Illinois.

23. Plaintiff, Sergeants Benevolent Association Health and Welfare Fund, is an employee welfare benefits fund with its principal place of business located in New York, New York.

24. Plaintiff, United Food and Commercial Workers Local 1500 Welfare Fund, is an employee welfare benefits fund with its principal place of business located in Westbury, New York.

25. Plaintiff, Philadelphia Federation of Teachers Health and Welfare Fund, is a voluntary employee benefits plan organized pursuant to § 501(c) of the Internal Revenue Code, with its principal place of business located in Philadelphia, Pennsylvania.

26. Plaintiffs, The Uniformed Firefighters Association of Greater New York Security Benefit Fund and the Retired Firefighter Security Benefit Fund of the Uniformed Firefighters Association, are health and welfare benefit plans headquartered and with their principal place of business located in New York, New York.

27. Plaintiff McKesson Corporation is a corporation formed and existing under the laws of the state of Delaware with a principal place of business in Irving, Texas.

28. Plaintiffs AmerisourceBergen Corporation and AmerisourceBergen Drug Corporation are corporations organized and existing under the laws of the state of Delaware with principal places of business in Conshohocken, Pennsylvania.

29. Plaintiff H.D. Smith, LLC, is a limited liability company organized under the laws of the state of Delaware with a principal place of business in Springfield, Illinois.

30. Plaintiff Smith Medical Partners, LLC is a limited liability company organized under the laws of the state of Delaware with a principal place of business in Springfield, Illinois.

31. Plaintiff Valley Wholesale Drug Company, LLC, is a limited liability company organized under the laws of the state of Delaware with a principal place of business in Stockton, California.

32. Plaintiff Cardinal Health, Inc, is a corporation formed and existing under the laws of the state of Ohio with a principal place of business in Dublin, Ohio.

33. Plaintiff The Harvard Drug Group, L.L.C. is a limited liability company organized under the laws of the state of Illinois with a principal place of business in Livonia, Michigan.

34. Plaintiff Cardinal Health P.R. 120, Inc., is a corporation formed and existing under the laws of the territory of Puerto Rico with a principal place of business in Guaynabo, Puerto Rico.

35. Plaintiffs Meijer, Inc. and Meijer Distribution, Inc. are corporations organized and existing under the laws of the state of Michigan with their principal place of business in Grand Rapids, Michigan.

36. Plaintiff SUPERVALU, Inc., is a corporation organized and existing under the laws of the state of Delaware with a principal place of business in Eden Prairie, Minnesota.

37. Plaintiff Wegmans Food Markets, Inc. is a corporation organized and existing under the laws of the state of New York with a principal place of business in Rochester, New York.

38. Plaintiff KPH Healthcare Services, Inc., a/k/a Kinney Drugs, Inc., is a corporation organized and existing under the laws of the state of New York with a principal place of business in East Syracuse, New York.

39. Plaintiff MLI RX, LLC, is a limited liability company organized under the laws of the state of New Jersey.

40. Plaintiff Burlington Drug Company, Inc. is a Vermont corporation with a principal place of business in Milton, Vermont.

41. Plaintiff Dakota Drug, Inc. is a North Dakota corporation with a principal place of business in Anoka, Minnesota.

42. Plaintiff J M Smith Corporation d/b/a Smith Drug company is a South Carolina corporation with a principal place of business in Spartanburg, South Carolina.

43. Plaintiff Louisiana Wholesale Drug Co., Inc. is a Louisiana corporation with a principal place of business in Sunset, Louisiana.

44. Plaintiff North Carolina Mutual Wholesale Drug Company is a North Carolina corporation with a principal place of business in Durham, North Carolina.

45. Plaintiff Prescription Supply, Inc. is an Ohio corporation with a principal place of business in Northwood, Ohio.

46. Plaintiff Value Drug Company is a Pennsylvania corporation with a principal place of business in Duncansville, Pennsylvania.

47. Plaintiff Giant Eagle, Inc. is a corporation organized and existing under the laws of the Commonwealth of Pennsylvania with its principal place of business located in Pittsburgh, Pennsylvania.

B. The Ezetimibe Patents.

48. On September 21, 1993, Schering Corporation filed U.S. Patent Application 102,440 ("the '440 Application").[2]

49. On June 9, 1994, Schering Corporation filed U.S. Patent Application 257,593 ("the '593 Application") as a continuation-in-part of the '440 Application.[3]

50. On September 14, 1994, Schering Corporation filed International PCT Application No. PCT/US94/10099 ("the '10099 Application") as a continuation-in-part of the '593 Application.[4]

51. On March 18, 1996, Schering-Plough Corporation filed U.S. Patent Application 617,751 ("the '751 Application") as the United States national application corresponding to the '10099 Application.[5]

52. On May 20, 1997, the '593 Application was issued as U.S. Patent No. 5,631,365.[6]

53. On October 14, 1997, Schering Corporation filed U.S. Patent Application 953,825 ("the '825 Application") as a continuation-in-part of the '751 Application.[7]

---

[2] USPTO-ZETIA-0000001 at 002.

[3] USPTO-ZETIA-0000001 at 002.

[4] USPTO-ZETIA-0000027 at 028.

[5] USPTO-ZETIA-0000027 at 028.

[6] USPTO-ZETIA-0000001 at 002.

[7] USPTO-ZETIA-0023950 at 951.

54. On June 16, 1998, the '751 Application was issued as U.S. Patent No. 5,767,115.[8]

55. On December 8, 1998, the '825 Application was issued as U.S. Patent No. 5,846,966.[9]

56. On June 15, 2000, Schering Corporation filed Reissue Application No. 09/594,996, seeking reissue of U.S. Patent No. 5,767,115.[10]

57. On May 28, 2002, U.S. Patent No. 5,767,115 was reissued as U.S. Reissued Patent No. RE37,721.[11]

58. On June 9, 2010, Schering Corporation filed Reissue Application No. 12/797,341, seeking reissue of U.S. Reissued Patent No. RE37,721.[12]

59. On June 14, 2011, U.S. Reissued Patent No. RE37,721 was reissued as U.S. Reissued Patent No. RE42,461.[13]

So stipulated.

Dated: April 3, 2023

Respectfully submitted,

---

[8] USPTO-ZETIA-0000027 at 028.

[9] USPTO-ZETIA-0023950 at 951.

[10] USPTO-ZETIA-0000052 at 059; USPTO-ZETIA-0001328 at 329.

[11] USPTO-ZETIA-0001328 at 329.

[12] USPTO-ZETIA-0001373 at 373; USPTO-ZETIA-0023606 at 607.

[13] USPTO-ZETIA-0023606 at 607.

/s/ *Stephen E. Noona*
Stephen E. Noona
Virginia State Bar No. 25367
KAUFMAN & CANOLES, P.C.
150 W. Main Street, Suite 2100
Norfolk, VA 23510-1665
Telephone: (757) 624-3239
Facsimile: (888) 360-9092
senoona@kaufcan.com

Samuel G. Liversidge (*pro hac vice*)
Christopher D. Dusseault (*pro hac vice*)
GIBSON, DUNN & CRUTCHER LLP
333 South Grand Avenue
Los Angeles, CA 90071-3197
Telephone: (213) 229-7855
Facsimile: (213) 229-6855
SLiversidge@gibsondunn.com
CDusseault@gibsondunn.com

Ashley Johnson (*pro hac vice*)
GIBSON, DUNN & CRUTCHER LLP
2001 Ross Avenue, Suite 2100
Dallas, TX 75201-6912
Telephone: (214) 698-3320
Facsimile: (214) 571-2936
AJohnson@gibsondunn.com

Eric J. Stock (*pro hac vice*)
GIBSON, DUNN & CRUTCHER LLP
200 Park Avenue
New York, NY 10166
Telephone: (212) 351-2301
Facsimile: (212) 716-0801
estock@gibsondunn.com

Tarek Ismail (*pro hac vice*)
Jennifer L. Greenblatt (*pro hac vice*)
GOLDMAN ISMAIL TOMASELLI BRENNAN & BAUM LLP
200 South Wacker Drive, 22nd Floor
Chicago, IL 60606
Telephone: (312) 681-6000
Facsimile: (312) 881-5191
tismail@goldmanismail.com
jgreenblatt@goldmanismail.com

/s/ William H. Monroe, Jr.
William H. Monroe, Jr. (VSB No. 27441)
Marc C. Greco (VSB No. 41496)
Kip A. Harbison (VSB No. 38648)
Michael A. Glasser (VSB No. 17651)
GLASSER AND GLASSER, P.L.C.
Crown Center, Suite 600
580 East Main Street
Norfolk, VA 23510
Telephone: (757) 625-6787
Facsimile: (757) 625-5959
bill@glasserlaw.com
marcg@glasserlaw.com
kip@glasserlaw.com
michael@glasserlaw.com

Local Counsel for Plaintiffs FWK Holdings, LLC, Rochester Drug Cooperative, Inc., Cesar Castillo, LLC, McKesson Corporation, AmerisourceBergen Corporation, AmerisourceBergen Drug Corporation, H.D. Smith, LLC, Smith Medical Partners, LLC, Valley Wholesale Drug Company, LLC, Cardinal Health, Inc., The Harvard Drug Group, L.L.C., Cardinal Health P.R. 120, Inc., Meijer, Inc., Meijer Distribution, Inc., SUPERVALU, Inc., Wegmans Food Markets, Inc., KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc., and MLI RX, LLC, and Member of the Direct Purchaser Executive Committee

Thomas M. Sobol (*pro hac vice)*
Kristen A. Johnson (*pro hac vice)*
Erin C. Burns (*pro hac vice*)
Hannah Schwarzschild (*pro hac vice*)
Rachel Downey (*pro hac vice*)
HAGENS BERMAN SOBOL SHAPIRO LLP
One Faneuil Hall Square, 5th Floor
Boston, MA 02109
Telephone: (617) 482-3700
Facsimile: (617) 482-3003
tom@hbsslaw.com
kristenj@hbsslaw.com
hannahs@hbsslaw.com
erinb@hbsslaw.com

racheld@hbsslaw.com

Counsel for Defendants Merck & Co., Inc.; Merck Sharp & Dohme Corp., now known as Merck Sharp & Dohme LLC; Schering-Plough Corp.; Schering Corp. and MSP Singapore Co. LLC

Lead Counsel for the Direct Purchaser Plaintiffs and Counsel for Plaintiffs FWK Holdings, LLC, McKesson Corporation, AmerisourceBergen Corporation, AmerisourceBergen Drug Corporation, H.D. Smith, LLC, Smith Medical Partners, LLC, Valley Wholesale Drug Company, LLC, Cardinal Health, Inc., The Harvard Drug Group, L.L.C., and Cardinal Health P.R. 120, Inc.

David F. Sorensen (*pro hac vice*)
Ellen T. Noteware (*pro hac vice*)
BERGER MONTAGUE PC
1818 Market Street, Suite 3600
Philadelphia, PA 19103
Telephone: (215) 875-3000
Facsimile: (215) 875-4604
dsorensen@bm.net
enoteware@bm.net

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs Rochester Drug Cooperative, Inc., McKesson Corporation, AmerisourceBergen Corporation, AmerisourceBergen Drug Corporation, H.D. Smith, LLC, Smith Medical Partners, LLC, Valley Wholesale Drug Company, LLC, Cardinal Health, Inc., The Harvard Drug Group, L.L.C., and Cardinal Health P.R. 120, Inc.

Peter R. Kohn (*pro hac vice*)
Joseph T. Lukens (*pro hac vice*)
Neill W. Clark (*pro hac vice*)
FARUQI & FARUQI, LLP
One Penn Center, Suite 1550
1617 John F. Kennedy Boulevard
Philadelphia, PA 19103
Telephone: (215) 277-5770
Facsimile: (215) 277-5771
pkohn@faruqilaw.com
jlukens@faruqilaw.com
nclark@faruqilaw.com

Bradley J. Demuth (*pro hac vice*)
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Telephone: (212) 983-9330
Facsimile: (212) 983-9331
bdemuth@faruqilaw.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs Rochester Drug Cooperative, Inc. and MLI RX, LLC

Paul E. Slater
Joseph M. Vanek (*pro hac vice*)
David P. Germaine (*pro hac vice*)
Alberto Rodriguez (*pro hac vice*)
SPERLING & SLATER, LLC
55 W. Monroe, Suite 3200
Chicago, IL 60603
Telephone: (312) 641-3200
Facsimile: (312) 641-6492
pes@sperling-law.com
jvanek@sperling-law.com
dgermaine@sperling-law.com

Michael L. Roberts (*pro hac vice*)
Karen Sharp Halbert (*pro hac vice*)
Stephanie Smith (*pro hac vice*)
Sarah E. DeLoach (*pro hac vice*)
ROBERTS LAW FIRM, P.A.
20 Rahling Circle
Little Rock, AR 72223

arodriguez@sperling-law.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs FWK Holdings, LLC, Meijer, Inc., Meijer Distribution, Inc., and SUPERVALU, Inc.

Linda P. Nussbaum (*pro hac vice*)
Peter Moran (*pro hac vice*)
NUSSBAUM LAW GROUP, P.C.
1211 Avenue of the Americas, 40th Floor
New York, NY 10036-8718
Telephone: (917) 438-9189
lnussbaum@nussbaumpc.com
pmoran@nussbaumpc.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs Cesar Castillo, LLC and Wegmans Food Markets, Inc.

John D. Radice (*pro hac vice*)
April Lambert (*pro hac vice*)
Daniel Rubenstein (*pro hac vice*)
Kenneth Pickle (*pro hac vice*)
Luck Smith (*pro hac vice*)
RADICE LAW FIRM, P.C.
475 Wall Street
Princeton, NJ 08540
Telephone: (646) 245-8502
Facsimile: (609) 385-0745
jradice@radicelawfirm.com
alambert@radicelawfirm.com
drubenstein@radicelawfirm.com
kpickle@radicelawfirm.com
lsmith@radicelawfirm.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

Sharon K. Robertson (*pro hac vice*)
Donna M. Evans (*pro hac vice*)
COHEN MILSTEIN SELLERS & TOLL PLLC
88 Pine Street, 14th Floor
New York, NY 10005
Telephone: (501) 821-5575
Facsimile: (501) 821-4474
mikeroberts@robertslawfirm.us
karenhalbert@robertslawfirm.us
stephaniesmith@robertslawfirm.us
sarahdeloach@robertslawfirm.us

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs FWK Holdings, LLC and KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc.

Steve D. Shadowen (*pro hac vice*)
Matthew C. Weiner (*pro hac vice*)
Tina Miranda (*pro hac vice*)
HILLIARD & SHADOWEN LLP
1135 W. 6th Street, Suite 125
Austin, TX 78703
Telephone: (855) 344-3298
steve@hilliardshadowenlaw.com
matt@hilliardshadowenlaw.com
tmiranda@hilliardshadowenlaw.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

Joseph H. Meltzer (*pro hac vice*)
Terence S. Ziegler (*pro hac vice*)
KESSLER TOPAZ MELTZER & CHECK LLP
280 King of Prussia Road
Radnor, PA 19087
Telephone: (610) 667-7706
Facsimile: (610) 667-7056
jmeltzer@ktmc.com
tziegler@ktmc.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

Barry Taus (*pro hac vice*)
Archana Tamoshunas (*pro hac vice*)
Kevin Landau (*pro hac vice*)
TAUS, CEBULASH & LANDAU, LLP
123 William Street, Suite 1900A

Telephone: (212) 838-7797
Facsimile: (212) 838-7745
srobertson@cohenmilstein.com
devans@cohenmilstein.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

New York, NY 10038
Telephone: (212) 931-0704
btaus@tcllaw.com
atamoshunas@tcllaw.com
klandau@tcllaw.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff Rochester Drug Cooperative, Inc.

Jayne A. Goldstein (*pro hac vice*)
Miller Shah, LLP
1625 North Commerce Parkway, Ste. 320
Fort Lauderdale, FL 33326
Telephone: (954) 515-0123
Facsimile: (866) 300-7367
jagoldstein@millershah.com

Counsel for Plaintiff Cesar Castillo, LLC

/s/ James A. Cales III
James A. Cales III (VSB No. 41317)
Alan Brody Rashkind (VSB No. 12658)
FURNISS, DAVID, RASHKIND & SAUNDERS PC
6160 Kempsville Circle, Suite 341B
Norfolk, VA 23502
Telephone: (757) 461-7100
arashkind@furnissdavis.com
jcales@furnissdavis.com

Local Counsel for the End-Payor Class

Marvin A. Miller (*pro hac vice*)
Lori A. Fanning (*pro hac vice*)
MILLER LAW LLC
115 S. LaSalle Street, Suite 2910
Chicago, IL 60603
Telephone: (312) 332-3400
mmiller@millerlawllc.com
lfanning@millerlawllc.com

Michael M. Buchman (*pro hac vice*)
MOTLEY RICE LLC
777 Third Avenue, 27th Floor
New York, NY 10017
Telephone: (212) 577-0040
mbuchman@motleyrice.com

Co-Lead Counsel for the End-Payor Class

/s/ John F. Sawyer
John F. Sawyer (VA Bar No. 65902)
WOLCOTT RIVERS GATES

Convergence Center V
200 Bendix Road, Suite 300
Virginia Beach, VA 23452
Telephone: 757-554-0249
Facsimile: 757-497-7267
sawyer@wolriv.com

Local Counsel for Burlington Drug Company, Inc., Dakota Drug, Inc., J M Smith Corporation d/b/a Smith Drug Company, Louisiana Wholesale Drug Co., Inc., North Carolina Mutual Wholesale Drug Company, Prescription Supply, Inc., and Value Drug Company, Giant Eagle, Inc., and the Retailer Plaintiffs

Bruce E. Gerstein (*pro hac vice*)
Kimberly Hennings (*pro hac vice*)
David B. Rochelson (*pro hac vice*)
GARWIN GERSTEIN & FISHER LLP
88 Pine St., 10th Floor
New York, NY 10005
Telephone: (212) 395-0055
bgerstein@garwingerstein.com
khennings@garwingerstein.com
drochelson@garwingerstein.com

Susan Segura
David Raphael
SMITH SEGURA RAPHAEL & LEGER LLP
221 Ansley Blvd.
Alexandria, LA
Telephone: (318) 445-4480
ssegura@ssrllp.com
draphael@ssrllp.com

Stuart E. Des Roches
ODOM & DES ROCHES LLC
650 Poydras Street, Suite 2020
New Orleans, LA 70130
Telephone: (504) 522-0077
stuart@odrlaw.com

Counsel for Burlington Drug Company, Inc., Dakota Drug, Inc., J M Smith Corporation d/b/a Smith Drug Company, Louisiana Wholesale Drug Co., Inc., North Carolina Mutual Wholesale Drug Company, Prescription Supply, Inc., and Value Drug Company

Scott E. Perwin (*pro hac vice*)
Lauren C. Ravkind (*pro hac vice*)
Anna T. Neill (*pro hac vice*)
KENNY NACHWALTER P.A.
Four Seasons Tower
1441 Brickell Avenue, Suite 1100
Miami, FL 33131
Telephone: (305) 373-1000
Facsimile: (305) 372-1861
sperwin@knpa.com

Barry L. Refsin (*pro hac vice*)
Eric L. Bloom (*pro hac vice*)
HANGLEY ARONCHICK SEGAL PUDLIN & SCHILLER P.A.
One Logan Square, 27th Floor
Philadelphia, PA 19103
Telephone: (215) 568-6200
brefsin@hangley.com
ebloom@hangley.com

lravkind@knpa.com
aneill@knpa.com

Counsel for the Retailer Plaintiffs (No. 2:18-cv-266) and Giant Eagle, Inc.

Counsel for the Retailer Plaintiffs CVS and Rite Aid (Nos. 2:18-cv-423 & 2:18-cv-439)

Bernard D. Marcus
Moira Cain-Mannix
Brian C. Hill
Erin Gibson Allen
MARCUS & SHAPIRA LLP
301 Grant Street
One Oxford Centre, 35th Floor
Pittsburgh, PA 15219-6401
Telephone: 412-471-3490
Facsimile: 412-391-8758
marcus@marcus-shapira.com
cain-mannix@marcus-shapira.com
hill@marcus-shapira.com
allen@marcus-shapira.com

Counsel for Giant Eagle, Inc.

/s/ Richard H. Ottinger
Richard H. Ottinger (VSB No.: 38842)
Dustin M. Paul (VSB No.: 75287)
Edward J. Powers (VSB No. 32146)
WOODS ROGERS VANDEVENTER BLACK
101 West Main Street, Suite 500
Norfolk, VA 23510
Telephone: (757) 446-8600
Facsimile: (757) 446-8670
rottinger@vanblacklaw.com
dpaul@vanblacklaw.com
epowers@vanblacklaw.com

Jay Philip Lefkowitz (*pro hac vice*)
Devora Whitman Allon (*pro hac vice*)
Kevin Michael Neylan, Jr. (*pro hac vice*)
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, NY 10022
Telephone: (212) 390-4092
Facsimile: (212) 446-4900
lefkowitz@kirkland.com
devora.allon@kirkland.com
kevin.neylan@kirkland.com

Counsel for Defendants Glenmark Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Inc., USA, incorrectly identified as Glenmark Generics Inc., US

EXHIBIT 2(a)

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0010	05/11/2017	Memo from D. Pakula and M. Exume to M. Strasburger, "Request for Approval and Signature to a Side Letter Agreement"	MRKZETIA_R000024575	MRKZETIA_R000024576
PX0019	09/12/2011	Expert Report of Andrew Myers	MRKZETIA_R000045264	MRKZETIA_R000045337
PX0021	08/30/2013	Settlement Agreement by and among Merck Sharp & Dohme Corporation and Sandoz Inc.	MRKZETIA_R000048316	MRKZETIA_R000048343
PX0023	01/19/2017	Zetia LOE Tracking Dashboard	MRKZETIA_R000051440	MRKZETIA_R000051440
PX0024	01/25/2017	Merck Presentation, "Zetia LOE Tracking Dashboard"	MRKZETIA_R000051451	MRKZETIA_R000051451
PX0032	10/23/2009	Email from V. Soni to P. Matukaitis, "Settlement Communication," with attached licensing prospectuses for GRC 6211 & 10693	MRKZETIA_R000061518	MRKZETIA_R000061535
PX0035	02/26/2010	Email from V. Soni to P. Matukaitis," Re: Glenmark-Merck"	MRKZETIA_R000061858	MRKZETIA_R000061861
PX0036	02/24/2010	Teleconference invitation from C. Mercer to E. Murray et al., "Zetia Potential Settlement Financial Analysis"	MRKZETIA_R000061917	MRKZETIA_R000061917
PX0038	10/31/2018	Merck Spreadsheet, "US Market Ezetimibe Family P&L" Actuals 2013-Sep YTD 2018	MRKZETIA_R000062439	MRKZETIA_R000062439
PX0039	11/01/2018	Merck Spreadsheet, "Zetia Products, US Pharma, 2010-2012 Actual Sales"	MRKZETIA_R000062456	MRKZETIA_R000062456
PX0048	03/26/2010	Email from P. Matukaitis to V. Soni, "RE: Temodar - Glenmark Meeting - Monday, March 29, 2010"	MRKZETIA_R000078807	MRKZETIA_R000078809
PX0049	06/21/2011	Email from Q. Kapadia to R. Watson et al., "Presentation materials for the 7:30 AM MSP Singapore Board teleconference," with attached presentation, "MSP Singapore Board: Manufacturing Update - Zetia/Ezetrol & Vytorin/Inegy, June 23, 2011"	MRKZETIA_R000079548	MRKZETIA_R000079548
PX0050	02/16/2010	Teleconference Confirmation from P. McCrorey to E. Murray, A. Misyan & L. Jakob, "Updated: ZETIA Generic Early Entry"	MRKZETIA_R000080384	MRKZETIA_R000080384
PX0051	03/22/2016	Email from D. Pakula to J. Hall, "US Region Approval for BD Deals"	MRKZETIA_R000080732	MRKZETIA_R000080737
PX0052	10/05/2017	Email from D. Pakula to Y. Gibble et al., "3Q17 AG List [Sensitive]" with attached "3Q 2017 AG List for Merck Team.xlsx"	MRKZETIA_R000080748	MRKZETIA_R000080749
PX0053	10/31/2017	Email from D. Dellaratta to J. Friga, "FW: Zetia AG Status"	MRKZETIA_R000080987	MRKZETIA_R000080987
PX0055	09/19/2016	Merck Memorandum from S. Simroth et al. to J. Hall et al., "Request for Concurrence: ZETIA Authorized Generic Supply and Distribution Agreement with Prasco"	MRKZETIA_R000081058	MRKZETIA_R000081060
PX0068	06/22/2005	Merck Presentation, "Proposal to Pursue Authorized Generics in the U.S."	MRKZETIA_R000090248	MRKZETIA_R000090248

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0072	08/07/2012	Memorandum from A. Robinson, S. Das & G. Dunlop to G. Bell & W. Deese, "Request for Concurrence and Finance Consultation: MAXALT and MAXALT MLT Authorized Generic Supply and Distribution Agreement with Par Pharmaceuticals"	MRKZETIA_R000090357	MRKZETIA_R000090359
PX0075	01/16/2007	Supply and Distribution Agreement by and between Merck & Co., Inc. and Prasco, LLC	MRKZETIA_R000090404	MRKZETIA_R000090776
PX0077	04/13/2007	Merck Presentation, "Hi-Tech Litigation and AG Status"	MRKZETIA_R000090543	MRKZETIA_R000090543
PX0081	02/22/2010	Memorandum from B. Cowen, A. Robinson & P. Rinnander to P. Kellogg, "Request for Concurrence and Finance Consultation: COZAAR/HYZAAR Authorized Generic Supply and Distribution Agreement with Sandoz"	MRKZETIA_R000090562	MRKZETIA_R000090564
PX0082	09/06/2007	Memo from T. Silfies, T. DeVenzio and H. Freeman to P Kellogg, et al., re: "FOSAMAX Once Weekly Authorized Generic License and Supply Agreement with Watson"	MRKZETIA_R000090577	MRKZETIA_R000090579
PX0087	01/09/2013	Merck Presentation, "Temodar Authorized Generic"	MRKZETIA_R000090665	MRKZETIA_R000090665
PX0089	02/22/2006	Merck Presentation, "Authorized Generics in the U.S."	MRKZETIA_R000090705	MRKZETIA_R000090705
PX0095	03/10/2006	Merck Presentation, "Fosamax - Post-Patent Expiry: Strategies to Maximize Income and Minimize Impact of Generic Competition with Authorized Generics"	MRKZETIA_R000090753	MRKZETIA_R000090753
PX0108	09/01/2016	Presentation: 2017 Athero Franchise Product Plan (US Market)	MRKZETIA_R000094835	MRKZETIA_R000094835
PX0110	11/28/2005	Letter from A. Afonso to J. Nelson Acknowledging Receipt of Nov. 14, 2005 Letter Rejecting Inventorship Claim for U.S. Patent Nos. 5,631,365 & RE37,721	MRKZETIA_SIDLEY000004439	MRKZETIA_SIDLEY000004439
PX0113	11/14/2005	Letter from D. Auth to A. Afonso, "Re: Investigation of Inventorship on U.S. Patent Nos. RE37,721 E and 5,631,365"	MRKZETIA_SIDLEY000007278	MRKZETIA_SIDLEY000007281
PX0114	08/18/1993	Adriano Afonso Schering Corporation Lab Notebook No. 32242 (Aug. 18, 1994-Sept. 20, 1994)	MRKZETIA_SIDLEY000009611	MRKZETIA_SIDLEY000009775
PX0116	01/25/2012	Joint Submission of the Parties' Respective Proposed Findings of Fact, Schering Corp. v. Mylan Pharm. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	MRKZETIA_SIDLEY000018053	MRKZETIA_SIDLEY000018162
PX0117	06/01/1993	Stuart Rosenblum Schering Corporation Lab Notebook No. 28581 (Mar. 1992-June 1993)	MRKZETIA_SIDLEY000018262	MRKZETIA_SIDLEY000018424
PX0119	08/16/2011	Expert Report of William R. Roush, Ph.D., Schering Corp. v. Mylan Pharm. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	MRKZETIA_SIDLEY000082080	MRKZETIA_SIDLEY000082175
PX0122	06/14/2011	U.S. Patent No. RE42,461	MRKZETIA_SIDLEY000118024	MRKZETIA_SIDLEY000118057
PX0123	06/09/2010	Merck Preliminary Amendment Filed with Narrowing Reissue Application	MRKZETIA_SIDLEY000118251	MRKZETIA_SIDLEY000118261

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0142	09/03/2011	Spreadsheet, "Final Budget Nov 2010"	MRKZETIA_SIDLEY000221517	MRKZETIA_SIDLEY000221517
PX0142_N	09/03/2011	Spreadsheet, "Final Budget Nov 2010"	MRKZETIA_SIDLEY000221517	MRKZETIA_SIDLEY000221517
PX0143	09/12/2011	Expert Report of Ronald G. Brisbois, Ph.D., Schering Corp. v. Mylan Pharm. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	MRKZETIA_SIDLEY000225731	MRKZETIA_SIDLEY000225943
PX0144	09/30/2011	Corrected Expert Report of Professor William R. Roush, Ph.D., Schering Corp. v. Mylan Pharm. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	MRKZETIA_SIDLEY000235636	MRKZETIA_SIDLEY000235888
PX0146	05/10/2010	Settlement Agreement by and among Schering Corporation, MSP Singapore Company LLC, and Glenmark Pharmaceuticals Inc., USA	MRKZETIA000000001	MRKZETIA000000032
PX0163	01/01/1993	84-1 from Stuart Rosenberg Schering Corporation Lab Notebook No. 31818 - NMR Spectra	MRKZETIA000419349	MRKZETIA000419353
PX0187	05/11/2017	Letter from E. Arrington to M. Strasburger re Merck-Prasco Supply and Distribution Agreement 10-20-2016	MRKZETIA000509729	MRKZETIA000509733
PX0188	05/11/2017	Letter from E. Arrington to M. Strasburger attaching Supply & Distribution Agreement	MRKZETIA000509734	MRKZETIA000509738
PX0189	10/20/2016	Merck-Prasco Supply and Distribution Agreement, executed	MRKZETIA000509809	MRKZETIA000509866
PX0200	02/01/2016	Merck Presentation, "WILLARD"	MRKZETIA000509927	MRKZETIA000509927
PX0204	10/20/2016	Email from D. Pakula to N. Miller-Rich, "WILLARD: Talking Points [Confidential]"	MRKZETIA000510131	MRKZETIA000510133
PX0205	10/11/2016	Email from D. Pakula to N. Miller-Rich and T. Covert, "Willard Feedback"	MRKZETIA000510177	MRKZETIA000510177
PX0209	01/27/2017	Merck/Prasco Supply Team Meeting Minutes	MRKZETIA000510349	MRKZETIA000510352
PX0210	01/27/2017	Merck/Prasco Supply Team Meeting Minutes	MRKZETIA000510356	MRKZETIA000510356
PX0211	01/27/2017	Spreadsheet, "AG Checklist"	MRKZETIA000510396	MRKZETIA000510396
PX0216	06/07/2017	Email from M. Keough to P. Davish et al., "Updated Pricing Catalog [Confidential]"	MRKZETIA000510616	MRKZETIA000510617
PX0217	06/07/2017	Excerpt of spreadsheet, "Price History Report v4.1f-Active File-6-08-17 after price increase.xlsm" ("Product Respon," "Price Change History," "Pivot Data from GPM Query," and "Product Formats" tabs)	MRKZETIA000510657	MRKZETIA000510657
PX0222	03/31/2017	Presentation, "Primary Care & Women's Health: May Forecast"	MRKZETIA000511061	MRKZETIA000511061
PX0223	07/12/2016	Presentation, "Updated Zetia - Aug FC LOE.pptx"	MRKZETIA000511083	MRKZETIA000511083
PX0224	02/24/2017	Merck/Prasco Supply Team Meeting Minutes	MRKZETIA000511232	MRKZETIA000511235
PX0226	01/09/2017	Supply Team (Internal) Meeting Minutes	MRKZETIA000511244	MRKZETIA000511247
PX0227	09/19/2016	Merck Slides, "Request Permission to Execute Agreement"	MRKZETIA000511333	MRKZETIA000511333

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0228	07/05/2016	Email from D. Pakula to A. Hosler et al., "RE: timeline for 3 month window"	MRKZETIA000511382	MRKZETIA000511385
PX0230	04/19/2017	Merck/Prasco Supply Team Meeting Minutes	MRKZETIA000511408	MRKZETIA000511411
PX0232	04/05/2017	Merck/Prasco Supply Team Meeting Minutes	MRKZETIA000511431	MRKZETIA000511434
PX0234	03/15/2017	Merck/Prasco Supply Team Meeting Minutes	MRKZETIA000511440	MRKZETIA000511443
PX0241	09/19/2016	Presentation, "Merck Product Going Out - Request Permission to Execute Agreement"	MRKZETIA000511811	MRKZETIA000511811
PX0243	01/05/2017	Merck Presentation, "Zetia LOE Tracking Dashboard"	MRKZETIA000512071	MRKZETIA000512071
PX0244	01/10/2017	Email from R. Celano to A. Brueggemeier et al., "MK-0653 (ZETIA) - Authorized Generic Update & Questions [Confidential]"	MRKZETIA000512150	MRKZETIA000512151
PX0252	10/04/2016	Merck Presentation, "Primary Care & Women's Health, 2017 Budget - November Forecast"	MRKZETIA000515635	MRKZETIA000515635
PX0255	12/18/2015	Presentation: EZETIMIBE Loss of Exclusivity Plan	MRKZETIA000517420	MRKZETIA000517420
PX0264	05/14/2010	Excerpt of spreadsheet, "Waculator Draft Template May 10 2010 (2).xls" ("WACulator," "Price Impact Data," "CS Calculation," and "CS Revenue Weights" tabs)	MRKZETIA000522987	MRKZETIA000522987
PX0265	05/14/2010	Excerpt of spreadsheet, "Waculator Draft Template May 10 2010 (2).xls" ("Price Impact Data" tab)	MRKZETIA000522987	MRKZETIA000522987
PX0267	06/19/2014	Email from P. Magri to P. Davish, "RE: final slides"	MRKZETIA000523058	MRKZETIA000523059
PX0268	06/23/2014	Presentation, "USPricingStrategyUSML6 23 Final"	MRKZETIA000523060	MRKZETIA000523060
PX0272	06/14/2012	Email from W. Collingwood to J. Morrissey et al., "FW: 2013 Volume Planning process/activities/calendar," with attached presentation, "Inventory Planning Training, 2013 Budget, May 2012"	MRKZETIA000529310	MRKZETIA000529314
PX0273	01/14/2012	Email from P. Lambotte to T. Covert et al., "Inventory BHAG McKinsey initiative - Situation Analysis Update/Inventory - expectations" attaching "McKinsey 20120112 Discussion document.ppt	MRKZETIA000529456	MRKZETIA000529459
PX0274	05/31/2012	Email from P. Honigmann to I. Ang et al., "FW: COMPASS Review," with attached presentation, "Compass Review May 30"	MRKZETIA000529460	MRKZETIA000529461
PX0280	03/25/2014	Presentation, "Pricing Committee-LOE Planning ZETIA Family Franchise"	MRKZETIA000547885	MRKZETIA000547885
PX0283	11/06/2009	Email from V. Soni to P. Matukaitis, "RE: Settlement Communication"	MRKZETIA000598172	MRKZETIA000598177
PX0291	09/28/2016	Email from M. Exume to D. Gan, "Athero Profit Plan Slides [Confidential]," with attached presentation, "Athero Franchise Product Plan, September 2016, US Market"	MRKZETIA000601633	MRKZETIA000601635
PX0294	08/04/2016	Email from L. Jakob to D. Pakula, "Glenmark response" attaching Hirsch letter to L. Jakob dated 7-21-2016	MRKZETIA000614646	MRKZETIA000614647

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0295	04/27/2012	Opinion on Validity & Enforceability of '461 Patent, Schering Corp. v. Mylan Pharm. Inc., No. 09-cv-6383 (D.N.J.), ECF No. 444	MRKZETIA000615124	MRKZETIA000615154
PX0301	05/15/2017	Email from E. Rudnicki to N. Miller-Rich et al., "Letter from Brian Hirsch, Glenmark re ZETIA"	MRKZETIA000689529	MRKZETIA000689528
PX0306	11/21/2011	Defendant Mylan Pharmaceuticals Inc.'s Pretrial Brief, Schering Corp. v. Mylan Pharm., Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	MRKZETIA000847834	MRKZETIA000847858
PX0309	10/20/2016	Email from D. Pakula to M. Strasburger, "Project Willard - Request for Approval and Signature" with redaction, attaching "ZETIA AG - Supply & Distribution Agreement - EXECUTION COPY.docx"	MRKZETIA000848260	MRKZETIA000848261
PX0310	04/02/2010	Email from P. Matukaitis to V. Soni, "RE: Sunil called me with some concerns on the deal"	MRKZETIA000848666	MRKZETIA000848668
PX0311	11/02/2015	Memorandum from C. Antrosiglio & K. Robinson to B. McMahon et al., "Increased Discount Authority for Zetia After Loss of Exclusivity"	MRKZETIA000848706	MRKZETIA000848709
PX0318	06/08/2016	Letter from L. Jakob to Glenmark, attention Chief IP Counsel, "Glenmark Agreement," attaching same letter addressed to V. Soni	MRKZETIA000874087	MRKZETIA000874089
PX0330	10/07/2010	PTO Office letter to Ropes & Gray	MRKZETIA000933452	MRKZETIA000933483
PX0334	12/14/2009	Defendants' Trial Brief, Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	MRKZETIA000942633	MRKZETIA000942682
PX0338	06/30/2011	Settlement Agreement by and among Schering Corporation, MSP Singapore Company, LLC, and Teva Pharmaceuticals USA, Inc. in Schering Corp. v. Teva Pharm. USA, Inc., Nos. 10cv-1058 & 10-cv-4473 (D.N.J.)	MRKZETIA000988357	MRKZETIA000988392
PX0339	09/22/2010	Email from M. Redmond to P. McCrorey, "FW: MSP Singapore Board Teleconference - Thu 9/23, 7:00 AM," with attached presentation, "MSP Singapore Board: Manufacturing Update - Zetia/Ezetrol & Vytorin/Inegy, September 23, 2010"	MRKZETIA001027185	MRKZETIA001027190
PX0344	04/30/2010	Marketing and Distribution Agreement by and among Glenmark and Par	GLENMARK-ZETIA-00056715	GLENMARK-ZETIA-00056750
PX0345	12/05/2008	85-1 from Stuart Rosenberg Schering Corporation Lab Notebook No. 31818 - NMR Spectra	GLENMARK-ZETIA-00068619	GLENMARK-ZETIA-00068619
PX0346	08/03/1994	Rosenblum declaration for patent application	GLENMARK-ZETIA-00070950	GLENMARK-ZETIA-00071003
PX0353	04/20/2009	Expert Report of Ronald G. Brisbois, Ph.D., Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00082371	GLENMARK-ZETIA-00082601

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0354	04/20/2009	Expert Report of William R. Roush, Ph.D., Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00082607	GLENMARK-ZETIA-00082746
PX0356	05/08/2009	Rebuttal Expert Report of Clayton H. Heathcock, Ph.D., Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00082994	GLENMARK-ZETIA-00083043
PX0360	02/25/2009	Expert Report of Clayton H. Heathcock, Ph.D., Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00083263	GLENMARK-ZETIA-00083444
PX0368	11/18/1993	60-1 from Stuart Rosenberg Schering Corporation Lab Notebook No. 31818 - NMR Spectra	GLENMARK-ZETIA-00134013	GLENMARK-ZETIA-00134017
PX0380	12/14/2009	Plaintiffs' Pretrial Brief, Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.), ECF No. 186	GLENMARK-ZETIA-00149229	GLENMARK-ZETIA-00149267
PX0384	07/15/2005	Letter from A. Afonso to J. Nelson Requesting Revision of Inventor List for U.S. Patent Nos. 5,631,365 & 5,767,115	GLENMARK-ZETIA-00151701	GLENMARK-ZETIA-00151702
PX0387	04/24/2009	Tentative Approval Letter from FDA to Glenmark re: ANDA 78-560 for Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00159177	GLENMARK-ZETIA-00159182
PX0389	09/24/2008	Email from T. Coughlin to A. Maffia et al., "RE: Ezetimibe ANDA"	GLENMARK-ZETIA-00161776	GLENMARK-ZETIA-00161776
PX0393	12/21/2016	Presentation, "Ezetimibe US Launch Update"	GLENMARK-ZETIA-00166300	GLENMARK-ZETIA-00166300
PX0394	06/26/2015	FDA Approval Letter to Glenmark re: ANDA 078560 for Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00166675	GLENMARK-ZETIA-00166677
PX0395	11/30/2016	Presentation, "Ezetimibe US Launch Update"	GLENMARK-ZETIA-00166886	GLENMARK-ZETIA-00166886
PX0404	09/03/2015	Letter from FDA to Glenmark re Supplemental ANDA Approval	GLENMARK-ZETIA-00176756	GLENMARK-ZETIA-00176757
PX0417	02/07/2008	Email from J. Cangemi to P. Dutra, "Copy of Percy backup plan 2.7.08.xls," "Sales Break up 2.7.08.xls," with attachments	GLENMARK-ZETIA-00177685	GLENMARK-ZETIA-00177686
PX0424	06/23/2014	Email from S. Sridharan to T. Coughlin et al., "RE: Par-Glenmark JSC," with attached presentation, "Glenmark & PAR Project: Ezetimibe Steering Committee Meeting, 19 June 2014"	GLENMARK-ZETIA-00178546	GLENMARK-ZETIA-00178548
PX0426	09/24/2015	Email from A. Mehta to V. Soni et al., "Ezetimibe Par Model" with attachment "Par Ezetimibe Model.xlsx; Par Ezetimibe Model.pptx"	GLENMARK-ZETIA-00178560	GLENMARK-ZETIA-00178562
PX0432	07/20/2010	Email from M. Krishna to C. Vaithara et al., "RE: Ezetimibe 2nd source approval"	GLENMARK-ZETIA-00184122	GLENMARK-ZETIA-00184123
PX0433	04/16/2015	Ezetimibe - Overview Powerpoint.pptx	GLENMARK-ZETIA-00184224	GLENMARK-ZETIA-00184224
PX0438	03/29/2016	Email from P. Wagle to R. Reddy et al., "FW: Justification for Customs on Ezetimibe price"	GLENMARK-ZETIA-00186693	GLENMARK-ZETIA-00186693

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0444	09/03/2015	Letter from FDA to Glenmark Pharmaceuticals Inc., USA approving its Prior Approval Supplement for addition of MSN Laboratories Private Limited as an alternate drug substance source	GLENMARK-ZETIA-00192641	GLENMARK-ZETIA-00192642
PX0445	07/05/2015	MSN Laboratories Private Limited Certificates of Analysis dated April 28, 2015 and July 5, 2015	GLENMARK-ZETIA-00193128	GLENMARK-ZETIA-00193128_0013
PX0469	04/15/2010	Email from T. Coughlin to P. Campanelli, "Zetia"	GLENMARK-ZETIA-00201709	GLENMARK-ZETIA-00201709
PX0476	01/15/2014	Email from V. Yadav to M. Blashinsky, "Ezetimibe Valuation"	GLENMARK-ZETIA-00202255	GLENMARK-ZETIA-00202255
PX0477	01/15/2014	Email from M. Blashinsky to V. Yadav, "RE: Ezetimibe (Zetia) Business Case," with attached spreadsheet, "zetia projection 10-29-2013r1.xls"	GLENMARK-ZETIA-00202256	GLENMARK-ZETIA-00202257
PX0481	10/29/2013	Email from M. Blashinsky to P. Dutra, "Zetia sales projections," with attached spreadsheet, "zetia projection 10-29-2013"	GLENMARK-ZETIA-00202267	GLENMARK-ZETIA-00202268
PX0482	01/28/2014	Email from V. Yadav to P. Gioia et al., "Ezetimibe Forecast Comparison.pptx," with attached presentation	GLENMARK-ZETIA-00202285	GLENMARK-ZETIA-00202286
PX0483	01/23/2014	Email from V. Yadav to P. Gioia, "Ezetimibe Valuation," with attached spreadsheet, "NPV Ezetimibe 24 Jan 2014.xlsx"	GLENMARK-ZETIA-00202292	GLENMARK-ZETIA-00202294
PX0484	01/20/2014	Email from P. Dutra to V. Yadav et al., "RE: NPV Ezetimibe 16 Jan 2014.xlsx"	GLENMARK-ZETIA-00202305	GLENMARK-ZETIA-00202305
PX0491	05/31/2013	Letter from A. Maffia to FDA re: ANDA 078560, Ezetimibe Tablets 10 mg; Response to Complete Response Letter	GLENMARK-ZETIA-00204824	GLENMARK-ZETIA-00204827
PX0495	07/01/2014	Presentation, "Operations Induction Module"	GLENMARK-ZETIA-00209941	GLENMARK-ZETIA-00209941
PX0509	11/26/2014	Spreadsheet, "Copy of Zetia_RevenueModel_3rdMar_PL_UpdatedSMART_Q12015_May1 6-4-15"	GLENMARK-ZETIA-00214483	GLENMARK-ZETIA-00214483
PX0509_N	11/26/2014	Spreadsheet, "Copy of Zetia_RevenueModel_3rdMar_PL_UpdatedSMART_Q12015_May1 6-4-15"	GLENMARK-ZETIA-00214483	GLENMARK-ZETIA-00214483
PX0535	03/10/2009	Email from T. Coughlin to V. Soni & T. Coughlin, "Re: Merck - Schering"	GLENMARK-ZETIA-00218725	GLENMARK-ZETIA-00218727
PX0546	08/15/2013	Letter from K. Shen to W. McIntyre re DMF Information Request for Ezetimibe	GLENMARK-ZETIA-00224097	GLENMARK-ZETIA-00224099
PX0547	07/07/2010	Email from T. Coughlin to B. Mazumdar & V. Soni, "RE: PAR - wiring information"	GLENMARK-ZETIA-00225149	GLENMARK-ZETIA-00225152
PX0556	04/04/2012	Email from C. Almeida to V. Yadav, "RE" 2nd source/alt site," with attached spreadsheet, "Alternate API Evaluation_4.4.12"	GLENMARK-ZETIA-00235778	GLENMARK-ZETIA-00235781

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0556_N	04/04/2012	Email from C. Almeida to V. Yadav, "RE" 2nd source/alt site," with attached spreadsheet, "Alternate API Evaluation_4.4.12"	GLENMARK-ZETIA-00235778	GLENMARK-ZETIA-00235781
PX0562	11/25/2009	Email from T. Coughlin to V. Soni, "FW: Par"	GLENMARK-ZETIA-00237431	GLENMARK-ZETIA-00237431
PX0563	07/07/2011	Email from K. Reddy to V. Soni and C. Almeida, "RE: Meeting at our Office"	GLENMARK-ZETIA-00237679	GLENMARK-ZETIA-00237681
PX0569	06/08/2016	Letter from L. Jakob to V. Soni, "Glenmark Agreement"	GLENMARK-ZETIA-00245035	GLENMARK-ZETIA-00245035
PX0570	08/30/2016	Letter from B. Hirsch to W. Krovatin re August 11, 2016 Meeting re Merck-Glenmark Settlement Agreement	GLENMARK-ZETIA-00245040	GLENMARK-ZETIA-00245040
PX0571	02/08/2007	Glenmark Letter re Zetia Notice of Paragraph IV Certification	GLENMARK-ZETIA-00245149	GLENMARK-ZETIA-00245175
PX0582	08/19/2009	Email from S. Good to P. Dutra, "RE: Ezetimibe"	GLENMARK-ZETIA-00258084	GLENMARK-ZETIA-00258085
PX0585	12/23/2009	Email from P. Campanelli to T. Haughey, L. Brown & C. Gassert, "FW: Draft Term Sheet," with attached draft Memorandum of Understand by and between Glenmark and Par	GLENMARK-ZETIA-00259794	GLENMARK-ZETIA-00259798
PX0587	06/09/2009	Email from T. Coughlin to P. Campanelli, "RE: Update," with attached Memorandum of Understanding by and between Glenmark and Par	GLENMARK-ZETIA-00260804	GLEN MARK-ZETI A-00260810
PX0594	05/11/2010	Email from A. Gupta to T. Coughlin, "RE: Zetia" with attachment "Zetia monetization.xlsx"	GLENMARK-ZETIA-00261535	GLENMARK-ZETIA-00261537
PX0597	09/27/2013	Letter from FDA to Glenmark re Response to FDA's August 15, 2013 DMF Information Request and related amendment to the drug master file on Ezetimibe (Process II), DMF 24825	GLENMARK-ZETIA-00265486	GLENMARK-ZETIA-00265486
PX0603	10/20/2015	Report on Glenmark's October 20, 2015 Visit to MSN Laboratories Private Limited	GLENMARK-ZETIA-00277382	GLENMARK-ZETIA-00277383
PX0606	05/08/2010	Email from T. Hester to V. Soni, L. Brown, et al., "Zetia Settlement Agreement," with attached draft Merck-Glenmark settlement agreements	GLENMARK-ZETIA-00280901	GLENMARK-ZETIA-00280956
PX0609	03/29/2020	Email from P. Matukaitis to V. Soni, "Agreement," with attached draft Settlement Agreement	GLENMARK-ZETIA-00280962	GLENMARK-ZETIA-00280988
PX0612	08/06/2009	Email from T. Coughlin to G. Sandanha and V. Soni, "RE: Discussion with SP (Schering)"	GLENMARK-ZETIA-00281992	GLENMARK-ZETIA-00281993
PX0620	09/16/2014	MSN Laboratories Private Limited, Certificate of Analysis for Ezetimibe	GLENMARK-ZETIA-00284232	GLENMARK-ZETIA-00284233
PX0623	03/23/2010	V. Soni timeline notes re settlement discussions	GLENMARK-ZETIA-00304965	GLENMARK-ZETIA-00304966
PX0624	05/28/2010	Chart, "Ezetimibe settlement," with V. Soni handwritten notes	GLENMARK-ZETIA-00304970	GLENMARK-ZETIA-00304970
PX0625	03/01/2010	V. Soni draft proposed terms of settlement, with handwritten notes	GLENMARK-ZETIA-00304971	GLENMARK-ZETIA-00304971

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0626	05/05/2010	Email from L. Brown to T. Haughey, V. Soni & P. Campanelli, "RE: Zetia"	GLENMARK-ZETIA-00307003	GLENMARK-ZETIA-00307007
PX0642	06/10/2014	Certificate of Analysis from Ezetimibe	GLENMARK-ZETIA-00382078	GLENMARK-ZETIA-00382078_002
PX0643	04/28/2015	Certificates of Analysis of MSN Laboratories Private Limited	GLENMARK-ZETIA-00382731	GLENMARK-ZETIA-00382744
PX0644	08/20/2015	Response to the DMF Information Request dated June 19, 2014 Received from USFDA on Ezetimibe USDMF	GLENMARK-ZETIA-00391829	GLENMARK-ZETIA-00391933
PX0646	10/14/2015	E-mail from S. Sharma to N. Kothari re "FW: Ezetimibe"	GLENMARK-ZETIA-00418521	GLENMARK-ZETIA-00418527
PX0652	12/05/2013	Email from P. Gioia to A. Gupta re: Zetia monetization NPV - exclusivity period	GLENMARK-ZETIA-00428615	GLENMARK-ZETIA-00428615
PX0655	05/12/2010	Email from A. Gupta to A. Sun et al., "RE: Royalty monetization"	GLENMARK-ZETIA-00429743	GLENMARK-ZETIA-00429744
PX0656	05/12/2017	Letter from B. Hirsch to W. Krovatin re third party seeking to launch AG of Zetia	GLENMARK-ZETIA-00429934	GLENMARK-ZETIA-00429934
PX0657	01/25/2011	Email from T. Coughlin to V. Soni et al., "RE: Question regarding Tentative Approvals--FDA FEEDBACK"	GLENMARK-ZETIA-00432421	GLENMARK-ZETIA-00432425
PX0662	05/07/2010	Email from P. Campanelli to T. Coughlin, "Re: Hi"	GLENMARK-ZETIA-0434105	GLENMARK-ZETIA-0434106
PX0663	05/04/2010	Email from V. Soni to P. Campanelli, "RE: Good Luck"	GLENMARK-ZETIA-0434669	GLENMARK-ZETIA-0434669
PX0669	03/25/2010	Email from T. Coughlin to V. Soni & P. Dutra, "RE: Temodar - Glenmark Meeting - Monday, March 29, 2010"	GLENMARK-ZETIA-0435359	GLENMARK-ZETIA-0435360
PX0708	08/05/2009	Schering's Memorandum of Law in Opposition to Glenmark's Motion for Summary Judgment of Invalidity of Claims 1-5 And 7-13 (Double Patenting)	LWNSTNZETIA000003513	LWNSTNZETIA000003549
PX0710	03/22/2020	Final Pretrial Order, Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	LWNSTNZETIA000018088	LWNSTNZETIA000018177
PX0792	05/11/2010	Email from P. Campanelli to T. Coughlin, "FW: Ezetimibe updated," with attached spreadsheet, "Ezetimibe forecast May 2010.xls"	PAR_00008075	PAR_ 00008076
PX0795	05/03/2010	Email from C. Calabro to P. Campanelli, "Ezetimibe updated forecast," with attached spreadsheet	PAR_00008126	PAR_00008127
PX0905	04/02/2012	Cover Letter for Sandoz Inc.'s Original Submission of ANDA No. 203931 for Ezetimibe Tablets, 10 mg	SANDOZ-ZETIA-0000004	SANDOZ-ZETIA-0000005
PX0906	03/30/2012	Sandoz Patent and Exclusivity Certification for Zetia Ezetimibe, Oral tablet 10mg	SANDOZ-ZETIA-0000009	SANDOZ-ZETIA-0000010
PX0909	02/16/2017	Sandoz Minor Amendment - Final Approval Requested for ANDA 203931, Sequence 0010, Ezetimibe Tablets, 10 mg	SANDOZ-ZETIA-0000081	SAN DOZ-ZETIA-0000092
PX0911	02/10/2014	Letter from A. Sigler, USPHS, to J. Domenico, Sandoz Inc., "RE: Updated summary of filed and pending original ANDA(s)"	SANDOZ-ZETIA-0000130	SANDOZ-ZETIA-0000133
PX0912	01/13/2015	Letter from W. Rickman to C. Uhrn re: Complete Response for ANDA 203931, Ezetimibe Tablets 10 mg	SANDOZ-ZETIA-0000139	SANDOZ-ZETIA-0000145

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0913	02/17/2016	Tentative Approval Letter from FDA to Sandoz, Inc. re: ANDA No. 203931 for Ezetimibe Tablets, 10 mg	SANDOZ-ZETIA-0000147	SANDOZ-ZETIA-0000149
PX0915	06/12/2017	ANDA Approval Letter from FDA to Sandoz, Inc. re ANDA 203931	SANDOZ-ZETIA-0000151	SANDOZ-ZETIA-0000154
PX0916	12/11/2017	Letter from FDA to Sandoz, Inc. re Prior Approval Supplement Approval	SANDOZ-ZETIA-0000158	SANDOZ-ZETIA-0000160
PX0922	12/26/2006	Teva's Original Submission of Abbreviated New Drug Application for Ezetimibe Tablets, 10 mg	Teva-Zetia_00000001	Teva-Zetia_00000156
PX0923	07/20/2010	Teva's Patent Amendment: Revised Patent Certification ANDA No. 078724 for Ezetimibe Tablets, 10mg	Teva-Zetia_00001745	Teva-Zetia_00001747
PX0925	11/13/2015	Tentative Approval Letter from FDA to Teva Pharmaceuticals USA for ANDA No. 78724 for Ezetimibe Tablets, 10 mg	Teva-Zetia_00003100	Teva-Zetia_00003102
PX0926	06/12/2017	Letter from FDA to Teva Granting Final Approval of ANDA No. 078724 for Ezetimibe Tablets USP, 10 mg	Teva-Zetia_00003520	Teva-Zetia_00003523
PX0939	10/21/2009	MSN Laboratories - Letter of Authorization Issuance for Ezetimibe DMF No. 21554 (Type II)	Watson-Zetia_00000049	Watson-Zetia_00000050
PX0942	11/20/2009	Certificate of Analysis for Ezetimibe	Watson-Zetia_00002120	Watson-Zetia_00002121
PX0943	11/20/2009	Certificate of Analysis for Ezetimibe	Watson-Zetia_00002122	Watson-Zetia_00002123
PX0944	08/15/2013	Complete Response letter from FDA to Watson Laboratories, Inc. identifying deficiencies in ANDA 200831 for Ezetimibe Tablets, 10 mg	Watson-Zetia_00011192	Watson-Zetia_00011197
PX0946	12/15/2015	Tentative Approval of Watson ANDA 200831, Ezetimibe Tablets, 10 mg	Watson-Zetia_00011452	Watson-Zetia_00011454
PX0947	06/12/2017	Letter from FDA to Watson Granting Final Approval of ANDA No. 200831 for Ezetimibe Tablets USP, 10 mg	Watson-Zetia_00011753	Watson-Zetia_00011756
PX0948	04/19/2010	Email from L. Brown to P. Campanelli & D. Brown, "Re: Zetia '721 patent : Reissue SJ granted in favor of Glenmark"	WSGR-ZET003911	WSGR-ZET003912
PX1010	03/23/2018	Agreement for Assignment of Claims between McKesson and Albertsons	ALB_ZETIA_00000001	ALB_ZETIA_00000002
PX1011	03/23/2018	Agreement for Assignment of Claims between McKesson and Albertsons	ALB_ZETIA_00000003	ALB_ZETIA_00000004
PX1012	04/16/2018	Agreement for Assignment of Claims between Safeway and Albertsons	ALB_ZETIA_00000005	ALB_ZETIA_00000008
PX1013	08/30/2018	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and McKesson Corp.	CVS-ZET-0000001	CVS-ZET-0000002
PX1014	08/30/2018	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and Cardinal Health, Inc.	CVS-ZET-0000003	CVS-ZET-0000004
PX1015	12/12/2018	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and McKesson Corporation	CVS-ZET-0000008	CVS-ZET-0000009

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX1027	03/08/2018	Agreement for Assignment of Claims by and between McKesson Corp. and HEB	HEB_ZETIA_00000001	HEB_ZETIA_00000002
PX1029	03/12/2018	Agreement for Assignment of Claims between The Kroger Co. and Cardinal Health, Inc.	KRG_ZETIA_00000001	KRG_ZETIA_00000002
PX1031	04/09/2019	Agreement for Assignment of Claims between The Kroger Co. and Cardinal Health, Inc.	KRG_ZETIA_00000008	KRG_ZETIA_00000009
PX1032	07/27/2018	Agreement for Assignment of Claims between McKesson Corporation and Rite Aid Corporation	RA-ZET-0000001	RA-ZET-0000002
PX1035	03/20/2018	Agreement for Assignment of Claims between Walgreen and ABDC	WLG_ZETIA_00000001	WLG_ZETIA_00000002
PX1039	06/16/1998	U.S. Patent No. 5,767,115 (Certified Version)	USPTO-ZETIA-0000027	USPTO-ZETIA-0000051
PX1042	05/28/2002	U.S. Patent No. RE37,721 (Certified Version)	USPTO-ZETIA-0001328	USPTO-ZETIA-0001354
PX1043	06/09/2010	Reissue Application; Preliminary Amendment	USPTO-ZETIA-0001373	USPTO-ZETIA-0001387
PX1052	02/04/1993	International Patent Application No. PCT/US92/05972 (International Publication No. WO 93/02048)		
PX1153	03/09/2011	OGD/FDA Quality Deficiency Minor (Chemistry) to Watson re: ANDA 200831, Ezetimibe Tablets, 10mg		
PX1159	01/01/2012	Glenmark Annual Report 2010-11		
PX1351_N	11/18/2019	Exhibit 4 - Leitzinger 11-18-2019 report		
PX1660	10/10/2022	Agreement for Assignment of Claims between Giant Eagle, Inc. and Cardinal Health 110, LLC	GE-Zetia-000185	GE-Zetia-000187
PX1665	05/20/2018	Agreement for Assignment of Claims between McKesson Corporation and Giant Eagle, Inc.	MCK_ZETIA_0000010	MCK_ZETIA_0000011
PX1670	12/31/2020	Zetia/Ezetimibe Purchase Data for Meijer, 1/1/2014-12/31/2020	MCK_ZETIA_0000020	MCK_ZETIA_0000020
PX1670_N	12/31/2020	Zetia/Ezetimibe Purchase Data for Meijer, 1/1/2014-12/31/2020	MCK_ZETIA_0000020	MCK_ZETIA_0000020
PX1675	10/26/2022	Agreement for Assignment of Claims between Walgreen Co. and AmerisourceBergen Drug Corporation	WLG_ZETIA_00000012	WLG_ZETIA_00000013
PX1775	01/04/2023	Agreement for Assignment of Claims between McKesson Corporation and Albertsons Companies, LLC	ALB_ZETIA_00000014	ALB_ZETIA_00000015
PX1776	10/05/2022	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and Cardinal Health, Inc.	CVS-ZET-0053711	CVS-ZET-0053712
PX1777	01/04/2023	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and McKesson Corporation	CVS-ZET-0053713	CVS-ZET-0053714
PX1778	01/04/2023	Agreement for Assignment of Claims between McKesson Corporation and HEB Grocery Company LP	HEB_ZETIA_00000006	HEB_ZETIA_00000007
PX1779	01/04/2023	Agreement for Assignment of Claims between McKesson Corporation and Rite Aid Corporation and Rite Aid Hdqtrs. Corp.	RA-ZET-0034870	RA-ZET-0034871

Expect to Offer Exhibits Profferred by the Purchasers to Which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX1797	05/08/2010	Email from L. Brown to P. Campanelli, T. Coughlin & T. Haughey, "Fw: Zetia Settlement Agreement," with attachments	GLENMARK-ZETIA-00261739	GLENMARK-ZETIA-00261794
PX1798	05/05/2010	Email from V. Soni to P. Campanelli & T. Haughey, "Settlement agreement received from Merck on Mar 29 2010," with attachment	GLENMARK-ZETIA-00261882	GLENMARK-ZETIA-00261908
PX1800	11/21/2011	Plaintiffs' Pretrial Brief, Schering Corp. v. Mylan Pharms. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	LWNSTNZETIA000036195	LWNSTNZETIA000036214
PX1801	01/26/2010	Email from P. Magri to P. McCrorey, "FW: Financial analysis"	MRKZETIA001028678	MRKZETIA001028678
PX1802	08/21/2009	Reply Memorandum of Law in Support of Glenmark's Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Schering Corp. v. Glenmark Pharms. Inc., USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00142363	GLENMARK-ZETIA-00142379
PX1805	05/13/2010	Email from T. Hester to V. Soni & P. Matukaitis, "Execution Version of Settlement Agreement," with attachment	MRKZETIA_R000061727	MRKZETIA_R000061759
PX1806	07/22/2011	First Amended Complaint, Schering Corp. v. Mylan Pharms. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	MRKZETIA_SIDLEY000213145	MRKZETIA_SIDLEY000213244
PX1807	01/25/2012	Plaintiffs' Proposed Conclusions of Law, Schering Corp. v. Mylan Pharms. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	LWNSTNZETIA000040720	LWNSTNZETIA000040771
PX1808	01/25/2012	Mylan Pharmaceuticals Inc.'s Proposed Conclusions of Law, Schering Corp. v. Mylan Pharms. Inc., Nos. 09-cv-6383 & 10-cv-3085 (D.N.J.)	LWNSTNZETIA000041411	LWNSTNZETIA000041454

EXHIBIT 2(b)

Expect to Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0029	10/08/2015	Merck Presentation, "Zetia Proposed LOE Contracting Strategy"	MRKZETIA_R000055856	MRKZETIA_R000055856	FD
PX0030	02/25/2016	Email from M. Copeland to R. Rode et al., "LOE discussions - slides for 10am meeting [Confidential]," with attached presentation, "Athero Brand LOE 2 26 16.pptx"	MRKZETIA_R000058405	MRKZETIA_R000058406	FD
PX0083	08/22/2013	Spreadsheet, Temodar AG Model - Extended Contracting Scenario v5	MRKZETIA_R000090591	MRKZETIA_R000090591	FD
PX0083_N	08/22/2013	Spreadsheet, Temodar AG Model - Extended Contracting Scenario v5	MRKZETIA_R000090591	MRKZETIA_R000090591	FD
PX0162	10/27/2005	Adriano Afonso's "Summary of discussions at October 27, 2005 meeting with Baldwin / Auth on their 'preliminary conclusion'"	MRKZETIA000419184	MRKZETIA000419184	HS; 701; HWH
PX0193	11/01/2016	Spreadsheet, "Glenmark Estimates"	MRKZETIA000509916	MRKZETIA000509916	FD
PX0194	11/01/2016	Spreadsheet, "Scenario Table"	MRKZETIA000509917	MRKZETIA000509917	FD
PX0199	10/06/2016	Presentation, Willard	MRKZETIA000509926	MRKZETIA000509926	FD
PX0199_N	10/06/2016	Presentation, Willard	MRKZETIA000509926	MRKZETIA000509926	FD
PX0213	03/22/2017	Letter from D. Pakula to Prasco (M. Reedy and J. Lapps) re consent to pre-selling	MRKZETIA000510461	MRKZETIA000510463	Merck: NO Glenmark: R; 403
PX0253	06/01/2017	Merck Presentation, "Zetia Authorized Generic (AG) Status Update"	MRKZETIA000516334	MRKZETIA000516334	FD
PX0290	07/13/2016	Presentation, Athero Brand Update	MRKZETIA000601084	MRKZETIA000601084	FD
PX0292	10/11/2016	Presentation: 2017 ZETIA Family Product Plan (US Market)	MRKZETIA000601821	MRKZETIA000601821	FD
PX0333	12/04/2008	Transcript of Deposition of Stuart B. Rosenblum, Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	MRKZETIA000940942	MRKZETIA000941045	Merck: HS; HS; HWH; R; 403; FD Glenmark: HS; HWH; 701; R; 403; FD
PX0363	10/21/2008	Transcript of Deposition of Adriano Afonso, Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00123909	GLENMARK-ZETIA-00124120	Merck: HS; HWH; R; 403; FD Glenmark: HS; HWH; 701; R; 403; FD
PX0366	02/10/2010	Transcript of Feb. 10, 2009 Deposition of Stuart Rosenblum, Schering Corp. v. Glenmark Pharm. Inc., USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00132701	GLENMARK-ZETIA-00132863	Merck: HS; HWH; R; 601 Glenmark: HS; HWH; 701; R; 403; FD
PX0367	12/05/2008	Transcript of Deposition of Stuart B. Rosenblum, Schering Corp. v. Glenmark Pharm., Inc. USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00133755	GLENMARK-ZETIA-00133928	Merck: HS; HWH; R; 601; FD Glenmark: HS; HWH; 701; R; 403; FD

Expect to Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0391	10/14/2016	Email from R. Matsuk to R. Sharma, "RE: Ezetimibe Financials update from Par," with attached spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF.xlsx"	GLENMARK-ZETIA-00165620	GLENMARK-ZETIA-00165621	HS
PX0418	04/13/2009	Email from J. Brown to V. Soni, "Ezetimibe"	GLENMARK-ZETIA-00177775	GLENMARK-ZETIA-00177775	Merck: HS Glenmark: NO
PX0467	05/10/2010	Email from P. Birdy to T. Coughlin, "Re: Zetia"	GLENMARK-ZETIA-00201566	GLENMARK-ZETIA-00201567	Merck: HS Glenmark: NO
PX0468	05/10/2010	Email from G. Saldanha to T. Coughlin re Zetia	GLENMARK-ZETIA-00201568	GLENMARK-ZETIA-00201568	Merck: HS Glenmark: NO
PX0470	04/03/2010	Email from T. Coughlin to G. Saldanha, "Various"	GLENMARK-ZETIA-00201717	GLENMARK-ZETIA-00201717	Merck: HS Glenmark: NO
PX0479	11/20/2013	Email from A. Gupta to M. Blashinsky and P. Dutra, "RE: Zetia sales projections."	GLENMARK-ZETIA-00202263	GLENMARK-ZETIA-00202264	Merck: HS GM: NO
PX0520	11/20/2013	Email from M. Blashinsky to A. Gupta and P. Shinde, "RE: Zetia sales projections," with attached spreadsheet, "zetia projection 10-29-2013r1.xls"	GLENMARK-ZETIA-00216208	GLENMARK-ZETIA-00216210	Merck: HS Glenmark: NO
PX0533	06/22/2009	Email from V. Soni to T. Coughlin & P. Dutra, "RE: Par"	GLENMARK-ZETIA-00218110	GLENMARK-ZETIA-00218110	HS; HWH
PX0534	06/11/2009	Email from P. Campanelli to T. Coughlin, "Our Conversation Yesterday."	GLENMARK-ZETIA-00218115	GLENMARK-ZETIA-00218115	R
PX0589	06/21/2010	Email from A. Gupta to I. Boszko & gw@dricapital.com, "RE: Royalty monetization DRC:00270326"	GLENMARK-ZETIA-00261113	GLENMARK-ZETIA-00261168	R; 403; HS; 901; FD
PX0592	05/28/2010	Email from A. Gupta to M. Weinmann et al., "RE: Royalty monetization," with attached "Confidential Information Memorandum: Revenue Monetization Opportunity"	GLENMARK-ZETIA-00261273	GLENMARK-ZETIA-00261328	R; 403; HS; 901; FD
PX0658	09/13/2016	Email from C. Calabro to R. Matsuk, "Merck Discussion" with attachment "Ezetimibe (Zetia) forecast Sep 2016 NPF.xlsx"	GLENMARK-ZETIA-00433380	GLENMARK-ZETIA-00433382	HS
PX0659	03/28/2015	Email from R. Pettus to V. Soni, "Privileged and Confidential - Assessment of Ezetimibe Settlement Agreement," with attachment	GLENMARK-ZETIA-00435580	GLENMARK-ZETIA-00435582	R; 403; HS
PX0665	01/27/2010	Email from V. Soni to P. Matukaitis, "RE: Glenmark - Merck"	GLENMARK-ZETIA-0434757	GLENMARK-ZETIA-0434758	R; 403
PX0695	06/10/2017	Spreadsheet, "Product Summary"	APOTEX0000064	APOTEX0000072	R; 403; HS; 901
PX0705	03/06/2015	Email from D. Weider to R. Pettus, "RE: A chance to impress Vijay -- call me if you get this"	GT06_03_19_ZE1_000208	GT06_03_19_ZE1_000211	R; 403; HS; 901
PX0706	03/20/2015	Email from V. Soni to R. Pettus with attached March 29, 2010 Draft Settlement Agreement by and among Schering Corporation, MSP Singapore Company LLC, and Glenmark Pharmaceuticals Inc., USA	GT06_03_19_ZE1_000396	GT06_03_19_ZE1_000422	R; 403; HS; 901
PX0712	01/01/2017	Imaged Spreadsheet - Ezetimibe Forecast Request 2008-2017	MYL_ZETIA 011618	MYL_ZETIA 012075	403; HS
PX0716	12/17/2016	Email from V. Soni to P. Campanelli & T. Coughlin, "Meeting Request"	PAR_00000369	PAR_00000369	HS; 901
PX0719	12/01/2015	Email from J. Bueck to A. Adams et al., "NPL Notes for 12/2/2015," with attached spreadsheet, "NPL Launch Milestones_12_2_2015.xlsx"	PAR_00000731	PAR_00000733	HS; 403

Expect to Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0720	12/17/2015	Email from I. Gruber to A. Adams et al., "PD / Tech Ops Project Meeting 12/18/15," with attached presentation, "Technical Operations: Par Sterile Products, 12/18/15"	PAR_00000737	PAR_00000738	403; HS; 901
PX0728	02/18/2015	Email from C. Calabro to I. Gruber et al., "Ezetimibe model for Steering Committee meeting 2/25/15," with attached spreadsheet, "Ezetimibe (Zetia) forecast Jan. 2015.xlsx"	PAR_00002329	PAR_00002330	901; HS
PX0765	02/29/2016	Email from K. Mattox to P. Campanelli, "Re: EXTERNAL: major P4 exclusives"	PAR_00004800	PAR_00004803	403; HS
PX0768	01/28/2014	Email from M. Altamuro to P. Campanelli, "FW: Ezetimibe - please review," with attached spreadsheet, "Ezetimibe forecast Jan 2014.xlsx"	PAR_00005373	PAR_00005375	901; HS; 403
PX0773	06/19/2012	Email from M. Bonomi to P. Campanelli, "RE: Cheat Sheet," with attached document, "Regulatory ANDA Status 061812.docx"	PAR_00006514	PAR_00006574	403; HS; R
PX0776	05/12/2010	Email from I. Gruber to M. Zrebiec et al., "5/13/10 Meeting," with attached spreadsheet, "NPL Launch Milestones 5.13.10.xls"	PAR_00006717	PAR_00006718	403; HS; 901; R; FD
PX0781	01/01/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007273	PAR_00007273	901; HS
PX0790	02/23/2010	Email from C. Calabro to P. Campanelli, "Ezetimibe," with attached spreadsheet, "Ezetimibe forecast Feb 2010.xls"	PAR_00007866	PAR_00007867	901; HS
PX0793	05/10/2010	Email from P. Campanelli to S. Mock, "FW: Ezetimibe updated," with attached spreadsheet, "Ezetimibe forecast May 2010.xls"	PAR_00008082	PAR_00008083	403; HS; 901; FD
PX0794	05/10/2010	Email from P. Campanelli to S. Mock, "RE: EKR Therapeutics"	PAR_00008084	PAR_00008085	HS
PX0796	04/30/2010	Email from C. Gassert to P. Campanelli, "Zetia and Asacol Questions," with attached spreadsheet, "Ezetimibe forecast Apr 2010 (2) revised.xls"	PAR_00008140	PAR_00008143	403; HS; FD
PX0798	04/30/2010	Email from C. Vallilo to K. Burns, "Presentation," with attached presentation, "Ezetimibe (Zetia) Generic Transaction Review"	PAR_00008188	PAR 00008189	HS
PX0799	04/19/2010	Email from P. Campanelli to P. Campanelli, "FW: Zetia," with attached spreadsheet, "Ezetimibe forecast Apr 2010.xls"	PAR_00008219	PAR_00008221	HS; 901
PX0817	01/03/2017	Email from C. Sowa to S. Mock et al., "RE: Quetiapine ER and Ezetimibe - Market Share & Generic Conversion - 1.03.2017," with attached spreadsheet	PAR_00008470	PAR_00008472	HS
PX0823	01/10/2017	Email from C. Sowa to S. Mock et al., "Ezetimibe Tabs & Quetiapine ER Tabs - Market Share & Generic Conversion - 1.10.2017," with attached spreadsheet	PAR_00008647	PAR_00008648	HS
PX0896	04/29/2010	Email from P. Campanelli to S. Mock, "Glenmark press release," with attached draft press release, "Par Enters Into an Exclusive Licensing Agreement with Glenmark to Market Generic Zetia"	PAR_00023318	PAR 00023319	403; 901; HS

Expect to Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0897	04/06/2010	Email from P. Campanelli to C. Gassert, "Re: Glenmark comments on eze marketing & distribution agreement"	PAR_00023397	PAR_00023398	403; 901; HS
PX0898	12/13/2016	Email from M. Burton to J. Borchardt, "RE: Ezetimibe"	PAR_00025141	PAR_00025142	901; HS; 403; FD
PX0900	06/10/2017	Zetia (ezetimibe) Tablet Prasco AG launch against Par, Teva, Mylan and Sandoz on 6/10/2017 (Day 181 of Par Launch) No additional competitors to enter the market	PRASCO000081	PRASCO000081	Merck: 403; HS; 901; FD Glenmark: 403; HS; 901; FD
PX0901	05/24/2017	Email from M. Reedy to D. Pakula, T. Covert, and J. Lapps, "For Zetia Discussion" attaching "Zetia (Merck) Model Comparison (5.24.2017).pdf"	PRASCO000090	PRASCO000090	403; HS
PX0902	05/16/2017	Email from D. Sweeney to M. Reedy and Tony Gunn, "RE: Zetia AG 2018 forecast"	PRASCO000108	PRASCO000112	403; HS; 901
PX0903	06/30/2016	Spreadsheet, Ezetimibe TAB 10mg Forecast	SANDOZ-ZETIA-0000001	SANDOZ-ZETIA-0000001	403; HS; INC
PX0932	06/06/2011	Spreadsheet, "Teva USA: Sales Forecase"	TEVA-ZETIA_00003530	TEVA-ZETIA_00003530	403; HS
PX0932_N	06/06/2011	Spreadsheet, "Teva USA: Sales Forecase"	TEVA-ZETIA_00003530	TEVA-ZETIA_00003530	403; HS
PX0933	07/05/2012	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003531	TEVA-ZETIA_00003531	403; HS; INC
PX1071	07/01/2002	FTC, Generic Drug Entry Prior to Patent Expiration: An FTC Study (July 2002)			Merck: NO Glenmark: HS; 403
PX1090	01/01/2006	Paul M. Janicke & LiLan Ren, Who Wins Patent Infringement Cases?, 34 AIPLA Quarterly J. (2006)			Merck: HS; HWH Glenmark: HS; HWH; R; 403; 901
PX1097	06/23/2006	Gabriel Madway, Market Watch, "Dr. Reddy's Launches Proscar, Zocor Generics"	N/A	N/A	901; HS; HWH
PX1120	02/07/2008	Marc Iskowitz, MM&M, Merck Says "Goodbye, Fosamax," Launches Authorized Generic"			901; HS; HWH
PX1129	01/01/2009	Excerpts of AIPLA, Report of the Economic Survey 2009			HS; 901; INC
PX1136	01/01/2010	Mark A. Lemley, Where to File Your Patent Case, 38 AIPLA Quarterly J. (Fall 2010)			HS; HWH; R; 403; 901
PX1137	01/01/2010	FTC, Pay for Delay: How Drug Company Pay-Offs Cost Companies Billions (Jan. 2010)			403
PX1141	04/07/2010	FiercePharma, "Sandoz Launches Authorized Versions of Cozaar and Hyzaar Tablets"			901; HS; HWH
PX1149	01/01/2011	Excerpts of AIPLA, Report of the Economic Survey 2011			HS; 901
PX1155	08/01/2011	FTC, Authorized Generic Drugs: Short-Term Effects and Long-Term Impact (Aug. 2011)			HS; HWH
PX1190	01/02/2013	MPR, "Par Launches Generic Maxalt and Maxalt-MLT"			901; HS; HWH
PX1224	01/01/2016	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 - Overview of Agreements Filed in FY 2015: A Report by the Bureau of Competition			HS; 901
PX1229	02/03/2016	Ram Subramanian & Rehan Baqri, Branding: When One Is Not Enough, Pharm. Exec., Feb. 3, 2016, http://www.pharmexec.com/branding-when-one-not-enough			HS; 901

Expect to Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1241	01/01/2017	Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 - Overview of Agreements Filed in FY 2016: A Report by the Bureau of Competition			HS; 901
PX1248	05/22/2017	Label for Prasco Laboratories' Ezetimibe Tablets, 10 mg (https://medlibrary.org/lib/rx/meds/ezetimibe-1/page/7/)			FD; HS; 403
PX1258	01/01/2018	United States Court of Appeals for the Federal Circuit, Median Time to Disposition of Cases Terminated After Hearing or Submission, Docketing Date to Disposition Date in Months (FY 2009–2018)			Merck: HS; HWH Glenmark: HS; HWH; R; 901
PX1270	09/18/2018	Zetia WAC and Gross Prices			901; HS
PX1276	01/01/2019	U.S. Court of Appeals for the Federal Circuit, Median Time to Disposition in Cases Terminated After Hearing or Submission (2009-2018)			HS; 901; 1006; R
PX1284	05/15/2019	Notice of Rule 30(b)(6) Deposition of Merck Defendants			HS
PX1285	05/16/2019	Agreements Filed with FTC Under the Medicare Prescription Drug, Improvement and Modernization Act of 2003			HS; 901
PX1286	05/19/2019	Notice of Rule 30(b)(6) Deposition of Merck Defendants			HS
PX1288	08/27/2019	Defendants Merck & Co., Inc.'s, Merck Sharp & Dohme Corp.'s, Schering-Plough Corp.'s, Schering Corp.'s, and MSP Singapore Co. LLC's First Amended Disclosures			HS; R; 403
PX1290	09/09/2019	Zetia and Generic Ezetimibe Total Wholesale Price per Pill per Quarter			HS; 901
PX1292	11/12/2019	Excerpt from Merck Defendants' Privilege Logs			403; HS; R
PX1295	11/18/2019	Declaration of Teletha Brown for Sandoz Inc.			HS (Defendants object to this exhibit being used by the jury, but Merck does not object to the use of a qualifying declaration for the limited purpose under FRE902(11)-(12) of certifying documents)
PX1296	11/18/2019	Zetia WAC Prices (Ex. 3 to Leitzinger Declaration)			901; HS; 1006
PX1350_N	11/18/2019	Exhibit 3 - Leitzinger 11-18-2019 report			HS
PX1355	12/01/2019	Ryan Conrad & Randall Lutter, FDA, Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices			HS; 901
PX1395	01/13/2020	Leitzinger Report, Ex. 10 "But-For Generic Discounts			HS
PX1396	01/13/2020	Leitzinger Report, Ex. 9, "Class Brand Prices/Discounts Relative to Brand WAC"			HS
PX1397	01/13/2020	Leitzinger Report, Ex. 7, "Class Generic Prices Discount"			HS

Expect to Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1400	01/13/2020	Exhibit 6 to Leitzinger's 1/13/2020 Expert Report, Zetia WAC Prices			HS
PX1431	01/13/2020	Figure 4A from Expert Report of Thomas M. McGuire: A Compromise Date in a Settlement Without a Payment			HS; 403
PX1432	01/13/2020	Figure 4B from Expert Report of Thomas G. McGuire: A Payment Enables a Delay, Harming Purchasers			HS; 403
PX1433	01/13/2020	Figures 4A and 4B from Expert Report of Thomas G. McGuire			HS; 403
PX1434	01/13/2020	Table 3 from Expert Report of Thomas G. McGuire: The Timing of Generic Entry in Alternative Settlements Based on Glenmark's Chance of Winning the Zetia Patent Litigation			HS; 403
PX1436	01/13/2020	Figure 1 from Expert Report of Meredith Rosenthal: Brand-Name Share for Drugs, By Months After First Generic Entry, 1999-2008			HS; 403; 1006
PX1452	01/13/2020	Table 1 to Starr's 1/13/2020 Expert Report, Actual Gross Margins For Zetia, 2003-2016			HS; 403; 1006
PX1484	01/13/2020	Figure 4 from Expert Report of Martha Starr - Price of Ezetimibe Before and After Generic Entry			HS
PX1488	01/15/2020	RBC Capital Markets, Industry Comment, Analyzing Litigation Success Rates			HS; 901
PX1527	02/20/2020	Figure 3-4 from the 2020.02.20 Jeffrey Leitzinger Class Rebuttal Report			HS; 403
PX1549	05/08/2020	R. Lamb Trial Merits Reply Declaration: Table 5 - Unjust Enrichment by But-for Generic Entry Date			HS
PX1554	05/08/2020	R. Lamb Trial Merits Reply Declaration: Exhibit 5 - Lamb Alternative Damages Model, By But-for Entry Date			HS
PX1558	05/08/2020	R. Lamb Trial Merits Reply Declaration: Exhibit 9 - Antitrust States Population Shares			HS
PX1559	05/08/2020	R. Lamb Trial Merits Reply Declaration: Exhibit 10 - Unjust Enrichment States Population Shares			HS
PX1605	08/16/2020	FDA: "Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices"			HS; 901
PX1646_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "AltSettleAnalysisZetiaLOEReplyRevised.xlsx"			Merck: NO Glenmark: 702; HS
PX1674	10/05/2021	Asset Purchase and Sale Agreement between MLI RX, LLC and Miami Luken, Inc.	MLI-ZET000001	MLI-ZET000019	Merck: NO Glenmark: HS; 901; R
PX1676	10/14/2022	Exhibit 3 to 10/14/2022 Expert Report of Jeffrey Leitzinger, "But-For Entry Scenarios"			HS; 1006; 403
PX1677	10/14/2022	Exhibit 4 to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges"			HS; 1006; 403
PX1679	10/14/2022	Exhibit 6A to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Total for All Joinder Plaintiffs"			HS; 1006; 403

Expect to Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1680	10/14/2022	Exhibit 6B to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - AmerisourceBergen Corporation/AmerisourceBergen Drug Corporation"			HS; 1006; 403
PX1681	10/14/2022	Exhibit 6C to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Bellco Corporation"			HS; 1006; 403
PX1682	10/14/2022	Exhibit 6D to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Burlington Drug Company, Inc."			HS; 1006; 403
PX1683	10/14/2022	Exhibit 6E to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Cardinal Health, Inc./Cardinal Health P.R. 120, Inc."			HS; 1006; 403
PX1684	10/14/2022	Exhibit 6F to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Cesar Castillo, LLC"			HS; 1006; 403
PX1685	10/14/2022	Exhibit 6G to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Dakota Drug, Inc."			HS; 1006; 403
PX1686	10/14/2022	Exhibit 6H to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - FWK Holdings, LLC"			HS; 1006; 403
PX1687	10/14/2022	Exhibit 6I to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - H.D. Smith, LLC"			HS; 1006; 403
PX1688	10/14/2022	Exhibit 6J to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - J M Smith Corporation d/b/a Smith Drug Company"			HS; 1006; 403
PX1689	10/14/2022	Exhibit 6K to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Kinray, Inc."			HS; 1006; 403
PX1690	10/14/2022	Exhibit 6L to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc."			HS; 1006; 403
PX1691	10/14/2022	Exhibit 6M to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Louisiana Wholesale Drug Co., Inc."			HS; 1006; 403
PX1692	10/14/2022	Exhibit 6N to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - McKesson Corporation"			HS; 1006; 403
PX1693	10/14/2022	Exhibit 6O to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Meijer, Inc./Meijer Distribution, Inc."			HS; 1006; 403
PX1694	10/14/2022	Exhibit 6P to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - MLI RX, LLC"			HS; 1006; 403
PX1695	10/14/2022	Exhibit 6Q to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - North Carolina Mutual Wholesale Drug Company"			HS; 1006; 403
PX1696	10/14/2022	Exhibit 6R to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Prescription Supply, Inc."			HS; 1006; 403

Expect to Offer Exhibits Profferred by the Purchaser[illegible] to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1697	10/14/2022	Exhibit 6S to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Rochester Drug Cooperative, Inc."			HS; 1006; 403
PX1698	10/14/2022	Exhibit 6T to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Smith Medical Partners, LLC"			HS; 1006; 403
PX1699	10/14/2022	Exhibit 6U to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - SUPERVALU, Inc."			HS; 1006; 403
PX1700	10/14/2022	Exhibit 6V to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - The Harvard Drug Group, L.L.C."			HS; 1006; 403
PX1701	10/14/2022	Exhibit 6W to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Valley Wholesale Drug Company, LLC"			HS; 1006; 403
PX1702	10/14/2022	Exhibit 6X to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Value Drug Company"			HS; 1006; 403
PX1703	10/14/2022	Exhibit 6Y to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges - Wegmans Food Markets, Inc."			HS; 1006; 403
PX1749	01/01/2018	Association for Accessible Medicines, Generic Drug Access & Savings in the U.S.: Access in Jeopardy (2018)			HS; HWH; R; 403
PX1752	01/01/2013	Generic Pharmaceutical Association, Generic Drug Savings in the U.S. (2013)			HS; HWH; R; 403
PX1757	10/01/2009	Frank R. Lichtenberg & Gautier Duflos, Time Release: The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization by the Public, Center for Medical Program at the Manhattan Insitution, Medical Progress Report, No. II (Oct. 2009)			HS; HWH; R; 403
PX1764	10/14/2022	Table 1 to 10/14/2022 Supplemental Expert Report of Keith Leffler, "Zetia Overcharge Summary"			Merck: HS; 1006; 403 Glenmark: HS; 1006; 403; 702; 703
PX1792	03/18/2010	Email from P. Dutra to T. Morrow, "Zetia non confidential info"	GLENMARK-ZETIA-00216165	GLENMARK-ZETIA-00216165	Merck: HS Glenmark: NO
PX1793	06/16/2014	Email from G. Goyal to V. Soni, "RE: Clarifications on Agreement"	GLENMARK-ZETIA-00239424	GLENMARK-ZETIA-00239425	Merck: HS Glenmark: NO
PX1799	04/06/2015	Email from G. Saldanha to R. Matsuk, "FW: Pharma Morning Dose: Dr. Reddy's (acquiring UCB brands in India) | Sun Pharma (settlement for Angiomax) | Zydus Hospitals (to invest INR 10bn)"	GLENMARK-ZETIA-00276537	GLENMARK-ZETIA-00276540	Merck: HS Glenmark: HS; R; 403
PX1803	05/03/2010	Email from E. Murray to D. Pritikin et al., "Fw: NEWS ALERT: PR Newswire: Par Obtains Exclusive Rights to Market and Distribute Generic"	MRKZETIA000845666	MRKZETIA000845667	Merck: HWH Glenmark: HS; HWH
PX1804	05/11/2010	Email from P. Campanelli to T. Coughlin, "FW: Ezetimibe updated," with attached spreadsheet, "Ezetimibe forecast May 2010.xls"	GLENMARK-ZETIA-00261527	GLENMARK-ZETIA-00261529	HS

Expect to Offer Exhibits Profferred by the Purchaser to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1804_N	05/11/2010	Email from P. Campanelli to T. Coughlin, "FW: Ezetimibe updated," with attached spreadsheet, "Ezetimibe forecast May 2010.xls"	GLENMARK-ZETIA-00261527	GLENMARK-ZETIA-00261529	HS
PX1809	07/29/2014	Email from V. Soni to S. Bhaskar Bhirud et al., "Ezetimibe: API and Dosage plan," with attachment	GLENMARK-ZETIA-00209218	GLENMARK-ZETIA-00209220	Merck: HS Glenmark: NO
PX1810	12/16/2014	Email from S. Sridharan to V. Soni & J. D'Souza, "RE: Zetia meeting," with attachments	GLENMARK-ZETIA-00281288	GLENMARK-ZETIA-00281305	Merck: HS Glenmark: NO
PX1811	08/30/2014	Email from S. Rahman to M. Karnik et al., "RE: Ezetimibe - Alternate Source MSN"	GLENMARK-ZETIA-00281981	GLENMARK-ZETIA-00281982	Merck: HS; HWH Glenmark: NO
PX1813	03/16/2023	Rule 1006 Summary - Retailer Plaintiffs' Damages (Generic Entry Date: December 2014)			1006; R; 403; 901; HS
PX1814	03/16/2023	Rule 1006 Summary - Retailer Plaintiffs' Damages (Generic Entry Date: April 2015)			1006; R; 403; 901; HS
PX1815	03/16/2023	Rule 1006 Summary - Retailer Plaintiffs' Damages (Generic Entry Date: February 2016)			1006; R; 403; 901; HS
PX1816	03/16/2023	Rule 1006 Summary - Retailer Plaintiffs' Damages (All Generic Entry Dates)			1006; R; 403; 901; HS
PX1817	06/18/2019	Exhibit C to Rebuttal Expert Report of Luis A. Molina, "Merck LOE Events from November 2005 - December 2016 for Products with over $200 Million in Annual U.S. Sales"			Merck: HS; 1006; 403 Glenmark: 1006; R; 403; 901; HS

EXHIBIT 3

DEFENDANTS MERCK & CO., INC.; MERCK SHARP & DOHME CORP.; SCHERING-PLOUGH CORP.; SCHERING CORP.; AND MSP SINGAPORE CO. LLC'S TRIAL EXHIBIT LIST (April 3, 2023)

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0008	MRKZETIA_SIDLEY000006788	MRKZETIA_SIDLEY000006790	1976	Larsen, David et al., Active-Site-Directed Alkylation of Chymotrypsin by Reagents Utilizing Various Departing Groups, Journal of Medicinal Chemistry, 1976, 19, 1284-86	X		403; H; HWH; R
MDX0033	MRKZETIA_SIDLEY000008918	MRKZETIA_SIDLEY000008921	6/3/1991	Memo from J. Clader of Schering-Plough to Atherosclerosis Chemists re "New Atherosclerosis Chemical Program"	X		403; H; HWH; R
MDX0048	MRKZETIA_SIDLEY000004047	MRKZETIA_SIDLEY000004174	7/21/1992	International Patent Application No. PCT/US92/05972, International Publication No. WO 93/02048	X		NO
MDX0049	No Bates	No Bates	7/21/1992	International Application No. WO 08/02048	X		NO
MDX0055	MRKZETIA_SIDLEY000167189	MRKZETIA_SIDLEY000167316	2/4/1993	WIPO - International Application Published Under the Patent Cooperation Treat (PCT) - WO 93/02048	X		NO
MDX0072	MRKZETIA_SIDLEY000225972	MRKZETIA_SIDLEY000225994	12/1/1993	Semi-Annual Report, "CV - Atherosclerosis: Cholesterol Absorption Inhibition Program,"- December 1993-June 1994 from Stuart Rosenblum and Tram Huynh	X		NO
MDX0090	MRKZETIA_SIDLEY000239858	MRKZETIA_SIDLEY000239873	3/7/1995	Memo from H. Davis. and E. Sybertz of Schering Plough to PAC Members re "Recommendation of SCh 58235 for Development"	X		NO
MDX0096	USPTO-ZETIA-0051909	USPTO-ZETIA-0052366	3/18/1996	Application No. 08/617,751	X		NO
MDX0109	USPTO-ZETIA-0000001	USPTO-ZETIA-0000026	5/20/1997	U.S. Patent 5,631,365	X		NO
MDX0122	USPTO-ZETIA-0000027	USPTO-ZETIA-0000051	6/16/1998	U.S. Patent 5,767,115	X		NO
MDX0124	No Bates	No Bates	7/1/1998	CBO study titled, "How Increased Competition From Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry"	X		NO
MDX0154	MRKZETIA R000065237	MRKZETIA R000065260	5/28/2002	U.S. Patent No. RE37,721	X		NO
MDX0155	USPTO-ZETIA-0001328	USPTO-ZETIA-0001354	5/28/2002	U.S. Patent RE37,721	X		NO
MDX0157	No Bates	No Bates	7/1/2002	FTC Study, "Generic Drug Entry Prior to Patent Expiration" (July 2002)	X		NO
MDX0160	No Bates	No Bates	10/2002	Zetia® (ezetimibe) Tablet, Prescribing Label, U.S. Food and Drug Administration, 2002 Oct.	X		NO
MDX0165	MRKZETIA_SIDLEY000025596	MRKZETIA_SIDLEY000025597	11/3/2002	"How a quartet of Schering-Plough chemists took an idea and turned it into Zetia, a potential blockbluster drug - The Fab Four," Sunday Star Ledger	X		403; HS; R
MDX0214	GLENMARK-ZETIA-00151701	GLENMARK-ZETIA-00151702	7/15/2005	Letter from A. Afonso to J. Nelson	X		NO
MDX0216	GLENMARK-ZETIA-00149315	GLENMARK-ZETIA-00149318	11/14/2005	Letter from Morgan & Finnegan to A. Afonso	X		HS; HWH *Defs. Objections. Pending, Dkt. 2044*
MDX0221	USPTO-ZETIA-0001319	USPTO-ZETIA-0001320	1/17/2006	Notice of Final Determination from USPTO to T. Hoffman of Schering Corp. re "Patent Term Extension Application for U.S. Patent No. Re. 37,721"	X		NO
MDX0222	No Bates	No Bates	2/2006	Article titled, "Generic Competition in the US Pharmaceutical Industry"	X		NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0230	No Bates	No Bates	7/19/2006	Senate Bill 3695, titled "A BILL To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs"	X		403; MIL; R *MIL Objections overruled, Dkt. 2040*
MDX0231	No Bates	No Bates	7/28/2006	House Resolution 5993, titled "A BILL To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs"	X		403; MIL; R *MIL Objections overruled, Dkt. 2040*
MDX0248	GLENMARK-ZETIA-00119657	GLENMARK-ZETIA-00119658	2/1/2007	Email from B. SivaKumar to S. Sinha re "FW: New Ezetimibe"	X		HS; HWH; R
MDX0250	GLENMARK-ZETIA-00041585	GLENMARK-ZETIA-00041611	2/8/2007	Letter from Glenmark to Merck re ANDA for generic ezetimibe, Paragraph IV	X		NO
MDX0257	GLENMARK-ZETIA-0435482	GLENMARK-ZETIA-0435483	5/12/2007	Email from J. Gariolo to B. Hirsch re "Letter to Merck" with attachment	X		NO
MDX0262	GLENMARK-ZETIA-00316019	GLENMARK-ZETIA-00316036	9/28/2007	Email from R. Jha to W. McIntyre re "RE: Regulatory Issues - Videocon 08/13/07"	X		403; HS; HWH; R
MDX0283	No Bates	No Bates	6/13/2018	F. Prugo et al., Insight: Orange, Purple Book Patentees Hone PTAB Survival Skills, Bloomberg Law, BNA's Patent, Trademark & Copyright Journal, Vo. 17, No. 0 (2018)	X		403; H; HWH; R
MDX0286	MRKZETIA_SIDLEY000128261	MRKZETIA_SIDLEY000128264	9/5/2008	Stipulation with Respect to Infringement Issues Involving U.S. Patent No. RE37,721, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL), ECF No. 88	X		NO
MDX0289	GLENMARK_ZETIA-00123909	GLENMARK_ZETIA-00124120	10/21/2008	Deposition Transcript of Adriano Afonso, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0290	MRKZETIA_SIDLEY000105201	MRKZETIA_SIDLEY000105397	10/21/2008	Deposition Transcript of Adriano Afonso, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0316	MRKZETIA_SIDLEY000001597	MRKZETIA_SIDLEY000001693	2/25/2009	Expert Report of Clayton H. Heathcock, Ph.D.	X		NO
MDX0317	MRKZETIA000365313	MRKZETIA000365496	2/25/2009	Expert Report of Clayton Heathcock, Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334 (JLL)	X		NO
MDX0318	USPTO-ZETIA-0020671	USPTO-ZETIA-0020853	2/25/2009	Expert Report of Clayton H. Heathcock, Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0328	GLENMARK-ZETIA-00082371	GLENMARK-ZETIA-00082601	4/20/2009	Expert Report of Ronald G. Brisbois, Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0329	GLENMARK-ZETIA-00082607	GLENMARK-ZETIA-00082746	4/20/2009	Expert Report of William R. Roush, Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0330	MRKZETIA_SIDLEY000059993	MRKZETIA_SIDLEY000060223	4/20/2009	Expert Report of Ronald G. Brisbois, Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0337	GLENMARK-ZETIA-00082994	GLENMARK-ZETIA-00083043	5/8/2009	Rebuttal Expert Report of Clayton H. Heathcock, Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0338	USPTO-ZETIA-0014325	USPTO-ZETIA-0014374	5/8/2009	Rebuttal Expert Report of Clayton H. Heathcock Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0344	GLENMARK-ZETIA-00218110	GLENMARK-ZETIA-00218110	6/22/2009	Email from V. Soni to T. Coughlin and P. Dutra "RE: Par"	X		NO
MDX0346	MRKZETIA_SIDLEY000021157	MRKZETIA_SIDLEY000021189	6/29/2009	Memorandum of Law in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (improper reissue), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334	X		NO
MDX0349	No Bates	No Bates	7/2009	Zetia® (ezetimibe) Tablet, Prescribing Label, U.S. Food and Drug Administration, 2009 Jul.	X		NO
MDX0351	USPTO-ZETIA-0010879	USPTO-ZETIA-0010917	7/8/2009	Memorandum of Law in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334 (JLL), ECF Nos. 128-128-2	X		NO
MDX0353	MRKZETIA_SIDLEY000026820	MRKZETIA_SIDLEY000026850	7/22/2009	Memorandum of Law in Opposition to Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (reissue), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334	X		NO
MDX0356	GLENMARK-ZETIA-00426551	GLENMARK-ZETIA-00426565	8/4/2009	Email from T. Coughlin to G. Saldanha "RE: Ezetimibe"	X		HS; HWH
MDX0357	MRKZETIA_SIDLEY000052155	MRKZETIA_SIDLEY000052218	8/4/2009	Declaration of William R. Roush, Ph.D., Exhibit 69, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0359	GLENMARK-ZETIA-00281992	GLENMARK-ZETIA-00281993	8/6/2009	Email from T. Coughlin to G. Saldanha and V. Soni "RE: Discussion with SP (Schering)"	X		NO
MDX0362	GLENMARK-ZETIA-00142363	GLENMARK-ZETIA-00142379	8/21/2009	Reply Memorandum in Support of Glenmark's Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334	X		NO
MDX0370	MRKZETIA_R000073651	MRKZETIA_R000073651	11/3/2009	Printout of Tab "Zetia - US" titled, Chart titled, "Project Saturn Schedule 8.6.1 Valuation of MSP Joint Venture DRAFT - For Discussion Purposes Only" (from Excel spreadsheet with file name 'DRAFT - MSP JV Schedules and Workpapers 1-27-10.xls")	X		FD; HS *Objections overruled at PTC subject to Merck establishing FD at trial*
MDX0380	MRKZETIA_SIDLEY000098253	MRKZETIA_SIDLEY000098302	12/14/2009	Defendants' Trial Brief, Schering Corp. et al. v. Glenmark Pharm.et al., Case No. 07-CV-1334 (JLL)	X		NO
MDX0381	MRKZETIA_SIDLEY000098841	MRKZETIA_SIDLEY000098879	12/14/2009	Plaintiffs' Pretrial Brief, Schering Corp. et al. v. Glenmark Pharm.et al., Case No. 07-CV-1334 (JLL), ECF NO. 186	X		NO
MDX0382	No Bates	No Bates	12/14/2009	Exhibit 14 to the Declaration of G. Hykal, Defendants' Trial Brief, Schering Corp. et al. v. Glenmark Pharm.et al., Case No. 07-CV-1334, ECF No. 193-18	X		NO
MDX0383	USPTO-ZETIA-0014519	USPTO-ZETIA-0014568	12/14/2009	Defendants' Trial Brief, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX0402	MRKZETIA_R000061858	MRKZETIA_R000061861	2/26/2010	Email from V. Soni to P. Matukaitis "RE: Glenmark-Merck"	X		NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0404	No Bates	No Bates	3/1/2010	Merck & Co., Inc. 2009-Form-10-K	X		403; R *Objections overruled at PTC*
MDX0405	MRKZETIA_SIDLEY000196387	MRKZETIA_SIDLEY000196503	3/2/2010	Defendant Mylan Pharmaceuticals Inc.'s First Amended Answer to Plaintiffs' Complaint, Separate Defenses and Amended Counterclaims, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 2:09-cv-06383 (JLL), ECF No. 33	X		403; HS; MIL; R
MDX0409	USPTO-ZETIA-0008149	USPTO-ZETIA-0008263	3/2/2010	Defendant Mylan Pharmaceuticals Inc.'s First Amended Answer to Plaintiffs' Complaint, Separate Defenses and Amended Counterclaims, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 2:09-cv-06383 (JLL), ECF No. 33	X		403; HS; MIL; R
MDX0419	MRKZETIA_SIDLEY000018428	MRKZETIA_SIDLEY000018765	3/19/2010	Final Pre-trial Order, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334	X		NO
MDX0421	MRKZETIA_R000078807	MRKZETIA_R000078809	3/26/2010	Email from P. Matukaitis to V. Soni "RE: Temodar - Glenmark Meeting - Monday, March 29, 2010"	X		NO
MDX0422	GLENMARK-ZETIA-00280962	GLENMARK-ZETIA-00280988	3/29/2010	Email from P. Matukaitis to V. Soni re "Agreement"	X		NO
MDX0423	MRKZETIA000870261	MRKZETIA000870287	3/29/2010	Email from V. Soni to E. Murray and L. Jakob re "Agreement" with attachment	X		NO
MDX0424	GLENMARK-ZETIA-0435317	GLENMARK-ZETIA-0435318	3/30/2010	Email from V. Soni to S. Patel and J. Finn "RE: Thanks (Glenmark-Merck)" with attachment	X		NO
MDX0425	MRKZETIA000848666	MRKZETIA000848668	4/2/2010	Email from P. Matukaitis to V. Soni "RE: Sunil called me with some concerns on the deal. PI feel free to call me if we need to discuss..Vijay"	X		NO
MDX0430	GLENMARK-ZETIA-00178056	GLENMARK-ZETIA-00178062	4/19/2010	Opinion, Schering Corp. et al. v. Glenmark Pharm. Inc. USA et al., Case No. 07-cv-01334, ECF No. 220	X		NO
MDX0431	MRKZETIA_SIDLEY000014199	MRKZETIA_SIDLEY000014205	4/19/2010	Opinion, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334, ECF No. 220	X		NO
MDX0432	MRKZETIA_SIDLEY000014568	MRKZETIA_SIDLEY000014571	4/19/2010	Opinion, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334, ECF No. 222	X		NO
MDX0433	MRKZETIA_SIDLEY000026900	MRKZETIA_SIDLEY000026900	4/19/2010	Opinion, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334, ECF No. 222	X		NO
MDX0436	MRKZETIA_R000004105	MRKZETIA_R000004108	4/22/2010	Email from R. Clark to B. Kuhlik "Re: MRK - Legal Concerns Over Zetia Appear Grossly Overstated (Leerink): A Victory for Glenmark But Zetia's IP Likely OK to 2016 (Cowen)"	X		403; HS; HWH; MIL; R *Defs. Objections to MIL Pending, Dkt. 2043*

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0437	MRKZETIA_R000082920	MRKZETIA_R000082923	4/22/2010	Scala, S. et al., Quick Take: A Victory for Glenmark but Zetia's IP Likely OK to 2016, Cowen and Company	X		403; HS; MIL; R *Defs. Objections to MIL Pending, Dkt. 2043*
MDX0438	MRKZETIA000871251	MRKZETIA000871252	4/22/2010	Email from E. Murray to P. Matukaitis and L. Jakob re "FW: NEWS ALERT: Down Jones Newswires: Merck Gets Split Patent Decision; Zetia Copay Raised"	X		403; HS; HWH; MIL; R *Defs. Objections to MIL Pending, Dkt. 2043*
MDX0439	MRKZETIA000933269	MRKZETIA000933272	4/22/2010	Scala, Steve, A Victory For Glenmark But Zetia's IP Likely OK To 2016 Analysts, Cowen and Company	X		403; HS; HWH; MIL; R *Defs. Objections to MIL Pending, Dkt. 2043*
MDX0440	GLENMARK-ZETIA-00147835	GLENMARK-ZETIA-00147851	4/30/2010	Notice of Motion and Motion for Reconsideration, Schering Corp. et al. v. Glenmark Pharm.et al., Case No. 07-CV-1334, ECF No. 225-1-3	X		NO
MDX0445	MRKZETIA000845666	MRKZETIA000845667	5/3/2010	Email from E. Murray to D. Pritikin, T. Krause, K. Stoffan and L. Jakob re "Fw: NEWS ALERT: PR Newswire: Par Obtains Exclusive Rights to Market and Distribute Generic"	X		NO
MDX0446	LWNSTNZETIA000019643	LWNSTNZETIA000019654	5/4/2010	Glenmark's Opposition to Schering's Motion for Reconsideration of Order Granting Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10 Through 13, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334, ECF No. 228	X		NO
MDX0453	MRKZETIA_R000080162	MRKZETIA_R000080162	5/7/2010	Email from P. Matukaitis to T. Hester re "FW: Merck-Glenmark agreement"	X		NO
MDX0456	GLENMARK-ZETIA-00280901	GLENMARK-ZETIA-00280956	5/8/2010	Email from T. Hester to V. Soni, L. Brown and E. Choy re "Zetia Settlement Agreement" with attachments	X		NO
MDX0457	GLENMARK-ZETIA-00280930	GLENMARK-ZETIA-00280956	5/8/2010	Redline Draft of the Settlement Agreement	X		NO
MDX0458	MRKZETIA_R000048738	MRKZETIA_R000048798	5/9/2010	Email from T. Hester to P. Matukaitis, L. Jakob, E. Rudnicki et al. re "FW: Zetia Settlement Agreement" with attachments	X		NO
MDX0459	MRKZETIA_R000061595	MRKZETIA_R000061665	5/9/2010	Email from E. Choy to P. Matukaitis, L. Brown and V. Soni re "Zetia Settlement Agreement" with attachments	X		NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0460	MRKZETIA_R000062045	MRKZETIA_R000062047	5/9/2010	Email from V. Soni to P. Matukaitis, L. Brown and E. Choy "Re: Conference Confirmation - Matukaitis/Glenmark"	X		NO
MDX0461	MRKZETIA_R000080017	MRKZETIA_R000080018	5/9/2010	Email from T. Hester to P. Matukaitis, L. Jakob, E. Murray "RE: Zetia Settlement Agreement" with attachments	X		NO
MDX0462	MRKZETIA_R000061727	MRKZETIA_R000061759	5/13/2010	Email from T. Hester to V. Soni and P. Matukaitis re "Execution Version of Settlement Agreement" with attachment	X		NO
MDX0463	GLENMARK-ZETIA-00145924	GLENMARK-ZETIA-00145925	5/10/2010	Order Vacating Opinion and Order Granting Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL) (ES), ECF No. 242	X		NO
MDX0468	MRKZETIA_R000047913	MRKZETIA_R000047947	5/10/2010	Email from V. Soni to T. Hester, L. Brown, E. Choy et al. "RE: Execution Version of Zetia Agreement" with attachment	X		NO
MDX0470	MRKZETIA_R000061561	MRKZETIA_R000061564	5/10/2010	Email from V. Soni to P. Matukaitis and D. Pritikin "RE: Execution Version of Zetia Agreement"	X		NO
MDX0478	MRKZETIA000000001	MRKZETIA000000032	5/10/2010	Settlement Agreement between Schering Corp. and MS Singapore Company. LLC and Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd.	X		NO
MDX0481	MRKZETIA000848136	MRKZETIA000848225	5/10/2010	Email from T. Hester to P. Matukaitis, E. Rudnicki, K. Stoffan et al. re "FW: Revised Zetia Settlement Agreement" with attachments	X		NO
MDX0497	MRKZETIA000944238	MRKZETIA000944271	5/18/2010	Letter from T. Hester to FTC enclosing the May 20, 2010 Settlement Agreement between Schering, MSP Singapore and Glenmark	X		403; HS; MIL; R
MDX0500	MRKZETIA_R000061907	MRKZETIA_R000061908	6/7/2010	Email from E. Murray to V. Soni and P. Matukaitis "RE: Glenmark (Ezetimibe) Table for Invoices"	X		NO
MDX0501	MRKZETIA_R000062232	MRKZETIA_R000062244	6/9/2010	Email from V. Soni E. Murray "RE: Glenmark (Ezetimibe) Table for Invoices" with attachments	X		NO
MDX0502	USPTO-ZETIA-0001355	USPTO-ZETIA-0023605	6/9/2010	Application No. 12/797,341	X		403; HS; MIL; R
MDX0505	USPTO-ZETIA-0001377	USPTO-ZETIA-0001387	6/9/2010	Preliminary Amendment Filed with Narrowing Reissue Application, Docket No. 106527-0011-401 (Patent), RE37, 721 E	X		NO
MDX0511	USPTO-ZETIA-0023591	USPTO-ZETIA-0023597	6/9/2010	Information Disclosure Statement by Applicant, Application Number 12/97,341, B44, C367-C473	X		403; MIL; R
MDX0512	MRKZETIA_R000061909	MRKZETIA_R000061912	6/10/2010	Email from E. Murray to V. Soni "RE: Glenmark (Ezetimibe) Table for Invoices"	X		NO
MDX0517	MRKZETIA_R000061870	MRKZETIA_R000061872	6/18/2010	Email from V. Soni to E. Murray and P. Matukaitis re "FW: ZETIA - Settlement Payment (second payment)" with attachment	X		NO
MDX0536	USPTO-ZETIA-0013199	USPTO-ZETIA-0013205	10/7/2010	Communication from USPTO to Ropes & Gray LLP transmitting Office Action Summary re Application 12/797,341	X		403; HS; MIL; R
MDX0561	GLENMARK-ZETIA-00309983	GLENMARK-ZETIA-00309985	4/12/2011	Letter from Glenmark to FDA re "Original Submission Drug Master File Type II, Ezetimibe (Process II) Pre-assigned DMF No. 024825"	X		NO
MDX0563	MRKZETIA_SIDLEY000160493	MRKZETIA_SIDLEY000160502	5/17/2011	Opinion, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 195	X		403; HS; MIL; R
MDX0566	MRKZETIA_SIDLEY000118024	MRKZETIA_SIDLEY000118057	6/14/2011	U.S. Patent RE42,461	X		403; HS; MIL; R
MDX0567	USPTO-ZETIA-0023606	USPTO-ZETIA-0023642	6/14/2011	U.S. Patent RE42,461	X		403; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0569	MRKZETIA000988357	MRKZETIA000988392	6/30/2011	Settlement Agreement between Schering Corporation and Teva Pharmaceuticals USA, Inc.	X		NO
MDX0576	No Bates	No Bates	8/1/2011	FTC Report, "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact"	X		NO
MDX0577	No Bates	No Bates	8/1/2011	FTC report titled, "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact"	X		NO
MDX0578	No Bates	No Bates	8/1/2011	FTC report titled, "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact"	X		NO
MDX0579	No Bates	No Bates	8/1/2011	FTC report titled, "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact"	X		NO
MDX0580	No Bates	No Bates	8/1/2011	Excerpts from FTC report titled, "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact"	X		NO
MDX0583	GLENMARK-ZETIA-00282426	GLENMARK-ZETIA-00282431	8/5/2011	Letter from Glenmark to FDA re "ANDA # 078560, Ezetimibe Tablets 10 mg Gratuitous Preapproval Amendment"	X		NO
MDX0588	MRKZETIA000934056	MRKZETIA000934057	8/22/2011	Order, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383 (JLL), EFC No. 299	X		403; HS; MIL; R
MDX0590	No Bates	No Bates	8/23/2011	"Clarification of Criteria for Reissue Error in View of In re Tanaka," 1369 OG 230 (23 Aug 2011)	X		HS; MIL; R
MDX0603	GLENMARK-ZETIA-00217145	GLENMARK-ZETIA-00217150	10/14/2011	Email from J. Bermitz to A. Maffia, G. Chen, J. Albin et al., re "Received from FDA: DMF II Ezetimibe" with attachment	X		NO
MDX0628	GLENMARK-ZETIA-00312657	GLENMARK-ZETIA-00312687	3/15/2012	Glenmark response re "F.D.A. Letter, Vilayat Sayeed, Ph.D. to Dr. William McIntyre (October 14, 2011)"	X		NO
MDX0637	GLENMARK-ZETIA-00204603	GLENMARK-ZETIA-00204611	4/10/2012	Email from A. Maffia to S. Kaushal and M. Plastina re "FW: Ezetimibe Process comparison for review"	X		403; HS; HWH
MDX0639	MRKZETIA000615093	MRKZETIA000615123	4/27/2012	Opinion, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 444	X		403; HS; HWH; MIL; R
MDX0640	MRKZETIA000615124	MRKZETIA000615154	4/27/2012	Order, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383 (JLL), EFC No. 444	X		403; HS; HWH; MIL; R
MDX0651	MRKZETIA000937429	MRKZETIA000937565	8/3/2012	Brief for Defendant Appellant, US Court of Appeals, Merck Sharp & Dohme Corp. v. Mylan Pharm. Inc., Appeal No. 2012-1334, ECF No. 19	X		403; HS; MIL; R
MDX0667	GLENMARK-ZETIA-00312033	GLENMARK-ZETIA-00312038	11/11/2012	FDA letter to Glenmark re "GDUFA DMF COMPLETE RESPONSE"	X		NO
MDX0676	No Bates	No Bates	2/7/2013	Mylan v. Schering Corp., 496 F. App'x 87 (Fed. Cir. 2013)	X		403; HS; MIL; R
MDX0680	GLENMARK-ZETIA-00287501	GLENMARK-ZETIA-00287504	3/21/2013	FDA letter to Glenmark re "COMPLETE RESPONSE"	X		NO
MDX0694	GLENMARK-ZETIA-00285142	GLENMARK-ZETIA-00285145	5/31/2013	Glenmark letter to FDA re "ANDA 078560, Ezetimibe Tablets, 10 mg, Response to Complete Response Letter, RESUBMISSION/AFTER ACTION- MINOR AMENDMENT"	X		NO
MDX0698	No Bates	No Bates	8/1/2013	Zetia® (ezetimibe) Tablet, Prescribing Label, U.S. Food and Drug Administration, 2013 Aug.	X		NO
MDX0705	GLENMARK-ZETIA-00312011	GLENMARK-ZETIA-00312013	8/13/2013	FDA correspondence to Glenmark re "DMF INFORMATION REQUEST"	X		NO
MDX0708	MRKZETIA000526690	MRKZETIA000526691	8/29/2013	Email from J. Liebel to S. Koening, et al. re "Zetia LOE" with attachment	X		FD

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0710	MRKZETIA000845601	MRKZETIA000845628	8/30/2013	Settlement agreement between Merck Sharp & Dohme Corporation and MSD International GmbH and Sandoz Inc.	X		NO
MDX0713	GLENMARK-ZETIA-00311819	GLENMARK-ZETIA-00311821	9/26/2013	Glenmark response re "F.D.A. Letter, Susan Rosencrance to Dr. William McIntyre (August 14, 2013)"	X		NO
MDX0714	GLENMARK-ZETIA-00265485	GLENMARK-ZETIA-00265486	9/27/2013	Email from A. Kohli to S. Krishan, D. Bisaria, S. Sharma et al. re "Submitted to FDA: Ezetimibe (Process II) DMF 24825" with attachment	X		NO
MDX0749	GLENMARK-ZETIA-00204855	GLENMARK-ZETIA-00204861	5/13/2014	Email from M. Mathias to J. Bermitz, S. Sharma, A. Maffia et al. re "Submitted to the FDA: Ezetimibe Tablets : ANDA # 078560" with attachment	X		NO
MDX0754	MRKZETIA_R000025623	MRKZETIA_R000025687	6/16/2014	Email from G. Firestone to L. Stevens re "USA Ezetimibe LOE workshop June 19, 2012 v2.pptx" with attachment	X		403; HS; R
MDX0767	GLENMARK-ZETIA-00209192	GLENMARK-ZETIA-00209196	10/10/2014	Email from M. Mathias to C. Spinks, S. Damoci, J. Koczone et al. re "Submitted to FDA: Ezetimibe Tablets 10 mg : ANDA # 078560" with attachment	X		NO
MDX0772	No Bates	No Bates	11/20/2014	Press Release titled, "AMNEAL LAUNCHES AG FOR NOVO NORDISK'S ACTIVELLA® Authorized Generic offers brand product plus patient savings"	X		R
MDX0784	SANDOZ-ZETIA-0000140	SANDOZ-ZETIA-0000145	1/13/2015	Letter from FDA to Sandoz re "Complete Response"	X		NO
MDX0805	GLENMARK-ZETIA-00283456	GLENMARK-ZETIA-00283458	6/1/2015	Email from K. Vanam to S. Kaushal and J. Bermitz re "FW: INFORMATION REQUEST Original ANDA 078560" with attachment	X		NO
MDX0807	GLENMARK-ZETIA-00418368	GLENMARK-ZETIA-00418372	6/5/2015	Email from S. Sharma to R. CG and V. Arora re "Fw: Submitted to the FDA: Ezetimibe Tablets, 10 mg , ANDA # 078560" with attachment	X		NO
MDX0810	GLENMARK-ZETIA-00166675	GLENMARK-ZETIA-00166677	6/26/2015	FDA letter to Glenmark re "APPROVAL"	X		NO
MDX0811	GLENMARK-ZETIA-00166675	GLENMARK-ZETIA-00166677	6/26/2015	Letter from FDA to Glenmark re final approval of ANDA for generic ezetimibe	X		NO
MDX0815	GLENMARK-ZETIA-00187669	GLENMARK-ZETIA-00187677	7/7/2015	Email from P. Wagle to S. Thirumanathu re "FW: Submitted to FDA: Ezetimibe Tablets, 10 mg , ANDA # 078560" with attachment	X		NO
MDX0818	GLENMARK-ZETIA-00185719	GLENMARK-ZETIA-00185726	7/10/2015	Letter from Glenmark to FDA re "Prior Approval Supplement"	X		HS
MDX0820	GLENMARK-ZETIA-00285269	GLENMARK-ZETIA-00285276	7/10/2015	Letter from Glenmark to FDA re "ANDA # 078560, Ezetimibe Tablets, 10 mg Prior Approval Supplement (PAS) - API manufactured by alternate drug substance supplier (MSN Laboratories Private Limited) at alternate manufacturing site of drug product (Appco Pharma LLC, USA) Sequence No: 0020"	X		NO
MDX0829	GLENMARK-ZETIA-00294378	GLENMARK-ZETIA-00294380	8/19/2015	Letter from Glenmark to FDA re "ANDA 078560/S-002 Ezetimibe Tablets, 10 mg Information Request – Product Quality - Reference # 148696 Sequence 0021"	X		NO
MDX0833	GLENMARK-ZETIA-00391934	GLENMARK-ZETIA-00392044	8/26/2015	Email from H. Rane to S. Mungekar and S. Sharma re "FW: Glenmark: Ezetimibe EB Current Spec for US" with attachments	X		FD; HS
MDX0834	GLENMARK-ZETIA-00287387	GLENMARK-ZETIA-00287390	8/28/2015	Letter from Glenmark to FDA re "ANDA 078560/S-001 Ezetimibe Tablets, 10 mg Information Request – Product Quality - Reference # 150992 Sequence 0023"	X		NO
MDX0844	GLENMARK-ZETIA-00192640	GLENMARK-ZETIA-00192642	9/9/2015	Email from V. Soni to P. Wagle re "FW: Received From FDA: Ezetimibe Tablets, 10 mg" with attachment	X		NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0845	GLENMARK-ZETIA-00419891	GLENMARK-ZETIA-00419893	9/9/2015	Email from J. Bermitz to A. Sharma, D. Makhey, S. Sharma et al. re "Received From FDA: Ezetimibe Tablets, 10 mg" with attachment	X		NO
MDX0861	MRKZETIA000853645	MRKZETIA000853647	12/8/2015	Email from M. Reagan to A. Modlinger re "FW: Project Willard - Zetia Agx Kick-off Meeting Follow-up [Sensitive]" with attachment	X		NO
MDX0868	No Bates	No Bates	2016	DiMasi JA, Grabowski HG, Hansen RA. "Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs" *J. Health Economics*, 47:20-33 (2016)	X		403; 901; HS; MIL; R
MDX0871	No Bates	No Bates	1/2016	IMS Report titled, "Price Declines after Branded Medicines Lose Exclusivity in the U.S."	X		NO
MDX0875	MRKZETIA000517420	MRKZETIA000517420	2/1/2016	PowerPoint presentation titled, "EZETIMIBE Loss of Exclusivity Plan"	X		NO
MDX0900	MRKZETIA000514931	MRKZETIA000514932	6/2/2016	Email from M. Sangani to D. Gan and D. Heider "RE: for today's zetia review/discussion [Confidential]" with attachment	X		NO
MDX0903	MRKZETIA000874087	MRKZETIA000874089	6/8/2016	Letter from Merck to Glenmark re "Glenmark Agreement"	X		NO
MDX0916	MRKZETIA000515546	MRKZETIA000515548	7/14/2016	Email from D. Heider to M. Exume and D. Gan "RE: Executive summary slides draft [Confidential]" with attachment	X		NO
MDX0917	MRKZETIA000515548	MRKZETIA000515548	7/13/2016	PowerPoint presentation titled, "ZETIA LOE Contracting Strategy - US Market"	X		NO
MDX0920	MRKZETIA000874076	MRKZETIA000874077	7/13/2016	Email from R. Matsuk to L. Jakob "Re: Meeting for Week of August 15th"	X		NO
MDX0923	MRKZETIA000518695	MRKZETIA000518696	8/1/2016	Email from R. Matsuk to L. Jakob "Re: Meeting for Week of August 15th"	X		NO
MDX0924	MRKZETIA000614646	MRKZETIA000614647	8/4/2016	Email from L. Jakob to D. Pakula re "Glenmark Response" with attachment	X		NO
MDX0931	GLENMARK-ZETIA-00433380	GLENMARK-ZETIA-00433382	9/13/2016	Email from C. Calabro to R. Matsuk "RE: Merck Discussion" with attachment	X		NO
MDX0936	MRKZETIA000509924	MRKZETIA000509924	9/23/2016	PowerPoint presentation titled, "WILLARD"	X		NO
MDX0940	MRKZETIA000510244	MRKZETIA000510245	10/19/2016	Email from K. Hayward to D. Pakula and M. Exume re "Just spoke to Kathryn. She has a 1:1 with Matt later today and will inform him Thanks!"	X		NO
MDX0942	MRKZETIA000510131	MRKZETIA000510133	10/20/2016	Email from D. Pakula to N. Miller-Rich re "WILLARD: Talking Points [Confidential]"	X		NO
MDX0968	No Bates	No Bates	2017	Grabowski, Henry et al., Pharmaceutical Patent Challenges - Company Strategies and Litigation Outcomes, American Journal of Health Economics, 3(1), 33-59 (2017)	X		403; 901; MIL; R
MDX0978	PAR_00023422	PAR_00023423	2/16/2017	Email from P. Campanelli to J. Morales, C. Degnan and J. Boyle re "FW: IMPORTANT: 2017 Budget Update-Zetia/Merck"	X		HS; HWH
MDX0995	PAR_00020287	PAR_00020311	4/28/2017	Email from R. Valiga to T. Coughlin, T. Pera, J. Barbarite, et al re "U.S. Generics Q1'17 Results & FY'17 Board Approved April LBE Overview" with attachments	X		403; HS; HWH; R
MDX0997	MRKZETIA000859869	MRKZETIA000859869	5/12/2017	Letter from B. Hirsch (Glenmark) to W. Krovatin (Merck) re the Merck/Glenmark Settlement Agreement	X		NO
MDX0998	MRKZETIA000854327	MRKZETIA000854332	5/15/2017	Email from D. Gan to D. Jankiewicz, K. Hayward, M. Exume and D. Pakula re "FW: Scrip | Today's News & Analysis"	X		403; 901; HS; HWH
MDX1006	WLG_ZETIA_ED00046510	WLG_ZETIA_ED00046511	6/9/2017	Email from M. Twilleager cc'ing various re "Ezetimibe Tab (gZetia) LOE Landscape"	X		HS; HWH

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1035	MRKZETIA000854171	MRKZETIA000854173	11/7/2017	Email from M. Exume to D. Gan, J. Schwartz, D. Heider et al. "RE: ZETIA LOE Year To Date Accomplishment"	X		403; HS; R
MDX1036	MRKZETIA000854142	MRKZETIA000854146	11/8/2017	Email from M. Exume to D. Gan and J. Liebel "RE: ZETIA LOE Year to Date Accomplishment [Confidential]" with attachment	X		403; HS; R
MDX1052	HEB_ZETIA_00000001	HEB_ZETIA_00000002	3/8/2018	Agreement for Assignment of Claims between McKesson Corporation and HEB Grocery Company LP	X		NO
MDX1074	HEB_ZETIA_ED00010341	HEB_ZETIA_ED00010341	11/28/2018	Letter from D. Roccanovato E. Patek re "Ezetimibe Tablets: Compare to Zetia"	X		NO
MDX1092	MRKZETIA_R000061376	MRKZETIA_R000061376	4/18/2019	Excel Spreadsheet re Legal Expenses with file name, "matter_number_SP3505_invoices2019-04-18 085251Z.xls"	X		403; 901; FD; HS; MIL; R
MDX1093	USPTO-ZETIA-0025273	USPTO-ZETIA-0025383	4/19/2019	U.S. Application Number 08/102,440	X		NO
MDX1094	USPTO-ZETIA-0025384	USPTO-ZETIA-0025614	4/19/2019	U.S. Application Number 08/257,593	X		NO
MDX1125	No Bates	No Bates	12/19/2019	Document titled, "FDA Listing of Authorized Generics as of December 19, 2019"	X		NO
MDX1134	GLENMARK-ZETIA-00281045	GLENMARK-ZETIA-00281055	2/19/2010	IPD Analytics Pharmaceutical Patent Litigation Monitor "Zetia (Merck v. Glenmark): Merck Appears to Have Advantage Despite Possible Flaws in Patent"	X		403; HS; HWH; MIL; R *Defs. Objections to MIL Pending, Dkt. 2043*
MDX1155	No Bates	No Bates	7/6/2020	Excerpts from Teva "Full Product Catalog"	X		403; HS; INC; R
MDX1157	No Bates	No Bates	7/6/2020	Document titled, "National Drug Code Directory"	X		R
MDX1178	MRKZETIA000891502	MRKZETIA000891502	1998	Printout of Excel spreadsheet with file name "Zetia Litigation Support_Historical Costs 1998-2018"	X		403; 901; HS; HWH; INC; MIL; R
MDX1222	GLENMARK-ZETIA-00304970	GLENMARK-ZETIA-00304970		Draft-email, notes from V. Soni re "Ezetimibe settelment[sic]"	X		NO
MDX1224	LWNSTNZETIA000017782	LWNSTNZETIA000017871		Final Pretrial Order, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)	X		NO
MDX1230	MRKZETIA_R000062439	MRKZETIA_R000062439	9/2013	Printout of Excel spreadsheet with file name "US Eze Family P&Ls 2013 -Sep YTD 2018.xlsx"	X		NO
MDX1232	MRKZETIA_R000062449	MRKZETIA_R000062449	1/2013	Printout of Excel spreadsheet titled "US Pharma Zetia Total Materials & Production Costs Jan 2013 - Jan 2018"	X		403; HS; R
MDX1241	MRKZETIA_R000082822	MRKZETIA_R000082844	10/25/2002	Letter from FDA to U.S. Regulatory Affairs re NDA 21-445	X		NO
MDX1245	MRKZETIA_SIDLEY000010010	MRKZETIA_SIDLEY000010083	9/21/1993	USPTO - File History U.S. 08/102,440	X		HS (unless not offered for truth)
MDX1250	MRKZETIA_SIDLEY000047293	MRKZETIA_SIDLEY000047456	5/1993	Stuart Rosenblum Notebook No. 31818 (May 1993-August 1994)	X		NO
MDX1263	MRKZETIA_SIDLEY000280277	MRKZETIA_SIDLEY000280313	12/1/2011	Final Pretrial Order, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383, 10-01058 (JLL)	X		403; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1299	MRKZETIA001018207	MRKZETIA001018208	4/22/2010	Email from P. McCrorey to P. Magri re "FW: Flash Note/MRK/Legal Concerns Over Zetia Appear Grossly Overstated /Outperform"	X		403; HS; MIL; R *Defs. Objections to MIL Pending, Dkt. 2043*
MDX1308	No Bates	No Bates	6/24/2020	Printout of Excel file titled, "Attachment F. Calculation of generic entry date in an alternative no payment settlement ($ millions)" (Glenmark Odds)	X		NO
MDX1322	No Bates	No Bates	1/15/2009	H.R.573 - To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs	X		403; HS; MIL; R *MIL objection overruled, Dkt. 2040*
MDX1341	No Bates	No Bates	2/26/2009	S.501 - Fair Prescription Drug Competition Act	X		403; HS; MIL; R *MIL objection overruled, Dkt. 2040*
MDX1435	No Bates	No Bates	2/28/2020	Bruce Strombom Damages Backup: Exhibits 2 and 3: Adjustments to But-for Discounts.xlsx	X		403; HS; HWH; R
MDX1436	No Bates	No Bates	2/28/2020	Bruce Strombom Damages Backup: Exhibit 4: Leffler's Adjustments	X		403; HS; HWH; R
MDX1437	No Bates	No Bates	1/13/2020	Printout of Leffler Backup, "Client $$ Summary" file, "WAC + WTD Prices" sheet	X		NO
MDX1438	No Bates	No Bates	1/9/2020	Table: "Dr. Letizinger's but-For Generic Discount Rates"	X		R
MDX1532	No Bates	No Bates	5/1998	F. Lichtenberg: Pharmaceutical Innovation Mortality Reduction and Economic Growth (1998)	X		403; HS; HWH; MIL; R
MDX1579	PAR_00007273	PAR_00007273	12/2016	Printout of Excel file Ezetimibe (Zetia) Launch Date: December 2016	X		NO
MDX1586	PAR_00008449	PAR_00008449	11/2016	Printout of worksheet "Tiers"	X		NO
MDX1617	USPTO-ZETIA-0001373	USPTO-ZETIA-0001387	6/9/2010	Reissue Application Declaration by Assignee, Docket No. 106527-0011-401	X		NO
MDX1618	WLG_ZETIA_ED00084499	WLG_ZETIA_ED00084506	4/29/2016	PPT titled "Top 5 FY17 Generic Losers: April FY16"	X		403; MIL; R
MDX1626	ZETIA-SERGEANTS-000002R	ZETIA-SERGEANTS-000002R	9/3/2019	Excel spreadsheet with file name: ZETIA-SERGEANTS-000002R_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY.xlsx	X		NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1649	No Bates	No Bates	11/26/2019	Document titled, "30(b)(6) Deposition: Documents re Topic 9 (Litigation Expenses)"	X		403; 901; 1006; FD; HS; MC; MIL; R
MDX1650	MRKZETIA_R000061374	MRKZETIA_R000061374	4/11/2019	Excel spreadsheet with file name "Merck - Search All Invoices2019-04-11 114221Z (IP071015 GlenMark).xls"	X		403; 901; FD; HS; MIL; R
MDX1651	MRKZETIA_R000061378	MRKZETIA_R000061378	4/15/2019	Excel spreadsheet with file name "matter_number_201202635_invoices2019-04-15 150719Z Sandoz.xls"	X		403; 901; FD; HS; MIL; R
MDX1652	MRKZETIA_R000061379	MRKZETIA_R000061379	4/11/2019	Excel spreadsheet with file name "Merck - Search All Invoices2019-04-11 113922Z (SP3836 Vytorin).xls"	X		403; 901; FD; HS; MIL; R
MDX1653	MRKZETIA_R000061380	MRKZETIA_R000061380	4/11/2019	Excel spreadsheet with file name "Merck - Search All Invoices2019-04-11 091907Z (111960 Mylan).xls"	X		403; 901; FD; HS; MIL; R
MDX1764	MRKZETIA_SIDLEY000004439	MRKZETIA_SIDLEY000004439	11/28/2005	Letter from A. Afonso to J. Nelson re receipt of Nov. 14, 2005 Letter Rejecting Inventorship Claim for U.S. Patent Nos. 5,631,365 & RE37,721	X		NO
MDX1765	MRKZETIA_SIDLEY000007278	MRKZETIA_SIDLEY000007281	11/14/2005	Letter from D. Auth to A. Afonso Re: Investigation of Inventorship on U.S. Patent Nos. RE37,721 E and 5,631,365	X		NO
MDX1766	MRKZETIA000000720	MRKZETIA000000721	11/02/2005	Email from A. Afonso to J. Nelson re "Status of my Claim"	X		NO
MDX1768	GLENMARK-ZETIA-00149407	GLENMARK-ZETIA-00149408	08/19/2005	Email from A. Afonso to J. Nelson and G. Baldwin re "Message for Dorothy Auth"	X		NO
MDX1769	GLENMARK-ZETIA-00149518	GLENMARK-ZETIA-00149525	07/15/2005	Letter from A. Afonso to J. Nelson re Revision of Inventor List for U.S. Patent Nos. 5,631,365 & 5,767,115	X		NO
MDX1770	GLENMARK-ZETIA-00154970	GLENMARK-ZETIA-00154971	12/01/2005	Letter from J. Nelson to A. Afonso re Nov. 28, 2005 letter	X		901; HS; R
MDX1772	MRKZETIA_R000009153	MRKZETIA_R000009153	2009	Document titled, "Zetia (ezetimibe) - Adding ZETIA: Superior Achievement of LDL-C <100 mg/dl vs Titrating Atorvastatin 20 mg to 40mg[1]"	X		403; 901
MDX1773	MRKZETIA_R000023147	MRKZETIA_R000023148	6/17/2009	Letter by MERCK/Schering-Plough Pharmaceuticals re "Zetia (ezetimibe) + a statin… dramatic LDL-C reduction through dual inhibition"	X		403; 901; R
MDX1865	MRKZETIA_R000087798	MRKZETIA_R000087803	Jan-16	PowerPoint Presentation titled "ZETIA LOE Contracting Strategy - January 2016"	X		NO
MDX1867	MRKZETIA000512890	MRKZETIA000512891	5/3/2016	Email from D. Gan to J. Burleigh et al., re "ZETIA LoE [Confidential]"	X		NO
MDX1875	MRKZETIA_R000058457	MRKZETIA_R000058461	7/12/2016	Email from M. Exume to D., G. Dunlop and D. Gan "RE: Update on Athero AG Discussion [Confidential]" with attachments	X		NO
MDX1883	MRKZETIA000970900	MRKZETIA000970902	2/17/2017	Email from D. Gan to D. Hartenbaum, J. Roehm et al., re "FW: Attached: Latest Zetia LOE Dashboard [Confidential]" with attachment	X		NO
MDX1889	No Bates	No Bates	1/15/2010	RBC Capital Markets - Equity Research - Pharmaceuticals "Analyzing Litigation Success Rates"	X		NO
MDX1890	MRKZETIA000512394	MRKZETIA000512398	3/27/2017	Email from J. Wang to M. Exume "RE: Zetia Question"	X		HS; R
MDX1891	GLENMARK-ZETIA-0435063	GLENMARK-ZETIA-0435063	4/30/2010	Untitled email from P. Matukaitis to V. Soni	X		NO
MDX1898	GLENMARK-ZETIA-00340312	GLENMARK-ZETIA-00340314	6/10/2010	Email from E. Murray to V. Soni "RE: Glenmark (Ezetimibe) Table for Invoices"	X		NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1971	GLENMARK-ZETIA-00223333	GLENMARK-ZETIA-00223338	2/19/2015	Email G. Goyal to V. Soni "RE: Ezetimibe Supply Chain Security" with attachment	X		901; H; HWH
MDX1973	GLENMARK-ZETIA-00312020	GLENMARK-ZETIA-00312024	10/14/2011	Facsimile to W. McIntyre from the Office of Generic Drugs, CDER, FDA regarding DMF Deficiency (DMF 24825)	X		403; 901; HS; R
MDX1974	GLENMARK-ZETIA-00312033	GLENMARK-ZETIA-00312033	11/11/2012	Letter to W. McIntyre from the Office of Generic Drugs, CDER re GDUFA DMF Complete Response	X		403; 901; HS; R
MDX1975	GLENMARK-ZETIA-00219040	GLENMARK-ZETIA-00219041_00(	8/23/2010	Email from D. Bisaria to P. Chavakula and C. Almeida re "FW: Ezetimibe out sourcing issue" with attachment	X		403; 901; CF; HS; R
MDX1976	GLENMARK-ZETIA-00237682	GLENMARK-ZETIA-00237683	7/6/2011	Email from K. Reddy to V. Soni "RE: Meeting at our Office"	X		403; 901; CF; HS; R
MDX1977	GLENMARK-ZETIA-00209236	GLENMARK-ZETIA-00209237	6/25/2014	Email from C. Almeida to S. Rahman et al., "RE: Ezetimibe - 2nd Source"	X		403; 901; CF; HS; MS; R
MDX1982	GLENMARK-ZETIA-00244518	GLENMARK-ZETIA-00244637	7/18/2011	Email from glenmarkpharma@karvy.com to W. McIntrye re "Annual Report - 2010-11" with attachments	X		HS
MDX1983	GLENMARK-ZETIA-00185735	GLENMARK-ZETIA-00185736	4/21/2015	Email from P. Rane to J. Sharma re Offsite Presentation, Barcelona Operations with attachment	X		HS
MDX1984	GLENMARK-ZETIA-00209431	GLENMARK-ZETIA-00209433	7/31/2014	Email from V. Soni to S. Bhirud "RE: Cricital In-House API Delivery"	X		HS, HWH
MDX1985	GLENMARK-ZETIA-00220297	GLENMARK-ZETIA-00220303	3/11/2012	Email from K. Shah to S. Krishan "RE: R&D Cost Reduction Grid - Finalization with attachments	X		901, HS, HWH
MDX1986	GLENMARK-ZETIA-00374836	GLENMARK-ZETIA-00374847	5/10/2012	Email from S. Mungekar to D. Mhapsekar re "FW: Feedback from Changzhou Pharma on Ezetimibe - Alternative Source Development" with attachments	X		901, HS, HWH
MDX1987	GLENMARK-ZETIA-00203812	GLENMARK-ZETIA-00203820	4/10/2012	Email from A. Maffia to Sasikumar K., S. Mohanty and cc "RE: Ezetimibe Process comparison for review"	X		HS
MDX1988	GLENMARK-ZETIA-00211953	GLENMARK-ZETIA-00211954	2/25/2015	Email from S. Sridharan to V. Soni re "today's par ppt" with attachment	X		901, HS, UT

EXHIBIT 4

In re: Zetia (Ezetimibe) Antitrust Litigation, No 1:18-md-2836 (E.D. Va.)
Glenmark Trial Exhibit List (ALL)

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0014	7/11/2005	Email from S. Krishan to T. Coughlin, R. Garella, and V. Soni re New API Products	GLENMARK-ZETIA-00282102	GLENMARK-ZETIA-00282103	Expect to Offer	NO
GDX0021	8/30/2006	Letter from PharmaQ, Inc. to FDA regarding DMF Type II - Original Submission; Product: Ezetimibe; Holder: Glenmark Pharmaceuticals Limited	GLENMARK-ZETIA-00307557	GLENMARK-ZETIA-00307904	Expect to Offer	901; HS; HWH; R
GDX0023	10/25/2006	Letter from W. McIntyre to C. Buehler re Glenmark ANDA 78-560 filing for generic Zetia, with attachments	GLENMARK-ZETIA-00014842	GLENMARK-ZETIA-00014865	Expect to Offer	NO
GDX0025	12/26/2006	ANDA Submission for Ezetimibe 10 mg Tablets from Teva to the FDA	Teva-Zetia_00000001	Teva-Zetia_00000156	Expect to Offer	NO
GDX0030	2/1/2007	Email from B. V. SivaKumar to Sukumar Sinha regarding FW: New Ezetimibe, including internal communications between January 29 – January 31, 2007	GLENMARK-ZETIA-00119657	GLENMARK-ZETIA-00119658	Expect to Offer	HS; HWH
GDX0035	5/7/2007	Email from M. Biju to A. Saxena, B. SivaKumar, S. Sinha, R. Gangavati, D. Maduskar re DMF 19717 / Ezetimibe / Deficiency Letter with attachment	GLENMARK-ZETIA-00316289	GLENMARK-ZETIA-00316293	Expect to Offer	HS; HWH; R
GDX0036	5/31/2007	Email from Z. Sihorwala to G. Saldanha and ccs re Filing Strategies for Fluconazole, Zonisamide and Ezetimibe API Changes with attachments	GLENMARK-ZETIA-00175856	GLENMARK-ZETIA-00175867	Expect to Offer	HS; HWH; R
GDX0040	10/7/2007	Email from V. Soni to Rahul Garella and S. Krishan re Ezetimibe	GLENMARK-ZETIA-00220774	GLENMARK-ZETIA-00220774	Expect to Offer	HS; HWH; R
GDX0044	1/24/2008	Email from T. Coughlin to V. Soni re MSN	GLENMARK-ZETIA-00228886	GLENMARK-ZETIA-00228886	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0045	1/25/2008	Email from V. Soni to T. Coughlin and cc re Ezetimibe COA with attachment	GLENMARK-ZETIA-00231575	GLENMARK-ZETIA-00231577	Expect to Offer	NO
GDX0048	2/7/2008	Email from T. Coughlin to V. Soni regarding FW: Ezetimibe	GLENMARK-ZETIA-00270705	GLENMARK-ZETIA-00270707	Expect to Offer	HS; R
GDX0072	3/10/2009	Email from T. Coughlin to V. Soni and T. Coughlin, and ccs re Merck - Schering	GLENMARK-ZETIA-00218725	GLENMARK-ZETIA-00218727	Expect to Offer	NO
GDX0073	3/10/2009	Email from M. Khan to T. Coughlin, J. Sharma, and G. Saldanha re Ezetimibe - USDMF 19717 Telephone Deficiency Status	GLENMARK-ZETIA-00218764	GLENMARK-ZETIA-00218765	Expect to Offer	NO
GDX0074	3/10/2009	Communication from V. Sayeed, Center for Drug Evaluation and Research to W. McIntyre regarding listing Ezetimibe deficiencies	GLENMARK-ZETIA-00287511	GLENMARK-ZETIA-00287514	Expect to Offer	HS; MIL
GDX0098	8/4/2009	Email from T. Coughlin to G. Saldanha re Ezetimibe	GLENMARK-ZETIA-00426551	GLENMARK-ZETIA-00426565	Expect to Offer	HS; HWH
GDX0099	8/6/2009	Email from T. Coughlin to G. Saldanha and V. Soni re Discussion with SP (Schering)	GLENMARK-ZETIA-00281992	GLENMARK-ZETIA-00281993	Expect to Offer	NO
GDX0102	10/23/2009	Email from V. Soni to Matukaitis regarding Settlement Communication with attachments	MRKZETIA_R000061518	MRKZETIA_R000061535	Expect to Offer	NO
GDX0104	11/24/2009	Email from G. Saldanha to T. Coughlin re Par	GLENMARK-ZETIA-00259809	GLENMARK-ZETIA-00259810	Expect to Offer	NO
GDX0123	3/1/2010	Email from V. Soni to P. Matukaitis and cc re Glenmark- Merck	MRKZETIA_R000061545	MRKZETIA_R000061549	Expect to Offer	NO
GDX0124	3/1/2010	V. Soni handwritten notes re Ezetimibe settlement	GLENMARK-ZETIA-00304970	GLENMARK-ZETIA-00304970	Expect to Offer	NO
GDX0126	3/2/2010	Email from V. Soni to E. Murray and ccc re Glenmark- Merck	MRKZETIA000848697	MRKZETIA000848697	Expect to Offer	NO
GDX0129	3/23/2010	V. Soni notes re Zetia	GLENMARK-ZETIA-00304965	GLENMARK-ZETIA-00304966	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0130	3/25/2010	Email from T. Coughlin to V. Soni and P. Dutra re Temodar - Glenmark Meeting - Monday, March 29, 2010	GLENMARK-ZETIA-0435359	GLENMARK-ZETIA-0435360	Expect to Offer	NO
GDX0132	3/26/2010	Email from V. Soni to T. Coughlin and P. Dutra re Temodar - Glenmark Meeting - Monday, March 29, 2010	GLENMARK-ZETIA-0435354	GLENMARK-ZETIA-0435356	Expect to Offer	NO
GDX0133	3/29/2010	Email from V. Soni to T. Coughlin, P. Dutra re Agreement with attachment	GLENMARK-ZETIA-00258042	GLENMARK-ZETIA-00258068	Expect to Offer	NO
GDX0136	4/2/2010	Email from P. Matukaitis to V. Soni re Sunil called me with some concerns on the deal. Pl feel free to call me if we need to discuss.. Vijay	MRKZETIA000848666	MRKZETIA000848668	Expect to Offer	NO
GDX0137	4/3/2010	Email from T. Coughlin to G. Saldanha re Various	GLENMARK-ZETIA-00201717	GLENMARK-ZETIA-00201717	Expect to Offer	NO
GDX0142	4/19/2010	Opinion by Judge Linares, filed on April 19, 2010 (Dkt. 220), in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00178056	GLENMARK-ZETIA-00178062	Expect to Offer	NO
GDX0143	4/19/2010	Order by Judge Linares re Motions for Summary Judgment, filed on April 19, 2010 (Dkt. 221), in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D.N.J.)			Expect to Offer	NO
GDX0144	4/19/2010	Opinion by Judge Linares re Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), filed on April 19, 2010 (Dkt. 222), in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)	MRKZETIA_SIDLEY000014568	MRKZETIA_SIDLEY000014571	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0145	4/19/2010	IPD Analytics LLC Pharma Report - Zetia Update (MRK v. Glenmark): Despite Unfavorable Partial Summary Judgment Decision, Merck Still Appears Likely to Prevail in Lawsuit	HEB_ZETIA_ED00017751	HEB_ZETIA_ED00017753	Expect to Offer	403; HS; R
GDX0148	4/30/2010	Marketing and Distribution Agreement between Glenmark Generics, et al. and Par Pharmaceuticals	GLENMARK-ZETIA-0056715	GLENMARK-ZETIA-0056750	Expect to Offer	NO
GDX0153	5/4/2010	Email from V. Soni to P. Campanelli and cc re Good Luck	GLENMARK-ZETIA-0434669	GLENMARK-ZETIA-0434669	Expect to Offer	NO
GDX0158	5/7/2010	Email from C. Calabro to M. Altamuro, P. Campanelli re Carla	PAR_00007859	PAR_00007860	Expect to Offer	NO
GDX0159	5/7/2010	Email from P. Campanelli to T. Coughlin re Hi	GLENMARK-ZETIA-0434105	GLENMARK-ZETIA-0434106	Expect to Offer	NO
GDX0165	5/8/2010	Email from T. Hester to V. Soni, L. Brown, and E. Choy re Zetia Settlement Agreement with	GLENMARK-ZETIA-00280901	GLENMARK-ZETIA-00280956	Expect to Offer	NO
GDX0166	5/9/2010	Email from E. Choy to P. Matukaitis, L. Brown, V. Soni and ccs re Zetia Settlement Agreement with attachments	MRKZETIA_R000061597	MRKZETIA_R000061665	Expect to Offer	NO
GDX0167	5/9/2010	Email from E. Choy to P. Campanelli, L. Brown, V. Soni, T. Coughlin, and cc re Zetia Settlement Agreement with attachments	GLENMARK-ZETIA-00261795	GLENMARK-ZETIA-00261851	Expect to Offer	NO
GDX0168	5/9/2010	Email from L. Brown to D. Brown re Zetia Settlement Agreement with attachments	WSGR-ZET004044	WSGR-ZET004113	Expect to Offer	NO
GDX0169	5/9/2010	Email from T. Hester to P. Matukaitis, E. Rudnicki, K. Stoffan, L. Jakob, et al. re Zetia Settlement Agreement with attachments	MRKZETIA_R000048738	MRKZETIA_R000048798	Expect to Offer	NO
GDX0173	5/10/2010	Email from L. Brown to T. Hester, V. Soni, E. Choy, and ccs re a few more nits	MRKZETIA_R000046146	MRKZETIA_R000046152	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0178	5/10/2010	Email from L. Brown to T. Hester and cc re Revised agmt	Zetia_EDVA_00000337	Zetia_EDVA_00000370	Expect to Offer	NO
GDX0180	5/10/2010	Email from V. Soni to J. Lesser, D. Tellekson re Execution Version of Zetia Agreement	GLENMARK-ZETIA-00332457	GLENMARK-ZETIA-00332458	Expect to Offer	NO
GDX0181	5/10/2010	Email from P. Campanelli to S. Mock re Ezetimibe updated with attachment	PAR_00008082	PAR_00008083	Expect to Offer	NO
GDX0183	5/10/2010	Email from T. Hester to V. Soni, L. Brown, E. Choy re Revised Draft – 11 am version with attachments	GLENMARK-ZETIA-00280735	GLENMARK-ZETIA-00280767	Expect to Offer	NO
GDX0184	5/10/2010	Email from T. Hester to V. Soni, L. Brown, and E. Choy re Zetia Settlement Agreement with attachments	GLENMARK-ZETIA-00280800	GLENMARK-ZETIA-00280894	Expect to Offer	NO
GDX0195	5/18/2010	Letter from T. Hester to the Premerger Notification Office of the FTC and the Director of Operations and Civil Enforcement of the Antitrust Division of the DOJ, attaching a copy of the Execution Version of the Merck-Glenmark Settlement Agreement	MRKZETIA000944238	MRKZETIA000944271	Expect to Offer	403; HS; MIL
GDX0207	7/20/2010	Patent Amendment for U.S. Patent No. 5846966, RE37721 and 7612058 from Teva to the FDA	Teva-Zetia_00001745	Teva-Zetia_00001747	Expect to Offer	NO
GDX0212	8/26/2010	Email from D. Mhapsekar to R. Yelegaonkar regarding Ezetimibe Alternate process API Doc	GLENMARK-ZETIA-00373560	GLENMARK-ZETIA-00373564	Expect to Offer	HS
GDX0231	3/4/2011	DMF submission from Glenmark to the FDA regarding Process II	GLENMARK-ZETIA-00311152	GLENMARK-ZETIA-00311434	Expect to Offer	HS
GDX0241	4/12/2011	Gratuitous ANDA Amendment Letter from W. McIntyre to FDA Center for Drug Evaluation and Research regarding Original Submission Drug Master File Type II Ezetimibe (Process II) Pre-assigned DMF No. 024825	GLENMARK-ZETIA-00309983	GLENMARK-ZETIA-00309985	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0248	6/30/2011	Settlement Agreement between Merck and Teva	MRKZETIA000988357	MRKZETIA000988392	Expect to Offer	NO
GDX0259	9/2/2011	Letter from W. McIntyre to FDA Center for Drug Evaluation and Research regarding submission of preapproval amendment	GLENMARK-ZETIA-00291592	GLENMARK-ZETIA-00291601	Expect to Offer	NO
GDX0263	10/14/2011	Facsimile to W. McIntyre from the Office of Generic Drugs, CDER, FDA by A. Srinivasan on behalf of V. Sayeed, Ph.D. regarding DMF Deficiency (DMF# 24825) (Process II)	GLENMARK-ZETIA-00312020	GLENMARK-ZETIA-00312024	Expect to Offer	NO
GDX0275	4/10/2012	Email from A. Maffia to Sasikumar K., S. Mohanty and cc re Ezetimibe Process comparison for review	GLENMARK-ZETIA-00203812	GLENMARK-ZETIA-00203820	Expect to Offer	HS
GDX0279	5/10/2012	Email from Swapnali Mungekar to Durga Mhapsekar regarding FW: Feedback from Changzhou Pharma on Ezetimibe – Alternate Source Development	GLENMARK-ZETIA-00374836	GLENMARK-ZETIA-00374845	Expect to Offer	HS
GDX0280	5/16/2012	Email C. Almeida to T. Coughlin, et al re Status on Alternative Source Development attaching Spreadsheet	GLENMARK-ZETIA-00235776	GLENMARK-ZETIA-00235777	Expect to Offer	HS
GDX0291	11/19/2012	Letter from Gregory Geba to Glenmark, regarding Drug Master File not adequate, outlines chemistry reasons and facility inspections	GLENMARK-ZETIA-00312033	GLENMARK-ZETIA-00312038	Expect to Offer	NO
GDX0294	12/7/2012	Email from A. Maffia to Dr. S. Sharma regarding Proposal for process change – Ezetimibe	GLENMARK-ZETIA-00243544	GLENMARK-ZETIA-00243546	Expect to Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0301	3/21/2013	Letter to Glenmark Generics Inc., USA, Attn: A. Maffia from R. West on behalf of K. Uhl, M.D. bearing a received date of March 25, 2013 regarding ANDA 078560, specifically, minor deficiencies (Complete Response Letter)	GLENMARK-ZETIA-00287501	GLENMARK-ZETIA-00287504	Expect to Offer	NO
GDX0304	5/31/2013	Letter on behalf of A. Maffia to OGD/FDA Centre for Drug Evaluation and Research regarding ANDA 078560 – Ezetimibe Tablets, 10 mg Response to Complete Response Letter	GLENMARK-ZETIA-00285142	GLENMARK-ZETIA-00285145	Expect to Offer	NO
GDX0310	8/14/2013	Letter from the FDA to W. McIntyre regarding DMF Information Request, requesting further information for Ezetimibe	GLENMARK-ZETIA-00224097	GLENMARK-ZETIA-00224099	Expect to Offer	NO
GDX0311	8/15/2013	Complete Response and Deficiency Letter from the FDA to Watson	Watson-Zetia_00011192	Watson-Zetia_00011197	Expect to Offer	NO
GDX0313	8/30/2013	Settlement Agreement Between Merck and Sandoz	MRKZETIA_R000048316	MRKZETIA_R000048343	Expect to Offer	NO
GDX0314	9/27/2013	Response to DMF Information Request from A. Maffia to the FDA	GLENMARK-ZETIA-00265486	GLENMARK-ZETIA-00265486	Expect to Offer	NO
GDX0334	5/13/2014	Gratuitous ANDA Amendment for ANDA #78560 Ezetimibe Tablets 10 mg from Glenmark to the FDA regarding the addition of the DMF for Process III	GLENMARK-ZETIA-00292887	GLENMARK-ZETIA-00292892	Expect to Offer	HS
GDX0338	6/23/2014	Email from Sridharan regarding Par-Glenmark JSC	GLENMARK-ZETIA-00178546	GLENMARK-ZETIA-00178548	Expect to Offer	NO
GDX0340	6/24/2014	Email from A. Maffia to V. Soni, S. Kaushal and ccs re Ezetimibe - request for final approval	GLENMARK-ZETIA-00204282	GLENMARK-ZETIA-00204285	Expect to Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0350	9/26/2014	Email from S. Sridharan to T. Coughlin, P. Campanelli, I. Gruber, T. Pera, C. Gassert, M. Zrebiec, J. Bueck, M. Altamuro, C. Calabro, L. Brown, M. Bonomi, and ccs re Par-Glenmark JSC	GLENMARK-ZETIA-00178533	GLENMARK-ZETIA-00178535	Expect to Offer	NO
GDX0364	1/13/2015	Letter from FDA to Sandoz regarding denial of ANDA and recommendations	SANDOZ-ZETIA-0000139	SANDOZ-ZETIA-0000145	Expect to Offer	NO
GDX0372	2/25/2015	Par-Glenmark Ezetimibe JSC Meeting PowerPoint regarding Regulatory status, Update on Operations, Commercials, Regulatory Status	GLENMARK-ZETIA-00211954	GLENMARK-ZETIA-00211954	Expect to Offer	NO
GDX0378	3/18/2015	Email from Dr. Shekhar Bhirud to S. Krishan regarding API Requirement for FY 2015-16S	GLENMARK-ZETIA-00276696	GLENMARK-ZETIA-00276709	Expect to Offer	403; HS; HWH; R
GDX0379	4/21/2015	Email from S. Sridharan to S. Rahman, P. Wagle and ccs re Ezetimibe - US	GLENMARK-ZETIA-00178612	GLENMARK-ZETIA-00178614	Expect to Offer	HS
GDX0383	5/10/2015	Email from P. Chavakula to P. Wagle regarding Ezetimbe Process 2 for US	GLENMARK-ZETIA-00194958	GLENMARK-ZETIA-00194959	Expect to Offer	HS; HWH
GDX0390	5/21/2015	Powerpoint entitled Ezetimibe - Overview	GLENMARK-ZETIA-00202161	GLENMARK-ZETIA-00202161	Expect to Offer	HS
GDX0391	5/22/2015	MSN Laboratories Certificate of Analysis for Ezetimibe.	GLENMARK-ZETIA-00382731	GLENMARK-ZETIA-00382744	Expect to Offer	NO
GDX0397	6/9/2015	Par-Glenmark Ezetimbe JSC Meeting PowerPoint Agenda - Regulatory status, Update on Operations, Commercials, Regulatory Status	GLENMARK-ZETIA-00201966	GLENMARK-ZETIA-00201977	Expect to Offer	NO
GDX0401	6/17/2015	Email from S. Sridharan to P. Wagle and K. Vanam regarding Ezetimibe update – meeting with Glenn on 19-June	GLENMARK-ZETIA-00200260	GLENMARK-ZETIA-00200261	Expect to Offer	HS
GDX0402	6/26/2015	Letter from FDA approving ANDA 078560	GLENMARK-ZETIA-00166675	GLENMARK-ZETIA-00166677	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0407	7/10/2015	Prior Approval ANDA Supplement from Glenmark to the FDA (regarding MSN)	GLENMARK-ZETIA-00185719	GLENMARK-ZETIA-00185726	Expect to Offer	NO
GDX0413	8/1/2015	Response to the DMF Information Request Dated June 19, 2014 Received from USFDA on Ezetimibe USDMF	GLENMARK-ZETIA-00420226	GLENMARK-ZETIA-00420330	Expect to Offer	NO
GDX0414	8/5/2015	Sandoz responds to the FDA's Complete Response letter dated January 12, 2015 regarding ANDA 203931	SANDOZ-ZETIA-0000052	SANDOZ-ZETIA-0000073	Expect to Offer	NO
GDX0416	8/12/2015	Letter from Yaijun Tu, Center for Drug Evaluation and Research to K. Vanam, regarding requesting an updated Ezetimibe drug substance certificate of analysis and to correct impurities	GLENMARK-ZETIA-00287554	GLENMARK-ZETIA-00287555	Expect to Offer	NO
GDX0420	8/28/2015	Information Request Letter to Office of Generic Drugs, CDER, FDA from A. Mattia on behalf of K. Vanam regarding ANDA 078560/S-001 – Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00287387	GLENMARK-ZETIA-00287390	Expect to Offer	NO
GDX0424	9/9/2015	FDA Approval Letter to Glenmark Pharmaceuticals Inc., USA regarding sANDA 078560/S-002 for Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00287540	GLENMARK-ZETIA-00287541	Expect to Offer	NO
GDX0430	11/13/2015	Tentative ANDA Approval for Ezetimibe 10 mg Tablets from Teva to the FDA	Teva-Zetia_00003100	Teva-Zetia_00003102	Expect to Offer	NO
GDX0434	1/19/2016	Email from P. Wagle to V. Soni regarding Par-Glenmark JSC, includes meeting notes from June 2015	GLENMARK-ZETIA-00277571	GLENMARK-ZETIA-00277576	Expect to Offer	HS; HWH
GDX0452	10/13/2016	Letter to FDA to K. Vanam regarding approval of packaging facility change from Somerset to Piscataway of Appco Pharma	GLENMARK-ZETIA-00287498	GLENMARK-ZETIA-002874500	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0456	11/30/2016	Glenmark PowerPoint Presentation entitled, "Ezetimibe US Launch Update"	GLENMARK-ZETIA-00166885	GLENMARK-ZETIA-00166886	Expect to Offer	NO
GDX0457	12/13/2016	Email from M. Burton to J. Borchardt re Ezetimibe	PAR_00025141	PAR_00025142	Expect to Offer	NO
GDX0462	2/16/2017	Email from P. Campanelli to J. Morales, C. Degnan, and J. Boyle re IMPORTANT: 2017 Budget Update-Zetia/Merck	PAR_00023422	PAR_00023423	Expect to Offer	HS; HWH
GDX0475	6/30/2017	FDA Manual of Policies and Procedures (MAPP 5015.8) by Center for Drug Evaluation and Research (CDER) regarding Acceptance Criteria for Residual Solvents			Expect to Offer	NO
GDX0476	11/7/2017	Email from M. Exume to D. Gan, J. Schwartz, D. Heider, D. Jankiewicz, J. Liebel, D. Hartenbaum, S. Dorning, T. Fratus, and ccs re ZETIA LOE Year to Date Accomplishment	MRKZETIA000854171	MRKZETIA000854173	Expect to Offer	HS
GDX0486	6/26/2019	Email from M. Khan to S. Krishan regarding Ezetimibe US DMF/Actavis	GLENMARK-ZETIA-00377361	GLENMARK-ZETIA-00377364	Expect to Offer	HS; HWH; R
GDX0528	1/13/2020	Expert Report of Thomas McGuire and backup data			Expect to Offer	NO
GDX0630	8/28/2007	Email P. Viegas to Z. Sihorwala et al re Regulatory Issues - Meeting 8/30/07	GLENMARK-ZETIA-00316168	GLENMARK-ZETIA-00316181	Expect to Offer	HS; HWH
GDX0654	2/4/2010	Email S. Patel to C. Gassert re Due Diligence Report for Ezetimibe Tablets, 10 mg - Glenmark attaching Par Due Diligence Report dated Jan. 28, 2010	PAR_00018795	PAR_00018803	Expect to Offer	NO
GDX0663	3/29/2010	Email P. Matukaitis to V. Soni re Zetia Settlement Agreement.March 29 draft.DOC with attachment	GLENMARK-ZETIA-00280962	GLENMARK-ZETIA-00280988	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0666	4/22/2010	Quick Take: A Victory for Glenmark But Zetia's IP Likely OK to 2016 by Steve Scala, et al. (2010)	MRKZETIA000933269	MRKZETIA000933272	Expect to Offer	403; 901; MIL; R
GDX0667	4/22/2010	Email P. McCrorey to P. Magri re Flash Note/MRK/Legal Concerns Over Zetia Appear Grossly Overstated /Outperform	MRKZETIA001018207	MRKZETIA001018208	Expect to Offer	901; HS; HWH; MIL
GDX0671	5/10/2010	Settlement Agreement File between Schering Corporation/MSP Singapore Company LLC & Glenmark Pharmaceuticals Ltd.	MRKZETIA000000001	MRKZETIA000000032	Expect to Offer	NO
GDX0700	7/6/2011	Email K. Reddy to V. Soni re Meeting in Office related to Pricing of Ezetimibe API	GLENMARK-ZETIA-00237682	GLENMARK-ZETIA-00237683	Expect to Offer	NO
GDX0703	7/18/2011	Email glenmarkpharma@karvy.com to W. McIntrye re Glenmark 2010-11 Annual Report and Notice convening Annual General Meeting of Shareholders	GLENMARK-ZETIA-00244518	GLENMARK-ZETIA-00244637	Expect to Offer	HS
GDX0713	3/11/2012	Email K. Shah to S. Krishan re R&D Cost Reduction Grid - Finalization attaching Spreadsheet entitled Budgeted R&D Savings for the Year for 2012-13	GLENMARK-ZETIA-00220297	GLENMARK-ZETIA-00220303	Expect to Offer	901; HS; HWH
GDX0719	4/10/2012	Email S. K. to A. Maffia and S. Mohanty re Ezetimibe Process Comparison for Review	GLENMARK-ZETIA-00203123	GLENMARK-ZETIA-00203131	Expect to Offer	901; HS
GDX0723	5/10/2012	Email S. Mungekar to D. Mhapsekar re Feedback from Changzhou Pharma on Ezetimibe - Alternative Source Development	GLENMARK-ZETIA-00374836	GLENMARK-ZETIA-00374847	Expect to Offer	901; HS; HWH
GDX0725	5/18/2012	Email H. Rane to V. Soni and C. Almeida re API Master File attaching Spreadsheet	GLENMARK-ZETIA-00220506	GLENMARK-ZETIA-00220508	Expect to Offer	901; HS; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0741	4/5/2013	Email J. Sharma to P. Rane re Steering Committee Presentation - Operations and attaching slides	GLENMARK-ZETIA-00209956	GLENMARK-ZETIA-00209957	Expect to Offer	H; HWH
GDX0753	9/1/2013	Spreadsheet: US Market Ezetimibe Family P&L Merck Actual 2013 - Sep YTD 2018 Source (BPC 10.0)	MRKZETIA_R000062439	MRKZETIA_R000062439	Expect to Offer	NO
GDX0772	6/25/2014	Email C. Almeida to S. Rahman et al re Ezetimibe - 2d Source	GLENMARK-ZETIA-00209236	GLENMARK-ZETIA-00209237	Expect to Offer	HS; HWH
GDX0773	6/30/2014	Email J. Pandya to P. Shetty et al re MOM: Alternative Source Products Telecon [26.6.14]	GLENMARK-ZETIA-00235682	GLENMARK-ZETIA-00235685	Expect to Offer	HS; HWH
GDX0774	7/17/2014	Email Invite S. Rahman to G. Saldanha re Linezolid & Ezetimibe Critical Update	GLENMARK-ZETIA-00239339	GLENMARK-ZETIA-00239341	Expect to Offer	HS; HWH
GDX0775	7/31/2014	Email V. Soni to S. Bhirud re Cricital In-House API Delivery	GLENMARK-ZETIA-00209431	GLENMARK-ZETIA-00209433	Expect to Offer	HS; HWH
GDX0790	3/4/2015	Email V. Soni to R. Matsuk re Par - Glenmark JSC	GLENMARK-ZETIA-00263368	GLENMARK-ZETIA-00263373	Expect to Offer	403; 901; HS
GDX0795	4/21/2015	Email P. Rane to J. Sharma re Offsite Presentation, Barcelona Operations attaching Glenmark Presentation entitled Glenmark Global Offsite, April 2015, Barcelona, Spain Operations	GLENMARK-ZETIA-00185735	GLENMARK-ZETIA-00185736	Expect to Offer	HS
GDX0796	5/8/2015	Email P. Wagle to D. Makhey et al., re Ezetimibe (API + dosage) planning discussion	GLENMARK-ZETIA-00184436	GLENMARK-ZETIA-00184438	Expect to Offer	HS
GDX0797	5/8/2015	Email P. Wagle to D. Makhey et al re Ezetimibe (API + Dosage) Planning Discussion attaching Slides entitled Ezetimibe Overview	GLENMARK-ZETIA-00419605	GLENMARK-ZETIA-00419608	Expect to Offer	NO
GDX0849	7/13/2016	Presentation: ZETIA LOE Contracting Strategy - US Market by Deborah Gan and Daniel Heider	MRKZETIA000515546	MRKZETIA000515548	Expect to Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX1011	4/22/2010	Email E. Murray to P. Matukaitis re NEWS ALERT: Dow Jones Newswires: Merck Gets Split Patent Decision; Zetia Copay Raised	MRKZETIA000871251	MRKZETIA000871252	Expect to Offer	403; H; HWH; MIL; R
GDX1012	12/8/2014	Email U. Gandhi to J. Sharma, et al re API Ops. Update attaching Meeting Slides	GLENMARK-ZETIA-00401821	GLENMARK-ZETIA-00401823	Expect to Offer	403; 901; 1002; FD; R
GDX1013	8/21/2014	Email S. Rahman to R. Matsuk, et al re API-R&D Review Meeting Slides and attaching Glenmark Presentation entitled DMF Grid Product Review and Presentation entitled Cost Reduction Product Review	GLENMARK-ZETIA-00209427	GLENMARK-ZETIA-00209428	Expect to Offer	403; 901; 1002; FD; R

EXHIBIT 5(a)

May Offer Exhibits Profferred by the Purchasers to which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0013	06/08/2016	Zetia LOE Contracting Strategy	MRKZETIA_R000026752	MRKZETIA_R000026752
PX0014	06/08/2016	Presentation: ZETIA LOE Contracting Strategy	MRKZETIA_R000026783	MRKZETIA_R000026783
PX0018	08/16/2011	Expert Report of Jerry Atwood, Ph.D., Schering Corp. v. Mylan Pharm., Inc.	MRKZETIA_R000044121	MRKZETIA_R000044261
PX0022	05/09/2010	Email from T. Hester to P. Matukaitis et al., "FW Zetia Settlement Agreement," with attached draft agreement	MRKZETIA_R000048738	MRKZETIA_R000048798
PX0033	03/01/2010	Email from V. Soni to P. Matukaitis, "Re: Glenmark - Merck"	MRKZETIA_R000061545	MRKZETIA_R000061549
PX0034	03/26/2010	Email from V. Soni to E. Rudnicki, "RE: Temodar - Glenmark Meeting - Monday, March 29, 2010"	MRKZETIA_R000061591	MRKZETIA_R000061592
PX0046	09/24/2010	Presentation: Athero/Cardiovascular Franchise 2011 LROP	MRKZETIA_R000073381	MRKZETIA_R000073381
PX0061	10/26/2017	Email - D. Pakula to J. Frigga re Annual Report Alert Notice for NDA 21-44, MK-0653 Response Requested by Content	MRKZETIA_R000081254	MRKZETIA_R000081262
PX0073	11/30/2005	Merck Presentation: Project Caesar - UPDATE	MRKZETIA_R000090380	MRKZETIA_R000090380
PX0074	03/13/2008	Summary of Terms for Authorized Generic Agreement for Trusopt and Cosopt	MRKZETIA_R000090382	MRKZETIA_R000090385
PX0078	05/28/2013	Merck Memo, "Request for Concurrence and Finance Consultation: Temodar Capsules Authorized Generic Supply and Distribution Agreement with Sandoz"	MRKZETIA_R000090546	MRKZETIA_R000090548
PX0079	12/16/2005	Merck Presentation: USHH Authorized Generics Update	MRKZETIA_R000090553	MRKZETIA_R000090553
PX0080	09/06/2007	Memorandum from T. Silfies, T. DeVenzio & H. Freeman to P. Kellogg, "FOSAMAX Once Weekly Authorized Generic License and Supply Agreement with Watson"	MRKZETIA_R000090557	MRKZETIA_R000090557
PX0085	07/26/2013	Merck Presentation, "Temodar LOE"	MRKZETIA_R000090608	MRKZETIA_R000090608
PX0096	02/16/2007	Merck Presentation, "Patent Expiry Retrospective"	MRKZETIA_R000090757	MRKZETIA_R000090757
PX0098	09/12/2007	Memorandum from Richard T. Clark to Troy E. Silfies, "Authorized Generic Agreement for FOSAMAX Once Weekly"	MRKZETIA_R000090777	MRKZETIA_R000090777
PX0175	12/11/2018	Spreadsheet, "Zetia MCO Rebates 2014-Dec"	MRKZETIA000509558	MRKZETIA000509558
PX0175_N	12/11/2018	Spreadsheet, "Zetia MCO Rebates 2014-Dec"	MRKZETIA000509558	MRKZETIA000509558
PX0176	12/11/2018	Spreadsheet, "Zetia MCO Rebates 2014-Aug"	MRKZETIA000509559	MRKZETIA000509559
PX0176_N	12/11/2018	Spreadsheet, "Zetia MCO Rebates 2014-Aug"	MRKZETIA000509559	MRKZETIA000509559
PX0184	12/14/2018	Data - OMC 12/3/2018	MRKZETIA000509568	MRKZETIA000509568
PX0184_N	12/14/2018	Data - OMC 12/3/2018	MRKZETIA000509568	MRKZETIA000509568
PX0185	12/14/2018	Data - OMC 12/3/2018	MRKZETIA000509569	MRKZETIA000509569
PX0185_N	12/14/2018	Data - OMC 12/3/2018	MRKZETIA000509569	MRKZETIA000509569

May Offer Exhibits Profferred by the Purchasers to which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0201	10/04/2016	Memo - D. Pakula to A. Schechter, N. Miller, T. Covert re Zetia authorized generic update	MRKZETIA000509928	MRKZETIA000509930
PX0203	05/11/2017	Memo - D. Pakula, M. Exume to M. Strasburger re Request for approval and Signature to a Side Letter Agreement	MRKZETIA000510012	MRKZETIA000510013
PX0206	01/04/2016	Email - T. Salfi to J. Lapps cc D. Pakula re Zetia AG non-binding term sheet	MRKZETIA000510275	MRKZETIA000510275
PX0225	02/24/2017	Spreadsheet, "AG Checklist"	MRKZETIA000511236	MRKZETIA000511236
PX0231	04/19/2017	Spreadsheet, "AG Checklist"	MRKZETIA000511412	MRKZETIA000511412
PX0233	04/05/2017	Spreadsheet, "AG Checklist"	MRKZETIA000511435	MRKZETIA000511435
PX0235	03/15/2017	Spreadsheet, "AG Checklist"	MRKZETIA000511445	MRKZETIA000511445
PX0237	01/19/2017	Merck Presentation, "Zetia LOE Tracking Dashboard"	MRKZETIA000511575	MRKZETIA000511575
PX0242	10/29/2018	Presentation, "Zetia Federal LOE Strategy"	MRKZETIA000511816	MRKZETIA000511816
PX0245	03/04/2016	Presentation, "LoE Talking Points"	MRKZETIA000512571	MRKZETIA000512571
PX0247	04/11/2016	Email from H. Escobar to D. Hartenbaum & D. Gan, "RE: URGENT REQUEST FOR APPROVAL - Humana Med D ZETIA LOE"	MRKZETIA000512996	MRKZETIA000512998
PX0251	07/13/2016	Presentation, ZETIA LOE Contracting Strategy - US Market	MRKZETIA000515548	MRKZETIA000515548
PX0254	05/18/2017	Email from J. Lapps to D. Pakula, "RE: Zetia AG status update"	MRKZETIA000516477	MRKZETIA000516478
PX0315	11/02/2015	Email From T. Sprague to R. Hartz, J. Hall, I. Duffy, et al. re Approval Requested ASAP - LOE Strategy for Zetia with Attachment	MRKZETIA000854612	MRKZETIA000854617
PX0320	01/23/2009	Memo: C. Antrosiglio to B. McMahon, P. Davish, P. Magri, J. Hall, I. Duffy, R. Hartz cc J. Sanders, G. Dunlop, M. Copeland re Increased Discount Authority for Zetia After Loss of Exclusivity	MRKZETIA000886283	MRKZETIA000886286
PX0403	01/09/2008	Email from V. Soni to Z. Sihorwala and M. Khan, et al. re: "Tentative approval within 30 months is a MUST"	GLENMARK-ZETIA-00175788	GLENMARK-ZETIA-00175790
PX0423	09/26/2014	Email from S. Shivaranjani to T. Coughlin et al., "RE: Par-Glenmark JSC" attaching "PAR Glenmark - Ezetimibe 9th Sept 14 meeting.pdf	GLENMARK-ZETIA-00178533	GLENMARK-ZETIA-00178535
PX0434	07/10/2015	Letter from Glenmark to FDA re: Prior Approval Supplement for ANDA No. 078560 seeking approval for use of Ezetimibe API from an alternate source/manufacturer (MSN Laboratories Private Limited) at an alternate drug product manufacturing site (Appco Pharma LLC, USA)	GLENMARK-ZETIA-00185719	GLENMARK-ZETIA-00185726

May Offer Exhibits Profferred by the Purchasers to which the Parties Agree and No Objection Is Specified

Preliminary ID	Date	Description	Begin Bates	End Bates
PX0472	07/31/2015	Spreadsheet, "Glenmark Summary July 2015"	GLENMARK-ZETIA-00202055	GLENMARK-ZETIA-00202055
PX0472_N	07/31/2015	Spreadsheet, "Glenmark Summary July 2015"	GLENMARK-ZETIA-00202055	GLENMARK-ZETIA-00202055
PX0492	09/12/2014	Glenmark Request to withdraw Gratuitous Preapproval Amendment re: ANDA 078560 Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00204852	GLENMARK-ZETIA-00204854
PX0536	03/10/2009	Email from M. Khan to T. Coughlin, J. Sharma & G. Saldanha, "RE: Ezetimibe - USDMF 19717 Telephone Deficiency Status"	GLENMARK-ZETIA-00218764	GLENMARK-ZETIA-00218765
PX0539	06/06/2010	Spreadsheet, "Financials"	GLENMARK-ZETIA-00219452	GLENMARK-ZETIA-00219452
PX0539_N	06/06/2010	Spreadsheet, "Financials"	GLENMARK-ZETIA-00219452	GLENMARK-ZETIA-00219452
PX0540	08/05/2011	Glenmark Gratuitous Preapproval Amendment to ANDA No. 078560 for Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00219987	GLENMARK-ZETIA-00219992
PX0542	12/12/2007	Email from V. Soni to S. Krishan, "FW: Ezetimibe"	GLENMARK-ZETIA-00220774	GLENMARK-ZETIA-00220774
PX0578	07/14/2015	Email from P. Wagle to C. Almeida, "RE: Qty for Launch"	GLENMARK-ZETIA-00251924	GLENMARK-ZETIA-00251928
PX0583	03/25/2013	Letter from R. West at FDA to A. Maffia at Glenmark re Complete Response for ANDA 078560, Ezetimibe Tablets 10 mg	GLENMARK-ZETIA-00258850	GLENMARK-ZETIA-00258853
PX0586	11/24/2009	Email from G. Saldanha to T. Coughlin, "Re: Par"	GLENMARK-ZETIA-00259809	GLENMARK-ZETIA-00259810
PX0599	03/10/2010	Email from V. Soni to P. Matukaitis and E. Murray, "RE: Glenmark - Merck"	GLENMARK-ZETIA-00272713	GLENMARK-ZETIA-00272714
PX0607	05/08/2010	Draft Settlement Agreement by and among Schering Corporation, MSP Singapore Company LLC, and Glenmark Pharmaceuticals Inc., USA (Clean)	GLENMARK-ZETIA-00280902	GLENMARK-ZETIA-00280929
PX0608	05/08/2010	Draft Settlement Agreement by and among Schering Corporation, MSP Singapore Company LLC, and Glenmark Pharmaceuticals Inc., USA (Redline)	GLENMARK-ZETIA-00280930	GLENMARK-ZETIA-00280956
PX0634	05/27/2010	Email from V. Soni to A. Renjen et al., "FW: Para IV Monetization: CIM for review by counsel" attaching "260510_CIM_Truncated.doc"	GLENMARK-ZETIA-00323865	GLENMARK-ZETIA-00323884
PX0666	05/06/2010	Email from V. Soni to E. Rudnicki, "Re: Meeting with Paul Matukaitis on Friday, May 7 at 9:30 a.m. Rahway site"	GLENMARK-ZETIA-0434851	GLENMARK-ZETIA-0434852
PX0668	08/09/2016	Email from R. Matsuk to E. Rudnicki, "RE: Thursday August 11"	GLENMARK-ZETIA-0435237	GLENMARK-ZETIA-0435239
PX1038	05/20/1997	U.S. Patent No. 5,631,365 (Certified Version)	USPTO-ZETIA-0000001	USPTO-ZETIA-0000026
PX1040	02/04/2019	Certified File Wrapper for U.S. Patent No. RE37,721 (Certified Version)	USPTO-ZETIA-0000052	USPTO-ZETIA-0001327
PX1041	06/14/2000	Reissue Application for U.S. Patent No. 5,767,115 (Certified Version)	USPTO-ZETIA-0000106	USPTO-ZETIA-0000111
PX1818	09/21/1993	Certified File Wrapper for U.S. Patent Application No. 08/102,440	USPTO-ZETIA-0025273	USPTO-ZETIA-0025383

EXHIBIT 5(b)

May Offer Exhibits Profferred by the Purchasers ... Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0001	10/31/2014	Excerpt from Merck Annual Report (01-Nov-2013-31 - Oct-2014) on NDA-21-445 Zetia Tablets (Ezetimibe), 1.13.11 Distribution Data: "Drug Distribution"	MRKZETIA_NDA00021897	MRKZETIA_NDA00021897	FD
PX0002	10/31/2016	Excerpt from Merck Annual Report (01-Nov-2015 - 31-Oct-2016) on NDA-21-445 Zetia Tablets (Ezetimibe), 1.13.11 Distribution Data: "Drug Distribution"	MRKZETIA_NDA00034173	MRKZETIA_NDA00034173	FD
PX0003	10/31/2017	Excerpt from Merck Annual Report (01-Nov-2016 - 31-Oct-2017) for NDA 21-445 Zetia Tablets (Ezetimibe), 1.13.11 Distribution Data: "Drug Distribution"	MRKZETIA_NDA00052284	MRKZETIA_NDA00052284	FD
PX0005	10/25/2009	Excerpt from Merck Annual Report (10/26/08-10/25/09) on NDA-21-445 Zetia Tablets, 1.13.11 Distribution Data: "Distribution Data"	MRKZETIA_NDA00118198	MRKZETIA_NDA0011819	FD
PX0006	10/25/2010	Excerpt from Merck Annual Report (10/26/09-10/25/10) on NDA-21-445 Zetia Tablets, 1.13.11 Distribution Data: "Distribution Data"	MRKZETIA_NDA00124580	MRKZETIA_NDA00124580	FD
PX0008	09/25/2015	Email from J. Liebel to J. Burke, "LOE Overview (2).pptx" attaching PowerPoint	MRKZETIA_R000005261	MRKZETIA_R000005262	FD; 403; R
PX0044	06/25/2010	Spreadsheet, "ZY Schedules 0616.xls" - Zetia sales	MRKZETIA_R000071933	MRKZETIA_R000071933	FD; 901
PX0044_N	06/25/2010	Spreadsheet, "ZY Schedules 0616.xls" - Zetia sales	MRKZETIA_R000071933	MRKZETIA_R000071933	FD; 901
PX0047	06/30/2006	Briefing Document and Standby Statement Authorized Generics	MRKZETIA_R000078788	MRKZETIA_R000078792	901; FD
PX0058	11/01/2016	Spreadsheet, "4Q 2016 AG List for Merck Team"	MRKZETIA_R000081219	MRKZETIA_R000081219	FD; 901
PX0058_N	11/01/2016	Spreadsheet, "4Q 2016 AG List for Merck Team"	MRKZETIA_R000081219	MRKZETIA_R000081219	FD; 901
PX0059	04/10/2017	Spreadsheet, "2Q 2017 AG List for Merck Team"	MRKZETIA_R000081220	MRKZETIA_R000081220	FD; 901
PX0060	11/18/2016	Spreadsheet, "Partner Selection"	MRKZETIA_R000081243	MRKZETIA_R000081243	FD; 901
PX0060_N	11/18/2016	Spreadsheet, "Partner Selection"	MRKZETIA_R000081243	MRKZETIA_R000081243	FD; 901
PX0062	11/01/2016	Spreadsheet, "Summary Report_Merck US Agxs_2Q16"	MRKZETIA_R000081307	MRKZETIA_R000081307	FD; 901
PX0062_N	11/01/2016	Spreadsheet, "Summary Report_Merck US Agxs_2Q16"	MRKZETIA_R000081307	MRKZETIA_R000081307	FD; 901
PX0070	08/01/2012	Presentation, "Historical AG Performance - August 2012_v1.0"	MRKZETIA_R000090343	MRKZETIA_R000090343	FD; 901
PX0070_N	08/01/2012	Presentation, "Historical AG Performance - August 2012_v1.0"	MRKZETIA_R000090343	MRKZETIA_R000090343	FD; 901
PX0071	09/19/2016	Merck Presentation, "WILLARD - One Pager - 2016.09.19"	MRKZETIA_R000090350	MRKZETIA_R000090350	FD; 403; R
PX0084	03/19/2012	Presentation: MAXALT US Market Commercial Strategy & Planning LOE Planning	MRKZETIA_R000090598	MRKZETIA_R000090598	FD; 901
PX0094	10/19/2015	Summary Report - Merck US	MRKZETIA_R000090739	MRKZETIA_R000090739	FD; 901
PX0094_N	10/19/2015	Summary Report - Merck US	MRKZETIA_R000090739	MRKZETIA_R000090739	FD; 901
PX0097	03/13/2008	Spreadsheet, "Final Fosamax Master_Final_0905.xls"	MRKZETIA_R000090766	MRKZETIA_R000090766	FD; 901
PX0097_N	03/13/2008	Spreadsheet, "Final Fosamax Master_Final_0905.xls"	MRKZETIA_R000090766	MRKZETIA_R000090766	FD; 901
PX0118	12/04/2008	55-18 from Stuart Rosenblum Schering Corporation Lab Notebook No. 31838 - NMR Spectra	MRKZETIA_SIDLEY000032678	MRKZETIA_SIDLEY000032678	HS; R
PX0121	04/01/2019	Spreadsheet, "08-16-11 Warren-Boulton - Appendix D- 5-Year Plan 57772057"	MRKZETIA_SIDLEY000105916	MRKZETIA_SIDLEY000105916	HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0121_N	04/01/2019	Spreadsheet, "08-16-11 Warren-Boulton - Appendix D- 5-Year Plan 57772057"	MRKZETIA_SIDLEY000105916	MRKZETIA_SIDLEY000105916	HS
PX0126	08/25/2011	Spreadsheet, "Mylan098459"	MRKZETIA_SIDLEY000198087	MRKZETIA_SIDLEY000198087	HS
PX0126_N	08/25/2011	Spreadsheet, "Mylan098459"	MRKZETIA_SIDLEY000198087	MRKZETIA_SIDLEY000198087	HS
PX0127	08/16/2011	Spreadsheet, "Appendix D- 5-Year Plan"	MRKZETIA_SIDLEY000214899	MRKZETIA_SIDLEY000214899	HS
PX0127_N	08/16/2011	Spreadsheet, "Appendix D- 5-Year Plan"	MRKZETIA_SIDLEY000214899	MRKZETIA_SIDLEY000214899	HS
PX0128	08/31/2011	Spreadsheet, "Mylan 129696 (Mar 2009)"	MRKZETIA_SIDLEY000215596	MRKZETIA_SIDLEY000215596	HS
PX0128_N	08/31/2011	Spreadsheet, "Mylan 129696 (Mar 2009)"	MRKZETIA_SIDLEY000215596	MRKZETIA_SIDLEY000215596	HS
PX0129	08/31/2011	Spreadsheet, "Mylan 129698 (May 2009)"	MRKZETIA_SIDLEY000215597	MRKZETIA_SIDLEY000215597	HS
PX0129_N	08/31/2011	Spreadsheet, "Mylan 129698 (May 2009)"	MRKZETIA_SIDLEY000215597	MRKZETIA_SIDLEY000215597	HS
PX0130	08/31/2011	Spreadsheet, "Mylan 129695 (Feb 2009)"	MRKZETIA_SIDLEY000215598	MRKZETIA_SIDLEY000215598	HS
PX0130_N	08/31/2011	Spreadsheet, "Mylan 129695 (Feb 2009)"	MRKZETIA_SIDLEY000215598	MRKZETIA_SIDLEY000215598	HS
PX0131	08/31/2011	Spreadsheet, "Mylan 129699 (July 2009)"	MRKZETIA_SIDLEY000215599	MRKZETIA_SIDLEY000215599	HS
PX0131_N	08/31/2011	Spreadsheet, "Mylan 129699 (July 2009)"	MRKZETIA_SIDLEY000215599	MRKZETIA_SIDLEY000215599	HS
PX0132	08/31/2011	Spreadsheet, "Mylan 129701 (Budget Nov 2009)"	MRKZETIA_SIDLEY000215600	MRKZETIA_SIDLEY000215600	HS
PX0132_N	08/31/2011	Spreadsheet, "Mylan 129701 (Budget Nov 2009)"	MRKZETIA_SIDLEY000215600	MRKZETIA_SIDLEY000215600	HS
PX0133	08/31/2011	Spreadsheet, "Mylan 129694 (Budget Dec 2008)"	MRKZETIA_SIDLEY000215602	MRKZETIA_SIDLEY000215602	HS
PX0133_N	08/31/2011	Spreadsheet, "Mylan 129694 (Budget Dec 2008)"	MRKZETIA_SIDLEY000215602	MRKZETIA_SIDLEY000215602	HS
PX0134	08/31/2011	Spreadsheet, "Mylan 129691 (Aug 2008)"	MRKZETIA_SIDLEY000215603	MRKZETIA_SIDLEY000215603	HS
PX0134_N	08/31/2011	Spreadsheet, "Mylan 129691 (Aug 2008)"	MRKZETIA_SIDLEY000215603	MRKZETIA_SIDLEY000215603	HS
PX0135	08/31/2011	Spreadsheet, "Mylan 129689 (June 2008)"	MRKZETIA_SIDLEY000215604	MRKZETIA_SIDLEY000215604	HS
PX0135_N	08/31/2011	Spreadsheet, "Mylan 129689 (June 2008)"	MRKZETIA_SIDLEY000215604	MRKZETIA_SIDLEY000215604	HS
PX0136	08/31/2011	Spreadsheet, "Mylan 129700 (Oct 2009)"	MRKZETIA_SIDLEY000215605	MRKZETIA_SIDLEY000215605	HS
PX0136_N	08/31/2011	Spreadsheet, "Mylan 129700 (Oct 2009)"	MRKZETIA_SIDLEY000215605	MRKZETIA_SIDLEY000215605	HS
PX0137	08/31/2011	Spreadsheet, "Mylan 129697 (Apr 2009)"	MRKZETIA_SIDLEY000215606	MRKZETIA_SIDLEY000215606	HS
PX0137_N	08/31/2011	Spreadsheet, "Mylan 129697 (Apr 2009)"	MRKZETIA_SIDLEY000215606	MRKZETIA_SIDLEY000215606	HS
PX0138	08/31/2011	Spreadsheet, "Mylan 129688 (Apr 2008)"	MRKZETIA_SIDLEY000215608	MRKZETIA_SIDLEY000215608	HS
PX0138_N	08/31/2011	Spreadsheet, "Mylan 129688 (Apr 2008)"	MRKZETIA_SIDLEY000215608	MRKZETIA_SIDLEY000215608	HS
PX0139	08/31/2011	Spreadsheet, "Mylan 129693 (Nov 2008)"	MRKZETIA_SIDLEY000215609	MRKZETIA_SIDLEY000215609	HS
PX0139_N	08/31/2011	Spreadsheet, "Mylan 129693 (Nov 2008)"	MRKZETIA_SIDLEY000215609	MRKZETIA_SIDLEY000215609	HS
PX0141	09/05/2011	Spreadsheet, "Zetia Forecast Nov 2010"	MRKZETIA_SIDLEY000221516	MRKZETIA_SIDLEY000221516	HS
PX0141_N	09/05/2011	Spreadsheet, "Zetia Forecast Nov 2010"	MRKZETIA_SIDLEY000221516	MRKZETIA_SIDLEY000221516	HS
PX0147	11/02/2005	Email from A. Afonso to J. Nelson, "Status of my Claim"	MRKZETIA000000720	MRKZETIA000000721	HS; R; 403; 701; HWH
PX0148	11/21/1994	File Wrapper for U.S. Patent Application No. 08/257,593	MRKZETIA000001171	MRKZETIA000001351	HS; R; HWH
PX0159	01/01/1993	Page 60 from Stuart Rosenblum Schering Corporation Lab Notebook No. 31838	MRKZETIA000385083	MRKZETIA000385083	HS; INC; 1002
PX0160	01/01/1993	Stuart B. Rosenblum & Tram Huynh, Semi-Annual Chemical Research Progress Report, July 1993 - December 1993, CV-Atherosclerosis: Cholesterol Absorption Inhibition Program	MRKZETIA000387727	MRKZETIA000387752	HS; R; HWH

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0161	04/22/1994	Tram Huynh Schering Corporation Lab Notebook No. 31472 (March 25, 1993 - April 22, 1994)	MRKZETIA000389888	MRKZETIA000389972	HS; R; HWH
PX0190	03/22/2017	Prasco purchase order	MRKZETIA000509882	MRKZETIA000509882	HS; R
PX0191	2017-01-03	Merck Presentation, "Zetia AG Kick-Off Call"	MRKZETIA000509892	MRKZETIA000509892	FD; R; 403
PX0192	06/01/2017	Zetia Authorized Generic Status Update	MRKZETIA000509893	MRKZETIA000509893	FD; R; 403
PX0196	10/05/2016	Prasco Zetia Financial Model Version 6	MRKZETIA000509922	MRKZETIA000509922	FD; R; 403
PX0197	04/08/2016	Merck - Willard Status Update	MRKZETIA000509923	MRKZETIA000509923	FD; R; 403
PX0198	2016-09-23	Merck Presentation, "WILLARD"	MRKZETIA000509924	MRKZETIA000509924	FD; R; 403
PX0208	08/17/2017	Email from D. Pakula to P. Conroy, "Zetia AG: Launch Quantity Return"	MRKZETIA000510295	MRKZETIA000510296	R; 403
PX0212	10/19/2017	Email from J. Greenberg to D. Pakula and Y. Avent, "RE: Zetia AG Material Disposition [Confidential]"	MRKZETIA000510456	MRKZETIA000510456	R; 403
PX0214	2016-03-15	Email from D. Pakula to S. Graziano, "GHH BD Monthly Reporting Update - US [Sensitive]"	MRKZETIA000510480	MRKZETIA000510484	FD; R; 403
PX0215	2016-01-27	Email from G. Dunlop to T. Salfi and D. Pakula, "Willard Financials [Confidential]"	MRKZETIA000510501	MRKZETIA000510504	FD; R; 403
PX0236	03/09/2017	Email from D. Pakula to M. Exume et al., "RE: Zetia AG: Bulk Availability - Follow-up"	MRKZETIA000511466	MRKZETIA000511467	R; 403
PX0246	03/07/2016	Email from D. Gan to M. Strasburger, "RE: Action Request by COB March 10th - Generic placement by payers [Confidential]"	MRKZETIA000512932	MRKZETIA000512933	1002
PX0250	09/14/2014	Draft Summary LOE Ezetimibe Planning Slides	MRKZETIA000514959	MRKZETIA000514959	901; FD; R; 403
PX0258	11/09/2015	Presentation, "Athero Brand Review"	MRKZETIA000519053	MRKZETIA000519053	901; FD
PX0286	06/19/2014	Presentation, Ezetimibe LOE Workshop USA Late Lifecycle Management	MRKZETIA000599036	MRKZETIA000599036	901; FD; R; HS
PX0286_N	06/19/2014	Presentation, Ezetimibe LOE Workshop USA Late Lifecycle Management	MRKZETIA000599036	MRKZETIA000599036	901; FD; R; HS
PX0296	05/28/2002	Patent US RE37, 721 E	MRKZETIA000617448	MRKZETIA000617470	HS; R; CU
PX0300	06/01/2014	CV Franchise - LOE Payer Strategy Kick-Off Meeting	MRKZETIA000684205	MRKZETIA000684221	FD; R; 403
PX0302	08/01/2015	Presentation, 2016 Brand Workshops - LOE	MRKZETIA000843962	MRKZETIA000843962	901; FD
PX0302_N	08/01/2015	Presentation, 2016 Brand Workshops - LOE	MRKZETIA000843962	MRKZETIA000843962	901; FD
PX0303	09/30/2018	Spreadsheet, "Zetia Fee-For-Service Related Sales December 1, 2010 Through September 30, 2018"	MRKZETIA000845435	MRKZETIA000845435	901; FD
PX0303_N	09/30/2018	Spreadsheet, "Zetia Fee-For-Service Related Sales December 1, 2010 Through September 30, 2018"	MRKZETIA000845435	MRKZETIA000845435	901; FD
PX0304	05/01/2019	Data 12/1/2010 to 9/5/2018	MRKZETIA000845436	MRKZETIA000845436	901; FD
PX0304_N	05/01/2019	Data 12/1/2010 to 9/5/2018	MRKZETIA000845436	MRKZETIA000845436	901; FD
PX0327	06/18/2019	Spreadsheet - sales data	MRKZETIA000924419	MRKZETIA000924419	901; FD
PX0327_N	06/18/2019	Spreadsheet - sales data	MRKZETIA000924419	MRKZETIA000924419	901; FD
PX0328	06/18/2019	Spreadsheet - sales data	MRKZETIA000924420	MRKZETIA000924420	901; FD
PX0328_N	06/18/2019	Spreadsheet - sales data	MRKZETIA000924420	MRKZETIA000924420	901; FD
PX0329	06/18/2019	Spreadsheet - sales data	MRKZETIA000924421	MRKZETIA000924421	901; FD
PX0329_N	06/18/2019	Spreadsheet - sales data	MRKZETIA000924421	MRKZETIA000924421	901; FD

May Offer Exhibits Profferred by the Purchasers to W...ch the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0347	12/07/1993	Breslow presentation	GLENMARK-ZETIA-00071578	GLENMARK-ZETIA-00071593	HS; R; 901
PX0349	08/01/1994	Stuart Rosenberg Schering Corporation Lab Notebook No. 31818 (May 1993-Aug. 1994)	GLENMARK-ZETIA-00078526	GLENMARK-ZETIA-00078689	HS; 901
PX0364	09/23/2009	Transcript of Deposition of Ronald G. Brisbois, Schering Corp. v	GLENMARK-ZETIA-00131415	GLENMARK-ZETIA-00131507	HS; HWH; R; 403
PX0383	07/15/2005	Letter from A. Afonso to J. Nelson Requesting Revision of Inventor List for U.S. Patent Nos. 5,631,365 & 5,767,115	GLENMARK-ZETIA-00149518	GLENMARK-ZETIA-00149525	HS; R; 403; HWH
PX0386	2015-03-02	Email from M. Van Allen to J. Grauso, "RE: Ezetimibe model for Steering Committee meeting 2/25/15" with attachment "Copy of Ezetimibe_Zetia.xlsx"	GLENMARK-ZETIA-00156101	GLENMARK-ZETIA-00156103	HS
PX0390	08/03/2016	Email from P. Ganesh to R. Sharma, "Fwd: Ezetimibe," with attached spreadsheet, "Par Ezetimibe Model - revised 3rd Jun_Final"	GLENMARK-ZETIA-00165526	GLENMARK-ZETIA-00165527	403; HS
PX0390_N	06/03/2016	Native version of spreadsheet, "Par Ezetimibe Model - revised 3rd Jun_Final"	GLENMARK-ZETIA-00165527	GLENMARK-ZETIA-00165527	403; HS
PX0392	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00165847	GLENMARK-ZETIA-00165847	R; 403; HS; 901
PX0392_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00165847	GLENMARK-ZETIA-00165847	R; 403; HS; 901
PX0396	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00167079	GLENMARK-ZETIA-00167079	R; 403; HS; 901
PX0396_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00167079	GLENMARK-ZETIA-00167079	R; 403; HS; 901
PX0398	01/19/2017	Spreadsheet, "Ezetimibe-Raj"	GLENMARK-ZETIA-00167597	GLENMARK-ZETIA-00167597	R
PX0398_N	01/19/2017	Spreadsheet, "Ezetimibe-Raj"	GLENMARK-ZETIA-00167597	GLENMARK-ZETIA-00167597	403; HS
PX0400	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00168202	GLENMARK-ZETIA-00168202	403; HS; 901
PX0400_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00168202	GLENMARK-ZETIA-00168202	403; HS; 901
PX0401	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00168254	GLENMARK-ZETIA-00168254	403; HS; 901
PX0401_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00168254	GLENMARK-ZETIA-00168254	403; HS; 901
PX0402	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00168529	GLENMARK-ZETIA-00168529	403; HS; 901
PX0402_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00168529	GLENMARK-ZETIA-00168529	403; HS; 901
PX0405	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00176795	GLENMARK-ZETIA-00176795	403; HS; 901
PX0405_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00176795	GLENMARK-ZETIA-00176795	403; HS; 901
PX0406	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00176817	GLENMARK-ZETIA-00176817	403; HS; 901
PX0406_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00176817	GLENMARK-ZETIA-00176817	403; HS; 901
PX0407	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00176836	GLENMARK-ZETIA-00176836	403; HS; 901
PX0407_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00176836	GLENMARK-ZETIA-00176836	403; HS; 901
PX0408	11/26/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_P&L"	GLENMARK-ZETIA-00176853	GLENMARK-ZETIA-00176853	403; HS; 901
PX0408_N	11/26/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_P&L"	GLENMARK-ZETIA-00176853	GLENMARK-ZETIA-00176853	403; HS; 901
PX0409	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00177280	GLENMARK-ZETIA-00177280	403; HS; 901
PX0409_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00177280	GLENMARK-ZETIA-00177280	403; HS; 901
PX0410	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00177411	GLENMARK-ZETIA-00177411	403; HS; R; 901
PX0410_N	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00177411	GLENMARK-ZETIA-00177411	403; HS; R; 901
PX0411	09/22/2015	Spreadsheet, "Finances Ezetimibe Model R 10-29-15 from Prakash"	GLENMARK-ZETIA-00177463	GLENMARK-ZETIA-00177463	403; HS; R; 901

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0411_N	09/22/2015	Spreadsheet, "Finances Ezetimibe Model R 10-29-15 from Prakash"	GLENMARK-ZETIA-00177463	GLENMARK-ZETIA-00177463	403; HS; R; 901
PX0412	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00177478	GLENMARK-ZETIA-00177478	403; HS; R; 901
PX0412_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00177478	GLENMARK-ZETIA-00177478	403; HS; R; 901
PX0413	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00177486	GLENMARK-ZETIA-00177486	403; HS; R; 901
PX0413_N	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00177486	GLENMARK-ZETIA-00177486	403; HS; R; 901
PX0414	11/26/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_PL_UpdatedSMART_Q12015_May1 6-4-15"	GLENMARK-ZETIA-00177499	GLENMARK-ZETIA-00177499	403; HS; R
PX0414_N	11/26/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_PL_UpdatedSMART_Q12015_May1 6-4-15"	GLENMARK-ZETIA-00177499	GLENMARK-ZETIA-00177499	403; HS; R
PX0415	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00177557	GLENMARK-ZETIA-00177557	403; HS; R
PX0415_N	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00177557	GLENMARK-ZETIA-00177557	403; HS; R
PX0421	04/19/2010	Opinion on Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 of '721 Patent Based on Improper Reissue Under 35 U.S.C. 251, Schering Corp. v. Glenmark Pharm., Inc. USA, No. 07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00178056	GLENMARK-ZETIA-00178062	R; 403
PX0425	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	GLENMARK-ZETIA-00178557	GLENMARK-ZETIA-00178557	403; HS; 901; R
PX0425_N	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	GLENMARK-ZETIA-00178557	GLENMARK-ZETIA-00178557	403; HS; 901; R
PX0427	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00178563	GLENMARK-ZETIA-00178563	R; 901
PX0427_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00178563	GLENMARK-ZETIA-00178563	403; HS; 901
PX0428	03/21/2016	Email from A. Desai to P. Vijaivargia and P. Patil	GLENMARK-ZETIA-00178573	GLENMARK-ZETIA-00178586	403; HS
PX0429	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00178590	GLENMARK-ZETIA-00178590	R; 403; 901; HS
PX0429_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00178590	GLENMARK-ZETIA-00178590	R; 403; 901; HS
PX0430	06/22/2016	Presentation, "Ezetimibe US Launch Update"	GLENMARK-ZETIA-00178607	GLENMARK-ZETIA-00178607	403; HS
PX0435	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	GLENMARK-ZETIA-00186342	GLENMARK-ZETIA-00186342	403; HS; 901
PX0435_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	GLENMARK-ZETIA-00186342	GLENMARK-ZETIA-00186342	403; HS; 901
PX0436	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00186375	GLENMARK-ZETIA-00186375	403; HS; 901
PX0436_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00186375	GLENMARK-ZETIA-00186375	403; HS; 901
PX0437	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00186646	GLENMARK-ZETIA-00186646	403; HS; 901
PX0437_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00186646	GLENMARK-ZETIA-00186646	403; HS; 901
PX0439	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00187331	GLENMARK-ZETIA-00187331	R
PX0439_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00187331	GLENMARK-ZETIA-00187331	403; HS
PX0443	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00192603	GLENMARK-ZETIA-00192603	403; HS; 901
PX0443_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00192603	GLENMARK-ZETIA-00192603	403; HS; 901
PX0446_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00194738	GLENMARK-ZETIA-00194738	403; HS

May Offer Exhibits Profferred by the Purchasers to W...ch the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0447	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	GLENMARK-ZETIA-00195160	GLENMARK-ZETIA-00195160	403; HS; 901
PX0447_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	GLENMARK-ZETIA-00195160	GLENMARK-ZETIA-00195160	403; HS; 901
PX0448	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00195202	GLENMARK-ZETIA-00195202	403; HS; 901
PX0448_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00195202	GLENMARK-ZETIA-00195202	403; HS; 901
PX0449	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00198555	GLENMARK-ZETIA-00198555	403; HS; 901
PX0449_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00198555	GLENMARK-ZETIA-00198555	403; HS; 901
PX0450_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00199034	GLENMARK-ZETIA-00199034	R; 901; HS; 403
PX0451	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00199052	GLENMARK-ZETIA-00199052	R; 403; HS
PX0451_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00199052	GLENMARK-ZETIA-00199052	R; 403; HS
PX0453	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00199279	GLENMARK-ZETIA-00199279	R; 901; HS; 403
PX0453_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00199279	GLENMARK-ZETIA-00199279	R; 901; HS; 403
PX0454	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00199291	GLENMARK-ZETIA-00199291	R; 403; HS
PX0454_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00199291	GLENMARK-ZETIA-00199291	R; 403; HS
PX0455	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00199685	GLENMARK-ZETIA-00199685	R; 403; HS
PX0455_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00199685	GLENMARK-ZETIA-00199685	R; 403; HS
PX0456	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00199710	GLENMARK-ZETIA-00199710	R; 403; HS
PX0456_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00199710	GLENMARK-ZETIA-00199710	R; 403; HS
PX0457	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00199712	GLENMARK-ZETIA-00199712	R; 403; HS
PX0457_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00199712	GLENMARK-ZETIA-00199712	R; 403; HS
PX0458	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00199718	GLENMARK-ZETIA-00199718	403; HS; 901; R
PX0458_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00199718	GLENMARK-ZETIA-00199718	403; HS; 901; R
PX0459	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00199723	GLENMARK-ZETIA-00199723	403; HS; 901; R
PX0459_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00199723	GLENMARK-ZETIA-00199723	403; HS; 901; R
PX0460	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00199888	GLENMARK-ZETIA-00199888	403; HS; 901; R
PX0460_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00199888	GLENMARK-ZETIA-00199888	403; HS; 901; R
PX0461	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00199890	GLENMARK-ZETIA-00199890	403; HS; 901; R
PX0461_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00199890	GLENMARK-ZETIA-00199890	403; HS; 901; R
PX0462	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00200092	GLENMARK-ZETIA-00200092	403; HS; R
PX0462_N	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00200092	GLENMARK-ZETIA-00200092	403; HS; R
PX0463	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00200094	GLENMARK-ZETIA-00200094	403; HS; R
PX0463_N	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00200094	GLENMARK-ZETIA-00200094	403; HS; R
PX0465	09/23/2009	Email from V. Soni to T. Coughlin, "RE: GSK settlement: draft"	GLENMARK-ZETIA-00201088	GLENMARK-ZETIA-00201089	R; 403
PX0471	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00202054	GLENMARK-ZETIA-00202054	403; HS; R
PX0471_N	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00202054	GLENMARK-ZETIA-00202054	403; HS; R
PX0473	11/26/2011	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00202088	GLENMARK-ZETIA-00202088	R; 901; 403; HS
PX0473_N	11/26/2011	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00202088	GLENMARK-ZETIA-00202088	R; 901; 403; HS
PX0474	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00202136	GLENMARK-ZETIA-00202136	R; 901; 403; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0474_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00202136	GLENMARK-ZETIA-00202136	R; 901; 403; HS
PX0475	03/31/2006	Spreadsheet, "NPV Ezetimibe 16 Jan 2014"	GLENMARK-ZETIA-00202253	GLENMARK-ZETIA-00202253	INC; R
PX0475_N	03/31/2006	Spreadsheet, "NPV Ezetimibe 16 Jan 2014"	GLENMARK-ZETIA-00202253	GLENMARK-ZETIA-00202253	INC; R
PX0478	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00202262	GLENMARK-ZETIA-00202262	R; 403; HS
PX0478_N	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00202262	GLENMARK-ZETIA-00202262	R; 403; HS
PX0480	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00202266	GLENMARK-ZETIA-00202266	R; 403; HS
PX0480_N	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00202266	GLENMARK-ZETIA-00202266	R; 403; HS
PX0485	10/02/2014	Spreadsheet, "Ezetimibe forecast from Par 10.4.14"	GLENMARK-ZETIA-00202383	GLENMARK-ZETIA-00202383	403; HS; 901; R
PX0485_N	10/02/2014	Spreadsheet, "Ezetimibe forecast from Par 10.4.14"	GLENMARK-ZETIA-00202383	GLENMARK-ZETIA-00202383	403; HS; 901; R
PX0486	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00202402	GLENMARK-ZETIA-00202402	403; HS; 901; R
PX0486_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00202402	GLENMARK-ZETIA-00202402	403; HS; 901; R
PX0497	02/06/2008	Spreadsheet, "Copy of Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00211818	GLENMARK-ZETIA-00211818	R; 901; 403; HS
PX0497_N	02/06/2008	Spreadsheet, "Copy of Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00211818	GLENMARK-ZETIA-00211818	R; 901; 403; HS
PX0499	03/31/2006	Spreadsheet, "NPV Ezetimibe 28 Jan 2014 v3"	GLENMARK-ZETIA-00211909	GLENMARK-ZETIA-00211909	R; 403; HS
PX0499_N	03/31/2006	Spreadsheet, "NPV Ezetimibe 28 Jan 2014 v3"	GLENMARK-ZETIA-00211909	GLENMARK-ZETIA-00211909	R; 403; HS
PX0500	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00211950	GLENMARK-ZETIA-00211950	R; 901; 403; HS
PX0500_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00211950	GLENMARK-ZETIA-00211950	R; 901; 403; HS
PX0501	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00213545	GLENMARK-ZETIA-00213545	R; 901; 403; HS
PX0501_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	GLENMARK-ZETIA-00213545	GLENMARK-ZETIA-00213545	R; 901; 403; HS
PX0502	10/02/2014	Spreadsheet, "Ezetimibe forecast from Par 10.4.14"	GLENMARK-ZETIA-00213598	GLENMARK-ZETIA-00213598	R; 901; 403; HS
PX0502_N	10/02/2014	Spreadsheet, "Ezetimibe forecast from Par 10.4.14"	GLENMARK-ZETIA-00213598	GLENMARK-ZETIA-00213598	R; 901; 403; HS
PX0503	09/22/2015	Spreadsheet, "Finances Ezetimibe Model R 10-29-15 from Prakash"	GLENMARK-ZETIA-00214438	GLENMARK-ZETIA-00214438	R; 403; HS
PX0503_N	09/22/2015	Spreadsheet, "Finances Ezetimibe Model R 10-29-15 from Prakash"	GLENMARK-ZETIA-00214438	GLENMARK-ZETIA-00214438	R; 403; HS
PX0504	09/22/2015	Spreadsheet, "Finances Ezetimibe Model R 10-29-15 from Prakash"	GLENMARK-ZETIA-00214449	GLENMARK-ZETIA-00214449	R; 403; HS
PX0504_N	09/22/2015	Spreadsheet, "Finances Ezetimibe Model R 10-29-15 from Prakash"	GLENMARK-ZETIA-00214449	GLENMARK-ZETIA-00214449	R; 403; HS
PX0505	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF."	GLENMARK-ZETIA-00214454	GLENMARK-ZETIA-00214454	R; 901; 403; HS
PX0505_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF."	GLENMARK-ZETIA-00214454	GLENMARK-ZETIA-00214454	R; 901; 403; HS
PX0506	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00214456	GLENMARK-ZETIA-00214456	R; 403; HS
PX0506_N	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00214456	GLENMARK-ZETIA-00214456	R; 403; HS
PX0507	07/31/2015	Spreadsheet, "Glenmark Summary July 2015"	GLENMARK-ZETIA-00214457	GLENMARK-ZETIA-00214457	R; 403; HS
PX0507_N	07/31/2015	Spreadsheet, "Glenmark Summary July 2015"	GLENMARK-ZETIA-00214457	GLENMARK-ZETIA-00214457	R; 403; HS
PX0508	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00214477	GLENMARK-ZETIA-00214477	R; 403; HS
PX0508_N	11/26/2014	Spreadsheet, "Zetia Revenue Model 7-14-15"	GLENMARK-ZETIA-00214477	GLENMARK-ZETIA-00214477	R; 403; HS
PX0510	02/06/2008	Spreadsheet, "Par Model Ezetimibe (Zetia) Gaurav JG 3-4-15"	GLENMARK-ZETIA-00214485	GLENMARK-ZETIA-00214485	R; 901; 403; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0510_N	02/06/2008	Spreadsheet, "Par Model Ezetimibe (Zetia) Gaurav JG 3-4-15"	GLENMARK-ZETIA-00214485	GLENMARK-ZETIA-00214485	R; 901; 403; HS
PX0512	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00214703	GLENMARK-ZETIA-00214703	R; 403; HS; 901
PX0512_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00214703	GLENMARK-ZETIA-00214703	R; 403; HS; 901
PX0513	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00214723	GLENMARK-ZETIA-00214723	R; 403; HS; 901
PX0513_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00214723	GLENMARK-ZETIA-00214723	R; 403; HS; 901
PX0514	11/26/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_P&L_v2"	GLENMARK-ZETIA-00214760	GLENMARK-ZETIA-00214760	R; 403; HS; 901
PX0514_N	11/26/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_P&L_v2"	GLENMARK-ZETIA-00214760	GLENMARK-ZETIA-00214760	R; 403; HS; 901
PX0515	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00214784	GLENMARK-ZETIA-00214784	R; 403; HS; 901
PX0515_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	GLENMARK-ZETIA-00214784	GLENMARK-ZETIA-00214784	R; 403; HS; 901
PX0516	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00214808	GLENMARK-ZETIA-00214808	R; 403; HS; 901
PX0516_N	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00214808	GLENMARK-ZETIA-00214808	R; 403; HS; 901
PX0517	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00214881	GLENMARK-ZETIA-00214881	403; HS
PX0517_N	11/26/2014	Spreadsheet, "ZForecast Model 08-July-16"	GLENMARK-ZETIA-00214881	GLENMARK-ZETIA-00214881	403; HS
PX0518	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00214885	GLENMARK-ZETIA-00214885	R; 403; HS; 901
PX0518_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	GLENMARK-ZETIA-00214885	GLENMARK-ZETIA-00214885	R; 403; HS; 901
PX0519	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00216207	GLENMARK-ZETIA-00216207	R; 403; HS
PX0519_N	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00216207	GLENMARK-ZETIA-00216207	R; 403; HS
PX0521	11/20/2013	Spreadsheet, "Zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00216210	GLENMARK-ZETIA-00216210	INC; R; 403; HS
PX0522	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00216215	GLENMARK-ZETIA-00216215	R; 403; HS
PX0522_N	06/28/2005	Spreadsheet, "zetia projection 10-29-2013r1"	GLENMARK-ZETIA-00216215	GLENMARK-ZETIA-00216215	R; 403; HS
PX0523	03/31/2006	Spreadsheet, "NPV Ezetimibe 24 Jan 2014"	GLENMARK-ZETIA-00216822	GLENMARK-ZETIA-00216822	R; 403; HS
PX0523_N	03/31/2006	Spreadsheet, "NPV Ezetimibe 24 Jan 2014"	GLENMARK-ZETIA-00216822	GLENMARK-ZETIA-00216822	R; 403; HS
PX0524	03/31/2006	Spreadsheet, "NPV Ezetimibe 16 Jan 2014"	GLENMARK-ZETIA-00216824	GLENMARK-ZETIA-00216824	R; 403; HS
PX0524_N	03/31/2006	Spreadsheet, "NPV Ezetimibe 16 Jan 2014"	GLENMARK-ZETIA-00216824	GLENMARK-ZETIA-00216824	R; 403; HS
PX0525	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 3rd Jun_Final"	GLENMARK-ZETIA-00217627	GLENMARK-ZETIA-00217627	R; 403; HS
PX0525_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 3rd Jun_Final"	GLENMARK-ZETIA-00217627	GLENMARK-ZETIA-00217627	R; 403; HS
PX0526	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29 - Final"	GLENMARK-ZETIA-00217629	GLENMARK-ZETIA-00217629	R; 901
PX0526_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29 - Final"	GLENMARK-ZETIA-00217629	GLENMARK-ZETIA-00217629	R; 901
PX0527	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00217630	GLENMARK-ZETIA-00217630	R; 403; HS
PX0527_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00217630	GLENMARK-ZETIA-00217630	R; 403; HS
PX0528	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00217635	GLENMARK-ZETIA-00217635	R; 403; HS; 901
PX0528_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00217635	GLENMARK-ZETIA-00217635	R; 403; HS; 901
PX0529	01/19/2017	Spreadsheet, "Ezetimibe-Raj."	GLENMARK-ZETIA-00217680	GLENMARK-ZETIA-00217680	R; INC; 901
PX0529_N	01/19/2017	Spreadsheet, "Ezetimibe-Raj."	GLENMARK-ZETIA-00217680	GLENMARK-ZETIA-00217680	R; INC; 901
PX0530	01/19/2017	Spreadsheet, "Ezetimibe-Raj."	GLENMARK-ZETIA-00217687	GLENMARK-ZETIA-00217687	R; INC; 901
PX0530_N	01/19/2017	Spreadsheet, "Ezetimibe-Raj."	GLENMARK-ZETIA-00217687	GLENMARK-ZETIA-00217687	R; INC; 901
PX0531	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00217692	GLENMARK-ZETIA-00217692	R; 403; HS; 901

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0531_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00217692	GLENMARK-ZETIA-00217692	R; 403; HS; 901
PX0532	02/06/2008	Spreadsheet, "Copy of Ezetimibe (Zetia) forecast Sep 2016 NPF "	GLENMARK-ZETIA-00217703	GLENMARK-ZETIA-00217703	R; 403; HS; 901
PX0532_N	02/06/2008	Spreadsheet, "Copy of Ezetimibe (Zetia) forecast Sep 2016 NPF "	GLENMARK-ZETIA-00217703	GLENMARK-ZETIA-00217703	R; 403; HS; 901
PX0537	10/13/2010	Email from P. Chavakula to T. Coughlin re "Ezetimibe - dispatch dates required" attaching Ezetimibe out sourcing issue	GLENMARK-ZETIA-00219037	GLENMARK-ZETIA-00219039	403
PX0543	04/06/2015	Spreadsheet, "Ezetimibe forecast apr15"	GLENMARK-ZETIA-00223296	GLENMARK-ZETIA-00223296	403; HS
PX0543_N	04/06/2015	Spreadsheet, "Ezetimibe forecast apr15"	GLENMARK-ZETIA-00223296	GLENMARK-ZETIA-00223296	403; HS
PX0548	01/24/2008	Email from T. Coughlin to V. Soni, "Fw: MSN"	GLENMARK-ZETIA-00228886	GLENMARK-ZETIA-00228886	HS
PX0550	04/02/2010	Email from V. Soni to P. Matukaitis, "RE: Sunil called me with some concerns on the deal. Pl feel free to call me if we need to discuss..Vijay"	GLENMARK-ZETIA-00231379	GLENMARK-ZETIA-00231380	403
PX0551	01/25/2008	Email from V. Soni to T. Coughlin, "Fw: Ezetimibe COA"	GLENMARK-ZETIA-00231575	GLENMARK-ZETIA-00231575	HS
PX0553	03/31/2006	Spreadsheet, "NPV Ezetimibe 29 Jan 2014"	GLENMARK-ZETIA-00234719	GLENMARK-ZETIA-00234719	R; 403; HS
PX0553_N	03/31/2006	Spreadsheet, "NPV Ezetimibe 29 Jan 2014"	GLENMARK-ZETIA-00234719	GLENMARK-ZETIA-00234719	R; 403; HS
PX0554	03/31/2006	Spreadsheet, "NPV Ezetimibe 28 Jan 2014 v3"	GLENMARK-ZETIA-00234782	GLENMARK-ZETIA-00234782	R; 403; HS
PX0554_N	03/31/2006	Spreadsheet, "NPV Ezetimibe 28 Jan 2014 v3"	GLENMARK-ZETIA-00234782	GLENMARK-ZETIA-00234782	R; 403; HS
PX0557	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00237133	GLENMARK-ZETIA-00237133	901; 403; HS; R; FD
PX0557_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29"	GLENMARK-ZETIA-00237133	GLENMARK-ZETIA-00237133	901; 403; HS; R; FD
PX0559	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00237212	GLENMARK-ZETIA-00237212	901; 403; HS; R; FD
PX0559_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised SS"	GLENMARK-ZETIA-00237212	GLENMARK-ZETIA-00237212	901; 403; HS; R; FD
PX0560	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00237238	GLENMARK-ZETIA-00237238	901; 403; HS; R; FD
PX0560_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00237238	GLENMARK-ZETIA-00237238	901; 403; HS; R; FD
PX0561	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00237344	GLENMARK-ZETIA-00237344	901; 403; HS; R; FD
PX0561_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00237344	GLENMARK-ZETIA-00237344	901; 403; HS; R; FD
PX0564	07/06/2011	Email from K. Reddy, MSN Laboratories Private Limited, to V. Soni, "RE: Meeting at our Office"	GLENMARK-ZETIA-00237682	GLENMARK-ZETIA-00237683	403; HS
PX0567	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00241676	GLENMARK-ZETIA-00241676	R; 403; HS; 901
PX0567_N	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00241676	GLENMARK-ZETIA-00241676	R; 403; HS; 901
PX0568	08/28/2014	Spreadsheet, "2014_11_20_US LRP"	GLENMARK-ZETIA-00242022	GLENMARK-ZETIA-00242022	R; 403
PX0568_N	08/28/2014	Spreadsheet, "2014_11_20_US LRP"	GLENMARK-ZETIA-00242022	GLENMARK-ZETIA-00242022	R; 403
PX0576	10/13/2010	Email from P. Chavakula to T. Coughlin et al., re Ezetimibe - dispatch dates required	GLENMARK-ZETIA-00251206	GLENMARK-ZETIA-0025208	403
PX0577	07/14/2016	Presentation: "Ezetimibe US Launch Update"	GLENMARK-ZETIA-00251698	GLENMARK-ZETIA-00251698	403; CU
PX0579	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00254080	GLENMARK-ZETIA-00254080	R; 403; HS
PX0579_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00254080	GLENMARK-ZETIA-00254080	R; 403; HS
PX0580	03/04/2015	Email from Sridharan to Coughlin	GLENMARK-ZETIA-00254410	GLENMARK-ZETIA-00254413	403
PX0581	08/28/2014	Spreadsheet, "2014_11_20_US LRP"	GLENMARK-ZETIA-00256697	GLENMARK-ZETIA-00256697	R; 403
PX0581_N	08/28/2014	Spreadsheet, "2014_11_20_US LRP"	GLENMARK-ZETIA-00256697	GLENMARK-ZETIA-00256697	R; 403

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0584	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00259691	GLENMARK-ZETIA-00259691	R; 901
PX0584_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00259691	GLENMARK-ZETIA-00259691	403; HS; 901
PX0598	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00267725	GLENMARK-ZETIA-00267725	R; 403; HS; 901
PX0598_N	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00267725	GLENMARK-ZETIA-00267725	R; 901; 403; HS
PX0600	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00275752	GLENMARK-ZETIA-00275752	R; 403; HS; 901
PX0600_N	10/02/2014	Spreadsheet, "Ezetimibe forecasts"	GLENMARK-ZETIA-00275752	GLENMARK-ZETIA-00275752	R; 901; 403; HS
PX0604	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00277584	GLENMARK-ZETIA-00277584	R; 403; HS
PX0604_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00277584	GLENMARK-ZETIA-00277584	R; 403; HS
PX0614	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29 - Final"	GLENMARK-ZETIA-00282244	GLENMARK-ZETIA-00282244	R; 403; HS
PX0614_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 10.29 - Final"	GLENMARK-ZETIA-00282244	GLENMARK-ZETIA-00282244	R; 403; HS
PX0615	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00282284	GLENMARK-ZETIA-00282284	R; 901; 403; HS
PX0615_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	GLENMARK-ZETIA-00282284	GLENMARK-ZETIA-00282284	R; 403; HS; 901
PX0616	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 3rd Jun_Final"	GLENMARK-ZETIA-00282331	GLENMARK-ZETIA-00282331	R; 901
PX0616_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model -revised 3rd Jun_Final"	GLENMARK-ZETIA-00282331	GLENMARK-ZETIA-00282331	R; 901
PX0617	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00282333	GLENMARK-ZETIA-00282333	R; 403; HS
PX0617_N	09/22/2015	Spreadsheet, "Par Ezetimibe Model"	GLENMARK-ZETIA-00282333	GLENMARK-ZETIA-00282333	R; 403; HS
PX0618	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00282337	GLENMARK-ZETIA-00282337	R; 901; 403; HS
PX0618_N	02/06/2008	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2016 NPF"	GLENMARK-ZETIA-00282337	GLENMARK-ZETIA-00282337	R; 403; HS; 901
PX0627	07/07/2010	Email from V. Soni to P. Campanelli, "Merck settlement money split," with attachment, "Glenmark-Merck-Ezetimibe Invoices for PAR after 30 Apr 2020.pdf"	GLENMARK-ZETIA-00307372	GLENMARK-ZETIA-00307375	R; 403
PX0667	03/26/2010	Email from V. Soni to D. Weider, "FW: Temodar - Glenmark Meeting - Monday March 29, 2010"	GLENMARK-ZETIA-0434887	GLENMARK-ZETIA-0434888	403
PX0670	12/31/2012	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Mail Specialty" of Walgreens Accounts from 4/1/2008 to 12/31/2012	ABDC_ZETIA_0001	ABDC_ZETIA_0001	901; HS
PX0670_N	12/31/2012	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Mail Specialty" of Walgreens Accounts from 4/1/2008 to 12/31/2012	ABDC_ZETIA_0001	ABDC_ZETIA_0001	901; HS
PX0671	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Mail Specialty" of Walgreens Accounts from 1/1/2013 to 11/14/2018	ABDC_ZETIA_0002	ABDC_ZETIA_0002	901; HS
PX0671_N	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Mail Specialty" of Walgreens Accounts from 1/1/2013 to 11/14/2018	ABDC_ZETIA_0002	ABDC_ZETIA_0002	901; HS
PX0672	12/31/2012	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Hawaii" of Walgreens Accounts from 6/15/2009 to 12/31/2012	ABDC_ZETIA_0003	ABDC_ZETIA_0003	901; HS
PX0672_N	12/31/2012	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Hawaii" of Walgreens Accounts from 6/15/2009 to 12/31/2012	ABDC_ZETIA_0003	ABDC_ZETIA_0003	901; HS

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0673	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Hawaii" of Walgreens Accounts from 1/1/2013-11/14/2018	ABDC_ZETIA_0004	ABDC_ZETIA_0004	901; HS
PX0673_N	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Hawaii" of Walgreens Accounts from 1/1/2013-11/14/2018	ABDC_ZETIA_0004	ABDC_ZETIA_0004	901; HS
PX0674	12/31/2013	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 3/18/2013 to 12/31/2013	ABDC_ZETIA_0005	ABDC_ZETIA_0005	901; HS
PX0674_N	12/31/2013	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for "Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 3/18/2013 to 12/31/2013	ABDC_ZETIA_0005	ABDC_ZETIA_0005	901; HS
PX0675	12/31/2014	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2014 to 12/31/2014	ABDC_ZETIA_0006	ABDC_ZETIA_0006	901; HS
PX0675_N	12/31/2014	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2014 to 12/31/2014	ABDC_ZETIA_0006	ABDC_ZETIA_0006	901; HS
PX0676	12/31/2015	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2015 to 12/31/2015	ABDC_ZETIA_0007	ABDC_ZETIA_0007	901; HS
PX0676_N	12/31/2015	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2015 to 12/31/2015	ABDC_ZETIA_0007	ABDC_ZETIA_0007	901; HS
PX0677	12/31/2016	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2016 to 12/31/2016	ABDC_ZETIA_0008	ABDC_ZETIA_0008	901; HS
PX0677_N	12/31/2016	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2016 to 12/31/2016	ABDC_ZETIA_0008	ABDC_ZETIA_0008	901; HS
PX0678	12/31/2017	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2017 to 12/31/2017	ABDC_ZETIA_0009	ABDC_ZETIA_0009	901; HS
PX0678_N	12/31/2017	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2017 to 12/31/2017	ABDC_ZETIA_0009	ABDC_ZETIA_0009	901; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0679	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2018 to 11/14/2018	ABDC_ZETIA_0010	ABDC_ZETIA_0010	901; HS
PX0679_N	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 1/1/2018 to 11/14/2018	ABDC_ZETIA_0010	ABDC_ZETIA_0010	901; HS
PX0680	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 3/18/2013 to 11/14/2018	ABDC_ZETIA_0011	ABDC_ZETIA_0011	901; HS
PX0680_N	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 3/18/2013 to 11/14/2018	ABDC_ZETIA_0011	ABDC_ZETIA_0011	901; HS
PX0681	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 3/18/2013 to 11/14/2018	ABDC_ZETIA_0012	ABDC_ZETIA_0012	901; HS
PX0681_N	11/14/2018	Spreadsheet, AmerisourceBergen Invoice/Credits Data of Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 3/18/2013 to 11/14/2018	ABDC_ZETIA_0012	ABDC_ZETIA_0012	901; HS
PX0682	11/05/2015	Spreadsheet, AmerisourceBergen Invoice/Credits Bellco Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 4/1/2008 to 11/5/2016	ABDC_ZETIA_0013	ABDC_ZETIA_0013	901; HS
PX0682_N	11/05/2015	Spreadsheet, AmerisourceBergen Invoice/Credits Bellco Specific Items for Pharmaceutical Purchase and Distribution Agreement" of Walgreens Accounts From 4/1/2008 to 11/5/2016	ABDC_ZETIA_0013	ABDC_ZETIA_0013	901; HS
PX0686	02/05/2019	Spreadsheet, " Alkem Net Sales 2018"	ALKEM004760	ALKEM004760	R; 403; HS; 901
PX0686_N	02/05/2019	Spreadsheet, " Alkem Net Sales 2018"	ALKEM004760	ALKEM004760	R; 403; HS; 901
PX0688	07/18/2019	Spreadsheet, "Alkem Processed Claims 2018"	ALKEM004793	ALKEM004793	R; 403; HS; 901
PX0688_N	07/18/2019	Spreadsheet, "Alkem Processed Claims 2018"	ALKEM004793	ALKEM004793	R; 403; HS; 901
PX0689	08/29/2019	Spreadsheet, "2019-09-11 Ezetimibe_2018_by end customer"	ALKEM004794	ALKEM004794	R; 403; HS; 901
PX0689_N	08/29/2019	Spreadsheet, "2019-09-11 Ezetimibe_2018_by end customer"	ALKEM004794	ALKEM004794	R; 403; HS; 901
PX0691	03/23/2010	Spreadsheet, "Ezetimibe NDC 69238-1154-03 launch thru 3-26-19"	AMN-ZETIA0005425	AMN-ZETIA0005425	R; 403; HS; 901
PX0691_N	03/23/2010	Spreadsheet, "Ezetimibe NDC 69238-1154-03 launch thru 3-26-19"	AMN-ZETIA0005425	AMN-ZETIA0005425	R; 403; HS; 901

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0692	03/23/2010	Spreadsheet, "Ezetimibe NDC 69238-1154-05 & 09 launch thru 3-26-19"	AMN-ZETIA0005426	AMN-ZETIA0005426	R; 403; HS; 901
PX0692_N	03/23/2010	Spreadsheet, "Ezetimibe NDC 69238-1154-05 & 09 launch thru 3-26-19"	AMN-ZETIA0005426	AMN-ZETIA0005426	R; 403; HS; 901
PX0693	11/18/2019	Spreadsheet, "Product Summary"	APOTEX0000061	APOTEX0000061	R; 403; HS; 901
PX0694	11/18/2019	Spreadsheet, "Product Summary"	APOTEX0000062	APOTEX0000062	R; 403; HS; 901
PX0696	06/10/2017	Spreadsheet, "Product Summary"	APOTEX0000073	APOTEX0000082	R; 403; HS; 901
PX0697	06/10/2017	Spreadsheet, " Product Summary"	APOTEX0000083	APOTEX0000092	R; 403; HS; 901
PX0698	06/12/2017	Spreadsheet, " Product Summary"	APOTEX0000093	APOTEX0000101	R; 403; HS; 901
PX0699	06/12/2017	Spreadsheet, " Product Summary"	APOTEX0000102	APOTEX0000112	R; 403; HS; 901
PX0700	06/10/2017	Spreadsheet, " Product Summary"	APOTEX0000113	APOTEX0000122	R; 403; HS; 901
PX0703_N	03/31/2016	Spreadsheet, Cardinal Sales to Safeway 4/2/2012 - 3/31/2016	Cardinal_000001	Cardinal_000001	901; HS
PX0704_N	01/31/2014	Spreadsheet, Cardinal Sales to Kroger 1/3/2011-1/31/2014	Cardinal_000002	Cardinal_000002	901; HS
PX0713	12/01/2007	Mylan 5 Year Financial Plan	MYL_ZETIA012079	MYL_ZETIA012088	R; 403; HS; 901
PX0714	03/13/2019	Spreadsheet, "Sales Data"	PAR_00000001	PAR_00000001	901; HS; 403
PX0714_N	03/13/2019	Spreadsheet, "Sales Data"	PAR_00000001	PAR_00000001	901; HS; 403
PX0717	09/04/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	PAR_00000503	PAR_00000503	403; HS; 901
PX0717_N	09/04/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF"	PAR_00000503	PAR_00000503	403; HS; CU; 901
PX0718	09/18/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF - Summary for partner"	PAR_00000653	PAR_00000653	901; HS; 403
PX0718_N	09/18/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2015 NPF - Summary for partner"	PAR_00000653	PAR_00000653	901; HS; 403
PX0726	06/10/2015	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	PAR_00001545	PAR_00001545	403; HS; CU; 901
PX0726_N	06/10/2015	Spreadsheet, "Ezetimibe (Zetia) forecast June 2015 NPF"	PAR_00001545	PAR_00001545	403; HS; CU; 901
PX0729	09/08/2014	Spreadsheet, "Ezetimibe forecast Aug 2014"	PAR_00002332	PAR_00002332	901; HS
PX0729_N	09/08/2014	Spreadsheet, "Ezetimibe forecast Aug 2014"	PAR_00002332	PAR_00002332	901; HS
PX0730	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002915	PAR_00002915	901; HS
PX0730_N	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002915	PAR_00002915	901; HS
PX0733	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002918	PAR_00002918	403; CU; 901; HS
PX0733_N	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002918	PAR_00002918	403; CU; 901; HS
PX0736	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002921	PAR_00002921	403; CU; 901; HS
PX0736_N	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002921	PAR_00002921	403; CU; 901; HS
PX0739	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002930	PAR_00002930	403; CU; 901; HS
PX0739_N	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002930	PAR_00002930	403; CU; 901; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0742	12/22/2015	Endo Presentation, "U.S. Generic Pharmaceuticals 2016 Budget Review"	PAR_00002933	PAR_00002933	403; HS; CU; 901
PX0743	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00002934	PAR_00002934	403; CU; 901; HS
PX0746	03/18/2016	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	PAR_00003366	PAR_00003366	901; HS
PX0746_N	03/18/2016	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 NPF"	PAR_00003366	PAR_00003366	901; HS
PX0748	04/27/2016	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 updated for extra load"	PAR_00003509	PAR_00003509	901; HS
PX0748_N	04/27/2016	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 updated for extra load"	PAR_00003509	PAR_00003509	901; HS
PX0751	04/27/2016	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 updated for extra load"	PAR_00003512	PAR_00003512	403; HS; CU; 901
PX0751_N	04/27/2016	Spreadsheet, "Ezetimibe (Zetia) forecast Mar 2016 updated for extra load"	PAR_00003512	PAR_00003512	403; HS; CU; 901
PX0755	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00003644	PAR_00003644	403; CU; 901; HS
PX0755_N	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00003644	PAR_00003644	403; CU; 901; HS
PX0757	02/24/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015)"	PAR_00004234	PAR_00004234	403; HS; CU; 901
PX0757_N	02/24/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015)"	PAR_00004234	PAR_00004234	403; HS; CU; 901
PX0761	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16"	PAR_00004455	PAR_00004455	403; CU; 901; HS
PX0761_N	12/07/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16"	PAR_00004455	PAR_00004455	403; CU; 901; HS
PX0764	12/07/2015	Spreadsheet, " Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00004468	PAR_00004468	403; CU; 901; HS
PX0764_N	12/07/2015	Spreadsheet, " Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00004468	PAR_00004468	403; CU; 901; HS
PX0767	01/13/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00005152	PAR_00005152	901; HS
PX0767_N	01/13/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00005152	PAR_00005152	901; HS
PX0774	01/19/2011	Email from J. Bueck to I. Gruber et al., "RE: Updated NPL Spreadsheet"	PAR_00006690	PAR_00006690	403; 901; HS
PX0775	01/20/2011	Spreadsheet, "NPL Launch Milestones 1.20.2011"	PAR_00006691	PAR_00006691	901; HS
PX0775_N	01/20/2011	Spreadsheet, "NPL Launch Milestones 1.20.2011"	PAR_00006691	PAR_00006691	901; HS
PX0780	04/12/2012	Email from P. Campanelli to M. Tropiano, D. Friedman & J. Dragseth, "Fw: Strategic Plan Detail files - #4," with attached spreadsheet, "Ezetimibe forecast Jan 2012.xslx"	PAR_00007270 PAR_00007273	PAR_00007270 PAR_00007273	403; 901; HS
PX0780_N	04/12/2012	Native version of spreadsheet, "Ezetimibe forecast Jan 2012.xslx"	PAR_00007273	PAR_00007273	403; 901; HS
PX0782	04/11/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007284	PAR_00007284	901; HS
PX0782_N	04/11/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007284	PAR_00007284	901; HS
PX0783	01/29/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007332	PAR_00007332	901; HS
PX0783_N	01/29/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007332	PAR_00007332	901; HS
PX0784	04/11/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007496	PAR_00007496	901; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0784_N	04/11/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007496	PAR_00007496	901; HS
PX0788	05/07/2010	Email from C. Calabro to M. Altamuro and P. Campanelli, "RE: Carla"	PAR_00007859	PAR_00007860	901; HS
PX0789	02/23/2010	Email from C. Calabro to P. Campanelli re and attached Ezetimibe Forecast Feb 2010	PAR_00007866	PAR_00007867	901; HS
PX0791	04/11/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007905	PAR_00007905	901; HS
PX0791_N	04/11/2012	Spreadsheet, "Ezetimibe forecast Jan 2012"	PAR_00007905	PAR_00007905	901; HS
PX0797	04/30/2010	Spreadsheet, "Ezetimibe forecast Apr 2010 (2) revised"	PAR_00008143	PAR_00008143	901; HS
PX0797_N	04/30/2010	Spreadsheet, "Ezetimibe forecast Apr 2010 (2) revised"	PAR_00008143	PAR_00008143	901; HS
PX0804	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00008379	PAR_00008379	403; HS; CU; 901
PX0804_N	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00008379	PAR_00008379	403; HS; 901
PX0806	11/01/2016	Spreadsheet, "ezetimibe nov 2016"	PAR_00008449	PAR_00008449	901; HS
PX0806_N	11/01/2016	Spreadsheet, "ezetimibe nov 2016"	PAR_00008449	PAR_00008449	901; HS
PX0820	12/12/2016	Press Release, Endo, "Endo Begins Shipment of Generic ZETIA"	PAR_00008535	PAR_00008537	901; HS
PX0839	01/13/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00013890	PAR_00013890	403; HS; CU; 901
PX0839_N	01/13/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00013890	PAR_00013890	403; HS; 901
PX0841	01/13/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00013892	PAR_00013892	403; HS; CU; 901
PX0841_N	01/13/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00013892	PAR_00013892	403; HS; 901
PX0843	01/23/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00013911	PAR_00013911	403; HS; CU; 901
PX0843_N	01/23/2014	Spreadsheet, "Ezetimibe forecast Jan 2014"	PAR_00013911	PAR_00013911	403; HS; 901
PX0847	03/18/2014	Spreadsheet, "Ezetimibe forecast Mar 2014"	PAR_00014542	PAR_00014542	901; HS
PX0847_N	03/18/2014	Spreadsheet, "Ezetimibe forecast Mar 2014"	PAR_00014542	PAR_00014542	901; HS
PX0849	09/08/2014	Spreadsheet, "Ezetimibe forecast Aug 2014"	PAR_00014594	PAR_00014594	403; HS; CU; 901
PX0849_N	09/08/2014	Spreadsheet, "Ezetimibe forecast Aug 2014"	PAR_00014594	PAR_00014594	403; HS; 901
PX0850	02/24/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	PAR_00015157	PAR_00015157	403; HS; 901
PX0850_N	02/24/2015	Spreadsheet, "Ezetimibe (Zetia) forecast Jan 2015"	PAR_00015157	PAR_00015157	403; HS; CU; 901
PX0852	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00016088	PAR_00016088	403; HS; CU; 901
PX0852_N	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00016088	PAR_00016088	403; HS; 901
PX0854	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00016106	PAR_00016106	403; HS; CU; 901
PX0854_N	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00016106	PAR_00016106	403; HS; 901
PX0858	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00016381	PAR_00016381	403; HS; CU; 901
PX0858_N	08/02/2016	Spreadsheet, "Ezetimibe (Zetia) forecast August 2016 PC request"	PAR_00016381	PAR_00016381	403; HS; 901
PX0864	10/02/2014	Spreadsheet, "Copy of Ezetimibe (Zetia) forecast Sep 2014"	PAR_00018432	PAR_00018432	901; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0864_N	10/02/2014	Spreadsheet, "Copy of Ezetimibe (Zetia) forecast Sep 2014"	PAR_00018432	PAR_00018432	901; HS
PX0866	10/01/2014	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2014"	PAR_00018435	PAR_00018435	901; HS
PX0866_N	10/01/2014	Spreadsheet, "Ezetimibe (Zetia) forecast Sep 2014"	PAR_00018435	PAR_00018435	901; HS
PX0868	09/26/2014	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2014"	PAR_00018438	PAR_00018438	INC; CU; 901; HS
PX0868_N	09/26/2014	Spreadsheet, "Ezetimibe (Zetia) forecast Sept 2014"	PAR_00018438	PAR_00018438	INC; 901; HS
PX0870	04/20/2010	Spreadsheet, "Copy of Ezetimibe forecast Apr 2010"	PAR_00018770	PAR_00018770	901; HS
PX0870_N	04/20/2010	Spreadsheet, "Copy of Ezetimibe forecast Apr 2010"	PAR_00018770	PAR_00018770	901; HS
PX0871	09/04/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019197	PAR_00019197	403; HS; 901
PX0871_N	09/04/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019197	PAR_00019197	403; HS; 901
PX0873	02/10/2016	Spreadsheet, "Ezetimibe Tablet (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019291	PAR_00019291	901; HS
PX0873_N	02/10/2016	Spreadsheet, "Ezetimibe Tablet (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019291	PAR_00019291	901; HS
PX0875	09/04/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019296	PAR_00019296	403; HS; 901
PX0875_N	09/04/2015	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019296	PAR_00019296	403; HS; 901
PX0877	03/16/2016	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019333	PAR_00019333	901; HS
PX0877_N	03/16/2016	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00019333	PAR_00019333	901; HS
PX0886	11/29/2016	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00021367	PAR_00021367	403; CU; 901; HS
PX0886_N	11/29/2016	Spreadsheet, "Ezetimibe Tablets (Zetia) Launch Date: December 2016 (based on settlement date of 12/12/16)"	PAR_00021367	PAR_00021367	403; 901; HS
PX0891	03/12/2016	Spreadsheet, "Ezetimibe forecast Apr 2010 (2)"	PAR_00021842	PAR_00021842	901; HS
PX0891_N	03/12/2016	Spreadsheet, "Ezetimibe forecast Apr 2010 (2)"	PAR_00021842	PAR_00021842	901; HS
PX0892	03/12/2016	Spreadsheet, "Ezetimibe Forecast April 2010 (2) revised"	PAR_00021843	PAR_00021843	403; HS; CU; 901
PX0892_N	03/12/2016	Spreadsheet, "Ezetimibe Forecast April 2010 (2) revised"	PAR_00021843	PAR_00021843	403; HS; 901
PX0895	09/29/2011	Unsigned execution copy of Settlement Agreement by and among AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, Handa Pharmaceuticals, LLC, and Catalent Pharma Solutions, GmbH for AstraZeneca Pharm. LP v. Handa Pharm., LLC, Nos. 08-cv-3373, 08-cv-5328 & 08-cv-5997 (D.N.J.)	PAR_00021962	PAR_00022034	403; 901; HS; R
PX0904	05/24/2017	Spreadsheet, "Forecast Summary"	SANDOZ-ZETIA-0000003	SANDOZ-ZETIA-0000003	403; HS; 901
PX0904_N	05/24/2017	Spreadsheet, "Forecast Summary"	SANDOZ-ZETIA-0000003	SANDOZ-ZETIA-0000003	403; HS; 901
PX0908	11/05/2015	Sandoz Information Request, Chemistry Reference # 177498 - Response to Information Request Dated October 21, 2015 for ANDA 203941, Sequence 0008, Ezetimibe Tablets, 10 mg	SANDOZ-ZETIA-0000074	SANDOZ-ZETIA-0000076	901

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0910	10/13/2017	Sandoz Prior Approval Supplement for ANDA 203931, Ezetimibe Tablets, 10 mg	SANDOZ-ZETIA-0000095	SANDOZ-ZETIA-0000103	901
PX0919	03/11/2019	Spreadsheet, "Ezetimibe Sales"	SANDOZ-ZETIA-0000181	SANDOZ-ZETIA-0000181	403; HS; 901
PX0919_N	03/11/2019	Spreadsheet, "Ezetimibe Sales"	SANDOZ-ZETIA-0000181	SANDOZ-ZETIA-0000181	403; HS; 901
PX0920	04/26/2019	Spreadsheet, "Sales Data"	SANDOZ-ZETIA-0000182	SANDOZ-ZETIA-0000182	403; HS; 901
PX0920_N	04/26/2019	Spreadsheet, "Sales Data"	SANDOZ-ZETIA-0000182	SANDOZ-ZETIA-0000182	403; HS; 901
PX0921	05/24/2019	Spreadsheet, "Sales Register Entire History"	SUN-EZETIMIBIE_00021533	SUN-EZETIMIBIE_00021533	R; 403; HS; 901
PX0921_N	05/24/2019	Spreadsheet, "Sales Register Entire History"	SUN-EZETIMIBIE_00021533	SUN-EZETIMIBIE_00021533	R; 403; HS; 901
PX0927	02/20/2015	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003525	TEVA-ZETIA_00003525	901; HS; 403
PX0927_N	02/20/2015	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003525	TEVA-ZETIA_00003525	901; HS; 403
PX0928	03/14/2014	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003526	TEVA-ZETIA_00003526	403; HS; 901
PX0928_N	03/14/2014	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003526	TEVA-ZETIA_00003526	403; HS; 901
PX0929	03/14/2014	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003527	TEVA-ZETIA_00003527	403; HS; 901
PX0929_N	03/14/2014	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003527	TEVA-ZETIA_00003527	403; HS; 901
PX0930	02/20/2015	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003528	TEVA-ZETIA_00003528	403; HS; 901
PX0930_N	02/20/2015	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003528	TEVA-ZETIA_00003528	403; HS; 901
PX0931	02/20/2015	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003529	TEVA-ZETIA_00003529	403; HS; 901
PX0931_N	02/20/2015	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003529	TEVA-ZETIA_00003529	403; HS; 901
PX0934	07/05/2012	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003532	TEVA-ZETIA_00003532	403; HS; CU; 901
PX0934_N	07/05/2012	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003532	TEVA-ZETIA_00003532	403; HS; CU; 901
PX0935	07/05/2012	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003533	TEVA-ZETIA_00003533	403; HS; CU; 901
PX0935_N	07/05/2012	Spreadsheet, "Teva USA: Sales Forecast"	TEVA-ZETIA_00003533	TEVA-ZETIA_00003533	403; HS; CU; 901
PX0936	02/25/2019	Spreadsheet, "Ezetimibe 2017 AR Transactions"	TEVA-ZETIA_00003534	TEVA-ZETIA_00003534	403; HS; 901
PX0936_N	02/25/2019	Spreadsheet, "Ezetimibe 2017 AR Transactions"	TEVA-ZETIA_00003534	TEVA-ZETIA_00003534	403; HS; 901
PX0937	02/25/2019	Spreadsheet, "AR Transaction Activity 2018"	TEVA-ZETIA_00003535	TEVA-ZETIA_00003535	403; HS; 901
PX0937_N	02/25/2019	Spreadsheet, "AR Transaction Activity 2018"	TEVA-ZETIA_00003535	TEVA-ZETIA_00003535	403; HS; 901
PX0940	12/26/2006	Section 3.2.P.3.1 of Watson ANDA 200831 re Manufacturers, Ezetimibe Tablets 10mg	Watson-Zetia_00000421	Watson-Zetia_00000424	901
PX0941	12/26/2006	Section 3.2.S.2.1 of Watson ANDA 200831 re Manufacturer(s) Ezetimibe	Watson-Zetia_00001762	Watson-Zetia_00001763	901
PX0945	03/09/2017	Letter from FDA to Watson re: Minor Amendment - Final Approval Requested re ANDA No 200831, Sequence 0018, Ezetimibe Tablets USP, 10mg	Watson-Zetia_00011449	Watson-Zetia_00011451	901
PX0949	05/28/2019	Spreadsheet, "Zydus Pharmaceuticals - Gross Sales of Ezetimibe from March 2018 to April 2019"	ZYDUS-EZE_0000003	ZYDUS-EZE_0000003	R; 403; HS; 901
PX0949_N	05/28/2019	Spreadsheet, "Zydus Pharmaceuticals - Gross Sales of Ezetimibe from March 2018 to April 2019"	ZYDUS-EZE_0000003	ZYDUS-EZE_0000003	R; 403; HS; 901
PX0950	06/26/2019	Spreadsheet, "Zydus Pharmaceuticals - Ezetimibe Chargeback Data from March 2018 to April 2019"	ZYDUS-EZE_0000005	ZYDUS-EZE_0000005	R; 403; HS; 901
PX0950_N	06/26/2019	Spreadsheet, "Zydus Pharmaceuticals - Ezetimibe Chargeback Data from March 2018 to April 2019"	ZYDUS-EZE_0000005	ZYDUS-EZE_0000005	R; 403; HS; 901

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0951	06/26/2019	Spreadsheet, "Zydus Pharmaceuticals - payment to customers under various heads from March 2018 to April 2019"	ZYDUS-EZE_0000006	ZYDUS-EZE_0000006	R; 403; HS; 901
PX0951_N	06/26/2019	Spreadsheet, "Zydus Pharmaceuticals - payment to customers under various heads from March 2018 to April 2019"	ZYDUS-EZE_0000006	ZYDUS-EZE_0000006	R; 403; HS; 901
PX0952	10/01/2017	Cesar Castillo, Inc. Purchase Data for Branded Zetia (2010-2017)	CCI000002	CCI000002	901; HS
PX0954	08/13/2015	Cesar Castillo, Inc. Transactional Data for Zetia Chargebacks	CCI000005	CCI000005	901; INC; HS
PX0957	12/09/2016	Agreement for Assignment of Claims between Frank W. Kerr Co. and FWK Holdings LLC	FWK-ZETIA-0000001	FWK-ZETIA-0000002	901; HS
PX0958	03/15/2016	Spreadsheet, "Frank W. Kerr Co. Zetia Purchases 12/01/2010 - 3/15/2016"	FWK-ZETIA-0000004	FWK-ZETIA-0000019	901; HS
PX0959	12/11/2018	Spreadsheet, "Rochester Drug Cooperative, Inc. Zetia/Ezetimibe Item Purchases from 01/01/2009 through 12/11/2018"	RDC-ZET-029081	RDC-ZET-029081	901; HS; INC
PX0960	12/11/2018	Spreadsheet, "Rochester Drug Cooperative, Inc. Zetia & Ezetimibe Product Chargebacks from 01/01/2009 through 12/11/2018"	RDC-ZET-029082	RDC-ZET-029082	901; HS; INC
PX0961	08/03/2011	Prescription Benefit Services Agreement - Amendment No. 1 between CaremarkPCS Health LLC and City of Providence, Rhode Island	ZETIA-COP-000414	ZETIA-COP-000428	901; HS
PX0962	07/01/2013	Prescription Benefit Services Agreement - Amendment No. 3 between CaremarkPCS Health LLC and City of Providence, Rhode Island	ZETIA-COP-000438	ZETIA-COP-000455	901; HS
PX0963	07/01/2012	Prescription Benefit Services Agreement - Amendment No. 2 between CaremarkPCS Health LLC and City of Providence, Rhode Island	ZETIA-COP-000456	ZETIA-COP-000481	901; HS
PX0964	01/01/2009	Prescription Benefit Services Agreement between CaremarkPCS Health LLC and City of Providence, Rhode Island	ZETIA-COP-000488	ZETIA-COP-000547	901; HS
PX0965	01/01/2015	CVS Caremark Welcome Kit	ZETIA-COP-004724	ZETIA-COP-004735	901; HS
PX0966	08/15/2018	pdf file of CVS Caremark purchase data	ZETIA-COP-005594	ZETIA-COP-005594	901; HS
PX0967	09/14/2016	Letter from H. Medina at CVS Health to M. Wingate "re: Amendment No. 4 and MAC List" with attached Prescription Benefit Services Agreement - Amendment No. 4 between CaremarkPCS Health and City of Providence, Rhode Island	ZETIA-COP-005595	ZETIA-COP-005663	901; HS
PX0968_N	05/30/2019	Purchase Data - COP - 8/16/2018-5/30/2019	ZETIA-COP-005664	ZETIA-COP-005664	901; HS
PX0969	08/14/2019	City of Providence - Master Plan & Program Matrix v. 4.5	ZETIA-COP-005665	ZETIA-COP-005665	901; HS
PX0970	09/11/2019	City of Providence - Master Plan & Program Matrix v. 4.6	ZETIA-COP-005694	ZETIA-COP-005694	901; HS
PX0971	02/01/2018	Spreadsheet - Zetia Local 49 Updated Data from PBM	ZETIA-LOCAL49-0001	ZETIA-LOCAL49-0001	901; HS
PX0971_N	02/01/2018	Spreadsheet - Zetia Local 49 Updated Data from PBM	ZETIA-LOCAL49-0001	ZETIA-LOCAL49-0001	901; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX0975	01/28/2018	Spreadsheet, Zetia - Detailed Local 49ers Claim Detail Report	ZETIA-LOCAL49-000432	ZETIA-LOCAL49-000432	901; HS
PX0975_N	01/28/2018	Spreadsheet, Zetia - Detailed Local 49ers Claim Detail Report	ZETIA-LOCAL49-000432	ZETIA-LOCAL49-000432	901; HS
PX0976_N	05/28/2019	Purchase Data - IUOE - Local 49 - 2/28/2018-5/28/2019	ZETIA-LOCAL49-000620	ZETIA-LOCAL49-000620	901; HS
PX0977	03/31/2014	Claims Detail Zetia and Ezetimibe December 2011 through March 2014	ZETIA-PAINTERS-000001	ZETIA-PAINTERS-000001	901; HS
PX0978	03/01/2014	Painters Purchase Data	ZETIA-PAINTERS-000001R	ZETIA-PAINTERS-000001R	901; HS
PX0978_N	03/01/2014	Painters Purchase Data	ZETIA-PAINTERS-000001R	ZETIA-PAINTERS-000001R	901; HS
PX0979	12/01/2017	Spreadsheet, Painters Purchase Data for Zetia and Generic Zetia from PBM, Citizens RX	ZETIA-PAINTERS-000002	ZETIA-PAINTERS-000002	901; HS
PX0980	12/01/2017	Painters Purchase Data	ZETIA-PAINTERS-000002R	ZETIA-PAINTERS-000002R	901; HS
PX0980_N	12/01/2017	Painters Purchase Data	ZETIA-PAINTERS-000002R	ZETIA-PAINTERS-000002R	901; HS
PX0982	08/12/2019	Spreadsheet, Purchase Data for Painters District Council No. 30 Health & Welfare Fund for Ezetimibe 12/2017-2019	ZETIA-PAINTERS-000429	ZETIA-PAINTERS-000429	901; HS
PX0983	08/01/2019	Painters Purchase Data	ZETIA-PAINTERS-000429R	ZETIA-PAINTERS-000429R	901; HS
PX0983_N	08/01/2019	Painters Purchase Data	ZETIA-PAINTERS-000429R_N	ZETIA-PAINTERS-000429R_N	901; HS
PX0984	03/01/2014	Philadelphia Federation of Teachers Purchase Data	ZETIA-PFTHW-000001R	ZETIA-PFTHW-000001R	901; HS
PX0984_N	03/01/2014	Philadelphia Federation of Teachers Purchase Data	ZETIA-PFTHW-000001R	ZETIA-PFTHW-000001R	901; HS
PX0989	01/31/2018	Sergeants Purchase Data	ZETIA-SERGEANTS-000001R	ZETIA-SERGEANTS-000001R	901; HS
PX0989_N	01/31/2018	Sergeants Purchase Data	ZETIA-SERGEANTS-000001R	ZETIA-SERGEANTS-000001R	901; HS
PX0990	01/31/2018	Sergeants Supplemental Zetia data 7/2012-1/31/2018	ZETIA-SERGEANTS-000002	ZETIA-SERGEANTS-000002	901; HS
PX0991	01/31/2018	Sergeants Purchase Data	ZETIA-SERGEANTS-000002R	ZETIA-SERGEANTS-000002R	901; HS
PX0991_N	01/31/2018	Sergeants Purchase Data	ZETIA-SERGEANTS-000002R	ZETIA-SERGEANTS-000002R	901; HS
PX0998_N	05/15/2019	Purchase Data - SBA - 2/1/2018-8/15/2019	ZETIA-SERGEANTS-003185	ZETIA-SERGEANTS-003185	901; HS
PX1001	12/05/2018	Claims Data for Zetia as Created by CVS	ZETIA-UFA-000228	ZETIA-UFA-000228	901; HS
PX1002	05/20/2019	Uniformed Firefighters' Association Purchase Data	ZETIA-UFA-000228R	ZETIA-UFA-000228R	901; HS
PX1002_N	05/20/2019	Uniformed Firefighters' Association Purchase Data	ZETIA-UFA-000228R_N	ZETIA-UFA-000228R_N	901; HS
PX1008	05/28/2019	Purchase Data - UFCW - 12/7/2012-5/28/2018	ZETIA-UFCW-001042	ZETIA-UFCW-001042	901; HS
PX1008_N	05/28/2019	Purchase Data - UFCW - 12/7/2012-5/28/2018	ZETIA-UFCW-001042	ZETIA-UFCW-001042	901; HS
PX1009	08/15/2019	Express Scripts Claim Detail Report re UFCW Local 1500 12/2/2012-5/31/2019	ZETIA-UFCW-001042	ZETIA-UFCW-001042	901; HS
PX1016_N	08/28/2018	Spreadsheet, CVS Retail Direct Purchases for Ezetimibe Only (12/13/2016 - 08/24/2018) and CVS Mail Direct Purchases for Ezetimibe Only (12/22/2016 - 08/28/2018)	CVS-ZET-0000010	CVS-ZET-0000010	901; HS
PX1017	01/01/2011	Spreadsheet, CVS - Cardinal DSD Purchase data (2011-2012) (Excerpt)	CVS-ZET-0000011	CVS-ZET-0000011	901; INC; HS
PX1018_N	12/31/2012	Spreadsheet, CVS - Cardinal DSD Purchase Data (2011-2012)	CVS-ZET-0000011	CVS-ZET-0000011	901; HS
PX1019_N	12/31/2015	Spreadsheet, CVS - Cardinal DSD Purchase data (2013 - 2015)	CVS-ZET-0000012	CVS-ZET-0000012	901; HS
PX1020_N	12/31/2016	Spreadsheet, CVS - Cardinal DSD Purchase data (2016)	CVS-ZET-0000013	CVS-ZET-0000013	901; HS

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1021_N	03/31/2017	Spreadsheet, CVS - Cardinal DSD Purchase data (2017 - pt 1)	CVS-ZET-0000014	CVS-ZET-0000014	901; HS
PX1022_N	05/31/2017	Spreadsheet, CVS - Cardinal DSD Purchase data (2017 - pt 2)	CVS-ZET-0000015	CVS-ZET-0000015	901; HS
PX1023_N	12/31/2017	Spreadsheet, CVS - Cardinal DSD Purchase data (2017 - pt 3)	CVS-ZET-0000016	CVS-ZET-0000016	901; HS
PX1024_N	09/07/2018	Spreadsheet, CVS - Cardinal DSD Purchase data (2018)	CVS-ZET-0000017	CVS-ZET-0000017	901; HS
PX1025	01/01/2011	Spreadsheet, McKesson data for CVS Purchases (01/01/2011 - 11/26/2018)	CVS-ZET-0000018	CVS-ZET-0000018	901; HS
PX1026_N	11/26/2018	Spreadsheet, CVS McKesson DSD Purchase Data (1/1/2011 - 1	CVS-ZET-0000018	CVS-ZET-0000018	901; HS
PX1028_N	11/28/2018	Spreadsheet, "HEB Zetia Purchase Data 1.1.11_11.27.18.xls"	HEB_ZETIA_00000005	HEB_ZETIA_00000005	901; HS
PX1030	09/30/2018	Kroger Purchase Data for Zetia (Ezetimibe), 2/2/2014 - 9/30/2018	KRG_ZETIA_00000007	KRG_ZETIA_00000007	901; HS
PX1030_N	09/30/2018	Kroger Purchase Data for Zetia (Ezetimibe), 2/2/2014 - 9/30/2018	KRG_ZETIA_00000007	KRG_ZETIA_00000007	901; HS
PX1033	09/04/2018	Spreadsheet, Rite Aid - McKesson DSD (01/03/2011 - 09/03/2018) and DC Purchases (01/03/2011 - 09/22/2014) (excerpts)	RA-ZET-0000004	RA-ZET-0000004	901; HS
PX1034_N	09/04/2018	Spreadsheet, Rite Aid - McKesson DSD (01/03/2011 - 09/03/201	RA-ZET-0000004	RA-ZET-0000004	901; HS
PX1036_N	02/28/2018	Spreadsheet, Zetia-Generic_ABC_Purchases-01.01.2012-02.28.2018.xls	WLG_ZETIA_00000010	WLG_ZETIA_00000010	901; HS
PX1037_N	02/28/2018	Spreadsheet, Zetia-Generic_ABC_Purchases-01.01.2012-02.28.2018-1.xls	WLG_ZETIA_00000011	WLG_ZETIA_00000011	901; HS
PX1048	12/23/1991	Approval Date(s) and History, Letters, Labels, Reviews for NDA 019766, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process			901; HS; INC
PX1050	06/19/1992	Approval Date(s) and History, Letters, Labels, Reviews for NDA 020180, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process			901; HS; INC
PX1053	12/09/1994	Approval Date(s) and History, Letters, Labels, Reviews for NDA 020408, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process			901; HS; INC
PX1054	04/14/1995	Approval Date(s) and History, Letters, Labels, Reviews for NDA 020386, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process			901; HS; INC
PX1055	04/28/1995	Approval Date(s) and History, Letters, Labels, Reviews for NDA 020387, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process			901; HS; INC

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1056	09/29/1995	Approval Date(s) and History, Letters, Labels, Reviews for NDA 020560, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process			901; HS; INC
PX1059	10/01/1997	Final Approval Letter from FDA to Schering Corporation for NDA No. 020762 for Nasonex (Mometasone Furoate) Nasal Spray			901; HS; IL
PX1060	02/20/1998	Final Approval Letter from FDA to Merck Research Laboratories for NDA No. 020829 for Singulair (Montelukast Sodium) Tablets			901; HS
PX1061	04/07/1998	Final Approval Letter from FDA to Merck Research Laboratories for NDA No. 020829 for Cosopt Sterile Ophthalmic Solution			901; HS
PX1064	06/29/1998	Final Approval Letter from FDA to Merck & Co., Inc. for NDA Nos. 020864 & 020865 for Maxalt (Rizatriptan Benzoate) Tablet and RPD 5 mg and 10 mg			901; HS
PX1066	10/07/1998	MAPP 5015.4, Pharmaceutical Science: Chemistry Reviews of DMFs for Drug Substances/Intermediates (DSI) at section: "II. No Written Review Required" and "I. Written Review - Re-review"; Originated in August 1998 and Posted from March 2010 through March 2014. Found at: http://web.archive.org/web/20121020000309/http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/default.htm			HS; 901
PX1067	08/11/1999	Approval Date(s) and History, Letters, Labels, Reviews for NDA 021029, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process			901; HS; INC
PX1068	12/21/2001	Final Approval Letter from FDA to Schering Corporation for NDA No. 021165 for Clarinex (Desloratadine) Tablets			901; HS
PX1080	09/12/2003	Final Approval Letter from FDA to Cubist Pharmaceuticals, Inc. for NDA No. 021572 for Cubicin (Daptomycin for Injection) Intravenous Injection			901; HS
PX1094	06/19/2006	Press Release, Teva, Teva Receives First FDA Approval for Generic Proscar® Tablets			901; HS; HWH
PX1095	06/23/2006	Market Watch, "Dr. Reddy's Launches Proscar, Zocor Generics"			901; HS; HWH
PX1096	06/23/2006	Merck Prices Zocor Below Generic - June 23, 2006			HS; 901; HWH
PX1098	06/24/2006	Press Release, "FDA Approves Generic Versions of Merck's Zocor"			901; HS; HWH; INC
PX1099	06/25/2006	Press Release, Teva, Teva Receives First U.S. Approval of Generic Zocor® Tablets; Product to be Shipped Immediately			901; HS; HWH
PX1101	07/01/2006	Pharmacytimes.com Article: "Merck Selling Zocor Cheaper Than Generics"			HS; 901; HWH

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1106	12/20/2006	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 076685, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&ApplNo=076685			901; HS
PX1118	02/05/2008	Watson to Ship Generic Fosamax Under Merck Deal, Reuters			901; HS; HWH
PX1119	02/06/2008	Press Release, Teva, Teva Announces Approval of Generic Fosamax® Tablets			901; HS; HWH
PX1124	04/10/2008	Hi-Tech Pharmacal Receives Tentative Approval for Dorzolamide Hydrochloride with Timolol Maleate Ophthalmic Solution, Business Wire			HS; R; 403
PX1126	10/28/2008	Final Approval Letter from FDA to Hi-Tech Pharmacal Co., Inc. for ANDA No. 077847 for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%			901; HS
PX1127	10/28/2008	Press Release, Prasco, Prasco to Distribute Generic Forms of Dorzolamide Hydrochloride Timolol Maleate and Dorzolamide Hydrochloride Ophthalmic Solutions			901; HS; HWH
PX1128	10/29/2008	Hi-Tech Launches Generic Cosopt Without Exclusivity, Pink Sheet			901; HS; HWH
PX1133	08/12/2009	Schering-Plough Corporation Settles Final Clarinex Patent Litigation, BioSpace			901; HS
PX1138	04/06/2010	Final Approval Letter from FDA to Teva Pharmaceuticals USA for ANDA No. 076958 for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg			901; HS
PX1139	04/07/2010	Press Release, Teva, Teva Announces Final Approval of Generic Hyzaar® and Cozaar®			901; HS; HWH
PX1140	04/07/2010	Sandoz Launches Authorized Versions of Cozaar® and Hyzaar® Tablets, FiercePharma			901; HS; HWH
PX1142	04/12/2010	Teva Launches Generic Cozaar/Hyzaar with Market Exclusivity as FDA Seeks Court Action to Permit Other Entrants, Pink Sheet			901; HS; HWH
PX1145	10/01/2010	National Bureau of Economic Research: "Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation", Berndt & Aitken			HS; 901
PX1146	10/25/2010	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 078352, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078352			901; HS; INC
PX1147	11/16/2010	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 078359, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078359			901; HS; INC

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1148	12/03/2010	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 078364, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078364			901; HS; INC
PX1156	08/31/2011	RxDrugLabels, Prescription Drug Information: Dorzolamide Hydrochloride - Prasco Laboratories (Page 2 of 2)			HS; R; 403
PX1158	10/07/2011	RxDrugLabels, Prescription Drug Information for Dorzolamide Hydrochloride-Timolol Maleate - Prasco Laboratories (Page 5 of 5)			HS; 901; R
PX1168	08/03/2012	Final Approval Letter from FDA to Aurobindo Pharma USA, Inc. for ANDA No. 202468 for Montelukast Sodium Tablets, 10 mg			901; HS
PX1169	08/03/2012	Final Approval Letter from FDA to Glenmark Generics Inc., USA for ANDA No. 090926 for Montelukast Sodium Tablets, 10 mg			901; HS
PX1170	08/03/2012	Final Approval Letter from FDA to Kremers Urban Pharmaceuticals Inc. for ANDA No. 201522 for Montelukast Sodium Tablets, 10 mg			901; HS
PX1171	08/03/2012	Final Approval Letter from FDA to Sandoz Inc. for ANDA No. 200889 for Montelukast Sodium Tablets, 10 mg			901; HS
PX1172	08/03/2012	Final Approval Letter from FDA to Teva Pharmaceuticals USA for ANDA No. 078605 for Montelukast Sodium Tablets, 10 mg			901; HS
PX1173	08/03/2012	Final Approval Letter from FDA to Torrent Pharma, Inc. for ANDA No. 201515 for Montelukast Sodium Tablets, 10 mg			901; HS
PX1174_N	08/03/2012	Search Results for Montelukast Sodium Tablets Marketed Aug. 3, 2012, Drug Products in the Medicaid Drug Rebate Program, Medicaid, https://data.medicaid.gov/Drug-Pricing-and-Payment/Drug-Products-in-the-Medicaid-Drug-Rebate-Program/v48d-4e3e/data			HS; 901
PX1175	08/03/2012	Daniel J. DeNoon, Generic Singulair Approved - FDA: 10 Generic Drugmakers Approved to Make Montelukast Tablets, WebMD			901; HS; HWH
PX1178	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 202490, Drugs@FDA: FDA- Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202490			901; HS
PX1179	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 202047, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202047			901; HS
PX1180	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 201967, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201967			901; HS

May Offer Exhibits Profferred by the Purchasers to W...ch the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1181	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 201993, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201993			901; HS
PX1182	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 200482, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200482			901; HS
PX1183	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 079230, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079230			901; HS
PX1184	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 077263, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077263			901; HS
PX1185	12/31/2012	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 078173. Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078173			901; HS; INC
PX1186	01/01/2013	PwC, 2013 Patent Litigation Study			HS; 901
PX1188	01/02/2013	Press Release, Mylan, Mylan Launches First Generic Maxalt MLT® Tablets			901; HS
PX1189	01/02/2013	Par Launches Generic Maxalt and Maxalt-MLT, MPR			901; HS; HWH
PX1191	01/16/2013	RxDrugLabels, Prescription Drug Information: Rizatriptan Benzoate - Sandoz Inc. (Page 7 of 7)			HS; R; 403
PX1193	02/11/2013	DRUG MASTER FILES UNDER GDUFA: DMF Basics/DMFs Under GDUFA: DMF Basics Small Business Webinar 2013, https://www.fda.gov/media/85079/download			HS; 901
PX1196	04/30/2013	RxDrugLabels, Prescription Drug Information: Rizatriptan Benzoate - Glenmark Generics Inc., USA (Page 7 of 7)			HS; R; 403
PX1198	07/02/2013	C.H. Unnikrishnan, Glenmark to Sell Maxalt Generic in US from Tuesday, LiveMint			901; HS; HWH
PX1203	02/01/2014	Drugs.com, U.S. Pharmaceutical Sales - 2011, Top 100 Drugs for 2011 by Sales			HS; R
PX1208	09/12/2014	Final Approval Letter from FDA to Hospira, Inc. for ANDA No. 202857 for Daptomycin for Injection USP			901; HS
PX1212	03/24/2015	Press Release, Apotex, Apotex Launches First Generic Version of Merck's Nasonex®			901; HS; HWH
PX1219	08/18/2015	Press Release, Merck, Merck Recalls Temodar® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child-Resistant Closure Requirement			HS; HWH; 901
PX1220	09/15/2015	Press Release, Teva, Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin® (Daptomycin for Injection) in the United States			901; HS; HWH

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1232	02/26/2016	Cary S. Yonce, Maximize Your Brand's Value Post Patent Expiration Through Authorized Generics, PM360			HS; 901
PX1233	03/01/2016	Cardinal Listing of Customer Number, Name & Address			HS; 901
PX1235_N	03/31/2016	Spreadsheet, McKesson Sales Data: "Copy of FINAL Albertsons_Zetia_6-1-2013 to 3-31-2016"			901; HS
PX1238	07/23/2016	Dr. Reddy's Launches Authorized Generic Versions of Proscar® and Zocor®, Business Wire			901; HS; HWH
PX1247	05/04/2017	D. Bartholomew, In Defense of the Anti-Generic, PHARMA MANUFACTURING (May 4, 2017), https://www.pharmamanufacturing.com/articles/2017/in-defense-of-the-anti-aeneric/ (citing Cutting Edge Information survey)			HS; HWH; IL
PX1252_N	10/01/2017	Spreadsheet, "Ezetimibe NDCs 10.1.17 to 3.31.18-Chargeback data"			901; HS
PX1253	10/01/2017	Pharmacy Healthcare Solutions, LLC, 2017 Fall Newsletter – PHSI Analysis of Authorized Generic Drugs, available at http://phsirx.com/news-events/phsi-newsletters/2017-fall-newsletter-authorized-generic-drugs			HS; 901; HWH
PX1260_N	01/05/2018	Historical WAC			901; HS
PX1263	03/12/2018	Spreadsheet, Zetia brand and generic ABDC purchases from 1/1/2012-2/28/2018			HS
PX1264_N	04/01/2018	Spreadsheet, "Ezetimibe NDCs 4.1.18 to 11.30.18-Chargeback data"			901; HS
PX1268	06/30/2018	Zetia Monthly Sandoz Sales Volume, June 2017-June 2018			901; HS
PX1272	11/27/2018	Printout of HEB Purchase Data			HS
PX1273_N	12/01/2018	Spreadsheet, "Ezetimibe NDCs 12.1.18 to 3.31.19-Chargeback data"			901; HS
PX1275_N	12/06/2018	Spreadsheet, McKesson Sales Data: "Copy of FINAL Albertsons_ChainID 676_Zetia_4-1-2016 to 12-6-2018"			901; HS
PX1281_N	03/01/2019	Spreadsheet, "Ezetimibe sales data - Final till March 2019"			901; HS
PX1282_N	03/31/2019	Spreadsheet, "Ezetimibe Credit Note line"			901; HS
PX1283	05/06/2019	RxDrugLabels, Prescription Drug Information: Desloratadine - Sun Pharmaceutical Industries, Inc. (Page 4 of 4)			HS; R; 403
PX1287	07/31/2019	RxDrugLabels, Prescription Drug Information: Mometasone Furoate Monohydrate - Sandoz Inc. (Page 6 of 6)			HS; R; 403
PX1353	11/27/2019	RxDrugLabels, Prescription Drug Information: Rizatriptan Benzoate - Mylan Pharmaceuticals, Inc. (Page 7 of 7)			HS; R; 403
PX1354_N	12/01/2019	Spreadsheet, "CLIENT QTY SUMMARY"			HS; 901
PX1358	12/27/2019	RxDrugLabels, Prescription Drug Information: Dorzolamide Hydrochloride - Hi-Tech Pharmacal Co., Inc. (Page 3 of 3)			HS; R; 403

May Offer Exhibits Profferred by the Purchasers to W...ich the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1387_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "Margin Summary Zetia.xls"			702; HS
PX1388_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "Benefit Cost No AG.xls"			702; HS
PX1389_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "AltSettleAnalysisZetia.xls"			702; HS
PX1390_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "ValueActSettleZetia.xls"			702; HS
PX1391_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "OC Calculations Zetia.xls"			702; HS
PX1392_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "Client Qty Summary.xls"			702; HS
PX1393_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "Client $$ Summary.xls"			702; HS
PX1394_N	01/13/2020	Spreadsheet, Keith Leffler Backup File - "WTD Avg Price.xls"			702; HS
PX1419	01/13/2020	Table 1 from Expert Report of Susan Marchetti: Zetia Delivery Plan			HS; 1006
PX1420	01/13/2020	Attachment D.1 to Expert Report of Thomas G. McGuire: Merck's Litigation Costs			HS
PX1421	01/13/2020	Attachment D.4 to Expert Report of Thomas G. McGuire: Base Calculation of Merck Profit from Authorized Generic Assuming Entry in December 2016			HS; 702; 703
PX1422	01/13/2020	Attachment D.6.i to Expert Report of Thomas G. McGuire: Upside Calculations of Merck Profits from Authorized Generic Assuming Entry in December 2016 (Assuming 180-Day Exclusivity Period)			HS; 702; 703
PX1423	01/13/2020	Attachment D to Expert Report of Thomas G. McGuire: Evaluation of Merck's Potential Authorized Generic Profits			HS; 702; 703
PX1424	01/13/2020	Attachment E.1 to Expert Report of Thomas G. McGuire: Glenmark's Litigation Costs			HS
PX1425	01/13/2020	Attachment F from Expert Report of Thomas G. McGuire: Calculation of Generic Entry Date in an Alternative No Payment Settlement ($ Millions)			HS; 702; 703
PX1429	01/13/2020	Figure 2 from Expert Report of Thomas G. McGuire: Reciprocal Non-Compete Clauses in a Delay/No-AG Settlement			HS
PX1430	01/13/2020	Figure 3 from Expert Report of Thomas G. McGuire: Wealth Transfer from No-AG Agreement			HS; 403
PX1437	01/13/2020	Figure 2 from Expert Report of Meredith Rosenthal: Generic Competition and Drug Prices			HS; 403; 1006
PX1438	01/13/2020	Figure 3 from Expert Report of Meredith Rosenthal: Wholesale Expenditure Shares in Markets With an Authorized Generic			HS; 403; 1006

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1439	01/13/2020	Figure 4 from Expert Report of Meredith Rosenthal: Wholesale Expenditure Shares in Markets Without an Authorized Generic			HS; 403; 1006
PX1440	01/13/2020	Figure 5 from Expert Report of Meredith Rosenthal: Impact of Generic Entry on Brand Profitability			HS; 403; 1006
PX1489	01/31/2020	DailyMed, Drug Label Information for Temozolomide Capsule - Sandoz Inc.			HS; R; 403
PX1516_N	02/20/2020	CLIENT QTY SUMMARY_ALB			901; HS
PX1517_N	02/20/2020	CLIENT QTY SUMMARY_ALB			901; HS
PX1518_N	02/20/2020	CLIENT QTY SUMMARY_CVS			901; HS
PX1519_N	02/20/2020	CLIENT QTY SUMMARY_HEB			901; HS
PX1520_N	02/20/2020	CLIENT QTY SUMMARY_KRO			901; HS
PX1521_N	02/20/2020	CLIENT QTY SUMMARY_RA			901; HS
PX1522_N	02/20/2020	CLIENT QTY SUMMARY_WGN			901; HS
PX1528	03/26/2020	Attachment B to Rebuttal Expert Report of Thomas G. McGuire: The Value of the No-AG Clause Based on Glenmark and Par's Actual Profits			HS; 702; 703
PX1560_N	05/08/2020	Spreadsheet, Keith Leffler Backup File - "AltSettleAnalysisZetiaLOEReply.xls"			702; HS
PX1561_N	05/08/2020	Spreadsheet, Keith Leffler Backup File- "ValueActSettleZetiaEndoLitProbReply.xls"			702 HS
PX1562_N	05/08/2020	Spreadsheet, Keith Leffler Backup File - "LitActSettleEndogLitProbReply.xls"			702; HS
PX1563_N	05/08/2020	Spreadsheet, Keith Leffler Backup File - Client $$ Summary Reply.xls			702; HS
PX1564_N	05/08/2020	Spreadsheet, Keith Leffler Backup File - OC Calculations Zetia Reply.xls			702; HS
PX1606	08/19/2020	Press Release: "Merck signs deal for Fosamax authorized generic"			901; HS; HWH; IL
PX1608	09/14/2020	DailyMed, Drug Label Information for Dorzolamide Hydrochloride and Timolol Maleate Solution/Drops - Hi-Tech Pharmacal Co., Inc.			HS; R; 403
PX1614	02/29/2010	Approval Date(s) and History, Letters, Labels, Reviews for ANDA 078357, Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078357			901; HS
PX1647_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "AltSettleAnalysisZetiaRevised.xlsx"			702; HS
PX1648_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "CLIENT $$ SUMMARY REPLY S3 REVISED.xlsx"			702; HS
PX1649_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "CLIENT $$ SUMMARY S3 REVISED.xlsx"			702; HS
PX1650_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "OC CALCULATIONS ZETIA REPLY S3 REVISED.xlsx"			702; HS

May Offer Exhibits Profferred by the Purchasers to W...ich the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1651_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "OC CALCULATIONS ZETIA S3 REVISED.xlsx"			702; HS
PX1652_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "ValueActSettleZetiaEndoLitProbReplyRevised.xlsx"			702; HS
PX1653_N	07/07/2020	Spreadsheet, Keith Leffler Backup File - "ValueActSettleZetiaRevised.xlsx"			702; HS
PX1654	05/06/2022	Amended and Restated Agreement for Assignment of Claims between Humana Inc. and Humana Pharmacy, Inc. and AmerisourceBergen Drug Corporation	ABDC-ZETIA_0000014	ABDC-ZETIA_0000016	HS; 901
PX1655	05/06/2022	Agreement for Assignment of Claims between Humana Inc. and AmerisourceBergen Drug Corporation	ABDC-ZETIA_0000017	ABDC-ZETIA_0000018	HS; 901
PX1656	12/31/2020	Zetia/Ezetimibe Purchase Data for Humana Customers, 1/1/2014-12/31/2020	ABDC-ZETIA_0000019	ABDC-ZETIA_0000019	HS; 901
PX1656_N	12/31/2020	Zetia/Ezetimibe Purchase Data for Humana Customers, 1/1/2014-12/31/2020	ABDC-ZETIA_0000019	ABDC-ZETIA_0000019	HS; 901
PX1657	09/01/2020	Agreement for Assignment of Claims between OptumRx, Inc. and Cardinal Health110, LLC and Cardinal Health 112, LLC	CARDINAL_0000003	CARDINAL_0000005	HS; 901
PX1658	12/31/2020	Zetia/Ezetimibe Purchase Data for OptumRx, 1/1/2014-12/31/2020	CARDINAL_0000006	CARDINAL_0000006	HS; 901
PX1658_N	12/31/2020	Zetia/Ezetimibe Purchase Data for OptumRx, 1/1/2014-12/31/2020	CARDINAL_0000006	CARDINAL_0000006	HS; 901
PX1659_N	01/31/2020	Zetia/Ezetimibe Purchase Data for Giant Eagle, 1/1/2014-1/31/2020	GE-Zetia-000001	GE-Zetia-000001	HS; 901
PX1661	03/31/2018	Zetia/Ezetimibe Purchase Data for Giant Eagle, 1/1/2014-3/31/2018	MCK_ZETIA_0000001	MCK_ZETIA_0000001	HS; 901
PX1661_N	03/31/2018	Zetia/Ezetimibe Purchase Data for Giant Eagle, 1/1/2014-3/31/2018	MCK_ZETIA_0000001	MCK_ZETIA_0000001	HS; 901
PX1662	02/08/2019	Agreement for Assignment of Claims between McKesson Corporation and KPH Healthcare Services, Inc., d/b/a Kinney Drugs, Inc.	MCK_ZETIA_0000002	MCK_ZETIA_0000003	HS; 901
PX1663	05/30/2022	Agreement for Assignment of Claims between McKesson Corporation and KPH Healthcare Services, Inc., d/b/a Kinney Drugs, Inc.	MCK_ZETIA_0000004	MCK_ZETIA_0000006	HS; 901
PX1664	07/01/2014	Agreement for Assignment of Claims between McKesson Corporation and Wegmans Food Markets, Inc.	MCK_ZETIA_0000007	MCK_ZETIA_0000009	HS; 901
PX1666	09/01/2018	Agreement for Assignment of Claims between McKesson Corporation and SUPERVALU INC.	MCK_ZETIA_0000012	MCK_ZETIA_0000013	HS; 901
PX1667	12/12/2018	Agreement for Assignment of Claims between McKesson Corporation and Wegmans Food Market, Inc.	MCK_ZETIA_0000014	MCK_ZETIA_0000015	HS; 901
PX1668	06/15/2020	Agreement for Assignment of Claims between McKesson Corporation and Meijer Distribution, Inc. and Meijer, Inc.	MCK_ZETIA_0000016	MCK_ZETIA_0000018	HS; 901
PX1669	12/31/2020	Zetia/Ezetimibe Purchase Data for KPH, 1/1/2014-12/31/2020	MCK_ZETIA_0000019	MCK_ZETIA_0000019	HS; 901
PX1669_N	12/31/2020	Zetia/Ezetimibe Purchase Data for KPH, 1/1/2014-12/31/2020	MCK_ZETIA_0000019	MCK_ZETIA_0000019	HS; 901

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1671	12/31/2020	Zetia/Ezetimibe Purchase Data for SUPERVALU, 1/1/2014-12/31/2020	MCK_ZETIA_0000021	MCK_ZETIA_0000021	HS; 901
PX1671_N	12/31/2020	Zetia/Ezetimibe Purchase Data for SUPERVALU, 1/1/2014-12/31/2020	MCK_ZETIA_0000021	MCK_ZETIA_0000021	HS; 901
PX1672	12/31/2017	Zetia/Ezetimibe Purchase Data for Wegmans, 1/1/2014-12/31/2017	MCK_ZETIA_0000022	MCK_ZETIA_0000022	HS; 901
PX1672_N	12/31/2017	Zetia/Ezetimibe Purchase Data for Wegmans, 1/1/2014-12/31/2017	MCK_ZETIA_0000022	MCK_ZETIA_0000022	HS; 901
PX1673	12/31/2020	Zetia/Ezetimibe Purchase Data for Wegmans, 1/1/2018-12/31/2020	MCK_ZETIA_0000023	MCK_ZETIA_0000023	HS; 901
PX1673_N	12/31/2020	Zetia/Ezetimibe Purchase Data for Wegmans, 1/1/2018-12/31/2020	MCK_ZETIA_0000023	MCK_ZETIA_0000023	HS; 901
PX1678	10/14/2022	Exhibit 5 to 10/14/2022 Expert Report of Jeffrey Leitzinger, "Range of Overcharges Excluding Amounts Related to Additional Generic Conversion Due to Bypass"			HS; 1006; 403
PX1704	09/22/2015	Spreadsheet, "Par Ezitimibe Model"	GLENMARK-ZETIA-178561	GLENMARK-ZETIA-178561	HS; 403
PX1704_N	09/22/2015	Spreadsheet, "Par Ezitimibe Model"	GLENMARK-ZETIA-178561	GLENMARK-ZETIA-178561	HS; 403
PX1705	11/27/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_P&L_UpdatedSMART_Q12015_May1"	GLENMARK-ZETIA-214759	GLENMARK-ZETIA-214759	HS; 901; 403
PX1705_N	11/27/2014	Spreadsheet, "Zetia_RevenueModel_3rdMar_P&L_UpdatedSMART_Q12015_May1"	GLENMARK-ZETIA-214759	GLENMARK-ZETIA-214759	HS; 901; 403
PX1706	06/07/2010	Spreadsheet, "Capital Royalty Info June 15.zip?Financials"	GLENMARK-ZETIA-240142	GLENMARK-ZETIA-240142	HS; 901; 403
PX1706_N	06/07/2010	Spreadsheet, "Capital Royalty Info June 15.zip?Financials"	GLENMARK-ZETIA-240142	GLENMARK-ZETIA-240142	HS; 901; 403
PX1707_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "APOTEX0000063 HIGHLY CONFIDENTIAL ATTORNEYS EYES ONLY_Billing Types"			HS; 901
PX1708_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "APOTEX0000063 HIGHLY CONFIDENTIAL ATTORNEYS EYES ONLY_Customer_Lookup"			HS; 901
PX1709_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "APOTEX0000063 HIGHLY CONFIDENTIAL ATTORNEYS EYES ONLY_Material_NDC"			HS; 901
PX1710_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "CLIENT QTY SUMMARY REPLY_ALB"			HS; 901
PX1711_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "CLIENT QTY SUMMARY REPLY_CVS"			HS; 901
PX1712_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "CLIENT QTY SUMMARY REPLY_HEB"			HS; 901
PX1713_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "CLIENT QTY SUMMARY REPLY_KRO"			HS; 901
PX1714_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "CLIENT QTY SUMMARY REPLY_RA"			HS; 901

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1715_N	10/14/2022	Spreadsheet, Leitzinger 10/14/22 Report Work Papers, "CLIENT QTY SUMMARY REPLY_WGN"			HS; 901
PX1716_N	10/14/2022	Spreadsheet, 10/14/22 Leitzinger Report Work Papers, "GE QTY SUMMARY"			HS; 901
PX1717_N	10/14/2022	Spreadsheet, 10/14/22 Leitzinger Report Work Papers, "OC CALCULATIONS ZETIA REPLY GE_BRAND OCs"			HS; 901
PX1718_N	10/14/2022	Spreadsheet, 10/14/22 Leitzinger Report Work Papers, "OC CALCULATIONS ZETIA REPLY GE_BRAND QTY"			HS; 901
PX1765_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "AMNEAL SUMMARY + GE"			HS; 901; 702; 703
PX1766_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "APOTEX0000062 + GE"			HS; 901; 702; 703
PX1767_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "GE $$ SUMMARY"			HS; 901; 702; 703
PX1768_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "GE QTY SUMMARY"			HS; 901; 702; 703
PX1769_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "OC CALCULATIONS ZETIA REPLY + GE"			HS; 901; 702; 703; 1006
PX1770_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "PAR_00000001-Highly Confidential + GE"			HS; 901; 702; 703
PX1771_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "PAR_00000002-Highly Confidential + GE"			HS; 901; 702; 703
PX1772_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers,"SANDOZ-ZETIA-0000181 + GE"			HS; 901; 702; 703
PX1773_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "ZYDUS-EZE_0000003 + GE"			HS; 901; 702; 703
PX1774_N	10/14/2022	Spreadsheet, Supplemental Leffler Report Work Papers, "ZYDUS-EZE_0000006 + GE"			HS; 901; 702; 703
PX1780	01/13/2020	Table from Expert Report of Todd Clark - Known Generic Ezetimibe Filers Other than Glenmark			1006; HS
PX1781	06/18/2020	Exhibit 2 from Rebuttal Expert Report of Todd Clark - Potential Trial Exhibits/Demonstratives			1006; HS
PX1782	10/30/2019	Defendants Glenmark Pharmaceuticals, Ltd. and Glenmark Generics Inc., USA's Objections and Fourth Supplemental Set of Responses to Plaintiffs' First Set of Interrogatories to Defendants			HS
PX1786	01/28/2010	Email from A. Maffia to V. Soni, T. Coughlin & W. McIntyre, "Parr Visit"	GLENMARK-ZETIA-00159206	GLENMARK-ZETIA-00159206	HS; HWH
PX1787	04/14/2009	Email from A. Maffia to M. Mathias & S. Marquis, "RE: ANDA 78-560, Ezetimibe Tablets, 10 mg," with attachment	GLENMARK-ZETIA-00159411	GLENMARK-ZETIA-00159433	HS
PX1789	02/03/2010	Email from C. Almeida to S. Krishan & V. Mathur, "RE: MOM of comarketing meeting," with attachments	GLENMARK-ZETIA-00184978	GLENMARK-ZETIA-00184981	HS
PX1791	06/04/2014	Email from S. Kaushal to V. Soni, "RE: Ezetimibe Tablets History," with attachment	GLENMARK-ZETIA-00212724	GLENMARK-ZETIA-00212726	HS
PX1796	06/25/2009	Email from T. Coughlin to P. Dutra, "RE: MoU"	GLENMARK-ZETIA-00260788	GLENMARK-ZETIA-00260790	HS; HWH

May Offer Exhibits Profferred by the Purchasers to Which the Defendants Have Advanced Objections

Preliminary ID	Date	Description	Begin Bates	End Bates	Objection(s)
PX1819	04/02/2023	Rule 1006 Summary of End-Payor Plaintiff Class Purchases			1006; R; 403; 901; HS
PX1820	04/02/2023	Rule 1006 Summary, "Plaintiffs Bought 389 Million Zetia Tablets from Merck Between April 2015 - June 2018"			1006; R; 403; 901; HS
PX1821	02/03/2009	Letter from D. Tellekson, Darby & Darby, to Hon. Judge Esther Salas, USMJ, re Schering v. Glenmark (Ezetimibe Litigation), Civil Action No. 07-cv-1334	LWNSTNZETIA000006177	LWNSTNZETIA000006184	

EXHIBIT 6

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0001	MRKZETIA_SIDLEY000133625	MRKZETIA_SIDLEY000133698	1907	Staudinger, Hermann, *Berichte der deutschen chemischen Gesellschaft*, 1907, 356, 51-123		X	403; HWH; R
MDX0002	MRKZETIA_SIDLEY000149858	MRKZETIA_SIDLEY000149962	1952	Bray, H.G., James, S.P. et al., "The Metabolism of Ethers in the Rabbit" (1952) 547-551		X	403; R
MDX0003	No Bates	No Bates	1963	McGreer, D. E., and Mocek, M. M., "A Qualitative Approach to the Study of Complex NMR Spectra," *J Chem. Ed*. 1963, *40*, 358-361		X	403; R
MDX0004	MRKZETIA_SIDLEY000005893	MRKZETIA_SIDLEY000005895	1967	Franzen, V. Organic Synthesis Coll. Vol. 5, p 872; also can be found as Organic Syntheses Vol. 47, 1967, p 872		X	403; 901; R
MDX0005	No Bates	No Bates	1969	Jackman, L. M.; Sternhell, S., *Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry*. 2nd ed.; Pergamon Press: Oxford, 1969		X	403; R
MDX0006	MRKZETIA_SIDLEY000133269	MRKZETIA_SIDLEY000133272	1970	Oullette, R.J., Sinha B.K. et al., "Conformational Analysis. XIV. Conformations of Methyl-Ethyl-, and Isopropylarenes" Journal of the American Chemical Society (1970), 92, 7145-7148		X	403; HWH; R
MDX0007	No Bates	No Bates	1970	Patai, Saul, Chemistry of Functional Groups (1970)		X	403; HWH; R
MDX0009	No Bates	No Bates	1976	Larsen, D.; Shaw, E., Active-Site-Directed Alkylation of Chymotrypsin by Reagents Utilizing Various Departing Groups, *J. Med. Chem.* 1976, *19*, 1284-1286		X	403; R
MDX0010	No Bates	No Bates	1976	Rogers, G.A. et al., "Facile Alkylation of Methionine by Benzyl Bromide and Demonstration of Fumarase Inactivation Accompanied by Alkylation of a Methionine Residue," *J. Biol. Chem.*, 251(18):5711-5717 (1976)		X	403; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0011	No Bates	No Bates	1977	Brändström, A., Principles of Phase-Transfer Catalysis by Quaternary Ammonium Salts, Advances in Physical Organic Chemistry, 1977, 16, 267-330		X	403; R
MDX0012				WITHDRAWN			
MDX0013				WITHDRAWN			
MDX0014	No Bates	No Bates	12/16/1981	U.S. Patent Application 331,042		X	403; HWH; R
MDX0015				WITHDRAWN			
MDX0016	MRKZETIA_SIDLEY000161011	MRKZETIA_SIDLEY000161018	1986	Horita, K., Yoshoka, T. et al., "On The Selectivity of Deprotection of Benzyl, MPM (4-Methoxybenzyl) and DMPM (3,4-Dimethoxybenzyl) Protecting Groups for Hydroxy Functions" Tetrahedron Vol. 42 No. 11 (1986) 3021-3028		X	403; R
MDX0017	No Bates	No Bates	1986	Paradisi *et al.*, Selective Acylations of Aminophenols and Hydroxyalkylphenols With 1-Acetyl-v-Triazolo/4, 5-b/Pyridine, *Tetrahedron Letters*, 1986, *27*, 5029-5032		X	403; 901; R
MDX0018	No Bates	No Bates	12/2/1986	U.S. Patent 4,626,549		X	403; R
MDX0019	No Bates	No Bates	1988	Kahn, Alfred E., Economic Principles of Rate Making - Marginal Cost Pricing, The Economics of Regulation - Principles and Institutions (1988), 83-86		X	403; HWH; MIL; R
MDX0020	MRKZETIA_SIDLEY000240072	MRKZETIA_SIDLEY000240190	4/28/1988	Memo from Drs. Haslanger & Sybertz to Distribution re "Semi-Annual Report - Cardiovascular New Drug Discovery" and enclosing "Spring 1988 Cardiovascular New Drug Discovery Semi-Annual Report"		X	403; R
MDX0021	MRKZETIA_SIDLEY000130920	MRKZETIA_SIDLEY000130930	1989	Breen, P.J., Bernstein, E.R. et al., "Spectroscopic Observation and Geometry Assignment of the Minimum Energy Conformations of Methoxy-Substituted Benzenes" J. Chem. Soc. (1989), 1958-1968		X	403; R
MDX0022	No Bates	No Bates	2/21/1989	Bonito Boats v. Thunder Craft Boats Opinion		X	403; HWH; R
MDX0023	MRKZETIA_SIDLEY000274551	MRKZETIA_SIDLEY000274564	4/17/1989	Semi-Annual Report Atherosclerosis, "Acyl-CoA: Cholesterol Acyl Transferase Inhibition," D. Burnett and M. Caplen		X	403; R
MDX0024	MRKZETIA_SIDLEY000279942	MRKZETIA_SIDLEY000279949	10/16/1989	Semi-Annual Report Atherosclerosis, "Acyl-CoA: Cholesterol Acyl Transferase Inhibition," from D. Burnett and M. Caplen		X	403; 901; R
MDX0025	MRKZETIA_SIDLEY000005838	MRKZETIA_SIDLEY000005847	1990	Carey, F.A. and Sundber, R.J. *Advanced Organic Chemistry Part B: Reactions and Synthesis*, 3rd Ed., Plenum Press, New York, 1990, pp 615-623		X	403; R
MDX0026	MRKZETIA_SIDLEY000026599	MRKZETIA_SIDLEY000026604	8/22/1990	Goals Statement for D.. Burnett and M. Caplen		X	403; R
MDX0027	MRKZETIA_SIDLEY000264844	MRKZETIA_SIDLEY000264860	10/31/1990	Semi-Annual Report Atherosclerosis, "Acyl-CoA: Cholesterol Acyl Transferase Inhibition," D. Burnett and M. Caplen		X	403; R
MDX0028	MRKZETIA_SIDLEY000046601	MRKZETIA_SIDLEY000046604	1991	Georg, G.I., P. Mashava, "An Improved Method for the Stereoselective Synthesis of β-Lactams from Carboxylic Acids and Imines," Tetrahedron Letters, (1991), 32		X	403; R
MDX0029	MRKZETIA_SIDLEY000132700	MRKZETIA_SIDLEY000132742	1991	O'Brien, P.J. "Review Article - Molecular Mechanisms of Quinone Cytotoxitcity" Chem. Biol. Interactions, (1991) 80, 1-41		X	403; R
MDX0030	No Bates	No Bates	1991	Greene, T.W. and Wuts, P. *Protective Groups in Organic Synthesis*, 2d Ed. (1991), John Wiley & Sons, Inc.		X	403; HWH; R
MDX0031	No Bates	No Bates	1991	Caves, Richard E. et al., Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry, Brookings Papers: Microeconomics (1991), 1-66		X	403; HWH; R
MDX0032	MRKZETIA_SIDLEY000288709	MRKZETIA_SIDLEY000288723	5/1/1991	Semi-Annual Report from J. W. Clader and Martin Domalski		X	403; 901; R
MDX0034	MRKZETIA_SIDLEY000132120	MRKZETIA_SIDLEY000132152	6/11/1991	Schering Plough Transmittal Slip from N. Yumibe to Duane Burnett, with attachments		X	403; 901; HWH; R
MDX0035	MRKZETIA_SIDLEY000190849	MRKZETIA_SIDLEY000190881	6/11/1991	Transmittal Slip from N. Yumibe to D. Burnett transmitting notes and materials		X	403; 901; HWH; R
MDX0036	MRKZETIA_SIDLEY000241685	MRKZETIA_SIDLEY000241699	7/11/1991	Memo from Dr. N. Yumibe to Distribution re "SCH 47949 New Drug Discovery Memo" and enclosing D-25062 report, "SCH 47949: New Drug Discovery Exploratory Metabolism Studies"		X	403; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0037	No Bates	No Bates	7/23/1991	Public Patent Application Information Retrieval for U.S. Application No. 07/734,652 "Substituted Beta-lactam Compounds Useful as Hypocholesterolemic Agents"		X	403; 901; HS; R
MDX0038	MRKZETIA_SIDLEY000057077	MRKZETIA_SIDLEY000057086	10/7/1991	Memo from Dr. N. Yumibe, Schering-Plough to Distribution re "SCH 47949 New Drug Discovery Memo" enclosing report (D-25330), " SCH 47949: Identification of Plasma and Fecal Metabolites"		X	NO
MDX0039	MRKZETIA_SIDLEY000060253	MRKZETIA_SIDLEY000060266	10/31/1991	Semi-Annual Report from D. A. Burnett and M. A. Caplen, "Cholesterol Absorption Inhibitors"		X	901
MDX0040	MRKZETIA_SIDLEY000223248	MRKZETIA_SIDLEY000223267	11/1/1991	Semi-Annual Report, "Atherosclerosis: Acyl CoA: Cholesterol Acyl Transferase (ACAT) Inhibition and Cholesterol Absorption Inhibition," S. Dugar and J.R. Crouse		X	R
MDX0041	MRKZETIA_SIDLEY000343080	MRKZETIA_SIDLEY000343096	12/5/1991	Memo from J. Berger of Schering Plough to Dr. A. Ganguly re "Nomination of President Award 1991"		X	403; R
MDX0042	MRKZETIA_SIDLEY000149903	MRKZETIA_SIDLEY000149905	1992	Bunin, B.A. and Ellman, J.A. "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives" J. Am. Chem. Soc. (1992) 114, 10997-10998		X	403; R
MDX0043	MRKZETIA_SIDLEY000006229	MRKZETIA_SIDLEY000006304	1992	Georg, G.I. and Ravikumar, V.T. *Stereocontrolled Ketene-Imine Cycloaddition Reactions* in "The Organic Chemistry of β-Lactams," Georg, G.I., Ed.; VCH Publishers: New York, 1992; pp 295-368		X	403; R
MDX0044	MRKZETIA_SIDLEY000007422	MRKZETIA_SIDLEY000007430	1992	Srivastava, Vandana et al., Convenient and Selective Acetylations of Phenols, Amines and Alcohols, *Synthetic Comm.*, 1992, *22*, 2703- 2710		X	403; R
MDX0045	MRKZETIA_SIDLEY000063450	MRKZETIA_SIDLEY000063457	4/2/1992	Letter from D. N. Yumibe, Schering-Plough Research Institute Distribution re " SCH 48461 Drug Discovery Support Study Report" enclosing report (D-25755), "SCH 48461 / 48462 Comparative In Vitro Metabolism Studies"		X	403; R
MDX0046	MRKZETIA_SIDLEY000239966	MRKZETIA_SIDLEY000239968	4/21/1992	Consultation with Professor Barton, "Cholesterol Absorption Inhibition Program"		X	403; R
MDX0047	MRKZETIA_SIDLEY000134236	MRKZETIA_SIDLEY000134249	5/1/1992	Semi-Annual Report by Duane A. Burnett and Mary An Caplen re "Atherosclerosis"		X	403; R
MDX0050	MRKZETIA000675719	MRKZETIA000675719	9/16/1992	Memo from Dr. Harry R. Davis, Schering-Plough Research Institute to Distribution re "D-Report 26075" enclosing report (D-26075): "SCH 48461: Hypercholesterolemic Rhesus and Cynomolgus Monkeys"		X	NO
MDX0051	MRKZETIA_SIDLEY000365722	MRKZETIA_SIDLEY000365731	10/19/1992	Memo from Dr. N. Yumibe, Schering-Plough Research Institute to Distribution re "SCH 48461 Drug Discovery Report," enclosing report (D-26133): "SCH 48461/48462: Comparative In Vivo Metabolism Studies"		X	403; R
MDX0052	MRKZETIA_SIDLEY000134266	MRKZETIA_SIDLEY000134282	11/18/1992	Semi-Annual Report by Duane A. Burnett and Mary Ann Caplen re "Atherosclerosis (CAI)"		X	403; R
MDX0053	MRKZETIA_SIDLEY000134315	MRKZETIA_SIDLEY000134334	11/23/1992	Semi-Annual Report by Sundeep Dugar and J. R. Crouse re "Atherosclerosis: Cholesterol Absorption Inhibition (CAI)		X	403; R
MDX0054	MRKZETIA_SIDLEY000225951	MRKZETIA_SIDLEY000225968	12/1992	Semi-Annual Report, "CV - Atherosclerosis: Cholesterol Absorption Inhibition Program," December 1992-June 1993, S. Rosenblum and T. Huynli with handwritten notes		X	403; 901; HWH; R
MDX0056	MRKZETIA_SIDLEY000132752	MRKZETIA_SIDLEY000133180	2/23/1993	Schering-Plough Report D-25995 Report, "SCHE 48461: Absorption, Pharmacokinectics, Metabolism and Excretion of C-SCH 48461 Following a Single Oral or Intravenous dose to the Male Albino Rat"		X	403; R
MDX0057	MRKZETIA_SIDLEY000365733	MRKZETIA_SIDLEY000365743	3/31/1993	Memo from Dr. N. Yumibe, Schering-Plough Research Institute to Distribution re "SCH 48461 Drug Discovery Report," enclosing report (D-26346): "SCH 48461/48462: Rat In Vitro Intestinal Metabolism"		X	403; R
MDX0058	MRKZETIA_SIDLEY000281922	MRKZETIA_SIDLEY000281947	7/1993	July 1993 – December 1993 Semi-Annual Chemical Research Progress Report from Stuart Rosenblum and Tram Huynh, "CV-Atherosclerosis: Cholesterol Absorption Inhibition Program"		X	NO
MDX0059	MRKZETIA_SIDLEY000365383	MRKZETIA_SIDLEY000365398	7/7/1993	Memo from Dr. N. Yumibe, Schering-Plough Research Institute to Distribution re "SCH 48461 Drug Discovery Report," enclosing report (D-26428): "SCH 48461: Human In Vitro Metabolism Studies"		X	403; R
MDX0060	MRKZETIA_SIDLEY000197400	MRKZETIA_SIDLEY000197400	7/8/1993	Davis Testing of Compounds 4A-4D (PX 0274)		X	403; 901; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0061	MRKZETIA_SIDLEY000062985	MRKZETIA_SIDLEY000062994	8/9/1993	Memo from K. Alton, Schering-Plough to Distribution re "SCH 48461 Drug Metabolism Report" enclosing report (D-26435), " SCH 48461: A Pilot Single Dose Bioavailability and Metabolism Study in the Beagle Dog"		X	NO
MDX0062	MRKZETIA_SIDLEY000278235	MRKZETIA_SIDLEY000278689	8/10/1993	Semi-Annual Report re CV Pharmacology Drug Discovery from Ed Sybertz		X	403; 901; R
MDX0063	MRKZETIA_SIDLEY000199863	MRKZETIA_SIDLEY000199873	9/9/1993	CAI Effort Status Report 9,3,93 from S. Rosenblum and T. Huynh re SCH 48461 Metabolism		X	901
MDX0064	MRKZETIA_SIDLEY000130136	MRKZETIA_SIDLEY000130192	9/21/1993	Glenmark Pharm. - Section F: Production of Ezetimibe - Part 2. Production Flow Sheet		X	HS; INC
MDX0065	MRKZETIA_SIDLEY000044149	MRKZETIA_SIDLEY000044162	10/11/1993	Memo from Dr. N. Yumibe of Schering Plough to Distribution re "SCH 48461 Drug Discovery Report" attaching Schering Report No. D-26525, "SCH 48461: Biliary Metabolites in the Beagle Dog"		X	NO
MDX0066	MRKZETIA000681511	MRKZETIA000681511	10/11/1993	Memo from Dr. N. Yumibe, Schering-Plough Research Institute to Distribution re "SCH 48461 Drug Discovery Report," enclosing report (D-26525): "SCH 48461: Billary Metabolites in the Beagle Dog"		X	NO
MDX0067	MRKZETIA_SIDLEY000222939	MRKZETIA_SIDLEY000222954.	10/18/1993	CAI Project Report for AKG Staff Meeting		X	R
MDX0068	MRKZETIA_SIDLEY000190828	MRKZETIA_SIDLEY000190830	11/1/1993	Proton NMR Spectra for 60-1 and 60-3 Samples and HPLC for 60-1		X	403; 901; R
MDX0069	MRKZETIA_SIDLEY000183375	MRKZETIA_SIDLEY000183385	11/9/1993	Atherosclerosis (CAI) Project Update, Professor D. Barton's Consulting Session, S. Roseblum and T. Huynh		X	403; 901; R
MDX0070	GLENMARK-ZETIA-00134013	GLENMARK-ZETIA-00134017	11/18/1993	Chromatograms		X	403; R
MDX0071	MRKZETIA_SIDLEY000060825	MRKZETIA_SIDLEY000060835	12/1/1993	Semiannual Chemistry Report, A. Afonso		X	403; 901; R
MDX0073	MRKZETIA_SIDLEY000133735	MRKZETIA_SIDLEY000133740	1994	Schafer, T., Chan, W.K. et al., "Concerning the internal rotational barrier and the experimental and theoretical n J (13C,13C) and nJ (1H,13C) in ethylbenzene-J3-13C" Can. J. Chem. Vol 72 (1994) 1972-1977		X	403; R
MDX0074	No Bates	No Bates	3/23/1994	Merck & Co., Inc. 1993 Form-10-K		X	403; HS; MIL; R
MDX0075	MRKZETIA_SIDLEY000033684	MRKZETIA_SIDLEY000033698	5/5/1994	Memo from Dr. N. Yumibe, Schering-Plough Research Institute to Distribution re "SCH 48461 Drug Discovery Report," enclosing report (D-26684): "SCH 48461: Billary Metabolites in the Cynomolgus Monkey"		X	NO
MDX0076	MRKZETIA_SIDLEY000365417	MRKZETIA_SIDLEY000365425	5/5/1994	Memo from Dr. N. Yumibe, Schering-Plough Research Institute to Distribution re "SCH 48461 Drug Discovery Report," enclosing report (D-26735): "SCH 48461: Intestinal Metabolism and Portal Vein Uptake in the Rat"		X	403; 901; R
MDX0077	MRKZETIA_SIDLEY000222089	MRKZETIA_SIDLEY000222118	6/1/1994	June 1994 – December 1994 Semi-Annual Progress Report from Stuart Rosenblum and Tram Huynh		X	R
MDX0078	No Bates	No Bates	6/10/1994	Duane Burnett et al., Azetidinones as Inhibitors of Cholesterol Absorption, Journal of Medicinal Chemistry, 37(12)		X	403; MIL; R
MDX0079	No Bates	No Bates	6/10/1994	Merck & Co., Inc. 1993 Amended-Form-10-KA		X	403; HS; MIL; R
MDX0080	MRKZETIA_SIDLEY000283115	MRKZETIA_SIDLEY000283119	6/15/1994	Semi-Annual Chemistry Report Cardiovascular from A. Afonso, " Cholesterol Absorption Inhibition (CM) Project"		X	NO
MDX0081	MRKZETIA_SIDLEY000003393	MRKZETIA_SIDLEY000003456	9/14/1994	International Patent Application No. PCT/US94/10099, International Publication No. WO 95/08532		X	403; R
MDX0082	No Bates	No Bates	9/14/1994	PCT Application No. PCT/US94/10099		X	403; R
MDX0083	MRKZETIA_SIDLEY000180333	MRKZETIA_SIDLEY000180348	11/7/1994	SCH 58235: CAI Program Consulting Session with Professor D. Barton - SCH 58235 Update		X	403; 901; R
MDX0084	MRKZETIA_SIDLEY000224626	MRKZETIA_SIDLEY000224668	11/9/1994	Draft Report for SCH 58235 Update		X	403; 901; R
MDX0085	MRKZETIA_SIDLEY000052822	MRKZETIA_SIDLEY000052882	12/15/1994	SCH - 58235: CAI Program - SCH - 58235 Update		X	403; R
MDX0086	MRKZETIA_SIDLEY000132426	MRKZETIA_SIDLEY000132430	1995	Jambhekar, S.S. "Chapter 3 - Biopharmaceutical Properties of Drug Substances" (1995) 12, 19-21		X	403; R
MDX0087	MRKZETIA_SIDLEY000133892	MRKZETIA_SIDLEY000133931	1995	Terrett, N., Gardner, M. et al., "Combinatorial Synthesis - The Design of Compound Libraries and their Application to Drug Discovery" Tetrahedron Vol 51 (1995) 8135-8173		X	403; R
MDX0088	No Bates	No Bates	1995	Rosenblum, Stuart B., et al., Abstract, Discovery of SCH 58235: A Potent Orally Active Inhibitor of Cholesterol Absorption, 61 (1995)		X	403; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0089	MRKZETIA_SIDLEY000034517	MRKZETIA_SIDLEY000034795	1/3/1995	Notebook titled "SCH 48461 - IND 42,075 Cholesterol Absorption Inhibitor Capsules"		X	403; R
MDX0091	No Bates	No Bates	3/22/1995	Merck & Co., Inc. 1994 Form-10-K		X	403; HS; MIL; R
MDX0092	No Bates	No Bates	1995	Berndt, Ernst R. et al., Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market, The American Economic Review (1995), Vol. 85, No. 2, 100-105		X	403; MIL; R
MDX0093	No Bates	No Bates	6/1/1995	Grabowski, Henry et al., Longer Patents for Increased Generic Competition: The Waxman-Hatch Act After One Decade, Duke Economics Working Paper #95-11, SSRN: https://ssrn.com/abstract=40940 or http://dx.doi.org/10.2139/ssrn.40940		X	403; 901; R
MDX0094	No Bates	No Bates	1996	Dugar, Sundeep et al., Metabolism and Structure Activity Data Based Drug Design: Discovery of (-) SCH 53079, an Analog of the Potent Cholesterol Absorption Inhibitor (-) SCH 48461, Biorganic and Medicinal Chemistry Letters, Vol. 6, No. 11, pp. 1271-1274, 1996		X	403; R
MDX0095	No Bates	No Bates	1996	Berndt, Ernst R. et al., The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the U.S. Antiulcer Drug Industry, The National Bureau of Economic Research (1996), Ch. 7, 277-328		X	NO
MDX0097	No Bates	No Bates	3/20/1996	Merck & Co., Inc. 1995-Form-10-K		X	403; HS; MIL; R
MDX0098	No Bates	No Bates	6/7/1996	Clader, John W., et al., 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus, J. Med. Chem. 1996, 39, 3684-3693		X	403; R
MDX0099	No Bates	No Bates	6/24/1996	Merck & Co., Inc. 1995-Amended-Form-10-KA		X	403; HS; MIL; R
MDX0100	USPTO-ZETIA-0052278	USPTO-ZETIA-0052279	6/24/1996	Preliminary Amendment, In re Application of Stuart Rosenblum et al., Patent Hydroxy-Substituted Azetidinone Compounds Useful as Hypocholesterolemic Agents		X	901
MDX0101				WITHDRAWN			
MDX0102	MRKZETIA_SIDLEY000133258	MRKZETIA_SIDLEY000133264	1997	Salamme, F. R., Spurlino, J. et al., "Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery" Structure (1997) Vol. 5 No. 3 319-324		X	403; R
MDX0103	No Bates	No Bates	1997	1997 Handbook Of Phase Transfer Catalysis		X	403; R
MDX0104	No Bates	No Bates	1997	Richard G. Frank & David S. Salkever, *Generic Entry and the Pricing of Pharmaceuticals*, 6 J. Econ. & Mgmt. Strategy 75 (1997)		X	NO
MDX0105	No Bates	No Bates	1997	Ellison, Sara Fisher et al., Characteristics of demand for pharmaceutical products: an examination of four cephalosporins, RAND Journal of Economics (1997) Vol. 28, No. 3, 426-446		X	403; MIL; R
MDX0106	USPTO-ZETIA-0052283	USPTO-ZETIA-0052287	2/3/1997	USPTO communication to Schering Plough Corp. re Office Action Summary, Application Number 08/617,751		X	403; R
MDX0107	USPTO-ZETIA-0023711	USPTO-ZETIA-0023715	2/27/1997	Declaration of H. Davis Under 37 C.F.R. 132, In re Application of Stuart Rosenblum et al., Patent Hydroxy-Subsituted Azetidinone Compounds Useful as Hypocholesterolemic Agents		X	403; R
MDX0108	No Bates	No Bates	3/19/1997	Merck & Co., Inc. 1996-Form-10-K		X	403; HS; MIL; R
MDX0110	USPTO-ZETIA-0052288	USPTO-ZETIA-0052291	6/6/1997	Amendments, In re Application of Stuart Rosenblum et al., Patent Hydroxy-Substituted Azetidinone Compounds Useful as Hypocholesterolemic Agents		X	HS
MDX0111	No Bates	No Bates	6/16/1997	Merck & Co., Inc. 1996-Amended-Form-10-KA		X	403; HS; MIL; R
MDX0112	No Bates	No Bates	6/30/1997	Van Heek, Margaret et al., In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the Identification of the Active Metabolites of SCH 48461, The Journal of Pharmacology and Experimental Therapeutics, Vol. 283, No. 1		X	403; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0113	USPTO-ZETIA-0052292	USPTO-ZETIA-0052293	7/28/1997	USPTO communication to Schering Plough Corp. re Office Action Summary, Application Number 08/617,751		X	403; R
MDX0114	No Bates	No Bates	10/16/1997	Stuart Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, J. Med. Chem. 1998. 41, 973-980 (Oct. 16, 1997)		X	403; R
MDX0115	MRKZETIA_SIDLEY000007269	MRKZETIA_SIDLEY000007276	1998	Rosenblum, Stuart, et al., "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption"		X	403; HS; R
MDX0116	MRKZETIA_SIDLEY000132438	MRKZETIA_SIDLEY000132449	1998	Kubinyi, H. "Structure-based design of enzyme inhibitors and receptor ligands" Current Opinion in Drug Discovery and Development (1998) Vol.1, No. 1, 4-15		X	403; HS; R
MDX0117	No Bates	No Bates	1998	Gregory J. Werden, *Demand Elasticities in Antitrust Analysis*, 66 Antitrust L. J. 363 (1998)		X	403; HS; MIL; R
MDX0118	USPTO-ZETIA-0023702	USPTO-ZETIA-0023710	3/19/1998	Preliminary Amendment, In re Application of Stuart Rosenblum et al.		X	403; HS; R
MDX0119	No Bates	No Bates	3/25/1998	Merck & Co., Inc. 1997-Form-10-K		X	403; HS; MIL; R
MDX0120	MRKZETIA_SIDLEY000006573	MRKZETIA_SIDLEY000006591	5/14/1998	Kalgutkar, Amit et al., Covalent Modification of Cyclooxygensase-2 (COX-2 by 2-Acetocyphenyl Alkyl Sulfides, a New Class of Selective COX-2 Inactivators, J. Med. Chem. 1998, 41, 4800-4818		X	403; HS; R
MDX0121	No Bates	No Bates	6/16/1998	U.S. Patent 5,767,126		X	403; R
MDX0123	No Bates	No Bates	6/24/1998	Merck & Co., Inc. 1997-Amended-Form-10-KA		X	403; HS; MIL; R
MDX0125	No Bates	No Bates	7/7/1998	U.S. Patent 5,776,943		X	403; R
MDX0126	MRKZETIA_SIDLEY000335600	MRKZETIA_SIDLEY000335604	8/26/1998	SCH 58235 Capsules, Controlled Clinical Study, Protocol Nos: C96-411 and C96-345, "Pilot Dose-Ranging Study of the Safety and Efficacy of SCH 58235 Compared to Placebo and Lovastatin in Patients with Primary Hypercholesterolemia"		X	403; HS; MIL; R
MDX0127	No Bates	No Bates	3/24/1999	Merck & Co., Inc. 1998-Form-10-K		X	403; HS; MIL; R
MDX0128	No Bates	No Bates	6/11/1999	Merck & Co., Inc. 1998-Amended-Form-10-KA		X	403; HS; MIL; R
MDX0129	MRKZETIA000365285	MRKZETIA000365286	9/8/1999	Fax Cover Sheet from D. Auth to K. Goldman transmitting document titled, "Questions for Anita Magatti)		X	403; HS; R
MDX0130	No Bates	No Bates	2000	O'Donnell, Asymmetric Phase-Transfer Reactions, 2000 - Catalytic Asymmetric Synthesis, Second Edition		X	403; HS; R
MDX0131	No Bates	No Bates	2000	Wang, Zhiqiang *et al.*, Synthesis of B-Ring Homologated Estradiol Analogues that Modulate Tubulin Polymerization and Microtubule Stability, *J. Med. Chem.* 2000, *43*, 2419-2429		X	403; HS; R
MDX0132	No Bates	No Bates	2000	Church, Jeffrey R. et al., Industrial Organization: A Strategic Approach, (2000) 1-960		X	403; HS; MIL; R
MDX0133	No Bates	No Bates	2000	Article titled, "The Pharmaceutical Industry"		X	403; HS; MIL; R
MDX0134	No Bates	No Bates	1/2/2000	Article titled, "Effective patent life in pharmaceuticals"		X	403; HS; R
MDX0135	No Bates	No Bates	3/22/2000	Merck & Co., Inc. 1999-Form-10-K		X	403; HS; MIL; R
MDX0136	No Bates	No Bates	4/27/2000	"Glenmark Gets First Nod for Zetia Generic" The Economic Times		X	403; HS; R
MDX0137	No Bates	No Bates	5/3/2000	FDA Letter Niacor Approval		X	403; MIL; R
MDX0138	USPTO-ZETIA-0000106	USPTO-ZETIA-0000111	6/4/2000	USPTO Docket No. 2976-4032 - Box Reissue Application U.S. Patent No. 5,767,115, "Reissue Application Declaration of Designee"		X	HS
MDX0139	USPTO-ZETIA-0000052	USPTO-ZETIA-0001327	6/15/2000	Application No. 09/594,996		X	HS
MDX0140	USPTO-ZETIA-0000524	USPTO-ZETIA-0000527	6/15/2000	USPTO Docket No. 2976-4032 - Box Reissue Application U.S. Patent No. 5,767,115, "Preliminary Remarks"		X	HS
MDX0141	No Bates	No Bates	6/27/2000	Merck & Co., Inc. 1999-Amended-Form-10-KA		X	403; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0142				WITHDRAWN			
MDX0143	USPTO-ZETIA-0000885	USPTO-ZETIA-0000888	3/12/2001	Communication from USPTO to Morgan & Finnegan transmitting Office Action Summary re Application No. 09/594,996		X	HS
MDX0144	No Bates	No Bates	3/23/2001	Merck & Co., Inc. 2000-Form-10-K		X	403; HS; MIL; R
MDX0145				WITHDRAWN			
MDX0146				WITHDRAWN			
MDX0147	No Bates	No Bates	6/20/2001	Merck & Co., Inc. 2000-Amended-Form-10-KA		X	403; HS; MIL; R
MDX0148	No Bates	No Bates	9/1/2001	ATSDR Public Health Statement, 1 2 Dichloroethane		X	403; HS; MIL; R
MDX0149				WITHDRAWN			
MDX0150	No Bates	No Bates	2002	Gange, Claude et al., Efficacy and Safety of Ezetimibe Added to Ongoing Statin Therapy for Treatment of Patients with Primary Hypercholesterolemia, The American Journal of Cardiology (2002), Vol. 90, 1084-1091		X	403; HS; MIL; R
MDX0151	No Bates	No Bates	3/21/2002	Merck & Co., Inc. 2001-Form-10-K		X	403; HS; MIL; R
MDX0152	No Bates	No Bates	4/16/2002	U.S. Patent 6,372,756		X	403; R
MDX0153	MRKZETIA_SIDLEY000611392	MRKZETIA_SIDLEY000611555	5/1/2002	SCH 58235 Investigator's Brochure, "Information for the Investigational Product MK-653/SCH 58235 Ezetimibe"		X	403; HS; MIL; R
MDX0156	No Bates	No Bates	6/26/2002	FDA Letter - Altoprev Approval		X	403; MIL; R
MDX0158				WITHDRAWN			
MDX0159	No Bates	No Bates	9/24/2002	U.S. Patent 6,455,572		X	403; R
MDX0161	No Bates	No Bates	10/15/2002	U.S. Patent 6,465,490		X	403; HS; R
MDX0162	MRKZETIA_SIDLEY000144929	MRKZETIA_SIDLEY000144962	10/25/2002	Merck/Schering Plough Pharmaceuticals News Release, "FDA Approves Zetia (ezetimibe) for Cholesterol Reduction First New Class to Treat Cholesterol Since Statins Introduced 15 Years Ago; Studies Show Significant Reductions in LDL Cholesterol when Added to All Statins Tested"		X	403; HS; MIL; R
MDX0163	No Bates	No Bates	10/25/2002	FDA Letter - Zetia Approval		X	NO
MDX0164	No Bates	No Bates	10/25/2002	Letter from R. Meyer to J. Lamendola re approval of Application No. 21-445		X	NO
MDX0166	USPTO-ZETIA-0001160	USPTO-ZETIA-0001161	12/12/2002	USPTO Declaration and Power of Attorney by Official for Assignee re Stuart Rosenblum et al., US 5,767,115		X	403; HS; R
MDX0167	USPTO-ZETIA-0001164	USPTO-ZETIA-0001195	12/12/2002	Letter of Transmittal of Application for Extension of Patent Term, In re: U.S. Patent No. Re37, 721		X	403; HS; R
MDX0168				WITHDRAWN			
MDX0169	No Bates	No Bates	2003	Gilbert, Jim et al., Rebuilding Big Pharma's Business Model, Invivo The Business & Medicine Report (2003), Vol 21, No. 10		X	403; 901; HS; MIL; R
MDX0170	No Bates	No Bates	2003	Merck &B Co. 2003 Annual Report		X	403; HS; MIL; R
MDX0171				WITHDRAWN			
MDX0172	No Bates	No Bates	2003	Ernst, Berndt R. et al., The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches, National Bureau of Economic Research (2003), Ch. 8, 229-273		X	NO
MDX0173				WITHDRAWN			
MDX0174	USPTO-ZETIA-0001311	USPTO-ZETIA-0001311	1/3/2003	Letter from USPTO to David T. Read of FDA re Application for Patent Term Extension of U.S. Patent No. Re37, 721		X	HS
MDX0175	No Bates	No Bates	3/21/2003	Merck & Co., Inc. 2002-Form-10-K		X	403; HS; MIL; R
MDX0176				WITHDRAWN			
MDX0177				WITHDRAWN			
MDX0178				WITHDRAWN			
MDX0179	GLENMARK-ZETIA-00265486	GLENMARK-ZETIA-00265486	9/27/2003	Letter from Glenmark to FDA re response to the August 15, 2013 DMF Information Request		X	HS

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0180	No Bates	No Bates	2/26/2004	Schering-Plough Corp. 2003 FORM 10-K		X	403; HS; MIL; R
MDX0181	No Bates	No Bates	12/31/2003	Merck & Co., Inc. Annual Report 2003		X	403; HS; MIL; R
MDX0182	MRKZETIA_SIDLEY000130874	MRKZETIA_SIDLEY000130881	2004	Altmann, Scott et al., Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption, *Science* 303(5661):1201-1204 (2004)		X	403; HS; MIL; R
MDX0183	MRKZETIA_SIDLEY000131250	MRKZETIA_SIDLEY000131264	2004	Burnett, D.A. " B-Lactam Cholesterol Absorption Inhibitors" Current Medical Chemistry (2004) 1873-1887		X	403; HS; MIL; R
MDX0184	MRKZETIA_SIDLEY000148636	MRKZETIA_SIDLEY000148677	2004	Silverman, R.B "The Organic Chemistry of Drug Design and Drug Action Second Edition"		X	403; HS; R
MDX0185	MRKZETIA_SIDLEY000153803	MRKZETIA_SIDLEY000153812	2004	Clader, J.W., The Discovery of Ezetimibe: A View from Outside the Receptor, Journal of Medicinal Chemistry Vol 47 No. 1 (2004) 1-9		X	403; HS; R
MDX0186	MRKZETIA_SIDLEY000153804	MRKZETIA_SIDLEY000153812	1/1/2004	John Clader, The Discovery of Ezetimibe: A View from Outside the Receptor, Journal of Medicinal Chemistry, Vol. 47, No. 1		X	403; HS; R
MDX0187				WITHDRAWN			
MDX0188	No Bates	No Bates	1/1/2004	Clader, John W. , The Discovery of Ezetimibe: A View from Outside the Receptor, 47 J. Med. Chem. 1 (2004)		X	403; HS; R
MDX0189	No Bates	No Bates	2004	Silverman, Richard B., The Organic Chemistry of Drug Design and Drug Action, 2nd Edition (Elsevier, 2004)		X	403; HS; R
MDX0190	No Bates	No Bates	2004	Article titled, "Efficiency Trade-offs in Patent Litigation Settlements: Analysis Gone Astray?"		X	403; HS; MIL; R
MDX0191	No Bates	No Bates	2004	Article titled, "Settling the Controversy Over Patent Settlements: Payments by the Patent Holder Should Be Per Say Illegal"		X	403; HS; MIL; R
MDX0192	No Bates	No Bates	2004	Willig, Robert D. et al., Antitrust policy toward agreements that settle patent litigation, The Antitrust Bulletin (2014), 655-698		X	403; HS; MIL; R
MDX0193				WITHDRAWN			
MDX0194	No Bates	No Bates	3/10/2004	Merck & Co., Inc. 2003-Form-10-K		X	403; HS; MIL; R
MDX0195	No Bates	No Bates	4/29/2004	Schering-Plough Corp. 2003-Amended-Form-10-KA		X	403; HS; MIL; R
MDX0196				WITHDRAWN			
MDX0197				WITHDRAWN			
MDX0198	MRKZETIA000604071	MRKZETIA000604074	7/23/2004	Facsimile transmittal from M. Johnson of FDA to D. Louie of Singapore Co. re "Vytorin, NDA 21-687 Action Letter"		X	403; MIL; R
MDX0199	No Bates	No Bates	7/23/2004	FDA Letter - Vytorin Approval		X	403; MIL; R
MDX0200				WITHDRAWN			
MDX0201	No Bates	No Bates	3/31/2005	Schering-Plough Corp. FORM 10-K/A		X	403; 901; HS; MIL; R
MDX0202	MRKZETIA_R000062457	MRKZETIA_R000062466	2005	Document titled "Merck/Schering Plough Cholesterol Partnership 2005 Combined Financial Statement"		X	403; 901; HS; INC; MIL; R
MDX0203	MRKZETIA_SIDLEY000122888	MRKZETIA_SIDLEY000122925	2005	Wilson, Don et al. Mammal Species of the World A Taxonomic and Geographic Reference, 3rd Ed., Vol. 1		X	403; INC; R
MDX0204	MRKZETIA_SIDLEY000131406	MRKZETIA_SIDLEY000131420	2005	Clader, J. W. "Ezetimibe and other Azetidinone Cholesterol Absorption Inhibitors" Current Tropics in Medicinal Chemistry (2005), Vol. 5, 243-256		X	403; R
MDX0205				WITHDRAWN			
MDX0206				WITHDRAWN			
MDX0207				WITHDRAWN			
MDX0208	No Bates	No Bates	2005	Article titled, "Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain", Prepared for the Kaiser Family Foundation by The Health Strategies Consultancy LLC (2005)		X	403; MIL; R
MDX0209	No Bates	No Bates	3/11/2005	Merck & Co., Inc. 2004-Form-10-K		X	403; HS; MIL; R
MDX0210	No Bates	No Bates	3/31/2005	Schering-Plough Corp. 2004-Amended-Form-10-KA		X	403; HS; MIL; R
MDX0211				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0212				WITHDRAWN			
MDX0213	No Bates	No Bates	5/12/2005	Article titled, "Health Care and the FTC: The Agency as Prosecutor and Policy Wonk", FTC		X	403; 701; HS; R
MDX0215				WITHDRAWN			
MDX0217				WITHDRAWN			
MDX0218	No Bates	No Bates	2006	Donald Degnan and Libby Huskey, Inventorship: What Happens When You Don't Get It Right? AIPLA (2006)		X	403; 701; HS; R
MDX0219				WITHDRAWN			
MDX0220				WITHDRAWN			
MDX0223	MRKZETIA_R000068419	MRKZETIA_R000068428	2/28/2006	Document titled "Merck/Schering Plough Cholesterol Partnership 2005 Combined Financial Statement"		X	403; 901; INC; MIL; R
MDX0224	No Bates	No Bates	3/13/2006	Merck & Co., Inc. 2005-Form-10-K		X	HS; MIL; R
MDX0225	MRKZETIA_SIDLEY000188229	MRKZETIA_SIDLEY000188230	4/5/2006	Email from D. Burnett to W. Greenlee "RE: Authors for ISMC2006 presentation" with CAI Contributors' List		X	HS; MIL; R
MDX0226	No Bates	No Bates	4/18/2006	U.S. Patent 7,030,106		X	403; MIL; R
MDX0227				WITHDRAWN			
MDX0228	No Bates	No Bates	5/6/2006	Pollack, Andrew, Lilly Loses Patent Case to Ariad, N.Y. Times		X	403; R
MDX0229	No Bates	No Bates	7/10/2006	Head of Eli Lilly's Legal Division Works to Protect Patented Drugs, Law.Com		X	403; HS; HWH; R
MDX0232	GLENMARK-ZETIA-00000827	GLENMARK-ZETIA-00001160	8/1/2006	Glenmark, "Ezetimibe Drug Master File Type II Original Submission (Volume 1 of 4)"		X	901; HS
MDX0233	GLENMARK-ZETIA-00001161	GLENMARK-ZETIA-00001466	8/1/2006	Glenmark, "Ezetimibe Drug Master File Type II Original Submission (Volume 2 of 4)"		X	901; HS
MDX0234	GLENMARK-ZETIA-00001467	GLENMARK-ZETIA-00001865	8/1/2006	Glenmark, "Ezetimibe Drug Master File Type II Original Submission (Volume 3 of 4)"		X	901; HS
MDX0235	GLENMARK-ZETIA-00001866	GLENMARK-ZETIA-00002087	8/1/2006	Glenmark, "Ezetimibe Drug Master File Type II Original Submission (Volume 4 of 4)"		X	901; HS
MDX0236	GLENMARK-ZETIA-00178557	GLENMARK-ZETIA-00178557	8/2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast August 2016 PC request.xlsx		X	NO
MDX0237	USPTO-ZETIA-0001321	USPTO-ZETIA-0001322	8/29/2006	Letter from USPTO to T. Hoffman of Schering Corp. re "Patent Term Extension Application for U.S. Patent No. Re. 37,721"		X	403; R
MDX0238	MRKZETIA_SIDLEY000017903	MRKZETIA_SIDLEY000017974	10/25/2006	Letter from Glenmark to FDA re Abbreviated New Drug Application		X	NO
MDX0239	MRKZETIA_SIDLEY000017704	MRKZETIA_SIDLEY000017705	10/25/2006	Letter from Glenmark to FDA re Abbreviated New Drug Application for for generic ezetimibe		X	NO
MDX0240	GLENMARK-ZETIA-00247054	GLENMARK-ZETIA-00247055	10/26/2006	Email from G. Patel to B. SivaKumar re "cost Comparison of Ezetimibe" with attachment		X	403; 901; INC; R
MDX0241	MRKZETIA_SIDLEY000026094	MRKZETIA_SIDLEY000026229	10/27/2006	PowerPoint Presentation titled "The Discovery of Zetia (Ezetimibe) A Novel Cholesterol Absorption Inhibitor"		X	403; MIL; R
MDX0242	Teva-Zetia_00000001	Teva-Zetia_00000156	12/26/2006	Letter from TEVA to FDA re ANDA		X	NO
MDX0243				WITHDRAWN			
MDX0244	No Bates	No Bates	2007	Reiffen, David et al., 'Branded Generics' as a Strategy to Limit Cannibalization of Pharmaceutical Markets, Manage. Decis. Econ. 28: 251–265 (2007)		X	NO
MDX0245	No Bates	No Bates	2007	Goldman, Dana P. et al., Prescription Drug Cost Sharing - Associations with Medication and Medical Utilization and Spending and Health, American Medical Association (2007) Vol. 298, No. 1, 61-E18		X	403; MIL; R
MDX0246	No Bates	No Bates	1/30/2007	Congressional Record - Senate, p. S1352		X	403; HS; MIL; R
MDX0247	No Bates	No Bates	1/30/2007	153 Cong. Rec. S. 1352		X	403; HS; MIL; R
MDX0249	MRKZETIA000663222	MRKZETIA000663222	2/1/2007	PowerPoint presentation titled, "Epocrates Handheld DocAlert Message"		X	403; R
MDX0251	MRKZETIA_SIDLEY000009235	MRKZETIA_SIDLEY000009262	2/8/2007	Letter from V. Soni of Glenmark Pharm. to A. Magatti, P. Kay-Mugford of Schering Corp re "Zetia (ezetimibe) Notice of Paragraph IV Certification U.S. Patent Nos. re 37,721, 5,846,966 and 7,030,106"		X	NO
MDX0252	MRKZETIA_R000113269	MRKZETIA_R000113278	2/27/2007	Document titled "Merck/Schering Plough Cholesterol Partnership 2006 Combined Financial Statement"		X	403; 901; INC; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0253	No Bates	No Bates	2/28/2007	Merck & Co., Inc. 2006-Form-10-K		X	901; HS; MIL; R
MDX0254	MRKZETIA_SIDLEY000000027	MRKZETIA_SIDLEY000000058	3/22/2007	Complaint, Schering Corp. et al., v. Glenmark Pharm. Inc. et al., Case No. 2:07-cv-01334 (JLL), ECF No. 1		X	NO
MDX0255	GLENMARK-ZETIA-00175864	GLENMARK-ZETIA-00175867	3/27/2007	Email from W. McIntyre to Z. Sihorwala "RE: Ezetimibe"		X	HS; HWH
MDX0256	GLENMARK-ZETIA-00041724	GLENMARK-ZETIA-00041725	5/3/2007	Letter from FDA to Glenmark re "DMF Deficiency, DMF #19717"		X	403; R
MDX0258	No Bates	No Bates	6/1/2007	Zetia Label		X	NO
MDX0259				WITHDRAWN			
MDX0260				WITHDRAWN			
MDX0261	Teva-Zetia_00001054	Teva-Zetia_00001068	9/14/2007	Letter from TEVA to FDA re patent amendment		X	403; HS; R
MDX0263	GLENMARK-ZETIA-00271247	GLENMARK-ZETIA-00271250	10/16/2007	Email from S. Krishan to T. Coughlin et al. re "RE: Ezetimibe"		X	403; HS; HWH; R
MDX0264	GLENMARK-ZETIA-00220774	GLENMARK-ZETIA-00220774	12/12/2007	Email from V. Soni to S. Krishan re "FW: Ezetimibe"		X	HS; HWH
MDX0265	MRKZETIA_SIDLEY000133840	MRKZETIA_SIDLEY000133845	2008	Tidwell, Thomas, Hugo (Ugo) Schiff, Schiff Bases, and a Century of β-Lactam Synthesis, Angewandte Chemie, 2008, 47, 1016-1020		X	403; R
MDX0266				WITHDRAWN			
MDX0267	No Bates	No Bates	2008	Article titled, "Pharmaceutical Pricing Policies in a Global Market", OECD Health Policy Studies		X	403; HS; HWH; MIL; R
MDX0268	GLENMARK-ZETIA-00228886	GLENMARK-ZETIA-00228886	1/24/2008	Email from T. Coughlin to V. Soni re "Fw: MSN"		X	NO
MDX0269	GLENMARK-ZETIA-00270705	GLENMARK-ZETIA-00270707	2/7/2008	Email from T. Coughlin to V. Soni re "FW: Ezetimibe"		X	HS; R
MDX0270	MRKZETIA000584034	MRKZETIA000584035	2/14/2008	Facsimile transmittal from M. Simoneau of FDA to P. Kay-Mugford of MSP Singapore Company re "Pediatric Exclusivity" with attachment		X	NO
MDX0271	MRKZETIA_R000113279	MRKZETIA_R000113289	2/27/2008	Document titled "Merck/Schering Plough Cholesterol Partnership 2007 Combined Financial Statement"		X	403; 901; INC; MIL; R
MDX0272	No Bates	No Bates	2/28/2008	Merck & Co., Inc. 2007-Form-10-K		X	901; HS; R
MDX0273	No Bates	No Bates	2008	Gonzalez, Jorge et al., Can Branded Drugs Benefit from Generic Entry? Switching to Non-Bioequivalent Molecules and the Role of Physician Response to Detailing and Prices, Abstract (2008)		X	403; 701; HS; R
MDX0274	MRKZETIA_SIDLEY000000948	MRKZETIA_SIDLEY000000991	3/10/2008	Glenmark Pharm. Inc. USA's First Amended Answer and Counterclaims, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-cv-01334 (JLL)		X	NO
MDX0275	GLENMARK-ZETIA-00162681	GLENMARK-ZETIA-00162681_0082	4/1/2008	Glenmark response re "F.D.A. Letter, Vilayat A. Sayeed, Ph.D. to PharmaQ Inc. (May 3, 2007)"		X	HS; MIL
MDX0276	MRKZETIA_SIDLEY000215608	MRKZETIA_SIDLEY000215608	4/2008	Excel spreadsheet with file name: Mylan129688 (Apr 2008) - Outside Attorneys_ Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0277	No Bates	No Bates	4/3/2008	Kastelein, John J.P. et al., Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia, The New England Journal of Medicine (2008), Vol. 358, No. 14, 1431 - 1443		X	403; HS; MIL; R
MDX0278	No Bates	No Bates	4/3/2008	Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med 2008;358(14):1431–43		X	403; HS; MIL; R
MDX0279	GLENMARK-ZETIA-00295986	GLENMARK-ZETIA-00296588	4/30/2008	Lettr from Glenmark to FDA re "ANDA 78-560 Ezetimibe Tablets 10mg Minor Amendment - Chemistry"		X	HS; HWH; MIL
MDX0280	MRKZETIA000884457	MRKZETIA000884457	2018	PowerPoint presentation titled, Merck/Schering-Plough Pharmaceuticals - Business Plan / LROP 2009-2013 Clinical Program Planning CDC Review May 1, 2008		X	403; HS; MIL; R
MDX0281	MRKZETIA_SIDLEY000077729	MRKZETIA_SIDLEY000077970	5/9/2008	Deposition Transcript of Nathan Yumibe, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0282	MRKZETIA_SIDLEY000215604	MRKZETIA_SIDLEY000215604	6/2008	Excel spreadsheet with file name: Mylan129689 (June 2008) - Outside Attorneys Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0284	MRKZETIA_SIDLEY000215603	MRKZETIA_SIDLEY000215603	8/2008	Excel spreadsheet with file name: Mylan129691 (Aug 2008) - Outside Attorneys_ Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0285	Teva-Zetia_00001101	Teva-Zetia_00001373	8/22/2008	Letter from TEVA to FDA re "Minor Amendment"		X	HS; HWH; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0287	MRKZETIA_SIDLEY000102365	MRKZETIA_SIDLEY000102673	9/25/2008	Deposition Transcript of Duane Burnett, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0288	MRKZETIA_SIDLEY000104676	MRKZETIA_SIDLEY000104984	9/25/2008	Deposition Transcript of Duane Burnett, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0291	USPTO-ZETIA-0019933	USPTO-ZETIA-0019997	10/21/2008	Deposition Transcript of Adriano Afonso, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	NO
MDX0292	MRKZETIA_SIDLEY000106977	MRKZETIA_SIDLEY000107160	10/29/2008	Deposition Transcript of James Nelson, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0293	MRKZETIA_SIDLEY000108578	MRKZETIA_SIDLEY000108754	10/30/2008	Deposition Transcript of James Nelson, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0294	MRKZETIA_SIDLEY000215609	MRKZETIA_SIDLEY000215609	11/2008	Excel spreadsheet with file name: Mylan129693 (Nov 2008) - Outside Attorneys_ Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0295				WITHDRAWN			
MDX0296	MRKZETIA_SIDLEY000025180	MRKZETIA_SIDLEY000025198	12/2/2008	PowerPoint Presentation titled "The Discovery and Development of Zetia"		X	HS
MDX0297	GLENMARK-ZETIA-00132895	GLENMARK-ZETIA-00133232	12/4/2008	Deposition Transcript of Stuart Rosenblum, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0298	MRKZETIA_SIDLEY000111961	MRKZETIA_SIDLEY000112119	12/5/2008	Deposition Transcript of Stuart Rosenblum, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0299	MRKZETIA_SIDLEY000111465	MRKZETIA_SIDLEY000111623	12/5/2008	Deposition Transcript of Stuart Rosenblum, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0300	MRKZETIA_SIDLEY000111707	MRKZETIA_SIDLEY000111865	12/5/2008	Deposition Transcript of Stuart Rosenblum, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0301	GLENMARK_ZETIA-00132056	GLENMARK_ZETIA-00132384	12/11/2008	Deposition Transcript of John Clader Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0302	MRKZETIA_SIDLEY000112126	MRKZETIA_SIDLEY000112431	12/11/2008	Deposition Transcript of John Clader, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0303				WITHDRAWN			
MDX0304	No Bates	No Bates	12/15/2008	U.S. Pharmacist: Generic Trends		X	403; MIL; R
MDX0305				WITHDRAWN			
MDX0306	No Bates	No Bates	2009	Navarro, Robert P., Overview of Prescription Drug Benefits in Managed Care, Managed Care Pharmacy Practice (2009), 2nd ed, CH, 2, 17-47		X	403; HS; INC; R
MDX0307	No Bates	No Bates	2009	Emily Cox, et. al, Express Scripts, "2008 Drug Trend Report," 2009		X	403; HS; MIL; R
MDX0308	No Bates	No Bates	1/14/2009	Transcript of Proceedings		X	403; HS; HWH; R
MDX0309	MRKZETIA_SIDLEY000215598	MRKZETIA_SIDLEY000215598	2/2009	Excel spreadsheet with file name: Mylan129695 (Feb 2009) - Outside Attorneys_ Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0310	MRKZETIA_R000073356	MRKZETIA_R000073356	2/2/2009	Excel spreadsheet with file name: : WW Nov 2010-2013 LROP.xls		X	403; HS; R
MDX0311				WITHDRAWN			
MDX0312	MRKZETIA_SIDLEY000075894	MRKZETIA_SIDLEY000076042	2/10/2009	Deposition Transcript of Stuart Rosenblum, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS; HWH
MDX0313	MRKZETIA000875932	MRKZETIA000875936	2/10/2009	Memo from Deepak Khanna to MSP U.S. Board re "MSP Summary of Discounting Authority for ZETIA and VYTORIN"		X	403; MIL; R
MDX0314				WITHDRAWN			
MDX0315				WITHDRAWN			
MDX0319	MRKZETIA_R000113312	MRKZETIA_R000113324	2/27/2009	Document titled "Merck/Schering Plough Cholesterol Partnership 2008 Combined Financial Statement"		X	403; 901; INC; MIL; R
MDX0320	No Bates	No Bates	2/27/2009	Merck & Co., Inc. 2008-Form-10-K		X	403; 901; HS; MIL; R
MDX0321	USPTO-ZETIA-0013262	USPTO-ZETIA-0013313	2/27/2009	Expert Report of Dr. Ronald N. Hines, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS
MDX0322	MRKZETIA_SIDLEY000215596	MRKZETIA_SIDLEY000215596	3/2009	Excel spreadsheet with file name: Mylan129696 (Mar 2009) - Outside Attorneys_ Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0323	GLENMARK-ZETIA-00183105	GLENMARK-ZETIA-00183105_0186	3/9/2009	Glenmark response re "F.D.A. Telephone, Ms. Suhas Patankar, Ph.D to PharmaQ Inc. (March 9, 2009)"		X	HS; HWH; MIL

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0324	No Bates	No Bates	3/9/2009	Singer, Natasha, Merck to Buy Schering-Plough for $41.1 Billion, N.Y. Times		X	403; HWH; R
MDX0325	GLENMARK-ZETIA-00164522	GLENMARK-ZETIA-00164538	3/14/2009	Email from B. Kamat to V. Rodrigues et al. re "deficiency - Ezetimibe tablets - URGENT" with attachments		X	HS; HWH; MIL
MDX0326	GLENMARK-ZETIA-00195268	GLENMARK-ZETIA-00195556	3/16/2009	Correspondence from Glenmark to FDA re Minor Amendment - Chemistry		X	HS; MIL
MDX0327	MRKZETIA_SIDLEY000125610	MRKZETIA_SIDLEY000125765	4/16/2009	Expert Report of F. Peter Guengerich, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	701; HS
MDX0331	MRKZETIA_SIDLEY000068068	MRKZETIA_SIDLEY000068118	4/20/2009	Expert Report of W. Virgil Brown, M.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	701; HS; HWH
MDX0332	MRKZETIA_SIDLEY000139394	MRKZETIA_SIDLEY000139533	4/20/2009	Expert report of William R. Roush, Ph.D., Schering Corp. v. Glenmark Pharms. Inc., USA, No. 2:07-cv-01334-JLL-ES		X	701; HS; HWH
MDX0333	GLENMARK-ZETIA-00159177	GLENMARK-ZETIA-00159182	4/24/2009	Fax Transmittal from J. Skanchy (FDA) to W. McIntyre (Glenmark) transmitting letter from FDA re tentative approval of the ANDA		X	NO
MDX0334	GLENMARK-ZETIA-00283269	GLENMARK-ZETIA-00283274	4/24/2009	Correspondence from FDA to Glenmark re tentative approval		X	NO
MDX0335	MRKZETIA_SIDLEY000215597	MRKZETIA_SIDLEY000215597	5/2009	Excel spreadsheet with file name: Mylan129698 (May 2009) - Outside Attorneys_ Eyes Only 1 (2).XLS		X	403; HS; MIL; R
MDX0336	MRKZETIA_SIDLEY000000532	MRKZETIA_SIDLEY000000562	5/7/2009	Rebuttal Expert Report of Paul Ortiz de Montellano, Ph.D., Schering Corp. et al., v. Glenmark Pharm. et al., Case No. 2:07-cv-01334 (JLL)		X	701; HS
MDX0339	Teva-Zetia 00001491	Teva-Zetia 00001494	5/5/2009	Correspondence from FDA to Teva re chemistry deficiencies		X	HS; MIL; R
MDX0340	GLENMARK-ZETIA-00082602	GLENMARK-ZETIA-00082606	5/22/2009	Supplemental Expert Report of Ronald G. Brisbois, Ph.D., Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	701; HS; HWH
MDX0341	MRKZETIA000892356	MRKZETIA000892356	6/2009	PowerPoint Presentation titled, "CLARITY Payer Research Final Deliverable"		X	403; HS; MIL; R
MDX0342				WITHDRAWN			
MDX0343	MRKZETIA_SIDLEY000090144	MRKZETIA_SIDLEY000090451	6/2/2009	Deposition Transcript of William Roush, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	HS
MDX0345	GLENMARK-ZETIA-00377361	GLENMARK-ZETIA-00377364	6/26/2009	Email from M. Khan to S. Krishan "RE: Ezetimibe US DMF/Actavis"		X	HS
MDX0347	USPTO-ZETIA-0010499	USPTO-ZETIA-0010531	6/29/2009	Memorandum of Law in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (improper reissue), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL)		X	NO
MDX0348	MRKZETIA_SIDLEY000215599	MRKZETIA_SIDLEY000215599	7/2009	Excel spreadsheet with file name: Mylan129699 (July 2009) - Outside Attorneys_ Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0350	MRKZETIA_SIDLEY000034033	MRKZETIA_SIDLEY000034059	7/8/2009	Memorandum of Law in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334 (JLL), ECF No. 128-3		X	NO
MDX0352	USPTO-ZETIA-0010891	USPTO-ZETIA-0010917	7/8/2009	Memorandum of Law in Support of Glenmark's Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-1334 (JLL) , ECF No. 128-2		X	NO
MDX0354				WITHDRAWN			
MDX0355				WITHDRAWN			
MDX0358	MRKZETIA_SIDLEY000036826	MRKZETIA_SIDLEY000036862	8/5/2009	Memorandum of Law in Opposition to Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334		X	HS
MDX0360	GLENMARK-ZETIA-00146185	GLENMARK-ZETIA-00146383	8/10/2009	Glenmark's Reply in Support of Motion for Partial Summary Judgment of Invalidity of Claims 10–13 (Improper Reissue), Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334, ECF No. 137		X	HS
MDX0361				WITHDRAWN			
MDX0363				WITHDRAWN			
MDX0364	No Bates	No Bates	2009	Lichtenberg, Frank R. et al., Time Release: The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization by the Public, Medical Progree Report (2009), No. II, 1-16		X	403; HS; R
MDX0365	No Bates	No Bates	10/2009	Medical Progress Report titled, "Time Release: The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization by the Public"		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0366				WITHDRAWN			
MDX0367	MRKZETIA_R000061518	MRKZETIA_R000061535	10/23/2009	Email from V. Soni to P. Matukaitis re "Settlement Communication" with attachments		X	NO
MDX0368	MRKZETIA_R000073356	MRKZETIA_R000073356	11/1/2009	Printout of Excel file with file name, "WW Nov 2010-2013 LROP.xls"		X	403; 901; MIL
MDX0369	MRKZETIA_SIDLEY000215600	MRKZETIA_SIDLEY000215600	11/2009	Excel spreadsheet with file name: Mylan129701 (Budget Nov2009) - Outside Attorneys Eyes Only 1.XLS		X	403; HS; MIL; R
MDX0371	No Bates	No Bates	11/3/2009	U.S. Patent 7,612,058		X	403; MIL; R
MDX0372	USPTO-ZETIA-0025227	USPTO-ZETIA-0025272	11/3/2009	United States Patent No. 7,612,058		X	403; MIL; R
MDX0373	No Bates	No Bates	11/16/2009	New Study Gives B Vitamin a Boost. Wall Street Journal. 2009		X	403; R
MDX0374	GLENMARK-ZETIA-00237431	GLENMARK-ZETIA-00237431	11/25/2009	Email from T. Coughlin to V. Soni re "FW: Par"		X	NO
MDX0375	MRKZETIA_R000061811	MRKZETIA_R000061818	12/2/2009	Email from V. Soni to P. Matukaitis "RE: Settlement Communication"		X	NO
MDX0376	No Bates	No Bates	12/2/2009	Article titled, "Promotional Spending for Prescription Drugs", Congressional Budget Office (CBO) - Economic and Budget Issue Brief, 1-8		X	403; R
MDX0377	Watson-Zetia_00000001	Watson-Zetia_00000002	12/7/2009	Watson Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use		X	NO
MDX0378	Watson-Zetia_00000026	Watson-Zetia_00000031	12/7/2009	Document titled "1.3.5.2. Patent Certification" re Watson ANDA 200831		X	403; HS; R
MDX0379	Watson-Zetia_00000204	Watson-Zetia_00000205	12/7/2009	Letter from Watson to FDA re "Preassigned Original ANDA Application 200831 Ezetimibe Tablets, 10 mg"		X	NO
MDX0384	MRKZETIA_SIDLEY000238225	MRKZETIA_SIDLEY000238285	12/16/2009	Complaint, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL)		X	403; HS; MIL; R
MDX0385	No Bates	No Bates	12/22/2009	Press release titled, "Mylan Confirms First-to-File Patent Challenge Relating to Vytorin® Cholesterol Medication"		X	403; HS; MIL; R
MDX0386	No Bates	No Bates	12/22/2009	Press release titled, "Mylan Confirms First-to-File Patent Challenge Relating to Vytorin® Cholesterol Medication"		X	403; HS; MIL; R
MDX0387	MRKZETIA_R000113294	MRKZETIA_R000113311	12/31/2009	Document titled "Schering Plough Cholesterol Partnership Combined Financial Statement"		X	403; 901; MIL; R
MDX0388				WITHDRAWN			
MDX0389	No Bates	No Bates	2010	Reich 2010 - NMR Spectroscopy – 5-HMR-2 Chemical Shift		X	403; INC; R
MDX0390	No Bates	No Bates	2010	Dickey, Bret et al., An Economic Assessment of Patent Settlements in the Pharmaceutical Industry, Annals of Health Law (2010), Vol. 19, No. 2, 367-400		X	403; R
MDX0391				WITHDRAWN			
MDX0392	MRKZETIA_R000061593	MRKZETIA_R000061593	1/7/2010	Email from P. Matukaitis to V. Soni "RE: Glenmark-Merck : settlement purpose only"		X	NO
MDX0393	MRKZETIA_R000061593	MRKZETIA_R000061593	1/7/2010	Email from P. Matukaitis to V. Soni "RE: Glenmark-Merck : settlement purpose only"		X	NO
MDX0394	MRKZETIA_R000016128	MRKZETIA_R000016128	1/13/2010	PowerPoint presentation titled, Vytorin ® /Zetia®(ezetimibe/simvastatin)/(ezetimibe)Managed Markets & Policy Meeting"		X	403; MIL; R
MDX0395				WITHDRAWN			
MDX0396	MRKZETIA_SIDLEY000190244	MRKZETIA_SIDLEY000190362	2/12/2010	Defendant Mylan Pharm Inc.'s Answer to Plaintiffs' Complaint, Separate Defenses and Counterclaims, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL)		X	403; HS; MIL; R
MDX0397	Watson-Zetia_00010433	Watson-Zetia_00010434	2/12/2010	Letter from Watson to FDA re "Ezetimibe Tablets, 10 mg ANDA 200831 Patent Amendment Sequence #0002"		X	NO
MDX0398	CVS-ZET-0046439	CVS-ZET-0046448	2/19/2010	Email from H. Krass to H. Krass re "Zetia: Merck Appears To Have Advantage Despite Possible Flaws in Patent" with attachment		X	403; 701; FD; HS; HWH; R
MDX0399	MRKZETIA_R000061917	MRKZETIA_R000061917	2/24/2010	Email from C. Mercer, Carol E. Murray, F. Clyburn, P. Magri et al. re "Zetia Potential Settlement Financial Analysis"		X	NO
MDX0400	MRKZETIA_R000061768	MRKZETIA_R000061770	2/25/2010	Email from V. Soni to P. Matukaitis re "Merck-Glenmark"		X	403; HS; HWH; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0401	MRKZETIA000847515	MRKZETIA000847515	2/25/2010	Calendar invite from P. Matukaitis to E. Murray re "Glenmark - Merck - Vijay Soni, Ed Murray"		X	NO
MDX0403	MRKZETIA_R000061545	MRKZETIA_R000061549	3/1/2010	Email from V. Soni to P. Matukaitis "RE: Glenmark-Merck"		X	NO
MDX0406	MRKZETIA000848697	MRKZETIA000848697	3/2/2010	Email from V. Soni to P. Matukaitis and E. Murray "RE: Glenmark-Merck"		X	NO
MDX0407	No Bates	No Bates	3/2/2010	Complaint, Schering Corp., et al., v. Teva Pharm., et al., Case No. 2:10-cv-01058-JLL-ES, ECF No. 1		X	HS; MIL
MDX0408	No Bates	No Bates	3/2/2010	Complaint, Schering Corp., et al., v. Teva Pharm., et al., Case No. 10-cv-01058-JLL-ES, ECF No. 1		X	HS; MIL
MDX0410	MRKZETIA001011591	MRKZETIA001011592	3/3/2010	Email from M. Redmond to P. McCrorey and D. John Majka re "FW: D&P US MSP Forecast Refresh 1-13" with attachment		X	403; HS; MIL
MDX0411	MRKZETIA000847518	MRKZETIA000847518	3/4/2010	Calendar invite from E. Rudnicki to E. Murray and L. Jakob re "Glenmark - Merck - Vijay Soni, Ed Murray, Lisa Jakob"		X	NO
MDX0412	Watson-Zetia_00010439	Watson-Zetia_00010439	3/4/2010	Letter from Watson to FDA re "Ezetimibe Tablets, 10 mg ANDA 200831 Patent Amendment - to include Added US Patent 7,612,058 (the "106 patent") Sequence #0003"		X	403; MIL; R
MDX0413	MRKZETIA_R000062140	MRKZETIA_R000062142	3/8/2010	Email from V. Soni to E. Murray "RE: ZETIA Discussions" with attachment		X	NO
MDX0414	MRKZETIA_R000062267	MRKZETIA_R000062268	3/8/2010	Email from E. Murray to V. Soni re "ZETIA Discussions" with attachment		X	NO
MDX0415	MRKZETIA000845437	MRKZETIA000845437	3/8/2010	Calendar invite from P. Matukaitis, E. Murray and L. Jakob re "Glenmark - Merck - Vijay Soni, Ed Murray, Lisa Jakob"		X	NO
MDX0416	MRKZETIA000845438	MRKZETIA000845438	3/9/2010	Calendar Invite from P. Matukaitis re "Glenmark - Merck - Vijay Soni, Ed Murray"		X	NO
MDX0417	MRKZETIA_R000080385	MRKZETIA_R000080385	3/10/2010	Calendar Invite from P. Matukaitis re "Updated: Glenmark - Merck - Vijay Soni, Ed Murray"		X	NO
MDX0418	MRKZETIA000845440	MRKZETIA000845440	3/18/2010	Calendar Invite from P. Matukaitis re "Updated: Glenmark - Merck - Vijay Soni, Ed Murray"		X	NO
MDX0420	MRKZETIA_R000080383	MRKZETIA_R000080383	3/23/2010	Calendar Invite from P. Matukaitis re "Glenmark - Merck - Vijay Soni, Ed Murray"		X	NO
MDX0426	MRKZETIA000874328	MRKZETIA000874331	4/2/2010	Email from D. Pritikin to P. Matukaitis, E. Murray, L. Jakob et al. "RE: Negotiations"		X	HS
MDX0427	GLENMARK-ZETIA-00201717	GLENMARK-ZETIA-00201717	4/3/2010	Email from T. Coughlin to G. Sladanha re "Various"		X	NO
MDX0428	No Bates	No Bates	4/12/2010	Teva Pharm. USA Inc.'s Answer, Schering Corp., et al., v. Teva Pharm., et al., Case No. 2:10-cv-01058-JLL-ES, ECF No. 16		X	HS; R
MDX0429	No Bates	No Bates	4/12/2010	TEVA Pharm. USA Inc.'s Answer, Schering Corp., et al., v. Teva Pharm., et al., Case No. 10-cv-01058-JLL-ES, ECF No. 16		X	HS; R
MDX0434	PAR_00008219	PAR_00008221	4/19/2010	Email from P. Campanelli to P. Campanelli re "FW: Zetia" with attachment		X	HS
MDX0435	MRKZETIA000933269	MRKZETIA000933272	4/22/2010	Steve Scala et al., A Victory For Glenmark But Zetia's IP Likely OK to 2016, Cowen Take		X	403; 701; FD; HS; HWH; R
MDX0441	GLENMARK-ZETIA-00165707	GLENMARK-ZETIA-00165742	4/30/2010	Marketing and Distribution Agreement between Glenmark and Par Pharmaceutical		X	NO
MDX0442	MRKZETIA_SIDLEY000028554	MRKZETIA_SIDLEY000028570	4/30/2010	Notice Motion for Reconsideration, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334, ECF No. 225-1-225-3		X	HS
MDX0443	No Bates	No Bates	4/30/2010	Notice of Motion and Motion for Reconsideration, Schering Corp. et al. v. Glenmark Pharm.et al., Case No. 07-CV-1334, ECF No. 225-1-225-3		X	HS
MDX0444	PAR_00003009	PAR_00003044	4/30/2010	Marketing and Distribution Agreement between Glenmark and Par Pharmaceutical		X	NO
MDX0447	No Bates	No Bates	5/4/2010	"Glenmark In Licensing Deal with US Co. for Cholesterol Drug," The Economic Times		X	403; HS; HWH; MIL
MDX0448	GLENMARK-ZETIA-00261882	GLENMARK-ZETIA-00261908	5/5/2010	Email from V. Soni to P. Campanelli and T. Haughey re "Settlement agreement received from Merck on Mar 29 2010"		X	NO
MDX0449	GLENMARK-ZETIA-00434851	GLENMARK-ZETIA-00434438	5/6/2010	Email from V. Soni to E. Rudnicki "Re: Meeting with Paul Matukaitis on Friday, May 7 at 9:30 a.m. Rahway site"		X	HS
MDX0450	GLENMARK-ZETIA-0434851	GLENMARK-ZETIA-0434852	5/6/2010	Email from V. Soni to E. Rudnicki "Re: Meeting with Paul Matukaitis on Friday, May 7 at 9:30 a.m. Rahway site"		X	HS
MDX0451	MYL ZETIA 000002	MYL ZETIA 000005	5/6/2010	Letter from FDA to Mylan acknowledging receipt of Ezetimibe ANDA		X	R
MDX0452	GLENMARK-ZETIA-0434105	GLENMARK-ZETIA-0434106	5/7/2010	Email from P. Campanelli to T. Coughlin "Re: Hi"		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0454	MRKZETIA000870220	MRKZETIA000870246	5/7/2010	Email from P. Matukaitis to D. Pritikin, T. Krause and W. Baumgartner re "FW: Agreement" with attachment		X	NO
MDX0455	GLENMARK-ZETIA-00261739	GLENMARK-ZETIA-00261794	5/8/2010	Email from L. Brown to P. Campanelli, T. Coughlin and T. Haughey re "Fw: Zetia Settlement Agreement" with attachments		X	NO
MDX0464	GLENMARK-ZETIA-00201566	GLENMARK-ZETIA-00201567	5/10/2010	Email from P. Birdy to T. Coughlin "Re: Zetia"		X	HS
MDX0465	GLENMARK-ZETIA-00201566	GLENMARK-ZETIA-00201567	5/10/2010	Email from P. Birdy to T. Coughlin "Re: Zetia"		X	HS
MDX0466	MRKZETIA_R000043924	MRKZETIA_R000043924	5/10/2010	Email from T. Hester to V. Soni, L. Brown and E. Choy re "Execution Version of Zetia Agreement"		X	NO
MDX0467	MRKZETIA_R000044820	MRKZETIA_R000044852	5/10/2010	Email from T. Hester to T. Hester, V. Soni, L. Brown et al. "RE: Execution Version of Zetia Agreement" with attachment		X	NO
MDX0469	MRKZETIA_R000049731	MRKZETIA_R000049794	5/10/2010	Email from T. Hester to P. Matukaitis, E. Rudnicki, K. Stoffan et al. re "FW: Revised Draft - - 11 am version" with attachments		X	NO
MDX0471	MRKZETIA_R000061565	MRKZETIA_R000061573	5/10/2010	Email from E. Murray to V. Soni and P. Matukaitis "RE: ZETIA Settlement - Draft Press Release" with attachment		X	403; HS; MIL; R
MDX0472	MRKZETIA_R000061848	MRKZETIA_R000061851	5/10/2010	Email from V. Soni to E. Murray and P. Matukaitis "RE: ZETIA Settlement - Draft Press Release" with attachment		X	403; HS; MIL; R
MDX0473	MRKZETIA_R000061852	MRKZETIA_R000061853	5/10/2010	Email from T. Hester to L. Brown, V. Soni and E. Choy "RE: Zetia Settlement Agreement"		X	NO
MDX0474	MRKZETIA_R000061877	MRKZETIA_R000061878	5/10/2010	Email from V. Soni to T. Hester "RE: Revised Draft -- 11 am version" with attachment		X	NO
MDX0475	MRKZETIA_R000061887	MRKZETIA_R000061893	5/10/2010	Email from L. Brown to E. Murray, V. Soni and P. Matukaitis "RE: ZETIA Settlement - Draft Press Release"		X	403; HS; MIL; R
MDX0476	MRKZETIA_R000062075	MRKZETIA_R000062081	5/10/2010	Email from L. Brown to T. Hester and V. Soni re "a few more nits"		X	NO
MDX0477	MRKZETIA_R000080268	MRKZETIA_R000080300	5/11/2010	Email from P. Matukaitis to T. Hester re "FW: Merck-Glenmark Execution Version of Zetia Agreement" with attachment		X	NO
MDX0479	MRKZETIA000845447	MRKZETIA000845449	5/10/2010	Email from T. Hester to P. Matukaitis, D. Pritikin, W. Baumgartner, E. Murray "RE: Zetia Settlement Agreement"		X	NO
MDX0480	MRKZETIA000845460	MRKZETIA000845461	5/10/2010	Email from W. Baumgartner to T. Hester "RE: Revised Zetia Settlement Agreement"		X	NO
MDX0482	Zetia_EDVA_00000301	Zetia_EDVA_00000302	5/10/2010	Email from L. Brown to T. Hester "RE: Revised agmt"		X	NO
MDX0483	Zetia_EDVA_00000455	Zetia_EDVA_00000460	5/10/2010	Email from L. Brown to T. Hester "RE: Zetia Settlement Agreement"		X	NO
MDX0484	Zetia_EDVA_00000471	Zetia_EDVA_00000473	5/10/2010	Email from L. Brown to T. Hester "RE: Zetia Settlement Agreement"		X	NO
MDX0485	Zetia_EDVA_00000477	Zetia_EDVA_00000478	5/10/2010	Email from L. Brown to T. Hester "RE: Zetia Settlement Agreement"		X	NO
MDX0486	No Bates	No Bates	5/11/2010	"Glenmark Pharmaceuticals Enters Into a Settlement Agreement with Merck," BioSpace.com		X	403; HS; MIL; R
MDX0487	Zetia_EDVA_00000146	Zetia_EDVA_00000148	5/11/2010	Email from V. Soni to P. Matukaitis "RE: Execution Version of Zetia Agreement"		X	NO
MDX0488	MRKZETIA_SIDLEY000014259	MRKZETIA_SIDLEY000014493	5/12/2010	Mylan Pharm. Inc's Invalidity and Non-Infringement Contentions Pursuant to Local Patent Rules 3.3 and 3.6, Schering Corp., et al. v. Mylan Pharm. Inc., et al., Case No. 09-cv-06383-JLL-ES		X	403; HS; MIL; R
MDX0489	MRKZETIA_SIDLEY000014259	MRKZETIA_SIDLEY000014493	5/12/2010	Defendant Mylan Pharm. Inc.'s Invalidity and Non-Infringement Contentions Pursuant to Local Patent Rules 3.3 and 3.6, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383, 10-01058 (JLL)		X	403; CU; HS; MIL; R
MDX0490	Watson-Zetia_00010456	Watson-Zetia_00010456	5/12/2010	Letter from Watson to FDA re "Ezetimibe Tablets, 10 mg ANDA 200831 Patent Amendment Sequence #0005"		X	NO
MDX0491	MRKZETIA_R000061693	MRKZETIA_R000061726	5/14/2010	Email from T. Hester to L. Brown and P. Matukaitis re "FW: Execution Version of Settlement Agreement"		X	403; HS; MIL; R
MDX0492	MRKZETIA_R000062163	MRKZETIA_R000062196	5/14/2010	Email from V. Soni to T. Hester and P. Matukaitis re "FW: Execution Version of Settlement Agreement" with attachment		X	403; HS; MIL; R
MDX0493	MRKZETIA_R000062197	MRKZETIA_R000062198	5/14/2010	Email from V. Soni to T. Hester. And P. Matukaitis "RE: Execution Version of Settlement Agreement"		X	403; HS; MIL; R
MDX0494	MRKZETIA_R000062159	MRKZETIA_R000062231	5/17/2010	Email from T. Hester to J. Lessler "RE: Execution Version of Settlement Agreement" with attachments		X	403; HS; MIL; R
MDX0495	MRKZETIA_R000024588	MRKZETIA_R000024621	5/18/2010	Letter from T. Hester to FTC enclosing the May 20, 2010 Settlement Agreement between Schering, MSP Singapore and Glenmark		X	403; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0496	MRKZETIA000847860	MRKZETIA000847893	5/18/2010	Letter from T. Hester to FTC enclosing the May 20, 2010 Settlement Agreement between Schering, MSP Singapore and Glenmark		X	MIL (cover letter only)
MDX0498	Teva-Zetia_00001483	Teva-Zetia_00001487	5/19/2010	Letter from Teva to FDA re "Minor Amendment"		X	HS
MDX0499	No Bates	No Bates	5/27/2010	Pretrial Scheduling Order, Schering Corp., et al., v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 62		X	403; HS; MIL; R
MDX0503	USPTO-ZETIA-0001363	USPTO-ZETIA-0001366	6/9/2010	Reissue Application Declaration by Assignee, Docket No. 106527-0011-401		X	403; HS; MIL; R
MDX0504	USPTO-ZETIA-0001374	USPTO-ZETIA-0001376	6/9/2010	Reissue Application Declaration by Assignee, Docket No. 106527-0011-401		X	403; HS; MIL; R
MDX0506	USPTO-ZETIA-0001421	USPTO-ZETIA-0001423	6/9/2010	Information Disclosure Statement by Applicant, Application Number 12/97,341, A1-A39, B1-B20, C1-C28		X	403; MIL; R
MDX0507	USPTO-ZETIA-0002436	USPTO-ZETIA-0002450	6/9/2010	Information Disclosure Statement by Applicant, Application Number 12/97,341. A40-A63, B21-B43, C-29-C303		X	403; HS; MIL; R
MDX0508	USPTO-ZETIA-0007140	USPTO-ZETIA-0007146	6/9/2010	Information Disclosure Statement by Applicant, Application Number 12/97,341, C304-C366		X	403; MIL; R
MDX0509	USPTO-ZETIA-0013208	USPTO-ZETIA-0013232	6/9/2010	Information Disclosure Statement by Applicant, Application Number 12/97,341, A1-A39, B1-B20, C1-C28, A40-A63, B21-B43, C-29-C366		X	403; MIL; R
MDX0510	USPTO-ZETIA-0013250	USPTO-ZETIA-0013256	6/9/2010	Information Disclosure Statement by Applicant, Application Number 12/97,341, B44, C367-C473		X	403; MIL; R
MDX0513	MRKZETIA_SIDLEY000098235	MRKZETIA_SIDLEY000098235	6/15/2010	Email from J. Suh to T. Parker, D. Mukerjee, J. Malik et al. re "Schering Corp v. Mylan Pharms. Inc., Civ. A. No. 09-6383 (JLL)(ES)" with attachments		X	HS; R
MDX0514				WITHDRAWN			
MDX0515	MRKZETIA_SIDLEY000006670	MRKZETIA_SIDLEY000006779	6/16/2010	Complaint, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 1		X	HS; MIL
MDX0516	MRKZETIA000547519	MRKZETIA000547519	6/16/2010	PowerPoint presentation titled, "ZETIA/VYTORIN US Brand Review"		X	403; HS; HWH; MIL; R
MDX0518				WITHDRAWN			
MDX0519	Teva-Zetia_00001750	Teva-Zetia_00001750	7/16/2010	Teva Patent Certification re Ezetimibe Tablets, 10 mg		X	NO
MDX0520	Teva-Zetia_00001745	Teva-Zetia_00001747	7/20/2010	Letter from Teva to FDA re "Patent Amendment: Revised Patent Certification"		X	NO
MDX0521	MRKZETIA_SIDLEY000008810	MRKZETIA_SIDLEY000008897	7/28/2010	Defendant Mylan Pharm. Inc.'s Answer to Plaintiffs' Complaint, Separate Defenses and Counterclaims , Schering Corp., et al. v. Mylan Pharm., et al., Case No. 2:10-cv-03085 (JLL)		X	403; HS; MIL; R
MDX0522				WITHDRAWN			
MDX0523	No Bates	No Bates	8/19/2010	Complaint, Schering Corp., et al. v. Impax Labs. Inc., Case No. 10-cv-4270-JLL-MAH, ECF No. 1		X	HS
MDX0524				WITHDRAWN			
MDX0525	USPTO-ZETIA-0007150	USPTO-ZETIA-0013190	8/19/2010	Notice of Dismissal without Prejudice, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 1:10-cv-99-IMK , ECF No. 9		X	403; HS; MIL; R
MDX0526	GLENMARK-ZETIA-00250319	GLENMARK-ZETIA-00250321_0005	8/23/2010	Email from D. Bisaria to P. Chavakula and C. Almeida re "FW: Ezetimibe out sourcing issue" with attachment		X	HS
MDX0527	No Bates	No Bates	9/1/2010	Complaint, Schering Corp., et al., v. Teva Pharm., et al., Case No. 2:10-cv-04473-JLL-ES, ECF No. 1		X	HS
MDX0528	No Bates	No Bates	9/1/2010	Complaint, Schering Corp., et al., v. Teva Pharm., et al., Case No. 10-cv-04473-JLL-ES, ECF No. 1		X	HS
MDX0529	MRKZETIA_SIDLEY000011155	MRKZETIA_SIDLEY000011156	9/9/2010	Order Consolidating Cases on Consent, Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL), ECF No. 89		X	403; HS; MIL; R
MDX0530	USPTO-ZETIA-0015200	USPTO-ZETIA-0015442	9/9/2010	Defendant Mylan Pharmaceuticals Inc.'s Amended Invalidity and Non-Infringement Contentions Pursuant to Local Patent Rules 3.3 and 3.6, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 2:10-cv-03085 (JLL), 10-3085 (JLL)		X	403; HS; MIL; R
MDX0531	No Bates	No Bates	9/10/2010	Memorandum and Order on Motions to Exclude, In re Intuniv Antitrust Litigation, Civil Action 1:16-cv-12653-ADB, 1:16-cv-12396-ADB		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0532	MRKZETIA_R000073381	MRKZETIA_R000073381	9/24/2010	PowerPoint presentation titled, Athero/Cardiovascular Franchise 2011 LROP September 24, 2010		X	403; HS; R
MDX0533	No Bates	No Bates	9/24/2010	Defendant Impax Labs. Inc.'s Answer, Affirmative Defenses, Counterclaim and Jury Demand, Schering Corp., et al. v. Impax Labs. Inc., Case No. 10-cv-4270-JLL-MAH, ECF No. 9		X	HS
MDX0534	No Bates	No Bates	10/7/2010	Answer to Complaint, Schering Corp., et al., v. Teva Pharm., et al., Case No. 2:10-cv-04473-JLL-ES, ECF No. 11		X	HS
MDX0535	No Bates	No Bates	10/7/2010	TEVA Pharm. USA Inc.'s Answer, Schering Corp., et al., v. Teva Pharm., et al., Case No. 10-cv-04473-JLL-ES, ECF No. 11		X	HS
MDX0537				WITHDRAWN			
MDX0538	MRKZETIA000547290	MRKZETIA000547290	10/27/2010	PowerPoint presentation titled, "2011 Franchise Priorities"		X	403; HS; HWH; MIL; R
MDX0539	MYL_ZETIA 000048	MYL_ZETIA 000050	10/28/2010	Correspondence from FDA to Mylan re "Bioequivalence Amendment"		X	HS; R
MDX0540	MRKZETIA_SIDLEY000221516	MRKZETIA_SIDLEY000221516	11/2010	Excel spreadsheet with file name: Zetia Forecast Nov 2010_1.XLS		X	403; HS; MIL; R
MDX0541	MYL_ZETIA 000051	MYL_ZETIA 000052	11/8/2010	Letter from Mylan to FDA re "Bioequivalence Amendment"		X	HS; R
MDX0542	MYL_ZETIA 000066	MYL_ZETIA 000067	11/8/2010	Letter from Mylan to FDA re "Gratuitous Chemistry Amendment"		X	HS; R
MDX0543	No Bates	No Bates	11/15/2010	Consent Judgment on Counterclaim, Schering Corp., et al., v. Teva Pharm., et al., Case No. 2:10-cv-04473-JLL-ES, ECF No. 23		X	HS; R
MDX0544	No Bates	No Bates	12/10/2010	Corrected Consent Order Staying Action, Schering Corp. et al., v. Impax Lab. Inc., Case No. 10-cv-4270-JLL-MAH, ECF No. 23		X	HS
MDX0545	No Bates	No Bates	12/13/2010	Case Consolidation and Scheduling Order, Schering Corp., et al. v. Mylan Pharm. Inc., et al and Schering Corp., et al., v. Teva Pharm., et al., Case No. 10-cv-04473-JLL-ES, ECF No. 24		X	403; HS; MIL; R
MDX0546	Teva-Zetia_00001758	Teva-Zetia_00001760	12/13/2010	Correspondence from FDA to Teva re chemistry deficiencies		X	HS
MDX0547	ENV_004648	ENV_004718	2011	Document titled, "EnvisionRx Plus Gold (DPP) 2011 Formulary (List of Covered Drugs)"		X	403; HS; MIL; R
MDX0548				WITHDRAWN			
MDX0549	No Bates	No Bates	1/1/2011	Grabowski, Henry et al., Data exclusivity for biologics, 10:15 (2011)		X	403; HS; HWH; R
MDX0550				WITHDRAWN			
MDX0551	USPTO-ZETIA-0023581	USPTO-ZETIA-0023584	1/20/2011	USPTO Notice of Allowance and Fee(s) Due to Ropes & Gray re Application No. 12/797,341		X	403; HS; MIL; R
MDX0552	Teva-Zetia_00001761	Teva-Zetia_00001761	1/28/2011	Teva Letter to FDA re "Response to Deficiency - Ezetimibe - DMF# 20039"		X	HS
MDX0553	No Bates	No Bates	2/28/2011	Merck & Co., Inc. 2010-Form-10-K		X	403; 901; HS; R
MDX0554	No Bates	No Bates	3/2/2011	Amicus Curie Brief for the United States Supreme Court on Pliva Inc., et al vs. Mensing (with Mark Law, John Abramson, Julie Donahue, Michael Fisher, and Meredith Rosenthal) Case No. Nos. 09-993, 09-1039, and 09-1501		X	403; HS; R
MDX0555	No Bates	No Bates	3/8/2011	Correspondence from FDA to Watson re chemistry deficiencies		X	HS
MDX0556	MRKZETIA_SIDLEY000196898	MRKZETIA_SIDLEY000196913	3/11/2011	Plaintiffs' Brief in Support of Their Motion for Partial Summary Judgment of No Inequitable Conduct During the Patent Term Extension, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL), 10-3085 (JLL), 10-1058 (JLL), 10-4473 (JLL)		X	403; HS; MIL; R
MDX0557	Teva-Zetia_00001752	Teva-Zetia_00001754	3/14/2011	Letter from Teva to FDA re "Quality Minor Amendment / Response to Information Request"		X	HS
MDX0558	MYL_ZETIA 000234	MYL_ZETIA 000238	3/15/2011	Correspondence from FDA to Mylan re chemistry deficiencies		X	HS; R
MDX0559	MRKZETIA000614936	MRKZETIA000614937	3/31/2011	Email from G. Eater to S. Metelow re "CV Slides" with attachment		X	403; HS; HWH; MIL; R
MDX0560	No Bates	No Bates	4/11/2011	Business Wire: UnitedHealth Group Announces "Optum" Master Brand for Its Health Services Businesses		X	403; HS; HWH; R
MDX0562				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0564	No Bates	No Bates	5/17/2011	Schering Corp. v. Mylan Pharms., Inc., 2011 WL 1885709 (D. N.J. May 17, 2011)		X	403; CU; HS; MIL; R
MDX0565	MRKZETIA000614938	MRKZETIA000614938	5/19/2011	Email from J. Laux to K. Wolfe, G. Eater and Y. Pascual re "Fwd: Vytorin-Zetia Pricing"		X	HS
MDX0568	No Bates	No Bates	6/16/2011	Watson letter to FDA re "Quality Minor Amendment/Response to Information Request"		X	HS
MDX0570	GLENMARK-ZETIA-00237679	GLENMARK-ZETIA-00237681	7/7/2011	Email from K. Reddy to V. Soni "RE: Meeting at our Office"		X	HS
MDX0571	MRKZETIA000935981	MRKZETIA000936018	7/7/2011	Letter from T. Hester to FTC re "Filing Pursuant to Section 1112(a) of the Medicare Prescription Drug, Improvement and Modernization Act of 2003" and settlement agreement		X	403; HS; MIL; R
MDX0572	MRKZETIA_SIDLEY000210945	MRKZETIA_SIDLEY000210958	7/8/2011	Plaintiffs' Brief in Support of Their Motion for Partial Summary Judgment of Infringement and no Invalidity with Respect to Certain Mylan Defenses and Counterclaims, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL), 10-3085 (JLL), 10-1058 (JLL), 10-4473 (JLL)		X	403; HS; MIL; R
MDX0573	MRKZETIA_SIDLEY000211368	MRKZETIA_SIDLEY000211389	7/8/2011	Plaintiffs' Brief in Support of Their Motion for Partial Summary Judgment on Mylan's Inequitable Conduct Defenses and Counterclaims, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL), 10-3085 (JLL), 10-1058 (JLL), 10-4473 (JLL), ECF No. 240-2		X	403; HS; MIL; R
MDX0574	MRKZETIA_SIDLEY000211365	MRKZETIA_SIDLEY000211367	7/11/2011	Consent Judgment, Schering Corp., et al., v. Teva Pharm., et al., Case No. 09-cv-06383-JLL-MF, ECF No. 245		X	HS
MDX0575	MRKZETIA_SIDLEY000213145	MRKZETIA_SIDLEY000213244	7/22/2011	First Amended Complaint, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL), 10-3085 (JLL), 10-1058 (JLL), 10-4473 (JLL), ECF No. 253-253-4		X	403; HS; MIL; R
MDX0581	MYL_ZETIA 000239	MYL_ZETIA 000250	8/4/2011	Letter from Mylan to FDA re "Quality Minor Amendment"		X	HS; R
MDX0582	Teva-Zetia_00001859	Teva-Zetia_00001861	8/4/2011	Correspondence from FDA to Teva re chemistry deficiencies		X	HS
MDX0584	MRKZETIA_R000044121	MRKZETIA_R000044261	8/15/2011	Expert Report of Jerry Atwood, Ph.D., Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL)		X	403; HS; MIL; R
MDX0585	MRKZETIA_SIDLEY000082080	MRKZETIA_SIDLEY000082175	8/16/2011	Expert Report of William Roush, Ph.D., Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL)		X	403; HS; MIL; R
MDX0586	MRKZETIA_SIDLEY000105916	MRKZETIA_SIDLEY000105916	8/16/2011	Excel spreadsheet with file name: 08-16-11 Warren-Boulton - Appendix D- 5-Year Plan 57772057_1.XLS		X	403; HS; R
MDX0587	MYL_ZETIA013211	MYL_ZETIA013214	8/19/2011	Letter from FDA to Mylan re tentative approval of ANDA 200082		X	R
MDX0589	MRKZETIA000934058	MRKZETIA000934078	8/22/2011	Opinion, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 298		X	403; HS; MIL; R
MDX0591				WITHDRAWN			
MDX0592	MRKZETIA_SIDLEY000024826	MRKZETIA_SIDLEY000024997	9/9/2011	Expert Report of Pierre-Yves Cremieux, Ph.D., Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383 (JLL)		X	403; HS; MIL; R
MDX0593	Teva-Zetia_00001847	Teva-Zetia_00001849	9/9/2011	Letter from Teva to FDA re "Bioequivalence Amendment"		X	HS
MDX0594	Teva-Zetia_00001878	Teva-Zetia_00001880	9/9/2011	Letter from TEVA to FDA re "Quality Minor Amendment / Response to Information Request"		X	HS
MDX0595	MRKZETIA_R000045264	MRKZETIA_R000045337	9/12/2011	Expert Report of Andrew G. Myers, Ph.D., Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL)		X	403; HS; MIL; R
MDX0596	MRKZETIA_SIDLEY000225731	MRKZETIA_SIDLEY000225943	9/12/2011	Expert Report of Ronald Brisbois, Ph.D., Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL)		X	403; HS; MIL; R
MDX0597	MRKZETIA_SIDLEY000040388	MRKZETIA_SIDLEY000040495	9/19/2011	Defendant Mylan Pharm. Inc.'s Amended Invalidity and Non-Infringement Contentions to Include U.S. Patent No. RE42,461, Schering Corp., et al. v. Mylan Pharm., et al., Case No. 09-6383, 10-03085, 10-1058, 10-04473 (JLL)		X	403; HS; MIL; R
MDX0598	Teva-Zetia_00001903	Teva-Zetia_00001905	9/23/2011	Letter from Teva to FDA re "Patent Amendment - Receipt of Notice, 45-day Clock and Legal Status"		X	HS
MDX0599	MRKZETIA_SIDLEY000085397	MRKZETIA_SIDLEY000085649	9/30/2011	Corrected Expert Report of Professor William R. Roush, Ph.D., Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL), 10-3085 (JLL)		X	403; HS; MIL; R
MDX0600	No Bates	No Bates	9/30/2011	Sanofi-Aventis v. Glenmark Pharm. Inc., 821 F Supp. 2d 681		X	403; R
MDX0601				WITHDRAWN			
MDX0602	No Bates	No Bates	10/13/2011	Complaint, Schering Corp. et al., v. Actavis Inc. et al., 2:11-cv-06067, ECF No. 1		X	403; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0604	No Bates	No Bates	11/1/2011	Amended Complaint, Schering Corp. et al., v. Actavis Inc. et al., 2:11-cv-06067, ECF No. 7		X	403; HS
MDX0605	No Bates	No Bates	11/10/2011	Consent Order Staying Action, Schering Corp. et al., v. Actavis Inc. et al., 2:11-cv-06067, ECF No. 11		X	403; HS; MIL
MDX0606	MRKZETIA_SIDLEY000235974	MRKZETIA_SIDLEY000236000	11/21/2011	Defendant Mylan Pharmaceuticals Inc.'s Pretrial Brief, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL), 10-3085 (JLL)		X	403; HS; MIL; R
MDX0607	MRKZETIA_SIDLEY000236056	MRKZETIA_SIDLEY000236077	11/21/2011	Plaintiff's PreTrial Brief, Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL), ECF No. 382		X	403; HS; MIL
MDX0608	No Bates	No Bates	12/5/2011	Transcript of Proceedings, Schering Corp., et al., v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 459		X	403; HS; MIL
MDX0609	No Bates	No Bates	12/7/2011	Transcript of Proceedings, Schering Corp., et al., v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 460		X	403; HS; MIL
MDX0610	MRKZETIA_SIDLEY000204549	MRKZETIA_SIDLEY000204596	12/8/2011	Transcript of Proceedings, Volume 3 in the Mylan litigation		X	403; HS; MIL
MDX0611	No Bates	No Bates	12/8/2011	Transcript of Proceedings, Schering Corp., et al., v. Mylan Pharm., et al., Case No. 09-6383 (JLL), ECF No. 461		X	403; HS; MIL
MDX0612	Watson-Zetia_00010690	Watson-Zetia_00010693	12/12/2011	Correspondence from FDA to Watson re deficiencies		X	NO
MDX0613				WITHDRAWN			
MDX0614	MRKZETIA_SIDLEY000204814	MRKZETIA_SIDLEY000204848	12/16/2011	Trial Transcripts, Vol. 9, Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL)		X	403; HS
MDX0615				WITHDRAWN			
MDX0616	ENV_005093	ENV_005145	2012	Document titled, "EnvisionRx Plus Gold (DPP) 2012 Formulary (List of Covered Drugs)"		X	403; 901; HS; MIL; R
MDX0617				WITHDRAWN			
MDX0618	No Bates	No Bates	2012	2012 Profile, PHRMA, http://phrmadocs, phrma.org/sites/default/files/pdf/phrma_industry_profile.pdf		X	403; 901; HS; R
MDX0619	No Bates	No Bates	2012	FDA Zetia Label		X	NO
MDX0620				WITHDRAWN			
MDX0621				WITHDRAWN			
MDX0622				WITHDRAWN			
MDX0623	MRKZETIA000522994	MRKZETIA000523055	1/24/2012	Document titled, "Summary of Approved Pricing and Discounting Authority for All Merck Products Marketed in the US Market"		X	NO
MDX0624	MRKZETIA_SIDLEY000188135	MRKZETIA_SIDLEY000188178	1/26/2012	Mylan Pharm. Inc's Proposed Conclusions of Law, Schering Corp., et al. v. Mylan Pharm. Inc., et al., Case No. 09-cv-06383-JLL-ES, ECF No. 423		X	403; HS; MIL
MDX0625				WITHDRAWN			
MDX0626	No Bates	No Bates	2/28/2012	Merck & Co., Inc. 2011-Form-10-K		X	403; HS; MIL; R
MDX0627	MYL_ZETIA 000862	MYL_ZETIA 000866	3/13/2012	Correspondence from FDA to Mylan re "Bioequivalence Amendment"		X	403; HS; MIL
MDX0629	MRKZETIA_R000084623	MRKZETIA_R000084624	3/15/2012	Memo from G. Eater and Tammy Sprague to G. Bell, I. Duffy, P. Davish et al., re "Exception to ZETIA Medicare Part D authority-CVS/Caremark Tier 3(#1203-15-R00)"		X	HS; R
MDX0630	MRKZETIA000875909	MRKZETIA000875926	3/15/2012	Document titled, "CVS Caremark Account Team MC Branding Marketing Medicare D 2013 Zetia Proposal"		X	HS
MDX0631	Watson-Zetia_00010567	Watson-Zetia_00010689	3/23/2012	Letter from Watson to FDA re "Ezetimibe Tablets, 10 mg ANDA 200831 Sequence #0012 Bioequivalence Response to Information Request"		X	403; HS
MDX0632				WITHDRAWN			
MDX0633	MRKZETIA000550441	MRKZETIA000550443	3/30/2012	Email from S. Allen to S. Shermer and M. Copeland re "FW: Impact Rx Data - February 2012" with attachment		X	403; HS; MIL; R
MDX0634	SANDOZ-ZETIA-0000009	SANDOZ-ZETIA-0000010	3/30/2012	Sandoz document titled "Patent and Exclusivity Certification"		X	NO
MDX0635	No Bates	No Bates	2012	Express Scripts, "2011 Drug Trend Report," 2012		X	403; HS; MIL; R
MDX0636	SANDOZ-ZETIA-0000004	SANDOZ-ZETIA-0000005	4/2/2012	Letter from Sandoz to FDA re "ANDA #203931 Ezetimibe Tablets, 10mg Original ANDA Submission"		X	NO
MDX0638	PAR_00006499	PAR_00006500	4/11/2012	Email from P. Campanelli to M. Tropiano and T. Haughey re "FW: Zetia Slide.pptx" with attachment		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0641	MRKZETIA_SIDLEY000205387	MRKZETIA_SIDLEY000205388	5/3/2012	Order, Schering Corp. et al. v. Mylan Pharmaceuticals Inc., Case No. 9-cv-06383-JLL-MAH, ECF No. 448		X	403; MIL; R
MDX0642	MYL_ZETIA 000871	MYL_ZETIA 000877	5/4/2012	Letter from Mylan to FDA re "Bioequivalence Amendment"		X	403; MIL; R
MDX0643	MRKZETIA_SIDLEY000206431	MRKZETIA_SIDLEY000206434	5/17/2012	Final Judgment, Schering Corp., et al. v. Mylan Pharm., Case No. 09-6383 (JLL), ECF No. 453-1		X	403; MIL; R
MDX0644	MYL_ZETIA 010590	MYL_ZETIA 010590	5/22/2012	Telephone request from FDA to Mylan re Mylan ANDA 201790		X	403; MIL; R
MDX0645				WITHDRAWN			
MDX0646	No Bates	No Bates	2012	Bigelow, John P., Pharmaceutical Patents, Settlements, "Reverse Payments," and Exclusion, CPI Antitrust Chronicle (2012), 1-7		X	403; HS; MIL; R
MDX0647	MYL_ZETIA 010586	MYL_ZETIA 010589	6/6/2012	Letter from Mylan to FDA re "Telephone Amendment"		X	403; HS; MIL; R
MDX0648	MRKZETIA000526189	MRKZETIA000526190	7/23/2012	Email from G. Eater to G. Firestone and J. Niekelski re "WellPoint Commercial Request-Please reply by EOB Today"		X	403; HS; HWH; MIL; R
MDX0649				WITHDRAWN			
MDX0650	No Bates	No Bates	8/1/2012	Manual of Patent Examining Procedure, § 1402 Grounds for Filing [R-09.2012]		X	403; HS
MDX0652	MYL_ZETIA 010808	MYL_ZETIA 010809	8/6/2012	Correspondence from FDA to Mylan re "Telephone Amendment"		X	403; HS; MIL; R
MDX0653	SANDOZ-ZETIA-0000123	SANDOZ-ZETIA-0000126	8/24/2012	Letter from FDA to Sandoz re "Request to Withdraw Applications from the Generic Drug Backlog to Avoid Incurring Backlog Fee"		X	403
MDX0654	MYL_ZETIA 010812	MYL_ZETIA 010815	8/22/2012	Letter from Mylan to FDA re "Ezetimibe Tablets, 10 mg ANDA 201790 Sequence Number: 0005 (Response to Agency Correspondence Dated August 06, 2012)"		X	403; HS; MIL; R
MDX0655	MRKZETIA000600523	MRKZETIA000600529	9/13/2012	Email from M. Molano re 'UPDATE - Global Strategic Plan for Athero Portfolio (Brand Book) - 2013-2017"		X	403; HS; MIL; R
MDX0656	MYL_ZETIA 010824	MYL_ZETIA 010825	9/17/2012	Correspondence from FDA to Mylan re "Telephone Amendment"		X	403; HS; MIL; R
MDX0657	No Bates	No Bates	9/17/2012	Brief for Plaintiffs-Appellees, Merck Sharp & Dohme Corp et al. v. Mylan Pharm. Inc., No. 12-1434, Fed. Cir., ECF No. 23		X	403; HS; MIL; R
MDX0658	No Bates	No Bates	9/18/2012	Crouch, Dennis, Harvard's US OncoMouse Patents are All Expired (For the Time Being)," Patently-O (Sept. 18, 2012)		X	403; HS; MIL; R
MDX0659	MYL_ZETIA 010827	MYL_ZETIA 010829	9/24/2012	Letter from Mylan to FDA re "Ezetimibe Tablets, 10 mg ANDA 201790 Sequence Number: 0006 (Response to Agency Correspondence Dated September 17, 2012)"		X	403; HS; MIL; R
MDX0660	MRKZETIA_SIDLEY000006055	MRKZETIA_SIDLEY000006067	9/27/2012	Complaint, Merck Sharp & Dohme, et al. v. Sandoz Inc., Case No. 2:12-cv-06077 (JLL), ECF No. 1		X	403; HS; R
MDX0661	No Bates	No Bates	10/4/2012	Reply Brief for Defendant-Appellant, Merck Sharp & Dohme Corp et al. v. Mylan Pharm. Inc., No. 12-1434, Fed. Cir., ECF No. 27		X	403; HS; MIL; R
MDX0662	MRKZETIA000523220	MRKZETIA000523220	10/17/2012	PowerPoint presentation titled, Atherosclerosis Franchise Brand Review October 17th, 2012 US Market		X	403; HS; MIL; R
MDX0663	Teva-Zetia_00001991	Teva-Zetia_00001997	10/23/2012	Letter from FDA to Teva re "Complete Response"		X	NO
MDX0664				WITHDRAWN			
MDX0665	SANDOZ-ZETIA-0000011	SANDOZ-ZETIA-0000012	11/6/2012	Letter from Sandoz to FDA re "Patent Amendment"		X	NO
MDX0666	SANDOZ-ZETIA-0000037	SANDOZ-ZETIA-0000041	11/6/2012	Letter from Sandoz to FDA re "Bioequivalence Amendment"		X	NO
MDX0668	MRKZETIA000524610	MRKZETIA000524612	12/11/2012	Email from G. Brunner to G. Firestone, T. Donovan re "VYTORIN Message Effectiveness - WAVE 2" with attachment		X	403; HS; MIL; R
MDX0669				WITHDRAWN			
MDX0670	No Bates	No Bates	2013	Approved Drug Products with Therapeutic Equivalence Evaluations, FDA (33rd ed. 2013)		X	403; R
MDX0671	No Bates	No Bates	2013	Optum, "Retrospective Database Analysis," 2013		X	403; HS; MIL; R
MDX0672				WITHDRAWN			
MDX0673	No Bates	No Bates	1/2/2013	Rantanen, Jason, Federal Circuit Statistics – FY 2012, Patently-O.htm		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0674	MRKZETIA000893850	MRKZETIA000893850	1/25/2013	Health Strategies Group presentation to Merck entitled "Dyslipidemia Agents: Market Landscape – Final Presentation"		X	403; HS; MIL; R
MDX0675	No Bates	No Bates	2/7/2013	Judgment, Merck Sharp & Dohme Corp et al. v. Mylan Pharm. Inc., No. 12-1434, Fed. Cir.		X	403; HS; MIL; R
MDX0677	SANDOZ-ZETIA-0000166	SANDOZ-ZETIA-0000166	2/20/2013	Sandoz document titled "FDA communication"		X	NO
MDX0678	SANDOZ-ZETIA-0000166	SANDOZ-ZETIA-0000166	2/20/2013	Sandoz document titled "FDA communication"		X	NO
MDX0679	No Bates	No Bates	2/28/2013	Merck & Co., Inc. 2012-Form-10-K		X	403; HS; MIL; R
MDX0681	No Bates	No Bates	3/22/2013	Scott Hemphill and Bhaven Sampat, Drug Patents at the Supreme Court, 339 Science 1386-87 (22 March 2013)		X	403; HS; R
MDX0682				WITHDRAWN			
MDX0683	GLENMARK-ZETIA-00281722	GLENMARK-ZETIA-00281723	4/1/2013	Email from A. Maffia to S. Krishan et al. "RE: Ezetimibe Tablets - Alternate mfg site to Par"		X	HS
MDX0684	No Bates	No Bates	2013	Olson, Luke M. et al., The Effect of Generic Drug Competition on Generic Drug Prices During the Hatch-Waxman 180-Day Exclusivity Period, The Federal Trade Commission (2013)		X	403; HS
MDX0685	MYL_ZETIA 010987	MYL_ZETIA 010989	4/10/2013	Correspondence from FDA to Mylan re "Easily Correctrable Labeling Deficiency"		X	403; HS; MIL; R
MDX0686	GLENMARK-ZETIA-00312092	GLENMARK-ZETIA-00312092	4/19/2013	Letter from Glenmark to FDA re "Ezetimibe (Process II) as manufactured in Gujarat, India"		X	NO
MDX0687	MYL_ZETIA 010922	MYL_ZETIA 010924	4/22/2013	Letter from Mylan to FDA re "Easily Correctable Labeling Deficiency Amendment"		X	403; HS; MIL; R
MDX0688	No Bates	No Bates	4/24/2013	Final Judgment, Schering Corp. et al., v. Impax Lab. Inc., Case No. 10-cv-4270-JLL-MAH, ECF No. 43		X	403; HS; R
MDX0689	MRKZETIA_R000089958	MRKZETIA_R000089958	5/1/2013	Memo from G. Eater and Tammy Sprague to G. Bell, I. Duffy, P. Davish et al., re "Exception to ZETIA and VYTORIN Medicare Part D authority-CVS/Caremark Tier 3(#1305-01-SPR)		X	403; HS; MIL; R
MDX0690	No Bates	No Bates	5/3/2013	FDA Letter - Liptruzet Approval		X	403; HS; MIL; R
MDX0691	MRKZETIA_SIDLEY000007968	MRKZETIA_SIDLEY000008001	5/6/2013	Sandoz Inc.'s Answer and Counterclaims to Complaint for Patent Infringement, Merck Sharp & Dohme, et al. v. Sandoz Inc., Case No. 2:12-cv-06077 (JLL), ECF No. 23		X	403; HS; R
MDX0692	SANDOZ-ZETIA-0000167	SANDOZ-ZETIA-0000167	5/28/2013	Sandoz document titled "FDA communication"		X	NO
MDX0693	SANDOZ-ZETIA-0000167	SANDOZ-ZETIA-0000167	5/28/2013	Sandoz document titled "FDA communication"		X	NO
MDX0695	No Bates	No Bates	2013	Bokhari, Farasat A. S. et al., Entry in the ADHD Drug Market: Welfare Impact of Generics and Me-Too's, The Journal of Industrial Economics (2013), Vol LXI No. 2, 339-392		X	403; HS; R
MDX0696	Teva-Zetia_00001968	Teva-Zetia_00001975	7/3/2013	Letter from Teva to FDA re "Resubmission/After Action - Minor Amendment"		X	403
MDX0697				WITHDRAWN			
MDX0699	MYL_ZETIA 000038	MYL_ZETIA 000042	8/7/2013	Letter from FDA to Mylan re tentative approval of Mylan ANDA 201790		X	403; HS; MIL; R
MDX0700	MYL_ZETIA 011186	MYL_ZETIA 011190	8/7/2013	Letter from FDA to Mylan re tentative approval of Mylan's ANDA 201790		X	403; HS; MIL; R
MDX0701	MRKZETIA000600509	MRKZETIA000600512	8/9/2013	Email from M. Fornwall to D. Cole, et al. re "LOE scenario modeling"		X	NO
MDX0702	No Bates	No Bates	8/12/2013	"Teva, Perrigo to Launch Generic Temodar," Genetic Engineering & Biotechnology News		X	403; HS; MIL; R
MDX0703	SANDOZ-ZETIA-0000168	SANDOZ-ZETIA-0000168	8/12/2013	Sandoz document titled "FDA communication"		X	NO
MDX0704	SANDOZ-ZETIA-0000168	SANDOZ-ZETIA-0000168	8/12/2013	Sandoz document titled "FDA communication"		X	NO
MDX0706	Watson-Zetia_00011192	Watson-Zetia_00011197	8/15/2013	Correspondence from FDA to Watson re "Complete Response"		X	NO
MDX0707	No Bates	No Bates	8/23/2013	Consent Order Staying Action, Schering Corp. et al., v. Actavis Inc. et al., 2:11-cv-06067, ECF No. 19		X	403; HS; R
MDX0709	MRKZETIA_R000048316	MRKZETIA_R000048343	8/30/2013	Settlement Agreement between Merck Sharp & Dohme Corporation and Sandoz		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0711	MRKZETIA000526668	MRKZETIA000526669	9/3/2013	Email from J. Liebel to S. Okin and G. Firestone re "Clyburn Revised Update for 9-6-13 Meeting CFM v2. pptx" with attachment		X	403; HS; MIL; R
MDX0712	MRKZETIA_SIDLEY000013042	MRKZETIA_SIDLEY000013044	9/9/2013	Consent Judgment, Merck Sharp & Dohme, et al. v. Sandoz Inc., Case No. 2:12-cv-06077 (JLL), ECF No. 48		X	HS; R
MDX0715	MRKZETIA000519753	MRKZETIA000519753	10/3/2013	PowerPoint presentation titled, "US Athero Franchise 2013-2018 5YP Global Alignment US Revenue Forecasting"		X	403; HS; R
MDX0716	MRKZETIA000600580	MRKZETIA000600583	10/7/2013	Email from M. Fornwall to D. Cole re "Athero profit plan templates v1.ppt" with attachment		X	403; HS; MIL; R
MDX0717	MRKZETIA_R000092849	MRKZETIA_R000092849	10/18/2013	PowerPoint presentation titled, Atherosclerosis Franchise Brand Review October 18th, 2013 US Market		X	403; HS; HWH; MIL; R
MDX0718	GLENMARK-ZETIA-00202257	GLENMARK-ZETIA-00202257	10/29/2013	Excel spreadsheet with file name: zetia projection 10-29-2013r1.xls		X	NO
MDX0719	GLENMARK-ZETIA-00202267	GLENMARK-ZETIA-00202268	10/29/2013	Email from M. Blashinsky to P. Dutra re "Zetia sales projections" with attachment		X	NO
MDX0720	GLENMARK-ZETIA-00202268	GLENMARK-ZETIA-00202268	10/29/2013	Excel spreadsheet with file name: zetia projection 10-29-2013.xls		X	NO
MDX0721	No Bates	No Bates	10/29/2013	Testimony of Robert A. Armitage before the House Judiciary Committee on the Innovation Act (October 29, 2013)		X	403; HS; R
MDX0722	GLENMARK-ZETIA-00216208	GLENMARK-ZETIA-00216210	11/20/2013	Email from M. Blashinsky to A. Gupta and P. Shinde "RE: Zetia sales projections" with attachment		X	NO
MDX0723	No Bates	No Bates	11/29/2013	FDA Letter - Caduet Generic Approval		X	403; HS; MIL; R
MDX0724	GLENMARK-ZETIA-00220775	GLENMARK-ZETIA-00220776	12/3/2013	Email from P. Shinde to V. Soni re "FW: Zetia sales projections" with attachment		X	HS
MDX0725	SANDOZ-ZETIA-0000161	SANDOZ-ZETIA-0000161	12/12/2013	Email from R. Gaines to C. Uhrn "RE: ANDA 203931. Ezetimibe Tablets"		X	HS
MDX0726	No Bates	No Bates	12/18/2013	Grundy SM. Then and Now: ATP III v IV. American College of Cardiology 2013 Dec 18		X	403; HS; MIL; R
MDX0727				WITHDRAWN			
MDX0728	No Bates	No Bates	2014	Addanki, Sumanth et al., Activating Actavis: Economic Issues in Applying the Rule of Reason to Reverse Payment Settlements, Minnesota Journal of Law, Science & Technology (2014), Vol. 15, No. 1 , 77-94		X	403; HS; R
MDX0729	No Bates	No Bates	2014	Harris, Barry G. et al., Activating Actavis: A More Complete Story, Antitrust by American Bar Association (2014), Vol. 28, No. 2, 83-89		X	403; HS; R
MDX0730				WITHDRAWN			
MDX0731	No Bates	No Bates	2014	Ross, Joseph S. et al., Trends in Use of Ezetimibe After the ENHANCED Trial, 2007 Through 2010, American Medical Association (2014), Vol. 174, No. 9, 1486-1493.		X	403; HS; R
MDX0732	GLENMARK-ZETIA-00202256	GLENMARK-ZETIA-00202257	1/15/2014	Email from M. Blashinsky to V. Yadav, cc'ing P. Dutra "RE: Ezetimibe (Zetia) Business Case" with attachment		X	NO
MDX0733	GLENMARK-ZETIA-00202253	GLENMARK-ZETIA-00202253	1/16/2014	Excel spreadsheet with file name: NPV Ezetimibe 16 Jan 2014.xlsx		X	NO
MDX0734	GLENMARK-ZETIA-00202294	GLENMARK-ZETIA-00202294	1/24/2014	Excel spreadsheet with file name: NPV Ezetimibe 24 Jan 2014.xlsx		X	NO
MDX0735	GLENMARK-ZETIA-00211772	GLENMARK-ZETIA-00211772	1/28/2014	Excel spreadsheet with file name: NPV Ezetimibe 28 Jan 2014 v3.xlsx		X	NO
MDX0736	GLENMARK-ZETIA-00234719	GLENMARK-ZETIA-00234719	1/26/2014	Excel spreadsheet with file name: NPV Ezetimibe 29 Jan 2014.xlsx		X	NO
MDX0737				WITHDRAWN			
MDX0738	SANDOZ-ZETIA-0000130	SANDOZ-ZETIA-0000133	2/10/2014	Letter from FDA to Sandoz re "Update summary of filed and pending original ANDA(s)"		X	NO
MDX0739	No Bates	No Bates	2/27/2014	Merck & Co., Inc. 2013-Form-10-K		X	403; HS; MIL; R
MDX0740	No Bates	No Bates	2014	Express Scripts, "2013 Drug Trend Report," 2014		X	403; HS; MIL; R
MDX0741	ZETIA-PAINTERS-000274	ZETIA-PAINTERS-000307	4/1/2014	Prescription Drug Program Management Services Agreement between Citizens Rx, LLC and Painters District Council No. 30 Health & Welfare Fund		X	NO
MDX0742	SANDOZ-ZETIA-0000171	SANDOZ-ZETIA-0000171	4/18/2014	Sandoz document titled "FDA communication"		X	NO
MDX0743	SANDOZ-ZETIA-0000171	SANDOZ-ZETIA-0000171	4/18/2014	Sandoz document titled "FDA communication"		X	NO
MDX0744	No Bates	No Bates	4/21/2014	Sanofi-Aventis v. Glenmark Pharm. Inc., 748 F.3d 1354		X	403; HS; R
MDX0745				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0746	MRKZETIA000547886	MRKZETIA000547888	4/29/2014	Email from K, Robinson to G. Eater re "Pricing Committee - Zetia Family discussion"		X	HS
MDX0747	No Bates	No Bates	2014	Liptruzet Label		X	403; HS; MIL; R
MDX0748				WITHDRAWN.			
MDX0750	GLENMARK-ZETIA-00204856	GLENMARK-ZETIA-00204861	5/13/2014	Letter from Glenmark to FDA re "Gratuitous Pre-Approval Amendment"		X	NO
MDX0751	Watson-Zetia_00011187	Watson-Zetia_00011191	5/15/2014	Letter from Watson to FDA re "Resubmission/After Action- Minor Amendment"		X	NO
MDX0752	MRKZETIA000599022	MRKZETIA000599029	5/21/2014	Email from K. Pendleton to G. Firestone re "FOR YOUR REVIEW: DRAFT Pricing Deck for Conversation with R. Hartz Tomorrow" with attachments		X	403; HS; MIL; R
MDX0753	MRKZETIA000533503	MRKZETIA000533503	6/1/2014	PowerPoint Presentation titled, "LOE Payer Strategy Kick-Off Meeting"		X	403; HS; R
MDX0755	SUN-EZETIMIBIE_00017510	SUN-EZETIMIBIE_00017514	6/17/2014	Letter from Ohm to FDA re "ANDA 207311 Ezetimibe Tablets, 10 mg"		X	R
MDX0756				WITHDRAWN			
MDX0757	No Bates	No Bates	6/24/2014	Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on The Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation 2014;129:S1–S45		X	403; HS; MIL; R
MDX0758	MRKZETIA000600195	MRKZETIA000600195	7/8/2014	Email T. Sprague to P. Davish re "VYTORIN/ZETIA pricing action"		X	403; HS; HWH; MIL; R
MDX0759				WITHDRAWN			
MDX0760	MRKZETIA000605015	MRKZETIA000605015	7/28/2014	PowerPoint presentation titled, "Draft USA Athero Franchise LOE Strategy"		X	403; HS; R
MDX0761	GLENMARK-ZETIA-00204852	GLENMARK-ZETIA-00204854	9/12/2014	Letter from Glenmark to FDA re "Withdrawal of Gratuitous Pre-Approval Amendment"		X	NO
MDX0762	SANDOZ-ZETIA-0000172	SANDOZ-ZETIA-0000172	9/18/2014	Sandoz document titled "FDA communication"		X	NO
MDX0763	SANDOZ-ZETIA-0000172	SANDOZ-ZETIA-0000172	9/18/2014	Sandoz document titled "FDA communication"		X	NO
MDX0764	GLENMARK-ZETIA-00178533	GLENMARK-ZETIA-00178535	9/26/2014	Email from S. Sridiharan to T. Coughlin, P. Campanelli, I. Gruber, et al. "RE: Par - Glenmark JSC" without attachment		X	HS
MDX0765	No Bates	No Bates	9/30/2014	U.S. Patent 8,846,966		X	403; R
MDX0766				WITHDRAWN			
MDX0768	GLENMARK-ZETIA-00209193	GLENMARK-ZETIA-00209196	10/10/2014	Letter from Glenmark to FDA re "Minor Amendment - Final Approval Request"		X	NO
MDX0769	GLENMARK-ZETIA-00209174	GLENMARK-ZETIA-00209177	10/29/2014	Email from M. Mathias to C. Spinks et al. re "Submitted to FDA: Ezetimibe Tablets 10 mg : ANDA # 078560" with attachment		X	NO
MDX0770	Teva-Zetia_00002832	Teva-Zetia_00002835	10/29/2014	Correspondence from FDA to Teva re "Complete Response"		X	NO
MDX0771	GLENMARK-ZETIA-00256697	GLENMARK-ZETIA-00256697	11/20/2014	Excel spreadsheet with file name: 2014_11_20_US LRP.xlsx		X	HS; HWH
MDX0773	No Bates	No Bates	11/20/2014	Press Release titled, "AMNEAL LAUNCHES AG FOR NOVO NORDISK'S ACTIVELLA® Authorized Generic offers brand product plus patient savings"		X	HS
MDX0774	No Bates	No Bates	11/20/2014	Amneal Launches AG for Novo Nordisk's Activella - Authorized Generic Offers Brand Product Plus Patient Savings		X	HS; R
MDX0775	Teva-Zetia_00002819	Teva-Zetia_00002821	11/20/2014	Letter from Teva to FDA re "Resubmission Minor Complete Response Amendment Chemistry"		X	NO
MDX0776	MRKZETIA000519959	MRKZETIA000519961	12/5/2014	Email from J. Liebel to G. Dunlop, et al. "RE: Zetia Family Request"		X	403; HS; MIL; R
MDX0777	SANDOZ-ZETIA-0000173	SANDOZ-ZETIA-0000173	12/23/2014	Sandoz document titled "FDA communication"		X	NO
MDX0778	SANDOZ-ZETIA-0000173	SANDOZ-ZETIA-0000173	12/23/2014	Sandoz document titled "FDA communication"		X	NO
MDX0779	GLENMARK-ZETIA-00211818	GLENMARK-ZETIA-00211818	1/2015	Excel spreadsheet with file name: Copy of Ezetimibe (Zetia) forecast Jan 2015.xlsx		X	NO
MDX0780	GLENMARK-ZETIA-00214483	GLENMARK-ZETIA-00214483	11/27/2014	Excel spreadsheet with file name: Copy of Zetia_RevenueModel_3rdMar_PL_UpdatedSMART_Q12015_May1 6-4-15.xlsx		X	NO
MDX0781				WITHDRAWN			
MDX0782	No Bates	No Bates	2015	Moon, J. et al. Abstract, Generic Competition and Authorized Generics in the United States, Value in Health 18 (2015)		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0783	MRKZETIA000854696	MRKZETIA000854701	1/6/2015	Email from James Lengel to C. Antrosiglio "RE: united/optum timing /approval" with attachment		X	403; HS; HWH; MIL; R
MDX0785	GLENMARK-ZETIA-00292655	GLENMARK-ZETIA-00292657	1/23/2015	Letter from Glenmark to FDA re "ANDA 078560 Ezetimibe Tablets, 10mg Sequence Number 0014"		X	403; HS; MIL; R
MDX0786	GLENMARK-ZETIA-00236137	GLENMARK-ZETIA-00236138	2/2/2015	Calendar invite from D. Vaysman to G. Goya, J. D'souza, V. Soni et al. re "Glenmark / Greenhill Call - Dr. Soni"		X	403; HS; HWH
MDX0787	MRKZETIA_R000005370	MRKZETIA_R000005370	2/20/2015	PowerPoint presentation titled, "US Ezetimibe LOE planning and implementation kick-off meeting"		X	403; HS; MIL; R
MDX0788	No Bates	No Bates	2/27/2015	Merck & Co., Inc. 2014-Form-10-K		X	403; HS; MIL; R
MDX0789				WITHDRAWN			
MDX0790	GLENMARK-ZETIA-00435580	GLENMARK-ZETIA-00435580	3/28/2015	Email from R. Pettus to V. Soni re "Privileged and Confidential - Assessment of Ezetimibe Settlement Agreement" (without attachment)		X	NO
MDX0791	APOTEX0000029	APOTEX0000032	3/31/2015	Letter from Apotex to FDA re "Original Abbreviated New Drug Application Pre-Assigned ANDA No. 208322 Ezetimibe Tablets 10 MG"		X	R
MDX0792	APOTEX0000033	APOTEX0000033	3/31/2015	Apotex Patent Certification Statement		X	HS; R
MDX0793				WITHDRAWN			
MDX0794	Watson-Zetia_00011312	Watson-Zetia_00011313	4/16/2015	Letter from FDA to Watson re "Information Request"		X	HS; HWH
MDX0795	MRKZETIA000520597	MRKZETIA000520599	5/6/2015	Email from J. Sanders to L. Stevens, M. Copeland, James Burke et al. "RE: Cleveland Clinic Health Network Formulary Change for ZETIA and VYTORIN"		X	403; HS; MIL; R
MDX0796	GLENMARK-ZETIA-00184436	GLENMARK-ZETIA-00184438	5/8/2015	Email from P. Wagle to D. Makhey et al. re "Ezetimibe (API + dosage) planning discussion"		X	HS
MDX0797	GLENMARK-ZETIA-00184436	GLENMARK-ZETIA-00184438	5/8/2015	Email from P. Wagle to various re "Ezetimibe (API + dosage_ planning discussion"		X	HS
MDX0798	GLENMARK-ZETIA-00184432	GLENMARK-ZETIA-00184434	5/14/2015	Email from P. Wagle to D. Makhey et al. re "Ezetimibe (API + dosage) planning discussion"		X	HS
MDX0799	GLENMARK-ZETIA-00184435	GLENMARK-ZETIA-00184435	5/14/2015	PowerPoint presentation with first slide titled "Ezetimibe - Overview"		X	HS
MDX0800	Watson-Zetia_00011310	Watson-Zetia_00011311	5/15/2015	Letter from Watson to FDA re "ANDA 200831 Ezetimibe Tablets, 10 mg Sequence 0016"		X	NO
MDX0801	No Bates	No Bates	5/19/2015	FDA/CDER SBIA Chronicles: Patents and Exclusivity		X	403; 901; R
MDX0802	Teva-Zetia_00002859	Teva-Zetia_00002862	5/26/2015	Correspondence from FDA to Teva re "Complete Response"		X	403; MIL; R
MDX0803	GLENMARK-ZETIA-00184430	GLENMARK-ZETIA-00184431	6/1/2015	Letter from FDA to Glenmark re deficiencies		X	HS
MDX0804	GLENMARK-ZETIA-00199723	GLENMARK-ZETIA-00199723	6/2015	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast June 2015 NPF.XLSX		X	NO
MDX0806	GLENMARK-ZETIA-00195659	GLENMARK-ZETIA-00195662	6/5/2015	Letter from Glenmark to FDA re "Information Request - Product Quality # 118127"		X	HS
MDX0808	GLENMARK-ZETIA-00201963	GLENMARK-ZETIA-00201977	6/16/2015	Email from S. Sridharan to M. Van Allen et al. re "JSC Notes" with attachments		X	HS
MDX0809	No Bates	No Bates	6/18/2015	Cannon C, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387–2397		X	403; 901; MIL; R
MDX0812	No Bates	No Bates	6/26/2015	FDA Zetia Generic Approval		X	NO
MDX0813	No Bates	No Bates	6/26/2015	Letter from FDA to Glenmark re final approval of ANDA for generic ezetimibe		X	NO
MDX0814	GLENMARK-ZETIA-00202055	GLENMARK-ZETIA-00202055	7/2015	Excel spreadsheet with file name: Glenmark Summary July 2015.xlsx		X	NO
MDX0816	GLENMARK-ZETIA-00187671	GLENMARK-ZETIA-00187677	7/7/2015	Letter from Glenmark to FDA re "Prior Approval Supplement"		X	HS
MDX0817	RDC-ZET-029025	RDC-ZET-029265	7/8/2015	Consent Order, United States v. Rochester Drug Cooperative, Inc., ECF No. 2		X	403; 404; HS; MIL; R
MDX0819	GLENMARK-ZETIA-00185719	GLENMARK-ZETIA-00185726	7/10/2015	Letter from Glenmark to FDA re "Prior Approval Supplement"		X	HS
MDX0821	GLENMARK-ZETIA-00290991	GLENMARK-ZETIA-00290991	7/13/2015	Email from L. Forino to C. Spinks re "FW: Pay.Gov Payment Confirmation: FDA User Fees"		X	HS
MDX0822	GLENMARK-ZETIA-00177486	GLENMARK-ZETIA-00177486	7/14/2015	Excel spreadsheet with file name: Zetia Revenue Model 7-14-15.xlsx		X	NO
MDX0823	No Bates	No Bates	7/16/2015	Pollock, B., The Backlog at OGD – a Historical Look, Lachman Consultants		X	403; 901; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0824	No Bates	No Bates	7/27/2015	Teva Form 6-K dated July 2015		X	403; 901; HS; MIL; R
MDX0825	No Bates	No Bates	7/27/2015	Article, "Teva Pharmaceuticals to Buy Allergan's Generic Business," N.Y. Times		X	901; HS
MDX0826				WITHDRAWN			
MDX0827	SANDOZ-ZETIA-0000052	SANDOZ-ZETIA-0000073	8/5/2015	Letter from Sandoz to FDA re "Resubmission Minor Complete Response Amendment Chemistry / Bioequivalence"		X	HS
MDX0828	Teva-Zetia_00002851	Teva-Zetia_00002857	8/13/2015	Letter from Teva to FDA re "Resubmission Minor Complete Response Amendment Chemistry"		X	NO
MDX0830	GLENMARK-ZETIA-00287556	GLENMARK-ZETIA-00287557	8/20/2015	Letter from FDA to Glenmark re "Information Request"		X	403; R
MDX0831	GLENMARK-ZETIA-00276599	GLENMARK-ZETIA-00276605	8/21/2015	Letter from Glenmark to FDA re "Change Being Effected - 30 Days Supplement"		X	HS
MDX0832	GLENMARK-ZETIA-00286187	GLENMARK-ZETIA-00286193	8/21/2015	Letter from Glenmark to FDA re "ANDA #078560, Ezetimibe Tablets, 10 mg, Change being Effected 30 days (CBE-30): to propose use of alternate manufacturing facility for the drug product (Appco Pharma LLC, USA Sequence No. 0022"		X	HS
MDX0835	MRKZETIA000859594	MRKZETIA000859683	8/31/2015	Document titled, "Summary of Approved Pricing and Discounting Authority for All Merck Products Marketed in the US Market"		X	403; HS
MDX0836	GLENMARK-ZETIA-00176836	GLENMARK-ZETIA-00176836	2015	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Sept 2015 NPF.XLSX		X	NO
MDX0837	GLENMARK-ZETIA-00176756	GLENMARK-ZETIA-00176757	9/3/2015	Letter from FDA to Glenmark acknowledging receipt of the August 19, 2015 amendment and approving the ANDA		X	NO
MDX0838	GLENMARK-ZETIA-00192641	GLENMARK-ZETIA-00192642	9/3/2015	Letter from FDA to Glenmark acknowledging receipt of the August 28, 2015 amendment and approving the ANDA		X	NO
MDX0839	GLENMARK-ZETIA-00192641	GLENMARK-ZETIA-00192642	9/3/2015	Letter from FDA to Glenmark acknowledging receipt of the August 28, 2015 amendment and approving the ANDA		X	NO
MDX0840	GLENMARK-ZETIA-00195263	GLENMARK-ZETIA-00195267	9/4/2015	Email from P. Kulkami to S. Thirumanathu V. re "Questions for Glenmark - Ezetimibe"		X	HS
MDX0841	GLENMARK-ZETIA-00283390	GLENMARK-ZETIA-00283442	9/4/2015	Email from S. Mungekar to K. Vanam et al. re "FDA Call - General Guidance" with attachments		X	HS
MDX0842	GLENMARK-ZETIA-00287538	GLENMARK-ZETIA-00287539	9/4/2015	Letter from FDA to Glenmark re "Approval"		X	NO
MDX0843	GLENMARK-ZETIA-00351303	GLENMARK-ZETIA-00351304	9/4/2015	Letter from FDA to Glenmark re review of "Changes Being Effected in 20 Days" and approving the ANDA		X	403; CU; HS; R
MDX0846	ENV_008652	ENV_008682	9/14/2015	2015 Commercial Description Formulary Four Tier Program		X	403; 901; HS; MIL; R
MDX0847	MRKZETIA_R000005261	MRKZETIA_R000005262	9/25/2015	Email from J. Liebel to J. Burke re "LOE Overview (2).pptx [Confidential]" with attachment		X	HS
MDX0848	MRKZETIA000854906	MRKZETIA000854908	10/9/2015	Email from T. Salfi to D. Pakula re "Project Willard - Zetia AGx Kick-Off Meeting Follow-up [Sensitive]" with attachments		X	HS; INC
MDX0849	MRKZETIA000854906 MRKZETIA000854908	MRKZETIA000854906 MRKZETIA000854908	10/9/2015	Presentation titled "Project Willard Kick Off Meeting Zetia Authorized Generic October 8, 2015"		X	HS
MDX0850	SUN-EZETIMIBIE_00017578	SUN-EZETIMIBIE_00017578	10/16/2015	Ohm "ANDA 207311 Ezetimibe Tablets, 10 mg Response to Information Request - Bioequivalence - Dissolution (Reference #175391) dated October 16, 2015"		X	403; R
MDX0851	GLENMARK-ZETIA-00277382	GLENMARK-ZETIA-00277383	10/20/2015	Glenmark document titled "Visit to MSN on October 20, 2015"		X	HS
MDX0852	No Bates	No Bates	2015	National Lipid Association, "Commonly Used Lipidcentric ICD-10 (ICD-9) Codes," 2015		X	403; 901; HS; MIL; R
MDX0853	MRKZETIA000854608	MRKZETIA000854611	11/2/2015	Merck Memo from C. Antrosiglio to B. McMahon, P. Davis, P. Magri et al., re "Increased Discount Authority for Zetia After Loss of Exclusivity"		X	403; HS; R
MDX0854	SANDOZ-ZETIA-0000074	SANDOZ-ZETIA-0000076	11/5/2015	Letter from Sandoz to FDA re "Information Request Chemistry Reference # 177498"		X	NO
MDX0855	SUN-EZETIMIBIE_00017613	SUN-EZETIMIBIE_00017614	11/12/2015	Letter from Sun to FDA re " Reference: ANDA 207311, Ezetimibe Tablets, 10mg, Response to Information Request Bioequivalence - Dissolution Reference # 175391"		X	403; R
MDX0856	Teva-Zetia_00003100	Teva-Zetia_00003102	11/13/2015	Letter from FDA to Teva re "Tentative Approval"		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0857	No Bates	No Bates	11/20/2015	Food and Drug Administration, "Determination that LIPTRUZET (Ezetimibe and Atorvastatin) Tablets, 10 Milligrams/10 Milligrams, 10 Milligrams/20 Milligrams, 10 Milligrams/40 Milligrams, and 10 Milligrams/80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"		X	403; 901; HS; MIL; R
MDX0858	No Bates	No Bates	11/20/2015	Determination That LIPTRUZET (Ezetimibe and Atorvastatin) Tablets Were Not Withdrawn from Sale for Reasons of Safety or Effectiveness. Federal Register		X	403; 901; HS; MIL; R
MDX0859	AMN-ZETIA0000017	AMN-ZETIA0000051	12/4/2015	Letter from Amneal to FDA re "ANDA #208803 (Sequence #0001) Ezetimibe Tablets, 10mg, Quality - Response to Information Request "		X	403; R
MDX0860	No Bates	No Bates	12/4/2015	Mercado, Carla et al., Prevalence of Cholesterol Treatment Eligibility and Medication Use Among Adults - United States, 2005-2012, Center for Disease Control and Prevention (2015), Vol. 64, No. 47 , 1305-1320		X	403; HS; R
MDX0862	MRKZETIA000521962	MRKZETIA000522061	12/14/2015	IMPROVE -IT Study titled, "NDA 021687 and NDA 021445 VYTORIN ® (ezetimibe/simvastatin) / ZETIA ® (ezetimibe) Endocrinologic and Metabolic Drug Products Advisory Committee Briefing Document December 14, 2015 Merck Sharp and Dohme"		X	HS; HWH; R
MDX0863	Watson-Zetia_00011452	Watson-Zetia_00011454	12/15/2015	Letter from FDA to Watson re "Tentative Approval"		X	NO
MDX0864	APOTEX0000023	APOTEX0000027	12/16/2015	Letter from FDA to Apotex re "Information Request"		X	403; R
MDX0865	GLENMARK-ZETIA-00145435	GLENMARK-ZETIA-00145435	2016	Document titled, "Par Pharmaceutical Companies Inc. Ezetimibe Tabs Sales and Profit Split 2016"		X	901; HS
MDX0866				WITHDRAWN			
MDX0867	No Bates	No Bates	2016	Pharm. Research & Mfrs. of Am., 2016 Biopharmaceutical Research Industry Profile 2 (2016), http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-profile.pdf		X	403; 901; HS; MIL; R
MDX0869	No Bates	No Bates	2016	Leitzan, Erika et al., The Law of 180-Day Exclusivity, Food and Drug Law Journal (2016),Vol. 71, No. 3 , 327-400		X	403; 901; HS; MIL; R
MDX0870	No Bates	No Bates	2016	DiMasi J. et al., Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs, J. Health Economics, 47:20-33 (2016)		X	403; 901; HS; MIL; R
MDX0872				WITHDRAWN			
MDX0873				WITHDRAWN			
MDX0874	MRKZETIA_R000002645	MRKZETIA_R000002650	1/22/2016	Email from C. Antrosiglio to I. Duffy, J. Hall, J. Schwarz et al. re "Notification of Approval: Approval Requested: Amendment to ZETIA LOE pricing doc: #1512-18-TSS [Confidential]" with attachment		X	403; HS; R
MDX0876	No Bates	No Bates	2/3/2016	Article titled, "Branding: When One is Not Enough"		X	403; 901; HS; MIL; R
MDX0877	GLENMARK-ZETIA-00411214	GLENMARK-ZETIA-00411220	2/11/2016	Email from R. Kasula to P. Wagle and V. Kumar "RE: Ezetimibe - Launch update"		X	HS
MDX0878	GLENMARK-ZETIA-00411221	GLENMARK-ZETIA-00411221	2/11/2016	Printout of Excel spreadsheet with file name "Ezetimibe schedule 11-02-16.xlsx"		X	HS
MDX0879	SANDOZ-ZETIA-0000147	SANDOZ-ZETIA-0000149	2/16/2016	Letter from FDA to Sandoz re "Tentative Approval"		X	HS
MDX0880	MRKZETIA_R000058405	MRKZETIA_R000058406	2/25/2016	Email from M. Copeland to various re "LOE discussion - slides for 10am meeting [Confidential]" with attachment		X	HS
MDX0881	No Bates	No Bates	2/26/2016	Merck & Co., Inc. 2015-Form-10-K		X	403; 901; HS; MIL; R
MDX0882	MRKZETIA000522314	MRKZETIA000522315	3/14/2016	Email from J. Turner to M. Copeland re "NBRx Weekly (February 26, 2016 Data) with attachment		X	403; HS; MIL; R
MDX0883	MRKZETIA000601848	MRKZETIA000601849	3/15/2016	Presentation titled "Atherosclerosis Franchise Brand Review March 14, 2016"		X	403; HS; MIL
MDX0884				WITHDRAWN			
MDX0885	AMN-ZETIA0002090	AMN-ZETIA0002096	3/25/2016	Letter from Amneal to FDA re " ANDA #208803 (Sequence #0005) Ezetimibe Tablets, 10 mg, Information Request: Bioequivalence - Reference #223077"		X	403; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0886	APOTEX0000007	APOTEX0000010	3/29/2016	Letter from FDA to Apotex re "Information Request"		X	403; R
MDX0887	MRKZETIA000522438	MRKZETIA000522442	4/1/2016	Email from J. Turner to M. Copeland re "FW: IMS Deliverable: Merck - Zetia and Vytorin LRx Custom Tracking Jan-16 data month (Opp #1094972)" with attachments		X	403; HS; MIL; R
MDX0888				WITHDRAWN			
MDX0889	ZETIA-PAINTERS-000123	ZETIA-PAINTERS-000130	4/1/2016	Painters District Council No. 30 Health & Welfare Fund Summary of Benefits and Coverage: What this Plan Covers & What Costs Coverage Period: 04/01/2016-03/31/2017 Coverage For: Individual + Family | Plan Type: PPO		X	403; HS; MIL; R
MDX0890	SUN-EZETIMIBIE 00018383	SUN-EZETIMIBIE 00018384	4/8/2016	Correspondence from FDA to Sun re "Easily Correctable Deficiency"		X	403; R
MDX0891	No Bates	No Bates	4/18/2016	Food and Drug Administration, "AbbVie Inc. Withdrawal of Approval of New Drug Application for ADVICOR and SIMCOR," 2016		X	403; 901; HS; MIL; R
MDX0892	No Bates	No Bates	4/18/2016	AbbVie Inc. Simcor and Advicor Withdrawal. Federal Register		X	403; 901; HS; MIL; R
MDX0893	No Bates	No Bates	4/29/2016	FDA Letter - Crestor Gereneric Approval		X	403; MIL; R
MDX0894	ALKEM000022	ALKEM000025	5/5/2016	Email from H. Schiff to Pal et al. re " FWD: ANDA 209234 Filing Review Comments"		X	403; CF; INC; R
MDX0895	ALKEM000018	ALKEM000021	5/6/2016	Letter from Alkem to FDA re "ANDA #209234 - Ezetimibe Tablets, USP 10mg Quality - Response to Informative Request"		X	403; R
MDX0896	MRKZETIA_R000029337	MRKZETIA_R000029339	5/10/2016	Email from M. Copeland to K. Hayward re "LOE Deck - Z/V [Confidential]" with attachment		X	HS
MDX0897	CVS-ZET-0009514	CVS-ZET-0009522	5/23/2016	Email from J. Ptaszek to R. Clements re "May CVS Retail 2018 Budget Submission & May Generic Launch Expectations Discrepancies" and Attachment		X	403; HS; MIL; R
MDX0898	APOTEX0000011	APOTEX0000012	5/27/2016	Letter from FDA to Apotex re "Information Request"		X	403; R
MDX0899	AMN-ZETIA0002413	AMN-ZETIA0002418	6/2/2016	Letter from Amneal to FDA re "ANDA #208803 (Sequence #0006), Ezetimibe Tablets, 10mg, Easily Correctible Deficiency Bioquivalence Reference #8079480"		X	403; R
MDX0901	GLENMARK-ZETIA-00245035	GLENMARK-ZETIA-00245035	6/8/2016	Letter from L. Jakob (Merck) to V. Soni (Glenmark) re "ezetimibe patent settlement agreement"		X	NO
MDX0902	MRKZETIA R000026752	MRKZETIA R000026752	6/8/2016	Power Point presentation titled, "ZETIA LOE Contracting Strategy"		X	403; HS; R
MDX0904	MRKZETIA000854018	MRKZETIA000854023	6/9/2016	Email from C. Antrosiglio to P. Davish, I. Duffy, J. Hall et al. re "Approval Requested by EOD Friday 6/10: ZETIA LoE Contracting Update [Sensitive]" with attachment		X	HS; R
MDX0905	MRKZETIA_R000002688	MRKZETIA_R000002691	6/10/2016	Email from D. Gan to T. Sprague, C. Antrosiglio and J. Schwartz "RE: Approval Requested by EOD Friday 6/10: ZETIA LoE Contracting Update [Confidential]"		X	HS; R
MDX0906	APOTEX0000017	APOTEX0000019	6/20/2016	Letter from FDA to Apotext re "Complete Response"		X	403; R
MDX0907	GLENMARK-ZETIA-00198777	GLENMARK-ZETIA-00198777	6/22/2016	PowerPoint presentation with file name "Ezetimibe schedule 11-02-16.xlsx"		X	HS
MDX0908				WITHDRAWN			
MDX0909	MRKZETIA000511858	MRKZETIA000511858	7/1/2016	PowerPoint presentation titled, "Vytorin / Zetia US S&OP"		X	403; HS; INC; R
MDX0910				WITHDRAWN			
MDX0911	MRKZETIA_R000051180	MRKZETIA_R000051182	7/5/2016	Email from M. Exume to K. Hayward RE: "Zetia Family Aug FC [Confidential]"		X	HS
MDX0912	AMN-ZETIA0002930	AMN-ZETIA0003110	7/8/2016	Letter from Amneal to FDA re "Ezetimibe Tablets USP, 10mg, Information Request Quality Reference #774996, ANDA #208803 (Sequence #0007)"		X	403; R
MDX0913	GLENMARK-ZETIA-00177411	GLENMARK-ZETIA-00177411	7/8/2016	Excel spreadsheet with file name: ZForecast Model 08-July-16.xlsx		X	NO
MDX0914	SUN-EZETIMIBIE_00018365	SUN-EZETIMIBIE_00018375	7/11/2016	Letter from Sun to FDA re "ANDA 207311 Ezetimibe Tablets, 10mg, Response to Information Request (Chemistry) - Reference 7945804"		X	403; 901; HS; R
MDX0915	MRKZETIA_R000049663	MRKZETIA_R000049663	7/12/2016	Calendar Invite from D. Pakula to G. Devlin, L. Jakob and N. Miller-Rich re "Discuss Zetia AG"		X	HS; R
MDX0918	MRKZETIA000601091	MRKZETIA000601091	7/13/2016	PowerPoint presentation titled, "Athero Brand Update"		X	NO
MDX0919	MRKZETIA000854108	MRKZETIA000854108	7/13/2016	Calendar Invite from D. Pakula to R. McMahon, M. Strasburger, K. Hayward et al. re "Zetia AG Update"		X	HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0921	GLENMARK-ZETIA-00251697	GLENMARK-ZETIA-00251698	7/14/2016	Email from P. Wagle to A. Desai re "Ezetimibe ppt" with attachment		X	HS
MDX0922	SUN-EZETIMIBIE_00018546	SUN-EZETIMBIE_00018547	7/29/2016	Leetter from Sun to FDA re "ESG Easily Correctable Deficiency Labeling Reference #235743 eCTD sequence 0006"		X	403; R
MDX0925	No Bates	No Bates	8/30/2016	Macit, C. et al. Brand Loyalty as a Strategy for the Competition with Generic Drugs: Physicians Perspective, Journal of Developing Drugs, Vol. 5, Issue 3, 1000159		X	403; 901; HS; MIL; R
MDX0926	GLENMARK-ZETIA-00165621	GLENMARK-ZETIA-00165621	2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Sep 2016 NPF.xlsx		X	NO
MDX0927	GLENMARK-ZETIA-00165847	GLENMARK-ZETIA-00165847	2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Sep 2016 NPF.xlsx		X	NO
MDX0928	GLENMARK-ZETIA-00167079	GLENMARK-ZETIA-00167079	2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Sep 2016 NPF.xlsx		X	NO
MDX0929	GLENMARK-ZETIA-00217703	GLENMARK-ZETIA-00217703	2016	Excel spreadsheet with file name: Copy of Ezetimibe (Zetia) forecast Sep 2016 NPF (3).xlsx		X	NO
MDX0930	CVS-ZET-0010164	CVS-ZET-0010167	9/13/2016	Email from L. Barish to J. Simonovich & C. Rubin re "FW: CVS - Generic Marketplace"		X	403; 901; HS; MIL; R
MDX0932	MRKZETIA000510339	MRKZETIA000510341	9/19/2016	Merck memo from S. Simroth, D. Pakula, G. Dunlop to J. Hall, M. Polizzi and M. Paciulli re "Request for Concurrence: ZETIA Authorized Generic Supply and Distribution Agreement with Prasco"		X	HS
MDX0933	ALKEM002701	ALKEM002702	9/21/2016	Email from S. Roundal to G. Devi et al. re "FW: [EASILY CORRECTIBLE DEFICIENCY] Original ANDA 209234 - Bioequivalence"		X	HS
MDX0934	No Bates	No Bates	9/21/2016	Prioritizing Public Health The FDA's Role in the Generic Drug Marketplace, Statement by Janet Woodcock		X	403; 901; MIL; R
MDX0935	ALKEM002700	ALKEM002700	9/23/2016	Letter from Alkem to FDA re "Easily Correctable Deficiency Bioequivalence Reference # 10266034"		X	HS
MDX0937	MRKZETIA_R000094835	MRKZETIA_R000094835	9/26/2016	PowerPoint presentation titled, "2017 Athero Franchise Product Plan"		X	HS
MDX0938	MRKZETIA000601633	MRKZETIA000601635	9/30/2016	Email from M. Exume to D. Gan, cc'ing D. Jankiewicz re "Athero profit Plan Slides" with attachment		X	HS
MDX0939	MRKZETIA000601821	MRKZETIA000601821	10/11/2016	PowerPoint presentation titled, "2017 ZETIA Family Product Plan"		X	HS
MDX0941	MRKZETIA000509809	MRKZETIA000509866	10/20/2016	Supply and Distribution Agreement between Merck Sharp & Dohme Corp. and Prasco, LLC.		X	NO
MDX0943	SUN-EZETIMIBIE_00018557	SUN-EZETIMIBIE_00018559	10/25/2016	Letter from FDA to Sun re "Information Request"		X	403; R
MDX0944	KRG_ZETIA_ED00003998	KRG_ZETIA_ED00003998	10/26/2016	Optum Rx's Notice of Important Information Regarding "Brand Zetia and it's generic Ezetimibe"		X	901; HS; MIL; R
MDX0945	AUROBINDO_00000169	AUROBINDO_00000172	10/27/2016	Letter from Aurobindo to FDA re "Pre Assigned ANDA #209838 Original Application Sequence #0000"		X	403; R
MDX0946	No Bates	No Bates	11/9/2016	Article titled, "Loss of Exclusivity Strategies to Maximaze Product Value"		X	901; HS; MIL; R
MDX0947	FWK-ZETIA-0000079	FWK-ZETIA-0000081	11/22/2016	Loan Agreement and Promissory Note between FWK Holdings and Bruce Sperling		X	403; HS; R
MDX0948	FWK-ZETIA-0000082	FWK-ZETIA-0000084	11/22/2016	Loan Agreement and Promissory Note between FWK and Germane		X	403; HS; R
MDX0949	FWK-ZETIA-0000088	FWK-ZETIA-0000090	11/22/2016	Loan Agreement and Promissory Note between FWK and Paul Slater		X	403; HS; R
MDX0950	FWK-ZETIA-0000085	FWK-ZETIA-0000087	12/1/2016	Loan Agreement and Promissory Note between FWK and Joseph Vanek		X	403; HS; R
MDX0951	KRG_ZETIA_ED00012568	KRG_ZETIA_ED00012568	12/2/2016	Email from B. Breetz to L. Kent re "Humana Zetia Notification"		X	403; HS; INC; R
MDX0952	ALKEM002757	ALKEM002762	12/5/2016	Letter from FDA to Alkem re "Information Request"		X	403; R
MDX0953	No Bates	No Bates	12/5/2016	21 C.F.R. § 314.3		X	403; MIL; R
MDX0954	SUN-EZETIMIBIE_00018618	SUN-EZETIMIBIE_00018619	12/6/2016	Letter from Sun to FDA re "Information Request"		X	403; R
MDX0955	FWK-ZETIA-0003487	FWK-ZETIA-0003489	12/7/2016	Master Retention Agreement between FWK and Vanek, Vickers & Masini, P.C.		X	403; HS; R
MDX0956	KRG_ZETIA_ED00002207	KRG_ZETIA_ED00002208	12/7/2016	Email from L. Pitcher to B. Breetz re "Kroger's Ezetimibe 10mg Pos"		X	403; HS; R
MDX0957	FWK-ZETIA-0000001	FWK-ZETIA-0000002	12/9/2016	Agreement for Assignment of Claims between Frank W. Kerr Co. and FWK Holdings, LLC		X	NO
MDX0958	No Bates	No Bates	12/12/2016	"Glenmark Launches Generic Version of Zetia in US Market," The Economic Time		X	901; HS

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0959	No Bates	No Bates	12/12/2016	Endo Press Release, "Endo Begins Shipment of Generic ZETIA®"		X	NO
MDX0960	No Bates	No Bates	12/12/2016	Press Release titled "ENDO Begins Shipment of Generic Zetia"		X	NO
MDX0961				WITHDRAWN			
MDX0962	ENV_001241	ENV_001388	1/1/2017	Document titled, "BMC QHP Exchange Formulary"		X	403; HS; R
MDX0963	GLENMARK-ZETIA-00145433	GLENMARK-ZETIA-00145433	2017	Document titled, "Par Pharmaceutical Companies Inc. Ezetimibe Tabs Sales and Profit Split 2017" (file name "Ezetimibe Profit Share Report_2017.xlsx")		X	HS
MDX0964	GLENMARK-ZETIA-00145437	GLENMARK-ZETIA-00145437	2017	Document titled, "Par Pharmaceutical Companies Inc. Ezetimibe Tabs Sales and Profit Split 2017" (file name "Ezetimibe Profit Share Report_2017_.xlsx")		X	HS
MDX0965	GLENMARK-ZETIA-00145438	GLENMARK-ZETIA-00145438	2017	Document titled, "Par Pharmaceutical Companies Inc. Ezetimibe Tabs Sales and Profit Split 2017" (file name "Ezetimibe Profit Share Report_2017_.xlsx")		X	HS
MDX0966	GLENMARK-ZETIA-00145439	GLENMARK-ZETIA-00145439	2017	Document titled, "Par Pharmaceutical Companies Inc. Ezetimibe Tabs Sales and Profit Split 2017" (file name "Ezetimibe June-17 Statement.xlsx")		X	HS
MDX0967				WITHDRAWN			
MDX0969	No Bates	No Bates	2017	PHSL 2017 Fall Newsletter titled, "PHSI Analysis of Authorized Generic Drugs"		X	403; 901; INC; MIL; R
MDX0970	No Bates	No Bates	2017	PHSL 2017 Fall Newsletter titled, "PHSI Analysis of Authorized Generic Drugs"		X	403; 901; INC; MIL; R
MDX0971	No Bates	No Bates	2017	PHSL 2017 Fall Newsletter titled, "PHSI Analysis of Authorized Generic Drugs"		X	403; 901; MIL; R
MDX0972	ALKEM002755	ALKEM002756	1/5/2017	Letter from Alkem to FDA re "Information Request"		X	403; R
MDX0973	PAR_00021226	PAR_00021230	1/5/2017	Email from R. Lasser to R. Sharma "RE: Ezetimibe - units shipped"		X	HS
MDX0974	APOTEX0000001	APOTEX0000004	1/10/2017	Letter from FDA to Apotex re "Complete Response"		X	403; R
MDX0975	KRG_ZETIA_ED00008432	KRG_ZETIA_ED00008433	2/2/2017	Email from J. Porter to D. Bird, et al. re "Generic Substitution Conference Call		X	403; 901; HS
MDX0976	SUN-EZETIMIBIE_00018637	SUN-EZETIMIBIE_00018639	2/10/2017	Letter from FDA to Sun re "Information Request"		X	403; R
MDX0977	ALKEM003559	ALKEM003561	2/17/2017	Letter from FDA to Alkem re "Information Request"		X	403; R
MDX0979	SANDOZ-ZETIA-0000081	SANDOZ-ZETIA-0000092	2/16/2017	Letter from Sandoz to FDA re "Minor Amendment - Final Approval Requested"		X	NO
MDX0980	MRKZETIA000854566	MRKZETIA000854567	2/17/2017	Email from J. Roehm to D. Gan "RE: Attached: Latest Zetia LOE Dashboard [Confidential]		X	HS
MDX0981	SANDOZ-ZETIA-0000150	SANDOZ-ZETIA-0000150	2/21/2017	Correspondence from FDA to Sandoz re "Notification - - Target Action Date"		X	NO
MDX0982	AMN-ZETIA0003821	AMN-ZETIA0003880	2/24/2017	Letter from Amneal to FDA re " ANDA #208803 - Sequence #0008, Ezetimibe Tablets USP, 10 mg - RESUBMISSION / 1ST MINOR / COMPLETE RESPONSE AMENDMENT / DRUG SUBSTANCE / PROCESS"		X	403; R
MDX0983	No Bates	No Bates	2/28/2017	Merck & Co., Inc. 2016-Form-10-K		X	403; 901; HS; MIL; R
MDX0984	Teva-Zetia_00003021	Teva-Zetia_00003022	2/28/2017	Letter from Teva to FDA re "Minor Amendment - Final Approval Requested"		X	NO
MDX0985	MRKZETIA000513679	MRKZETIA000513680	3/1/2017	Email from M. Exume to D. Gan "RE: Zetia generic?"		X	HS
MDX0986	WLG_ZETIA_ED00056862	WLG_ZETIA_ED00056869	3/2/2017	Email from J. Pham to D. Dzierzanowska re "Generic Strategy Meeting 3/2/17, 3pm"		X	901; HS; HWH; MIL; R
MDX0987	SUN-EZETIMIBIE_00018723	SUN-EZETIMIBIE_00018724	3/10/2017	Letter from Sun to FDA re "Information Request"		X	403; R
MDX0988	Watson-Zetia_00011449	Watson-Zetia_00011451	3/9/2017	Letter from Watson to FDA re "Minor Amendment - Final Approval Requested"		X	NO
MDX0989	ALKEM003557	ALKEM003558	3/16/2017	Letter from Alkem to FDA re "Information Request - Quality"		X	403; R
MDX0990	AUROBINDO_00000160	AUROBINDO_00000164	3/17/2017	Letter from FDA to Aurobindo re "Information Request"		X	R
MDX0991	PAR_00009672	PAR_00009688	3/23/2017	Email from C. Degnam to P. Campanelli, B. Coleman, T. Pera et al. "RE: March Latest View"		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX0992	No Bates	No Bates	4/2017	Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease, Endocr Pract 2017 Apr 2;23(4):479-497		X	403; 901; HS; MIL; R
MDX0993	No Bates	No Bates	4/3/2017	Warning letter from FDA to Mylan		X	403; R
MDX0994	AUROBINDO_00000188	AUROBINDO_00000188	4/25/2017	Email from C. Gentles to B. Johns re "Easily Correctable Deficiency - ANDA 209838"		X	403; R
MDX0996	AUROBINDO_00000146	AUROBINDO_00000147	5/2/2017	Letter from Aurobindo to FDA re "ANDA #209838 Easily Correctable Deficiency Bioequivalence Reference # 14632087 Sequence #0004"		X	403; R
MDX0999	AUROBINDO_00000118	AUROBINDO_00000129	5/17/2017	Letter from Aurobindo to FDA re "Ezetimibe Tablets USP 10 mg (ANDA #2099838) - Information Request Quality"		X	403; R
MDX1000	KRG_ZETIA_ED00007672	KRG_ZETIA_ED00007674	5/22/2017	Email from B. Turner to B. Shinton re "2016_retail_less_than_cost_wk15_columbus.xlsx"		X	901; HS; HWH; MIL; R
MDX1001	PRASCO 000090	PRASCO 000091	5/24/2017	Email from M. Reedy to D. Pakula, T. Covert and J. Lapps re "For Zetia Discussion" with attachment		X	HS; HWH
MDX1002	AMN-ZETIA0004212	AMN-ZETIA0004232	5/30/2017	Letter from Amneal to FDA re "Resubmission / 2nd Minor / Complete Response Amendment / Drug Substance / Drug Product ANDA #208803 (Seq. #0009)"		X	403; HS; HWH; R
MDX1003	No Bates	No Bates	6/1/2017	FDA, Q3C- Tables and List Guidance for Industry		X	NO
MDX1004	MRKZETIA000516333	MRKZETIA000516335	6/5/2017	Email from D. Pakula to T. Covert and G. Dunlop re "For Review and Comments: Zetia AG Status Update [Confidential]"		X	901; HS; HWH; INC
MDX1005	MRKZETIA000516334	MRKZETIA000516334	6/5/2017	PowerPoint presentation titled, "Zetia Authorized Generic (AG) Status Update"		X	HS; HWH
MDX1007	APOTEX0000013	APOTEX0000016	6/12/2017	Letter from FDA to Apotex re "ANDA Approval"		X	NO
MDX1008	No Bates	No Bates	6/12/2017	Teva press release titled, "Teva Announces Launch of Generic Zetia in the United States"		X	HS
MDX1009	SANDOZ-ZETIA-0000151	SANDOZ-ZETIA-0000154	6/12/2017	Letter from FDA to Sandoz re "ANDA Approval"		X	NO
MDX1010	SUN-EZETIMIBIE_00021485	SUN-EZETIMIBIE_00021488	6/12/2017	Letter from FDA to Sun re "ANDA Approval"		X	NO
MDX1011	Teva-Zetia_00003520	Teva-Zetia_00003523	6/12/2017	Letter from FDA to Teva re "ANDA Approval"		X	NO
MDX1012	Watson-Zetia_00011753	Watson-Zetia_00011756	6/12/2017	Letter from FDA to Watson re "ANDA Approval"		X	NO
MDX1013	ALKEM003801	ALKEM003805	6/14/2017	Letter from FDA to Alkem re "Complete Response"		X	R
MDX1014	ALKEM003806	ALKEM003807	6/20/2017	Letter from Alkem to FDA re "ANDA #209234 (0009) 1st Minor Complete Response Amendment"		X	HS; R
MDX1015	ALKEM003855	ALKEM003857	7/10/2017	Letter from FDA to Alkem re "Information Request"		X	R
MDX1016	No Bates	No Bates	7/12/2017	Eli Lilly and Co. Press Release, "Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation"		X	HS; R
MDX1017	AUROBINDO_00000416	AUROBINDO_00000418	7/14/2017	Letter from FDA to Aurobindo re "Information Request"		X	R
MDX1018	ALKEM003846	ALKEM003847	7/18/2017	Letter from Alkem to FDA re "ANDA #209234 (0010) Information Request Quality"		X	HS
MDX1019	AUROBINDO_00000076	AUROBINDO_00000079	7/18/2017	Letter from Aurobindo to FDA re "ANDA #209838 Information Request Quality Sequence #0006"		X	HS
MDX1020	MRKZETIA000510423	MRKZETIA000510423	7/18/2017	Email from D. Pakula to S. Cimmino, R. Pecoraro, D. Catalano et al. re "Zetia AG Status"		X	HS
MDX1021				WITHDRAWN			
MDX1022	AUROBINDO_00000397	AUROBINDO_00000397	8/8/2017	Email from M. Johnson-Nimo to B. Johns re "Information Request for ANDA-209838-Orig-1"		X	R
MDX1023	No Bates	No Bates	8/8/2017	LABEL: OCELLA- drospirenone and ethinyl estradiol ki,"		X	403; HS; HWH; R
MDX1024	AUROBINDO_00000166	AUROBINDO_00000167	8/9/2017	Letter from Aurobindo to FDA re "ANDA #209838 Information Request Quality Sequence #0007"		X	HS
MDX1025	No Bates	No Bates	8/9/2017	Label: GIANVI- drospirenone and ethinyl estradiol kit		X	403; HS; HWH; R
MDX1026	AUROBINDO_00014800	AUROBINDO_00014803	8/25/2017	Letter from FDA to Aurobindo re "ANDA Approval"		X	NO
MDX1027	RA-ZET-0000004	RA-ZET-0000004	8/29/2017	Printout of Excel spreadsheet titled, "Rite Aid - McKesson DSD Purchases"		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1028	ALKEM003899	ALKEM003902	9/1/2017	Letter from FDA to Alkem re "Complete Response"		X	R
MDX1029	ALKEM003896	ALKEM003898	9/26/2017	Letter from Alkem to FDA re "ANDA #209234 (0011) Minor Complete Response Amendment Drug Substance/Drug Product"		X	HS
MDX1030				WITHDRAWN			
MDX1031	No Bates	No Bates	10/1/2017	FDA, Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry		X	NO
MDX1032	ZETIA-PFTHW-000248	ZETIA-PFTHW-000312	10/1/2017	Prescription Benefit Services Agreement between CaremarkPCS Health and Philadelphia Federation of Teachers Health and Welfare Fund		X	403; HS; R
MDX1033	SANDOZ-ZETIA-0000095	SANDOZ-ZETIA-0000103	10/13/2017	Letter from Sandoz to FDA re "Prior Approval Supplement"		X	HS
MDX1034	FWK-ZETIA-0003490	FWK-ZETIA-0003491	11/6/2017	Referral agreement between Hagens Berman Sobol Shapiro LLP and Vanek, Vickers & Masini, P.C.		X	403; HS; R
MDX1037	ALKEM003959	ALKEM003961	12/4/2017	Letter from FDA to Alkem re "Information Request"		X	NO
MDX1038	SANDOZ-ZETIA-0000158	SANDOZ-ZETIA-0000160	12/4/2017	Letter from FDA to Sandoz re "Prior Approval Supplement Approval"		X	NO
MDX1039	ALKEM003955	ALKEM003958	12/5/2017	Letter from Alkem to FDA re "ANDA #209234 (0012) Information Request - Quality - Amendment"		X	HS
MDX1040	GLENMARK-ZETIA-00145436	GLENMARK-ZETIA-00145436	2018	Document titled, "Par Pharmaceutical Companies Inc. Ezetimibe Tabs Sales and Profit Split 2018" (file name "Ezetimibe Profit Share Report_2018_.xlsx")		X	403; 901; HS; R
MDX1041				WITHDRAWN			
MDX1042	No Bates	No Bates	2018	2018 Integrated Summary Report, ELI, LILLY &CO		X	403; 901; FD; HS; R
MDX1043	No Bates	No Bates	2018	Hoch, D.G. et al., "Chysteine-Reactive Probes and Their Use in Chemical Proteomics," *Chem. Commun.* , 54:4501-4512 (2018)		X	HS; HWH; R
MDX1044	No Bates	No Bates	2018	Article titled, "Pharmaceutical Industry Antitrust Handbook", American Bar Association, 2nd ed., 1-632 (2018)		X	403; HS; HWH; R
MDX1045	No Bates	No Bates	2018	Article titled, "Pharmaceutical Industry Antitrust Handbook, Section - Assessing		X	403; HS; HWH; INC
MDX1046	No Bates	No Bates	2018	Mantsiou, Chrysanthi et al., Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients, Current Medical Research and Opinion (2018), 1713-1715		X	403; HS; HWH; MIL; R
MDX1047	No Bates	No Bates	2018	NBER Working Paper titled, "Subways and Urban Air Pollution"		X	HS; HWH; R
MDX1048	FWK-ZETIA-0003492	FWK-ZETIA-0003493	1/11/2018	Referral agreement between Kessler Topaz Meltzer & Check, LLP and Vanek, Vickers & Masini, P.C.		X	403; HS; R
MDX1049	FWK-ZETIA-0003494	FWK-ZETIA-0003495	1/11/2018	Referral agreement between Radice Law Firm, P.C. and Vanek, Vickers & Masini, P.C.		X	403; HS; R
MDX1050	FWK-ZETIA-0003496	FWK-ZETIA-0003497	1/11/2018	Referral agreement between Hilliard & Shadowen, LLP and Vanek, Vickers &		X	403; HS; R
MDX1051				WITHDRAWN			
MDX1053	KRG_ZETIA_00000001	KRG_ZETIA_00000002	3/12/2018	Agreement for Assignment of Claims between The Kroger Co. and Cardinal Health, Inc.		X	NO
MDX1054	WLG_ZETIA_00000001	WLG_ZETIA_00000002	3/20/2018	Agreement for Assignment of Claims between Walgreen Co. and AmerisourceBergen Drug Corporation		X	NO
MDX1055	ALB_ZETIA_00000001	ALB_ZETIA_00000002	3/23/2018	Agreement for Assignment of Claims between McKesson and Albertsons Companies (50% of the rights)		X	NO
MDX1056	ALB_ZETIA_00000003	ALB_ZETIA_00000004	3/23/2018	Agreement for Assignment of Claims between McKesson and Albertsons Companies (100% of the rights)		X	NO
MDX1057				WITHDRAWN			
MDX1058	No Bates	No Bates	4/5/2018	Article titled, "Big Pharma, Insurance Giants in Heated Battle Over Drug Coupons"		X	403; HS; HWH; R
MDX1059	ALB_ZETIA_00000005	ALB_ZETIA_00000008	4/16/2018	Agreement for Assignment of Claims between Safeway and Albertsons Companies		X	NO
MDX1060				WITHDRAWN			
MDX1061	No Bates	No Bates	6/13/2018	Prugo, Filko, et al., Insight: Orange, Purple Book Patentees Hone PTAB Survival Skills, 17 Patent, Trademark & Copyright J. 1, 3 (2018)		X	403; HS; HWH; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1062	RA-ZET-0000001	RA-ZET-0000002	7/27/2018	Agreement for Assignment of Claims between McKesson Corporation and Rite Aid Corporation and Rite Aid HDQTRS Corp.		X	NO
MDX1063	CVS-ZET-0000001	CVS-ZET-0000002	8/30/2018	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and McKesson Corporation		X	NO
MDX1064	CVS-ZET-0000003	CVS-ZET-0000004	8/30/2018	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and Cardinal Health, Inc.		X	NO
MDX1065	No Bates	No Bates	10/24/2018	21 USCA § 355 (Excerpt of Full copy)		X	R
MDX1066	No Bates	No Bates	10/24/2018	21 USCA § 355, New Drugs		X	R
MDX1067	No Bates	No Bates	10/26/2018	Document titled, "Orange Book: Approved Drugs Products with Therapeutic Equivalence Evaluations" (Accord Approval)		X	NO
MDX1068				WITHDRAWN			
MDX1069				WITHDRAWN			
MDX1070				WITHDRAWN			
MDX1071				WITHDRAWN			
MDX1072				WITHDRAWN			
MDX1073				WITHDRAWN			
MDX1075				WITHDRAWN			
MDX1076				WITHDRAWN			
MDX1077	No Bates	No Bates	2019	Amphastar Pharmaceuticals, "About Us"		X	HS; R
MDX1078				WITHDRAWN			
MDX1079				WITHDRAWN			
MDX1080	CCI000543	CCI000551	1/4/2019	Email from J. Willaman to H. Rolon and M. Bower, cc'ing Luis Vazquez "RE: Next Order"		X	R
MDX1081	No Bates	No Bates	2/1/2019	PEW Charitable Trusts, "FDA Approves More Generic Drugs, but Competition Still Lags"		X	403; HS; HWH; MIL; R
MDX1082				WITHDRAWN			
MDX1083	MYL_ZETIA 011618	MYL_ZETIA 012075	2/27/2019	Excel spreadsheet with file name: Ezetimibe forecast request 2008-2017.xlsx		X	403; INC
MDX1084	No Bates	No Bates	2/27/2018	Merck & Co., Inc. 2017-Form-10-K		X	403; 901; HS; MIL; R
MDX1085	No Bates	No Bates	3/2019	Bruce Strombom Damages Backup: Ezetimibe sales data - Final till March 2019.csv		X	901; HS; INC
MDX1086	No Bates	No Bates	3/20/2019	Optimixerx.com article titled, "See These Physician Survey Results that Detail New Rx Pricing Insights"		X	HS; R
MDX1087				WITHDRAWN			
MDX1088				WITHDRAWN			
MDX1089				WITHDRAWN			
MDX1090	MRKZETIA_R000061377	MRKZETIA_R000061377	4/11/2019	Excel Spreadsheet re Litigation Expenses with file name, "Merck - Search All Invoices2019-04-11 113458Z (IP091663 Mylan).xls"		X	403; 901; FD; HS; MIL; R
MDX1091	GLENMARK-ZETIA-00281894	GLENMARK-ZETIA-00281899	4/18/2019	Email from T. Coughlin to V. Soni and S. Krishan re "FW: API Concerns"		X	403; HS; R
MDX1095	No Bates	No Bates	4/22/2019	Deferred Prosecution Agreement for Rochester Drug Cooperative		X	403; 404; HS; HWH; MIL; R
MDX1096	No Bates	No Bates	4/24/2019	"AbbeVie Inc.; Withdrawal of Approval of New Drug Applications for ADVICOR and SIMCOR", Federal Register		X	HS; R
MDX1097	MYL_ZETIA012089	MYL_ZETIA102092	4/26/2019	Letter from FDA to Mylan re "ANDA Approval"		X	NO
MDX1098	No Bates	No Bates	4/26/2019	Document titled, "Orange Book: Approved Drugs Products with Therapeutic Equivalence Evaluations" (Mylan Approval)		X	NO
MDX1099				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1100				WITHDRAWN			
MDX1101				WITHDRAWN			
MDX1102				WITHDRAWN			
MDX1103	No Bates	No Bates	7/9/2019	Digiovannd, Francis, et al., The Restoration of (Bad) Faith: The Proper Standard for a Factual Finding of Willful Infringement, The National Law Review		X	403; HS; HWH; R
MDX1104	No Bates	No Bates	8/2/2019	Notice of Dismissal of Defendant Pharmaceutical, Inc., In re: Zetia (Ezetimibe) Antitrust Litigation, Case No. 18-md-02836-RBS-DEM, ECF No. 464		X	403; R
MDX1105	No Bates	No Bates	8/14/2019	Memorandum, ECF No. 687		X	403; R
MDX1106				WITHDRAWN			
MDX1107				WITHDRAWN			
MDX1108	No Bates	No Bates	9/26/2019	A. W. Mathews: U.S. News - Cost of Employer Health Plans Jumps		X	403; HS; HWH; MIL; R
MDX1109				WITHDRAWN			
MDX1110	No Bates	No Bates	2019	Vytorin Label		X	403; HS; HWH; MIL; R
MDX1111	No Bates	No Bates	2019	Food and Drug Administration, "Drug Label for Zocor," 2019		X	403; HS; HWH; MIL; R
MDX1112	No Bates	No Bates	10/7/2019	Plaintiffs' Supplemental Responses and Objections to Defendants' First Set of Request for Admissions		X	R
MDX1113	MRKZETIA_SIDLEY000014568	MRKZETIA_SIDLEY000014571	4/19/2010	Opinion, Schering Corp., et al. v. Glenmark Pharm., et al., Case No. 07-CV-1334, ECF No. 222		X	MIL; R
MDX1114	No Bates	No Bates	10/16/2019	Supplemental Deposition Errata For Vijay Soni		X	INC
MDX1115				WITHDRAWN			
MDX1116				WITHDRAWN			
MDX1117	No Bates	No Bates	11/8/2019	Declaration of Teletha Brown		X	R
MDX1118	No Bates	No Bates	11/22/2019	Order, In re: Zetia (Ezetimibe) Antitrust Litigation, Case No. 18-md-02836-RBS-DEM, ECF No. 751		X	403; R
MDX1119	No Bates	No Bates	12/1/2019	FDA Report titled "Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices"		X	NO
MDX1120				WITHDRAWN			
MDX1121				WITHDRAWN			
MDX1122	No Bates	No Bates	12/9/2019	Article titled, "Drug Rebates and Formulary Design: Evidence from Statins and Medicare Part D"		X	403; HS; HWH; R
MDX1123	No Bates	No Bates	12/13/2019	"FDA In Brief: New Analysis Highlights Link Between Generic Drug Competition and Lower Drug Prices, Underscores Importance of FDA Efforts to Spur Generic Drug Development and Market Entry," FDA		X	NO
MDX1124	No Bates	No Bates	12/19/2019	FDA Listing of Authorized Generics		X	NO
MDX1126	No Bates	No Bates	12/20/2019	Memorandum Opinion and Order, In re: Zetia (Ezetimibe) Antitrust Litigation, Case No. 18-md-02836-RBS-DEM, EFC No. 795		X	403; R
MDX1127				WITHDRAWN			
MDX1128	No Bates	No Bates	4/25/2019	Rite Aid Corporation Form 10-K For The Fiscal Year Ended March 2, 2019		X	403; HS; HWH; MIL; R
MDX1129	No Bates	No Bates	2020	Amneal Pharmaceuticals, "Generic Products"		X	901; HS; R
MDX1130	No Bates	No Bates	2020	Elanco, "Products & Services For Protecting Poultry Health"		X	HS; R
MDX1131				WITHDRAWN			
MDX1132	No Bates	No Bates	2020	Chronic Conditions Data Warehouse, "CMS CCW Condition Algorithms," February 2020		X	403; 901; HS; HWH; MIL; R
MDX1133				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1135	No Bates	No Bates	2/27/2019	Merck & Co., Inc. 2018-Form-10-K		X	403; 901; HS; MIL; R
MDX1136	No Bates	No Bates	2/26/2020	Merck & Co., Inc. 2019-Form-10-K		X	403; 901; HS; MIL; R
MDX1137	No Bates	No Bates	2/28/2020	Exhibit C to the Expert Report of William Roush, "Calculation of Extra Compounds, Claims 1-4 of '365 Patent"		X	403; HS; R
MDX1138	No Bates	No Bates	2/28/2020	Exhibit D to the Expert Report of William Roush, "Calculation of Extra Compounds in Claims 1-4 of the '365 patent over Claim 3 of the '721 patent (holding everything constant except Ar1)"		X	403; HS; R
MDX1139	No Bates	No Bates	2/28/2020	Exhibit E to the Expert Report of William Roush, "EXHIBIT E1 – Schering's Ezetimibe Synthesis[37]"		X	403; HS; R
MDX1140	No Bates	No Bates	2/28/2020	Exhibit F - Expert Report of William Roush		X	403; HS; R
MDX1141	No Bates	No Bates	2/28/2020	Appendix C to the Expert Report of Robert Armitage, "Approved Uses of Zetia & Vytorin"		X	901; HS; HWH; INC
MDX1142	No Bates	No Bates	2/28/2020	Exhibit 3 to the Expert Report of Sumanth Addanki: Approved Abbreviated New Drug Applications for Ezetimibe Tablets		X	403; 901; 1006; FD; HS; HWH; R
MDX1143	No Bates	No Bates	2/28/2020	Exhibit 4 to the Expert Report of Sumanth Addanki: Commercial and Medicare Part D Plan Rebates Paid by Merck for Zetia December 2016 through December 2017		X	403; 901; 1006; FD; HS; HWH; R
MDX1144	No Bates	No Bates	2/28/2020	Exhibit 5 to the Expert Report of Sumanth Addanki: Zetia's Share of the Total Dispensed Tablets of Ezetimibe December 2016 through December 2018		X	403; 901; 1006; FD; HS; HWH; R
MDX1145	No Bates	No Bates	2/28/2020	Exhibit 6 to the Expert Report of Sumanth Addanki: Sales and Pricing of Glenmark's Generic Ezetimibe Tablets by Par December 2016 through March 2018		X	403; 901; 1006; FD; HS; HWH; R
MDX1146	No Bates	No Bates	2/28/2020	Exhibit 7 to the Expert Report of Sumanth Addanki: The Percentage Discount Off the Zetia WAC for Glenmark's Generic Ezetimibe Compared to Merck's Rebates on Zetia as a Percentage of the Zetia WAC December 2016 through May 2017		X	403; 901; 1006; FD; HS; HWH; R
MDX1147	No Bates	No Bates	2/28/2020	Exhibit 8 to the Expert Report of Sumanth Addanki: Shares of Total Generic Ezetimibe Tablets Dispensed, by Generic Manufacturer December 2016 through December 2018		X	403; 901; 1006; FD; HS; HWH; R
MDX1148	No Bates	No Bates	2/28/2020	Exhibit 9A to the Expert Report of Sumanth Addanki: Feasibility of a "Pure" Term-Split Settlement Depends Upon Patentee's and Would-Be Entrant's Respective Valuations of Litigation and Settlement		X	403; 901; 1006; FD; HS; R
MDX1149	No Bates	No Bates	2/28/2020	Exhibit 9B to the Expert Report of Sumanth Addanki: Feasibility of a "Pure" Term-Split Settlement Depends Upon Patentee's and Would-Be Entrant's Respective Valuations of Litigation and Settlement		X	403; 901; 1006; FD; HS; R
MDX1150	No Bates	No Bates	2/28/2020	Exhibit 10 to the Expert Report of Sumanth Addanki: Glenmark's Expected Profits from Sales of Generic Ezetimibe During its 180-Day Exclusivity Period as a Share of Glenmark's Total Expected Profits from Sales of Generic Ezetimibe as Projected by Drs. McGuire and Leffler January 2014 through December 2016		X	403; 901; 1006; FD; HS; HWH; R
MDX1151				WITHDRAWN			
MDX1152				WITHDRAWN			
MDX1153	No Bates	No Bates	6/28/2020	Howard Krass, CEO, IPD Analytics & Managing Member, IPD Capital Biography		X	403; 901; HS; R
MDX1154				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1156	No Bates	No Bates	7/6/2020	Excerpts from Teva "Full Product Catalog"		X	403; HS; INC; R
MDX1158				WITHDRAWN			
MDX1159				WITHDRAWN			
MDX1160				WITHDRAWN			
MDX1161				WITHDRAWN			
MDX1162				WITHDRAWN			
MDX1163				WITHDRAWN			
MDX1164				WITHDRAWN			
MDX1165	No Bates	No Bates	9/2020	Vytorin® (ezetimibe and simvastatin) Prescribing Label, U.S. Food and Drug Administration, 2020 Sept.		X	403; HS; HWH; MIL; R
MDX1166				WITHDRAWN			
MDX1167	No Bates	No Bates	10/12/2020	Teva, "Full Product Catalog"		X	403; HS; R
MDX1168	No Bates	No Bates	12/9/2009	Decision on Appeal, Ex Parte Yushito Tanaka, USPTO Board of Patent Appeals and Interferences, http://djf.typepad.com/files/bpai-decision-ex-parte-tanaka-1.pdf		X	403; HS; R
MDX1169				WITHDRAWN			
MDX1170	MRKZETIA_SIDLEY000130369	MRKZETIA_SIDLEY000130375	1985	Georg, Gunda et al., Stero- and Enantio-controlled Synthesis of Chiral Intermediates for the Total Synthesis of Thienamycin and Related β-Lactam Antibiotics from 3-Hydroxybutyrates, J. Chem. Soc., Chem. Comm. 1985, 1433-35		X	403; R
MDX1171	MRKZETIA_SIDLEY000221517	MRKZETIA_SIDLEY000221517	11/2010	Excel spreadsheet with file name: FinalBudget Nov2010_1 (2).XLS		X	403; HS; MIL; R
MDX1172	MRKZETIA_SIDLEY000215602	MRKZETIA_SIDLEY000215602	12/2008	Excel spreadsheet with file name: Mylan129694 (Budget Dec2008) - Outside Attorneys_Eyes Only_1.XLS		X	403; HS; MIL; R
MDX1173	MRKZETIA_SIDLEY000224703	MRKZETIA_SIDLEY000224712	12/1/1993	Semi-Annual Report from B. McKittrick and K. Ma, "Inhibition of Cholesterol Absorption"		X	403; R
MDX1174	GLENMARK-ZETIA-00177280	GLENMARK-ZETIA-00177280	3/2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Mar 2016 NPF.XLSX		X	NO
MDX1175	MRKZETIA_SIDLEY000215606	MRKZETIA_SIDLEY000215606	4/2009	Excel spreadsheet with file name: Mylan129697 (Apr 2009) - Outside Attorneys_Eyes Only_1.XLS		X	403; HS; MIL; R
MDX1176	No Bates	No Bates	5/4/2017	Article titled, "In Defense of the Atlantic-Generic"		X	HS; HWH
MDX1177	MRKZETIA_R000062509	MRKZETIA_R000062509	8/17/2015	Power Point presentation titled, "Zetia® Post-LOE Contracting Strategy Final Report Merck RGA"		X	403; 901; HS; HWH; R
MDX1179	ALKEM002703	ALKEM002706		Response "Ezetimibe Tablets, USP 10 mg ANDA #209234 (0005) Alkem Laboratories Limited, INDIA Response to Easily Correctable Deficiency Bioequivalence Reference #10266034"		X	HS
MDX1180	ALKEM002763	ALKEM002790		Response "Ezetimibe Tablets USP, 10 mg ANDA #209234 (0006) Alkem Laboratories Limited, INDIA Response to Information Request Quality Reference #11704040"		X	HS
MDX1181	ALKEM003562	ALKEM003570		Response "Ezetimibe Tablets USP, 10 mg ANDA #209234 (0008) Alkem Laboratories Limited, INDIA Response to Information Request Quality Reference"		X	HS
MDX1182	ALKEM003808	ALKEM003811		Response "Ezetimibe Tablets, USP 10 mg ANDA #209234 (0009) Alkem Laboratories Limited, INDIA Response to 1st Minor Complete Response Amendment"		X	HS
MDX1183	ALKEM003858	ALKEM003861		Response "Ezetimibe Tablets USP, 10 mg ANDA#209234 (0010) Alkem Laboratories Limited, INDIA Response to Information Request Quality"		X	HS
MDX1184	ALKEM004760	ALKEM004760	2/28/2020	Bruce Strombom Damages Backup: ALKEM004760_Net sales		X	INC
MDX1185	AMN-ZETIA0005425	AMN-ZETIA0005425	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005425_Chargebacks		X	NO
MDX1186	AMN-ZETIA0005425	AMN-ZETIA0005425	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005425_Credits_FLEX		X	NO
MDX1187	AMN-ZETIA0005425	AMN-ZETIA0005425	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005425_Credits_JDE		X	NO
MDX1188	AMN-ZETIA0005425	AMN-ZETIA0005425	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005425_Sales		X	NO
MDX1189	AMN-ZETIA0005426	AMN-ZETIA0005426	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005426_Chargebacks		X	NO
MDX1190	AMN-ZETIA0005426	AMN-ZETIA0005426	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005426_Credits_FLEX		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1191	AMN-ZETIA0005426	AMN-ZETIA0005426	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005426 Credits JDE		X	NO
MDX1192	AMN-ZETIA0005426	AMN-ZETIA0005426	2/28/2020	Bruce Strombom Damages Backup: AMN-ZETIA0005426 Sales		X	NO
MDX1193	APOTEX0000062	APOTEX0000062	2/28/2020	Bruce Strombom Damages Backup: APOTEX0000062 HIGHLY CONFIDENTIAL ATTORNEYS EYES ONLY		X	NO
MDX1194	APOTEX0000064	APOTEX0000064		Apotex Forecast File		X	HS
MDX1195	APOTEX0000073	APOTEX0000073		Apotex Forecast File		X	HS
MDX1196	APOTEX0000083	APOTEX0000083		Apotex Forecast File		X	HS
MDX1197	APOTEX0000093	APOTEX0000093		Apotex Forecast File		X	HS
MDX1198	APOTEX0000102	APOTEX0000102		Apotex Forecast File		X	HS
MDX1199	APOTEX0000113	APOTEX0000113		Apotex Forecast File		X	HS
MDX1200	CCI000002	CCI000002		PDF of excel sheet titled CCI000002		X	R
MDX1201	ENV_004268	ENV_004329		EnvisonRX Formulary re Zetia - Tier 4		X	403; HS; MIL; R
MDX1202	ENV_005027	ENV_005092		EnvisonRX Formulary re Zetia - Tier 4		X	403; HS; MIL; R
MDX1203	FWK-ZETIA-0003486	FWK-ZETIA-0003486		FWK Holdings, LLC, Income Statement, November 2016-March 2019		X	403; MIL; R
MDX1204	GLENMARK-ZETIA-00156103	GLENMARK-ZETIA-00156103	1/5/2015	Excel spreadsheet with file name: Copy of Ezetimibe_Zetia.xlsx		X	NO
MDX1205	GLENMARK-ZETIA-00176817	GLENMARK-ZETIA-00176817	9/22/2015	Excel spreadsheet with file name: Par Ezetimibe Model -revised 10.29.xlsx		X	NO
MDX1206	GLENMARK-ZETIA-00176853	GLENMARK-ZETIA-00176853	11/27/2014	Excel spreadsheet with file name: Zetia_RevenueModel_3rdMar_P&L.xlsx		X	NO
MDX1207	GLENMARK-ZETIA-00178561	GLENMARK-ZETIA-00178561	9/22/2015	Excel spreadsheet with file name: Par Ezitimibe Model.xlsx		X	HS
MDX1208	GLENMARK-ZETIA-00178590	GLENMARK-ZETIA-00178590	9/22/2015	Excel spreadsheet with file name: Par Ezitimibe Model.xlsx		X	HS
MDX1209	GLENMARK-ZETIA-00199718	GLENMARK-ZETIA-00199718	9/22/2015	Excel spreadsheet with file name: Par Ezitimibe Model.xlsx		X	HS
MDX1210	GLENMARK-ZETIA-00199888	GLENMARK-ZETIA-00199888	9/22/2015	Excel spreadsheet with file name: Par Ezitimibe Model -revised SS.xlsx		X	HS
MDX1211	GLENMARK-ZETIA-00202383	GLENMARK-ZETIA-00202383	10/2/2014	Excel spreadsheet with file name: Ezetimibe forecast from Par 10.4.14.xlsx		X	HS
MDX1212	GLENMARK-ZETIA-00214485	GLENMARK-ZETIA-00214485	3/4/2015	Excel spreadsheet with file name: Par Model Ezetimibe (Zetia) Gaurav JG 3-4-15.xlsx		X	NO
MDX1213	GLENMARK-ZETIA-00214760	GLENMARK-ZETIA-00214760	11/27/2014	Excel spreadsheet with file name: Zetia_RevenueModel_3rdMar_P&L_v2.xlsx		X	NO
MDX1214	GLENMARK-ZETIA-00217629	GLENMARK-ZETIA-00217629	9/22/2015	Excel spreadsheet with file name: Par Ezetimibe Model -revised 10.29 - Final.xlsx		X	HS
MDX1215	GLENMARK-ZETIA-00217680	GLENMARK-ZETIA-00217680	1/19/2017	Excel spreadsheet with file name: Ezetimibe-Raj.xlsx		X	HS
MDX1216	GLENMARK-ZETIA-00217687	GLENMARK-ZETIA-00217687	1/19/2017	Excel spreadsheet with file name: Ezetimibe-Raj.xlsx		X	HS
MDX1217	GLENMARK-ZETIA-00219452	GLENMARK-ZETIA-00219452	6/7/2010	Excel spreadsheet with file name: Financials.xls		X	HS
MDX1218	GLENMARK-ZETIA-00237212	GLENMARK-ZETIA-00237212	9/22/2015	Excel spreadsheet with file name: Par Ezitimibe Model -revised SS.xlsx		X	HS
MDX1219	GLENMARK-ZETIA-00282331	GLENMARK-ZETIA-00282331	9/22/2015	Excel spreadsheet with file name: Par Ezetimibe Model -revised 3rd Jun Final.xlsx		X	HS
MDX1220	GLENMARK-ZETIA-00283502	GLENMARK-ZETIA-00283513		Glenmark document titled, "Stability Study Report"		X	HS
MDX1221	GLENMARK-ZETIA-00283581	GLENMARK-ZETIA-00283581		Glenmark document titled, "3.2.P.5.4 Batch Analyses"		X	HS
MDX1223	GLENMARK-ZETIA-00304971	GLENMARK-ZETIA-00304971		Draft-email, notes from V. Soni re "draft"		X	NO
MDX1225				WITHDRAWN			
MDX1226				WITHDRAWN			
MDX1227				WITHDRAWN			
MDX1228	MRKZETIA_R000055856	MRKZETIA_R000055856		PowerPoint presentation titled, "ZETIA Proposed LOE Contracting Strategy"		X	HS
MDX1229	MRKZETIA_R000062439	MRKZETIA_R000062439	9/2013	Excel spreadsheet with file name, "US Eze Family P&Ls 2013 -Sep YTD 2018.xlsx"		X	HS
MDX1231	MRKZETIA_R000062448	MRKZETIA_R000062448	1/2013	Printout of Excel spreadsheet titled "US Pharma Zetia & Ezetimibe Family Promotional & Direct Selling Costs Jan 2013 - Jan 2018"		X	403; HS; R
MDX1233	MRKZETIA_R000062456	MRKZETIA_R000062456	2010	Printout of Excel spreadsheet with file name "US Eze Family P&Ls 2010 - 2012.xlsx"		X	HS
MDX1234	MRKZETIA_R000066212	MRKZETIA_R000066212	2010	Excel spreadsheet with file name, "US PL - 2010 - 100509_entire P L.xl"		X	403; HS; MIL; R
MDX1235	MRKZETIA_R000067906	MRKZETIA_R000067906	2002	Printout of Excel spreadsheet titled "U.S. Zetia Full P&L's 2002-2007"		X	HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1236	MRKZETIA_R000068832	MRKZETIA_R000068832	9/12/2016	Excel spreadsheet with file name: S&OP_ZETIA_091216_fcst_sales.xls		X	403; HS; R
MDX1237	MRKZETIA_R000069507	MRKZETIA_R000069507	5/1/2008	Excel spreadsheet with file name "Chol R&D 08 LROP CDC Presentation 1 May08"		X	403; HS; MIL; R
MDX1238	MRKZETIA_R000070930	MRKZETIA_R000070930	3/20/2009	Excel spreadsheet with file name, "08 Zetia Ph V R&D Cost Adj's Final.xls"		X	403; HS; MIL; R
MDX1239	MRKZETIA_R000071879	MRKZETIA_R000071879	11/2008	Excel spreadsheet with file name: Change in pricing assumptions based on Nov 08 PP .xls		X	403; 901; HS; MIL; R
MDX1240	MRKZETIA_R000073234	MRKZETIA_R000073234	6/9/2008	Excel spreadsheet with file name: Change in pricing assumptions to MR update to PL Rollup_060908_Scen #2_base w EZA per disc with US JV.xls		X	403; HS; MIL; R
MDX1242	MRKZETIA_R000093176	MRKZETIA_R000093176	2014	Document titled, "Competitive and Market Event Planning Atheroclerosis Franchise"		X	403; HS; MIL; R
MDX1243	MRKZETIA_R000094338	MRKZETIA_R000094338	8/4/2010	PowerPoint presentation titled, ZETIA, Vytorin & Eze-Atorva - US Market Commercial Strategy & Plan 2010 EA / 2011 Plan / 2012-2015 LROP		X	403; HS; MIL; R
MDX1244	MRKZETIA_SIDLEY000009831	MRKZETIA_SIDLEY000009868		Schering-Plough Research Institute President's Award for Discovery 19__ Nomination, " The Discovery of Novel Zetidinone Inhibitors of Cholesterol Absorption with Improved Potency, Pharmacokinetics, and Safety"		X	HS
MDX1246	MRKZETIA_SIDLEY000013087	MRKZETIA_SIDLEY000013250	5/1993	Stuart Rosenblum Notebook No. 31818 (May 1993-August 1994)		X	901
MDX1247	MRKZETIA_SIDLEY000013949	MRKZETIA_SIDLEY000014113	8/18/1993	Adriano Afonso Notebook No. 32242 (August 18, 1993-September 20, 1994)		X	901
MDX1248	MRKZETIA_SIDLEY000023478	MRKZETIA_SIDLEY000023640	3/1992	Stuart Rosenblum Notebook No. 28581 (March 1992-June 1993)		X	901
MDX1249	MRKZETIA_SIDLEY000029796	MRKZETIA_SIDLEY000029796		Excel spreadsheet with file name, "Exhibits 12 and 17.xls"		X	HS
MDX1251	MRKZETIA_SIDLEY000052576	MRKZETIA_SIDLEY000052739	5/1993	Stuart Rosenblum Notebook No. 31818 (May 1993-August 1994)		X	901
MDX1252	MRKZETIA_SIDLEY000057494	MRKZETIA_SIDLEY000059974		"Original Submission ANDA Ezetimibe Tables 10 mg Glenmark Pharmaceuticals Limited"		X	HS
MDX1253	MRKZETIA_SIDLEY000064347	MRKZETIA_SIDLEY000064350	1991	Gunda Georg et al., An Improved Method for the Stereoselective Synthesis of β-Lactams from Carboxylic Acids and Imines, Tetrahedron Letters, 1991, 32, 581-84		X	HS
MDX1254	MRKZETIA_SIDLEY000093429	MRKZETIA_SIDLEY000093513	3/25/1993	Tram Huynh Notebook No. 31472 (March 25, 1993-April 22, 1994)		X	901
MDX1255	MRKZETIA_SIDLEY000105800	MRKZETIA_SIDLEY000105896	1/3/1995	SCH 48461 - Drug Metabolism and Pharmacokinetics, Study No./Report C93-012-01, Drug Metabolism/Clinical Pharmacology Study Report "SCH48461: Absorption, Metabolism and Excretion of C-SCH 48461 Administered Orally to Healthy Male Volunteers"		X	HS
MDX1256	MRKZETIA_SIDLEY000134011	MRKZETIA_SIDLEY000134030		Document SCH 58235(Ezetimibe) - Section 4.A.4 Synthesis/Method of Manufacture		X	901; HS
MDX1257	MRKZETIA_SIDLEY000136628	MRKZETIA_SIDLEY000136870		Document In Vivo Data		X	901; HS
MDX1258	MRKZETIA_SIDLEY000188255	MRKZETIA_SIDLEY000188349		Chromatograms of 28581-141-2 (DTX 0540)		X	901; HS
MDX1259	MRKZETIA_SIDLEY000190938	MRKZETIA_SIDLEY000190940		Alternative Version of November 1993 Proton NMR Spectra for 60-1 and 60-3 Samples and HPLC for 60-1		X	901; HS
MDX1260	MRKZETIA_SIDLEY000191115	MRKZETIA_SIDLEY000191199	3/25/1993	Tram Huynh Notebook No. 31472 (March 25, 1993-April 22, 1994)		X	901
MDX1261	MRKZETIA_SIDLEY000191288	MRKZETIA_SIDLEY000191293	11/18/1993	Smaller Scale Version of November 1993 Proton NMR Spectra for 60-1 and 60-3 Samples and HPLC for 60-1		X	901; HS
MDX1262	MRKZETIA_SIDLEY000198087	MRKZETIA_SIDLEY000198087	8/25/2011	Excel spreadsheet with file name: Mylan098459 OUTSIDE ATTORNEYS' EYES ONLY.XLS		X	NO
MDX1264	MRKZETIA_SIDLEY000285771	MRKZETIA_SIDLEY000285794	12/8/1998	U.S. Patent No. 5,846,966		X	403; MIL; R
MDX1265	MRKZETIA000509547	MRKZETIA000509547	7/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Jul_66582041476.xlsx"		X	403; 901; HS
MDX1266	MRKZETIA000509548	MRKZETIA000509548	7/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Jul_66582041428.xlsx		X	403; 901; HS
MDX1267	MRKZETIA000509549	MRKZETIA000509549	12/31/2015	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2015Q4.xlsx""		X	403; 901; HS
MDX1268	MRKZETIA000509551	MRKZETIA000509551	9/30/2016	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2016Q3.xlsx"		X	403; 901; HS
MDX1269	MRKZETIA000509552	MRKZETIA000509552	12/31/2016	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2016Q4.xlsx"		X	403; 901; HS

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1270	MRKZETIA000509553	MRKZETIA000509553	9/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Sep.xlsx"		X	403; 901; HS
MDX1271	MRKZETIA000509554	MRKZETIA000509554	9/30/2015	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2015Q3.xlsx"		X	403; 901; HS
MDX1272	MRKZETIA000509555	MRKZETIA000509555	2017	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2017.xlsx"		X	403; 901; HS
MDX1273	MRKZETIA000509556	MRKZETIA000509556	11/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Nov.xlsx"		X	403; 901; HS
MDX1274	MRKZETIA000509557	MRKZETIA000509557	7/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Jul_66582041454.xlsx"		X	403; 901; HS
MDX1275	MRKZETIA000509558	MRKZETIA000509558	12/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Dec.xlsx"		X	403; 901; HS
MDX1276	MRKZETIA000509559	MRKZETIA000509559	8/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Aug.xlsx"		X	403; 901; HS
MDX1277	MRKZETIA000509560	MRKZETIA000509560	6/30/2015	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2015Q2.xlsx"		X	403; 901; HS
MDX1278	MRKZETIA000509561	MRKZETIA000509561	3/31/2015	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2015Q1.xlsx"		X	403; 901; HS
MDX1279	MRKZETIA000509562	MRKZETIA000509562	6/30/2016	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2016Q2.xlsx"		X	403; 901; HS
MDX1280	MRKZETIA000509563	MRKZETIA000509563	7/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Jul_66582041474.xlsx"		X	403; 901; HS
MDX1281	MRKZETIA000509564	MRKZETIA000509564	10/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Oct.xlsx"		X	403; 901; HS
MDX1282	MRKZETIA000509565	MRKZETIA000509565	3/31/2016	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2016Q1.xlsx"		X	403; 901; HS
MDX1283	MRKZETIA000509566	MRKZETIA000509566	7/2014	Excel spreadsheet with file name, "ZETIA_MCO_Rebates_2014-Jul_66582041431.xlsx"		X	403; 901; HS
MDX1284	MRKZETIA000509916	MRKZETIA000509916	4/26/2017	Excel spreadsheet with file name: Glenmark Estimates.xlsx (April 26, 2017-June 9, 2017)		X	901; HS
MDX1285	MRKZETIA000509917	MRKZETIA000509917		Excel spreadsheet with file name: Scenario Table.xlsx		X	HS
MDX1286	MRKZETIA000517429	MRKZETIA000517429	12/17/2018	PowerPoint Presentation titled, "ZETIA/VYTORIN – LROP Price Plan"		X	403; HS; R
MDX1287	MRKZETIA000521875	MRKZETIA000521875		Power Point presentation titled, "ZETIA Proposed LOE Contracting Strategy"		X	HS
MDX1288	MRKZETIA000533673	MRKZETIA000533673	9/24/2015	Untitled PowerPoint presentation re "SOB buckets"		X	403; HS; MIL; R
MDX1289	MRKZETIA000598352	MRKZETIA000598352	2010	PowerPoint presentation titled,"MRK US Pricing Policy & Strategy: Catalog Pricing 2010-2011"		X	HS
MDX1290	MRKZETIA000629334	MRKZETIA000629334	6/30/2009	Excel spreadsheet with file name: LS_MRK-postQ209-telcagepant.xls		X	901; HS; R
MDX1291				WITHDRAWN			
MDX1292				WITHDRAWN			
MDX1293	MRKZETIA000843971	MRKZETIA000843971	2005	Printout of Excel spreadsheet with file name "Document Zetia Litigation Support 2005 to 2018"		X	403; 901; 1006; HS; MIL; R
MDX1294	MRKZETIA000843972	MRKZETIA000843972		Printout of Excel spreadsheet with file name "Zetia Cost Information Submitted"		X	403; 901; HS; MIL; R
MDX1295	MRKZETIA000907799	MRKZETIA000907833		File, "Afonso Correspondence re Inventorship"		X	NO
MDX1296	MRKZETIA000918647	MRKZETIA000919646	12/5/2011-12/20/2011	Trial Transcripts, Schering Corp., et al. v. Mylan Pharm., et al., Case Nos. 09-6383 (JLL) and 10-3085 (JLL)		X	403; HS; MIL; R
MDX1297	MRKZETIA000931442	MRKZETIA000931442		Printout of Excel spreadsheet with file name "Zetia Medicare Part D worksheet"		X	HS
MDX1298	MRKZETIA000944465	MRKZETIA000944481	1/1/2016	Seventh Amendment to the Medicare Part D Program Rebate Agreement between Merck and CVS		X	HS
MDX1300	MYL_ZETIA 011343	MYL_ZETIA 011345		Mylan document titled, "Section 3.2.P.3.1 Manufacturer(s)"		X	403; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1301	No Bates	No Bates	3/11/2020	Wikipedia - Jose L. Linares		X	403; 901; HS; MIL; R
MDX1302	No Bates	No Bates	3/11/2020	Patent Terms Extended Under 35 USC Section 156		X	403; 901; HS; R
MDX1303	No Bates	No Bates	2009	United States Court of Appeals for the Federal Circuit, Median Time to Disposition of Cases Terminated After Hearing or Submission, Docketing Date to Disposition Date in Months (FY2009–2018), http://www.cafc.uscourts.gov/sites/default/files/the-court/statistics/07_Med_Disp_Time_MERITS_table.pdf		X	NO
MDX1304	No Bates	No Bates	2/28/2020	Timeline of Key Events Relating To Glenmark's Pre-Trial Defenses (Exhibit E to Linck Report)		X	403; HS
MDX1305	No Bates	No Bates	11/1995	Van Heek, Margaret et al., Abstract, Isolation and Identification of the Active Metabolite(s) of SCH48461 and Possible in Vivo Mechanism of Action for their Inhibition of Cholesterol Absorption, DALM		X	403; HS; MIL; R
MDX1306	No Bates	No Bates	11/1995	Davis, Harry R. Jr., et al., Abstract, The Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor SCH 58235 Alone and in Combination with HMG CoA Reductase Inhibitors, DALM		X	403; HS; MIL; R
MDX1307	No Bates	No Bates	10/15/2020	Corey-Itsuno Reduction, Wikipedia		X	403; 901; HS; R
MDX1309	No Bates	No Bates	12/5/2016	Code 21 C.F.R. § 314.3		X	403; R
MDX1310	No Bates	No Bates	11/29/2016	Code 21 C.F.R. § 314.81 Other Postmarketing Reports		X	403; R
MDX1311	No Bates	No Bates	10/20/2020	Article, "6 Steps to Effective Late-Stage Lifecycle Drug Management"		X	403; 901; HS; R
MDX1312	No Bates	No Bates		"'Do Brands Have Value After Exclusivity?"		X	403; 901; HS; R
MDX1313	No Bates	No Bates	10/26/2018	FDA Ezetimibe Approval, Accord Healthcare Inc.		X	NO
MDX1314	No Bates	No Bates	12/21/2017	FDA Ezetimibe Approval, Alkem Laboratories Ltd		X	NO
MDX1315	No Bates	No Bates	6/12/2017	FDA Ezetimibe Approval, Amneal Pharmaceuticals Co. GMBH		X	NO
MDX1316	No Bates	No Bates	6/12/2017	FDA Ezetimibe Approval, Apotex Inc.		X	NO
MDX1317	No Bates	No Bates	8/25/2017	FDA Ezetimibe Approval, Aurobindo Pharma Ltd		X	NO
MDX1318	No Bates	No Bates		Demonstrative: Modified Addanki Report Exhibit 4 (Leffler) Commercial and Medicare Part D Plan Rebates Paid by Merck for Zetia December 2016 through December 2017		X	403; 901; 1006; FD; HS; R
MDX1319	No Bates	No Bates		Demonstrative: Expected Entry Date Had the Lawsuit Been Adjudicated		X	403; 901
MDX1320	No Bates	No Bates		Demonstrative: Modified Addanki Report Exhibit 4 (McGuire) Commercial and Medicare Part D Plan Rebates Paid by Merck for Zetia December 2016 through December 2017		X	403; 901; 1006; FD; HS; R
MDX1321	No Bates	No Bates	6/26/2015	FDA Ezetimibe Approval, Glenmark Pharmaceuticals Ltd.		X	NO
MDX1323	No Bates	No Bates	2/16/2011	H.R.741 - To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs		X	403; HS; MIL; R
MDX1324	No Bates	No Bates	2/5/2007	H.R.806 - To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs		X	403; HS; MIL; R
MDX1325	No Bates	No Bates	7/28/2006	H.R.5993 - To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs		X	403; HS; MIL; R
MDX1326	No Bates	No Bates	7/9/2020	Printout of Leffler Excel spreadsheet titled "Assumptions ZETIA Sources or Values for the Analysis of the Profitability of Litigation and Early Entry Settlement" (file name "LitActSettleEndogLitProbReply.xlsx")		X	NO
MDX1327	No Bates	No Bates	7/9/2020	Printout of Leffler Excel spreadsheet with file name "ValueActSettleZetiaRevised.xlsx"		X	NO
MDX1328	No Bates	No Bates	2/21/2011	Article titled, "Legislation to Ban Authorized Generics During 180-Day Exclusivity, Period Makes a Comeback in Congress"		X	403; 901; HS; MIL; R
MDX1329	No Bates	No Bates	1/13/2020	McGuire Opening Report Attachment F		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1330	No Bates	No Bates		Demonstrative: McGuire Attachment F with Glenmark expectations changed to 60%		X	403; 901; FD; HS; R
MDX1331	No Bates	No Bates		Demonstrative: McGuire Attachment F with Merck expectations changed to 28%		X	403; 901; FD; HS; R
MDX1332	No Bates	No Bates		Demonstrative: McGuire Attachment F with Parties expectations changed to 11%		X	403; 901; FD; HS; R
MDX1333	No Bates	No Bates		Demonstrative: McGuire Attachment F Glenmark Wins Scenario		X	403; 901; FD; HS; R
MDX1334	No Bates	No Bates	4/26/2019	FDA Ezetimibe Approval, Mylan Pharmaceuticals Inc.		X	NO
MDX1335	No Bates	No Bates	1/9/2020	FDA Ezetimibe Approval, OHM Laboratories Inc.		X	NO
MDX1336	No Bates	No Bates	1/2020	Teva, "Oral Contraceptive Identification Chart," January 2020		X	403; 901; HS; MIL; R
MDX1337	No Bates	No Bates	1/9/2020	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations		X	403; MIL; R
MDX1338	No Bates	No Bates	1/30/2020	CellCept "Preserve Your Branded Choice"		X	403; 901; HS; MIL; R
MDX1339	No Bates	No Bates	2/16/2011	S.373 - Fair Prescription Drug Competition Act		X	403; HS; MIL; R
MDX1340	No Bates	No Bates	1/30/2007	S.438 - Fair Prescription Drug Competition Act		X	403; HS; MIL; R
MDX1342	No Bates	No Bates	7/19/2006	S.3695 - A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs		X	403; HS; MIL; R
MDX1343	No Bates	No Bates	6/12/2017	FDA Ezetimibe Approval, Sandoz Inc.		X	NO
MDX1344	No Bates	No Bates	6/12/2017	FDA Ezetimibe Approval, Teva Pharmaceuticals USA		X	NO
MDX1345	No Bates	No Bates	2/4/2020	SUN Pharmaceuticals Industries, Ltd. Profile		X	403; 901; HS; R
MDX1346	No Bates	No Bates	10/2019	Vytorin Label		X	403; HS; MIL; R
MDX1347	No Bates	No Bates	6/12/2017	FDA Ezetimibe Approval, Watson Laboratories Inc.		X	NO
MDX1348	No Bates	No Bates	8/2013	Zetia Label		X	403; HS; MIL; R
MDX1349	No Bates	No Bates	6/12/2017	FDA Ezetimibe Approval, Zydus Pharmaceuticals USA Inc.		X	NO
MDX1350	No Bates	No Bates		Article titled, "Your Health Plan's Formulary: The List of Preferred Prescription Drugs, Consumer Report Health.org - Best Buy Drugs		X	403; 901; HS; MIL; R
MDX1351				WITHDRAWN			
MDX1352				WITHDRAWN			
MDX1353				WITHDRAWN			
MDX1354				WITHDRAWN			
MDX1355				WITHDRAWN			
MDX1356	No Bates	No Bates		FDA Antara Generic Approval		X	403; MIL; R
MDX1357	No Bates	No Bates	2/25/2020	Celexus, "Who Are We"		X	403; 901; HS
MDX1358	No Bates	No Bates	7/19/1994	FDA Colestid Approval		X	403; MIL; R
MDX1359	No Bates	No Bates	2/5/2019	Express Scripts, "Previous Drug Trend Reports," 2019		X	403; 901; HS; R
MDX1360	No Bates	No Bates	2/28/2020	Food and Drug Administration, "ANDA (Generic) Drug Approvals - Previous Years"		X	403; HS; R
MDX1361	No Bates	No Bates	12/13/2019	Food and Drug Administration, "Generic Competition and Drug Prices"		X	NO
MDX1362	No Bates	No Bates	2/28/2020	Food and Drug Administration, "Drugs@FDA: FDA-Approved Drugs"		X	403; R
MDX1363				WITHDRAWN			
MDX1364				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1365				WITHDRAWN			
MDX1366				WITHDRAWN			
MDX1367				WITHDRAWN			
MDX1368				WITHDRAWN			
MDX1369				WITHDRAWN			
MDX1370				WITHDRAWN			
MDX1371				WITHDRAWN			
MDX1372				WITHDRAWN			
MDX1373				WITHDRAWN			
MDX1374				WITHDRAWN			
MDX1375				WITHDRAWN			
MDX1376				WITHDRAWN			
MDX1377				WITHDRAWN			
MDX1378				WITHDRAWN			
MDX1379				WITHDRAWN			
MDX1380				WITHDRAWN			
MDX1381				WITHDRAWN			
MDX1382				WITHDRAWN			
MDX1383				WITHDRAWN			
MDX1384	No Bates	No Bates	4/26/2017	FDA Vytorin Generic Approval		X	403; MIL; R
MDX1385				WITHDRAWN			
MDX1386				WITHDRAWN			
MDX1387				WITHDRAWN			
MDX1388				WITHDRAWN			
MDX1389				WITHDRAWN			
MDX1390				WITHDRAWN			
MDX1391				WITHDRAWN			
MDX1392				WITHDRAWN			
MDX1393				WITHDRAWN			
MDX1394				WITHDRAWN			
MDX1395				WITHDRAWN			
MDX1396				WITHDRAWN			
MDX1397				WITHDRAWN			
MDX1398				WITHDRAWN			
MDX1399				WITHDRAWN			
MDX1400				WITHDRAWN			
MDX1401	No Bates	No Bates	12/12/2011	21 C.F.R. 210		X	403; 901; HS; R
MDX1402	No Bates	No Bates	11/16/2015	21 C.F.R. 211		X	403; 901; HS; R
MDX1403	No Bates	No Bates	4/1/2019	21 C.F.R. 314.126		X	403; 901; HS; R
MDX1404	No Bates	No Bates	4/1/2019	21 C.F.R. 314.53		X	403; 901; HS; R
MDX1405	No Bates	No Bates	4/1/2019	21 C.F.R. 314.95		X	403; 901; HS; R
MDX1406	No Bates	No Bates	10/24/2018	21 U.S.C. 355		X	403; 901; HS; R
MDX1407	No Bates	No Bates	10/24/2018	21 U.S.C. 355a		X	403; 901; HS; R
MDX1408	No Bates	No Bates	1/7/2002	Center for Drug Evaluation and Research Application Number 21-445 Medical Review(s) (January 7, 2002-September 17, 2002)		X	901; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1409	No Bates	No Bates		CDC - NIOSH Pocket Guide to Chemical Hazards - Ethylene dichloride		X	403; 901; HS; MIL; R
MDX1410	No Bates	No Bates	5/8/2018	Agata Dabrowska et al., How FDA Approves Drugs and Regulates Their Safety and Effectiveness, Congressional Research Service		X	901; HS; R
MDX1411	No Bates	No Bates	10/26/2018	Drugs@FDA, ANDA No. 211550 (Accord Healthcare)		X	901; HS
MDX1412	No Bates	No Bates	12/21/2017	Drugs@FDA, ANDA No. 209234 (Alkem Labs Ltd.)		X	901; HS
MDX1413	No Bates	No Bates	6/12/2017	Drugs@FDA, ANDA No. 208803 (Amneal Pharms Co.)		X	901; HS
MDX1414	No Bates	No Bates	6/12/2017	Drugs@FDA, ANDA No. 204331 (Zydus Pharms)		X	901; HS
MDX1415	No Bates	No Bates	1/2000	EPA, Ethylene Dicholoride		X	403; 901; HS; MIL; R
MDX1416	No Bates	No Bates	1/2000	EPA, Methylene Chloride		X	403; 901; HS; MIL; R
MDX1417	No Bates	No Bates	10/2019	FDA, Drug Master Files Guidance for Industry Draft Guidance		X	403; 901; HS
MDX1418	No Bates	No Bates	9/1989	FDA, Drug Master Files: Guidelines		X	403; 901; HS
MDX1419	No Bates	No Bates	10/17/2020	FDA, Generic Drug User Fee Amendments		X	403; 901; HS; R
MDX1420	No Bates	No Bates	1/7/2019	FDA, How Drugs are Developed and Approved		X	403; 901; HS; R
MDX1421	No Bates	No Bates	3/28/2018	FDA, What We Do		X	403; 901; HS; R
MDX1422	No Bates	No Bates	1/2017	FDA, Guidance for Industry 180-Day Exclusivity: Questions and Answers Draft Guidance		X	901; HS
MDX1423	No Bates	No Bates	4/22/2015	Toufanian, Maryll, et al. , Hatch-Waxman 101 (April 22-23, 2015)		X	403; 901; HS; HWH; R
MDX1424	No Bates	No Bates	12/2012	Mestre-Ferrandiz, J. et al., The R&D Cost of a New Medicine		X	403; 901; HS; HWH; MIL; R
MDX1425	No Bates	No Bates	2015	Moon, N. et al., Generic Competition and Authorized Generics in the United States		X	403; 901; HS; INC; MIL; R
MDX1426	No Bates	No Bates	10/17/2020	NDC Directory, Next Choice One Dose		X	403; 901; HS; MIL; R
MDX1427	No Bates	No Bates	10/17/2020	NDC Directory, Camrese Lo		X	403; 901; HS; MIL; R
MDX1428	No Bates	No Bates	10/17/2020	NDC Directory, Camrese		X	403; 901; HS; MIL; R
MDX1429	No Bates	No Bates	10/17/2020	NDC Directory, Nora BE		X	403; 901; HS; MIL; R
MDX1430	No Bates	No Bates	10/17/2020	NDC Directory, Rivelsa		X	403; 901; HS; MIL; R
MDX1431	No Bates	No Bates	6/30/2020	PhRMA, Code on Interactions with Health Care Professionals		X	403; 901; HS; R
MDX1432	No Bates	No Bates	9/21/2016	Senate Hearing, Prioritizing Public Health The FDA's Role in the Generic Drug Marketplace		X	403; 901; HS; HWH; MIL; R
MDX1433	No Bates	No Bates	11/1995	Document titled, "Guidance for Industry, Immediate Release Solid Oral Dosage Forms, Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation"		X	NO
MDX1434	No Bates	No Bates	9/16/2012	35 U.S.C. 284		X	403; 901; CLC; HS; R
MDX1439				WITHDRAWN			
MDX1440	No Bates	No Bates	1/13/2020	Jeffrey Leitzinger Damages Backup: Exhibit 6.xlsx		X	NO
MDX1441	No Bates	No Bates	1/13/2020	Jeffrey Leitzinger Damages Backup: Exhibit 7.xlsx		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1442	No Bates	No Bates	1/13/2020	Jeffrey Leitzinger Damages Backup: Exhibit 8.xlsx		X	NO
MDX1443	No Bates	No Bates	1/13/2020	JJeffrey Leitzinger Damages Backup: Exhibit 9.xlsx		X	NO
MDX1444	No Bates	No Bates	1/13/2020	Jeffrey Leitzinger Damages Backup: Exhibit 10.xlsx		X	NO
MDX1445	No Bates	No Bates	1/13/2020	Jeffrey Leitzinger Damages Backup: Exhibit 12A.xlsx		X	NO
MDX1446	No Bates	No Bates	1/13/2020	Jeffrey Leitzinger Damages Backup: Exhibit 12B.xlsx		X	NO
MDX1447	No Bates	No Bates	5/8/2020	Jeffrey Leitzinger Rebuttal Damages Backup: Exhibit 4A.xlsx		X	NO
MDX1448	No Bates	No Bates	5/8/2020	Jeffrey Leitzinger Rebuttal Damages Backup: Exhibit 4B.xlsx		X	NO
MDX1449	No Bates	No Bates	5/8/2020	Jeffrey Leitzinger Rebuttal Damages Backup: Exhibit 5A.xlsx		X	NO
MDX1450	No Bates	No Bates	5/8/2020	Jeffrey Leitzinger Rebuttal Damages Backup: Exhibit 5B.xlsx		X	NO
MDX1451	No Bates	No Bates	1/20/2020	Bruce Strombom Class Certification Backup: Exhibit 2.xlsx		X	403; HS; HWH; MIL; R
MDX1452	No Bates	No Bates	1/20/2020	Bruce Strombom Class Certification Backup: Exhibit 3.xlsx		X	403; HS; HWH; MIL; R
MDX1453	No Bates	No Bates	1/20/2020	Bruce Strombom Class Certification Backup: Exhibit 4.xlsx		X	403; HS; HWH; MIL; R
MDX1454	No Bates	No Bates	6/1/2018	FDA, "Generic Drugs: Questions & Answers"		X	403; 901; HS; R
MDX1455	No Bates	No Bates	2012	Document titled "White Paper Report United States Patent Invalidity Study 2012		X	403; 901; HS; R
MDX1456				WITHDRAWN			
MDX1457				WITHDRAWN			
MDX1458				WITHDRAWN			
MDX1459				WITHDRAWN			
MDX1460				WITHDRAWN			
MDX1461				WITHDRAWN			
MDX1462				WITHDRAWN			
MDX1463				WITHDRAWN			
MDX1464	No Bates	No Bates	11/2013	Excel Spreadsheet: NPA Audit from November 2013 to October 2019 for Ezetimibe/Zetia		X	901; HS; INC
MDX1465	No Bates	No Bates	7/9/2020	Printout of Excel file, tab "WAC + WTD PRICES" in Excel file "CLIENT $$ SUMMARY REPLY S3 REVISED.xlsx"		X	NO
MDX1466	No Bates	No Bates	7/9/2020	Printout of Excel file "SALES DATA COMBINED.xlsx"		X	901; HS; INC
MDX1467	No Bates	No Bates	2/28/2020	Exhibit 3A to the Report of Lauren Stiroh: Illustrative Plan Payments for Brand and Generic Ezetimibe Placing Branded Zetia on Preferred Tier		X	403; HS; R
MDX1468	No Bates	No Bates	2/28/2020	Exhibit 3B to the Report of Lauren Stiroh: Illustrative Plan Payments for Brand and Generic Ezetimibe Placing Branded Zetia on Non-Preferred Tier		X	403; HS; R
MDX1469	No Bates	No Bates	2/28/2020	Exhibit 4A to the Report of Lauren Stiroh: Illustrative Plan Payments for Brand and Generic Ezetimibe without Authorized Generic Placing Branded Zetia on Preferred Tier		X	403; HS; R
MDX1470	No Bates	No Bates	2/28/2020	Exhibit 4B to the Report of Lauren Stiroh: Illustrative Plan Payments for Brand and Generic Ezetimibe without Authorized Generic Placing Branded Zetia on Non-Preferred Tier		X	403; HS; R
MDX1471	No Bates	No Bates	2/28/2020	Exhibit 5A to the Report of Lauren Stiroh: Illustrative Plan Payment for Brand and Generic Ezetimibe by Medicare Part D Period Placing Brand and Genetic Ezetimibe on Preferred Tiers		X	403; HS; R
MDX1472	No Bates	No Bates	2/28/2020	Exhibit 5B to the Report of Lauren Stiroh: Illustrative Plan Payment for Brand and Generic Ezetimibe by Medicare Part D Period Placing Branded Zetia on Non-Preferred Tier and Generic Ezetimibe on Preferred Tier		X	403; HS; R
MDX1473	No Bates	No Bates	2/28/2020	Exhibit 5C to the Report of Lauren Stiroh: Illustrative Plan Payment for Brand and Generic Ezetimibe by Medicare Part D Period Placing Branded Zetia on Preferred Tier and Generic Ezetimibe on Non-Preferred Tier		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1474	No Bates	No Bates	2/28/2020	Exhibit 5D to the Report of Lauren Stiroh: Illustrative Plan Payment for Brand and Generic Ezetimibe by Medicare Part D Period Placing Brand and Genetic Ezetimibe on Non-Preferred Tiers		X	403; HS; R
MDX1475	No Bates	No Bates	2/28/2020	Exhibit 6A to the Report of Lauren Stiroh: Correcting Dr. Lamb's Errors in His Overcharge Damages Calculations		X	HS
MDX1476	No Bates	No Bates	2/28/2020	Exhibit 6B to the Report of Lauren Stiroh: Correcting Dr. Lamb's Errors in His Overcharge Damages Calculations		X	HS
MDX1477	No Bates	No Bates	2/28/2020	Exhibit 7 to the Report of Lauren Stiroh: Non-Glenmark Generic Sales Volume by Month		X	HS
MDX1478	No Bates	No Bates	2/28/2020	Exhibit 8A to the Report of Lauren Stiroh: Reproducing Dr. Lamb's Unjust Enrichment Calculations Using But-for Generic Entry on November 12, 2016		X	HS
MDX1479	No Bates	No Bates	2/28/2020	Exhibit 8B to the Report of Lauren Stiroh: Reproducing Dr. Lamb's Unjust Enrichment Calculations Using But-for Generic Entry on November 12, 2016 Restricted to Brand Subclass		X	HS
MDX1480	No Bates	No Bates	2/28/2020	Exhibit 9A to the Report of Lauren Stiroh: Reproducing Dr. Lamb's Unjust Enrichment Calculations Using But-for Generic Entry on November 28, 2016		X	HS
MDX1481	No Bates	No Bates	2/28/2020	Exhibit 9B to the Report of Lauren Stiroh: Reproducing Dr. Lamb's Unjust Enrichment Calculations Using But-for Generic Entry on November 28, 2016 Restricted to Brand Subclass		X	HS
MDX1482	No Bates	No Bates	1/2020	AAM White Paper Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution		X	403; 901; HS; HWH; R
MDX1483	No Bates	No Bates	2008	The SAGE Handbook of Healthcare		X	403; 901; HS; HWH; MIL; R
MDX1484	No Bates	No Bates		PDF of excel sheet titled "Confidential - 'Share of Enrollees' tab in Medicare Part D Benefit Design.xlsx		X	901; HS; INC
MDX1485	No Bates	No Bates	2011	Q1Medicare.com: The Medicare Part D Donut Hole Discount (2011 to 2020)		X	403; 901; HS; HWH; R
MDX1486	No Bates	No Bates	1/2017	Department of Health and Human Services, Office of Inspector General: High-Price Drugs Are Increasing Federal Payments For Medicare Part D Catastrophic Coverage		X	403; 901; HS; HWH; R
MDX1487	No Bates	No Bates	3/2020	USC Schaeffer: How would Sharing Rebates At The Point-of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?		X	403; 901; HS; HWH; R
MDX1488	No Bates	No Bates	4/1/2010	Excel Spreadsheet: Table of Annual Estimates of the Resident Population for the United States, Regions, States (April 1, 2010-July 1, 2019)		X	403; 901; HS; R
MDX1489	No Bates	No Bates	1970	Excel Spreadsheet: Table of Retail Prescription Drug Expenditures; Levels, Percent Change, and Percent Distribution, by Source of Funds (Selected Calendar Years 1970-2018)		X	403; 901; HS; R
MDX1490	No Bates	No Bates	2012	Bessen & Meurer: The Private Costs of Patent Litigation 2012		X	403; 901; HS; HWH; R
MDX1491	No Bates	No Bates	2/2013	N. Carroll: A Comparison of the Costs of Dispensing Prescriptions through Retail and Mail Order Pharmacies 2013		X	403; 901; HS; HWH; R
MDX1492	No Bates	No Bates	8/2011	The Hamilton Project: A Dozen Economic Facts About Innovation 2011		X	403; 901; HS; HWH; R
MDX1493	No Bates	No Bates	2017	American Bar Association - Proving Antitrust Damages - 3rd Edition, 2017		X	403; 901; HS; HWH; INC; R
MDX1494	No Bates	No Bates	1/12/2017	Antitrust Guidelines for the Licensing of Intellectual Property		X	403; 901; HS; HWH; R
MDX1495	No Bates	No Bates	9/2001	F. Lichtenberg: Are the Benefits of Newer Drugs Worth Their Cost 2001		X	403; 901; HS; HWH; R
MDX1496	No Bates	No Bates	8/2011	Federal Trade Commission: Authorized Generic Drugs Short-Term Effects and Long-Term Impact (August 2011)		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1497	No Bates	No Bates	8/2014	S. Barlas: Are Specialty Drug Prices Destroying Insurers		X	403; 901; HS; HWH; R
MDX1498	No Bates	No Bates	10/1992	H. Grabowski & J. Vernon: Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act 1992		X	NO
MDX1499	No Bates	No Bates	2018	M. Cabral & et al.: Do Larger Health Insurance Subsidies Benefit Patients or Producers		X	403; 901; HS; HWH; R
MDX1500	No Bates	No Bates	2/26/2020	P. Alguire: Understanding Capitation		X	403; 901; HS; R
MDX1501	No Bates	No Bates	3/2017	MedPac Report (2017): Ch14 - Status report on the Medicare prescription drug program (Part D)		X	403; 901; HS; HWH; INC; R
MDX1502	No Bates	No Bates	8/21/2018	J. Cubanski: Closing the Medicare Part D Coverage Gap: Trends, Recent Changes, and What's Ahead		X	403; 901; HS; HWH; R
MDX1503	No Bates	No Bates	1/30/2019	CMS Report 2019 Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Part D Payment Policies		X	403; 901; HS; HWH; R
MDX1504	No Bates	No Bates	2010	T. Cowen and A. Tabarrok: Modern Principles of Economics		X	403; 901; HS; HWH; INC; IL; R
MDX1505	No Bates	No Bates	5/2018	G. Dieguez: A primer on prescription drug rebates		X	403; 901; HS; HWH; R
MDX1506	No Bates	No Bates	2/28/2020	The Economist - Economics A-Z terms beginning with C		X	403; 901; HS; R
MDX1507	No Bates	No Bates	2014	Kaiser Family Foundation: Employer Health Benefits 2014 Annual Survey		X	403; 901; HS; HWH; R
MDX1508	No Bates	No Bates	3/17/2008	SEC: Frequently Asked Questions and Answers Exhibit 99.1 2008		X	HS; INC
MDX1509	No Bates	No Bates	1997	R. Frank: Generic Entry and the Pricing of Pharmaceuticals		X	NO
MDX1510	No Bates	No Bates	2014	H. Grabowski & et al: Recent Trends in Brand-Name and Generic Drug Competition		X	403; 901; HS; HWH; MIL; R
MDX1511	No Bates	No Bates	3/23/2010	H.R.3590 - 111th Congress (2009-2010) Patient Protection and Affordable Care Act		X	403; 901; HS; R
MDX1512	No Bates	No Bates	2010	H. Varian: Intermediate Microeconomics - A Modern Approach		X	403; 901; HS; HWH; R
MDX1513	No Bates	No Bates	7/19/2018	FDA: Hatch-Waxman Letters		X	403; 901; HS; R
MDX1514	No Bates	No Bates	4/22/2015	M. Toufanian & M. Shimer: Hatch-Waxman 101 (April 22-23, 2015)		X	403; 901; HS; HWH; R
MDX1515	No Bates	No Bates	1/13/2020	Centers for Medicare & Medicaid Services: History - CMS' program history		X	403; 901; HS; R
MDX1516	No Bates	No Bates	7/2004	Report by FTC and DOJ: Improving Health Care - A Dose of Competition		X	403; HS; MIL; R
MDX1517	No Bates	No Bates	1/31/2020	World Intellectual Property Organization: Innovation and Intellectual Property		X	403; HS; MIL; R
MDX1518	No Bates	No Bates	2/12/2016	Journal of Health Economics: Innovation in the pharmaceutical industry - New estimates of R&D costs		X	403; HS; HWH; MIL; R
MDX1519	No Bates	No Bates	6/8/2018	IP Law News: INSIGHT Orange Purple Book Patentees Hone PTAB Survival Skills 2018		X	403; HS; HWH; MIL; R
MDX1520	No Bates	No Bates	2007	Litigation Services Handbook The Role of the Financial Expert		X	403; 901; HS; INC; R
MDX1521	No Bates	No Bates	9/18/2008	M. McCarthy: Less is Better On Biologic Exclusivity, Candidates' Health Advisers Say		X	403; 901; HS; HWH; MIL; R
MDX1522	No Bates	No Bates	2006	M. Megallas: Medicare modernization the new prescription drug benefit and redesigned Part B and Part C		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1523	No Bates	No Bates	10/2016	Kaiser Family Foundation: Medicare Part D - A First Look at Prescription Drug Plans in 2017		X	403; HS; R
MDX1524	No Bates	No Bates	7/2019	U.S. Government Accountability Office: Medicare Part D - Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and Utilization		X	403; HS; R
MDX1525	No Bates	No Bates	10/2015	Kaiser Family Foundation: Medicare Part D at Ten Years 2006-2015		X	HS
MDX1526	No Bates	No Bates	5/17/2018	J. Cubanski & et al.: Medicare Part D in 2018: The latest on enrollment, premiums, and cost sharing		X	403; HS; HWH; R
MDX1527	No Bates	No Bates	9/2014	Kaiser Family Foundation: The Medicare Part D Prescription Drug Benefit		X	403; HS; HWH; R
MDX1528	No Bates	No Bates	6/2015	MedPac: Chapter 6 Sharing Risk in Medicare Part D		X	403; 901; HS; R
MDX1529	No Bates	No Bates	2018	National Health Expenditure Accounts Methodology Paper, 2018		X	403; HS; HWH; R
MDX1530	No Bates	No Bates	8/17/2014	P. Kanavos: Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States		X	403; HS; HWH; R
MDX1531	No Bates	No Bates	2003	R. Eisenberg: Patents, Product Exclusivity, and Information Dissemination How Law Directs Biopharmaceutical Research and Development - Fordham Law Review		X	403; HS; HWH; R
MDX1533	No Bates	No Bates	2/7/2020	Medicare Interactive: Phases of Part D coverage		X	403; HS; HWH; R
MDX1534	No Bates	No Bates	8/2017	HealthAffairs: Prescription Drug Pricing, Medicare Part D		X	403; HS; HWH; R
MDX1535	No Bates	No Bates	10/1992	R. Frank & D. Salkever: Pricing, Patent Loss and the Market for Pharmaceuticals		X	HS; HWH
MDX1536	No Bates	No Bates	1/31/2020	Orange Book: Product Details for ANDA 078560		X	NO
MDX1537	No Bates	No Bates	3/2004	NERA Economic Consulting: Proving Causation in Damage Analyses (March-April 2004)		X	403; HS; HWH; R
MDX1538	No Bates	No Bates	2014	L. Purvis: Medicare Part D Open Enrollment for 2014: Popular Plans Continue to Evolve		X	403; HS; HWH; MIL; R
MDX1539	No Bates	No Bates	3/2011	J. Liberman: Recent Trends in the Dispensing of 90-Day-Supply Prescriptions at Retail Pharmacies (March-April 2011)		X	HS; HWH; R
MDX1540	No Bates	No Bates	2011	National Academies Press: Reference Manual on Scientific Evidence Third Edition		X	403; HS; HWH; R
MDX1541	No Bates	No Bates	8/31/2007	T. Regan: Generic entry price competition and market segmentation in the prescription drug market		X	HS; HWH
MDX1542	No Bates	No Bates	2007	National Academies Press: Rising Above Gathering Storm, Energizing and Employing America for a Brighter Economic Future		X	403; HS; HWH; R
MDX1543	No Bates	No Bates	2017	J. Rubleski: Prescription Drug Prices Will Drive Health Insurance Premium Increases in 2017		X	HS; R
MDX1544	No Bates	No Bates	10/2014	E. Saadi & G. White: Rewarding Innovation in Drug Development		X	403; HS; HWH; MIL; R
MDX1545	No Bates	No Bates	2/2006	A. Saha & et al.: Generic Competition in the US Pharmaceutical Industry		X	NO
MDX1546	No Bates	No Bates	1/31/2020	FDA: Small Business Assistance Frequently Asked Questions on the Patent Term Restoration Program		X	403; HS; R
MDX1547	No Bates	No Bates	10/1/2019	Blue MedicareRx: The Four Coverage Stages of Medicare's Part D Program		X	403; HS; R
MDX1548	No Bates	No Bates	9/2014	E. Berndt & I. Cockburn: The Hidden Cost of Low Prices Limited Access to New Drugs in India - Health Affairs		X	403; HS; HWH; R
MDX1549	No Bates	No Bates	10/2003	FTC: To Promote Innovation - The Proper Balance of Competition and Patent Law and Policy		X	403; HS; HWH; R
MDX1550	No Bates	No Bates	1/2014	A. Hausman: The role of innovation in driving the economy: Lessons from the global financial crisis		X	403; HS; HWH; R
MDX1551				WITHDRAWN			
MDX1552				WITHDRAWN			

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1553				WITHDRAWN			
MDX1554				WITHDRAWN			
MDX1555				WITHDRAWN			
MDX1556				WITHDRAWN			
MDX1557				WITHDRAWN			
MDX1558				WITHDRAWN			
MDX1559				WITHDRAWN			
MDX1560				WITHDRAWN			
MDX1561				WITHDRAWN			
MDX1562				WITHDRAWN			
MDX1563				WITHDRAWN			
MDX1564	No Bates	No Bates	2/28/2020	Sumanth Addanki Native Exhibit 3.xlsx		X	403; 901; 1006; FD; HS; HWH; R
MDX1565	No Bates	No Bates	2/28/2020	Sumanth Addanki Native Exhibit 10.xlsx		X	403; 901; 1006; FD; HS; HWH; R
MDX1566	No Bates	No Bates	2/28/2020	Sumanth Addanki Native Exhibit 4, 6 and 7.xlsx		X	403; 901; 1006; FD; HS; HWH; R
MDX1567	No Bates	No Bates	2/28/2020	Sumanth Addanki Native Exhibit 5 and 8.xlsx		X	403; 901; 1006; FD; HS; HWH; R
MDX1568	No Bates	No Bates	9/17/2019	PDF of untitled spreadsheet of transactional data for ezetimibe		X	403; HS; INC
MDX1569	PAR_00000001	PAR_00000001	2/28/2020	Bruce Strombom Damages Backup: PAR_00000001.csv		X	NO
MDX1570	PAR_00000001-Highly Confidential	PAR_00000001-Highly Confidential		Excel spreadsheet with file name: PAR_00000001-Highly Confidential.XLSX		X	NO
MDX1571	PAR_00000653	PAR_00000653	9/2015	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Sept 2015 NPF - Summary for partner.xlsx		X	NO
MDX1572	PAR_00002330	PAR_00002330	1/2015	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Jan 2015.xlsx		X	HS
MDX1573	PAR_00002332	PAR_00002332	8/2014	Excel spreadsheet with file name: Ezetimibe forecast Aug 2014.xlsx		X	HS
MDX1574	PAR_00002915	PAR_00002915		Excel spreadsheet with file name: Microsoft Excel Worksheet1.xlsx		X	HS
MDX1575	PAR_00003366	PAR_00003366	3/2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Mar 2016 NPF.xlsx		X	HS
MDX1576	PAR_00003509	PAR_00003509	3/2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Mar 2016 updated for extra load.xlsx		X	HS
MDX1577	PAR_00005152	PAR_00005152	1/2014	Excel spreadsheet with file name: Ezetimibe forecast Jan 2014.xlsx		X	HS
MDX1578	PAR_00005375	PAR_00005375	1/2014	Excel spreadsheet with file name: Ezetimibe forecast Jan 2014.xlsx		X	HS
MDX1580	PAR_00007332	PAR_00007332	1/2012	Excel spreadsheet with file name: Ezetimibe forecast Jan 2012.xlsx		X	NO
MDX1581	PAR_00007867	PAR_00007867	2/2010	Excel spreadsheet with file name: Ezetimibe forecast Feb 2010.xls		X	NO
MDX1582	PAR_00008076	PAR_00008076	5/2010	Excel spreadsheet with file name: Ezetimibe forecast May 2010.xls		X	NO
MDX1583	PAR_00008127	PAR_00008127	5/2010	Excel spreadsheet with file name: Ezetimibe forecast May 2010.xls		X	NO
MDX1584	PAR_00008143	PAR_00008143	4/2010	Excel spreadsheet with file name: Ezetimibe forecast Apr 2010 (2) revised.xls		X	NO
MDX1585	PAR_00008221	PAR_00008221	4/2010	Excel spreadsheet with file name: Ezetimibe forecast Apr 2010.xls		X	NO
MDX1587	PAR_00014542	PAR_00014542	3/2014	Excel spreadsheet with file name: Ezetimibe forecast Mar 2014.xlsx		X	HS
MDX1588	PAR_00018432	PAR_00018432	9/2014	Copy of Ezetimibe (Zetia) forecast Sep 2014 w COGS at transfer.xlsx		X	HS
MDX1589	PAR_00018433	PAR_00018434	10/1/2014	Email string from C. Calabro to M. Altamuro, S. Carey and C. Gassert "RE: Zetia"		X	HS
MDX1590	PAR_00018435	PAR_00018435	10/1/2014	Excel spreadsheet with file name: Copy of Ezetimibe (Zetia) forecast Sep 2014 w COGS at transfer.xlsx		X	HS
MDX1591	PAR_00018436	PAR_00018438	10/1/2014	Email from C. Calabro to M. Altamuro, S. Carey and C. Gassert "RE: Zetia" with attachment		X	HS; HWH
MDX1592	PAR_00018770	PAR_00018770	4/2010	Excel spreadsheet with file name: Copy of Ezetimibe forecast Apr 2010.xls		X	HS

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1593	PAR_00019291	PAR_00019291	9/2015	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Sept 2015 NPF - updated budget final.xlsx		X	HS
MDX1594	PAR_00019333	PAR_00019333	3/2016	Excel spreadsheet with file name: Ezetimibe (Zetia) forecast Mar 2016 NPF.xlsx		X	HS
MDX1595	PAR_00021842	PAR_00021842	3/12/2016	Excel spreadsheet with file name: Ezetimibe forecast Apr 2010 (2).xls		X	HS
MDX1596	PRASCO 000081	PRASCO 000081		Zetia (ezetimibe) Tablet label		X	403; HS
MDX1597	RDC-ZET-029266	RDC-ZET-029343		Compendium of articles of incorporation, amendments and bylaws of Rochester Drug Co-Operative, Inc.		X	403; 404; R
MDX1598	SANDOZ-ZETIA-0000001	SANDOZ-ZETIA-0000001	6/30/2016	Excel spreadsheet - SANDOZ-ZETIA-0000001.xlsx		X	HS
MDX1599	SANDOZ-ZETIA-0000003	SANDOZ-ZETIA-0000003	5/24/2017	Excel spreadsheet - SANDOZ-ZETIA-0000003.xlsx		X	HS
MDX1600	SANDOZ-ZETIA-0000182	SANDOZ-ZETIA-0000182	2/28/2020	Bruce Strombom Damages Backup: SANDOZ-ZETIA-0000182.csv		X	403; 901; HS; R
MDX1601	SUN-EZETIMIBIE_00000101	SUN-EZETIMIBIE_00000102		Document titled, "Patent Certification and Exclusivity Statement"		X	HS; R
MDX1602	SUN-EZETIMIBIE_00017579	SUN-EZETIMIBIE_00017580		Letter from FDA to Ohm re "Information Request"		X	HS; R
MDX1603	SUN-EZETIMIBIE_00018344	SUN-EZETIMIBIE_00018357		Response titled, "Ezetimibe Tablets, 10 mg (ANDA 207311) Response to Information Request (Reference 795804) (eCTD Sequence 0005) Summary - Response to FDA Information Request Dated May 12, 2016 (Reference 795804)"		X	HS; R
MDX1604	SUN-EZETIMIBIE_00018380	SUN-EZETIMIBIE_00018382		Response titled, "ANDA 207311 Ezetimibe Tablets USP, 10 mg Response to the Agency's Easily Correctable Deficiency Letter dated April 08, 2016"		X	HS; R
MDX1605	SUN-EZETIMIBIE_00018620	SUN-EZETIMIBIE_00018622		Response titled, "Ezetimibe Tablets, 10 mg, ANDA 207311, Response to Information Request (Chemistry) (Reference 10935178) (eCTD Sequence 0007), Summary - Response to FDA Information Request dated October 25, 2016 (Reference 10935178)"		X	HS; R
MDX1606	SUN-EZETIMIBIE_00018718	SUN-EZETIMIBIE_00018720		Response titled, "Ezetimibe Tablets, 10 mg, ANDA 207311 Response to Information Request (Drug Product) (eCTD Sequence 0009)"		X	HS; R
MDX1607	SUN-EZETIMIBIE_00021533	SUN-EZETIMIBIE_00021533	2/28/2020	Bruce Strombom Damages Backup: SUN-EZETIMIBIE_00021533.csv		X	NO
MDX1608	TEVA-ZETIA_00003525_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY	TEVA-ZETIA_00003525_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		Excel spreadsheet with file name: TEVA-ZETIA_00003525_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		X	HS
MDX1609	TEVA-ZETIA_00003526_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY	TEVA-ZETIA_00003526_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		Excel spreadsheet with file name: TEVA-ZETIA_00003526_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		X	HS
MDX1610	TEVA-ZETIA_00003528_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY	TEVA-ZETIA_00003528_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		Excel spreadsheet with file name: TEVA-ZETIA_00003528_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		X	HS
MDX1611	TEVA-ZETIA_00003529_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY	TEVA-ZETIA_00003529_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		Excel spreadsheet with file name: TEVA-ZETIA_00003529_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		X	HS
MDX1612	TEVA-ZETIA_00003530_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY	TEVA-ZETIA_00003530_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY.xls		Excel spreadsheet with file name: TEVA-ZETIA_00003530_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY.xls		X	HS
MDX1613	TEVA-ZETIA_00003531_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY	TEVA-ZETIA_00003531_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		Excel spreadsheet with file name: TEVA-ZETIA_00003531_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		X	HS
MDX1614	TEVA-ZETIA_00003533_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY	TEVA-ZETIA_00003533_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		Excel spreadsheet with file name: TEVA-ZETIA_00003533_HIGHLY CONFIDENTIAL-ATTORNEYS' EYES ONLY		X	HS
MDX1615	TEVA-ZETIA_00003534	TEVA-ZETIA_00003534	2/28/2020	Bruce Strombom Damages Backup: TEVA-ZETIA_00003534.csv		X	NO
MDX1616	TEVA-ZETIA_00003535	TEVA-ZETIA_00003535	2/28/2020	Bruce Strombom Damages Backup: TEVA-ZETIA_00003535.csv		X	NO
MDX1619	ZETIA-LOCAL49-000010	ZETIA-LOCAL49-000014	6/1/2018	Operating Engineers Local #49 Health and Welfare Fund - Active Employees, Retirees Under Age 65, and Dependents (West River) (Coverage Period: 06/01/2018 to 05/31/2019)		X	403; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1620	ZETIA-LOCAL49-000036	ZETIA-LOCAL49-000040	6/1/2018	Operating Engineers Local #49 Health and Welfare Fund - Active Employeees, Retirees Under Age 65, and Dependents (Non-West River) (Coverage Period: 06/01/2018 to 05/31/2019)		X	403; MIL; R
MDX1621	ZETIA-LOCAL49-000383	ZETIA-LOCAL49-000406	2/1/2011	Pharmacy Benefit Management Services Agreement between IUOE Local 49 Health & Welfare Fund and Catalyst Rx.		X	403; R
MDX1622	ZETIA-PAINTERS-000106	ZETIA-PAINTERS-000113	4/1/2013	Painters District Council No. 30 Health & Welfare Fund Summary of Benefits and Coverage: What this Plan Covers & What Costs Coverage Period: Beginning on or after 04/01/2013 Coverage For: Individual + Family | Plan Type: PPO		X	403; R
MDX1623	ZETIA-PAINTERS-000310	ZETIA-PAINTERS-000347	11/1/2008	Participating Group Prescription Benefit Services Agreement between Caremark and Painters District Council Local #30 Health and Welfare Fund		X	403; R
MDX1624	ZETIA-PFTHW-000022	ZETIA-PFTHW-000043		Philadelphia Federation of Teachers Health and Welfare Fund Summary of Benefits		X	403; HS; R
MDX1625	ZETIA-PFTHW-000064	ZETIA-PFTHW-000071	9/1/2017	Philadelphia Federation of Teachers Health and Welfare Fund - Retiree Plan, Coverage Period 09/01/2017 - 08/31/2018		X	403; HS; R
MDX1627	ZETIA-SERGEANTS-000046	ZETIA-SERGEANTS-000046	4/1/2013	PDF of spreadsheet titled ZETIA-SERGEANTS-000064		X	403; R
MDX1628	ZETIA-SERGEANTS-000047	ZETIA-SERGEANTS-000084	1/1/2006	Prescription Benefit Administration Agreement between True Health Benefits, Inc. and Sergeants Benevolent Association Health & Welfare Fund		X	403; R
MDX1629	ZETIA-SERGEANTS-000125	ZETIA-SERGEANTS-000128		Sergeants Benevolent Association Document titled, "Prescription Drug Retiree Plan B Benefit Information"		X	403; R
MDX1630	ZETIA-SERGEANTS-003116	ZETIA-SERGEANTS-003116	9/21/2016	PDF of spreadsheet titled ZETIA-SERGEANTS-003116		X	403; R
MDX1631	ZETIA-UFA-000186	ZETIA-UFA-000199		Retired Firefighter Security Benefit Fund (RFSBF) Summary of Benefits		X	403; R
MDX1632	ZETIA-UFA-000312	ZETIA-UFA-000312	5/2012	Prescription Drug Plan Design Active and Retired Summary		X	403; R
MDX1633	ZYDUS-EZE_0000003	ZYDUS-EZE_0000003	2/28/2020	Bruce Strombom Damages Backup: ZYDUS-EZE_0000003.csv		X	NO
MDX1634	No Bates	No Bates	8/9/2019	Opinion on Defendants' Motions to Dismiss, ECF No. 489		X	403; CLC; HS; HWH; MIL; R
MDX1635	No Bates	No Bates	3/6/2019	Plaintiffs' Response to Glenmark's Objection to the Magistrate Judge's Report and Recommendations Regarding Reverse Payment Allegations, ECF No. 239		X	403; CLC; HS; HWH; MIL; R
MDX1636	No Bates	No Bates	9/13/2018	End-Payor Plaintiffs' Consolidated Class Action Complaint and Demand for Jury Trial, ECF No. 130		X	403; CLC; HS; HWH; MIL; R
MDX1637	No Bates	No Bates	6/27/2019	Direct Purchaser Plaintiffs' Amended Consolidated Class Action Complaint and Demand for Jury Trial, ECF No. 315		X	403; CLC; HS; HWH; MIL; R
MDX1638	No Bates	No Bates	7/1/2019	Plaintiffs Walgreen Co., The Kroger Co., Albertsons Companies Inc., and HEB Grocery L.P.'s Amended Complaint and Demand for Jury Trial		X	403; CLC; HS; HWH; MIL; R
MDX1639	No Bates	No Bates	7/1/2019	Plaintiff CVS Pharmacy, Inc.'s Amended Complaint and Demand for Jury Trial		X	403; CLC; HS; HWH; MIL; R
MDX1640	No Bates	No Bates	7/1/2019	Plaintiffs Rite Aid Corporation and Rite Aid Hdqtrs. Corp's Amended Complaint and Demand for Jury Trial		X	403; CLC; HS; HWH; MIL; R
MDX1641	MRKZETIA001007989	MRKZETIA001008000	6/29/2015	Merck Authorized Distributor Agreement with AmerisourceBergen Corporation		X	403; 901; MIL; R
MDX1642	MRKZETIA001008012	MRKZETIA001008025	11/14/2013	Merck Authorized Distributor Agreement with Cardinal Health and Amendment No. 1		X	403; 901; MIL; R
MDX1643	MRKZETIA001008001	MRKZETIA001008011	11/6/2012	Merck Authorized Distributor Agreement with McKesson		X	403; 901; MIL; R
MDX1644	No Bates	No Bates	11/20/2018	Direct Purchaser Plaintiffs' Objections and Responses to Defendants' First Set of Interrogatories to Plaintiffs		X	403; 404; R
MDX1645	No Bates	No Bates	11/20/2018	End Payor Plaintiffs' Responses and Objections to Defendants' First Set of Interrogatories to Plaintiffs		X	403; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1646	No Bates	No Bates	11/20/2018	Retailer Plaintiffs' Objections and Responses to Defendants' First Set of Interrogatories to Plaintiffs		X	403; R
MDX1647	No Bates	No Bates	10/7/2019	Plaintiffs' Supplemental Responses and Objections to Defendants' Second Set of Interrogatories to Plaintiffs		X	403; HS; MIL; R
MDX1648	No Bates	No Bates	10/30/2019	End-Payor Plaintiff UFCW Local 1500 Welfare Fund's Second Supplemental Response to Defendants' Interrogatory No. 4 to Plaintiffs		X	403; R
MDX1654	PAR_00008126	PAR_00008127	5/3/2010	Email from C. Calabro to P. Campanelli re "Ezetimibe updated forecast" with attachment		X	NO
MDX1655	PAR_00012456	PAR_00012456	5/1/2017	Printout of Excel spreadsheet titled, "Par Pharmaceutical Companies Inc. Ezetimibe Tabs Sales and Profit Split 2017"		X	HS
MDX1656	GLENMARK-ZETIA-00280966	GLENMARK-ZETIA-00280967	3/29/2010	Excerpt from Draft of the Settlement Agreement		X	NO
MDX1657	GLENMARK-ZETIA-00280800	GLENMARK-ZETIA-00280800	5/10/2010	Email from T. Hester to V. Soni, L. Brown and E. Choy re "Revised Zetia Settlement Agreement"		X	HS; INC; R
MDX1658	GLENMARK-ZETIA-00280801	GLENMARK-ZETIA-00280830	5/10/2010	Draft of the Settlement Agreement		X	NO
MDX1659	GLENMARK-ZETIA-00280831	GLENMARK-ZETIA-00280863	5/10/2010	Redline Draft of the Settlement Agreement		X	NO
MDX1660	GLENMARK-ZETIA-00280864	GLENMARK-ZETIA-00280894	5/10/2010	Redline Draft of the Settlement Agreement		X	NO
MDX1661	RDC-ZET-029025	RDC-ZET-029265	9/10/2019	Exhibits 14-19 marked in the deposition of Christopher Masseth (30(b)(6) Rochester Drug Co-Operative, Inc.) taken on May 16, 2019, ECF No. 616-2, Case No. 2:18-md-02836		X	403; 404; HS; MIL; R
MDX1662	ZETIA-SERGEANTS-000210	ZETIA-SERGEANTS-000215	2/12/2011	Sergeants Benevolent Prescription Drug Active Benefit Information		X	NO
MDX1663	ZETIA-SERGEANTS-000003	ZETIA-SERGEANTS-000039	2/9/2017	Sergeants Benevolent Summary Plan Description Active Members (for the period late 2017-early 2018)		X	NO
MDX1664	ZETIA-SERGEANTS-000170	ZETIA-SERGEANTS-000205	8/15/2012	Sergeants Benevolent Summary Plan Description Active Members (for the period late 2016-early 2017)		X	NO
MDX1665	No Bates	No Bates	12/14/2016	List of Zetia Generic and Brand Orders, 12/14/2016 through 11/27/2018		X	NO
MDX1666	No Bates	No Bates	2010	AmerisourceBergen Corporation Summary Annual Report		X	403; HS; MIL; R
MDX1667	No Bates	No Bates	2011	AmerisourceBergen Corporation Summary Annual Report		X	403; HS; MIL; R
MDX1668	No Bates	No Bates	2012	AmerisourceBergen Corporation Summary Annual Report		X	403; HS; MIL; R
MDX1669	No Bates	No Bates	2013	AmerisourceBergen Corporation Summary Annual Report		X	403; HS; MIL; R
MDX1670	No Bates	No Bates	2014	AmerisourceBergen Corporation Summary Annual Report		X	403; HS; MIL; R
MDX1671	No Bates	No Bates	2015	AmerisourceBergen Corporation Summary Annual Report		X	403; HS; MIL; R
MDX1672	No Bates	No Bates	2016	AmerisourceBergen Corporation Summary Annual Report		X	403; HS; MIL; R
MDX1673	No Bates	No Bates	11/23/2010	AmerisourceBergen Corporation 10-K for the fiscal year ending September 30, 2010		X	403; HS; MIL; R
MDX1674	No Bates	No Bates	11/22/2011	AmerisourceBergen Corporation 10-K for the fiscal year ending September 30, 2011		X	403; HS; MIL; R
MDX1675	No Bates	No Bates	11/27/2012	AmerisourceBergen Corporation 10-K for the fiscal year ending September 30, 2012		X	403; HS; MIL; R
MDX1676	No Bates	No Bates	11/26/2013	AmerisourceBergen Corporation 10-K for the fiscal year ending September 30, 2013		X	403; HS; MIL; R
MDX1677	No Bates	No Bates	11/25/2014	AmerisourceBergen Corporation 10-K for the fiscal year ending September 30, 2014		X	403; HS; MIL; R
MDX1678	No Bates	No Bates	11/24/2015	AmerisourceBergen Corporation 10-K for the fiscal year ending September 30, 2015		X	403; HS; MIL; R
MDX1679	No Bates	No Bates	11/22/2016	AmerisourceBergen Corporation 10-K for the fiscal year ending September 30, 2016		X	403; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1680	No Bates	No Bates	2010	Cardinal Health, Inc. 2010 Annual Report		X	403; HS; MIL; R
MDX1681	No Bates	No Bates	2011	Cardinal Health, Inc. 2011 Annual Report		X	403; HS; MIL; R
MDX1682	No Bates	No Bates	2012	Cardinal Health, Inc. 2012 Annual Report		X	403; HS; MIL; R
MDX1683	No Bates	No Bates	2013	Cardinal Health, Inc. 2013 Annual Report		X	403; HS; MIL; R
MDX1684	No Bates	No Bates	2014	Cardinal Health, Inc. 2014 Annual Report		X	403; HS; MIL; R
MDX1685	No Bates	No Bates	2015	Cardinal Health, Inc. 2015 Annual Report		X	403; HS; MIL; R
MDX1686	No Bates	No Bates	2016	Cardinal Health, Inc. 2016 Annual Report		X	403; HS; MIL; R
MDX1687	No Bates	No Bates	2010	CVS Caremark Corporation 2010 Annual Report		X	403; HS; R
MDX1688	No Bates	No Bates	2011	CVS Caremark Corporation 2011 Annual Report		X	403; HS; R
MDX1689	No Bates	No Bates	2012	CVS Caremark Corporation 2012 Annual Report		X	403; HS; R
MDX1690	No Bates	No Bates	2013	CVS Caremark Corporation 2013 Annual Report		X	403; HS; R
MDX1691	No Bates	No Bates	2014	CVS Caremark Corporation 2014 Annual Report		X	403; HS; R
MDX1692	No Bates	No Bates	2015	CVS Caremark Corporation 2015 Annual Report		X	403; HS; R
MDX1693	No Bates	No Bates	2016	CVS Caremark Corporation 2016 Annual Report		X	403; HS; R
MDX1694	No Bates	No Bates	2/18/2011	CVS Caremark Corporation 10-K for the fiscal year ending December 31, 2010		X	403; HS; R
MDX1695	No Bates	No Bates	2/17/2012	CVS Caremark Corporation 10-K for the fiscal year ending December 31, 2011		X	403; HS; R
MDX1696	No Bates	No Bates	2/15/2013	CVS Caremark Corporation 10-K for the fiscal year ending December 31, 2012		X	403; HS; R
MDX1697	No Bates	No Bates	2/11/2014	CVS Caremark Corporation 10-K for the fiscal year ending December 31, 2013		X	403; HS; R
MDX1698	No Bates	No Bates	2/10/2015	CVS Caremark Corporation 10-K for the fiscal year ending December 31, 2014		X	403; HS; R
MDX1699	No Bates	No Bates	2/9/2016	CVS Caremark Corporation 10-K for the fiscal year ending December 31, 2015		X	403; HS; R
MDX1700	No Bates	No Bates	2/9/2017	CVS Caremark Corporation 10-K for the fiscal year ending December 31, 2016		X	403; HS; R
MDX1701	No Bates	No Bates	2010	The Kroger Co. Proxy Notice of Annual Meeting of Shareholders Proxy Statement and 2010 Annual Report		X	403; HS; R
MDX1702	No Bates	No Bates	2011	The Kroger Co. Proxy Notice of Annual Meeting of Shareholders Proxy Statement and 2011 Annual Report		X	403; HS; R
MDX1703	No Bates	No Bates	2012	The Kroger Co. Proxy Notice of Annual Meeting of Shareholders Proxy Statement and 2012 Annual Report		X	403; HS; R
MDX1704	No Bates	No Bates	2013	The Kroger Co. Proxy Notice of Annual Meeting of Shareholders Proxy Statement and 2013 Annual Report		X	403; HS; R
MDX1705	No Bates	No Bates	2014	The Kroger Co. Proxy Notice of Annual Meeting of Shareholders Proxy Statement and 2014 Annual Report		X	403; HS; R
MDX1706	No Bates	No Bates	2015	The Kroger Co. Proxy Notice of Annual Meeting of Shareholders Proxy Statement and 2015 Annual Report		X	403; HS; R
MDX1707	No Bates	No Bates	2016	The Kroger Co. Proxy Notice of Annual Meeting of Shareholders Proxy Statement and 2016 Annual Report		X	403; HS; R
MDX1708	No Bates	No Bates	3/30/2010	The Kroger Co. 10-K for the fiscal year ending January 30, 2010		X	403; HS; R
MDX1709	No Bates	No Bates	3/29/2011	The Kroger Co. 10-K for the fiscal year ending January 29, 2011		X	403; HS; R
MDX1710	No Bates	No Bates	3/27/2012	The Kroger Co. 10-K for the fiscal year ending January 28, 2012		X	403; HS; R
MDX1711	No Bates	No Bates	4/2/2013	The Kroger Co. 10-K for the fiscal year ending February 2, 2013		X	403; HS; R
MDX1712	No Bates	No Bates	4/1/2014	The Kroger Co. 10-K for the fiscal year ending February 1, 2014		X	403; HS; R
MDX1713	No Bates	No Bates	3/31/2015	The Kroger Co. 10-K for the fiscal year ending January 31, 2015		X	403; HS; R
MDX1714	No Bates	No Bates	4/1/2015	The Kroger Co. 10-K/A for the fiscal year ending January 31, 2015		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1715	No Bates	No Bates	3/29/2016	The Kroger Co. 10-K for the fiscal year ending January 30, 2016		X	403; HS; R
MDX1716	No Bates	No Bates	2010	McKesson Corporation 2010 Annual Report		X	403; HS; MIL; R
MDX1717	No Bates	No Bates	2011	McKesson Corporation 2011 Annual Report		X	403; HS; MIL; R
MDX1718	No Bates	No Bates	2012	McKesson Corporation 2012 Annual Report		X	403; HS; MIL; R
MDX1719	No Bates	No Bates	2013	McKesson Corporation 2013 Annual Report		X	403; HS; MIL; R
MDX1720	No Bates	No Bates	2014	McKesson Corporation 2014 Annual Report		X	403; HS; MIL; R
MDX1721	No Bates	No Bates	2015	McKesson Corporation 2015 Annual Report		X	403; HS; MIL; R
MDX1722	No Bates	No Bates	2016	McKesson Corporation 2016 Annual Report		X	403; HS; MIL; R
MDX1723	No Bates	No Bates	5/4/2010	McKesson Corporation for the fiscal year ending March 31, 2010		X	403; HS; MIL; R
MDX1724	No Bates	No Bates	5/5/2011	McKesson Corporation for the fiscal year ending March 31, 2011		X	403; HS; MIL; R
MDX1725	No Bates	No Bates	5/2/2012	McKesson Corporation for the fiscal year ending March 31, 2012		X	403; HS; MIL; R
MDX1726	No Bates	No Bates	5/7/2013	McKesson Corporation for the fiscal year ending March 31, 2013		X	403; HS; MIL; R
MDX1727	No Bates	No Bates	5/14/2014	McKesson Corporation for the fiscal year ending March 31, 2014		X	403; HS; MIL; R
MDX1728	No Bates	No Bates	5/12/2015	McKesson Corporation for the fiscal year ending March 31, 2015		X	403; HS; MIL; R
MDX1729	No Bates	No Bates	5/5/2016	McKesson Corporation for the fiscal year ending March 31, 2016		X	403; HS; MIL; R
MDX1730	No Bates	No Bates	4/28/2010	Rite Aid Corporation 10-K for the fiscal year ending February 27, 2010		X	403; HS; R
MDX1731	No Bates	No Bates	4/26/2011	Rite Aid Corporation 10-K for the fiscal year ending February 26, 2011		X	403; HS; R
MDX1732	No Bates	No Bates	4/24/2012	Rite Aid Corporation 10-K for the fiscal year ending March 3, 2012		X	403; HS; R
MDX1733	No Bates	No Bates	4/23/2013	Rite Aid Corporation 10-K for the fiscal year ending March 2, 2013		X	403; HS; R
MDX1734	No Bates	No Bates	4/24/2014	Rite Aid Corporation 10-K for the fiscal year ending March 1, 2014		X	403; HS; R
MDX1735	No Bates	No Bates	4/23/2015	Rite Aid Corporation 10-K for the fiscal year ending February 28, 2015		X	403; HS; R
MDX1736	No Bates	No Bates	4/25/2016	Rite Aid Corporation 10-K for the fiscal year ending February 27, 2016		X	403; HS; R
MDX1737	No Bates	No Bates	2010	SuperValue Inc. Annual Report and 10-K for the fiscal year ending February 27, 2010 (filed 4/26/2010)		X	403; HS; MIL; PM; R
MDX1738	No Bates	No Bates	2011	SuperValue Inc. Annual Report and 10-K for the fiscal year ending February 26, 2011 (filed 4/21/2011)		X	403; HS; MIL; PM; R
MDX1739	No Bates	No Bates	2012	SuperValue Inc. Annual Report and 10-K for the fiscal year ending February 25, 2012 (filed 4/19/2012)		X	403; HS; MIL; PM; R
MDX1740	No Bates	No Bates	2012	SuperValue Inc. 10-K/A for the fiscal year ending February 25, 2012 (filed 4/26/2012)		X	403; HS; MIL; PM; R
MDX1741	No Bates	No Bates	2013	SuperValue Inc. Annual Report and 10-K for the fiscal year ending February 23, 2013 (filed 4/24/2013)		X	403; HS; MIL; PM; R
MDX1742	No Bates	No Bates	2014	SuperValue Inc. Annual Report and 10-K for the fiscal year ending February 22, 2014 (filed 4/23/2014)		X	403; HS; MIL; PM; R
MDX1743	No Bates	No Bates	2015	SuperValue Inc. Annual Report and 10-K for the fiscal year ending February 28, 2015 (filed 4/28/2015)		X	403; HS; MIL; PM; R
MDX1744	No Bates	No Bates	2016	SuperValue Inc. 10-K for the fiscal year ending February 27, 2016 (filed 4/26/2016)		X	403; HS; MIL; PM; R
MDX1745	No Bates	No Bates	2010	Walgreen Co. 2010 Annual Report		X	403; HS; R
MDX1746	No Bates	No Bates	2011	Walgreen Co. 2011 Annual Report		X	403; HS; R
MDX1747	No Bates	No Bates	2012	Walgreen Co. 2012 Annual Report		X	403; HS; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1748	No Bates	No Bates	2013	Walgreen Co. 2013 Annual Report		X	403; HS; R
MDX1749	No Bates	No Bates	2014	Walgreen Co. 2014 Annual Report		X	403; HS; R
MDX1750	No Bates	No Bates	2015	Walgreen Co. 2015 Annual Report		X	403; HS; R
MDX1751	No Bates	No Bates	2016	Walgreen Co. 2016 Annual Report		X	403; HS; R
MDX1752	No Bates	No Bates	10/26/2010	Walgreen Co. 10-K for the fiscal year ending August 31, 2010		X	403; HS; R
MDX1753	No Bates	No Bates	10/25/2011	Walgreen Co. 10-K for the fiscal year ending August 31, 2011		X	403; HS; R
MDX1754	No Bates	No Bates	10/19/2012	Walgreen Co. 10-K for the fiscal year ending August 31, 2012		X	403; HS; R
MDX1755	No Bates	No Bates	10/21/2013	Walgreen Co. 10-K for the fiscal year ending August 31, 2013		X	403; HS; R
MDX1756	No Bates	No Bates	10/20/2014	Walgreen Co. 10-K for the fiscal year ending August 31, 2014		X	403; HS; R
MDX1757	No Bates	No Bates	11/3/2014	Walgreen Co. 10-K (Amendment No. 1) for the fiscal year ending August 31, 2014		X	403; HS; R
MDX1758	No Bates	No Bates	11/20/2014	Walgreen Co. 10-K (Amendment No. 2) for the fiscal year ending August 31, 2014		X	403; HS; R
MDX1759	No Bates	No Bates	10/28/2015	Walgreen Boots Alliance, Inc. 10-K for the fiscal year ending August 31, 2015		X	403; HS; R
MDX1760	No Bates	No Bates	10/20/2016	Walgreen Boots Alliance, Inc. 10-K for the fiscal year ending August 31, 2016		X	403; HS; R
MDX1761	MRKZETIA000869504	MRKZETIA000869506	5/10/2010	Consent Judgment, Schering Corp. v. Glenmark Pharmaceuticals - Case No. 2:07-cv-1334-JLL-ES, ECF No. 243		X	901
MDX1762	MRKZETIA000989434	MRKZETIA000989434	5/28/2010	Letter from S. Clark-Coleman (FTC) to T. Hester re Medicare Prescription Drug, Improvement, and Modernization Act of 2003 - Transaction Identification Number: 20100387 - Schering Corporation/Glenmark Pharmaceuticals Ltd.		X	403; 901; HS; MIL
MDX1763	GLENMARK-ZETIA-00244948	GLENMARK-ZETIA-00244948	5/28/2010	Letter from S. Clark-Coleman (FTC) to R. Jacobson re Medicare Prescription Drug, Improvement, and Modernization Act of 2003 - Transaction Identification Number: 20100387 - Schering Corporation/Glenmark Pharmaceuticals Ltd.		X	901; MIL
MDX1767	MRKZETIA000419184	MRKZETIA000419184	10/27/2005	Document titled, "Summary of discussions at October 27, 2005 meeting with Baldwin / Auth on their 'preliminary conclusion"		X	901; HS; INC; R
MDX1771	MRKZETIA_R000009151	MRKZETIA_R000009151	2009	Document titled, "Zetia (ezetimibe) - In Multiple Studies, Adding ZETIA to a Statin Delivered Dramatic Additional Mean LDL-C Reduction"		X	403; 901; R
MDX1774	MRKZETIA_R000011810	MRKZETIA_R000011813	2010	US Field Communication Team - Communications Central Content Template re "Leave Pieces - ZETIA & VYTORIN"		X	403; 901; R
MDX1775	MRKZETIA_R000100758	MRKZETIA_R000100765	5/1/2015	Proof Certificate re "Zetia (ezetimibe) + a statin For powerful LDL-C reduction"		X	403; 901; R
MDX1776	ABDC-ZETIA-0000019	ABDC-ZETIA-0000019		Excel spreadsheet - ABDC SAP Invoice/Credits Specific Items report for Zetia for Humana Customers(Acct#100085856 & multiple) from 01/01/2014 to 12/31/2020		X	NO
MDX1777	CARDINAL_0000007	CARDINAL_0000007	1/1/2000	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens with Cash Discount 5.23 (Zetia)		X	403; MIL; R
MDX1778	CARDINAL_0000008	CARDINAL_0000008	8/7/2015	Excel spreadsheet with file name: 2015 - 2019 Launches and Break Opens without Cash Discount 5.23		X	403; MIL; R
MDX1779	CARDINAL_0000009	CARDINAL_0000009	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens FINAL with Cash Discount		X	403; MIL; R
MDX1780	CARDINAL_0000010	CARDINAL_0000010	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens FINAL without Cash Discount		X	403; MIL; R
MDX1781	CARDINAL_0000011	CARDINAL_0000011	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens WITHOUT Safeway UPDATED AWP		X	403; MIL; R
MDX1782	CARDINAL_0000012	CARDINAL_0000012	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens WITHOUT Safeway with Optum		X	403; MIL; R
MDX1783	CARDINAL_0000013	CARDINAL_0000013	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens WITHOUT Safeway		X	403; MIL; R
MDX1784	CARDINAL_0000014	CARDINAL_0000014	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens with Cash Discount 4.6		X	403; MIL; R
MDX1785	CARDINAL_0000015	CARDINAL_0000015	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens with Cash Discount 5.23		X	403; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1786	CARDINAL_0000016	CARDINAL_0000016	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens with Cash Discount 5.3		X	403; MIL; R
MDX1787	CARDINAL_0000017	CARDINAL_0000017	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens with Safeway		X	403; MIL; R
MDX1788	CARDINAL_0000018	CARDINAL_0000018	8/7/2015	Excel spreadsheet with file name: 2015 – 2019 Launches and Break Opens without Cash Discount 4.6		X	403; MIL; R
MDX1789	CARDINAL_0000019	CARDINAL_0000019	8/7/2015	Excel spreadsheet with file name: 2016 – 2020 Launches and Break Opens Updated Conversion Rate		X	403; MIL; R
MDX1790	CARDINAL_0000020	CARDINAL_0000020	8/7/2015	Excel spreadsheet with file name: 2016 – 2020 Launches and Break Opens Updated Source-NonSource Classification		X	403; MIL; R
MDX1791	CARDINAL_0000021	CARDINAL_0000021	8/7/2015	Excel spreadsheet with file name: 2016 – 2020 Launches and Break Opens including CD and NLC - Non-Source Changes		X	403; MIL; R
MDX1792	CARDINAL_0000022	CARDINAL_0000022	8/7/2015	Excel spreadsheet with file name: 2016 – 2020 Launches and Break Opens including CD and NLC working file DD		X	403; MIL; R
MDX1793	CARDINAL_0000023	CARDINAL_0000023	8/7/2015	Excel spreadsheet with file name: 2016 – 2020 Launches and Break Opens including CD and NLC		X	403; MIL; R
MDX1794	CARDINAL_0000024	CARDINAL_0000024	8/7/2015	Excel spreadsheet with file name: 2016 – 2020 New Items excluding CD and NLC		X	403; MIL; R
MDX1795	CARDINAL_0000025	CARDINAL_0000025	8/7/2015	Excel spreadsheet with file name: 2016 – 2020 New Items including CD and NLC		X	403; MIL; R
MDX1796	CARDINAL_0000026	CARDINAL_0000026	8/7/2015	Excel spreadsheet with file name: 60% Conversion SPF Launches Calendar Year 16 - 19 v2		X	403; MIL; R
MDX1797	CARDINAL_0000027	CARDINAL_0000027	8/7/2015	Excel spreadsheet with file name: 60% Conversion SPF Launches Calendar Year 16 - 19		X	403; MIL; R
MDX1798	CARDINAL_0000028	CARDINAL_0000028	8/7/2015	Excel spreadsheet with file name: 80% Conversion SPF Launches Calendar Year 16 - 19		X	403; MIL; R
MDX1799	CARDINAL_0000029	CARDINAL_0000029	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 12 13 14 15 16 17 04112012		X	403; MIL; R
MDX1800	CARDINAL_0000030	CARDINAL_0000030	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 12 13 14 15 16 17 090412		X	403; MIL; R
MDX1801	CARDINAL_0000031	CARDINAL_0000031	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 12 13 14 15 16 17 091112		X	403; MIL; R
MDX1802	CARDINAL_0000032	CARDINAL_0000032	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 12 13 14 15 16 17 091812		X	403; MIL; R
MDX1803	CARDINAL_0000033	CARDINAL_0000033	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 12 13 14 15 16 17 092012		X	403; MIL; R
MDX1804	CARDINAL_0000034	CARDINAL_0000034	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 12 13 14 15 16 17 Assigned List 072913		X	403; MIL; R
MDX1805	CARDINAL_0000035	CARDINAL_0000035	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 14 15 16 17 18 - December 2013 Update v2		X	403; MIL; R
MDX1806	CARDINAL_0000036	CARDINAL_0000036	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 14 15 16 17 18 - December 2013		X	403; MIL; R
MDX1807	CARDINAL_0000037	CARDINAL_0000037	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 14 15 16 17 18 - Source Nonsource add		X	403; MIL; R
MDX1808	CARDINAL_0000038	CARDINAL_0000038	4/21/2010	Excel spreadsheet with file name: Budget and Unbudget FY 14 15 16 17 18 Draft		X	403; MIL; R
MDX1809	CARDINAL_0000039	CARDINAL_0000039	12/12/2014	Excel spreadsheet with file name: Budget and Unbudget FY 15 16 17 18 - December 2014 Summary		X	403; MIL; R
MDX1810	CARDINAL_0000040	CARDINAL_0000040	4/21/2010	Excel spreadsheet with file name: Budgeted FY 12 13 14 15 16 17 010913 Legacy Assumptions		X	403; MIL; R
MDX1811	CARDINAL_0000041	CARDINAL_0000041	4/21/2010	Excel spreadsheet with file name: Budgeted FY 12 13 14 15 16 17 11272012		X	403; MIL; R
MDX1812	CARDINAL_0000042	CARDINAL_0000042	1/16/2013	Excel spreadsheet with file name: Budgeted Launch Summary to Kelty_01_16_13 TZ		X	403; MIL; R
MDX1813	CARDINAL_0000043	CARDINAL_0000043	4/22/2014	Excel spreadsheet with file name: FY14-17 New Item Assumptions FY15 Budget 4 22 14 CP		X	403; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1814	CARDINAL_0000044	CARDINAL_0000044	4/22/2014	Excel spreadsheet with file name: FY14-17 New Item Assumptions FY15 Budget 4 22 14		X	403; MIL; R
MDX1815	CARDINAL_0000045	CARDINAL_0000045	7/8/2014	Excel spreadsheet with file name: FY14-17 New Item Assumptions FY15 Budget 7.7.14		X	403; MIL; R
MDX1816	CARDINAL_0000046	CARDINAL_0000046	9/16/2014	Excel spreadsheet with file name: FY15 SPF New Items		X	403; MIL; R
MDX1817	CARDINAL_0000047	CARDINAL_0000047	8/29/2012	Excel spreadsheet with file name: FY15-18 New Item Assumptions FY16 Budget working file v3.0		X	403; MIL; R
MDX1818	CARDINAL_0000048	CARDINAL_0000048	8/29/2012	Excel spreadsheet with file name: FY15-18 New Item Assumptions FY16 Budget working file v4 0		X	403; MIL; R
MDX1819	CARDINAL_0000049	CARDINAL_0000049	7/7/2015	Excel spreadsheet with file name: FY16 Budget - Generic Launch Assumptions 7 7 2015 - FINAL		X	403; MIL; R
MDX1820	CARDINAL_0000050	CARDINAL_0000050	7/7/2015	Excel spreadsheet with file name: FY16 Budget - Generic Launch Assumptions 7 7 2015		X	403; MIL; R
MDX1821	CARDINAL_0000051	CARDINAL_0000051	1/4/2016	Excel spreadsheet with file name: FY16-FY19 New Item Budget Summary		X	403; MIL; R
MDX1822	CARDINAL_0000052	CARDINAL_0000052	1/8/2015	Excel spreadsheet with file name: Generic Launches Budget_Forecast FY17		X	403; MIL; R
MDX1823	CARDINAL_0000053	CARDINAL_0000053	1/30/2014	Excel spreadsheet with file name: New Item Assumptions FY15 Budget 1.30.14		X	403; MIL; R
MDX1824	CARDINAL_0000054	CARDINAL_0000054	2/12/2014	Excel spreadsheet with file name: New Item Assumptions FY15 Budget 2.10.14		X	403; MIL; R
MDX1825	CARDINAL_0000055	CARDINAL_0000055	2/4/2014	Excel spreadsheet with file name: New Item Assumptions FY15 Budget 2.4.14		X	403; MIL; R
MDX1826	CARDINAL_0000056	CARDINAL_0000056	3/18/2014	Excel spreadsheet with file name: New Item Assumptions FY15 Budget 3.17.14		X	403; MIL; R
MDX1827	CARDINAL_0000057	CARDINAL_0000057	4/21/2010	Excel spreadsheet with file name: New Item Forecasts - March 2013 SPF		X	403; MIL; R
MDX1828	CARDINAL_0000058	CARDINAL_0000058	9/14/2015	Excel spreadsheet with file name: SPF Launches FY16 - 19 60% vs 80% Conversion Less Safeway		X	403; MIL; R
MDX1829	CARDINAL_0000059	CARDINAL_0000059	9/14/2015	Excel spreadsheet with file name: SPF Launches FY16 - 19 60% vs 80% Conversion		X	403; MIL; R
MDX1830	CARDINAL_0000060	CARDINAL_0000060	8/7/2015	Excel spreadsheet with file name: Zetia 121216 DAN FCST		X	403; MIL; R
MDX1831	GE-Zetia-000004	GE-Zetia-000004	9/27/2022	Excel spreadsheet with file name: Top Brand Name Drugs		X	403; 701; FD; HS; HWH; R
MDX1832	GE-Zetia-000005	GE-Zetia-000005	9/27/2022	Excel spreadsheet with file name: Patent Expiration by Drug		X	403; 701; FD; HS; HWH; R
MDX1833	GE-Zetia-000006	GE-Zetia-000006	9/27/2022	Excel spreadsheet with file name: New Generics Template		X	403; 701; FD; HS; HWH; R
MDX1834	GE-Zetia-000182	GE-Zetia-000182	9/27/2022	Excel spreadsheet with file name: Brand Tracker		X	403; 701; FD; HS; HWH; R
MDX1835	GE-Zetia-000183	GE-Zetia-000183	9/29/2022	Excel spreadsheet with file name: Data Table		X	NO
MDX1836	GE-Zetia-000184	GE-Zetia-000184	9/27/2022	Excel spreadsheet with multiple tabs re Patent Expiration and Data Tracker		X	403; 701; FD; HS; HWH; R
MDX1837	MCK_ZETIA_0000001	MCK_ZETIA_0000001		Excel spreadsheet re Giant Eagle - Zetia		X	NO
MDX1838	MCK_ZETIA_0000019	MCK_ZETIA_0000019		Excel spreadsheet re KPH - Zetia		X	NO
MDX1839	MCK_ZETIA_0000020	MCK_ZETIA_0000020		Excel spreadsheet re Meijer - Zetia		X	NO
MDX1840	MCK_ZETIA_0000021	MCK_ZETIA_0000021		Excel spreadsheet re SuperValu - Zetia		X	NO
MDX1841	MCK_ZETIA_0000022	MCK_ZETIA_0000022		Excel spreadsheet re Wegman - Zetia		X	NO
MDX1842	MCK_ZETIA_0000023	MCK_ZETIA_0000023		Excel spreadsheet re Wegman - Zetia		X	NO
MDX1843	MLI-ZET-000001	MLI-ZET-000019	10/5/2021	Asset Purchase and Sale Agreement between MLI RX LLC and Miami Luken		X	NO
MDX1844	WLG_ZETIA_00000012	WLG_ZETIA_00000013	10/26/2022	Agreement for Assignment of Claims between Walgreen Co. and AmerisourceBergen Drug Corporation		X	NO
MDX1845	WEGMANS_0000001	WEGMANS_0000002	12/12/2018	Agreement for Assignment of Claims between McKesson Corporation and Wegmans Food Market, Inc.		X	NO

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1846	ABDC-ZETIA-0000014	ABDC-ZETIA-0000016	5/6/2022	Amended and Restated Agreement for Assignment of Claims between Humana Inc., Humana Pharmacy, Inc. and AmerisourceBergen Drug Corporation		X	NO
MDX1847	ABDC-ZETIA-0000017	ABDC-ZETIA-0000018	5/6/2022	Agreement for Assignment of Claims between Humana Inc. and AmerisourceBergen Drug Corporation		X	NO
MDX1848	CARDINAL_0000003	CARDINAL_0000005	9/1/2020	Agreement for Assignment of Claims between OptumRx, Inc. and Cardinal Health 110, LLC and Cardinal Health 112, LLC		X	NO
MDX1849	CARDINAL_0000006	CARDINAL_0000006		TSV file		X	NO
MDX1850	GE-Zetia-000002	GE-Zetia-000003	3/20/2018	Agreement for Assignment of Claims between McKesson Corporation and Giant Eagle, Inc.		X	NO
MDX1851	GE-Zetia-000007	GE-Zetia-000013		Document title "Major Drug Patent or Exclusivity Expirations 2007-2023"		X	403; 701; FD; HS; HWH; R
MDX1852	GE-Zetia-000014	GE-Zetia-000181	3/8/2010	Cowen and Company Pharmaceuticals Industry Overview - Generic Industry Overview and Patent Case Reviews		X	403; 701; FD; HS; HWH; R
MDX1853	GE-Zetia-000185	GE-Zetia-000187	10/10/2022	Agreement for Assignment of Claims between Giant Eagle, Inc. and Cardinal Health 110, LLC		X	NO
MDX1854	MCK_ZETIA_0000002	MCK_ZETIA_0000003	2/8/2019	Agreement for Assignment of Claims between McKesson Corporation and KPH Healthcare Services, Inc., d/b/a Kinney Drugs, Inc.		X	NO
MDX1855	MCK_ZETIA_0000004	MCK_ZETIA_0000006	5/30/2022	Agreement for Assignment of Claims between McKesson Corporation and KPH Healthcare Services, Inc., d/b/a Kinney Drugs, Inc.		X	NO
MDX1856	MCK_ZETIA_0000007	MCK_ZETIA_0000009	7/1/2014	Agreement for the Assignment of Claims between McKesson Corporation and Wegmans Food Markets, Inc.		X	1002; CU; MC
MDX1857	MCK_ZETIA_0000010	MCK_ZETIA_0000011	3/20/2018	Agreement for Assignment of Claims between McKesson Corporation and Giant Eagle, Inc.		X	NO
MDX1858	MCK_ZETIA_0000012	MCK_ZETIA_0000013	Sep-18	Agreement for Assignment of Claims between McKesson Corporation and SUPERVALU INC.		X	NO
MDX1859	MCK_ZETIA_0000014	MCK_ZETIA_0000015	12/12/2018	Agreement for Assignment of Claims between McKesson Corporation and Wegmans Food Market, Inc.		X	NO
MDX1860	MCK_ZETIA_0000016	MCK_ZETIA_0000018	6/15/2020	Agreement for Assignment of Claims between McKesson Corporation and Meijer Distribution, Inc. and Meijer, Inc.		X	NO
MDX1861	No Bates	No Bates	3/31/2006	IP Law 360 article titled "Authorized Generics: Antitrust Issues and the Hatch-Waxman Act"		X	901; FD; HS; MIL
MDX1862	No Bates	No Bates	3/31/2006	IP Law 360 article titled "Authorized Generics Under Scrutiny by the FTC"		X	901; FD; HS; MIL
MDX1863	No Bates	No Bates	1/27/2010	PowerPoint Presentation titled "Project Saturn Valuation of MSP Joint Venture as of November 3, 2009 - MERCK - Issued as of January 27, 2010"		X	403; HS; MIL; R
MDX1864	No Bates	No Bates	11/20/2014	Article titled "Amneal Launches AG for Novo Nordisk's Activella - Authorized Generic offers brand product plus patient savings"		X	403; 901; HS; HWH; R
MDX1866	MRKZETIA000515643	MRKZETIA000515644	5/3/2016	Email from M. Sangani to D. Gan re "FW: quick feedback request [if possible - Thanks!] [Confidential]"		X	HS; HWH
MDX1868	MRKZETIA_R000026784	MRKZETIA_R000026785	5/12/2016	Email from M. Sangani to D. Pakula "RE: AG for Zetia [Confidential]"		X	HS
MDX1869	MRKZETIA000515321	MRKZETIA000515322	5/12/2016	Email from M. Sangani to D. Pakula and D. Gan "RE: Zetia AG"		X	HS
MDX1870	MRKZETIA000512666	MRKZETIA000512674	6/6/2016	Email from D. Gan to C. Cavicchi "RE: 2016-70 Proposals - Par Pharma Non-Merck Ezetimibe in US Payor Strategy Primary CI Research"		X	HS
MDX1871	MRKZETIA000514688	MRKZETIA000514689	7/5/2016	Email from D. Gan to J. Burleigh and D. Heider "RE: VYTORIN/ZETIA Question(s) [Confidential]"		X	HS
MDX1872	MRKZETIA000514683	MRKZETIA000514683	7/7/2016	Email from D. Gan to J. Burleigh re "Zetia LOE - Interim Discounts"		X	HS; HWH
MDX1873	MRKZETIA000513509	MRKZETIA000513510	7/8/2016	Email from D. Gan to R. Hartz re "Heads Up on Zetia LOE"		X	HS
MDX1874	MRKZETIA000511358	MRKZETIA000511360	7/8/2016	Email from D. Gan to M. Exume "RE: Input Requested: LOE slides [Confidential]"		X	HS
MDX1876	MRKZETIA000512749	MRKZETIA000512751	7/29/2016	Email from M. Exume to D. Gan "RE: Input Requested (end of August) - ZETIA - Bottle Size Counts"		X	HS; HWH
MDX1877	MRKZETIA000514053	MRKZETIA000514056	9/14/2016	Email from D. Gan to E. Carr "RE: Cardio Zetia/Vytorin Point Update ?"		X	403; 701; HS

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1878	MRKZETIA000601577	MRKZETIA000601577	10/20/2016	Email from D. Gan to J. Harrington "RE: Price increase for Zetia"		X	HS
MDX1879	MRKZETIA000513400	MRKZETIA000513405	10/25/2016	Email from D. Gan to K. Hayward re "FW: Action Requested: Update to LOE Contracting Grid" with attachment		X	HS; HWH; IPR
MDX1880	MRKZETIA000515539	MRKZETIA000515540	11/16/2016	Email from J. Burleigh to D. Gan "RE: Zetia LOE Deals" with attachments		X	HS; INC
MDX1881	MRKZETIA_R000051343	MRKZETIA_R000051345	12/9/2016	Email from M. Exume to D. Jankiewicz "RE: CNBC-TV18 (Money Control): Glenmark to launch cholesterol drug Zetia in US on Dec 12"		X	HS; HWH
MDX1882	MRKZETIA_R000058648	MRKZETIA_R000058649	12/20/2016	Email from C. Tickner to D. Jankiewicz "RE: AG Update [Confidential]"		X	HS
MDX1884	MRKZETIA000514165	MRKZETIA000514165	5/4/2017	Email from D. Gan to J. Burleigh re "FW: ZETIA LOE"		X	403; 901; HS; HWH
MDX1885	MRKZETIA000513588	MRKZETIA000513588	6/14/2017	Email from D. Gan to C. Antrosiglio "RE: Gx ezetimibe pricing: new entrants"		X	HS
MDX1886	MRKZETIA000854093	MRKZETIA000854095	11/7/2017	Email from D. Gan to J. Schwartz, D. Heider et al., "RE: ZETIA LOE Year to Date Accomplishment"		X	403; HS; R
MDX1887	GLENMARK-ZETIA-00250287	GLENMARK-ZETIA-00250289	10/13/2010	Email from C. Almeida to P. Chavakula "RE: Ezetimbe 50kg+50Kg"		X	HS
MDX1888	GLENMARK-ZETIA-00251206	GLENMARK-ZETIA-00251219	10/13/2010	Email from P. Chavakula to T. Coughlin re "Ezetimbe - dispatch dates required" with attachments		X	HS
MDX1892	No Bates	No Bates	6/21/2007	Thomson StreetEvents Final Transcript, "MCK - McKesson Corporation Analyst Meeting"		X	403; FD; HS; R
MDX1893	No Bates	No Bates	2014	White Paper, "Making Smarter Purchasing Decision: It Starts with Data"		X	403; FD; HS; R
MDX1894	No Bates	No Bates	6/30/2010	Transcript, "McKesson F1Q11 (Qtr 06/30/2010 Earnings Call)"		X	403; FD; HS; R
MDX1895	No Bates	No Bates	6/22/2006	Thomson StreetEvents Final Transcript, "MCK - McKesson Corporation Analyst Meeting"		X	403; FD; HS; R
MDX1896	No Bates	No Bates	11/20/2007	Schering Corp., et al. v. Glenmark Pharmaceuticals, Inc. USA, et al., Civil Action No. 07-1334 (JLL), Pretrial Scheduling Order and Order on Oral Motion		X	R
MDX1897	MRKZETIA000847720	MRKZETIA000847721	6/14/2010	Email from V. Soni to P. Matukaitis re "Glenmark (Ezetimibe) Table for Invoices"		X	HS; R
MDX1899	GLENMARK-ZETIA-00240136	GLENMARK-ZETIA-00240136	6/22/2010	Email from E. Murray to V. Soni and P. Matukaitis "RE: ZETIA - Settlement Payment (second payment)"		X	HS; R
MDX1900	RA-ZET-0008203	RA-ZET-0008204	4/19/2010	Email from H. Krass to H. Krass re "Zetia Update (MRK v Glenmark): Despite Unfavorable Partial Summary Judgment Decision, Merck Still Appears Likely to Prevail in Lawsuit"		X	403; 701; FD; HS; HWH; R
MDX1901	HEB_ZETIA_ED00017751	HEB_ZETIA_ED00017753	4/19/2010	Email from H. Krass to H. Krass re "Zetia Update (MRK v Glenmark): Despite Unfavorable Partial Summary Judgment Decision, Merck Still Appears Likely to Prevail in Lawsuit"		X	403; 701; FD; HS; HWH; R
MDX1902	No Bates	No Bates	4/22/2010	ProQuest article, "Merck Gets Split Patent Decision; Zetia Copay Raised"		X	403; HS; HWH; R
MDX1903	No Bates	No Bates	2/16/2011	Senate Bill S. 373 "To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs"		X	403; HS; MS; R
MDX1904	CARDINAL_0000030	CARDINAL_0000030	9/4/2012	Printout of Excel file, "Budget and Unbudget FY 12 13 14 15 16 17 090412.xls" (Excerpt)		X	403; HS; INC; R
MDX1905	CARDINAL_0000030	CARDINAL_0000030	9/4/2012	Printout of Excel file, "Budget and Unbudget FY 12 13 14 15 16 17 090412.xls" (Excerpt)		X	403; HS; INC; R
MDX1906	CARDINAL_0000028	CARDINAL_0000028		Printout of Excel file, "80% Conversion SPF Launches Calendar Year 16 - 19.xlsx" (Excerpt)		X	403; HS; INC; R
MDX1907	CARDINAL_0000028	CARDINAL_0000028		Printout of Excel file, "80% Conversion SPF Launches Calendar Year 16 - 19.xlsx" (Excerpt)		X	403; HS; INC; R
MDX1908	REDOAK-ZETIA000000001	REDOAK-ZETIA000000001		Printout of Excel spreadsheet titled, "(Zetia Tablet) Launch Date from May 2015 - Apr 2016 for Retail" (file name "Red Oak COGS Workouts for Zetia Launch.pdf")		X	403; FD; HS; R
MDX1909	No Bates	No Bates	8/12/2016	Cardinal Health, Inc. 10-K For The Fiscal Year Ending June 30, 2016		X	403; FD; HS; MIL; R
MDX1910	No Bates	No Bates	8/10/2017	Cardinal Health, Inc. 10-K For The Fiscal Year Ending June 30, 2017		X	403; FD; HS; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1911	ABDC-ZETIA-000038	ABDC-ZETIA-000039	3/30/2017	Email from M. Cottone to BRx Global Sourcing, et al. re "PRxO Generics Current Events 03/30/17"		X	FD; INC
MDX1912	ABDC-ZETIA-000040	ABDC-ZETIA-000040	3/30/2017	Excel spreadsheet with file name "PRxO_Generics_Weekly_Log_3-30-17_ABC_SOURCING.xlsx"		X	403; FD; INC
MDX1913	ABDC-ZETIA-000021	ABDC-ZETIA-000021	9/2/2016	Excel spreadsheet with file name "PRxO Generics Weekly Log 9-2-16_ABC INTERNAL.xlsx"		X	403; FD; INC
MDX1914	ABDC-ZETIA-000020	ABDC-ZETIA-000020	12/9/2016	Excel spreadsheet with file name "PRxO Generics Weekly Log 12-9-16_ABC INTERNAL.xlsx"		X	FD; INC
MDX1915	ABDC-ZETIA-000023	ABDC-ZETIA-000023	5/6/2016	Excel spreadsheet with file name "PRxO Generics Weekly Log 5-6-16.xlsx"		X	403; FD; INC
MDX1916	ABDC-ZETIA-000031	ABDC-ZETIA-000037	5/1/2017	Email from S. Evans to A. Ratliff, A. Kugler, A, Illig, et al. re "ABC/WBAD Notes 05.01.17"		X	FD
MDX1917	ABDC-ZETIA-000027	ABDC-ZETIA-000027	5/18/2017	Email from R. Rhone re "Zetia-Ezetimibe"		X	FD
MDX1918	ABDC-ZETIA-000024	ABDC-ZETIA-000026	5/24/2017	Email from S. Evans to H. Odenwelder, A. Ratliff, R.Blanka et al. re "Zetia LOE - Revision"		X	FD
MDX1919	ABDC-ZETIA-000028	ABDC-ZETIA-000030	6/15/2017	Email from F. Harris to H. Odenwelder "FW: Ezetimibe Tab (gZetia) LOE Landscape"		X	FD; HS
MDX1920	No Bates	No Bates		CV of Stephen Stalker		X	403; R
MDX1921	No Bates	No Bates	5/11/2010	PHARMABIZ.com article, "Glenmark, Merck settle patent litigation regarding Zetia"		X	403; FD; HS; HWH; R
MDX1922	No Bates	No Bates	5/11/2010	Fierce Pharma, "Merck, Glenmark forge Zetia patent settlement; Ranbaxy beats quarterly estimates"		X	403; FD; HS; HWH; R
MDX1923	No Bates	No Bates	2021	McKesson white paper, "Deciphering the industry drivers behind drug shortages"		X	403; FD; MS; R
MDX1924	MCK_ZETIA_000024	MCK_ZETIA_000025	8/4/2014	Email from H. Krass re "IPD Life Cycle Forecast, New Brand/PDUFA Tracker & Biologic Tracker Changes for 08/04/2014"		X	403; FD; HS; R
MDX1925	MCK_ZETIA_000026	MCK_ZETIA_000026	8/4/2014	Excel spreadsheet with file name "IPD_Life_Cycle_Forecast_2014_08_04_publication.xls"		X	403; FD; HS; R
MDX1926	No Bates	No Bates		Printout of Metadata		X	403; FD; HS; R
MDX1927	MCK_ZETIA_000030	MCK_ZETIA_000061	3/3/2016	PowerPoint presentation, "McKesson FY17 Generics Plan"		X	403; FD; HS; R
MDX1928	MCK_ZETIA_000027	MCK_ZETIA_000029	12/19/2016	Email from A. Mitchell to T. Boyle and C. Rector "RE: Approval Needed - Zetia - New to Market Gx Launch"		X	403; FD; HS; R
MDX1929	No Bates	No Bates	2022	McKesson Annual Report For The Fiscal Year Ending March 31		X	403; FD; HS; R
MDX1930	CVS-ZET-0052927	CVS-ZET-0052928	2/19/2010	Email from H. Krass to H. Krass re "Zetia: Merck Appears To Have Advantage Despite Possible Flaws in Patent"		X	403; 701; FD; HS; HWH; MIL; R
MDX1931	HEB_ZETIA_ED00017754	HEB_ZETIA_ED00017763	2/19/2010	Email from H. Krass to H. Krass re "Zetia: Merck Appears To Have Advantage Despite Possible Flaws in Patent"		X	403; 701; FD; HS; HWH; MIL; R
MDX1932	MRKZETIA000956328	MRKZETIA000956376	1/1/2011	Agreement between Merck Sharp & Dohme Corp and MSP Distribution Services Inc. - Contract No. 10-8305		X	403; H; HWH; MIL; R
MDX1933	MRKZETIA000955883	MRKZETIA000955911	10/28/2011	Memo from J. Holsinger and K. Kolstad to R. Patrylak re Humana Commercial 10-8305 Amendment #1		X	403; H; HWH; MIL; R
MDX1934	MRKZETIA000955912	MRKZETIA000955937	2/8/2012	Memo from J. Holsinger and K. Kolstad to P. Magri re Humana Commercial Contract 10-8305 Amendment #2		X	403; H; HWH; MIL; R
MDX1935	MRKZETIA000956122	MRKZETIA000956150	3/29/2012	Memo from J. Holsinger and K. Kolstad to P. Magri re Humana Commercial Contract 10-8305 Amendment #3		X	403; H; HWH; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1936	MRKZETIA000856151	MRKZETIA000856181	6/21/2012	Memo from J. Holsinger and K. Kolstad to P. Magri re Humana Commercial Contract 10-8305 Amendment #4		X	403; H; HWH; MIL; R
MDX1937	MRKZETIA000956182	MRKZETIA000956211	12/1/2012	Memo from J. Holsinger and K. Kolstad to P. Magri re Humana Commercial Contract 10-8305 Amendment #5		X	403; H; HWH; MIL; R
MDX1938	MRKZETIA000956400	MRKZETIA000956432	9/9/2013	Memo from M. Killough to M. McCullough re Contract 10-8305, Amendment #6		X	403; H; HWH; MIL; R
MDX1939	MRKZETIA000956445	MRKZETIA000956485	12/11/2013	Memo from M. Killough to M. McCullough re Contract 10-8305, Amendment #7		X	403; H; HWH; MIL; R
MDX1940	MRKZETIA000956774	MRKZETIA000956817	8/28/2014	Memo from H. Escobar to P. Magri re Humana - Commercial Contract No. 10-8305, Amendment #8		X	403; H; HWH; MIL; R
MDX1941	MRKZETIA000956507	MRKZETIA000956534	12/23/2014	Memo from H. Escobar to P. Magri re Humana - Commercial Contract No. 10-8305, Amendment #9		X	403; H; HWH; MIL; R
MDX1942	MRKZETIA000957306	MRKZETIA000957342	5/28/2015	Memo from H. Escobar to P. Magri re Humana - Commercial Contract No. 10-8305, Amendment #10		X	403; H; HWH; MIL; R
MDX1943	MRKZETIA000958339	MRKZETIA000958397	10/29/2015	Memo from H. Escobar to P. Magri re Humana - Commercial Contract No. 00138598		X	403; H; HWH; MIL; R
MDX1944	MRKZETIA000956433	MRKZETIA000956444	12/17/2015	Memo from H. Escobar to R. Hartz re Humana - Commercial Contract No. 00138596, Amendment #1		X	403; H; HWH; MIL; R
MDX1945	MRKZETIA000956535	MRKZETIA000956547	8/26/2016	Memo from H. Escobar to R. Hartz re Humana - Commercial Contract No. 00138596, Amendment #2		X	403; H; HWH; MIL; R
MDX1946	MRKZETIA000957997	MRKZETIA000958035	12/6/2016	Memo from H. Escobar to R. Hartz re Humana - Commercial Contract No. 00138596, Amendment #3		X	403; H; HWH; MIL; R
MDX1947	MRKZETIA000958086	MRKZETIA000958115	12/19/2017	Letter from M. Upright and H. Page to R. Hartz re Humana - Commercial Contract No. 00138596, Amendment #4		X	403; H; HWH; MIL; R
MDX1948	MRKZETIA000948568	MRKZETIA000948589	9/7/2015	Memo from S. Shermer to J. Martiello and J. Van Arsdale re Humana Medicare Part D Contract #05-0377		X	403; H; HWH; MIL; R
MDX1949	MRKZETIA000948590	MRKZETIA000948594	3/13/2006	Letter from S. Shermer to F. Brownfield re MSP/Humana Medicare Part D Contract No. 05-0377 - Amendment #2		X	403; H; HWH; MIL; R
MDX1950	MRKZETIA000948712	MRKZETIA000948715	5/21/2007	Memo from S. Shermer and K. Robinson to M. Stevens, I. Duffy and J. Albright re Humana Medicare D Contract # 05-0377, Amendment #4		X	403; H; HWH; MIL; R
MDX1951	MRKZETIA000972070	MRKZETIA000972074	5/22/2007	Memo from S. Shermer and K. Robinson to M. Stevens, I. Duffy re Humana Inc. Contract # 05-0377, Amendment #5		X	403; H; HWH; MIL; R
MDX1952	MRKZETIA000948745	MRKZETIA000948751	8/1/2007	Memo from S. Shermer and K. Robinson to M. Stevens, I. Duffy and J. Albright re Humana Medicare D Contract # 05-0377, Amendment #6		X	403; H; HWH; MIL; R
MDX1953	MRKZETIA000948769	MRKZETIA000948773	11/6/2009	Memo from M. Theissen to J. Albright to M. Stevens re Humana Inc. Contract #: 05-0377 Amendment #10		X	403; H; HWH; MIL; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1954	MRKZETIA000948774	MRKZETIA000948781	10/28/2010	Letter from J. Holsinger to D. Vanderpoel re MSP/Humana Medicare Part D Contract No. 05-0377 - Amendment #11		X	403; H; HWH; MIL; R
MDX1955	MRKZETIA000958036	MRKZETIA000958085	12/14/2011	Memo from J. Holsinger and K. Kolstad to R. Patrylak re Humana Medicare Part D 11-9298 (Harmonized)		X	403; H; HWH; MIL; R
MDX1956	MRKZETIA000956486	MRKZETIA000956506	2/8/2012	Memo from J. Holsinger and K. Kolstad to P. Magri re Humana Medicare Contract 11-9298 Amendment #1		X	403; H; HWH; MIL; R
MDX1957	MRKZETIA000956662	MRKZETIA000956682	2/16/2012	Memo from J. Holsinger and K. Kolstad to P. Magri re Humana Medicare Contract 11-9298 Amendment #2		X	403; H; HWH; MIL; R
MDX1958	MRKZETIA000957009	MRKZETIA000957029	3/29/2012	Memo from J. Holsinger and K. Kolstad to P. Magri re Humana Medicare Contract 11-9298 Amendment #3		X	403; H; HWH; MIL; R
MDX1959	MRKZETIA000957079	MRKZETIA000957100	12/19/2012	Memo from J. Holsinger and Deb Gan to P. Magri re Humana Medicare Contract 11-9298 Amendment #4		X	403; H; HWH; MIL; R
MDX1960	MRKZETIA000957455	MRKZETIA000957482	5/28/2013	Memo from M. Killough to P. Magri re Humana - Medicare Part D Contract # 11-9298, Amendment #5		X	403; H; HWH; MIL; R
MDX1961	MRKZETIA000957808	MRKZETIA000957842	7/31/2014	Memo from H. Escobar to P. Magri re Humana Medicare Part D Contract 11-9298, Amendment #7		X	403; H; HWH; MIL; R
MDX1962	MRKZETIA000958398	MRKZETIA000958405	12/15/2014	Memo from H. Escobar to P. Magri re Humana Medicare Part D Cont. # 11-9298, Amend. #8		X	403; H; HWH; MIL; R
MDX1963	MRKZETIA000959043	MRKZETIA000959077	4/30/2015	Memo from H. Escobar to P. Magri re Humana Medicare Part D Cont. # 11-9298, Amend. #9		X	403; H; HWH; MIL; R
MDX1964	MRKZETIA000959709	MRKZETIA000959760	6/1/2015	Memo from H. Escobar to P. Magri re Humana Medicare Part D Cont. # 11-9298, Amend. #10		X	403; H; HWH; MIL; R
MDX1965	MRKZETIA000959979	MRKZETIA000960031	9/8/2015	Memo from H. Escobar to P. Magri re Humana Medicare Part D Cont. # 11-9298, Amend. #11		X	403; H; HWH; MIL; R
MDX1966	MRKZETIA000959610	MRKZETIA000959658	12/16/2015	Memo from H. Escobar to R. Hartz re Humana Medicare Part D Cont. # 11-9298, Amend. #12		X	403; H; HWH; MIL; R
MDX1967	MRKZETIA000960198	MRKZETIA000960232	5/31/2016	Memo from H. Escobar to R. Hartz re Humana Medicare Part D Cont. # 11-9298, Amend. #13		X	403; H; HWH; MIL; R
MDX1968	MRKZETIA000959892	MRKZETIA000959925	6/22/2016	Memo from H. Escobar to R. Hartz re Humana Medicare Part D Cont. # 11-9298 Amend #14		X	403; H; HWH; MIL; R
MDX1969	MRKZETIA000960466	MRKZETIA000960511	12/7/2016	Memo from H. Escobar to R. Hartz re Humana Medicare Part D Cont. # 11-9298, Amend. #15		X	403; H; HWH; MIL; R
MDX1970	MRKZETIA000960440	MRKZETIA000960465	12/19/2017	Memo from Michael Upright and Heather Page to R. Hartz re Humana - Commercial Contract No. 11-9298; Amendment #16		X	403; H; HWH; MIL; R
MDX1972	GLENMARK-ZETIA-00426550	GLENMARK-ZETIA-00426565	8/4/2009	Email from T. Coughlin to G. Saldanha "RE: Ezetimibe" with attachment		X	403; 901; HS; HWH; R
MDX1978	No Bates	No Bates	9/11/2020	Purchasers' Opposition to Defendants' Motion to Exclude the Testimony and Opinions of Plaintiffs' Experts Drs. Thomas McGuire and Keith Leffler (ECF No. 1114)		X	403; FD; HS; HWH; R

Preliminary Identifier	BegBates	EndBates	Date	Description	Will Use	May Use	Plaintiffs' Objection(s)
MDX1979	No Bates	No Bates	9/11/2020	Sealed Purchasers' Opposition to the Merck and Glenmark Defendants' Motions for Summary Judgment (ECF No. 1156)		X	403; FD; HS; HWH; R
MDX1980	No Bates	No Bates	1/30/2023	Purchasers' Opposition to Defendants' Motion in Limine No. 24 to Exclude Statements Suggesting that the Glenmark and Mylan Case Would Have Been Evaluated Differently at the Time of the Glenmark Settlement (ECF No. 1898)		X	403; FD; HS; HWH; R
MDX1981	No Bates	No Bates	3/24/2023	Retailer Plaintiffs Memorandum in Support of Objection to Memorandum Opinion and Order Denying Purchasers' Motion in Limine No. 19		X	403; FD; HS; HWH; R

EXHIBIT 7

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
		review				
GDX0001	1/1/1980	Heathcock J. Org. Chem. 1980, 45, 1066 and Evans J. Am. Chem. Soc. 1982, 104, 1737			May Offer	HS
GDX0002	1/1/1982	Evans J. Am. Chem. Soc. 1982, 104, 1737			May Offer	HS
GDX0003	1/1/1984	Asymmetric Synthesis, Volume 3, Chapters 1 and 2, Ed J.D Morrison, Wiley 1984.			May Offer	HS
GDX0004	1/1/1987	Corey. J. Am. Chem. Soc. 1987, 109, 5551; for a review see Ang. Chem. Int. Ed. 1998, 37 (15), 1986; US005631365A			May Offer	HS
GDX0005	3/30/1995	Excerpts of International Application No. PCT/US94/10099	MRKZETIA_SIDLEY000180215	MRKZETIA_SIDLEY000180278	May Offer	HS; INC
GDX0006	6/14/2000	Excerpts of the Reissue Application Declaration by the Assignee, signed by James Nelson in support of U.S. Patent Application No. 09/594,996	USPTO-ZETIA-0000106	USPTO-ZETIA-0000111	May Offer	HS
GDX0007	8/1/2001	Guidance for Industry ICH M4Q: CTD – Quality, August 2001			May Offer	HS
GDX0008	12/27/2001	Excerpts from the file history of Merck's New Drug Application for Zetia	USPTO-ZETIA-0001225	USPTO-ZETIA-0001245	May Offer	901; HS; INC
GDX0009	10/25/2002	Food and Drug Administration's October 25, 2002 letter approving Merck's New Drug Application for Zetia	MRKZETIA_R000082822	MRKZETIA_R000082844	May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0010	1/1/2004	The Discovery of Ezetimibe: A View from Outside the Receptor, by Clader, John W., January 2004	MRKZETIA_SIDLEY000153803	MRKZETIA_SIDLEY000153812	May Offer	HS
GDX0011	7/13/2004	Scott M. Grundy, et al., Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, Vol. 110 (July 13, 2004), https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.0000133317.49796.0E.			May Offer	HS; R
GDX0012	7/23/2004	Food and Drug Administration's July 23, 2004 letter approving Merck's New Drug Application for Vytorin	MRKZETIA000604071	MRKZETIA000604074	May Offer	HS; R
GDX0013	1/1/2005	Excerpts from Dennis W. Carlton & Jeffrey M. Perloff, Modern Industrial Organization (4th ed. 2005)			May Offer	HS; INC
GDX0015	7/15/2005	Letter A. Afonso to J. Nelson re Revising Inventor List for U.S. Patent Nos. 5,631,365 and 5,767,115	GLENMARK-ZETIA-00151701	GLENMARK-ZETIA-00151702	May Offer	NO
GDX0016	11/14/2005	Letter from Dorothy R. Auth to Adriano Afonso	MRKZETIA_SIDLEY000007278	MRKZETIA_SIDLEY000007281	May Offer	HS; HWH
GDX0018	7/19/2006	Senate Bill 3695, dated July 19, 2006 and titled "A BILL To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs."			May Offer	403; MIL; R
GDX0019	7/28/2006	House Resolution 5993, dated July 28, 2006 and titled "A BILL To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs."			May Offer	403; MIL; R
GDX0020	8/1/2006	Original Submission, Ezetimibe Drug Master File Type II, Glenmark Pharmaceuticals Limited, Ankleshwar, Gujarat (India) (Volume: 4 of 4)	GLENMARK-ZETIA-00001866	GLENMARK-ZETIA-0002087	May Offer	901; HS
GDX0022	9/18/2006	Email from V. Sodha to R. Garella and ccs re Gideon Richter	GLENMARK-ZETIA-00240755	GLENMARK-ZETIA-00240756	May Offer	HS; HWH

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0024	11/1/2006	Letter from to Z. T. Sihorwala to FDA regarding Glenmark Pharmaceuticals Limited Justification for the Presence of 1,2-Dichloroethane, (Class I solvent as designated in ICH Q3C(R3)) in Glenmark's Ezetimibe	GLENMARK-ZETIA-00174772	GLENMARK-ZETIA-00174773	May Offer	901; HS
GDX0026	1/1/2007	VOI Consulting. "Authorized Generics: What's Really Going on?"			May Offer	403; HS; HWH; R
GDX0027	1/1/2007	Richard G. Frank & David S. Salkever, Generic Entry and the Pricing of Pharmaceuticals, 6 J. Econ. & Mgmt. Strategy 75 (1997)			May Offer	NO
GDX0028	1/2/2007	Test Request for - Glenmark Research Centre Analytical Research Laboratory, regarding reflecting sample tested for impurities	GLENMARK-ZETIA-00024526	GLENMARK-ZETIA-00024783	May Offer	901; HS; R
GDX0029	1/31/2007	Email from B.V. SivaKumar to S. Sinha regarding FW: New Ezetimibe	GLENMARK-ZETIA-00247065	GLENMARK-ZETIA-00247066	May Offer	HS; HWH
GDX0031	2/8/2007	Letter from Glenmark regarding Zetia Notice of Paragraph IV Certification	GLENMARK-ZETIA-00041585	GLENMARK-ZETIA-00041611	May Offer	NO
GDX0032	3/22/2007	Merck's Complaint against Glenmark for patent infringement of U.S. Patent No. RE37,721	MRKZETIA_SIDLEY000000027	MRKZETIA_SIDLEY000000034	May Offer	NO
GDX0033	3/27/2007	Email from W. McIntyre to Z. Sihorwala copying G. Saldanha, T. Coughlin, V. Soni, and K. Anand regarding Ezetimibe	GLENMARK-ZETIA-00175864	GLENMARK-ZETIA-00175867	May Offer	HS; HWH
GDX0034	5/7/2007	Letter from J. Skanchy, FDA to W. McIntyre, Glenmark re deficiencies to abbreviated new drug application for Ezetimibe Tablets, 400 mg	GLENMARK-ZETIA-00287515	GLENMARK-ZETIA-00287519	May Offer	HS
GDX0037	6/7/2007	Glenmark's Answer, filed on June 7, 2007 (Dkt. 20), in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)			May Offer	NO
GDX0038	9/14/2007	Notice of Certification for U.S. Patent No. 7,030,106 from Teva to the FDA	Teva-Zetia_00001054	Teva-Zetia _00001068	May Offer	HS; R
GDX0039	9/28/2007	Email from R. Jha to W. McIntyre regarding Regulatory Issues – Videocon 08/13/07	GLENMARK-ZETIA-00316019	GLENMARK-ZETIA-00316036	May Offer	HS; HWH; R
GDX0041	10/16/2007	Email from S. Krishan to T. Coughlin, R. Garella, G. Chen, and V. Soni regarding Ezetimibe	GLENMARK-ZETIA-00271247	GLENMARK-ZETIA-00271250	May Offer	HS; HWH; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0042	1/1/2008	Emily Cox, et. al, 2008 Drug Trend Report, Express Scripts (2008)			May Offer	901; HS; HWH; R
GDX0043	1/9/2008	Email from V. Soni to Z. Sihorwala, M. Khan, and ccs re Tentative approval within 30 months is a MUST	GLENMARK-ZETIA-00175788	GLENMARK-ZETIA-00175790	May Offer	HS; HWH
GDX0046	2/5/2008	Email from P. Birdy to P. Dutra re Sales Break up_US (3).xls with attachment	GLENMARK-ZETIA-00177883	GLENMARK-ZETIA-00177884	May Offer	901; HS; R
GDX0047	2/7/2008	Email from J. Cangemi to P. Dutro re [no subject], with attachments	GLENMARK-ZETIA-00177685	GLENMARK-ZETIA-00177687	May Offer	NO
GDX0049	2/14/2008	Email from T. Coughlin to M. Khan and ccs re Ezetimibe -4 kgs	GLENMARK-ZETIA-00270694	GLENMARK-ZETIA-00270695	May Offer	HS; HWH; R
GDX0050	2/14/2008	Food and Drug Administration's February 14, 2008 facsimile notifying Merck that it had been granted pediatric exclusivity for ezetimibe	MRKZETIA000584034	MRKZETIA000584035	May Offer	NO
GDX0051	3/6/2008	Email from P. Khatkul to G. Chen and ccs re API Pricing	GLENMARK-ZETIA-00177862	GLENMARK-ZETIA-00177864	May Offer	HS; HWH; R
GDX0052	3/11/2008	Email from R. Jha to W. McIntyre, M. Khan, and ccs re Deficiencies- Ezetimibe with attachments	GLENMARK-ZETIA-00175657	GLENMARK-ZETIA-00175699	May Offer	HS; HWH
GDX0053	3/17/2008	Biographical information for Antitrust Team Leader, Luis A. Molina			May Offer	403; 901; HS; R
GDX0054	4/22/2008	Email from S. Kotwal to D. Sunday and ccs re Ezetimibe DMF 19717 deficiency response with attachments	GLENMARK-ZETIA-00162518	GLENMARK-ZETIA-00162626	May Offer	HS; HWH; MIL
GDX0055	4/30/2008	Letter from A. Maffia, III to G. Buehler regarding ANDA 78-560 – Ezetimibe Tablets 10 mg Minor Amendment-Chemistry	GLENMARK-ZETIA-00295986	GLENMARK-ZETIA-00296588	May Offer	HS; HWH; MIL
GDX0056	6/5/2008	Deposition transcript of V. Soni, dated June 5, 2008, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)	GLENMARK-ZETIA-00120975	GLENMARK-ZETIA-00121055	May Offer	403; HS; HWH
GDX0057	6/6/2008	Deposition transcript of 30(b)(6) V. Soni, dated June 6 2008, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)	GLENMARK-ZETIA-00121428	GLENMARK-ZETIA-00121462	May Offer	403; HS; HWH
GDX0058	6/22/2008	Email Thread from Jessica Cangemi to Prasad Khatkul, regarding FW: Model attaching Sales Backup 6.22.08.xls.	GLENMARK-ZETIA-00177683	GLENMARK-ZETIA-00177684	May Offer	HS; HWH; INC

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0059	8/22/2008	Letter from Teva to G. Buehler, OGD, FDA, re ANDA #78-724 Ezetimibe Tablets, 10 mg - Minor Amendment-Response to July 7, 2007 Review Letter	Teva-Zetia_00001101	Teva-Zetia _00001373	May Offer	HS; MIL; R
GDX0060	9/5/2008	Glenmark's September 5, 2008 Stipulation with Respect to Infringement Issues Involving U.S. Patent No. RE37,721	MRKZETIA_SIDLEY000128261	MRKZETIA_SIDLEY000128264	May Offer	NO
GDX0061	9/24/2008	Email from T. Coughlin to A. Maffia, W. McIntyre, V. Soni, S. Mohanty, P. Virkar re Ezetimibe ANDA	GLENMARK-ZETIA-00161776	GLENMARK-ZETIA-00161776	May Offer	HS; HWH; MIL
GDX0062	10/21/2008	Deposition transcript of Adriano Afonso, dated October 21, 2008, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)	GLENMARK-ZETIA-00124367	GLENMARK-ZETIA-00124431	May Offer	NO
GDX0063	12/4/2008	Deposition transcript of Stuart B. Rosenblum, dated December 4, 2008, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)	GLENMARK-ZETIA-00132895	GLENMARK-ZETIA-00133232	May Offer	HS; HWH
GDX0064	12/5/2008	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (ED Pa. [12/5/2008]), Deposition Transcript of Stuart B. Rosenblum	GLENMARK-ZETIA-00133755	GLENMARK-ZETIA-00133928	May Offer	HS; HWH
GDX0065	12/15/2008	Email from Thakur to Jalaj Sharma regarding US Capacity Roundup.ppt (snapshot of Glenmark's US Capacity update)	GLENMARK-ZETIA-00186065	GLENMARK-ZETIA-00186066	May Offer	403; HS; HWH
GDX0066	12/18/2008	Letter from counsel for Glenmark to G. Buehler, OGD, re Glenmark Generics, Inc., USA: ANDA 78-560, Ezetimibe Tablets 10 mg - Request for Completion of Review and Tentative Approval before the Expiration of the 30 Month Stay	GLENMARK-ZETIA-00290994	GLENMARK-ZETIA-00290996	May Offer	HS
GDX0067	1/1/2009	PowerPoint highlighting Glenmark's vision and values while also describing its objectives, projections and estimates	GLENMARK-ZETIA-00424724	GLENMARK-ZETIA-00424724	May Offer	403; HS; R
GDX0068	2/10/2009	Deposition transcript of Stuart B. Rosenblum, dated February 10, 2009, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D.N.J.)	GLENMARK-ZETIA-00132701	GLENMARK-ZETIA-00132863	May Offer	HS; HWH

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0069	2/19/2009	Email from W. McIntyre to Robert West regarding Glenmark ANDA 78-560 Ezetimibe Tablets 10 mg – Review History	GLENMARK-ZETIA-00201484	GLENMARK-ZETIA-00201486	May Offer	HS; HWH; MIL
GDX0070	2/25/2009	Expert Report of Clayton H. Heathcock, Ph.D., Schering v. Glenmark, 07-1334	GLENMARK-ZETIA-00083263	GLENMARK-ZETIA-00083444	May Offer	NO
GDX0071	3/10/2009	Email from W. McIntyre to T. Coughlin, P. Dutra, V. Soni, S. Krishan, S. Mohanty, A. Maffia and ccs re FDA Contact Report - Ezetimibe Tablets ANDA 78-560	GLENMARK-ZETIA-00159729	GLENMARK-ZETIA-00159729	May Offer	HS; HWH; MIL
GDX0075	3/13/2009	Email from Terrance Coughlin to Sanjeev Mohanty, et al, regarding Coughlin advises that an agreement needs to be reached with following FDA's specifications	GLENMARK-ZETIA-00367069	GLENMARK-ZETIA-00367073	May Offer	HS; HWH; INC; MIL
GDX0076	3/14/2009	Email B. Kamat to V. Rodrigues et al re Meeting regarding Deficiency - Ezetimibe Tables - URGENT attaching Draft Response Communications	GLENMARK-ZETIA-00164522	GLENMARK-ZETIA-00164538	May Offer	HS; HWH; INC; MIL
GDX0077	3/15/2009	Email from S. Mohanty to M. Khan, N. Tiwari, W. McIntyre, A. Maffia, K. Mehta, M. Krishna and ccs re Received from the FDA: Ezetimibe Tablets with attachments	GLENMARK-ZETIA-00212258	GLENMARK-ZETIA-00212282	May Offer	HS; HWH; MIL
GDX0078	3/16/2009	Email from D. Swar to S. Kaushal, A. Maffia and ccs re Received from the FDA: Ezetimibe Tablets with attachment	GLENMARK-ZETIA-00157183	GLENMARK-ZETIA-00157199	May Offer	HS; HWH; MIL
GDX0079	3/20/2009	Letter from A. Maffia, Glenmark to OGD, FDA regarding ANDA 78-560 Ezetimibe Tablets, 10 mg - Additional Information to Minor Amendment - Chemistry (Submitted on 3/16/2009) Field Copy	GLENMARK-ZETIA-00295142	GLENMARK-ZETIA-00295153	May Offer	HS; MIL
GDX0080	4/2/2009	Letter from A. Maffia, Glenmark to OGD, FDA regarding ANDA 78-560 Ezetimibe Tablets, 10 mg - Telephone Amendment - Chemistry Field Copy	GLENMARK-ZETIA-00295455	GLENMARK-ZETIA-00295516	May Offer	HS; MIL

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0081	4/18/2009	Email from Terrance Coughlin to Vijay Soni and Sanjeev Krishan re: email sent to Jalaj Sharma and Glenn Saldanha, regarding changes in R&D for a successful API business	GLENMARK-ZETIA-00281894	GLENMARK-ZETIA-00281899	May Offer	HS; HWH
GDX0082	4/20/2009	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (ED Pa. [4/20/2009]), Expert Report of William R. Roush, Ph.D.	GLENMARK-ZETIA-00082607	GLENMARK-ZETIA-00082746	May Offer	403; HS; HWH
GDX0083	4/20/2009	Expert Report of Ronald G. Brisbois, Ph.D., Schering v. Glenmark, 07-1334 (D.N.J.)	GLENMARK-ZETIA-00082371	GLENMARK-ZETIA-00082601	May Offer	HS; HWH
GDX0084	4/24/2009	Letter from FDA to Glenmark re tentative approval of ANDA for Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00159300	GLENMARK-ZETIA-00159305	May Offer	NO
GDX0085	5/5/2009	Facsimile to P. Erickson, Teva from J. Skanchy, FDA re Complete Response -- Minor ANDA 78-724	Teva-Zetia_00001491	Teva-Zetia_00001494	May Offer	HS; MIL; R
GDX0086	5/8/2009	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (ED Pa. [5/8/2009]), Rebuttal Expert Report of Clayton H. Heathcock, Ph.D.	GLENMARK-ZETIA-00082994	GLENMARK-ZETIA-00083043	May Offer	NO
GDX0087	5/22/2009	Supplemental Expert Report of Ronald G. Brisbois, Ph.D., Schering v. Glenmark, 07-1334 (D.N.J.)	GLENMARK-ZETIA-00082602	GLENMARK-ZETIA-00082606	May Offer	403; HS; HWH
GDX0088	5/28/2009	Email from P. Dutra to T. Coughlin re Term sheet with attachments	GLENMARK-ZETIA-00178376	GLENMARK-ZETIA-00178386	May Offer	HS; INC
GDX0089	5/30/2009	Email from Campanelli to T. Coughlin regarding [term sheet] update	GLENMARK-ZETIA-00260804	GLENMARK-ZETIA-00260810	May Offer	HS
GDX0090	6/10/2009	Excerpts from a June 2009 Campbell Alliance Group, Inc. presentation entitled CLARITY Payer Research: Final Deliverable	MRKZETIA000892356	MRKZETIA000892356	May Offer	4.3; HS; MIL
GDX0091	6/11/2009	Email from Campanelli to Coughlin regarding Our Conversation Yesterday	GLENMARK-ZETIA-00218115	GLENMARK-ZETIA-00218115	May Offer	NO
GDX0092	6/22/2009	Email from V. Soni to T. Coughlin, P. Dutra re Par	GLENMARK-ZETIA-00218110	GLENMARK-ZETIA-00218110	May Offer	NO
GDX0093	6/29/2009	Glenmark's June 29, 2009 motion for summary judgment concerning improper reissue in the Glenmark Litigation	MRKZETIA_SIDLEY000021157	MRKZETIA_SIDLEY000021189	May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0094	7/8/2009	Glenmark's July 8, 2009 motion for summary judgment concerning obviousness-type double patenting in the Glenmark Litigation	MRKZETIA_SIDLEY000034033	MRKZETIA_SIDLEY000034059	May Offer	NO
GDX0095	7/23/2009	Email from T. Coughlin to S. Krishan, V. Soni, and W. McIntyre re Discussion on critical Products	GLENMARK-ZETIA-00182846	GLENMARK-ZETIA-00182849	May Offer	HS; HWH; MIL
GDX0096	7/24/2009	Email from Krishan to Jalaj Sharma regarding [ezetimibe] Projections with attachment	GLENMARK-ZETIA-00186120	GLENMARK-ZETIA-00186122	May Offer	HS; HWH
GDX0097	8/1/2009	Email from T. Coughlin to Group regarding Teva	GLENMARK-ZETIA-00426184	GLENMARK-ZETIA-00426187	May Offer	HS; HWH
GDX0100	8/31/2009	Email from T. Coughlin to M. Khan and ccs re Weekly updated on Critical Products	GLENMARK-ZETIA-00280322	GLENMARK-ZETIA-00280326	May Offer	HS; HWH
GDX0101	9/23/2009	Email from V. Soni to T. Coughlin re GSK settlement: draft	GLENMARK-ZETIA-00201088	GLENMARK-ZETIA-00201089	May Offer	HS
GDX0103	11/3/2009	Excerpt of a November 3, 2009 Merck forecast	MRKZETIA_R000073651	MRKZETIA_R000073651	May Offer	HS; R
GDX0105	12/1/2009	Email from T. Krause to L. Kostinas and ccs re 07-1334 (JLL) Schering v. Glenmark	MRKZETIA_SIDLEY000219265	MRKZETIA_SIDLEY000219266	May Offer	R
GDX0106	12/7/2009	Watson's Original ANDA application for Ezetimibe Tablets, 10 mg	Watson-Zetia_00000001	Watson-Zetia_00000002	May Offer	NO
GDX0107	12/14/2009	Plaintiffs' Pretrial Brief, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D.N.J.)	MRKZETIA_SIDLEY000098841	MRKZETIA_SIDLEY000098879	May Offer	HS
GDX0108	12/14/2009	Defendants' Trial Brief, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D.N.J.)	MRKZETIA_SIDLEY000098253	MRKZETIA_SIDLEY000098302	May Offer	NO
GDX0109	12/16/2009	Schering-MSP Complaint against Mylan, filed in Schering v. Mylan, 09-06383 (D.N.J.) with exhibits	MRKZETIA_SIDLEY000238225	MRKZETIA_SIDLEY000238285	May Offer	HS; MIL; R
GDX0110	12/21/2009	Email from Mehta to Vijayanand Kotkar; Anil Agrawal; and Ajay Varshney regarding Indore/Goa EBs	GLENMARK-ZETIA-00185618	GLENMARK-ZETIA-00185619	May Offer	HS; R
GDX0111	12/22/2009	Glenmark API Manufacturing Facility Master Production and Control Record - Ezetimibe	GLENMARK-ZETIA-00309214	GLENMARK-ZETIA-00309263	May Offer	HS
GDX0112	12/23/2009	Email from P. Campanelli to T. Coughlin and ccs re Draft Term Sheet	GLENMARK-ZETIA-00259794	GLENMARK-ZETIA-00259795	May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0113	1/7/2010	Email from V. Soni to P. Matukaitis re Glenmark-Merck: settlement purpose only	MRKZETIA_R000061593	MRKZETIA_R000061593	May Offer	HS
GDX0114	1/25/2010	Glenmark API Manufacturing Facility Master Production and Control Record - Ezetimibe - Validation Batch	GLENMARK-ZETIA-00309383	GLENMARK-ZETIA-00309418	May Offer	HS
GDX0115	2/1/2010	IPD Analytics LLC Pharma Report - Zetia (MRK) February 2010	GLENMARK-ZETIA-00281045	GLENMARK-ZETIA-00281055	May Offer	403; 701; FD; HS; HWH; R
GDX0116	2/3/2010	Email from K. Rocco to C. Gassert and ccs re Regulatory Due Diligence Report for Ezetimibe Tablets, 10 mg - Glenmark with attachments	PAR_00007721	PAR_00007727	May Offer	HS
GDX0117	2/4/2010	Email from C. Gassert to T. Coughlin, V. Soni, and ccs re Due Diligence Status	GLENMARK-ZETIA-0434206	GLENMARK-ZETIA-0434206	May Offer	HS; R
GDX0118	2/22/2010	Email from S. Mohanty to N. Kothari and cc re Ezetimibe Process Comparison and Trend Analysis with attachments	GLENMARK-ZETIA-00362886	GLENMARK-ZETIA-00362889	May Offer	HS
GDX0119	2/23/2010	Email from C. Calabro to P. Campanelli and ccs re Ezetimibe with attachment	PAR_00007866	PAR_00007867	May Offer	HS
GDX0120	2/25/2010	Email from R. Gangavati to B. Patankar and ccs re Ezetimibe new process GGL-B060	GLENMARK-ZETIA-00374797	GLENMARK-ZETIA-00374800	May Offer	HS
GDX0121	2/26/2010	Email from V. Soni to P. Matukaitis and cc re Glenmark- Merck	GLENMARK-ZETIA-0434912	GLENMARK-ZETIA-0434915	May Offer	NO
GDX0122	2/26/2010	Email from V. Soni to P. Matukaitis and cc re Glenmark- Merck	MRKZETIA_R000061858	MRKZETIA_R000061861	May Offer	INC
GDX0125	3/1/2010	V. Soni handwritten notes re draft	GLENMARK-ZETIA-00304971	GLENMARK-ZETIA-00304971	May Offer	NO
GDX0127	3/3/2010	Proposed Final Pretrial Order, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D.N.J.)			May Offer	HS; R
GDX0128	3/10/2010	Email from V. Soni to P. Matukaitis and E. Murray re Glenmark- Merck	GLENMARK-ZETIA-00272713	GLENMARK-ZETIA-00272714	May Offer	R
GDX0131	3/25/2010	Draft Settlement Negotiation between Glenmark and Merck	GLENMARK-ZETIA-00261883	GLENMARK-ZETIA-00261908	May Offer	INC
GDX0134	3/29/2010	Email from Matukaitis to Sonl re: draft settlement agreement b/w Schering, MSP, Glenmark with attachment	MRKZETIA000870261	MRKZETIA000870287	May Offer	NO
GDX0135	4/1/2010	Email from P. Dutra to Mylan regarding Mylan Draft Terms	GLENMARK-ZETIA-00178485	GLENMARK-ZETIA-00178485	May Offer	403; HS; MIL; R
GDX0138	4/15/2010	Email from P. Campanelli to L. Brown and cc re Zetia	PAR_00007720	PAR_00007720	May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0139	4/19/2010	Email from P. Campanelli to P. Campanelli re Zetia with attachment	PAR_00008219	PAR_00008221	May Offer	HS
GDX0140	4/19/2010	Email from V. Soni to P. Dutra re Zetia '721 patent : Reissue summary judgment granted in favor of Glenmark with attachments	GLENMARK-ZETIA-00216152	GLENMARK-ZETIA-00216155	May Offer	403; R
GDX0141	4/19/2010	Email from V. Soni to P. Campanelli and cc re Zetia '721 patent : Reissue SJ granted in favor of Glenmark	GLENMARK-ZETIA-00219669	GLENMARK-ZETIA-00219672	May Offer	403; R
GDX0146	4/22/2010	Email from J. Romanelli to Various re: MRK - Legal Concerns Over Zetia Appear Grossly Overstated (Leerink); A Victor for Glenmark But Zetia's IP Likely OK to 2016 (Cowen)	MRKZETIA_R000004105	MRKZETIA_R000004108	May Offer	403; 701; FD; HS; HWH; R
GDX0147	4/30/2010	Email from C. Gassert to P. Campanelli and cc re Zetia and Asacol Questions with attachments	PAR_00008140	PAR_00008143	May Offer	HS
GDX0149	4/30/2010	Merck's Notice of Motion for Reconsideration and the Brief in Support of its Motion for Reconsideration, filed in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)	GLENMARK-ZETIA-00147835	GLENMARK-ZETIA-00147851	May Offer	HS
GDX0150	4/30/2010	Presentation from Carol Valillo, Executive Assistant to Campanelli, to the revised Board presentation [regarding the Par/Glenmark Marketing & Distribution Agreement] to Katherine Burns [Tom Haughey's Assistant].	PAR_00008188	PAR_00008189	May Offer	INC
GDX0151	5/3/2010	Joint Proposed Final Pre-Trial Order, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 7-cv- 1334 (D.N.J. [5/3/2010]), Joint Proposed Final Pre-Trial Order			May Offer	HS
GDX0152	5/3/2010	Email from C. Calabro to P. Campanelli and cc re Ezetimibe updated forecast with attachment	PAR_00008126	PAR_00008127	May Offer	NO
GDX0154	5/5/2010	Email from L. Brown to T. Haughey, P. Campanelli, and cc re Zetia	GLENMARK-ZETIA-00307003	GLENMARK-ZETIA-00307007	May Offer	403; HS; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0155	5/5/2010	Email from P. Campanelli to V. Soni, T. Haughey, and ccs re Settlement agreement received from Merck on Mar 29 2010	PAR_00007896	PAR_00007897	May Offer	NO
GDX0156	5/6/2010	Email from V. Soni to E. Rudnicki re Meeting with Paul Matukaitis on Friday, May 7 at 9:30 a.m. Rahway site	GLENMARK-ZETIA-0434851	GLENMARK-ZETIA-0434852	May Offer	HS
GDX0157	5/6/2010	Letter from FDA to Mylan confirming receipt of ANDA for Ezetimibe Tablets, 10 mg	MYL_ZETIA 000002	MYL_ZETIA 000005	May Offer	R
GDX0160	5/7/2010	Email from P. Matukaitis to T. Hester and cc re Merck-Glenmark agreement	MRKZETIA_R000080162	MRKZETIA_R000080162	May Offer	403; HS
GDX0161	5/7/2010	Email from P. Campanelli to S. Mock re EKR Therapeutics	PAR_00008084	PAR_00008085	May Offer	NO
GDX0162	5/8/2010	Email from T. Hester to V. Soni , L. Brown, E. Choy re Zetia Settlement Agreement	GLENMARK-ZETIA-00339682	GLENMARK-ZETIA-00339683	May Offer	403; HS; INC
GDX0163	5/8/2010	Email from T. Hester to P. Matukaitis, E. Murray, L. Jakob re Zetia Settlement Agreement	MRKZETIA_000061827	MRKZETIA_000061828	May Offer	403; HS; INC
GDX0164	5/8/2010	Email from L. Brown to P. Campanelli, T. Coughlin, T. Haughey, and ccs re Zetia Settlement Agreement with attachments	GLENMARK-ZETIA-00261739	GLENMARK-ZETIA-00261794	May Offer	HS
GDX0170	5/9/2010	Email from T. Hester to P. Matukaitis, et al. re Revised Zetia Settlement Agreement and an attached draft settlement agreement	MRKZETIA000848136	MRKZETIA000848166	May Offer	NO
GDX0171	5/10/2010	Email from V. Soni to L. Brown, E. Choy re Zetia Settlement Agreement	GLENMARK-ZETIA-00272708	GLENMARK-ZETIA-00272709	May Offer	403; HS; R
GDX0172	5/10/2010	Email from V. Soni to T. Coughlin re Zetia Settlement Agreement	GLENMARK-ZETIA-00261666	GLENMARK-ZETIA-00261667	May Offer	HS
GDX0174	5/10/2010	Email from V. Soni to T. Coughlin re Zetia Settlement - Draft Press Release with attachment	GLENMARK-ZETIA-00261619	GLENMARK-ZETIA-00261624	May Offer	403; HS; R
GDX0175	5/10/2010	Email from V. Soni to T. Coughlin re Zetia Settlement - Draft Press Release with attachment	GLENMARK-ZETIA-00261628	GLENMARK-ZETIA-00261630	May Offer	403; HS; R
GDX0176	5/10/2010	Email from V. Soni to T. Hester and ccs re Revised Draft -- 11 am version and attachment	GLENMARK-ZETIA-00272688	GLENMARK-ZETIA-00272689	May Offer	HS; HWH; INC
GDX0177	5/10/2010	Email from L. Brown to T. Hester and cc re Revised agmt	WSGR-ZET002716	WSGR-ZET002717	May Offer	901; HS; HWH; INC

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0179	5/10/2010	Email from V. Soni to E. Murray, P. Matukaitis and ccs re ZETIA Settlement - Draft Press Release and attachment	GLENMARK-ZETIA-00272690	GLENMARK-ZETIA-00272695	May Offer	403; HS; HWH
GDX0182	5/10/2010	Email from V. Soni to L. Brown, P. Campanelli and ccs re ZETIA Settlement - Draft Press Release with attachment	GLENMARK-ZETIA-00323944	GLENMARK-ZETIA-00323946	May Offer	403; HS; HWH
GDX0185	5/10/2010	Email from L. Brown to T. Hester, V. Sony, E. Choy, and ccs re Zetia Settlement Agreement	GLENMARK-ZETIA-00280777	GLENMARK-ZETIA-00280782	May Offer	HS
GDX0186	5/10/2010	Order Vacating Opinion and Order Granting Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Reissue) in Schering v. Glenmark Litigation	GLENMARK-ZETIA-00145924	GLENMARK-ZETIA-00145925	May Offer	NO
GDX0187	5/10/2010	Email from P. Birdy to T. Coughlin re Zetia	GLENMARK-ZETIA-00201566	GLENMARK-ZETIA-00201567	May Offer	HS
GDX0188	5/11/2010	Email from P. Birdy to T. Coughlin re Zetia	GLENMARK-ZETIA-00201566	GLENMARK-ZETIA-00201567	May Offer	HS
GDX0189	5/11/2010	Email from G. Saldanha to T. Coughlin re Zetia	GLENMARK-ZETIA-00201568	GLENMARK-ZETIA-00201568	May Offer	NO
GDX0190	5/11/2010	Email from P. Campanelli to T. Coughlin re Ezetimibe updated with attachment	GLENMARK-ZETIA-00261527	GLENMARK-ZETIA-00261529	May Offer	403; HS
GDX0191	5/12/2010	Mylan's Invalidity and Non-Infringement Contentions in the Vytorin patent infringement litigation	MRKZETIA_SIDLEY000014259	MRKZETIA_SIDLEY000014493	May Offer	403; 901; HS; MIL
GDX0192	5/13/2010	Email from T. Hester to V. Soni and P. Matukaitis re Execution Version of Settlement Agreement with attachments	MRKZETIA_R000062162	MRKZETIA_R000062231	May Offer	403; HS
GDX0193	5/17/2010	Email from T. Hester to J. Lesser and ccs re Execution Version of Settlement Agreement with attachments	GLENMARK-ZETIA-00340388	GLENMARK-ZETIA-00340460	May Offer	403; HS; HWH
GDX0194	5/17/2010	Email from J. Cangemi to J. D'Souza and ccs re MD&A update for Q4 FY 09-10	GLENMARK-ZETIA-00264102	GLENMARK-ZETIA-00264103	May Offer	HS
GDX0196	5/19/2010	Letter from Philip Erickson from Teva to Keith Webber, regarding Amendment to ANDA 07824,	Teva-Zetia_00001483	Teva-Zetia_00001487	May Offer	403; 901; HS; INC; MIL
GDX0197	5/25/2010	Email from W. McIntyre to A. Maffia re Ezetimibe Draft DMF	GLENMARK-ZETIA-00182576	GLENMARK-ZETIA-00182577	May Offer	HS; HWH

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0198	5/27/2010	Email from V. Soni to A. Renjen and ccs re Para IV Monetization: CIM for review by counsel with attachment	GLENMARK-ZETIA-00323865	GLENMARK-ZETIA-00323884	May Offer	403; FD; HS; HWH; R
GDX0199	5/28/2010	Email from A. Gupta to M. Weinmann and ccs re Royalty monetization with attachment	GLENMARK-ZETIA-00261273	GLENMARK-ZETIA-00261328	May Offer	NO
GDX0200	6/9/2010	Email from V. Soni to E. Murray and cc re Glenmark (Ezetimibe) Table for Invoices with attachment	MRKZETIA_R000062232	MRKZETIA_R000062244	May Offer	HS; R
GDX0201	6/9/2010	Merck's June 9, 2010 reissue application for the '721 patent in support of U.S. Patent Application No. 09/594,996	USPTO-ZETIA-0001373	USPTO-ZETIA-0001387	May Offer	403; HS; MIL; R
GDX0203	6/21/2010	Email from A. Gupta to I. Bosziko and ccs re: Royalty monetization DRC:02270326	GLENMARK-ZETIA-00261113	GLENMARK-ZETIA-00261163	May Offer	403; FD; HS; HWH; R
GDX0204	6/29/2010	Email from I. Blumen to P. Matukaitis re Invoice for your approval with attachments	MRKZETIA000928921	MRKZETIA000928998	May Offer	HS
GDX0205	7/7/2010	Email from T. Coughlin to B. Mazumdar, V. Soni re PAR - wiring information	GLENMARK-ZETIA-00225149	GLENMARK-ZETIA-00225152	May Offer	NO
GDX0206	7/19/2010	Email from Muralee Krishna to Cyril Almeida and Ciji Vaithara regarding Ezetimibe 2nd source	GLENMARK-ZETIA-00184122	GLENMARK-ZETIA-00184123	May Offer	NO
GDX0208	7/20/2010	Email from C. Vaithara to M. Krishna regarding Ezetimibe 2nd source approval	GLENMARK-ZETIA-00184210	GLENMARK-ZETIA-00184210	May Offer	HS
GDX0209	7/29/2010	Email from C. Gebbia to E. Murray, T. Krause, and ccs re re Invoice from Hilton Hotel re Schering vs Glenmark Trial (Newark)	MRKZETIA000928816	MRKZETIA000928820	May Offer	HS; HWH; R
GDX0210	8/1/2010	August 2010 Merck presentation, Merck Athero Franchise: U.S. Monthly Market Monitoring	MRKZETIA000534915	MRKZETIA000534915	May Offer	403; HS; MIL; R
GDX0211	8/23/2010	Email from D. Bisaria to P. Chavakula, C. Almeida, and ccs re Ezetimibe out sourcing issue with attachment	GLENMARK-ZETIA-00251209	GLENMARK-ZETIA-00251216	May Offer	HS
GDX0214	9/9/2010	Merck's September 9, 2010 Information Disclosure Statement	USPTO-ZETIA-0007140	USPTO-ZETIA-0007146	May Offer	403; 901; MIL; R
GDX0215	10/7/2010	Ex parte Quayle Office Action filed by Examiner Mark L. Berch for Merck's reissue application for the '721 patent	USPTO-ZETIA-0013199	USPTO-ZETIA-0013205	May Offer	403; 901; MIL; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0216	10/7/2010	Examiner Mark L. Berch's list of references cited by applicant and considered by examiner on Merck's reissue application for the '721 patent, filed on October 7, 2010	USPTO-ZETIA-0013208	USPTO-ZETIA-0013232	May Offer	403; 901; MIL; R
GDX0217	10/11/2010	Email from Chavakula to Cyril Almeida; Hetal Rane; and Vikas Yadav regarding Ezetimibe DMF/GOA requirements	GLENMARK-ZETIA-00184798	GLENMARK-ZETIA-00184798	May Offer	HS
GDX0218	10/12/2010	Email from V. Soni to T. Coughlin, G. Chen re Teva meeting	GLENMARK-ZETIA-00201502	GLENMARK-ZETIA-00201502	May Offer	NO
GDX0219	10/13/2010	Email from Parasuram Chavakula to Terrance Coughlin, regarding Ezetimibe	GLENMARK-ZETIA-00219037	GLENMARK-ZETIA-00219039	May Offer	NO
GDX0220	10/27/2010	Merck presentation, 2011 Franchise Priorities	MRKZETIA000547290	MRKZETIA000547290	May Offer	403; HS; MIL; R
GDX0221	10/28/2010	Letter from FDA to Mylan re Bioequivalence Amendment for ANDA 201790	MYL_ZETIA 000048	MYL_ZETIA 000050	May Offer	901; HS
GDX0222	12/3/2010	Email from P. Shinde to V. Soni and cc re Zetia sales projections with attachment	GLENMARK-ZETIA-00220775	GLENMARK-ZETIA-00220777	May Offer	NO
GDX0223	12/7/2010	Merck's Information Disclosure Statement	USPTO-ZETIA-00013250	USPTO-ZETIA-00013256	May Offer	403; 901; MIL; R
GDX0224	12/13/2010	Facsimile to P. Erickson, Teva from L. Bradford, FDA re Quality Deficiency -- Minor ANDA 78-724	Teva-Zetia_00001758	Teva-Zetia_00001760	May Offer	403; R
GDX0225	1/1/2011	FDA Guidance for Industry Process Validation: General Principles and Practices, January 2011, pg 11			May Offer	NO
GDX0226	1/1/2011	Pharma 2020: Supplying the Future			May Offer	901; 403; HS; HWH; R
GDX0227	1/12/2011	Email from V. Soni to S. Bhawsar re Ezetimibe stage-C	GLENMARK-ZETIA-00227946	GLENMARK-ZETIA-00227947	May Offer	HS
GDX0228	1/20/2011	Examiner Mark L. Berch's list of references cited by applicant and considered by examiner on Merck's reissue application for the '721 patent, filed on January 20, 2011	USPTO-ZETIA-0023591	USPTO-ZETIA-0023597	May Offer	403; MIL; R
GDX0229	1/25/2011	Email from T. Coughlin to A. Maffia, W. McIntyre, V. Soni re Question regarding Tentative Approvals-- FDA Feedback	GLENMARK-ZETIA-00432421	GLENMARK-ZETIA-00432425	May Offer	NO
GDX0230	1/27/2011	Email from S. Mohanty to A. Maffia, J. Sharma, N. Tiwari, and ccs re Ezetimibe with new process API	GLENMARK-ZETIA-00237910	GLENMARK-ZETIA-00237912	May Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0232	3/4/2011	Original Submission Type II DMF Ezetimibe; Section 3.2.S.4.4. Batch analyses	GLENMARK-ZETIA-00310111	GLENMARK-ZETIA-00310119	May Offer	HS; INC
GDX0233	3/4/2011	Original Submission Type II DMF Ezetimibe; Section 3.2.S.2.3 Control of Materials	GLENMARK-ZETIA-00310952	GLENMARK-ZETIA-00310985	May Offer	HS; INC
GDX0234	3/4/2011	Process II batch record - 3.2.S.2 Manufacture	GLENMARK-ZETIA-00311152	GLENMARK-ZETIA000311434	May Offer	HS; INC
GDX0235	3/14/2011	Letter from Teva to K. Webber, OGD, FDA re Quality Minor Amendment / Response to Information Request	Teva-Zetia_00001752	Teva-Zetia_00001754	May Offer	NO
GDX0236	3/21/2011	Email from A. Maffia to Sasikumar K., S. Mohanty, J. Albin and ccs re Ezetimibe secondary DMF	GLENMARK-ZETIA-00203631	GLENMARK-ZETIA-00203634	May Offer	HS; HWH
GDX0237	3/22/2011	Email from A. Maffia to S. Mohanty and ccs re DMF FDA contact (New Ezetimibe process was trigger)	GLENMARK-ZETIA-00204628	GLENMARK-ZETIA-0020462830	May Offer	HS; HWH
GDX0238	3/22/2011	Email from A. Maffia to S. Brownewell re Ezetimibe Follow-up (Glenmark) [A. Maffia says they will amend the DMF for Glenmark Process I for the new name]	GLENMARK-ZETIA-00203616	GLENMARK-ZETIA-00203618	May Offer	HS
GDX0239	3/22/2011	Email from C. Finetti to L. Jakob and cc re Schering Corporation, et al. v. Glenmark Pharmaceuticals USA, Inc. - Dkt. No. 07-1334 with attachments (Amended Pretrial Order and Exhibits)	LWNSTNZETIA000017566	LWNSTNZETIA000017871	May Offer	901; HS
GDX0240	3/23/2011	Email from A. Maffia to J. Bermitz, Sasikumar K., and ccs re Submitted to FDA: Ezetimibe DMF 19717	GLENMARK-ZETIA-00204627	GLENMARK-ZETIA-00204627	May Offer	HS
GDX0242	4/15/2011	In re Tanaka, 640 F.3d 1246 (Fed. Cir. 2011)			May Offer	403; HS; R
GDX0243	4/25/2011	Letter from DHHS, DMF Acknowledgment Letter addressed to K.C. Sasikumar, acknowledging receipt for Ezetimibe	GLENMARK-ZETIA-00204790	GLENMARK-ZETIA-00204792	May Offer	NO
GDX0244	5/1/2011	Merck excel sheet with Vytorin pricing chart, ZETIA pricing chart, percentage chart, and yearly price history	MRKZETIA000614940	MRKZETIA000614940	May Offer	403; HS; MIL; R
GDX0245	5/17/2011	Summary Judgment Opinion in the Mylan Litigation, Dkt. No. 195, 09-cv-06383 (D.N.J.)	MRKZETIA_SIDLEY000160493	MRKZETIA_SIDLEY000160502	May Offer	403; HS; MIL; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0246	5/19/2011	Email from Jennifer Laux to Tammy Sprague, Kimberly Wolfe, Greg Eater and Yanina Pascual re Vytorin- Zetia Pricing with attachment	MRKZETIA000614938	MRKZETIA000614941	May Offer	403; HS; MIL; R
GDX0247	6/15/2011	Excerpts of the file wrapper for the application for reissue for the '115 patent, U.S. Patent Application No. 09/594,996	USPTO-ZETIA-0000052	USPTO-ZETIA-0001327	May Offer	HS; INC
GDX0249	7/7/2011	Email from krishnareddy@msnlabs.com to V. Soni regarding Meeting at our Office relating to pricing matters	GLENMARK-ZETIA-00237679	GLENMARK-ZETIA-00237681	May Offer	NO
GDX0250	7/11/2011	Consent Judgment for Case 2:09-cv-06383-JLL, Schering Corporation v. Teva Pharmaceuticals	Teva-Zetia_00001934	Teva-Zetia_00001936	May Offer	403; 901; HS; MIL; R
GDX0251	7/16/2011	Letter from Joyce Anne Delgaudio from Watson to Dr. Keith Webber of OGD, regarding Quality minor amendment/response to information request			May Offer	901; HS
GDX0252	7/19/2011	Email from J. Bermitz to J. Albin and ccs re LOA to DMF 024825_Ezetimibe New process API with attachment	GLENMARK-ZETIA-00203382	GLENMARK-ZETIA-00203386	May Offer	HS
GDX0253	7/20/2011	Gratuitous Preapproval Amendment, Proposal to use API manufactured by new route of synthesis, ANDA 78-560 Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00282404	GLENMARK-ZETIA-00282412	May Offer	HS
GDX0254	7/22/2011	Merck's First Amended Complaint, filed July 22, 2011 in the Mylan Litigation	MRKZETIA_SIDLEY000213145	MRKZETIA_SIDLEY000213158	May Offer	403; 901; HS; MIL; R
GDX0255	8/1/2011	Authorized Generic Drugs: Short-Term Effects and Long-Term Impact			May Offer	NO
GDX0256	8/19/2011	Correspondence from the FDA to Mylan	MYL_ZETIA013211	MYL_ZETIA013214	May Offer	403; MIL; R
GDX0257	8/22/2011	Summary Judgment Opinion by Judge Linares, filed on August 22, 2011, in Schering Corp. v. Glenmark Pharms., Inc. USA, Case No. 2:07-cv-1334 (D. NJ)			May Offer	403; HS; HWH; MIL; R
GDX0260	9/11/2011	Mylan's Amended Invalidity and Non-Infringement Contentions in the Mylan Litigation	MRKZETIA_SIDLEY000040388	MRKZETIA_SIDLEY000040495	May Offer	403; HS; MIL; R
GDX0261	9/23/2011	Revised Notice of Certification for U.S. Patent No. 5846966, RE37721 and 7612058 from Teva to the FDA	Teva-Zetia_00001903	Teva-Zetia_00001905	May Offer	403; HS; MIL; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0262	10/13/2011	Patent Amendment for U.S. Patent No. RE42461 from Teva to the FDA	Teva-Zetia_00001938	Teva-Zetia_00001939	May Offer	403; HS; MIL; R
GDX0264	10/14/2011	Email from J. Bermitz to A. Maffia, et al. regarding Received from FDA: DMF II Ezetimibe with attachment	GLENMARK-ZETIA-00217145	GLENMARK-ZETIA-00217150	May Offer	HS
GDX0265	11/21/2011	Mylan's November 21, 2011 Pretrial Brief in the Mylan Litigation	MRKZETIA_SIDLEY000235974	MRKZETIA_SIDLEY000236000	May Offer	403; HS; MIL; R
GDX0267	3/7/2012	Process II batch record - 3.2.S.2 Manufacture	GLENMARK-ZETIA-00314609	GLENMARK-ZETIA-00314891	May Offer	HS; INC
GDX0268	3/15/2012	Letter from Dr. William McIntyre to FDA, regarding enclosed amendment to Ezetimibe drug master file, outlines submission filed through Electronic Submission Gateway	GLENMARK-ZETIA-00312736	GLENMARK-ZETIA-00312736	May Offer	HS; INC
GDX0269	3/15/2012	Memo summary of a letter from Vilayat Sayeed to Dr. William McIntyre on 10/14/2011 with comments and responses regarding structure of Ezetimibe, impurity content, etc.	GLENMARK-ZETIA-00312657	GLENMARK-ZETIA-00312687	May Offer	HS
GDX0270	3/15/2012	March 15, 2012 Memo from Greg Eater to Tammy Sprague, et al. re Exception to ZETIA Medicare Part D authority-CVS/Caremark Tier 3 (#1203-15-R00)	MRKZETIA_R000084623	MRKZETIA_R000084624	May Offer	403; HS; HWH; MIL; R
GDX0272	3/20/2012	Revised Notice of Certification for U.S. Patent No. RE42461 from Teva to the FDA	Teva-Zetia_00001951	Teva-Zetia_00001953	May Offer	403; HS; MIL; R
GDX0273	3/28/2012	IPD Analytics LLC Pharma Report - Vytorin and Zetia (MRK) March 2012.pdf	HEB_ZETIA_ED00017460	HEB_ZETIA_ED00017468	May Offer	403; HS; MIL; R
GDX0274	3/30/2012	Sandoz Patent and Exclusivity Certification for Zetia Ezetimibe, Oral tablet 10 mg	SANDOZ-ZETIA-0000009	SANDOZ-ZETIA-0000010	May Offer	NO
GDX0276	4/27/2012	Email from M. Blashinsky to P. Dutra re Vytorin and Zetia Update (MRK v. MYL): District Court Issues Decision In Favor of Merck; Generic Competition Unlikely Until April 2017 (Vytorin) and December 2016 (Zetia)	GLENMARK-ZETIA-00259439	GLENMARK-ZETIA-00259441	May Offer	403; HS; MIL; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0277	4/27/2012	IPD Analytics LLC Pharma Report - Vytorin and Zetia Update (MRK v. MYL): District Court Issues Decision In Favor of Merck; Generic Competition Unlikely Until April 2017 (Vytorin) and December 2016 (Zetia)	GLENMARK-ZETIA-00241902	GLENMARK-ZETIA-00241904	May Offer	403; 701; FD; HS; HWH; R
GDX0278	4/27/2012	Opinion, Schering Corp., et al. v. Mylan Pharms., Inc., No. 09-cv-6383, ECF No. 444 (D.N.J.)	MRKZETIA000615093	MRKZETIA000615123	May Offer	403; HS; MIL; R
GDX0281	5/17/2012	Letter on behalf of W. McIntyre to FDA Center for Drug Evaluation and Research regarding Ezetimibe (Process II) as manufactured in Gujarat, India, specifically, amendment to the Drug Master File No.	GLENMARK-ZETIA-00311439	GLENMARK-ZETIA-00311439	May Offer	HS
GDX0282	6/4/2012	24825 Letter from Glenmark to OGD/FDA re ANDA 078560 Ezetimibe Tablets 10 mg, Gratuitous Preapproval Amendment - Revision of the drug substance specification for Ezetimibe in line with changes filed by the DMF holder	GLENMARK-ZETIA-00284774	GLENMARK-ZETIA-00284777	May Offer	HS
GDX0283	6/4/2012	Gratuitous Preapproval Amendment - Revision of specification of Ezetimibe in line with the changes filed by the DMF holder - ANDA 078560 Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00291003	GLENMARK-ZETIA-00291006	May Offer	HS
GDX0285	7/31/2012	Powerpoint re Cost reduction Product Review	GLENMARK-ZETIA-00205624	GLENMARK-ZETIA-00205624	May Offer	403; HS; R
GDX0286	8/3/2012	Mylan's appeal brief, filed August 3, 2012, that appealed Judge Linares's post-trial opinion in the Mylan Litigation	MRKZETIA000937429	MRKZETIA000937526	May Offer	403; HS; MIL; R
GDX0287	8/15/2012	Notice of Certification for U.S. Patent No. 7,030,106 etc. from Sandoz to the FDA	MRKZETIA000932837	MRKZETIA000932839	May Offer	HS; INC; R
GDX0288	10/1/2012	Guidance for Industry Initial Completeness Assessments for Type II API DMFs Under GDUFA			May Offer	NO
GDX0289	10/11/2012	Email from Chen to Terrance Coughlin; and Vijay Soni regarding Teva meeting	GLENMARK-ZETIA-00201502	GLENMARK-ZETIA-00201502	May Offer	HS; HWH
GDX0290	11/6/2012	November 6, 2012 Merck presentation entitled ZETIA Performance Review	MRKZETIA000598656	MRKZETIA000598656	May Offer	403; HS; HWH; MIL; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0292	11/23/2012	Glenmark PowerPoint, focusing on the company's track record, business overview and financials, including Slide 17.	GLENMARK-ZETIA-00421189	GLENMARK-ZETIA-00421189	May Offer	403; HS; MIL; R
GDX0295	12/7/2012	Email from S. Sharma to W. McIntyre, A. Maffia, and ccs re Proposal for process change - Ezetimibe	GLENMARK-ZETIA-00243854	GLENMARK-ZETIA-00243855	May Offer	HS
GDX0296	1/1/2013	M. Howard Morse, Product Market Definition in the Pharmaceutical Industry, 71 Antitrust L. J. 2 (2003)			May Offer	403; HS; MIL; R
GDX0298	2/7/2013	Merck Sharp & Dohme Corp. et al. v. Mylan Pharms. Inc., No. 2012-1434, ECF No. 49-1 (Fed. Cir. Feb. 7, 2013).			May Offer	403; HS; MIL; R
GDX0299	2/7/2013	IPD Analytics LLC Pharma Report - Vytorin and Zetia Update (MRK v. MYL): Appeals Court Upholds District Court Decision In Favor of Merck; Generic Competition Likely Prevented Until April 2017 (Vytorin) and December 2016 (Zetia)	HEB_ZETIA_ED00016599	HEB_ZETIA_ED00016600	May Offer	403; 701; FD; HS; HWH; R
GDX0300	2/20/2013	FDA Communication for Sandoz Ezetimibe Tablets In response to our email request, Mr. Robert responded that all reviews are pending for this application. Once all reviews are complete, FDA will issue a Complete Response letter. Please allow 3 to 4 months before following up again.	SANDOZ-ZETIA-0000166	SANDOZ-ZETIA-0000166	May Offer	NO
GDX0302	4/19/2013	Letter on behalf of A. Maffia to FDA Center for Drug Evaluation and Research regarding Ezetimibe (Process II) as manufactured in Gujarat, India	GLENMARK-ZETIA-00285137	GLENMARK-ZETIA-00285137	May Offer	HS
GDX0303	5/28/2013	FDA Communication for Sandoz Ezetimibe Tablets re status of the ANDA	SANDOZ-ZETIA-0000167	SANDOZ-ZETIA-0000167	May Offer	NO
GDX0305	6/3/2013	Letter from Anthony Maffia to Centre for Drug Evaluation and Research, regarding addressing product quality and submission formats	GLENMARK-ZETIA-00294445	GLENMARK-ZETIA-00294447	May Offer	HS
GDX0306	6/3/2013	Application to Market a New or Abbreviated New Drug or Biologic for Human Use - Ezetimibe Tablets - Application Number 078560	GLENMARK-ZETIA-00294448	GLENMARK-ZETIA-00294450	May Offer	HS; INC; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0307	7/23/2013	July 23, 2012 Email from Greg Eater to Glen Firestone, Jeffrey Niekelski	MRKZETIA000526189	MRKZETIA000526190	May Offer	403; HS; HWH; MIL; R
GDX0308	8/12/2013	FDA Communication for Sandoz Ezetimibe Tablets re status of the ANDA	SANDOZ-ZETIA-0000168	SANDOZ-ZETIA-0000168	May Offer	NO
GDX0309	8/14/2013	Type II DMF 24825 Ezetimibe - Process II	GLENMARK-ZETIA-00311819	GLENMARK-ZETIA-00311821	May Offer	HS; INC
GDX0312	8/15/2013	Email from J. Bermitz, et al. re Received from FDA: Ezetimibe DMF 24825 with attachment	GLENMARK-ZETIA-00216059	GLENMARK-ZETIA-00216062	May Offer	NO
GDX0315	9/27/2013	Letter from A. Maffia to Center for Drug Evaluation and Research, regarding letter outlining electronic submission of information and summary of changes with an amendment	GLENMARK-ZETIA-00311824	GLENMARK-ZETIA-00311824	May Offer	HS
GDX0316	10/18/2013	October 18, 2013 Merck presentation, Atherosclerosis Franchise Brand Review	MRKZETIA_R000092849	MRKZETIA_R000092849	May Offer	403; HS; HWH; MIL; R
GDX0317	10/31/2013	Email from J. Bermitz, et al. re Received from FDA: Ezetimibe (D067 Process) DMF 27303 with attachment	GLENMARK-ZETIA-00216370	GLENMARK-ZETIA-00216374	May Offer	HS
GDX0318	11/25/2013	Process II batch record - 3.2.S.2 Manufacture	GLENMARK-ZETIA-00309670	GLENMARK-ZETIA-00309944	May Offer	HS
GDX0319	12/12/2013	Email from Robert Gaines to Christopher Uhrn - Regulatory affairs for Sandoz, regarding review status of Ezetimibe ANDA 203931 application	SANDOZ-ZETIA-0000161	SANDOZ-ZETIA-0000161	May Offer	HS
GDX0320	12/27/2013	Certification by Dr. Sanjiv Sharma, Head of Regulatory Affairs for Glenmark Generics Limited, India, for the Ankleshwar facility.	GLENMARK-ZETIA-00312091	GLENMARK-ZETIA-00312091	May Offer	HS
GDX0321	12/28/2013	Email from S. Bhirud to C. Almeida and ccs re Ezetimibe Pre-Launch Activities	GLENMARK-ZETIA-00209303	GLENMARK-ZETIA-00209304	May Offer	HS
GDX0322	1/1/2014	Glenmark PowerPoint of the company's track record business overview, and financials	GLENMARK-ZETIA-00431200	GLENMARK-ZETIA-00431200	May Offer	403; HS; R
GDX0323	1/8/2014	Email from A. Gupta to P. Campanelli and ccs re Zetia/SFO meeting	GLENMARK-ZETIA-00428957	GLENMARK-ZETIA-00428962	May Offer	HS
GDX0324	1/15/2014	Email from M. Blashinsky to V. Yadav and cc re Ezetimibe (Zetia) Business Case with attachment	GLENMARK-ZETIA-00202256	GLENMARK-ZETIA-00202257	May Offer	HS
GDX0325	1/15/2014	Email from V. Yadav to M. Blashinsky and ccs re Ezetimibe Valuation	GLENMARK-ZETIA-00202255	GLENMARK-ZETIA-00202255	May Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0326	1/17/2014	Email from P. Shinde to A. Gupta re Ezetimibe - updated forecast	GLENMARK-ZETIA-00428279	GLENMARK-ZETIA-00428280	May Offer	403; HS; HWH; R
GDX0327	1/20/2014	Email from P. Dutra to V. Yadav, M. Blashinsky, and cc re NPV Ezetimibe 16 Jan 2014.xlsx	GLENMARK-ZETIA-00202305	GLENMARK-ZETIA-00202305	May Offer	HS
GDX0328	1/23/2014	Email from V. Yadav to P. Gioia, P. Dutra, and cc re Ezetimibe Valuation with attachment	GLENMARK-ZETIA-00202292	GLENMARK-ZETIA-00202294	May Offer	HS
GDX0329	2/10/2014	Letter from OGD, FDA to J. Domenico, Sandoz re Update summary of filed and pending original ANDA(s)	SANDOZ-ZETIA-0000129	SANDOZ-ZETIA-0000133	May Offer	NO
GDX0330	3/1/2014	Guidance for Industry CMC Postapproval Manufacturing Changes to Be Documented in Annual Reports, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) [https://www.fda.gov/media/79182/download]			May Offer	NO
GDX0331	4/17/2014	Letter from A. Maffia, Glenmark to FDA regarding Letter of Authorization for Ezetimibe (D067 Process)	GLENMARK-ZETIA-00292874	GLENMARK-ZETIA-00292874	May Offer	HS
GDX0332	4/18/2014	FDA Communication for Sandoz Ezetimibe Tablets re check of review status	SANDOZ-ZETIA-0000171	SANDOZ-ZETIA-0000171	May Offer	NO
GDX0333	5/1/2014	May 2014 Merck presentation, Competitive and Market Event Planning: Atherosclerosis Franchise	MRKZETIA_R000093176	MRKZETIA_R000093243	May Offer	403; HS; HWH; MIL; R
GDX0335	6/19/2014	Glenmark & Par Steering Committee Meeting PowerPoint re: Contractual obligations, regulatory update, Operation (API and Formulation), Commercials	GLENMARK-ZETIA-00211854	GLENMARK-ZETIA-00211854	May Offer	CU
GDX0336	6/19/2014	Glenmark & Par Steering Committee Meeting PowerPoint	GLENMARK-ZETIA-00254409	GLENMARK-ZETIA-00254409	May Offer	CU
GDX0337	6/19/2014	Presentation Given To Members of the Glenmark & Par Steering Committee	GLENMARK-ZETIA-00281305	GLENMARK-ZETIA-00281305	May Offer	CU

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0339	6/24/2014	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines," Circulation			May Offer	403; HS; MIL; R
GDX0341	7/1/2014	Email from S. Sridharan to I. Gruber regarding forwarding Par Glenmark Ezetimibe 6-19 meeting PowerPoint	GLENMARK-ZETIA-00211851	GLENMARK-ZETIA-00211853	May Offer	HS
GDX0343	7/30/2014	Powerpoint presentation reflecting Operations Overview; structures, abbreviations, interfaces, manufacturing landscape, markets, development, regulatory requirements, dosage forms, budget	GLENMARK-ZETIA-00209941	GLENMARK-ZETIA-00209941	May Offer	HS
GDX0344	8/1/2014	An Overview of FDA-approved new molecular entities: 1827-2013, Drug Discovery Today, Vol. 19, No. 8 by Michael S. Kinch, et al (August 2014)			May Offer	403; HS; R
GDX0345	9/9/2014	Powerpoint presentation reflecting Glenmark and PAR's Project Ezetimibe Steering Committee Meeting	GLENMARK-ZETIA-00178536	GLENMARK-ZETIA-00178545	May Offer	HS
GDX0346	9/10/2014	Email from S. Kaushal to S. Mungekar, M. Biju, and ccs re Ezetimibe Tablets	GLENMARK-ZETIA-00361006	GLENMARK-ZETIA-00361007	May Offer	HS
GDX0347	9/12/2014	Letter from Sudhir Kashai to Centre for Drug Evaluation and Research, regarding Withdrawal of Gratuitous Preapproval Amendment	GLENMARK-ZETIA-00292858	GLENMARK-ZETIA-00292860	May Offer	HS
GDX0348	9/16/2014	Email from D. Mhapsekar to S. Kaushal re Ezetimibe Tablets with attachments	GLENMARK-ZETIA-00348782	GLENMARK-ZETIA-00348885	May Offer	403; HS; HWH
GDX0349	9/18/2014	FDA Communication for Sandoz Ezetimibe Tablets re check of review status	SANDOZ-ZETIA-0000172	SANDOZ-ZETIA-0000172	May Offer	NO
GDX0351	10/1/2014	Email from S. Sridharan to A. Vartak re Ezetimibe API cost for process 2	GLENMARK-ZETIA-00255262	GLENMARK-ZETIA-00255264	May Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0352	10/1/2014	Terry A. Jacobson, et al., National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1 — Executive Summary, J. of Clinical Lipidology, Vol. 8, No. 5 (Oct. 2014), https://www.lipidjournal.com/article/S1933-2874(14)00274-8/pdf.			May Offer	403; HS; MIL; R
GDX0353	10/10/2014	Letter from K. Vanam to Center for Drug Evaluation and Research regarding Minor Amendment - Final Approval Request	GLENMARK-ZETIA-00283276	GLENMARK-ZETIA-00283279	May Offer	HS
GDX0354	10/16/2014	Email from A. Sagvekar to A. Sharma and ccs re Ezetimibe: MSN (21 kgs shipment to US APPCO Pharma)	GLENMARK-ZETIA-00423422	GLENMARK-ZETIA-00423436	May Offer	403; HS; HWH
GDX0355	10/17/2014	Email from Shanawaz Shaikh to Sherri Damoci, et al., regarding Ezetimibe tablets, revised leaflets, updated package labels	GLENMARK-ZETIA-00345188	GLENMARK-ZETIA-00345196	May Offer	HS
GDX0356	10/20/2014	October 18–20, 2016 email thread among David Pakula, Greg Dunlop, Theresa Covert, and Nancy Miller- Rich	MRKZETIA000510131	MRKZETIA000510132	May Offer	HS
GDX0357	10/21/2014	PowerPoint Slide Deck regarding (1) 0.3 Status; (2) Key Products for 0.4 & Beyond; (3) API Investment phasing; (4) Current bottlenecks; (5) Launch timings; and (6) Transfer of Ankleshwar to KSM to KK/Mohol	GLENMARK-ZETIA-00401823	GLENMARK-ZETIA-00401823	May Offer	403; HS
GDX0358	10/29/2014	Letter to Center for Drug Evaluation and Research from K. Varnam, regarding Gratuitous Labeling Amendment	GLENMARK-ZETIA-00283107	GLENMARK-ZETIA-00283109	May Offer	HS
GDX0359	11/20/2014	Article: Amneal Launches AG for Novo Nordisk's Activella			May Offer	403; 901; HS; R
GDX0360	12/8/2014	Email from Rane to Jalaj Sharma regarding Updated – Supply Chain Induction_July 2014.pptx	GLENMARK-ZETIA-00209940	GLENMARK-ZETIA-00209941	May Offer	HS
GDX0361	12/16/2014	Email from Sridharan to D'souza regarding [the minutes of] the Zetia meeting [the last two Joint Steering Committee Minutes] with attachments	GLENMARK-ZETIA-00281288	GLENMARK-ZETIA-00281305	May Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0362	12/23/2014	FDA Communication for Sandoz Ezetimibe Tablets re Chemistry review status	SANDOZ-ZETIA-0000173	SANDOZ-ZETIA-0000173	May Offer	NO
GDX0363	1/6/2015	Email from James Lengel to Caralee Antrosiglio re united/optum timing / approval with attachment	MRKZETIA000854696	MRKZETIA000854701	May Offer	403; HS; HWH; MIL; R
GDX0365	1/15/2015	Email from S. Sridharan to H. Rane and cc re MSN API - Ezetimibe for PAR	GLENMARK-ZETIA-00212020	GLENMARK-ZETIA-00212026	May Offer	HS
GDX0366	1/23/2015	Letter from K. Vanam to Centre for Drug Evaluation and Research, regarding email received from Martin Shiner from OGD/FDA on 1/13 and 1/15/2015. Addresses patent amendment, litigation status update.	GLENMARK-ZETIA-00292655	GLENMARK-ZETIA-00292657	May Offer	403; HS; MIL; R
GDX0367	1/23/2015	Letter from Glenmark to Merck Sharp & Dohme and MSD International re Paragraph IV Patent Certification Notice regarding U.S. Patent Nos. 7,612,058 and RE42,461 - Glenmark Generics Limited's ANDA No. 78-560 for Ezetimibe 10 mg tablets	GLENMARK-ZETIA-00286158	GLENMARK-ZETIA-00286160	May Offer	403; HS; MIL; R
GDX0368	1/23/2015	Email from M. Mathias forwarding email from M. Shimer to K. Vanam re ANDA 78560 dated January 15, 2015	GLENMARK-ZETIA-00292644	GLENMARK-ZETIA-00292646	May Offer	403; HS; MIL; R
GDX0369	1/29/2015	Email from A. Sharma to H. Rane and ccs re Ezetimibe	GLENMARK-ZETIA-00421482	GLENMARK-ZETIA-00421489	May Offer	HS
GDX0370	2/18/2015	Email from C. Calabro to I. Gruber, P. Campanelli, R. Polke, M. Bonomi, R. Surapanaene, T. Coughlin, L. Brown, M. Zrebiec, C. Gassert, M. Altamuro, and J. Bueck re Ezetimibe model for Steering Committee meeting 2/25/15 with attachment	PAR_00002329	PAR_00002330	May Offer	NO
GDX0371	2/25/2015	PowerPoint attachment to above, chart of Competitive Landscape, Historical Brand Pricing, Business Case, Molecular Landscape: Sales, Volume	GLENMARK-ZETIA-00241678	GLENMARK-ZETIA-00241678	May Offer	HS
GDX0373	2/26/2015	Email from Matt Van Allen to Jim Grauso forwarding Par-Glenmark 2-25-15 PowerPoint	GLENMARK-ZETIA-00241677	GLENMARK-ZETIA-00241677	May Offer	HS
GDX0374	3/1/2015	The Actavis Inference: Theory and Practice by Aaron Edlin, Rutgers Univ. Law Rev. 2015			May Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0375	3/2/2015	Email between Van Allen and Grauso regarding Ezetimibe model for Steering Committee meeting 2/25/15, with attachment "Copy of Ezetimibe_Zetia.xlsx."	GLENMARK-ZETIA-00156101	GLENMARK-ZETIA-00156103	May Offer	HS
GDX0376	3/4/2015	Email from S. Sridharan to T. Coughlin, P. Campanelli, I. Gruber, T. Pera, C. Gassert, M. Zrebiec, J. Bueck, M. Altamuro, C. Calabro, L. Brown, M. Bonomi, and ccs re Par- Glenmark JSC	GLENMARK-ZETIA-00178549	GLENMARK-ZETIA-00178552	May Offer	HS
GDX0377	3/16/2015	Letter from K. Vanam to FDA regarding response to email from Martin Shimer of OGD, listing previously submitted patent amendments	GLENMARK-ZETIA-00287080		May Offer	403; HS; MIL; R
GDX0380	4/29/2015	Email from P. Wagle to A. Sharma regarding Ezetimibe US, Operations plan	GLENMARK-ZETIA-00223299	GLENMARK-ZETIA-00223301	May Offer	HS
GDX0381	4/29/2015	Email from Gandhi to Jalaj Sharma; Sanjeev Krishan; Shekhar Bhaskar Bhirud; Umesh Kapre; Parasuram Chavakula; Dheeraj Bisaria; Robert Matsuk; Kalpana Vanam; and Dr. Sanjiv Sharma regarding API Ops. Update, with attachment	GLENMARK-ZETIA-00401821	GLENMARK-ZETIA-00401823	May Offer	HS
GDX0382	5/8/2015	Email from P. Wagle to Glenn Saldanha; Dr. Darshan Makhey; Robert Matsuk; Abhishek Sharma; Kalpana Vanam; Jalaj Sharma; Dr. Shekhar Bhirud; Utkarsh Gandhi; Cyril Almeida; Ram Biyani; Rajasekhara Reddy; Nitin Tiwari; Swapn Malpani; and Dr. Sanjiv Sharma regarding Ezetimibe (API + dosage) planning discussion, with attachment	GLENMARK-ZETIA-00187809	GLENMARK-ZETIA-00187811	May Offer	HS
GDX0384	5/14/2015	Email from P. Wagle to D. Makhey, et al. re Ezetimibe (API + dosage) planning discussion with attachment	GLENMARK-ZETIA-00184432	GLENMARK-ZETIA-00184435	May Offer	HS
GDX0385	5/14/2015	Environmental Consideration: Environmental Assessment (EA) or Claim of Categorical Exclusion (§ 314.94(A)(9))	GLENMARK-ZETIA-00285248	GLENMARK-ZETIA-00285248	May Offer	HS; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0386	5/15/2015	Email from P. Wagle to V. Soni re Ezetimibe (API + dosage) planning discussion	GLENMARK-ZETIA-00187809	GLENMARK-ZETIA-00187811	May Offer	HS
GDX0387	5/18/2015	Email from S.Sridharan to P. Wagle, regarding MOM of last meeting with Par with attachments	GLENMARK-ZETIA-00178532	GLENMARK-ZETIA-00178552	May Offer	NO
GDX0388	5/18/2015	Letter from K. Vanam, Glenmark to FDA re General Information: Administrative/Change in Agent Name; General Information: Administrative/Change in Holder Name: Internal Name Change; Original: Quality/Facility Information	GLENMARK-ZETIA-00308240	GLENMARK-ZETIA-00308243	May Offer	403; HS; R
GDX0389	5/21/2015	Application to Market a New or Abbreviated New Drug or Biologic for Human Use - Ezetimibe Tablets - Application Number 078560	GLENMARK-ZETIA-00294508	GLENMARK-ZETIA-00294511	May Offer	HS; R
GDX0392	5/25/2015	Elizabeth F. Lindquist, Country of Origin Compliance for Federal Pharmaceutical Contracts			May Offer	403; HS; R
GDX0393	6/1/2015	Letter to K. Vanam from Leigh Ann Sears, Center for Drug Evaluation and Research, regarding recommendation to adopt a limit on impurities in Ezetimibe.	GLENMARK-ZETIA-00287548	GLENMARK-ZETIA-00287549	May Offer	403; HS; R
GDX0394	6/5/2015	Letter from K. Vanam to FDA regarding responding to information request regarding Ezetimibe	GLENMARK-ZETIA-00287440	GLENMARK-ZETIA-00287443	May Offer	403; HS; R
GDX0395	6/5/2015	Application to Market a New or Abbreviated New Drug or Biologic for Human Use - Ezetimibe Tablets - Application Number 078560	GLENMARK-ZETIA-00287444	GLENMARK-ZETIA-00287449	May Offer	403; HS; R
GDX0396	6/5/2015	ANDA 078560 Ezetimibe Tablets, 10 mg - Information Request - Product Quality #118127	GLENMARK-ZETIA-00287483	GLENMARK-ZETIA-00287490	May Offer	403; HS; R
GDX0398	6/9/2015	Email from S. Sridharan to R. Matsuk et al re Glenmark-Par JSC	GLENMARK-ZETIA-00256664	GLENMARK-ZETIA-00256665	May Offer	HS
GDX0399	6/10/2015	Ezetimbe Steering Committee Meeting PowerPoint from Par	GLENMARK-ZETIA-00201965	GLENMARK-ZETIA-00201965	May Offer	HS
GDX0400	6/16/2015	Email from S. Sridharan to M. Van Allen et al. regarding Notes and actions items from JSC, with attachments	GLENMARK-ZETIA-00201963	GLENMARK-ZETIA-00201977	May Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0403	6/26/2015	Email from C. Capella to M. Van Allen, J. Grauso, H. Rizkalla, R. Matsuk, K. Vanam, A. Abdul, and V. Soni re Received from FDA: Ezetimibe Tablets, 10 mg with attachment	GLENMARK-ZETIA-00304369	GLENMARK-ZETIA-00304374	May Offer	NO
GDX0404	6/30/2015	Email from pavan@msnlabs.com to Prateek Vijaivargia regarding Qty for Launch, including the delivery schedules and requirements, accompanied by MSN's responses to each schedule, launch and monthly requirement.	GLENMARK-ZETIA-00251924	GENMARK-ZETIA-00251928	May Offer	HS
GDX0405	7/7/2015	Email from S. Sridharan to M. Van Allen regarding JSC notes - Endo acquisition, Regulatory, Operation, API/tablets de-risking	GLENMARK-ZETIA-00200253	GLENMARK-ZETIA-00200254	May Offer	HS
GDX0406	7/7/2015	Letter from Kalpana Vanam at Glenmark to Centre for Drug Evaluation and Research regarding Prior Approval Supplement regarding alternate source/manufacturer	GLENMARK-ZETIA-00283486	GLENMARK-ZETIA-00283492	May Offer	NO
GDX0408	7/10/2015	Letter from Kalpana Vanam at Glenmark to Centre for Drug Evaluation and Research regarding Prior Approval Supplement	GLENMARK-ZETIA-00285269	GLENMARK-ZETIA-00285276	May Offer	NO
GDX0409	7/10/2015	Application to Market a New or Abbreviated New Drug or Biologic for Human Use - Ezetimibe Tablets - Application Number 078560	GLENMARK-ZETIA-00285277	GLENMARK-ZETIA-00285283	May Offer	HS
GDX0410	7/13/2015	Email from Laura Forino to Crystal Spinks, cc: Kalpana Vanam, regarding Payment confirmation to pay.gov for FDA User fees of $29,370.00	GLENMARK-ZETIA-00290991	GLENMARK-ZETIA-00290991	May Offer	HS
GDX0411	7/29/2015	Email from S. Sridharan to P. Wagle, V. Soni, J. Grauso, and ccs re Ezetimibe Open Items	GLENMARK-ZETIA-00304352	GLENMARK-ZETIA-00304355	May Offer	HS; HWH
GDX0412	8/1/2015	Response to the DMF Information Request Dated June 19, 2014 Received From USFDA on Ezetimibe USDMF	GLENMARK-ZETIA-00391829	GLENMARK-ZETIA-00391933	May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0415	8/6/2015	Glenmark Slide Deck regarding (1) Ezetimibe Overview; (2) Updates; (3) FP Capacity; (4) Strategy; and (5)Ezetimibe Regulatory Overview (Native File)	GLENMARK-ZETIA-00184224	GLENMARK-ZETIA-00184224	May Offer	NO
GDX0417	8/19/2015	Letter to K. Vanam to OGD, regarding response to questions in the agency's deficiency letter dated 8/12/15	GLENMARK-ZETIA-00294378	GLENMARK-ZETIA-00294380	May Offer	NO
GDX0418	8/21/2015	Letter to FDA Centre for Drug Evaluation and Research from C. Spinks, Ph.D. on behalf of K. Vanam regarding alternate manufacturing facilities for ANDA # 078560 – Ezetimibe Tablets, 10 mg	GLENMARK-ZETIA-00286187	GLENMARK-ZETIA-00286193	May Offer	HS
GDX0419	8/26/2015	Email from H. Rane to C. Jethva and ccs re URGENT: Ezetimibe API - MSN - XRD test related with attachments	GLENMARK-ZETIA-00192652	GLENMARK-ZETIA-00192704	May Offer	HS; HWH
GDX0421	8/28/2015	Application to Market a New or Abbreviated New Drug or Biologic for Human Use - Ezetimibe Tablets - Application Number 078560	GLENMARK-ZETIA-00287391	GLENMARK-ZETIA-00287395	May Offer	HS
GDX0422	9/4/2015	Email from S. Mungekar to K. Vanam; Dr. S. Sharma, and M. Biju, et al., regarding FDA call – General guidance	GLENMARK-ZETIA-00283390	GLENMARK-ZETIA-00283391	May Offer	HS; INC
GDX0423	9/9/2015	Letter from Paul Schwartz, Center for Drug Evaluation and Research to K. Vanam, regarding Supplemental ANDA approved	GLENMARK-ZETIA-00287542	GLENMARK-ZETIA-00287543	May Offer	NO
GDX0425	9/10/2015	Letter from Paul Schwartz, Center for Drug Evaluation and Research to K. Vanam, regarding Supplemental ANDA approved	GLENMARK-ZETIA-00287538	GLENMARK-ZETIA-00287539	May Offer	NO
GDX0426	9/19/2015	Email from V. Soni to J. Grauso re Ezetimibe with attachments	GLENMARK-ZETIA-00176902	GLENMARK-ZETIA-00176906	May Offer	HS; HWH
GDX0427	9/24/2015	Email from A. Mehta to V. Soni, R. Matsuk, P. Chainani and cc re Ezetimibe Par Model with attachments	GLENMARK-ZETIA-00178560	GLENMARK-ZETIA-00178562	May Offer	HS
GDX0428	10/8/2015	Powerpoint re ZETIA Proposed LOE Contracting Strategy	MRKZETIA_R000055856	MRKZETIA_R000055856	May Offer	HS
GDX0429	10/30/2015	Email from C. Almeida to M. Karnik, S. Kamath, D. Upadhyay, N. Kothari, S. Bhawsar, and ccs re Visit to MSN - Hyderabad with attachments	GLENMARK-ZETIA-00277379	GLENMARK-ZETIA-00277386	May Offer	HS; HWH

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0431	12/8/2015	Email from N. Kothari to R. Ram and ccs re Ezetimibe (D067 Process) - Gap Analysis with attachments	GLENMARK-ZETIA-00414637	GLENMARK-ZETIA-00414961	May Offer	HS
GDX0432	1/1/2016	Spreadsheet containing sales forecasts for ezetimibe 10 mg by Teva USA	Teva-Zetia_00003525	Teva-Zetia_00003525	May Offer	HS
GDX0433	1/1/2016	Powerpoint presentation reflecting Glenmark's Company Overview, Financial Overview, Business Overview, Manufacturing Capabilities, Drug Discovery and Research, Corporate Functions	GLENMARK-ZETIA-00177417	GLENMARK-ZETIA-00177417	May Offer	HS
GDX0435	1/19/2016	Email from P. Wagle to V. Soni re Par-Glenmark JSC	GLENMARK-ZETIA-00186776	GLENMARK-ZETIA-00186781	May Offer	HS; HWH
GDX0436	2/16/2016	Letter from FDA to Sandoz re Tentative Approval for Ezetimibe Tablets 10 mg	SANDOZ-ZETIA-0000147	SANDOZ-ZETIA-0000149	May Offer	NO
GDX0437	3/9/2016	TPMG Pharmacy & Therapeutics Committee and Formulary Subcommittee Combined Meeting Minutes	KP_ZETIA_000012	KP_ZETIA_000019	May Offer	403; HS; MIL; R
GDX0438	4/4/2016	Email from P. Wagle to A. Desai regarding attaching Par-Glenmark JSC March 2016 PowerPoint, with attachment	GLENMARK-ZETIA-00186672	GLENMARK-ZETIA-00186673	May Offer	HS
GDX0439	4/26/2016	Letter from K. Vanam to FDA-OGD regarding Change in packaging facility for Ezetimibe from Somerset to Piscataway of Appco Pharma	GLENMARK-ZETIA-00287093	GLENMARK-ZETIA-00287096	May Offer	HS
GDX0440	5/1/2016	Glenmark Pharmaceuticals Limited - Corporate Overview	GLENMARK-ZETIA-00213696	GLENMARK-ZETIA-00213696	May Offer	HS
GDX0441	5/4/2016	Letter from K. Vanam to Center for Drug Evaluation and Research regarding Supplement-Changes Being Effected in 30 Days, listing documents provided with submission	GLENMARK-ZETIA-00300727	GLENMARK-ZETIA-00300730	May Offer	HS
GDX0442	6/3/2016	Letter from Avani Patel of FDA to Kalpana Vanam, regarding information request from Product Quality section of Glenmark's request	GLENMARK-ZETIA-00284886	GLENMARK-ZETIA-00284888	May Offer	HS
GDX0443	6/9/2016	Letter from K. Vanam to A. Patel at FDA, responding to the agency's information request CBE-30 deficiency letter	GLENMARK-ZETIA-00186551	GLENMARK-ZETIA-00186552	May Offer	HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0444	6/9/2016	Letter from Glenmark to FDA regarding Information Request Product Quality Ref.# 8312958	GLENMARK-ZETIA-00186553	GLENMARK-ZETIA-00186557	May Offer	HS
GDX0445	6/22/2016	Powerpoint Presentation from P. Wagle entitled, "Ezetimibe US Launch Update"	GLENMARK-ZETIA-00198777	GLENMARK-ZETIA-00198777	May Offer	HS
GDX0446	6/27/2016	Email from S. Gupte to K. Vanam re Approval Letter - Ezetimibe with attachments	GLENMARK-ZETIA-00361370	GLENMARK-ZETIA-00361376	May Offer	NO
GDX0448	8/4/2016	Letter from K. Vanam to Center for Drug Evaluation and Research, regarding authorizing Glenmark Pharmaceuticals Limited and FDA to review information in DMF 24825, ANDA 078560 and that information remain confidential	GLENMARK-ZETIA-00360136	GLENMARK-ZETIA-00360136	May Offer	HS
GDX0449	8/23/2016	Glenmark PowerPoint Deck entitled, "Ezetimibe US Launch Update."	GLENMARK-ZETIA-00178602	GLENMARK-ZETIA-00178602	May Offer	HS
GDX0450	8/24/2016	Email chain from Amish Desai to Prateek Vijaivargia regarding Ezetimibe API Procurement – 300 kg.	GLENMARK-ZETIA-00251634	GLENMARK-ZETIA-00251640	May Offer	HS
GDX0451	10/5/2016	Email from I. Gruber to A. Desai regarding Ezetimibe – Launch Plan, including internal communications originally initiated on July 30, 2015	GLENMARK-ZETIA-00178649	GLENMARK-ZETIA-00178661	May Offer	NO
GDX0453	10/18/2016	Email from R. Matsuk to T. Coughlin re Ezetimibe	GLENMARK-ZETIA-00430747	GLENMARK-ZETIA-00430747	May Offer	HS; HWH
GDX0454	10/20/2016	Quality guidelines by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)			May Offer	403; HS
GDX0455	11/18/2016	IPD Analytics Rx Insights_Zetia-Vytorin	HEB_ZETIA_ED00001644	HEB_ZETIA_ED00001647	May Offer	403; 701; FD; HS; HWH; R
GDX0458	12/13/2016	Letter to Center for Drug Evaluation and Research from K. Varnam, regarding application enclosures for 180 days Ezetimibe exclusivity	GLENMARK-ZETIA-00287559	GLENMARK-ZETIA-00287560	May Offer	HS
GDX0459	1/1/2017	Fall Newsletter - PHSI Analysis of Authorized Generic Drugs by Pharmacy Healthcare Solutions, LLC			May Offer	403; 901; HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0460	1/3/2017	Email from C. Sowa to S. Mock, T. Pera, P. Campanelli, B. Coleman, J. Morales, R. Valiga, J. Holden, M. Altamuro, C. Calabro, and cc re Quetiapine ER and Ezetimibe - Market Share & Generic Conversion - 1.03.2017 with attachment	PAR_00008470	PAR_00008472	May Offer	HS; HWH
GDX0461	1/5/2017	Email from R. Lasser to R. Sharma and cc re Ezetimibe - units shipped	PAR_00021226	PAR_00021230	May Offer	HS; HWH
GDX0463	3/23/2017	Email from C. Degnan to P. Campanelli, B. Coleman, T. Pera, J. Morales, P. Barry, S. Mock, L. Smith, D. Rudio, J. Boyle, R. Valiga and cc re March Latest View with attachment	PAR_00009672	PAR_00009688	May Offer	HS; HWH
GDX0464	4/28/2017	Email from R. Valiga to T. Coughlin, T. Pera, J. Barbarite, M. Altamuro, T. Basso, V. Chavarria, J. Holden, S. Sims, B. Rockwell, and ccs re U.S. Generics Q1'17 Results & FY'17 Board Approved April LBE Overview with attachments	PAR_00020287	PAR_00020311	May Offer	HS; HWH
GDX0465	4/3/2017	Letter from FDA to Rajiv Malik of Mylan, regarding outlining violations of manufacturing process			May Offer	403
GDX0466	5/1/2017	Glenmark Chief Bullish Despite Generic Zetia's Poor US Start, Scrip Intelligence			May Offer	403; HS; HWH
GDX0467	5/12/2017	Glenmark Pharma, High erosion in base business and lower debt reduction keep us cautious			May Offer	403; 901; HS; HWH
GDX0468	5/13/2017	Glenmark scrip tanks on results shock			May Offer	403; 901; HS; HWH
GDX0469	5/15/2017	Email from D. Gan to D. Jankiewicz, K. Hayward, M. Exume, D. Pakula re Scrip / Today's News & Analysis	MRKZETIA000854327	MRKZETIA000854332	May Offer	403; 901; HS; HWH
GDX0470	5/17/2017	Glenmark Zetia Sales, Glenmark falters no generic Zetia losing steam midway through exclusivity			May Offer	403; 901; HS; HWH
GDX0471	6/4/2017	Glenmark Pharmaceuticals: Long road to recovery			May Offer	403; 901; HS; MIL; R
GDX0472	6/12/2017	Letter from Dept. of Health and Human Services to Teva approving ANDA for Ezetimibe Tablets USP, 10 mg	Teva-Zetia_00003520	Teva-Zetia _00003523	May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0473	6/12/2017	Letter from Dept. of Health and Human Services to Watson approving ANDA for Ezetimibe Tablets USP, 10 mg	Watson-Zetia _00011753	Watson-Zetia_00011756	May Offer	NO
GDX0474	6/12/2017	Letter from FDA to Sandoz re ANDA Approval for Ezetimibe Tablets 10 mg	SANDOZ-ZETIA-0000151	SANDOZ-ZETIA-0000154	May Offer	NO
GDX0477	1/1/2018	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA /AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines," Journal of the American College of Cardiology			May Offer	403; 901; HS; MIL; R
GDX0478	3/28/2018	What We Do (March 28, 2018), https://www.fda.gov/about-fda/what-we-do.			May Offer	403; 901; HS; R
GDX0479	6/13/2018	Insight: Orange, Purple Book Patentees Hone PTAB Survival Skills, Bloomberg Law, Vol. 17, (June 13, 2018)			May Offer	403; 901; HS
GDX0480	6/13/2018	Copy of Filko Prugo, et al., 17 BNA PATENT, TRADEMARK & COPYRIGHT J. 1 (2018)			May Offer	403; 901; HS
GDX0481	12/17/2018	Powerpoint re Zetia/Vytorin - LROP Price Plan	MRKZETIA000517429	MRKZETIA000517429	May Offer	403; HS; MIL
GDX0482	1/1/2019	Katherine Eban, Bottle of Lies: The Inside Story of the Generic Drug Boom			May Offer	403; 901; HS; INC; MIL
GDX0483	1/31/2019	Ari Altstedter and Anna Edney, Culture of 'Bending Rules' in India Challenges U.S. Drug Agency			May Offer	403; 901; HS; HWH; MIL
GDX0484	5/1/2019	Nachajski, M.J., et al., Effect of API on Powder Flowability, Direct Compression and Properties of Orally Disintegrating Tablets: A Preformulation Study, Medical University of Lodz, Poland, Muszynkiego			May Offer	403; 901; HS; HWH
GDX0485	6/5/2019	Plaintiffs' Responses and Objections to Defendants' Second Set of Interrogatories to Plaintiffs			May Offer	403

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0487	7/22/2019	Dinesh Thakur, The Indian pharmaceutical industry is in denial over drug-quality charges, STAT			May Offer	403; 901; HS; HWH; MIL
GDX0488	8/9/2019	Report from European Medicines Agency by the Committee for Human Medicinal Products, regarding ICH Guideline Q3C (R6) on impurities: guideline for residual solvents, at 8			May Offer	403; 901; HS; MIL
GDX0489	9/4/2019	Designated testimony from the deposition William Johnson, taken on September 4, 2019			May Offer	30B6; 403; 602; 701; AA; AF; AR; CF; CLC; CQ; HS; HWH; IH; MIL; MS; OBJ; R
GDX0490	9/11/2019	Designated testimony from the deposition Patrick Davish, taken on September 11, 2019			May Offer	30B6; 403; 602; 611; 701; AA; BTS; CQ; FD; HS; HWH; IH; MC; MIL; OBJ; OO; R
GDX0491	9/18/2019	Designated testimony from the deposition Owen McMahon, taken on September 18, 2019			May Offer	30B6; 403; 602; 611; 701; AA; AF; CF; CLC; FD; HS; HWH; MIL; OBJ; R
GDX0492	9/26/2019	Designated testimony from the deposition Paul Dutra, taken on September 26, 2019			May Offer	403; 602; 611; 701; AA; FD; HS; HWH; IH; MC; MIL; MS; NR; OBJ; R; STR
GDX0493	10/3/2019	Designated testimony from the deposition Luis Vazquez, taken on October 3, 2019			May Offer	403; 602; 611; 1002; AA; AF; CF; CU; ER; HS; HWH; INC; MC; MIL; R
GDX0494	10/7/2019	Plaintiffs' Supplemental Responses and Objections to Defendants' First Set of Requests for Admission to Plaintiffs			May Offer	403
GDX0495	10/7/2019	Plaintiffs' Supplemental Responses and Objections to Defendants' Second Set of Interrogatories to Plaintiffs			May Offer	403
GDX0496	10/7/2019	End-Payor Plaintiffs' Supplemental Responses to Objections to Defendants' First Set of Interrogatories to Plaintiffs			May Offer	403

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0497	10/9/2019	Designated testimony from the deposition Scott Johnson, taken on October 9, 2019			May Offer	30B6; 403; 602; 702; CF; CLC; CQ; FD; HS; HWH; MIL; OBJ; R
GDX0499	10/15/2019	Designated testimony from the deposition of Timothy Hester, taken on October 15, 2019.			May Offer	403; 602; FD; HS; HWH; INC; MC; MIL; MS; NR; OBJ; OO; PM; R; STR
GDX0501	10/16/2019	Designated testimony from the deposition of Vijay Soni, taken on October 16, 2019.			May Offer	403; 602; 611; AA; AF; AR; BTS; CF; CU; CQ; FD; HS; HWH; MC; MIL; MS; NR; OBJ; OO; R; STR
GDX0503	10/17/2019	Testimony from the deposition of Paresh Wagle, taken on October 17, 2019			May Offer	30B6; 403; 602; 611; 701; BTS; FD; CF; CQ; CU; HS; HWH; INC; MC; MIL; MS; NR; OO; R
GDX0504	10/17/2019	Designated testimony from the deposition Rajkiran Jain, taken on October 17, 2019			May Offer	30B6; 403; 602; 611; 701; 702; AF; AR; BTS; CF; FD; HS; HWH; INC; MC; MIL; MS; NR; OO; R; STR
GDX0505	10/18/2019	Designated testimony from the deposition of Paul Matukaitis, taken on October 18, 2019.			May Offer	403; 602; CF; CU; HS; HWH; MC; MS; NR; OBJ; PM; STR
GDX0508	10/24/2019	Designated testimony from the deposition of Lawrence M. Brown, taken on October 24, 2019.			May Offer	403; 602; 611; 901; CF; FD; HS; HWH; IH; MC; MS; NR; OBJ; OO; R; STR
GDX0509	10/29/2019	Designated testimony from the deposition Zachary Mikulak, taken on October 29, 2019			May Offer	30B6; 403; 602; 702; AA; AF; CF; CLC; CQ; HS; HWH; IH; MC; OBJ; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0510	10/29/2019	Designated testimony from the deposition of John Kovaleski, the 30(b)(6) Designee for Non-Party Teva.			May Offer	403; HS; HWH
GDX0513	11/12/2019	Designated testimony from the deposition of David Mitchell, taken on November 12, 2019.			May Offer	30B6; 403; 602; 611; 701; 702; AA; AF; CF; CLC; CQ; FD; HS; HWH; IH; MIL; MS; R
GDX0515	11/19/2019	Designated testimony from the deposition of Teletha G. Brown, the 30(b)(6) Designee for Non-Party Sandoz.			May Offer	403; HS; HWH
GDX0517	11/26/2019	Designated testimony from the deposition of Lisa Jakob, taken on November 26, 2019.			May Offer	30B6; 403; 602; 611; 701; CF; CLC; HS; FD; HS; HWH; MC; MIL; MS; NR; OBJ; PM; R
GDX0518	12/6/2019	Designated testimony from the deposition Paul Campanelli, taken on December 6, 2019			May Offer	403; 602; CU; FD; HS; HWH; MC; MS; NR; OBJ; OO; R
GDX0519	12/19/2019	FDA Listing of Authorized Generics as of December 19, 2019			May Offer	R
GDX0520	1/13/2020	Expert Report of Jon Clark			May Offer	NO
GDX0521	1/13/2020	Expert Report of Todd Clark and backup data			May Offer	NO
GDX0522	1/13/2020	Expert Report of Joseph Dellaria			May Offer	NO
GDX0523	1/13/2020	Expert Report of Robert Hrubiec			May Offer	NO
GDX0524	1/13/2020	Expert Report of Russell Lamb (Merits) and backup data			May Offer	NO
GDX0525	1/13/2020	Expert Report of Keith Leffler (Merits) and backup data			May Offer	NO
GDX0526	1/13/2020	Expert Report of Jeffrey Leitzinger (Merits) and backup data			May Offer	NO
GDX0527	1/13/2020	Expert Report of Susan Marchetti			May Offer	NO
GDX0529	1/13/2020	Expert Report of James Miller and backup data			May Offer	NO
GDX0530	1/13/2020	Expert Report of Luis Molina			May Offer	NO
GDX0531	1/13/2020	Expert Report of Meredith Rosenthal and backup data			May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0532	1/13/2020	Expert Report of Arthur Schwartzbard and backup data			May Offer	NO
GDX0533	1/13/2020	Expert Report of Martha Starr			May Offer	NO
GDX0534	1/13/2020	Expert Report of Shashank Upadhye			May Offer	403; HS; R
GDX0535	1/13/2020	Biographical information for Antitrust Consultant, Susan Marchetti	Marchetti Dep Ex. 3		May Offer	R
GDX0536	2/20/2020	Webpage by Glenmark Life Sciences, titled Product List			May Offer	403; 901; R
GDX0537	2/24/2020	FDA webpage providing guidance regarding Drug Master Files			May Offer	403; R
GDX0538	2/24/2020	Ranbaxy whistleblower reveals how he exposed massive pharmaceutical fraud, CBSNews			May Offer	403; 901; HS; HWH; R
GDX0539	2/28/2020	Expert Report of Sumanth Addank and backup data			May Offer	403; HS; HWH; R
GDX0540	2/28/2020	Expert Report of Robert Armitage and backup data			May Offer	403; HS; HWH; R
GDX0541	2/28/2020	Expert Report of Sergio Fazio			May Offer	403; HS; HWH; R
GDX0542	2/28/2020	Expert Report of Anthony Figg			May Offer	403; HS; HWH; R
GDX0543	2/28/2020	Expert Report of Anupam Jena and backup data			May Offer	403; HS; HWH; MIL; R
GDX0544	2/28/2020	Expert Report of Nancy Linck			May Offer	403; HS; HWH; R
GDX0545	2/28/2020	Expert Report of Elizabeth Lindsey			May Offer	403; HS; HWH; R
GDX0546	2/28/2020	Expert Report of Timothy Maloney			May Offer	403; HS; HWH; R
GDX0547	2/28/2020	Expert Report of Alan Millar and backup data			May Offer	403; HS; HWH; R
GDX0548	2/28/2020	Expert Report of Mark Robbins			May Offer	403; HS; HWH; MIL; R
GDX0549	2/28/2020	Expert Report of William Rousch			May Offer	403; HS; HWH; R
GDX0550	2/28/2020	Expert Report of Lauren Stiroh and backup data			May Offer	403; HS; HWH; R
GDX0551	2/28/2020	Expert Report of Bruce Strombom (Merits) and backup data			May Offer	403; HS; HWH; R
GDX0552	2/28/2020	Expert Report of Deepak Tareja and backup data			May Offer	403; HS; HWH; R
GDX0553	2/28/2020	Expert Report of Jeffrey Winkler and backup data			May Offer	403; HS; HWH; R
GDX0554	3/10/2020	Testimony from the deposition of Lauren Stiroh, March 10, 2020			May Offer	403; 602; 701; 702; 703; FD; HS; HWH; NR; R
GDX0555	3/13/2020	Testimony from the deposition of Robert Armitage, taken on March 13, 2020			May Offer	403; 602; 702; 703; HS; HWH; MIL; NR; R

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0556	3/13/2020	Testimony from the deposition of Sumanth Addanki, March 13, 2020			May Offer	403; 602; 702; 703; FD; HS; HWH; MIL; R
GDX0557	4/20/2020	Supplemented Expert Report of Dr. Deepak Talreja			May Offer	403; HS; HWH; R
GDX0558	4/27/2020	Testimony from the deposition of Mark Robbins, taken on April 27, 2020			May Offer	403; 602; 702; 703; DB; FD; HS; HWH; MIL; NR; R; STR
GDX0559	4/29/2020	Testimony from the deposition of Nancy Linck, taken on April 29, 2020			May Offer	403; 602; 701; 702; 703; FD; HS; HWH; NR; MIL; R
GDX0560	4/29/2020	Testimony from the deposition of Sergio Fazio, taken on April 29, 2020			May Offer	403; 602; 702; 703; FD; HS; HWH; MIL; NR; STR; R
GDX0561	5/8/2020	Rebuttal Report of Jon Clark			May Offer	NO
GDX0562	5/8/2020	Expert Rebuttal Report of Joseph Dellaria			May Offer	NO
GDX0563	5/8/2020	Expert Rebuttal Report of Robert Hurbiec			May Offer	NO
GDX0564	5/8/2020	Expert Rebuttal Report of Russell Lamb (Merits)			May Offer	NO
GDX0565	5/8/2020	Expert Rebuttal Report of Keith Leffler (Merits)			May Offer	NO
GDX0566	5/8/2020	Expert Rebuttal Report of Jeffrey Leitzinger (Merits)			May Offer	NO
GDX0567	5/8/2020	Expert Rebuttal Report of Thomas McGuire			May Offer	NO
GDX0568	5/8/2020	Expert Rebuttal Report of James Miller			May Offer	NO
GDX0569	5/8/2020	Expert Rebuttal Report of Luis Molina			May Offer	NO
GDX0570	5/8/2020	Expert Rebuttal Report of Meredith Rosenthal			May Offer	NO
GDX0571	5/8/2020	Expert Rebuttal Report of Arthur Schwartzbard			May Offer	NO
GDX0572	5/8/2020	Expert Rebuttal Report of Martha Starr			May Offer	NO
GDX0573	5/8/2020	Expert Rebuttal Report of Shashank Upadhye			May Offer	NO
GDX0574	6/11/2020	Testimony from the deposition of Timothy Maloney, taken on June 11, 2020			May Offer	403; 702; 703; 602; AF; FD; HS; HWH; NR; R; STR
GDX0575	6/18/2020	Expert Rebuttal Report of Todd Clark			May Offer	NO

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0576	6/18/2020	Expert Rebuttal Report of Susan Marchetti			May Offer	NO
GDX0577	2007-2011	Spreadsheet showing Merck's litigation expenses in the Glenmark Litigation	MRKZETIA_R000061376	MRKZETIA_R000061376	May Offer	403; 901; FD; HS; MIL; R
GDX0578	2011-2014	Spreadsheet showing Merck's expenses in the Mylan Litigation	MRKZETIA_R000061377	MRKZETIA_R000061377	May Offer	403; 901; FD; HS; MIL; R
GDX0579		U.S. Patent No. 7,030,106-B2			May Offer	403; HS; MIL; R
GDX0580		U.S. Patent No. RE37,721-E1			May Offer	403; R
GDX0581		U.S. Patent No. RE37,721	USPTO-ZETIA-0001319	USPTO-ZETIA-0001322	May Offer	403; R
GDX0582		U.S. Patent No. RE42,461	USPTO-ZETIA-0013199	USPTO-ZETIA-00131205	May Offer	403; 901; MIL; R
GDX0583		U.S. Patent No. 5,631,365 with USPTO Certification Cover	USPTO-ZETIA-0000001	USPTO-ZETIA-0000026	May Offer	NO
GDX0584		U.S. Patent No. 5,767,115	MRKZETIA_SIDLEY0052278	MRKZETIA_SIDLEY0052279	May Offer	403; 901; HS; R
GDX0585		WO 93/02048			May Offer	NO
GDX0586		Original Submission ANDA Ezetimibe Tablets 10 mg - Section VIII: Raw Materials	GLENMARK-ZETIA-00298655	GLENMARK-ZETIA-00298819	May Offer	NO
GDX0587		Original Submission ANDA Ezetimibe Tablets 10 mg - Section III: Patent Certification [21 CFR 314.94(a)(12)] and Exclusivity Statement [21 CFR 314.94(a)(3)(ii)]	GLENMARK-ZETIA-00299147	GLENMARK-ZETIA-00299157	May Offer	901; HS
GDX0588		Type II DMF 24825 Ezetimibe - Process II, Response to Nov. 19, 2012 Letter	GLENMARK-ZETIA-00312066	GLENMARK-ZETIA-00312086	May Offer	403; 901; HS; R
GDX0589		Spreadsheet of Estimated Glenmark Financials 4/26/17 through 6/9/17	MRKZETIA000509916	MRKZETIA000509916	May Offer	NO
GDX0590		Teva Full Product Catalog			May Offer	403; 901; R
GDX0591		National Drug Code Directory			May Offer	403; 901; R
GDX0592		U.S. Patent No. 5,631,365			May Offer	NO
GDX0593		U.S. Patent No. 6,207,822			May Offer	403; MIL; R
GDX0594		U.S. Patent No. 8,013,150			May Offer	403; MIL; R
GDX0595		U.S. Patent No. 8,178,665			May Offer	403; MIL; R
GDX0596	1982	Asymmetric Alkylation Reactions of Chiral Imide Enolates. A Practical Approach to the Enantioselective Synthesis of a Substituted Carboxyllic Acid Deriatives, American Chemical Society, J. Am. Chem. Soc. 1982, 104, 1737-1739 by D.A. Evans, M.D. Enmis and D.J. Mathre (1982)			May Offer	901; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0597	2008	Generic entry, price competition, and market segmentation in the prescription drug market by Tracy Regan (2008)			May Offer	901; HS; MIL; UT
GDX0598	2011	Reference Guide on Estimation of Economic Damages, Reference Manual on Scientific: Third Edition by Mark Allen, et al. (2011)			May Offer	901; HS; MIL; UT
GDX0599	2/12/2016	Innovation in the pharmaceutical industry: New estimates of R&D costs by Joseph DiMasi, et al. (2016)			May Offer	901; HS; MIL; UT
GDX0600	2/13/1963	In re Handel, 312 F.2d 943 (C.C.P.A. 1963)			May Offer	R; UT
GDX0601	9/28/1984	Paper Converting Machine Co. v. Magna-Graphics Corp., 745 F.2d 11 (Fed. Cir. 1984)			May Offer	R; UT
GDX0602	4/11/1985	In re Longi, 759 F.2d 887 (Fed. Cir. 1985)			May Offer	R; UT
GDX0603	8/9/1989	Hewlett-Packard Co. v. Bausch & Lomb Inc., 882 F.2d 1556 (Fed. Cir. 1989)			May Offer	R; UT
GDX0604	8/1/1991	Pricing, Patent Loss and the Market for Pharmaceuticals by Richard Frank and David Salkever (1991)			May Offer	901; HS; MIL; UT
GDX0605	11/13/1991	In re Continental Can Co. USA, Inc. v. Monsanto Co., 948 F.2d 1264 (Fed. Cir. 1991)			May Offer	R; UT
GDX0606	10/1/1995	Generic Entry and the Pricing of Pharmaceuticals by Richard Frank and David Salkever (1995)			May Offer	901; HS; MIL; UT
GDX0607	5/20/1997	US Patent No. 5,631,365			May Offer	901; HS; MIL; UT
GDX0608	5/1/1998	Pharmaceutical Innovation, Mortality Reduction, and Economic Growth by Frank R. Lichtenberg			May Offer	901; HS; MIL; UT
GDX0609	8/6/1998	Pannu v. Iolab Corp., 155 F.3d 1344 (Fed. Cir. 1998)			May Offer	R; UT
GDX0610	8/1/2001	Guidance for Industry, M4Q: The CTD - Quality, U.S. Department of Health & Human Services, FDA by ICH (2001)			May Offer	HS; R; UT
GDX0611	7/1/2002	Generic Drug Entry Prior to Patent Expiration: An FTC Study (2002)			May Offer	MIL; HS; UT
GDX0612	10/25/2002	Food and Drug Administration, NDA 21-445 Approval Letter			May Offer	UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0613	8/1/2003	Schering Corp. v. Geneva Pharmaceuticals, Inc., 339 F.3d 1373 (Fed. Cir. 2003)			May Offer	R; UT
GDX0614	10/2003	To Promote Innovation - The Proper Balance of Competition and Patent Law and Policy (2003)			May Offer	MIL; HS; UT
GDX0615	07/2004	Improving Health Care: A Dose of Competitition (2004)			May Offer	MIL; HS; UT
GDX0616	12/20/2005	Perricone v. Medicis Pharmaceutical Corp., 432 F.3d 1368 (Fed. Cir. 2005)			May Offer	R; UT
GDX0617	1/1/2006	Prescription Benefit Administrative Agreement between True Health & Sergeants Benevolent Association (1/1/2006)	Zetia-Sergeants-000047	Zetia-Sergeants-000084	May Offer	901; HIS; R; UT
GDX0618	08/2006	Ezetimibe Drug Master File Type II Original Submission (Volume 1 of 4)	GLENMARK-ZETIA-00000827	GLENMARK-ZETIA-00001160	May Offer	901; HS; UT
GDX0619	08/2006	Ezetimibe Drug Master File Type II Original Submission (Volume 2 of 4)	GLENMARK-ZETIA-00001161	GLENMARK-ZETIA-00001466	May Offer	901; HS; UT
GDX0620	08/2006	Ezetimibe Drug Master File Type II Original Submission (Volume 3 of 4)	GLENMARK-ZETIA-00001467	GLENMARK-ZETIA-00001865	May Offer	901; HS; UT
GDX0621	10/25/2006	Letter W. McIntrye to Office of Generic Drugs, FDA re ANDA Ezetimibe Tablets, 10 mg Original ANDA Submission	MRKZETIA_SIDLEY000017903	MRKZETIA_SIDLEY000017974	May Offer	901; UT
GDX0622	10/26/2006	Email G. Patel to B. SivaKumar re Cost Comparison of Ezetimibe with Attachment	GLENMARK-ZETIA-00247054	GLENMARK-ZETIA-00247055	May Offer	901; HS; UT
GDX0623	11/3/2006	Email Z. Sihorwala to V. Soni et al., attaching Presentation: Ezetimibe EDC 1006	GLENMARK-ZETIA-00174771	GLENMARK-ZETIA-00174773	May Offer	901; HS; HWH; UT
GDX0625	3/14/2007	Email R. Jha to P. Ples re Ezetimibe attaching Justification for Use of 1,2-Cichloroethane in Manufacturing Process of Ezetimibe	GLENMARK-ZETIA-00316296	GLENMARK-ZETIA-00316303	May Offer	901; HS; HWH; UT
GDX0626	3/22/2007	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [3/22/2007]), Dkt. No. 1, Complaint	MRKZETIA_SIDLEY000000027	MRKZETIA_SIDLEY000000058	May Offer	901; UT
GDX0627	5/3/2007	Letter J. Skanchy to FDA re DMF Deficiency (DMF# 19717)	GLENMARK-ZETIA-00041724	GLENMARK-ZETIA-00041725	May Offer	901; UT
GDX0628	06/2007	ZETIA® (Exetimibe) Tablets Label (2007)			May Offer	901; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0629	6/7/2007	Schering Corp. v. Glenmark Pharms., Inc., No. 07-cv-1334 (JLL) (D.N.J. [June 7, 2007]), Dkt. 20, Defendant / Counterclaim Plaintiff Glenmark Pharmaceuticals Inc. USA's, Corrected Answer, Affirmative Defenses, and Counterclaims to Complaint	GLENMARK-ZETIA-00244787	GLENMARK-ZETIA-00244829	May Offer	901; UT
GDX0631	1/24/2008	Email T. Coughlin to V. Soni re MSN	GLENMARK-ZETIA-00228886	GLENMARK-ZETIA-00228887	May Offer	901; HS; UT
GDX0632	3/10/2008	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [3/10/2008]), Dkt. No. 55, Glenmark's First Amended Answer and Counterclaims	MRKZETIA_SIDLEY000000948	MRKZETIA_SIDLEY000000991	May Offer	901; UT
GDX0633	3/17/2008	Frequently Asked Questions and Answers for Vytorin and Zetia			May Offer	901; UT
GDX0634	4/19/2008	Email S. Kotwal to J. Gomes et al re Ezetimibie DMF 19717 Deficiency Response attaching Complete Response	GLENMARK-ZETIA-00162680 GLENMARK-ZETIA-00162681_0001	GLENMARK-ZETIA-00162695 GLENMARK-ZETIA-00162681_0082	May Offer	901; HS; HWH; UT
GDX0635	9/24/2008	Email T. Coughlin to A. Maffia, et al. re Ezetimibe ANDA	GLENMARK_ZETIA_00161776	GLENMARK_ZETIA_00161776	May Offer	901; HS; HWH; UT
GDX0636	10/1/2009	Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act by Henry Grabowski and John M. Vernon (1992)			May Offer	901; MIL; UT
GDX0637	3/19/2009	Email N. Kothari to T. Coughlin et al re Ezetimibe - USDMF 19717 Telephone Deficiency attaching 3/9/2009 FDA Telephone, S. Patankar to PharmaQ Deficiency and attaching DMF Amendment Drug Substance Specification & Standard Test Procedure for Ezetimibe	GLENMARK-ZETIA-00183094	GLENMARK-ZETIA-00183105 GLENMARK-ZETIA-00183105_0001 - _0186	May Offer	901; HS; HWH; UT
GDX0638	4/8/2009	Email J. Sharma to P. Chavakula and Y. Reddy re Projections attaching Spreadsheet: API Sales Projections	GLENMARK-ZETIA-00186119	GLENMARK-ZETIA-00186122	May Offer	901; HS; HWH; UT
GDX0639	4/10/2009	Takeda Pharmaceutical Co., Ltd. v. Doll, 561 F.3d 1372 (Fed. Cir. 2009)			May Offer	403; HS; R; UT
GDX0640	4/13/2009	Email J. Brown to S. Vijay re Ezetimibe	GLENMARK-ZETIA-00177775	GLENMARK-ZETIA-00177775	May Offer	901; HS; UT
GDX0641	4/17/2009	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [4/17/2009]), Expert Report of Christopher A. Vellturo, Ph.D.	GLENMARK-ZETIA-00082747	GLENMARK-ZETIA-00082945	May Offer	901; HS; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0642	4/20/2009	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [4/20/2009]), Expert Report of W. Virgil Brown, M.D.	GLENMARK-ZETIA-00082132	GLENMARK-ZETIA-00082182	May Offer	901; HS; R; UT
GDX0643	4/24/2009	Facsimile from Office of Generic Drugs, FDA to W. McIntrye (Glenmark) re Tentative Approval Ezetimibe Tablets, 10 mg	GLENMARK_ZETIA_00159177	GLENMARK_ZETIA_00159182	May Offer	901; UT
GDX0644	7/23/2009	Email T. Coughlin to S. Krishnan, et al re Discussion on critical Products with attachment email	GLENMARK-ZETIA-00182845	GLENMARK-ZETIA-00182849	May Offer	403; 901; HS; HWH; R; UT
GDX0645	7/29/2009	Spreadsheet reflecting GenericDelay-Zetia CVS Data 1/2011-11/2018	CVS-ZET-0000018	CVS-ZET-0000018	May Offer	UT
GDX0646	8/4/2009	Email T. Coughlin to G. Saldanha re Ezetimibe attaching background	GLENMARK-ZETIA-00426550	GLENMARK-ZETIA-00426565	May Offer	901; HS; HWH; UT
GDX0647	8/6/2009	Email T. Coughlin to G. Saldanha and V. Soni re Discussion with SP (Schering)	GLENMARK-ZETIA-00281991	GLENMARK-ZETIA-00281993	May Offer	901; HS; HWH; UT
GDX0648	8/12/2009	Spreadsheet reflecting Legal fees (redacted)	MRKZETIA000930792	MRKZETIA000930795	May Offer	901; 1002; HS; R; UT
GDX0649	10/21/2009	Letter MSN Labs to FDA re Letter of Authorization for DMF 21554	Watson-Zetia_00000049	Watson-Zetia_00000050	May Offer	901; UT
GDX0650	12/16/2009	Schering Corp., et al. v. Mylan Pharm., No. 09-06383-JLL (D.N.J. 12/16/2009]), Dkt. No. 1, Complaint	MRKZETIA_SIDLEY000238225	MRKZETIA_SIDLEY000238285	May Offer	901; HS; MIL; R; UT
GDX0651	12/7/2009	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Preassigned Original ANDA Application	Watson-Zetia_00000204	Watson-Zetia_00000205	May Offer	901; UT
GDX0652	5/10/2010	January 1 - May 10, 2010 Paul Mccrorey Privilege log Entries Excerpt from Merck Privilege Logs			May Offer	901; UT
GDX0653	1/15/2010	Pharmaceuticals - Analyzing Litigation Success Rates, RBC Capital Markets (2010)			May Offer	901; MIL; UT
GDX0655	2/12/2010	Schering Corp., et al. v. Mylan Pharm., No. 09-06383-JLL (D.N.J. 2/12/2010]), Dkt. No. 28, Defendant Mylan Pharmaceuticals Inc.'s Answer to Plaintiffs' Complaint, Separate Defenses and Counterclaims	MRKZETIA_SIDLEY000190244	MRKZETIA_SIDLEY000190362	May Offer	901; MIL; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0656	2/12/2010	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Patent Amendment Sequence # 0002	Watson-Zetia_00010433	Watson-Zetia_00010434	May Offer	901; UT
GDX0657	2/22/2010	Email A. Maffia to S. Miranda re Update Required for the RHP filing attaching TAs, FAs, and FDA Filing Acceptance Letters	GLENMARK-ZETIA-00159168	GLENMARK-ZETIA-00159182	May Offer	901; HS; HWH; UT
GDX0658	2/24/2010	Par Comments/Issues List for Ezetimibe Marketing & Distribution Agreement - 2/24/10 with handwritten marginalia	GLENMARK-ZETIA-00421375	GLENMARK-ZETIA-00421377	May Offer	901; HS; HWH; UT
GDX0659	3/2/2010	Schering Corp., et al v. Teva Pharm., et al, No. 10-01058-JLL (D.N.J. [3/2/2010]), Dkt. No. 1, Complaint			May Offer	901; UT
GDX0660	3/4/2010	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Patent Amendment - to include added U.S. Patent 7,612,058 Sequence # 0003	Watson-Zetia_00010439	Watson-Zetia_00010439	May Offer	901; UT
GDX0661	3/25/2010	Email V. Soni to E. Rudnicki re Tedmodar-Glenmark Meetring on March 29, 2010	MRKZETIA_R000062147	MRKZETIA_R000062148	May Offer	901; HS; HWH; UT
GDX0662	3/26/2010	Email V. Soni to D. Weider re Temodar - Glenmark Meeting dated 3/26/2010	GLENMARK-ZETIA-0434887	GLENMARK-ZETIA-0434888	May Offer	901; HS; HWH; UT
GDX0664	3/30/2010	Schering Corp., et al v. Teva Pharm., et al, No. 10-01058-JLL (D.N.J. [3/30/2010]), Dkt. No. 11, Stipulation Regarding Teva Pharmaceutical Industries Ltd.			May Offer	901; UT
GDX0665	4/19/2010	Schering Corp. v. Glenmark Pharmaceuticals, Inc. USA, No. 07-1334(JLL), 2010 WL 1566887 (D.N.J. Apr. 19, 2010)			May Offer	901; UT
GDX0668	4/30/2010	Marketing and Distribution Agreement by and among Glemark Generics Ltd., Glenmark House, and Glenmark Generics, and Par Pharmaceutical Inc. (2010)	GLENMARK-ZETIA-00056715	GLENMARK-ZETIA-00056750	May Offer	901; CU; UT
GDX0669	4/30/2010	Marketing and Distribution Agreement between Glenmark and Par	PAR_00003009	PAR_00003044	May Offer	901; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0670	5/10/2010	Email T. Hester to P. Matukaitis; et al. re Zetia Settlement Agreement (redacted)	MRKZETIA_R000061825	MRKZETIA_R000061826	May Offer	901; CU; HS; HWH; UT
GDX0672	5/11/2010	Spreadsheet: Ezetimibe forecast May 2010	PAR_00008076	PAR_00008076	May Offer	901; FD; HS; UT
GDX0673	5/12/2010	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Patent Amendment Sequence # 0005	Watson-Zetia_00010456	Watson-Zetia_00010456	May Offer	UT
GDX0674	5/18/2010	Letter from T. Hester (Schering and MSP Singapore) re Settlement Agreement	MRKZETIA_R000024588	MRKZETIA_ R000024621	May Offer	HS; MIL; R; UT
GDX0676	6/8/2010	Email Mike Bascone to Vijay Soni re IPD Analytics: Market Research/CI - Identifying Generic Drug Erosion Prior to Brand Patent Expiration attaching IPD Analytics Forecasts and Analyses	GLENMARK-ZETIA-00281040	GLENMARK-ZETIA-00281055	May Offer	403; 701; FD; HS; HWH; R
GDX0677	6/9/2010	USPTO Application No. 12/797,341	MRKZETIA000933452	MRKZETIA000933483	May Offer	403; HS; R; UT
GDX0678	6/16/2010	Schering Corp. and MSP Singapore Co. LLC v. Mylan Pharms. Inc. & Mylan, Inc., No. 10-03085-JLL-CCC (D.N.J. [6/16/2010]), Dkt. 1, Complaint	MRKZETIA_SIDLEY000006670	MRKZETIA_SIDLEY000006779	May Offer	HS; MIL; UT
GDX0679	7/10/2010	Email A. Sharma to K. Desai re Innovation Page attaching Innovation Pipeline Table	GLENMARK-ZETIA-00248944	GLENMARK-ZETIA-00248966	May Offer	901; FD; HS; HWH; UT
GDX0680	7/16/2010	Teva Pharmaceuticals Patent Certification Ezetimibe Tablets, 10 mg Revised to update certification from Paragraph III to IV for US Patent Nos. 5846966 and RE37721 and to certify U.S. Patent No. 7612058	Teva-Zetia_00001750	Teva-Zetia_00001750	May Offer	UT
GDX0681	7/20/2010	Email C. Vaithara to M. Krishna et al., re Ezetimibe 2nd source approval attaching Ezetimibe 2nd source approval	GLENMARK-ZETIA-00184209	GLENMARK-ZETIA-00184213	May Offer	901; HS; UT
GDX0682	7/28/2010	Schering Corp. and MSP Singapore Co. LLC v. Mylan Pharms. Inc. & Mylan, Inc., No. 10-03085-JLL-ES (D.N.J. [7/28/2010]), Dkt. __, Defendant Mylan Pharmaceuticals Inc.'s Answer to Plaintiffs' Complaint, Separate Defenses and Counterclaims	MRKZETIA_SIDLEY000008810	MRKZETIA_SIDLEY000008897	May Offer	403; HS; MIL; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0683	8/23/2010	Email D. Bisaria to P. Chavakula and C. Almeida re Ezetimibe Outsourcing Issue Attaching Water Content of Ezetimibe Tailing Batches	GLENMARK-ZETIA-00250319	GLENMARK-ZETIA-00250321 GLENMARK-ZETIA-00250321_0001 - _0005	May Offer	HS; UT
GDX0684	9/1/2010	Schering Corp., et al v. Teva Pharm., et al, No. 10-04473-JLL-ES (D.N.J. [9/1/2010]), Dkt. No. 1, Complaint			May Offer	HS; UT
GDX0685	10/13/2010	Email P. Chavakula to T. Coughlin re Ezetimibe - Dispatch Dates Required forwarding Attachments	GLENMARK-ZETIA-00219037	GLENMARK-ZETIA-00219043	May Offer	901; HS; UT
GDX0686	10/29/2010	Letter FDA to Mylan Pharm re reference 10 the bioequivance amendment data submitted on March 19, 2019	MYL_ZETIA 00004; MYL_ZETIA 000049; MYL_ZETIA 000050		May Offer	R; UT
GDX0687	11/8/2010	Letter S. Talton (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Ezetimibe Tablets, 10 mg Bioequivalence Amendment / Bioequivalence Dissolution Acknowledgement / Bioequivalence Response to Information Request	MYL_ZETIA 000051	MYL_ZETIA 000052	May Offer	HS; R; UT
GDX0688	11/8/2010	Letter S. Talton (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Ezetimibe Tablets, 10 mg Gratuitous Chemistry Amendment / Chemistry Information Provided	MYL_ZETIA 000066	MYL_ZETIA 000067	May Offer	HS; R; UT
GDX0689	12/13/2010	Schering Corp., et al v. Teva Pharm., et al, No. 10-04473-JLL-ES (D.N.J. [12/13/2010]), Dkt. No. 24, Case Consolidation and Scheduling Order			May Offer	403; HS; MIL; R; UT
GDX0690	1/1/2011	Guidance for Industry, Process Validation: General Principles and Practices, U.S. Department of Health & Human Services, FDA by CDER, CVM, CGMP (2011)			May Offer	UT
GDX0691	1/28/2011	Letter M. Avolio (Teva Active Pharm. Ingredients) to FDA re Response to Deficiency - EZETIMIBE - DMF# 20039	Teva-Zetia_00001761	Teva-Zetia_00001761	May Offer	901; HS; INC; UT
GDX0692	2/28/2011	Message FDA to Mylan Pharmaceuticals re Receipt for 200082.tar.gz.txt	MYL_ZETIA012089	MYL_ZETIA012091	May Offer	901; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0693	3/9/2011	Facsimile FDA to J. Delgaudio (Watson) re ANDA 200831 Quality Deficiency - Minor			May Offer	R; UT
GDX0694	3/16/2011	Letter FDA to to S. W. Talton re Quality Deficiency for ANDA 201790	MYL_ZETIA000234	MYL_ZETIA000238	May Offer	403; HS; MIL; R; UT
GDX0695	4/12/2011	Spreadsheet reflecting CVS Cardinal DSD Purchases 2011-2012	CVS-ZET-0000011	CVS-ZET-0000011	May Offer	UT
GDX0696	4/25/2011	Email J. Bermitz to A. Maffia et al., re Ezetimibe (Process II) DMF 24825 attaching Acknowledgement Receipt	GLENMARK-ZETIA-00204789	GLENMARK-ZETIA-00204792	May Offer	901; HS; UT
GDX0697	5/17/2011	Schering Corp. v. Mylan Pharmaceuticals, Inc., No. 09-6383(JLL), 2011 WL 1885709 (D.N.J. May 17, 2011)			May Offer	403; CU; HS; MIL; R; UT
GDX0698	5/24/2011	Letter S. Somasundaram to Center for Generic Drugs, FDA re DMF Deficiency # 21554 dated March 08, 2011 from Vilayat A. Sayeed, Ph.D.			May Offer	HS; UT
GDX0699	6/16/2011	Letter J. Delgaudio (Watson) to FDA re ANDA 200831, Quality Minor Amendment / Response to Information Request Sequence # 0009			May Offer	HS; UT
GDX0701	7/7/2011	Letter T. Hester to Premerger Notification Office, FTC re Filing of Settlement between Schering & MSP with Teva Settling Patent Litigation Concerning Vytorin and Zetia	MRKZETIA000935981	MRKZETIA000936018	May Offer	403; MIL; R; UT
GDX0702	7/11/2011	Schering Corp., et al. v. Mylan Pharm., No. 09-06383-JLL (D.N.J. 7/11/2011]), Dkt. No. 245, Consent Judgment	MRKZETIA_SIDLEY000211365	MRKZETIA_SIDLEY000211367	May Offer	403; HS; R; UT
GDX0704	8/4/2011	Letter S. Talton (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Quality Minor Amendment / Response to Information Request	MYL_ZETIA 000239	MYL_ZETIA 000250	May Offer	HS; R; UT
GDX0705	8/5/2011	Letter from Glenmark to FDA re ANDA 078560 Ezetimibe Tablets 10 mg Gratuitous Preapproval Amendment	GLENMARK-ZETIA-00282426	GLENMARK-ZETIA-00282431	May Offer	UT
GDX0706	8/5/2011	Letter FDA to J. Zwicker (TEVA) re Quality Deficiency - Minor to ANDA 078724	Teva-Zetia_00001859	Teva-Zetia_00001861	May Offer	HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0707	8/18/2011	Pharmacy Benefit Management Services Agreement between I.U.O.E. Local 49 Health & Welfare Fund & Catalyst Rx	ZETIA-LOCAL49-000383	ZETIA-LOCAL49-000406	May Offer	403; R; UT
GDX0708	9/9/2011	Letter J. Zwicker (TEVA) to K. Webber (FDA) re Bioequivalence Amendment to ANDA 078724	Teva-Zetia_00001847	Teva-Zetia_00001849	May Offer	HS; UT
GDX0709	9/9/2011	Letter J. Zwicker (TEVA) to K. Webber (FDA) re Quality Minor Amendment/Response to Information Request for ANDA 078724	Teva-Zetia_00001878	Teva-Zetia_00001880	May Offer	HS; UT
GDX0710	11/29/2011	Email M.Zrebiec to P. Campanelli re Follow-Up to Wednesday Meeting: Anchen Integration with attachments	PAR_00007204	PAR_00007208	May Offer	901; HS; UT
GDX0711	12/13/2011	Letter FDA to Watson re Bioequivalence Amendment for ANDA 200831	Watson-Zetia_ 00010690	Watson-Zetia_ 00010693	May Offer	HS; UT
GDX0714	3/14/2012	Facsimile FDA to S. Talton (Mylan) re ANDA 201790 Bioequivalence Amendment Deficiencies	MYL_ZETIA 000862	MYL_ZETIA 000866	May Offer	403; HS; MIL; UT
GDX0715	3/23/2012	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Bioequivalence Response to Information Request Sequence # 0012	Watson-Zetia_ 00010567	Watson-Zetia_ 00010689	May Offer	HS; UT
GDX0717	4/2/2012	Letter B. Attinger (Sandoz) to Office of Generic Drugs, FDA re ANDA 203931 Ezetimibe Tablets, 10 mg Original ANDA Submission Sequence # 0000	SANDOZ-ZETIA-0000004	SANDOZ-ZETIA-0000005	May Offer	UT
GDX0718	4/6/2012	Spreadsheet: Ezetimibe forecast Jan 2012	PAR_00007332	PAR_00007332	May Offer	HS; UT
GDX0720	4/10/2012	Email A. Maffia to S. Kaushal and M. Plastina re Ezetimibe Process comparison for review	GLENMARK-ZETIA-00204603	GLENMARK-ZETIA-00204611	May Offer	901; HS; UT
GDX0721	4/27/2012	Schering Corp. v. Mylan Pharmaceuticals, Inc., No. 09-6383(JLL), 2012 WL 1473329 (D.N.J. April 27, 2012)			May Offer	403; HS; HWH; MIL; R; UT
GDX0722	5/4/2012	Letter S. Talton (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Telephone Amendment / Bioequivalence Response to Information Request Sequence # 0002	MYL_ZETIA 000871	MYL_ZETIA 000877	May Offer	403; MIL; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0724	5/17/2012	Schering Corp., et al. v. Mylan Pharm., No. 09-06383-JLL (D.N.J. 5/17/2012]), Dkt. No. 455, Final Judgment	MRKZETIA_SIDLEY000206431	MRKZETIA_SIDLEY000206434	May Offer	403; MIL; R; UT
GDX0726	5/22/2012	Telephone Request FDA to S. Talton (Mylan) re Request for Information, Studies BA09101188-01 (fasting) and BA09101189-01 (fed)	MYL_ZETIA 010590	MYL_ZETIA 010590	May Offer	403; MIL; R; UT
GDX0727	6/1/2012	Operating Engineers Local #49 Health and Welfare Fund Coverage Period: 06/01/2012 to 05/31/2013 dated 6/1/2012	ZETIA-LOCAL49-000155	ZETIA-LOCAL49-000162	May Offer	403; HS; R; UT
GDX0728	6/6/2012	Letter S. Talton (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Telephone Amendment / Bioequivalence Response to Information Request Sequence # 0003	MYL_ZETIA_010586	MYL_ZETIA 010589	May Offer	UT
GDX0729	7/26/2012	Email S. Rahman to J. Sharma and V. Soni re Steering Committee Presentation attaching API R&D DMF Grid Development Status Slides	GLENMARK-ZETIA-00208754	GLENMARK-ZETIA-00208755	May Offer	901; HS; UT
GDX0730	8/6/2012	Letter FDA to S. Talton (Mylan) re ANDA 201790 Minor Deficiencies	MYL_ZETIA 010808	MYL_ZETIA 010809	May Offer	403; HS; MIL; R; UT
GDX0731	8/20/2012	Letter from Dept health & human services to Sandoz re Request to Withdraw Applications from the Generic Drug Backlog to Avoid Incurring Backlog Fee dated 8/20/2012	SANDOZ-ZETIA-0000123	SANDOZ-ZETIA-0000126	May Offer	403; UT
GDX0732	8/22/2012	Letter J. Sobecki (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Telephone Amendment / Chemistry Information Provided	MYL_ZETIA 010812	MYL_ZETIA 010815	May Offer	403; HS; MIL; R; UT
GDX0733	9/17/2012	Facsimile FDA to S. Talton (Mylan) re ANDA 201790 Telephone Amendment Fax	MYL_ZETIA 010824	MYL_ZETIA 010825	May Offer	403; HS; MIL; R; UT
GDX0734	9/24/2012	Letter J. Sobecki (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Telephone Amendment / Chemistry Information Provided Sequence # 0006	MYL_ZETIA 010827	MYL_ZETIA 010829	May Offer	HS; MIL; R; UT
GDX0735	9/27/2012	Merck Sharp & Dohme Corp. and MSD Int'l GmbH v. Sandoz, Inc., No. 12-06077-JLL-MAJ (D.N.J. [9/27/2012]), Dkt. No. 1, Complaint	MRKZETIA_SIDLEY000006055	MRKZETIA_SIDLEY000006067	May Offer	403; HS; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0736	11/6/2012	Letter B. Attinger (Sandoz) to Office of Generic Drugs, FDA re ANDA 203931 Bioequivalence Amendment / CMC Information Included Sequence # 0002	SANDOZ-ZETIA-0000037	SANDOZ-ZETIA-0000041	May Offer	901; HS; UT
GDX0737	11/9/2012	Email S. Sharma to A. Maffia re Update 2d Source - 07.11.12 attaching Slides entitled Alternate Source Products - EB Completed	GLENMARK-ZETIA-00202670	GLENMARK-ZETIA-00202672	May Offer	901; HS; HWH; UT
GDX0738	11/16/2012	Letter from Sandoz re Patent amendment dated 11/6/2012	SANDOZ-ZETIA-0000011	SAN DOZ-ZETIA-0000012	May Offer	HS; UT
GDX0739	12/30/2012	Email V. Soni to V. Nasare re MOM - Sourcing Meeting [28.12.12] attaching Alternate Source Products - EB Completed slides	GLENMARK-ZETIA-00329368	GLENMARK-ZETIA-00329371	May Offer	901; HS; INC; R; UT
GDX0740	4/1/2013	Email A. Maffia to S. Krishan, et al re Ezetimibe Tablets - Alternate mfg site to Par	GLENMARK-ZETIA-00281722	GLENMARK-ZETIA-00281723	May Offer	901; HS; HWH; UT
GDX0742	4/11/2013	Facsimile FDA to S. Talton (Mylan) re ANDA 201790 Easily Correctable Labeling Deficiency Fax	MYL_ZETIA 010987	MYL_ZETIA 010989	May Offer	403; HS; MIL; UT
GDX0743	4/19/2013	Letter Glenmark to FDA re Ezetimibe (Process II) as manufactured in Gujarat, India - response to GDUFA DMF Complete Response Letter	GLENMARK-ZETIA-00312092	GLENMARK-ZETIA-00312092	May Offer	901; INC; UT
GDX0744	4/22/2013	Letter J. Sobecki (Mylan) to Office of Generic Drugs, FDA re ANDA 201790 Easily Correctable Labeling Deficiency Amendment / Labeling Information Provided Sequence # 0008	MYL_ZETIA 010922	MYL_ZETIA 010924	May Offer	403; MIL; R; UT
GDX0745	5/6/2013	Merck Sharp & Dohme Corp. and MSD Int'l GmbH v. Sandoz, Inc., No. 12-06077-JLL-JAD (D.N.J. [5/6/2016]), Dkt. No. 23, Sandoz Inc.'s Answer and Counterclaims to Complaint for Patent Infringement	MRKZETIA_SIDLEY000007968	MRKZETIA_SIDLEY000008001	May Offer	UT
GDX0746	5/29/2013	Priviledged and Confidential chart for Ezetimibe tabs discussing Brand market, competition, timing comments, and general assumptions	SANDOZ-ZETIA-0000001	SANDOZ-ZETIA-0000001	May Offer	HS; UT
GDX0747	6/11/2013	Pfizer Obtains $2.15 Billion Settlement From Teva And Sun For Infringement Of Protonix® Patent			May Offer	403; 901; 1002; HS; MS; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0748	7/3/2013	Letter J. Zwicker to Office of Generic Drugs, FDA re ANDA 078724 Resubmission / After Action - Minor Amendment	Teva-Zetia_00001968	Teva-Zetia_00001975	May Offer	403; 901; HS; UT
GDX0749	8/7/2013	Letter FDA to J. Sobecki (Mylan) re ANDA 201790 Tentative Approval	MYL_ZETIA 000038	MYL_ZETIA 000042	May Offer	UT
GDX0751	8/14/2013	Letter FDA to Glenmark re DMF Information Request for DMF 24825	GLENMARK-ZETIA-00312011	GLENMARK-ZETIA-00312013	May Offer	901; UT
GDX0752	8/15/2013	Email J. Bermitz to S. Krishan et al., re Received from FDA: Ezetimibe DMF24825 attaching DMF Information Request	GLENMARK-ZETIA-00224096	GLENMARK-ZETIA-00224099	May Offer	901; UT
GDX0754	9/5/2013	Email L. Jakob to T. Hester (Covington) re Executed Ezetimibe Agreement attaching Settlement Agreement between Merck and Sandoz	MRKZETIA000845599	MRKZETIA000845628	May Offer	901; HS; HWH; UT
GDX0755	9/9/2013	Merck Sharp & Dohme Corp. and MSD Int'l GmbH v. Sandoz, Inc., No. 12-06077-JLL-JAD (D.N.J.[9/9/2013]), Dkt. No. 48, Consent Judgment	MRKZETIA_SIDLEY000013042	MRKZETIA_SIDLEY000013044	May Offer	901; MIL; UT
GDX0756	9/27/2013	Email A. Kohli to S. Krishan et al re Submitted to FDA Ezetimibe (Process II) DMF 24825 attaching Glenmark letter	GLENMARK-ZETIA-00265485	GLENMARK-ZETIA-00265486	May Offer	901; HS; UT
GDX0757	10/29/2013	Email M. Blashinsky to P. Dutra re Zetia Sales Projections attaching Spreadsheet	GLENMARK-ZETIA-00202267	GLENMARK-ZETIA-00202268	May Offer	403; 901; FD; HS; HWH; UT
GDX0758	1/14/2014	Spreadsheet: Ezetimibe forecast Jan 2014	PAR_00005152	PAR_00005152	May Offer	901; HS; UT
GDX0759	1/15/2014	Email M. Blashinsky to V. Yadav re Ezetimibe (Zetia) Business Case	GLENMARK-ZETIA-00202256	GLENMARK-ZETIA-00202257	May Offer	901; HS; UT
GDX0760	1/16/2014	Email V. Yadav to M. Blashinsky, et al., re NPV Ezetimibe 16 Jan 2014 attaching Spreadsheet: NPV Ezetimibe 16 Jan 2014	GLENMARK-ZETIA-00202252	GLENMARK-ZETIA-00202253	May Offer	901; HS; UT
GDX0761	1/17/2014	Email P. Davish to R. Byrne; et al. re Approval requested by Noon Thursday January 16, 2014; (January 24, 2014 Price Action) Approval requested by 1/17/2014	MRKZETIA_R000084875	MRKZETIA_R000084876	May Offer	901; HS; HWH; UT
GDX0762	1/24/2014	Spreadsheet: NPV Ezetimibe 24 Jan 2014	GLENMARK-ZETIA-00202294	GLENMARK-ZETIA-00202294	May Offer	901; HS; UT
GDX0763	1/28/2014	Spreadsheet: Ezetimibe forecast Jan 2014	PAR_00005375	PAR_00005375	May Offer	901; HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0764	2/18/2014	Letter A. W. Sigler to J. Domenico re Update summary of filed and pending original ANDA(s)	SANDOZ-ZETIA-0000130	SANDOZ-ZETIA-0000133	May Offer	901; MIL; UT
GDX0765	3/9/2017	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Minor Amendment - Final Approval Request Sequence # 0018	Watson-Zetia_00011449	Watson-Zetia_00011451	May Offer	901; HS; MIL; UT
GDX0766	3/25/2014	Email G. Eater to T. Sprague re For Your Comments-Pricing Committee-LOE Planning - ZETIA Family Franchise	MRKZETIA000547883	MRKZETIA000547884	May Offer	901; HS; HWH; UT
GDX0767	3/25/2014	Metadata Cover and Presentation entitled LOE Planning - ZETIA Family Franchise, USP Pricing Committee	MRKZETIA000547885	MRKZETIA000547885	May Offer	901; HS; UT
GDX0768	5/13/2014	Email M. Mathias to J. Bermitz et al re Submitted to the FDA: Ezetimibe tablets: ANDA # 078560 attaching cover-letter	GLENMARK-ZETIA-00204855	GLENMARK-ZETIA-00204861	May Offer	901; HS; HWH; UT
GDX0769	5/15/2014	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Resubmission / After Action-Minor Amendment Sequence # 0015	Watson-Zetia_00011187	Watson-Zetia_00011191	May Offer	901; HS; UT
GDX0770	6/16/2014	Email G. Goyal to V. Soni re Clarifications on Agreement attaching compendium of drafts of Settlement Papers (different bates numbers not all from the same family)	GLENMARK-ZETIA-00239424 GLENMARK-ZETIA-00280930 GLENMARK-ZETIA-00261119	GLENMARK-ZETIA-00239425 GLENMARK-ZETIA-00280956 GLENMARK-ZETIA-00261163	May Offer	403; 901; FD; HS; HWH; UT
GDX0771	6/17/2014	Letter S. Manan (Ohm Laboratories, Inc.) to Office of Generic Drugs, FDA re ANDA 207311 Ezetimibe Tablets, 10 mg ESG Original ANDA Submission Pre-Assigned ANDA Application Number eCTD Sequence 0000	SUN-EZETIMIBIE_00017510	SUN-EZETIMIBIE_00017514	May Offer	901; HS; UT
GDX0776	9/8/2014	Spreadsheet: Ezetimibe Forecast Aug 2014	PAR_00002332	PAR_00002332	May Offer	901; HS; UT
GDX0777	9/12/2014	Email P. Emanuel to S. Sharma et al., re Submitted to FDA: ANDA 078560: Ezetimibe Tablets, 10 mg- Withdrawal request attaching Cover Letter	GLENMARK-ZETIA-00204851	GLENMARK-ZETIA-00204854	May Offer	901; HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0778	9/25/2014	Email S. Rahman to R. Matsuk, et al re API-R&D Review Meeting Slides and attaching Glenmark Presentation entitled DMF Grid Product Review and Presentation entitled Cost Reduction Product Review	GLENMARK-ZETIA-00209401	GLENMARK-ZETIA-00209402	May Offer	901; HS; UT
GDX0779	10/1/2014	Email S. Sridharan to A. Vartak re Ezetimibe API cost for process 2	GLENMARK-ZETIA-00255262	GLENMARK-ZETIA-00255264	May Offer	901; HS; HWH; UT
GDX0780	10/1/2014	Email C. Calabro to M. Altamuro, et al. re Zetia, attaching Ezetimibe (Zetia) forecast Sep 2014	PAR_00018433	PAR_00018434	May Offer	901; HS; HWH; UT
GDX0781	10/10/2014	Email M. Mathias to C. Spinks et al re ANDA 78560 FDA Submission of Letter K. Vanam to Office of Generic Drugs, FDA re Minor Amendment - Final Approval Request	GLENMARK-ZETIA-00209192	GLENMARK-ZETIA-00209196	May Offer	901; HS; UT
GDX0782	10/28/2014	Glenmark Stability Study Report	GLENMARK-ZETIA-00283502	GLENMARK-ZETIA-00283513	May Offer	901; HS; UT
GDX0783	10/29/2014	Letter FDA to TEVA re Complete Response for ANDA 078724	Teva-Zetia_ 00002832	Teva-Zetia_ 00002835	May Offer	901; UT
GDX0784	10/29/2014	Facsimile FDA to S. Tomsky (Teva Pharms.) re ANDA 078724 Complete Response	Teva-Zetia_00002832	Teva-Zetia_00002835	May Offer	901; UT
GDX0785	10/23/2012	Letter FDA to P. Erickson (Teva Pharms.) re ANDA 078724 Complete Response	Teva-Zetia_00001991	Teva-Zetia_00001997	May Offer	901; UT
GDX0786	11/20/2014	Letter TEVA to FDA re Resubmission Minor Complete Response Amendment Chemistry for ANDA 078724	Teva-Zetia_00002819	Teva-Zetia_00002821	May Offer	901; HS; UT
GDX0787	1/13/2015	Letter D. McKan to C. Uhrn re Denied ANDA	SANDOZ-ZETIA-0000140	SANDOZ-ZETIA-0000145	May Offer	901; UT
GDX0788	2/19/2015	Email G. Goyal to V. Soni re Ezetimibe Supply Chain Security attaching Glenmark Presentation entitled Ezetimibe Supuply Chain De-risking	GLENMARK-ZETIA-00223333	GLENMARK-ZETIA-00223338	May Offer	901; HS; HWH; UT
GDX0789	2/25/2015	Email S. Sridharan to V. Soni re Today's Par attaching Presentation: Par-Glenmark Ezetemibe JSC Meeting	GLENMARK-ZETIA-00211953	GLENMARK-ZETIA-00211954	May Offer	901; HS; UT
GDX0791	3/31/2015	Letter R. Maclean to Office of Generic Drugs, FDA re Ezetimibe Tablets 10 mg Original ANDA Pre-Assigned ANDA 208322	APOTEX0000029	APOTEX0000032	May Offer	901; HS; UT
GDX0792	3/31/2015	Apotex ANDA Paragraph III Certification for Zetia 10 mg	APOTEX0000033	APOTEX0000033	May Offer	901; HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0794	4/16/2015	Letter FDA to J. Delgaudio (Watson) re ANDA 200831 Information Request	Watson-Zetia_00011312	Watson-Zetia_00011313	May Offer	901; HS; HWH; UT
GDX0798	5/15/2015	Letter J. Delgaudio (Watson) to Office of Generic Drugs, FDA re ANDA 200831, Ezetimibe Tablets, 10 mg Information Request Product Quality Reference 101114 Sequence # 0016	Watson-Zetia_00011310	Watson-Zetia_0001131	May Offer	901; HS; UT
GDX0799	5/18/2015	Email S. Sridharan to P. Wagle re MOM of last meeting with Par attaching 3 previous MOMs	GLENMARK-ZETIA-00178532	GLENMARK-ZETIA-00178552	May Offer	901; HS; UT
GDX0801	5/26/2015	Facsimile FDA to R. Leone (Teva Pharms.) re ANDA 078724 Complete Response	Teva-Zetia_00002859	Teva-Zetia_00002862	May Offer	403; 901; MIL; R; UT
GDX0802	6/1/2015	Email K. Vanam to S. Kaushal and J. Bermitz re Information Request for ANDA 78560 attaching Letter FDA	GLENMARK-ZETIA-00283456	GLENMARK-ZETIA-00283458	May Offer	403; 901; HS; HWH; UT
GDX0803	6/5/2015	Email DS. Sharma to N. Tiwari re Submitted to FDA Ezetimibe Tablets, 10 mg, ANDA 078560 attaching Glenmark Letter Response t FDA Sequence 0018	GLENMARK-ZETIA-00418368	GLENMARK-ZETIA-00418372	May Offer	901; HS; HWH; UT
GDX0804	6/9/2015	Presentation: Par-Glenmark Ezetemibe JSC Meeting	GLENMARK-ZETIA-00178556	GLENMARK-ZETIA-00178556	May Offer	901; HS; UT
GDX0805	6/10/2015	Presentation: Ezetimibe Steering Committee Meeting	GLENMARK-ZETIA-00178564	GLENMARK-ZETIA-00178564	May Offer	901; HS; UT
GDX0806	6/17/2015	Email S. Sridharan to P. Wagle re JSC Notes attaching Presentation: Ezetimibe Steering Committee Meeting and Presentation: Par-Glenmark Ezetemibe JSC Meeting	GLENMARK-ZETIA-00195627	GLENMARK-ZETIA-00195641	May Offer	901; HS; UT
GDX0807	6/26/2015	ANDA 078560 Approval Letter from FDA to Glenmark			May Offer	901; UT
GDX0808	6/30/2015	Email N. Yorke to S. Vijay; et al. re Letter Regarding Ezetimibe with attachment	GLENMARK-ZETIA-00236046	GLENMARK-ZETIA-00236050	May Offer	901; HS; UT
GDX0809	7/1/2015	Email J. Gariolo to L. Jakob re Letter Regarding Ezetimibe	GLENMARK-ZETIA-00223323	GLENMARK-ZETIA-00223325	May Offer	901; HS; HWH; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0810	7/7/2015	Email P. Wagle to S. Thirumanathu re Submitted to FDA attaching Letter K. Vanam to FDA re ANDA 78560, Ezetimibe Tablets, 10 mg Prior Approval Supplement (PAS) - To Propose Use of API from Alternate Source	GLENMARK-ZETIA-00187669	GLENMARK-ZETIA-00187677	May Offer	901; HS; HWH; UT
GDX0811	8/6/2015	Email P. Wagle to S. Gomes et al., re Ezetimibe (API + dosage) planning discussion attaching Presentation: Ezetimibe - Tracker	GLENMARK-ZETIA-00184222	GLENMARK-ZETIA-00184224	May Offer	901; HS; HWH; UT
GDX0812	8/13/2015	Letter D. DeCicco and R. Leone (Teva Pharms.) to Office of Generic Drugs, FDA re ANDA 078724 Resubmission Minor Complete Response Amendment / Chemistry Sequence # 0001	Teva-Zetia_00002851	Teva-Zetia_00002857	May Offer	901; HS; UT
GDX0813	8/17/2015	Presentation: Zetia Post-LOE Contracting Strategy Final Report	MRKZETIA_R000062509	MRKZETIA_R000062509	May Offer	901; HS; UT
GDX0814	8/20/2015	Letter FDA to Glenmark re ANDA 078560/S-001 Deficiencies Information Request	GLENMARK-ZETIA-00287556	GLENMARK-ZETIA-00287557	May Offer	403; 901; UT
GDX0815	8/21/2015	Letter K. Vanam (Glenmark) to FDA re ANDA 078560, Change Being Effected-30 Days Supplement	GLENMARK-ZETIA-00276599	GLENMARK-ZETIA-00276605	May Offer	901; HS; UT
GDX0816	8/26/2015	Email H. Rane to C. Almeida and A. Lavekar re Glenmark Ezetimibe EB Current Spec for US attaching MSN Submission re DMF 021554 Sequence # 0009	GLENMARK-ZETIA-00391934	GLENMARK-ZETIA-00392044	May Offer	901; HS; UT
GDX0817	9/4/2015	Email P. Kulkarni to S. Thirumanathu and P. Wagle re Questions for Glenmark - Ezetimibe attaching Ezetimibe Chemistry Amendment	GLENMARK-ZETIA-00195263	GLENMARK-ZETIA-00195556	May Offer	901; HS; UT
GDX0818	9/4/2015	Email S. Mungekar to K. Vanam re FDA call - General guidance attaching Ezetimibe Supplements	GLENMARK-ZETIA-00283390	GLENMARK-ZETIA-00283442	May Offer	901; HS; UT
GDX0819	9/9/2015	Email V. Soni to P. Wagle re Received Letter FDA re ANDA 78560 Prior Approval Supplement Approval	GLENMARK-ZETIA-00192640	GLENMARK-ZETIA-00192642	May Offer	901; HS; UT
GDX0820	9/9/2015	Email J. Bermitz to A. Sharma et al re Received from FDA Ezetimibe Tablets, 10 mg Prior Approval Supplement Approval Letter	GLENMARK-ZETIA-00419891	GLENMARK-ZETIA-00419893	May Offer	901; HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0821	10/13/2015	Presentation: ZETIA Proposed LOE Contracting Strategy	MRKZETIA000521875	MRKZETIA000521875	May Offer	901; HS; UT
GDX0822	11/5/2015	Letter M. Henry (Sandoz) to Office of Generic Drugs, FDA re ANDA 203931 Information Request Chemistry Reference #177498 Sequence # 0008	SANDOZ-ZETIA-0000074	SANDOZ-ZETIA-0000076	May Offer	901; HS; UT
GDX0823	11/12/2015	Letter S. Manan (Sun Pharms.) to Office of Generic Drugs, FDA re ESG Information Request Bioequivalence / Dissolution Reference 175391 Sequence # 0004	SUN-EZETIMIBIE_00017613	SUN-EZETIMIBIE_00017614	May Offer	403; 901; HS; UT
GDX0824	12/4/2015	Letter A. Patel (Amneal) to FDA re Quality - Response to Information Request to ANDA # 208803	AMN-ZETIA0000017	AMN-ZETIA0000051	May Offer	403; 901; HS; UT
GDX0825	12/8/2015	Spreadsheet: Ezetimibe Tablets Summary-Assumptions Table and Scenarios	PAR_00002915	PAR_00002915	May Offer	901; HS; UT
GDX0826	12/14/2015	Ezetimibe/Simvastatin and Ezetimibe-IMPROVE-IT Study	MRKETIA000521962	MRKETIA000522061	May Offer	901; HS; UT
GDX0827	12/15/2015	Letter FDA to J. Delgaudio (Watson) re ANDA 200837 Tentative Approval	Watson-Zetia_00011452	Watson-Zetia_00011454	May Offer	901; UT
GDX0828	12/16/2015	Letter FDA to K. Krishnan (Apotex) re ANDA 208332 Deficiency Comments	APOTEX0000023	APOTEX0000025	May Offer	403; 901; UT
GDX0829	1/22/2016	Email C. Antrosiglio to I. Duffy, et al., re Notification of Approval: Approval Requested: Amendment to ZETIA LOE pricing doc:# 1512-18-TSS	MRKZETIA000854606	MRKZETIA000854611	May Offer	901; HS; HWH; UT
GDX0830	2/25/2016	Email M. Copeland to R. Rode re LOE discussion - slides for 10am meeting dated 2/25/2016	MRKZETIA_R000058405	MRKZETIA_R000058406	May Offer	901; HS; HWH; UT
GDX0831	3/19/2016	Spreadsheet: Ezetimibe Tablets Summary-Assumptions Table and Forecasting	PAR_00003366	PAR_00003366	May Offer	901; HS; UT
GDX0832	3/25/2016	Letter A. Patel (Amneal) to Office of Generic Drugs, FDA re ANDA 208809 - Sequence # 0005, Ezetimibe Tablets USP, 10 mg Request: Bioequivalence - Reference # 223077	AMN-ZETIA0002090	AMN-ZETIA0002096	May Offer	403; 901; HS; UT
GDX0833	3/31/2016	Email A. Desai to P. Wagle re Ezetimibe attaching Glenmark Presentation entitled Ezetimbie US Launch Update	GLENMARK-ZETIA-00198983	GLENMARK-ZETIA-00198984	May Offer	901; HS; HWH; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0834	4/8/2016	Letter FDA to S. Manan (Ohm Laboratories, Inc.) re ANDA 207311 Easily Correctable Deficiency	SUN-EZETIMIBIE_00018383	SUN-EZETIMIBIE_00018384	May Offer	403; 901; UT
GDX0835	4/26/2016	Email A. Desai to P. Wagle re Ezetimibe ppt Rev3 attaching Glenmark Presentation entitled Ezetimbie US Launch Update	GLENMARK-ZETIA-00198968	GLENMARK-ZETIA-00198970	May Offer	901; HS; HWH; UT
GDX0836	4/27/2016	Spreadsheet: Ezetimibe (Zetia) forecast Mar 2016 updated for extra load	PAR_00003509	PAR_00003509	May Offer	901; HS; UT
GDX0837	5/5/2016	Email H. Schiff to S. Roundal et al re ANDA 209234 Filing Review Comments	ALKEM000022	ALKEM000025	May Offer	901; HS; HWH; INC; UT
GDX0838	5/27/2016	Letter FDA to K. Krishnan (Apotex) re ANDA 208332 Information request Product Quality Reference 8220977	APOTEX0000011	APOTEX0000012	May Offer	403; 901; UT
GDX0839	6/2/2016	Letter A. Patel (Amneal) to Office of Generic Drugs, FDA re ANDA 208809 - Sequence # 0006, Ezetimibe Tablets USP, 10 mg Easily Correctable Deficiency Bioequivalence Reference # 8079480	AMN-ZETIA0002413	AMN-ZETIA0002418	May Offer	403; 901; HS; UT
GDX0840	6/8/2016	Presentation: ZETIA LOE Contracting Strategy	MRKZETIA_R000026752	MRKZETIA_R000026752	May Offer	901; HS; UT
GDX0841	6/8/2016	Letter L. Jakob (Merck) to Glenmark re Patent Settlement Agreement between Merck and Glenmark	MRKZETIA000874087	MRKZETIA000874089	May Offer	901; HS; UT
GDX0842	6/9/2016	Email P. Wagle to A. Desai re Submitted to FDA: Response to Information Request for CBE-30 - Ezetimibe Tablets, 10 mg (ANDA078560) attaching FDA Information Request Cover Letter	GLENMARK-ZETIA-00186550	GLENMARK-ZETIA-00186557	May Offer	901; HS; HWH; UT
GDX0843	6/22/2016	Presentation: Ezetimibe US Launch Update	GLENMARK-ZETIA-00178607	GLENMARK-ZETIA-00178607	May Offer	901; HS; UT
GDX0844	6/22/2016	Email A. Desai to P. Wagle re Ezetimibe PPT attaching Presentation: Ezetimibe US Launch Update	GLENMARK-ZETIA-00198776	GLENMARK-ZETIA-00198777	May Offer	901; HS; UT
GDX0845	7/5/2016	Email M. Exume to K. Hayward re Zetia Family Aug FC	MRKZETIA_R000051180	MRKZETIA_R000051182	May Offer	901; HS; HWH; UT
GDX0846	7/8/2016	Letter A. Patel (Amneal) to Office of Generic Drugs, FDA re ANDA 208809 - Sequence # 0007, Ezetimibe Tablets USP, 10 mg Information Request Quality Reference # 7743996	AMN-ZETIA0002930	AMN-ZETIA0003110	May Offer	403; 901; HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0847	7/11/2016	Letter S. Qadry (Sun Pharms.) to Office of Generic Drugs, FDA re ANDA 207311 Information Request / Chemistry Reference 7945804 Sequence # 0005	SUN-EZETIMIBIE_00018365	SUN-EZETIMIBIE_00018375	May Offer	403; 901; HS; UT
GDX0848	7/13/2016	Email A. Desai to P. Wagle re Ezetimibe attaching Glenmark Presentation entitled Ezetimbie US Launch Update	GLENMARK-ZETIA-00198709	GLENMARK-ZETIA-00198710	May Offer	901; HS; HWH; UT
GDX0850	7/13/2016	Presentation: Athero Brand Update	MRKZETIA000601091	MRKZETIA000601091	May Offer	901; HS; UT
GDX0851	7/14/2016	Email P. Wagle to A. Desai re Ezetimibe PPT attaching Presentation: Ezetimibe US Launch Update	GLENMARK-ZETIA-00251697	GLENMARK-ZETIA-00251698	May Offer	901; HS; UT
GDX0852	7/18/2016	Email M. Hoang to H. Rizkalla et al., re PCP Experiential Education Site Visit attaching Presentation: Glenmark Pharmaceuticals Limited Corporate Overview May 2016	GLENMARK-ZETIA-00213693	GLENMARK-ZETIA-00213696	May Offer	901; HS; UT
GDX0853	7/29/2016	Letter S. Qadry (Sun Pharms.) to Office of Generic Drugs, FDA re ANDA 207311 ESG Easily Correctable Deficiency Labeling Reference 235743 Sequence # 0006	SUN-EZETIMIBIE_00018546	SUN-EZETIMIBIE_00018547	May Offer	901; HS; UT
GDX0854	8/4/2016	Email L. Jakob to D. Pakula re Glenmark Response with attachment	MRKZETIA000614646	MRKZETIA000614647	May Offer	901; HS; UT
GDX0855	8/22/2016	Email A. Desai to P. Wagle re Ezetimibe attaching Glenmark Presentation entitled Ezetimbie US Launch Update	GLENMARK-ZETIA-00198701	GLENMARK-ZETIA-00198702	May Offer	901; HS; UT
GDX0856	9/1/2016	Spreadsheet: Ezetimibe (Zetia) forecast Sep 2016 NPF	GLENMARK-ZETIA-00165621	GLENMARK-ZETIA-00165621	May Offer	901; HS; UT
GDX0857	9/21/2016	Email S. Roundal (Alkem) to G. Mavuleti re [EASILY CORRECTABLE DEFICIENCY] Original ANDA 209234 - Bioequivalence	ALKEM002701	ALKEM002702	May Offer	901; HS; HWH; UT
GDX0858	9/23/2016	Letter P. Pal to Office of Generic Drugs, FDA re ANDA 209234 Easily Correctable Deficiency Reference # 10266034	ALKEM002700	ALKEM002700	May Offer	901; HS; UT
GDX0859	10/17/2016	Letter P. Scwartz to K. Vanam re supplemental Abbreviated New Drug Application	GLENMARK-ZETIA-00287498	GLENMARK-ZETIA-00287500	May Offer	UT
GDX0860	10/25/2016	Letter FDA to S. Qadry (Sun Pharms.) re ANDA 207311 Information Request	SUN-EZETIMIBIE_00018557	SUN-EZETIMIBIE_00018559	May Offer	901; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0861	10/27/2016	Letter B. Johns to Office of Generic Drugs, FDA re Ezetimibe Tablets USP 10 mg Pre Assigned ANDA 209838 Original Application Sequence # 0000	AUROBINDO_00000169	AUROBINDO_00000172	May Offer	901; HS; UT
GDX0862	11/2016	Spreadsheet: Ezetimibe Nov 2016	PAR_00008449	PAR_00008449	May Offer	901; HS; UT
GDX0863	11/2/2016	Email A. Phan to J. Grauso re 1 pager attaching Presentation: Glenmark - Corporate Presentation FY 17	GLENMARK-ZETIA-00177415	GLENMARK-ZETIA-00177417	May Offer	901; HS; HWH; UT
GDX0864	12/5/2016	Letter FDA to H. Schiff (Ascend Labs) re Information Request	ALKEM002757	ALKEM002762	May Offer	901; UT
GDX0865	12/6/2016	Letter S. Qadry (Sun Pharms.) to Office of Generic Drugs, FDA re ANDA 207311 Response to Information Request (Chemistry) - Reference 10935178	SUN-EZETIMIBIE_00018618	SUN-EZETIMIBIE_00018619	May Offer	901; HS; UT
GDX0866	12/7/2016	Email S. Johnson to J. Owen re New Generics requesting 30 ct Zetia be preferred	ALB_ZETIA_ED00008218	ALB_ZETIA_ED00008221	May Offer	901; HS; HWH; UT
GDX0867	1/5/2017	Letter P. Pal to Office of Generic Drugs, FDA re ANDA 209234 (0008) Information Request - Quality Reference #11704040	ALKEM002755	ALKEM002756	May Offer	901; HS; UT
GDX0868	1/10/2017	Letter FDA to K. Krishnan (Apotex) re ANDA 208332 Complete Response	APOTEX0000001	APOTEX0000004	May Offer	901; UT
GDX0869	1/12/2017	Antitrust Guidelines for the Licensing of Intellectual Property			May Offer	901; MIL; UT
GDX0870	1/18/2017	Email K. Vanam to R. Sharma re ANDA 78560 attaching ANDA Approval Letter	GLENMARK-ZETIA-00166674	GLENMARK-ZETIA-00166677	May Offer	UT
GDX0871	2/10/2017	Letter FDA to S. Qadry (Sun Pharms.) re ANDA 207311 Information Request	SUN-EZETIMIBIE_00018637	SUN-EZETIMIBIE_00018639	May Offer	901; UT
GDX0872	2/16/2017	Letter M. Henry (Sandoz) to Office of Generic Drugs, FDA re ANDA 203931 Minor Amendment - Final Approval Requested Sequence # 0010	SANDOZ-ZETIA-0000081	SANDOZ-ZETIA-0000092	May Offer	UT
GDX0873	2/17/2017	Letter FDA to H. Schiff (Ascend Labs) re Information Request	ALKEM003559	ALKEM003561	May Offer	901; UT
GDX0874	2/21/2017	Letter from C. Poole (FDA) to M. Henry (Sandoz) re Notification - target action date dated 2/21/2017	SANDOZ-ZETIA-0000150	SANDOZ-ZETIA-0000150	May Offer	901; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0875	2/24/2017	Letter A. Patel (Amneal) to Office of Generic Drugs, FDA re ANDA 208809 - Sequence # 0008, Ezetimibe Tablets USP, 10 mg Resubmission / 1st Minor / Complete Response Amendement / Drug Substance / Process	AMN-ZETIA0003821	AMN-ZETIA0003880	May Offer	901; HS; UT
GDX0876	2/28/2017	Letter D. DeCicco and R. Leone (Teva Pharms.) re ANDA 078724 Minor Amendment - Final Approval Requested Sequence # 0003	Teva-Zetia_00003021	Teva-Zetia_00003022	May Offer	901; HS; UT
GDX0877	3/10/2017	Letter S. Qadry (Sun Pharms.) to Office of Generic Drugs, FDA re ANDA 207311 Information Request / Drug Product Sequence # 0009	SUN-EZETIMIBIE_00018723	SUN-EZETIMIBIE_00018724	May Offer	901; HS; UT
GDX0878	3/16/2017	Letter P. Pal to Office of Generic Drugs, FDA re ANDA 209234 (0008) Information Request - Quality	ALKEM003557	ALKEM003558	May Offer	901; HS; UT
GDX0879	3/17/2017	Letter FDA to B. Johns (Aurobindo Pharma) re ANDA 209838 Information Request	AUROBINDO_00000160	AUROBINDO_00000164	May Offer	901; UT
GDX0880	4/25/2017	Email C. Gentles to B. Johns re Easily Correctable Deficiency - ANDA 209838	AUROBINDO_00000188	AUROBINDO_00000188	May Offer	901; UT
GDX0881	5/2/2017	Letter B. Johns to Office of Generic Drugs, FDA re Ezetimibe Tablets USP 10 mg ANDA 209838 Easily Correctable Deficiency Bioequivalence Reference # 14632087 Sequence # 0004	AUROBINDO_00000146	AUROBINDO_00000147	May Offer	901; HS; UT
GDX0882	5/17/2017	Letter B. Johns to Office of Generic Drugs, FDA re Ezetimibe Tablets USP 10 mg ANDA 209838 Information Request Quality Sequence # 0005	AUROBINDO_00000118	AUROBINDO_00000129	May Offer	901; HS; UT
GDX0883	5/30/2017	Letter A. Patel (Amneal) to Office of Generic Drugs, FDA re ANDA 208809 - Sequence # 0009, Ezetimibe Tablets USP, 10 mg Resubmission / 2nd Minor / Complete Response Amendement / Drug Substance / Drug Produce	AMN-ZETIA0004212	AMN-ZETIA0004232	May Offer	901; HS; UT
GDX0884	06/2017	Q3C -- Tables and List Guidance for Industry, U.S. Department of Health and Human Services, FDA (CDER, CBER) (2017)			May Offer	901; UT
GDX0885	6/9/2017	Spreadsheet: Estimated Glenmar Financials 4/26/17 Through 6/9/17	MRKZETIA000509917	MRKZETIA000509917	May Offer	901; HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0886	6/12/2017	Letter FDA to K. Krishnan (Apotex) re ANDA 208332 Approval	APOTEX0000013	APOTEX0000016	May Offer	901; UT
GDX0887	6/12/2017	Letter FDA to S. Qadry (Sun Pharms.) re ANDA 207311 Approval	SUN-EZETIMIBIE_00021485	SUN-EZETIMIBIE_00021488	May Offer	901; UT
GDX0888	6/12/2017	Letter FDA to J. Delgaudio (Watson) re ANDA 200837 Approval	Watson-Zetia_00011753	Watson-Zetia_00011756	May Offer	901; UT
GDX0889	6/14/2017	Letter FDA to H. Schiff (Ascend Labs) re Complete Response and Denial of ANDA in its present form	ALKEM003801	ALKEM003804	May Offer	901; HS; UT
GDX0890	6/20/2017	Letter P. Pal to Office of Generic Drugs, FDA re ANDA 209234 1st Minor Complete Response Amendment	ALKEM003806	ALKEM003807	May Offer	901; HS; UT
GDX0891	7/10/2017	Letter FDA to H. Schiff (Ascend Labs) re ANDA 209234 Information Request	ALKEM003855	ALKEM003857	May Offer	901; UT
GDX0892	7/14/2017	Letter FDA to B. Johns (Aurobindo Pharma) re ANDA 209838 Information Request	AUROBINDO_00000416	AUROBINDO_00000418	May Offer	901; UT
GDX0893	7/18/2017	Letter U. Chhabra to Office of Generic Drugs, FDA re ANDA 209234 - Ezetimibe Tablets, USP 10mg Information Request - Quality	ALKEM003846	ALKEM003847	May Offer	901; HS; UT
GDX0894	7/18/2017	Letter B. Johns to Office of Generic Drugs, FDA re Ezetimibe Tablets USP 10 mg ANDA 209838 Information Request Quality Sequence # 0006	AUROBINDO_00000076	AUROBINDO_00000079	May Offer	901; HS; UT
GDX0895	8/8/2017	Email M. Johnson-Nimo to B. Johns re Information Request for ANDA-209838-ORIG-1	AUROBINDO_00000397	AUROBINDO_00000397	May Offer	901; UT
GDX0896	8/9/2017	Letter B. Johns to Office of Generic Drugs, FDA re Ezetimibe Tablets USP 10 mg ANDA 209838 Information Request Quality Sequence # 0007	AUROBINDO_00000166	AUROBINDO_00000167	May Offer	901; HS; UT
GDX0897	8/25/2017	Letter FDA to B. Johns (Aurobindo Pharma) re ANDA 209838 Approval	AUROBINDO_00014800	AUROBINDO_00014803	May Offer	901; UT
GDX0898	9/1/2017	Letter FDA to H. Schiff re ANDA 209234 Complete Response	ALKEM003899	ALKEM003902	May Offer	901; UT
GDX0899	9/26/2017	Letter U. Chhabra to Office of Generic Drugs, FDA re ANDA 209234 - Ezetimibe Tablets, USP 10mg Minor Complete Response Amendment Drug Substance/Drug Product	ALKEM003896	ALKEM003898	May Offer	901; HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0900	10/13/2017	Letter M. Henry (Sandoz) to Office of Generic Drugs, FDA re ANDA 203931 Prior Approval Supplement Sequence # 0012	SANDOZ-ZETIA-0000095	SANDOZ-ZETIA-0000103	May Offer	901; HS; UT
GDX0901	12/4/2017	Letter FDA to H. Schiff (Ascend Labs) re ANDA 209234 Information Request	ALKEM003959	ALKEM003961	May Offer	403; 901; UT
GDX0902	12/4/2017	Letter FDA to M. Henry (Sandoz) re ANDA 203931 Prior Approval Supplement Approval	SANDOZ-ZETIA-0000158	SANDOZ-ZETIA-0000160	May Offer	901; UT
GDX0903	12/5/2017	Letter U. Chhabra to Office of Generic Drugs, FDA re ANDA 209234, Ezetimibe Tablets USP, 10 mg Information Request - Quality, MMD Verification Statement - Sequence Nos. 0006 - 0009	ALKEM003955	ALKEM003958	May Offer	403; 901; HS; UT
GDX0904	3/12/2018	Agreement For Assignment of Claims between The Kroger Co. and Cardinal Health, Inc.	KRG ZETIA_ 00000001	KRG ZETIA_ 00000002	May Offer	UT
GDX0905	3/23/2018	Agreement for Assignment of Claims between McKesson Corp. and Albertsons Companies, LLC, for the	ALB_ZETIA_00000001	ALB_ZETIA_00000002	May Offer	UT
GDX0906	5/17/2018	Medicare Part D in 2018: The Latest on Enrollment, Premiums, and Cost Sharing by Juliette Cubanski, et al. (2018)			May Offer	UT; 901; HS
GDX0907	8/30/2018	Email B. Whalen to K. Blake re Assignments J Restasis & Zetia CVS - McKesson	CVS-ZET-0053692	CVS-ZET-0053700	May Offer	403; HS; HWH; R; UT
GDX0908	12/12/2018	Agreement for Assignment of Claims between CVS Pharmacy, Inc. and McKesson Corp.	CVS-ZET-0000008	CVS-ZET-0000009	May Offer	UT
GDX0909	1/4/2019	Email J. Willaman to H. Rolon re Next Order, dated 1/4/2019	CCI000543	CCI000551	May Offer	UT; 901; HS
GDX0910	1/25/2019	U.S. Patent and Trademark Office, Certified Copy of U.S. Patent No. RE42,461 issued June 14, 2011	USPTO-ZETIA-0023606	USPTO-ZETIA-0023642	May Offer	403; 901; UT
GDX0911	2/28/2019	U.S. Patent and Trademark Office, Certified Copy of U.S. Patent No. 7,612,058 issued November 3, 2009	USPTO-ZETIA-0025227	USPTO-ZETIA-0025272	May Offer	403; 901; HS; R; UT
GDX0912	4/9/2019	Agreement For Assignment of Claims between The Kroger Co. and Cardinal Health, Inc.	KRG_ZETIA_00000008	KRG_ZETIA_00000009	May Offer	UT; 901; HS

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0913	4/26/2019	Approval Letter FDA to Mylan Pharm re ANDA 201790	MYL ZETIA012089	MYL ZETIA012092	May Offer	403; 901; UT
GDX0914	6/7/2019	Plaintiffs' Corrected Responses and Objections to Defendants' First Set of Requests for Admission to Plaintiffs			May Offer	901; UT
GDX0915	07/2019	Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and Utilization (2019)			May Offer	901; UT
GDX0916	7/9/2019	The Restoration of (Bad) Faith: The Propoer Standard for a Factual Finding of Willful Ingringement, Faegre Drinker by F. DiGiovanni and T. Rahmeier (2019)			May Offer	901; HS; MIL; UT
GDX0917	7/10/2019	Notice of Deposition by Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., MSP Singapore Col LLC, Glenmark Pharmaceuticals, Ltd. and Glenmark Pharmaceuticals Inc., USA Pursuant to Federal Rule of Civil Procedures 30(b)(6)			May Offer	901; UT
GDX0918	8/27/2019	Defendants Merck & Co., Inc.'s, Merck Sharp & Dohme Corp.'s, Schering-Plough Corp.'s, Schering Corp.'s, And MSP Singapore Co. LLC's First Amended Disclosures			May Offer	901; UT
GDX0919	10/9/2019	Customer List with handwritten Cardinal 1 With address'			May Offer	901; HS; INC; UT
GDX0920	10/29/2019	Watson Labs Ezetimibe Tablets, 10 mg Document - Section 3.2.S.2.1 Manufacturer(s)	Watson-Zetia_00001762	Watson-Zetia_00001763	May Offer	901; HS; INC; UT
GDX0921	11/18/2019	Declaration of Teletha Brown re certification of data produced by Sandoz			May Offer	901; UT
GDX0922	11/18/2019	Declaration of Dr. Russell Lamb			May Offer	901; UT
GDX0923	1/13/2020	Expert Report of Keith Leffler			May Offer	CU; UT
GDX0924	3/23/2020	Website Page for Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (2020)			May Offer	901; 1002; INC; UT
GDX0925	5/8/2020	Trial Reply Declaration of Dr. Russell Lamb			May Offer	901; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0927	10/11/2022	Pharmaceuticals Sales 2010, Drugs.com (2010)			May Offer	901; HS; UT
GDX0928		Exetimibe Tablets, USP 10 mg ANDA 209234 (0009) Alkem Laboratories Limited, INDIA Response to Easily Correctable Deficiency Bioequivalence Reference # 10266034	ALKEM002703	ALKEM002706	May Offer	HS; UT
GDX0929		Exetimibe Tablets, USP 10 mg ANDA 209234 (0009) Alkem Laboratories Limited, INDIA Response to Information Request Quality Reference #11704040	ALKEM002763	ALKEM002790	May Offer	HS; UT
GDX0930		Exetimibe Tablets, USP 10 mg ANDA 209234 (0009) Alkem Laboratories Limited, INDIA Response to Information Request Quality Reference	ALKEM003562	ALKEM003570	May Offer	HS; UT
GDX0931		Exetimibe Tablets, USP 10 mg ANDA 209234 (0009) Alkem Laboratories Limited, INDIA Response to 1st Minor Complete Response Amendment	ALKEM003808	ALKEM003811	May Offer	HS; UT
GDX0932		Exetimibe Tablets, USP 10 mg ANDA 209234 (0010) Alkem Laboratories Limited, INDIA Response to Information Request Quality	ALKEM003858	ALKEM003861	May Offer	HS; UT
GDX0933		Ezetimibe Product Summary Table and Related Charts	APOTEX0000064	APOTEX0000072	May Offer	HS; UT
GDX0934		Ezetimibe Product Summary Table and Related Charts	APOTEX0000073	APOTEX0000082	May Offer	HS; UT
GDX0935		Ezetimibe Product Summary Table and Related Charts	APOTEX0000083	APOTEX0000092	May Offer	HS; UT
GDX0936		Ezetimibe Product Summary Table and Related Charts	APOTEX0000093	APOTEX0000101	May Offer	HS; UT
GDX0937		Ezetimibe Product Summary Table and Related Charts	APOTEX0000102	APOTEX0000112	May Offer	HS; UT
GDX0938		Ezetimibe Product Summary Table and Related Charts	APOTEX0000113	APOTEX0000122	May Offer	HS; UT
GDX0939		Spreadsheet entitled CCI000002 reflecting Merck Sharp & Cohme (IA) data with NDC numbers	CCI000002	CCI000002	May Offer	HS; UT
GDX0940		Email A. Maffia to S. Krishan et al re Exetimbie Tablets - Alternate Mfg Site to Par	GLENMARK-ZETIA-00220297	GLENMARK-ZETIA-00220303	May Offer	HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0941		Prior Approval Supplement of ANDA 078560 Ezetimibe Tablets, 10 mg - 3.2.P.5.4 Batch Analyses	GLENMARK-ZETIA-00283581	GLENMARK-ZETIA-00283581	May Offer	HS; UT
GDX0943		Kroger Zetia Manufacturer and Product Data	KRG_ZETIA_00000007	KRG_ZETIA_00000007	May Offer	UT
GDX0944		Schering Corp., et al. v. Mylan Pharm., No. 09-06383-JLL (D.N.J. [9/9/2010]), Dkt. No. 87-1, Order Consolidating Cases on Consent	MRKZETIA_SIDLEY000011155	MRKZETIA_SIDLEY000011156	May Offer	403; HS; MIL; R; UT
GDX0945		Original Submission, ANDA Ezetimibe Tablets 10 mg, Glenmark Pharmaceuticals Ltd.	MRKZETIA_SIDLEY000057494	MRKZETIA_SIDLEY000059974	May Offer	403; HS; MIL; R; UT
GDX0946		Launch MVP with Source and Notes	MRKZETIA000843969	MRKZETIA000843969	May Offer	403; HS; R; UT
GDX0947		Ezetimibe - 10 mg - Tablets, Manufacturer: Mylan Laboratories Limited (Naskik, India) 3.2.p.3.1 Manufacturers Tables	MYL_ZETIA 011343	MYL_ZETIA 011345	May Offer	403; HS; R; UT
GDX0948		Spreadsheet: Ezetimibe Tablets Summary-Assumptions Table and Forecast	PAR_00018435	PAR_00018435	May Offer	UT
GDX0949		Spreadsheet: Ezetimibe Tablets Summary-Assumptions Table and Forecast	PAR_00018438	PAR_00018438	May Offer	UT
GDX0950		S. Manan (Ohm Laboratories, Inc.) Patent Certification and Exclusivity Statement Ezetimibe Tablets, 10 mg	SUN-EZETIMIBIE_00000101	SUN-EZETIMIBIE_00000102	May Offer	403; HS; R; UT
GDX0951		ANDA 207311 Ezetimibe Tablets, 10 mg Response to Information Request - Bioequivalence - Dissolution Reference #175391) dated October 16, 2015	SUN-EZETIMIBIE_00017578	SUN-EZETIMIBIE_00017578	May Offer	403; HS; R; UT
GDX0952		Letter FDA to S. Manan (Ohm Laboratories, Inc.) re ANDA 207311 Request for Information	SUN-EZETIMIBIE_00017579	SUN-EZETIMIBIE_00017580	May Offer	403; HS; R; UT
GDX0953		ANDA 207311 Ezetimibe Tablets, 10 mg Response to Information Request Reference 7945804 Sequence # 0005 dated May 12, 2016	SUN-EZETIMIBIE_00018344	SUN-EZETIMIBIE_00018357	May Offer	403; HS; R; UT
GDX0954		ANDA 207311 Ezetimibe Tablets, 10 mg Response to Agency's Easily Correctable Deficiency Letter dated April 8, 2016	SUN-EZETIMIBIE_00018380	SUN-EZETIMIBIE_00018382	May Offer	403; HS; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0955		ANDA 207311 Ezetimibe Tablets, 10 mg Response to Information Request (Chemistry) - Reference 10935178 Sequence # 0007	SUN-EZETIMIBIE_00018620	SUN-EZETIMIBIE_00018622	May Offer	403; HS; R; UT
GDX0956		ANDA 207311 Ezetimibe Tablets, 10 mg Response to Information Request (Drug Product) - Sequence # 0009	SUN-EZETIMIBIE_00018718	SUN-EZETIMIBIE_00018720	May Offer	403; HS; R; UT
GDX0957		Teva USA: Sales Forecast	TEVA-ZETIA_00003530	TEVA-ZETIA_00003530	May Offer	HS; UT
GDX0958		Watson Laboratories, Inc. ANDA 200831 Ezetimibe Tablets, 10 mg 1.3.5.2 Patent Certification Sequence # 0000	Watson-Zetia_00000026	Watson-Zetia_00000031	May Offer	403; HS; R; UT
GDX0959		Spreadsheet: Sergeant's Benevolent, Rebates Disbursed Data	ZETIA-SERGEANTS-000046	ZETIA-SERGEANTS-000046	May Offer	403; HS; R; UT
GDX0960		Uniformed Firefighters Association Zetia Cost chart with Carrier ID, account name, group ID, Gross cost, total costs dated N/A	ZETIA-UFA-000228	ZETIA-UFA-000228	May Offer	HS; UT
GDX0961		Type II DMF - 024825, Ezetimibe - Process II, Section 3.2.S.2 Manufacture	GLENMARK-ZETIA-00309670	GLENMARK-ZETIA-00309964	May Offer	HS; R; UT
GDX0962		MPEP Section 806.05(F) Process of Making and Product Made [R-09.2012], Patent and Trademark Offices Manual of Patent Examining Proceudure, Chapter 800 Restriction in Applicatioins Filed under 35 U.S. C 111; Double Patenting			May Offer	HS; R; UT
GDX0963		APPCO Pharma, About Us Webpage (2022)			May Offer	HS; R; UT
GDX0964		GDUFA II Drug Master Files (DMFs), FDA (2022)			May Offer	HS; R; UT
GDX0965		Deposition Documents related to Topic 9 (Litigation Expenses)			May Offer	403; HS; R; UT
GDX0966		LinkedIn Page of Paul McCrorey			May Offer	HS; UT
GDX0967		Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act: Frequently Asked Question			May Offer	HS; UT
GDX0968		Report to the Congress: Medicare and the Health Care Delivery System, Chapter 6 - Sharing risk in Medicare Part D (MedPAC Study)			May Offer	901; HS; INC; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0969		The Four Coverage Stages of Medicare's Part D Program: Blue MedicareRx Prescription Drug 2023 Plans - Blue MedicareRx (PDP)			May Offer	403; HS; R; UT
GDX0970		Mylan Confirms First-to-File Patent Challenge Relating to Vytorin Cholestoral Medication: Expects to qualify for 180 days of sole marketing exclusivity, PRNewswire-FirstCall			May Offer	403; HS; R; UT
GDX0971	4/22/2010	Quick Take: A Victory for Glenmark But Zetia's IP Likely OK to 2016 by Steve Scala, et al. (2010)	MRKZETIA_R000082920	MRKZETIA_R000082923	May Offer	403; 701; HS; R; UT
GDX0972	2/8/2007	Letter from Glenmark re Notice of Paragraph IV Certification on U.S. Patent Nos. Re. 37,721 , 5,846,966 and 7,030,106	MRKZETIA_SIDLEY000009235	MRKZETIA_SIDLEY000009262	May Offer	UT
GDX0973	5/13/1993	Stuart Rosenblum, Schering Corporation Chemical Research Handwritten Notes	MRKZETIA_SIDLEY000047293	MRKZETIA_SIDLEY000047456	May Offer	UT; 901; HS
GDX0974	2/16/2019	Patent Application No. 08/953,825 for U.S. Patent No. 5,846,966	USPTO-ZETIA-0023643	USPTO-ZETIA-0023949	May Offer	403; HS; R; UT
GDX0975	4/19/2019	Patent Application No. 08/102,440	USPTO-ZETIA-0025273	USPTO-ZETIA-0025383	May Offer	403; HS; R; UT
GDX0976	4/19/2019	Patent Application No. 08/257,593 for U.S. Patent No. 5,631,365	USPTO-ZETIA-0025384	USPTO-ZETIA-0025614	May Offer	403; HS; R; UT
GDX0977	4/30/2019	Patent Application No. 08/617,751 for U.S. Patent No. 5,767,115	USPTO-ZETIA-0051909	USPTO-ZETIA-0052366	May Offer	403; HS; R; UT
GDX0978	04/2012	2012 Profile: Pharmaceutical Industry by PhRMA (2012)			May Offer	403; 901; HS; HWH; R; UT
GDX0979	5/27/2008	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [5/27/2008]), Glenmark Prvilege Log May 27, 2008	MRKZETIA_SIDLEY000000001	MRKZETIA_SIDLEY000000016	May Offer	403; HS; R; UT
GDX0980	4/19/2010	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [4/19/2010]), Dkt. No. 220, Opinion	MRKZETIA_SIDLEY000014199	MRKZETIA_SIDLEY000014205	May Offer	UT
GDX0981	2010	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [2010]) SEALED, Final Pretrial Order	MRKZETIA_SIDLEY000018428	MRKZETIA_SIDLEY000018765	May Offer	HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0982	7/22/2009	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [7/22/2009]), SEALED, Memorandum of Law in Opposition to Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Reissue)	MRKZETIA_SIDLEY000026820	MRKZETIA_SIDLEY000026850	May Offer	UT
GDX0983	4/19/2010	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [4/19/2010]), Dkt. No. 222, Opinion	MRKZETIA_SIDLEY000026900	MRKZETIA_SIDLEY000026903	May Offer	UT
GDX0984	7/1/2009	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [7/1/2009]), Dkt. No. 126-3, Memorandum of Law in Support of Glenmark's Motion for Partial Summary Judgment of Invalidity of Claims 10-13 (Improper Release)	MRKZETIA_SIDLEY000030844	MRKZETIA_SIDLEY000030876	May Offer	HS; UT
GDX0985	8/5/2009	Schering Corp. and MSP Singapore Co. v. Glenmark Pharm., No. 07-01334-JLL (D.N.J. [8/5/2009]), SEALED, Memorandum of Law in Opposition to Glenmark's Motion for Summary Judgment of Invalidity of Claims 1-5 and 7-13 (Double Patenting)	MRKZETIA_SIDLEY000036826	MRKZETIA_SIDLEY000036862	May Offer	UT
GDX0986	6/9/2010	Preliminary Amendment Filed with Narrowing Reissue Application for U.S. Patent No. RE37,721 E	MRKZETIA_SIDLEY000179029	MRKZETIA_SIDLEY000179042	May Offer	HS; UT
GDX0987		Exhibit E to the Expert Report of Nancy Linck entitled Timeline of Key Events Relating to Glenmark's Pre-Trial Defenses			May Offer	403; HS; UT
GDX0988	5/25/2011	Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (2011)			May Offer	403; HS; MIL; R; UT
GDX0989	1/25/2010	Boehringer Ingelheim International GmbH v. Barr Laboratories, Inc., 592 F.3d 1340 (Fed. Cir. 2010)			May Offer	403; HS; MIL; R; UT
GDX0991	2/11/2016	Email R. Kasula to P. Wagle and V. Kumar re Ezetimibe-Launch update, attaching Ezetimibe schedule-11-02-16.xlsx	GLENMARK-ZETIA-00411214	GLENMARK-ZETIA-00411220	May Offer	HS; UT
GDX0992	9/15/2006	Spreadsheet: Ezetimibe (GGII-B060) - 600 kg FG schedule of P-01 & P-15	GLENMARK-ZETIA-00411221	GLENMARK-ZETIA-00411221	May Offer	HS; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX0993	1907	H. Staudinger, Berichte der deutschen chemischen Gesellschaft, 356:51–123 (1907)	MRKZETIA_SIDLEY000133625	MRKZETIA_SIDLEY000133698	May Offer	403; HWH; R; UT
GDX0994	3/1/2017	Email M. Exume to D. Gan re Zetia Generic?	MRKZETIA000513679	MRKZETIA000513680	May Offer	HS; UT
GDX0995		Presentation: EZETIMIBE Loss of Exclusivity Plan	MRKZETIA000517420	MRKZETIA000517420	May Offer	HS; UT
GDX0996	8/29/2013	Email J. Liebel to S. Koenig, et al., re ZETIA LOE attaching Presentation: MCC Switch Overview	MRKZETIA000526690	MRKZETIA000526691	May Offer	403; HS; R; UT
GDX0997	6/1/2014	Presentation: CV Franchise - LOE Payer Strategy Kick-Off Meeting	MRKZETIA000533503	MRKZETIA000533503	May Offer	UT
GDX0998	10/10/2016	Email M. Exume to C. Broadway, et al., re FYI: Althero USMLT Presentation [Confidential] attaching Presentation: 2017 ZETIA Family Product Plan	MRKZETIA000601820	MRKZETIA000601821	May Offer	HS; UT
GDX0999	11/8/2017	Email M. Exume to D. Gan and J. Liebel re ZETIA LOE Year to Date Accomplishment [Confidential] attaching Presentation: Athero Award Nomination	MRKZETIA000854142	MRKZETIA000854146	May Offer	403; HS; R; UT
GDX1000	2/17/2017	Email J. Roehm to D. Gan, et al., re Latest Zetia LOE Dashboard [Confidential]	MRKZETIA000854566	MRKZETIA000854567	May Offer	HS; UT
GDX1001	2/19/2015	Email J. Liebel to M. Copeland and L. Stevens re US LOE Implementation Kick Off Meeting	MRKZETIA_R000005369	MRKZETIA_R000005371	May Offer	HS; UT
GDX1002	9/1/2016	Presentation: 2017 Athero Franchise Product Plan	MRKZETIA_R000094835	MRKZETIA_R000094835	May Offer	HS; UT
GDX1003	4/12/2010	Schering Corp., et al v. Teva Pharm., et al, No. 10-01058-JLL (D.N.J. [3/30/2010]), Dkt. No. 16, Teva Pharmaceuticals USA, Inc.'s Answer			May Offer	HS; R; UT
GDX1004		Spreadsheet: Montebello-Allocatable Inv Data	PAR_0000001	PAR_0000001	May Offer	UT
GDX1005	10/1/2014	Email C. Calabro to M. Altamuro, et al. re Zetia, attaching Ezetimibe (Zetia) forecast Sep 2014	PAR_00018436	PAR_00018437	May Offer	HS; HWH; UT
GDX1006	2/4/2019	Patent Application No. 12/797,341 for U.S. Patent No. RE42,461	USPTO-ZETIA-0001355	USPTO-ZETIA-0023605	May Offer	403; HS; MIL; R; UT

Tr. Ex. No.	Date	Description	Bates Nos.	End Bates Nos.	Expect to/May Offer	Objections
GDX1007	5/6/2016	Letter H. Schiff to Office of Generic Drugs, FDA re ANDA 209234 Quality - Response to Information Request, Sequence No. 0001	ALKEM000018	ALKEM000021	May Offer	403; R; UT
GDX1008	8/8/2012	Top 11 Fastest-Growing Generics Companies, Glenmark Pharmaceuticals, Fierce Pharma (Aug. 8, 2012)			May Offer	403; HS; HWH; MIL; R; UT
GDX1010	3/30/2010	Merck 10-K for the Fiscal Year Ended December 31, 2009			May Offer	403; H; HWH; R

EXHIBIT 8

In re Zetia (Ezetimibe) Antitrust Litigation
No. 2:18-md-2836 (E.D. Va.)

INDEX OF CODES FOR OBJECTIONS TO EXHIBITS & DEPOSITION DESIGNATIONS

Code	Definition
NO	No objection.
30B6	Beyond the scope of Rule 30(b)(6) designation.
403	Probative value is substantially outweighed by the risk of unfair prejudice, confusing the issues, misleading the jury, undue delay, wasting time, and/or needlessly presenting cumulative evidence (Fed. R. Evid. 403).
404	Impermissible character evidence or evidence of a crime, wrong, or other act (Fed. R. Evid. 404).
408	Evidence of settlement offer or conduct or statements made during settlement negotiations (Fed. R. Evid. 408).
602	Witness lacks personal knowledge/calls for speculation.
611	Leading question (Fed. R. Evid. 611) or coaching.
701	Improper lay witness opinion (Fed. R. Evid. 701).
702	Improper expert opinion (Fed. R. Evid. 702) (unless subject of a pending *Daubert* motion).
703	Improper basis for expert opinion (Fed. R. Evid. 703).
901	Not properly authenticated (Fed. R. Evid. 901).
1002	Violates best evidence rule (Fed. R. Evid. 1002).
1006	Improper summary, chart, or calculation (Fed. R. Evid. 1006).
AA	Asked and answered.
AF	Assumes fact(s) not in evidence.
AR	Argumentative.
BTS	Cross-examination beyond the scope of direct, or redirect beyond the scope of cross (Fed. R. Evid. 611).
CF	Question/testimony is confusing, misleading, vague, and/or ambiguous.
CLC	Calls for a legal conclusion.

CQ	Compound question.
CU	Cumulative.
DB	Expert testimony that is the subject of a pending *Daubert* challenge or subject to a ruling by the court on a *Daubert* challenge (Fed. R. Evid. 702 & 703).
ER	Designation does not reflect changes or corrections to testimony made in errata sheet.
FD	Lack of foundation.
HS	Inadmissible hearsay (Fed. R. Evid. 801-805).
HWH	Inadmissible hearsay within hearsay (Fed. R. Evid. 805).
ICD	Improper counter-designation (e.g., does not indicate the specific pages/lines of opposing party's designation that it is countering).
IPR	Improper assertion of attorney-client privilege.
IH	Improper hypothetical question.
IL	Illegible.
INC	Testimony or exhibit is incomplete (e.g., designation cuts off part of the question/answer or omits relevant context, exhibit is missing content/pages).
MC	Mischaracterizes/misstates prior testimony or other evidence.
MIL	Exhibit or testimony is the subject of a pending motion in limine.
MS	Misleading.
NR	Answer is non-responsive.
OBJ	Designation includes objections and/or attorney colloquy that should not be presented to the jury.
OO	Designation contains an objection that should be overruled.
PM	Testimony is the subject of a pending preclusion motion or subject to a ruling by the court on a preclusion motion.
PR	Attorney-client privileged and/or attorney work product.
R	Not relevant (Fed. R. Evid. 401 & 402).
STR	Designation contains a motion to strike and should be stricken.
UT	Untimely designation not served by the Court-ordered deadline for Rule 26(a)(3) disclosures in Pretrial Order No. 10.

EXHIBIT 9

UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF VIRGINIA
NORFOLK DIVISION

IN RE: ZETIA (EZETIMIBE) ANTITRUST LITIGATION THIS DOCUMENT RELATES TO: Direct Purchaser Actions End-Payor Actions Retailer Actions	MDL No. 2:18-md-2836

PURCHASERS' THIRD AMENDED TRIAL WITNESS LIST

The direct purchaser plaintiffs, end-payor plaintiffs, and retailer plaintiffs (collectively, the "purchasers") hereby submit this list of witnesses that they expect to call or may call to testify at trial.

This list is not a commitment that the purchasers will in fact call any particular witness at trial. The purchasers reserve their right to amend and supplement this list, to call all persons identified as witnesses by the defendants, to call additional witnesses to authenticate or otherwise lay a foundation for admission of evidence or for purposes of impeachment or rebuttal, to call any person whose deposition testimony has been designated by any party, and to supplement this list based on the Court's orders and/or rulings, including on the parties' motions for summary judgment, *Daubert* motions, and/or motions *in limine* and/or any issues, exhibits, or witnesses presented by any party. The purchasers also reserve the right to supplement this list if any unexpected dispute arises about the admissibility of data or assignments. In some cases, the purchasers have listed a witness as live and will still provide deposition designations for that witness.

A. Witnesses the Purchasers Expect to or May Call Live at Trial

Name	Type	Expect to/May Call
Timothy Hester[1] *May be contacted through counsel for the Merck defendants*[2]	Fact	Expect to Call
Lisa Jakob *May be contacted through counsel for the Merck defendants*	Fact	Expect to Call
Vijay Soni *May be contacted through counsel for the Glenmark defendants*[3]	Fact	Expect to Call
Paul Campanelli[4] *May be contacted through counsel for Par Pharmaceutical, Inc.*[5]	Fact	Expect to Call
Matthew Paulson *May be contacted through counsel for the direct purchaser plaintiffs*[6]	Fact	Expect to Call
Owen McMahon *May be contacted through counsel for the retailer plaintiffs*[7]	Fact	Expect to Call
Margaret Wingate	Fact	Expect to Call

[1] The plaintiffs will call Mr. Hester to testify live by contemporaneous video transmission if he agrees to testify voluntarily or is compelled to testify by order of the U.S. District Court for the Eastern District of Virginia, Alexandria Division. Otherwise, the plaintiffs expect to call Mr. Hester by deposition.

[2] Counsel for defendants Merck & Co., Inc., Merck Sharp & Dohme LLC, Schering-Plough Corp., Schering Corp., and MSP Singapore Co. LLC include Christopher D. Dusseault, Gibson Dunn & Crutcher LLP, (213) 229-7855, cdusseault@gibsondunn.com.

[3] Counsel for defendants Glenmark Pharmaceuticals, Ltd. and Glenmark Pharmaceuticals Inc., USA include Jay P. Lefkowitz, Kirkland & Ellis LLP, (212) 390-4092, lefkowitz@kirkland.com.

[4] The plaintiffs will call Mr. Campanelli to testify live by contemporaneous video transmission if he agrees to testify voluntarily or is compelled to testify by order of the U.S. District Court for the Southern District of New York. Otherwise, the plaintiffs expect to call Mr. Campanelli by deposition.

[5] Counsel for non-party Par Pharmaceutical, Inc. include Benjamin Greenblum, Williams & Connolly LLP, (202) 434-5919, bgreenblum@wc.com.

[6] Counsel for the direct purchaser plaintiffs include Thomas M. Sobol, Hagens Berman Sobol Shapiro LLP, (617) 482-3700, tom@hbsslaw.com.

[7] Counsel for the retailer plaintiffs include Barry L. Refsin, Hangley Aronchick Segal Pudlin & Schiller, (215) 496-7031, brefsin@hangley.com, and Scott E. Perwin, Kenny Nachwalter, P.A., (305) 373-1000, sep@knpa.com.

May be contacted through counsel for the end-payor plaintiffs[8]		
Maria Maloney *May be contacted through counsel for the end-payor plaintiffs*	Fact	May Call
Custodian of records for Merck *May be contacted through counsel for the Merck defendants*	Fact	May Call
Custodian of records for Glenmark *May be contacted through counsel for the Glenmark defendants*	Fact	May Call
Custodian of records for Par Pharmaceutical, Inc. *May be contacted through counsel for Par Pharmaceutical, Inc.*	Fact	May Call
Custodian of records for Greenberg Traurig, LLP *May be contacted through counsel for Greenberg Traurig, LLP*[9]	Fact	May Call
Richard C. Pettus *May be contacted through counsel for Greenberg Traurig, LLP*	Fact	May Call
Custodian of records for Alkem Laboratories Ltd.; Ascend Laboratories, LLC *May be contacted through counsel for Alkem Laboratories Ltd.; Ascend Laboratories, LLC*[10]	Fact	May Call

[8] Counsel for the end-payor plaintiffs include Michael M. Buchman, Motley Rice LLC, (212) 577-0040, mbuchman@motleyrice.com, and Marvin A. Miller, Miller Law LLC, (312) 332-3400, mmiller@millerlawllc.com.

[9] Counsel for non-party Greenberg Traurig LLP include Jim Tolpin, Greenberg Traurig LLP, (305) 579-0500, tolpinj@gtlaw.com.

[10] Counsel for non-parties Alkem Laboratories Ltd. and Ascend Laboratories, LLC include Michael E. Bloom, Benesch Friedlander Coplan & Aronoff LLP, (312) 212-4946, mbloom@beneschlaw.com.

Custodian of records for Amneal Pharmaceuticals LLC *May be contacted through counsel for Amneal Pharmaceuticals LLC*[11]	Fact	May Call
Custodian of records for Apotex Corp. *May be contacted through counsel for Apotex Corp.*[12]	Fact	May Call
Custodian of records for Aurobindo Pharma USA *May be contacted through counsel for Aurobindo Pharma USA*[13]	Fact	May Call
Custodian of records for MSN Laboratories Private Limited *May be contacted through U.S. agent for MSN Pharmaceuticals, Inc.*[14]	Fact	May Call
Custodian of records for Mylan Pharmaceuticals, Inc. *May be contacted through counsel for Mylan Pharmaceuticals, Inc.*[15]	Fact	May Call
Custodian of records for Prasco LLC *May be contacted through counsel for Prasco LLC*[16]	Fact	May Call
Custodian of records for Sandoz Inc. *May be contacted through counsel for Sandoz Inc.*[17]	Fact	May Call

[11] Counsel for non-party Amneal Pharmaceuticals LLC include Kellie Lerner, Robins Kaplan LLP, (212) 980-7400, klerner@robinskaplan.com.

[12] Counsel for non-party Apotex Corp. include Brian Sodikoff, Katten Muchin Rosenman LLP, (312) 902-5462, brian.sodikoff@katten.com.

[13] Counsel for non-party Aurobindo Pharma USA include Tini Thomas, Corporate Counsel, tthomas@aurobindousa.com.

[14] The address of the U.S. agent for non-party MSN Pharmaceuticals, Inc. is 20 Duke Road, Piscataway, NJ 08854.

[15] Counsel for non-party Mylan Pharmaceuticals, Inc. include Lance Soderstrom, Katten Muchin Rosenman LLP, (212) 940-6330, lance.soderstrom@katten.com.

[16] Counsel for non-party Prasco LLC include Alan H. Abes, Dinsmore & Shohl LLP, (513) 977-8149, alan.abes@dinsmore.com.

[17] Counsel for non-party Sandoz Inc. include Brian L. Bank, Rivkin Radler LLP, (516) 357-3516, brian.bank@rivkin.com.

Custodian of records for Sun Pharmaceuticals Industries, Ltd.; Ohm Laboratories, Inc. *May be contacted through counsel for Sun Pharmaceuticals Industries, Ltd.; Ohm Laboratories, Inc.*[18]	Fact	May Call
Custodian of records for Teva Pharmaceuticals USA Inc.; Actavis, Inc.; Watson Pharmaceuticals *May be contacted through counsel for Teva Pharmaceuticals USA Inc.; Actavis, Inc.; Watson Pharmaceuticals*[19]	Fact	May Call
Custodian of records for Zydus Pharmaceuticals (USA), Inc. *May be contacted through counsel for Zydus Pharmaceuticals (USA), Inc.*[20]	Fact	May Call
Witnesses to provide foundational testimony for FRE 1006 summaries	Fact	May Call
Jon Clark *May be contacted through plaintiffs' counsel*[21]	Expert[22]	Expect to Call
Todd Clark *May be contacted through plaintiffs' counsel*	Expert	Expect to Call
Laura Craft *May be contacted through counsel for the end-payor plaintiffs*	Expert	May Call
Joseph Dellaria *May be contacted through plaintiffs' counsel*	Expert	May Call

[18] Counsel for non-parties Sun Pharmaceuticals Industries, Ltd. and Ohm Laboratories, Inc. include Brendan J. Coffman, Wilson Sonsini, (202) 973-8891, bcoffman@wsgr.com.

[19] Counsel for non-parties Teva Pharmaceuticals USA Inc., Actavis, Inc., and Watson Pharmaceuticals include Christopher T. Holding, Goodwin Procter LLP, (617) 570-1000, cholding@goodwinlaw.com.

[20] Counsel for non-party Zydus Pharmaceuticals (USA), Inc. include Christopher J. Cassella, Locke Lord LLP, (312) 443-1813, christopher.cassella@lockelord.com.

[21] Counsel for the plaintiffs include Thomas M. Sobol, Hagens Berman Sobol Shapiro LLP, (617) 482-3700, tom@hbsslaw.com.

[22] Address information for each expert witness is provided in his or her curriculum vitae, which is attached to each expert report.

Robert Hrubiec *May be contacted through plaintiffs' counsel*	Expert	Expect to Call
Russell Lamb *May be contacted through counsel for the end-payor plaintiffs*	Expert	Expect to Call
Keith Leffler *May be contacted through counsel for the retailer plaintiffs*	Expert	Expect to Call
Jeffrey Leitzinger *May be contacted through counsel for the direct purchaser plaintiffs*	Expert	Expect to Call
Susan Marchetti *May be contacted through plaintiffs' counsel*	Expert	Expect to Call
Thomas McGuire *May be contacted through plaintiffs' counsel*	Expert	Expect to Call
Luis Molina *May be contacted through plaintiffs' counsel*	Expert	Expect to Call
Meredith Rosenthal *May be contacted through plaintiffs' counsel*	Expert	Expect to Call

B. Witnesses the Purchasers Expect to or May Call Via Deposition Testimony at Trial[23]

Name	Type	Expect to/May Call
Adriano Afonso[24]	Fact	May Call
Patrick Davish *May be contacted through counsel for the Merck defendants*	Fact	Expect to Call
Myriam Exume *May be contacted through counsel for the Merck defendants*	Fact	Expect to Call
David Jankiewicz *May be contacted through counsel for the Merck defendants*	Fact	Expect to Call
Paul McCrorey *May be contacted through counsel for the Merck defendants*	Fact	May Call[25]
David Pakula *May be contacted through counsel for the Merck defendants*	Fact	Expect to Call
Stuart Rosenblum *May be contacted through counsel for the Merck defendants*	Fact	May Call[26]
Mark Russell *May be contacted through counsel for the Merck defendants*	Fact	May Call
Theresa Covert Walker	Fact	Expect to Call

[23] The purchasers intend to present deposition testimony by video, with the possible exception of Stuart Rosenblum and Adriano Afonso.

[24] Deceased. Defendants did not produce a video of Mr. Afonso's deposition. Should the purchasers use his testimony, it will be by reading portions of his deposition into evidence.

[25] The purchasers' need for Mr. McCrorey's testimony at trial, either live or by deposition testimony designations, is contingent on the evidentiary developments at trial, including but not limited to, any rulings during trial or as a result of motions *in limine* regarding the consequences of Merck's assertion of privilege on matters to which Mr. McCrorey could testify.

[26] The defendants did not produce a video of Mr. Rosenblum's deposition. Should the purchasers use his testimony, it will be by reading portions of his deposition into evidence.

May be contacted through counsel for the Merck defendants		
Terrance Coughlin *May be contacted through counsel for the Glenmark defendants*	Fact	Expect to Call
Paul Dutra *May be contacted through counsel for the Glenmark defendants*	Fact	Expect to Call
Achin Gupta *May be contacted through counsel for the Glenmark defendants*	Fact	Expect to Call
Rajkiran Jain *May be contacted through counsel for the Glenmark defendants*	Fact	Expect to Call
Christina Koleto *May be contacted through counsel for the Glenmark defendants*	Fact	Expect to Call
Paresh Wagle *May be contacted through counsel for the Glenmark defendants*	Fact	Expect to Call
Lawrence Brown *May be contacted through counsel for Par Pharmaceutical, Inc.*	Fact	Expect to Call
Teletha Brown *May be contacted through counsel for Sandoz Inc.*	Fact	Expect to Call
John Kovaleski *May be contacted through counsel for Teva Pharmaceutical Industries, Ltd.*	Fact	Expect to Call
Scott Johnson *May be contacted through counsel for the retailer plaintiffs*	Fact	May Call
William Johnson *May be contacted through counsel for the retailer plaintiffs*	Fact	May Call
Zachary Mikulak *May be contacted through counsel for the retailer plaintiffs*	Fact	May Call

Ina Perales *May be contacted through counsel for the retailer plaintiffs*	Fact	May Call
Britt Turner *May be contacted through counsel for the retailer plaintiffs*	Fact	May Call
Erin Hart *May be contacted through counsel for Giant Eagle, Inc.*[27]	Fact	May Call

Dated: April 3, 2023

Respectfully submitted,

/s/ Thomas M. Sobol

Thomas M. Sobol (*pro hac vice)*
Kristen A. Johnson (*pro hac vice)*
Erin C. Burns (*pro hac vice*)
Hannah Schwarzschild (*pro hac vice*)
Rachel Downey (*pro hac vice*)
HAGENS BERMAN SOBOL SHAPIRO LLP
One Faneuil Hall Square, 5th Floor
Boston, MA 02109
Telephone: (617) 482-3700
Facsimile: (617) 482-3003
tom@hbsslaw.com
kristenj@hbsslaw.com
hannahs@hbsslaw.com
erinb@hbsslaw.com
racheld@hbsslaw.com

Lead Counsel for the Direct Purchaser Plaintiffs and Counsel for Plaintiffs FWK Holdings, LLC, McKesson Corporation, AmerisourceBergen Corporation, AmerisourceBergen Drug Corporation, H.D. Smith, LLC, Smith Medical Partners, LLC, Valley Wholesale Drug Company, LLC, Cardinal Health, Inc., The Harvard Drug Group, L.L.C., and Cardinal Health P.R. 120, Inc.

[27] Counsel for Giant Eagle, Inc. include Moira Cain-Mannix (cain-mannix@marcus-shapira.com), Brian C. Hill (hill@marcus-shapira.com), and Lauren Melfa Catanzarite (catanzarite@marcus-shapira.com), Marcus & Shapira LLP, (412) 471-3490.

William H. Monroe, Jr. (VSB No. 27441)
Marc C. Greco (VSB No. 41496)
Kip A. Harbison (VSB No. 38648)
Michael A. Glasser (VSB No. 17651)
GLASSER AND GLASSER, P.L.C.
Crown Center, Suite 600
580 East Main Street
Norfolk, VA 23510
Telephone: (757) 625-6787
Facsimile: (757) 625-5959
bill@glasserlaw.com
marcg@glasserlaw.com
kip@glasserlaw.com
michael@glasserlaw.com

Local Counsel for Plaintiffs FWK Holdings, LLC, Rochester Drug Cooperative, Inc., Cesar Castillo, LLC, McKesson Corporation, AmerisourceBergen Corporation, AmerisourceBergen Drug Corporation, H.D. Smith, LLC, Smith Medical Partners, LLC, Valley Wholesale Drug Company, LLC, Cardinal Health, Inc., The Harvard Drug Group, L.L.C., Cardinal Health P.R. 120, Inc., Meijer, Inc., Meijer Distribution, Inc., SUPERVALU, Inc., Wegmans Food Markets, Inc., KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc., and MLI RX, LLC, and Member of the Direct Purchaser Executive Committee

David F. Sorensen (*pro hac vice*)
Ellen T. Noteware (*pro hac vice*)
BERGER MONTAGUE PC
1818 Market Street, Suite 3600
Philadelphia, PA 19103
Telephone: (215) 875-3000
Facsimile: (215) 875-4604
dsorensen@bm.net
enoteware@bm.net

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs Rochester Drug Cooperative, Inc., McKesson Corporation, AmerisourceBergen Corporation, AmerisourceBergen Drug

Peter R. Kohn (*pro hac vice*)
Joseph T. Lukens (*pro hac vice*)
Neill W. Clark (*pro hac vice*)
FARUQI & FARUQI, LLP
One Penn Center, Suite 1550
1617 John F. Kennedy Boulevard
Philadelphia, PA 19103
Telephone: (215) 277-5770
Facsimile: (215) 277-5771
pkohn@faruqilaw.com
jlukens@faruqilaw.com
nclark@faruqilaw.com

Bradley J. Demuth (*pro hac vice*)
FARUQI & FARUQI, LLP

Corporation, H.D. Smith, LLC, Smith Medical Partners, LLC, Valley Wholesale Drug Company, LLC, Cardinal Health, Inc., The Harvard Drug Group, L.L.C., and Cardinal Health P.R. 120, Inc.

Paul E. Slater
Joseph M. Vanek (*pro hac vice*)
David P. Germaine (*pro hac vice*)
Alberto Rodriguez (*pro hac vice*)
SPERLING & SLATER, LLC
55 W. Monroe, Suite 3200
Chicago, IL 60603
Telephone: (312) 641-3200
Facsimile: (312) 641-6492
peslater@sperling-law.com
jvanek@sperling-law.com
dgermaine@sperling-law.com
arodriguez@sperling-law.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs FWK Holdings, LLC, Meijer, Inc., Meijer Distribution, Inc., and SUPERVALU, Inc.

Linda P. Nussbaum (*pro hac vice*)
Peter Moran (*pro hac vice*)
NUSSBAUM LAW GROUP, P.C.
1211 Avenue of the Americas, 40th Floor
New York, NY 10036-8718
Telephone: (917) 438-9189
lnussbaum@nussbaumpc.com
pmoran@nussbaumpc.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs Cesar Castillo, LLC and Wegmans Food Markets, Inc.

John D. Radice (*pro hac vice*)
April Lambert (*pro hac vice*)
Daniel Rubenstein (*pro hac vice*)
Kenneth Pickle (*pro hac vice*)
Luck Smith (*pro hac vice*)
RADICE LAW FIRM, P.C.
475 Wall Street
685 Third Avenue, 26th Floor
New York, NY 10017
Telephone: (212) 983-9330
Facsimile: (212) 983-9331
bdemuth@faruqilaw.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs Rochester Drug Cooperative, Inc. and MLI RX, LLC

Michael L. Roberts (*pro hac vice*)
Karen Sharp Halbert (*pro hac vice*)
Stephanie Smith (*pro hac vice*)
Sarah E. DeLoach (*pro hac vice*)
ROBERTS LAW FIRM, P.A.
20 Rahling Circle
Little Rock, AR 72223
Telephone: (501) 821-5575
Facsimile: (501) 821-4474
mikeroberts@robertslawfirm.us
karenhalbert@robertslawfirm.us
stephaniesmith@robertslawfirm.us
sarahdeloach@robertslawfirm.us

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiffs FWK Holdings, LLC and KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc.

Steve D. Shadowen (*pro hac vice*)
Matthew C. Weiner (*pro hac vice*)
Tina Miranda (*pro hac vice*)
HILLIARD & SHADOWEN LLP
1135 W. 6th Street, Suite 125
Austin, TX 78703
Telephone: (855) 344-3298
steve@hilliardshadowenlaw.com
matt@hilliardshadowenlaw.com
tmiranda@hilliardshadowenlaw.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

Joseph H. Meltzer (*pro hac vice*)

Princeton, NJ 08540
Telephone: (646) 245-8502
Facsimile: (609) 385-0745
jradice@radicelawfirm.com
alambert@radicelawfirm.com
drubenstein@radicelawfirm.com
kpickle@radicelawfirm.com
lsmith@radicelawfirm.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

Sharon K Robertson (*pro hac vice*)
Donna M. Evans (*pro hac vice*)
COHEN MILSTEIN SELLERS & TOLL PLLC
88 Pine Street, 14th Floor
New York, NY 10005
Telephone: (212) 838-7797
Facsimile: (212) 838-7745
srobertson@cohenmilstein.com
devans@cohenmilstein.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

Terence S. Ziegler (*pro hac vice*)
KESSLER TOPAZ MELTZER & CHECK LLP
280 King of Prussia Road
Radnor, PA 19087
Telephone: (610) 667-7706
Facsimile: (610) 667-7056
jmeltzer@ktmc.com
tziegler@ktmc.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff FWK Holdings, LLC

Barry Taus (*pro hac vice*)
Archana Tamoshunas (*pro hac vice*)
Kevin Landau (*pro hac vice*)
TAUS, CEBULASH & LANDAU, LLP
123 William Street, Suite 1900A
New York, NY 10038
Telephone: (646) 873-7654
btaus@tcllaw.com
atamoshunas@tcllaw.com
klandau@tcllaw.com

Member of the Direct Purchaser Executive Committee and Counsel for Plaintiff Rochester Drug Cooperative, Inc.

Jayne A. Goldstein (*pro hac vice*)
Miller Shah, LLP
1625 North Commerce Parkway, Ste. 320
Fort Lauderdale, FL 33326
Telephone: (954) 515-0123
Facsimile: (866) 300-7367
jagoldstein@millershah.com

Counsel for Plaintiff Cesar Castillo, LLC

James A. Cales III (VSB No. 41317)
Alan Brody Rashkind (VSB No. 12658)
FURNISS, DAVID, RASHKIND & SAUNDERS PC
6160 Kempsville Circle, Suite 341B
Norfolk, VA 23502
Telephone: (757) 461-7100
arashkind@furnissdavis.com
jcales@furnissdavis.com

Local Counsel for the End-Payor Class

Marvin A. Miller (*pro hac vice*)
Lori A. Fanning (*pro hac vice*)
MILLER LAW LLC
115 S. LaSalle Street, Suite 2910
Chicago, IL 60603
Telephone: (312) 332-3400
mmiller@millerlawllc.com
lfanning@millerlawllc.com

Michael M. Buchman (*pro hac vice*)
MOTLEY RICE LLC
777 Third Avenue, 27th Floor
New York, NY 10017
Telephone: (212) 577-0040
mbuchman@motleyrice.com

Co-Lead Counsel for the End-Payor Class

John F. Sawyer (VA Bar No. 65902)
WOLCOTT RIVERS GATES
Convergence Center V
200 Bendix Road, Suite 300
Virginia Beach, VA 23452
Telephone: 757-554-0249
Facsimile: 757-497-7267
sawyer@wolriv.com

Local Counsel for Burlington Drug Company, Inc., Dakota Drug, Inc., J M Smith Corporation d/b/a Smith Drug Company, Louisiana Wholesale Drug Co., Inc., North Carolina Mutual Wholesale Drug Company, Prescription Supply, Inc., and Value Drug Company, Giant Eagle, Inc., and the Retailer Plaintiffs

Bruce E. Gerstein (*pro hac vice*)
Kimberly Hennings (*pro hac vice*)
David B. Rochelson (*pro hac vice*)
GARWIN GERSTEIN & FISHER LLP
88 Pine St., 10th Floor
New York, NY 10005
Telephone: (212) 395-0055
bgerstein@garwingerstein.com
khennings@garwingerstein.com
drochelson@garwingerstein.com

Susan Segura
David Raphael
SMITH SEGURA RAPHAEL & LEGER LLP
221 Ansley Blvd.
Alexandria, LA
Telephone: (318) 445-4480
ssegura@ssrllp.com
draphael@ssrllp.com

Stuart E. Des Roches
ODOM & DES ROCHES LLC
650 Poydras Street, Suite 2020
New Orleans, LA 70130
Telephone: (504) 522-0077

stuart@odrlaw.com

Counsel for Burlington Drug Company, Inc., Dakota Drug, Inc., J M Smith Corporation d/b/a Smith Drug Company, Louisiana Wholesale Drug Co., Inc., North Carolina Mutual Wholesale Drug Company, Prescription Supply, Inc., and Value Drug Company

Scott E. Perwin (*pro hac vice*)
Lauren C. Ravkind (*pro hac vice*)
Anna T. Neill (*pro hac vice*)
KENNY NACHWALTER P.A.
Four Seasons Tower
1441 Brickell Avenue, Suite 1100
Miami, FL 33131
Telephone: (305) 373-1000
Facsimile: (305) 372-1861
sperwin@knpa.com
lravkind@knpa.com
aneill@knpa.com

Counsel for the Retailer Plaintiffs (No. 2:18-cv-266) and Giant Eagle, Inc.

Barry L. Refsin (*pro hac vice*)
Eric L. Bloom (*pro hac vice*)
HANGLEY ARONCHICK SEGAL PUDLIN & SCHILLER P.A.
One Logan Square, 27th Floor
Philadelphia, PA 19103
Telephone: (215) 568-6200
brefsin@hangley.com
mkiley@hangley.com
ebloom@hangley.com

Counsel for the Retailer Plaintiffs CVS and Rite Aid (Nos. 2:18-cv-423 & 2:18-cv-439)

Bernard D. Marcus
Moira Cain-Mannix
Brian C. Hill
Erin Gibson Allen
MARCUS & SHAPIRA LLP
301 Grant Street
One Oxford Centre, 35th Floor
Pittsburgh, PA 15219-6401
Telephone: 412-471-3490
Facsimile: 412-391-8758
marcus@marcus-shapira.com
cain-mannix@marcus-shapira.com
hill@marcus-shapira.com
allen@marcus-shapira.com

Counsel for Giant Eagle, Inc.

CERTIFICATE OF SERVICE

I, Thomas M. Sobol, certify that, on this date, I caused a copy of the foregoing to be served on the defendants via email.

Dated: April 3, 2023

/s/ Thomas M. Sobol
Thomas M. Sobol

EXHIBIT 10

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF VIRGINIA
NORFOLK DIVISION

IN RE: ZETIA (EZETIMIBE) ANTITRUST LITIGATION	MDL No. 2:18-md-2836
THIS DOCUMENT RELATES TO: ALL ACTIONS	

MERCK'S WITNESS LIST

Merck expects to call the following witnesses live at trial:

1. Sumanth Addanki (Expert)
2. Robert Armitage (Expert)
3. Duane Burnett (Fact)
4. Myriam Exume (Fact)
5. Deborah Gan (Fact)
6. Sanjeev Krishan (Fact)
7. Nancy Linck (Expert)
8. Elizabeth Lindsey (Expert)
9. Timothy Maloney (Expert)
10. Paul Matukaitis (Fact)
11. Alan Millar (Expert)
12. Mark Robbins (Expert)
13. William Roush (Expert)
14. Lauren Stiroh (Expert)

15. Bruce Strombom (Expert)

Merck expects to call the following witness by video deposition at trial:

1. Vijay Soni (Fact)
2. David Mitchell (Fact)

Merck may call the following witnesses live at trial:

1. Kathryn Hayward (Fact)
2. Lisa Jakob (Fact)
3. Joerg Liebel (Fact)
4. Patrick Magri (Fact)

Merck may call the following witnesses via video deposition at trial:

1. Adriano Afonso[1] (Fact)
2. Aaron Anderson (Fact)
3. Lawrence Brown (Fact)
4. Teletha Brown (Fact)
5. Paul Campanelli (Fact)
6. Theresa Carapella (Fact)
7. Terrance Coughlin (Fact)
8. Theresa Covert Walker (Fact)

[1] No video exists of Mr. Afonso's deposition. Should Merck use Mr. Afonso's testimony, it will be by reading portions of his deposition into evidence.

9. Paul Dutra (Fact)

10. E. Anthony Figg (Expert)

11. Erin Hart (Fact)

12. Owen Halloran (Fact)

13. Kathryn Hayward (Fact)

14. Timothy Hester (Fact)

15. Marty Igel (Fact)

16. Rapkisan Jain (Fact)

17. David Jankiewicz (Fact)

18. Scott Johnson (Fact)

19. William Johnson (Fact)

20. Thomas Kolschowsky (Fact)

21. John Kovaleski (Fact)

22. Joerg Liebel (Fact)

23. Patrick Magri (Fact)

24. Maria Maloney (Fact)

25. Christopher Masseth (Fact)

26. Paul McCrorey (Fact)

27. Owen McMahon (Fact)

28. Zachary Mikulak (Fact)

29. Heather Odenwelder (Fact)

30. Errol Ogman (Fact)

31. Dave Pakula (Fact)

32. Matthew Paulson (Fact)

33. Ina Perales (Fact)

34. Stuart Rosenblum[2] (Fact)

35. Meredith Rosenthal (Expert)

36. Michael Stahelin (Fact)

37. Stephen Stalker (Fact)

38. Arthur Steinberg (Fact)

39. Michael Theirl (Fact)

40. Britt Turner (Fact)

41. Luis Vazquez (Fact)

42. Paresh Wagle (Fact)

43. Margaret Wingate (Fact)

[2] No video exists of Mr. Rosenblum's deposition. Should Merck use Mr. Rosenblum's testimony, it will be by reading portions of his deposition into evidence.

EXHIBIT 11

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF VIRGINIA

IN RE: ZETIA (EZETIMIBE) ANTITRUST LITIGATION	MDL No. 2:18-md-2836
THIS DOCUMENT RELATES TO: DIRECT PURCHASER ACTIONS	

GLENMARK DEFENDANTS' AMENDED RULE 26(a)(3) DISCLOSURES

Pursuant to the Federal Rules of Civil Procedure and the parties' agreement regarding pretrial exchanges, Defendants Glenmark Pharmaceuticals, Ltd. and Glenmark Pharmaceuticals Inc., USA (collectively, "Glenmark"), hereby serve amended Rule 26(a)(3) disclosures. Glenmark reserves the right to supplement and/or amend these disclosures before trial.

I. Rule 26(a)(3)(A)(i): Amended Trial Witness List

A. Witnesses Glenmark Expects To Present Live

Glenmark identifies the following witnesses (in alphabetical order) whom Glenmark expects to call live in its case in chief. Glenmark reserves the right to amend and supplement this filing for any reason, including based on rulings by the Court and proceedings at trial. Glenmark further reserves the right to question or call to testify any witness identified by any plaintiff or by Defendants Merck & Co., Inc., Merck Sharp & Dohme Corp. (now known as Merck Sharp & Dohme LLC), Schering-Plough Corp., Schering Corp., and MSP Singapore Co. LLC (collectively "Merck").

1. Sumanth Addanki (Expert)
2. Robert Armitage (Expert)
3. Duane Burnett (Merck)

4. Myriam Exume (Merck)
5. Anthony Figg (Expert)
6. Deborah Gan (Merck)
7. Owen Halloran (KPH)
8. Erin Hart (Giant Eagle)
9. Lisa Jakob (Merck)
10. Sanjeev Krishan
11. Nancy Linck (Expert)
12. Elizabeth Lindsey (Expert)
13. Timothy Maloney (Expert)
14. Paul Matukaitis (Merck)
15. Alan Millar (Expert)
16. Matthew Paulson (Meijer)
17. Mark Robbins (Expert)
18. William Roush (Expert)
19. Vijay Soni[1]
20. Lauren Stiroh (Expert)
21. Bruce Strombom (Expert)
22. Jeffrey Winkler (Expert)

[1] As Glenmark has consistently informed Plaintiffs and represented to the Court, Glenmark does not control Dr. Soni, and is still assessing its trial strategy, so Glenmark has not yet made a final decision about whether Glenmark will call him. Thus, although Dr. Soni continues to be listed as a witness Glenmark expects to call live, that expectation is subject to change, as Plaintiffs are aware. If Glenmark determines that it no longer expects to call Dr. Soni live, it will inform Plaintiffs promptly.

B. Witnesses Glenmark May Present If The Need Arises

Glenmark identifies the following witnesses (in alphabetical order) whom Glenmark may call in its case in chief if the need arises, either live or by deposition, as indicated. Glenmark reserves the right to amend and supplement this filing for any reason, including based on rulings by the Court and proceedings at trial. Glenmark further reserves the right to question or call to testify any witness identified by any plaintiff or by Defendants Merck & Co., Inc., Merck Sharp & Dohme Corp. (now known as Merck Sharp & Dohme LLC), Schering-Plough Corp., Schering Corp., and MSP Singapore Co. LLC (collectively "Merck").

1. Aaron Anderson (Painters) (deposition)
2. Lawrence Brown (Par) (deposition)
3. Teletha Brown (Sandoz) (deposition)
4. Paul Campanelli (Par) (deposition)
5. Terrance Coughlin (deposition)
6. Theresa Covert (Merck) (deposition)
7. Patrick Davish (Merck) (deposition)
8. Paul Dutra (deposition)
9. Achin Gupta (deposition)
10. Kathryn Hayward (Merck) (live)
11. Timothy Hester (Merck) (deposition)
12. Marty Igel (Cardinal) (deposition)
13. Rajkiran Jain (live)
14. David Jankiewicz (Merck) (deposition)
15. Scott Johnson (Albertsons) (deposition)
16. William Johnson (CVS) (deposition)
17. Christina Koleto (live)

18. Thomas Kolschowsky (FWK) (deposition)
19. John Kovaleski (Teva) (deposition)
20. Jeorg Liebel (Merck) (live or deposition)
21. Patrick Magri (Merck) (live)
22. Christopher Masseth (RDC) (deposition)
23. Robert Matsuk (live)
24. Paul McCrorey (Merck) (deposition)
25. Owen McMahon (Rite Aid) (deposition)
26. Zachary Mikulak (Walgreens) (deposition)
27. David Mitchell (Mylan) (deposition)
28. Heather Odenwelder (Amerisource) (deposition)
29. Errol Ogman (Sergeants) (deposition)
30. Dave Pakula (Merck) (deposition)
31. Ina Perales (HEB) (deposition)
32. Stephen Stalker (McKesson) (deposition)
33. Michael Theirl (Int'l Union) (deposition)
34. Britt Turner (Kroger) (deposition)
35. Luis Vazquez (CCI) (deposition)
36. Paresh Wagle (live)
37. Any witness on plaintiffs' witness list
38. Any witness on Merck's witness list

Dated: April 3, 2023

Respectfully submitted,

/s/ Richard Ottinger

Richard H. Ottinger (VSB No.: 38842)
Dustin M. Paul (VSB No.: 75287)
Edward J. Powers (VSB No. 32146)
WOODS ROGERS VANDEVENTER BLACK
101 West Main Street, Suite 500 Norfolk, VA 23510
Tel: 757.446.8600
Fax: 757.446.8670
rottinger@vanblacklaw.com
dpaul@vanblacklaw.com
epowers@vanblacklaw.com

Jay Philip Lefkowitz (*pro hac vice*)
Devora Whitman Allon (*pro hac vice*)
Kevin Michael Neylan, Jr. (*pro hac vice*)
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, NY 10022
Tel: 212.390.4092
Fax: 212.446.4900
lefkowitz@kirkland.com
devora.allon@kirkland.com
kevin.neylan@kirkland.com

Counsel for Defendants Glenmark Pharmaceuticals, Ltd. and Glenmark Pharmaceuticals Inc., USA incorrectly identified as Glenmark Generics Inc., USA